0001558370-20-013349.txt : 20201109 0001558370-20-013349.hdr.sgml : 20201109 20201109160756 ACCESSION NUMBER: 0001558370-20-013349 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 99 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201109 DATE AS OF CHANGE: 20201109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Fortress Biotech, Inc. CENTRAL INDEX KEY: 0001429260 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205157386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35366 FILM NUMBER: 201297734 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: CORONADO BIOSCIENCES INC DATE OF NAME CHANGE: 20080310 10-Q 1 fbio-20200930x10q.htm 10-Q
August 1, 2021March 2, 2022May 1, 2022June 1, 2022August 1, 2022September 1, 2022August 1, 2021September 1, 2021September 1, 2021October 1, 2022August 1, 2025Accelerated Filer0001429260--12-312020Q3falsefalseFortress Biotech, Inc.740274259374837434271381341167P5Y10000001000000P15Y00014292602020-05-3100014292602020-03-230001429260us-gaap:NoncontrollingInterestMember2020-09-300001429260us-gaap:AdditionalPaidInCapitalMember2020-09-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-09-300001429260fbio:CommonSharesIssuableMember2020-09-300001429260us-gaap:NoncontrollingInterestMember2020-06-300001429260us-gaap:AdditionalPaidInCapitalMember2020-06-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-06-300001429260fbio:CommonSharesIssuableMember2020-06-3000014292602020-06-300001429260us-gaap:NoncontrollingInterestMember2019-12-310001429260us-gaap:AdditionalPaidInCapitalMember2019-12-310001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2019-12-310001429260fbio:CommonSharesIssuableMember2019-12-310001429260us-gaap:NoncontrollingInterestMember2019-09-300001429260us-gaap:AdditionalPaidInCapitalMember2019-09-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2019-09-300001429260fbio:CommonSharesIssuableMember2019-09-300001429260us-gaap:NoncontrollingInterestMember2019-06-300001429260us-gaap:AdditionalPaidInCapitalMember2019-06-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2019-06-300001429260fbio:CommonSharesIssuableMember2019-06-3000014292602019-06-300001429260us-gaap:NoncontrollingInterestMember2018-12-310001429260us-gaap:AdditionalPaidInCapitalMember2018-12-310001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2018-12-310001429260fbio:CommonSharesIssuableMember2018-12-310001429260us-gaap:SeriesAPreferredStockMember2020-09-300001429260us-gaap:CommonStockMember2020-09-300001429260us-gaap:SeriesAPreferredStockMember2020-06-300001429260us-gaap:CommonStockMember2020-06-300001429260us-gaap:SeriesAPreferredStockMember2019-12-310001429260us-gaap:CommonStockMember2019-12-310001429260us-gaap:SeriesAPreferredStockMember2019-09-300001429260us-gaap:CommonStockMember2019-09-300001429260us-gaap:SeriesAPreferredStockMember2019-06-300001429260us-gaap:CommonStockMember2019-06-300001429260us-gaap:SeriesAPreferredStockMember2018-12-310001429260us-gaap:CommonStockMember2018-12-310001429260fbio:MustangBioIncMember2019-09-300001429260us-gaap:WarrantMember2019-01-012019-12-310001429260us-gaap:RestrictedStockMember2020-09-300001429260us-gaap:RestrictedStockMember2019-12-310001429260fbio:TgTherapeuticsIncMemberfbio:SharedServicesAgreementMember2020-07-012020-09-300001429260fbio:TgTherapeuticsIncMemberfbio:DeskShareAgreementsMember2020-07-012020-09-300001429260fbio:OpusPointPartnersManagementLlcMemberfbio:DeskShareAgreementsMember2020-07-012020-09-300001429260fbio:TgTherapeuticsIncMemberfbio:SharedServicesAgreementMember2020-01-012020-09-300001429260fbio:TgTherapeuticsIncMemberfbio:DeskShareAgreementsMember2020-01-012020-09-300001429260fbio:TgTherapeuticsIncMemberfbio:SharedServicesAgreementMember2019-07-012019-09-300001429260fbio:OpusPointPartnersManagementLlcMemberfbio:DeskShareAgreementsMember2019-07-012019-09-300001429260fbio:TgTherapeuticsIncMemberfbio:SharedServicesAgreementMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:St.JudeChildrenSResearchHospitalXscidMb107Member2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:FredHutchinsonCancerResearchCenterCd20Mb106Member2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CohIl13raaMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeNationalMedicalCenterMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeManufacturingMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeCs1Member2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeCD123Member2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:BIDMCCRISPRMember2020-07-012020-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:UpennAavMember2020-07-012020-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:UmassAavMember2020-07-012020-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:DukeAavMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:UclaMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:SirionLentiboostMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:NationwideChildrensHospitalMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:FredHutchCd20CarTMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CslBehringCalimmuneMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CohHer2Member2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohSpacerMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohIl13r2CarTMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohCsiCarTMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopecohCd123Member2020-07-012020-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMember2020-07-012020-09-300001429260fbio:OncogenuityMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMember2020-07-012020-09-300001429260fbio:BaergicMember2020-07-012020-09-300001429260fbio:AevitasMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:St.JudeChildrenSResearchHospitalXscidMb107Member2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:FredHutchinsonCancerResearchCenterCd20Mb106Member2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CohIl13raaMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeNationalMedicalCenterMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeManufacturingMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeCs1Member2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeCD123Member2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:BIDMCCRISPRMember2020-01-012020-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:UpennAavMember2020-01-012020-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:UmassAavMember2020-01-012020-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:DukeAavMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:UclaMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:SirionLentiboostMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:NationwideChildrensHospitalMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:FredHutchCd20CarTMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CslBehringCalimmuneMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CohHer2Member2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohSpacerMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohIl13r2CarTMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohCsiCarTMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopecohCd123Member2020-01-012020-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMember2020-01-012020-09-300001429260fbio:OncogenuityMember2020-01-012020-09-300001429260fbio:BaergicMember2020-01-012020-09-300001429260fbio:AevitasMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:St.JudeChildrenSResearchHospitalXscidMb107Member2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:FredHutchinsonCancerResearchCenterCd20Mb106Member2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CohIl13raaMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeNationalMedicalCenterMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeManufacturingMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeCs1Member2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeCD123Member2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:BIDMCCRISPRMember2019-07-012019-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:UpennAavMember2019-07-012019-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:UmassAavMember2019-07-012019-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:DukeAavMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:UclaMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:SirionLentiboostMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:NationwideChildrensHospitalMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:FredHutchCd20CarTMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CslBehringCalimmuneMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CohHer2Member2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohSpacerMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohIl13r2CarTMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohCsiCarTMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopecohCd123Member2019-07-012019-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:St.JudeChildrenSResearchHospitalXscidMb107Member2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:FredHutchinsonCancerResearchCenterCd20Mb106Member2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CohIl13raaMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeNationalMedicalCenterMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeManufacturingMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeCs1Member2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:CityOfHopeCD123Member2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:BIDMCCRISPRMember2019-01-012019-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:UpennAavMember2019-01-012019-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:UmassAavMember2019-01-012019-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMemberfbio:DukeAavMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:UclaMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:SirionLentiboostMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:NationwideChildrensHospitalMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:FredHutchCd20CarTMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CslBehringCalimmuneMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CohHer2Member2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohSpacerMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohIl13r2CarTMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopeCohCsiCarTMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:CityOfHopecohCd123Member2019-01-012019-09-300001429260fbio:AevitasTherapeuticsIncMemberfbio:ResearchAndClinicalTrialAgreementsMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMember2019-01-012019-09-300001429260fbio:Notes2019Member2020-07-012020-09-300001429260fbio:VentureNotesThreeMember2019-01-012019-09-300001429260srt:MinimumMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2020-01-012020-09-300001429260srt:MaximumMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2020-01-012020-09-300001429260us-gaap:MachineryAndEquipmentMember2020-01-012020-09-300001429260us-gaap:FurnitureAndFixturesMember2020-01-012020-09-300001429260us-gaap:ComputerEquipmentMember2020-01-012020-09-300001429260fbio:FortressBiotechIncMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2020-09-300001429260us-gaap:MachineryAndEquipmentMember2020-09-300001429260us-gaap:FurnitureAndFixturesMember2020-09-300001429260us-gaap:ConstructionInProgressMember2020-09-300001429260us-gaap:ComputerEquipmentMember2020-09-300001429260fbio:FortressBiotechIncMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2019-12-310001429260us-gaap:MachineryAndEquipmentMember2019-12-310001429260us-gaap:FurnitureAndFixturesMember2019-12-310001429260us-gaap:ConstructionInProgressMember2019-12-310001429260us-gaap:ComputerEquipmentMember2019-12-310001429260us-gaap:PreferredStockMemberfbio:SeriesCumulativeRedeemablePerpetualPreferredStock9.375Member2020-05-292020-05-290001429260us-gaap:PreferredStockMemberfbio:SeriesCumulativeRedeemablePerpetualPreferredStock9.375Member2020-02-142020-02-140001429260us-gaap:PreferredStockMemberus-gaap:IPOMember2020-08-280001429260us-gaap:CommonStockMemberfbio:MarketOfferingMember2020-05-292020-05-290001429260us-gaap:CommonStockMemberfbio:MarketOfferingMember2020-02-142020-02-140001429260fbio:Notes2019Member2019-01-012019-09-300001429260fbio:HorizonNotesMember2020-01-012020-09-300001429260fbio:VentureNoteMember2019-01-012019-09-300001429260fbio:HorizonNotesMember2019-01-012019-09-300001429260fbio:DeskShareAgreementsMember2020-07-012020-09-300001429260fbio:DeskShareAgreementsMember2019-07-012019-09-300001429260fbio:TamidMember2020-01-012020-09-300001429260fbio:Oncogenuity.Member2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMember2020-01-012020-09-300001429260fbio:JmcMember2020-01-012020-09-300001429260fbio:HelocyteMember2020-01-012020-09-300001429260fbio:CypriumMember2020-01-012020-09-300001429260fbio:CoronadoSoCoIncMember2020-01-012020-09-300001429260fbio:CheckpointTherapeuticsIncMember2020-01-012020-09-300001429260fbio:CellvationMember2020-01-012020-09-300001429260fbio:BaergicMember2020-01-012020-09-300001429260fbio:AvenueMember2020-01-012020-09-300001429260fbio:AevitasMember2020-01-012020-09-300001429260fbio:TamidMember2019-01-012019-12-310001429260fbio:MustangTherapeuticsIncMember2019-01-012019-12-310001429260fbio:JmcMember2019-01-012019-12-310001429260fbio:HelocyteMember2019-01-012019-12-310001429260fbio:CypriumMember2019-01-012019-12-310001429260fbio:CoronadoSoCoIncMember2019-01-012019-12-310001429260fbio:CheckpointTherapeuticsIncMember2019-01-012019-12-310001429260fbio:CellvationMember2019-01-012019-12-310001429260fbio:BaergicMember2019-01-012019-12-310001429260fbio:AvenueMember2019-01-012019-12-310001429260fbio:AevitasMember2019-01-012019-12-310001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-07-012020-09-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-01-012020-09-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2019-07-012019-09-300001429260us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2019-01-012019-09-300001429260fbio:MustangBioIncMember2019-08-160001429260fbio:MustangBioIncMember2018-07-130001429260fbio:CheckpointTherapeuticsIncMember2017-11-300001429260fbio:OralAcneTreatmentAgreementMember2020-09-300001429260fbio:OralAcneTreatmentAgreementMember2019-12-310001429260fbio:Notes2019Memberfbio:MichealS.WeissMember2019-12-310001429260fbio:Notes2019Memberfbio:DrRosenwaldMember2019-12-310001429260fbio:Notes2019Memberfbio:DrRosenwaldAndMrWeissMember2019-12-310001429260fbio:DakCapitalIncMemberfbio:Notes2019Member2019-12-310001429260fbio:VentureNotesTwoMember2019-12-310001429260fbio:VentureNotesThreeMember2019-12-310001429260fbio:VentureNoteMember2019-12-310001429260fbio:SubordinatedNoteFinancingTwoMember2019-12-310001429260fbio:SubordinatedNoteFinancingThreeMember2019-12-310001429260fbio:SubordinatedNoteFinancingOneMember2019-12-310001429260fbio:SubordinatedNoteFinancingFourMember2019-12-310001429260fbio:SubordinatedNoteFinancingFiveMember2019-12-310001429260fbio:Notes2019Member2019-12-310001429260fbio:Mustang2019VentureDebtMember2019-12-310001429260fbio:IdbNotePayableMember2019-12-310001429260us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember2019-12-310001429260us-gaap:FairValueInputsLevel2Memberus-gaap:WarrantMember2019-12-310001429260us-gaap:FairValueInputsLevel1Memberus-gaap:WarrantMember2019-12-310001429260us-gaap:WarrantMember2019-12-310001429260us-gaap:FairValueInputsLevel3Memberfbio:CaelumConvertibleNotesMember2020-09-300001429260us-gaap:FairValueInputsLevel2Memberfbio:CaelumConvertibleNotesMember2020-09-300001429260us-gaap:FairValueInputsLevel1Memberfbio:CaelumConvertibleNotesMember2020-09-300001429260fbio:MeasurementInputInvestmentsMemberfbio:CaelumMember2020-09-300001429260fbio:CaelumConvertibleNotesMember2020-09-300001429260us-gaap:FairValueInputsLevel3Memberfbio:CaelumConvertibleNotesMember2019-12-310001429260us-gaap:FairValueInputsLevel2Memberfbio:CaelumConvertibleNotesMember2019-12-310001429260us-gaap:FairValueInputsLevel1Memberfbio:CaelumConvertibleNotesMember2019-12-310001429260fbio:MeasurementInputInvestmentsMemberfbio:CaelumMember2019-12-310001429260fbio:CaelumConvertibleNotesMember2019-12-310001429260fbio:Notes2019Member2020-01-012020-09-300001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2020-01-012020-09-300001429260srt:MinimumMemberus-gaap:FiniteLivedIntangibleAssetsMemberfbio:JourneyMedicalCorpMember2020-01-012020-09-300001429260srt:MaximumMemberus-gaap:FiniteLivedIntangibleAssetsMemberfbio:JourneyMedicalCorpMember2020-01-012020-09-300001429260fbio:LicenseAndSupplyAgreementMember2020-09-300001429260fbio:JourneyMedicalCorporationMember2019-12-310001429260fbio:JourneyMedicalCorpMember2020-09-300001429260fbio:JourneyMedicalCorpMember2019-12-310001429260us-gaap:WarrantMember2020-09-300001429260fbio:CaelumMember2020-09-300001429260us-gaap:WarrantMember2019-12-310001429260fbio:CaelumMember2019-12-310001429260us-gaap:WarrantMemberfbio:CaelumMember2020-01-012020-09-300001429260us-gaap:RestrictedStockMember2020-09-300001429260us-gaap:RestrictedStockUnitsRSUMember2019-09-300001429260us-gaap:RestrictedStockMember2020-01-012020-09-300001429260us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300001429260fbio:TgTherapeuticsIncMemberfbio:SharedServicesAgreementMember2020-09-300001429260fbio:TgTherapeuticsIncMemberfbio:DeskShareAgreementsMember2020-09-300001429260fbio:OpusPointPartnersManagementLlcMemberfbio:DeskShareAgreementsMember2020-09-300001429260fbio:CreditFacilityProvidedMemberfbio:AvenueMember2020-09-300001429260us-gaap:PreferredStockMemberus-gaap:IPOMember2020-01-012020-09-300001429260fbio:CaelumMember2020-01-012020-09-300001429260fbio:TwoThousandEighteenVentureNotesMember2020-09-300001429260fbio:Mustang2019VentureNotesMember2020-09-300001429260fbio:VentureNotesTwoMember2020-01-012020-09-300001429260fbio:VentureNotesThreeMember2020-01-012020-09-300001429260fbio:VentureNoteMember2020-01-012020-09-300001429260fbio:SubordinatedNoteFinancingTwoMember2020-01-012020-09-300001429260fbio:SubordinatedNoteFinancingThreeMember2020-01-012020-09-300001429260fbio:SubordinatedNoteFinancingFourMember2020-01-012020-09-300001429260fbio:SubordinatedNoteFinancingFiveMember2020-01-012020-09-300001429260fbio:Mustang2019VentureDebtMember2020-01-012020-09-300001429260us-gaap:LondonInterbankOfferedRateLIBORMember2020-09-300001429260fbio:VentureNotesTwoMember2020-09-300001429260fbio:VentureNotesThreeMember2020-09-300001429260fbio:VentureNoteMember2020-09-300001429260fbio:SubordinatedNoteFinancingTwoMember2020-09-300001429260fbio:SubordinatedNoteFinancingThreeMember2020-09-300001429260fbio:SubordinatedNoteFinancingOneMember2020-09-300001429260fbio:SubordinatedNoteFinancingFourMember2020-09-300001429260fbio:SubordinatedNoteFinancingFiveMember2020-09-300001429260fbio:SubordinatedNoteFinancing2017OneToFiveMember2020-09-300001429260fbio:OaktreeNoteMember2020-09-300001429260fbio:Notes2019Member2020-09-300001429260fbio:Mustang2019VentureDebtMember2020-09-300001429260fbio:IdbNotePayableMember2020-09-300001429260fbio:OaktreeNoteMember2020-08-270001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2020-07-012020-09-300001429260fbio:DermatologyProductsSalesMember2020-07-012020-09-300001429260fbio:ConsolidatedMember2020-07-012020-09-300001429260fbio:DermatologyProductsSalesMember2020-01-012020-09-300001429260fbio:ConsolidatedMember2020-01-012020-09-300001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2019-07-012019-09-300001429260fbio:DermatologyProductsSalesMember2019-07-012019-09-300001429260fbio:ConsolidatedMember2019-07-012019-09-300001429260fbio:DermatologyProductsSalesMember2019-01-012019-09-300001429260us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001429260fbio:ThreePlTitleModelMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001429260fbio:ThreePlTitleModelMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001429260us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2020-07-012020-09-300001429260us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2020-01-012020-09-300001429260us-gaap:AccountsReceivableMember2020-01-012020-09-300001429260us-gaap:AccountsReceivableMember2019-01-012019-09-300001429260fbio:StockIncentivePlanTwoThousandThirteenMember2020-06-300001429260fbio:StockIncentivePlanTwoThousandThirteenMember2020-06-2900014292602019-06-1600014292602019-06-170001429260us-gaap:PreferredStockMemberus-gaap:OverAllotmentOptionMember2020-08-280001429260fbio:OaktreeWarrantsMember2020-08-270001429260us-gaap:PreferredStockMemberus-gaap:IPOMember2020-08-260001429260us-gaap:PreferredStockMemberus-gaap:IPOMember2020-05-290001429260us-gaap:PreferredStockMemberus-gaap:IPOMember2020-02-1400014292602019-09-3000014292602018-12-310001429260srt:MinimumMember2020-09-300001429260srt:MaximumMember2020-09-300001429260fbio:FirstStageMemberMemberfbio:SPMMember2019-01-092019-02-080001429260fbio:SPMMember2019-01-092019-02-0800014292602018-11-120001429260us-gaap:FairValueInputsLevel3Member2020-09-300001429260us-gaap:FairValueInputsLevel2Member2020-09-300001429260us-gaap:FairValueInputsLevel1Member2020-09-300001429260us-gaap:FairValueInputsLevel3Member2019-12-310001429260us-gaap:FairValueInputsLevel2Member2019-12-310001429260us-gaap:FairValueInputsLevel1Member2019-12-310001429260us-gaap:WarrantMember2020-01-012020-09-300001429260us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001429260fbio:UnvestedRestrictedStockUnitsMember2020-01-012020-09-300001429260fbio:UnvestedRestrictedStockMember2020-01-012020-09-300001429260us-gaap:WarrantMember2019-01-012019-09-300001429260us-gaap:EmployeeStockOptionMember2019-01-012019-09-300001429260fbio:UnvestedRestrictedStockUnitsMember2019-01-012019-09-300001429260fbio:UnvestedRestrictedStockMember2019-01-012019-09-300001429260fbio:JourneyMedicalCorporationMember2020-01-012020-09-300001429260us-gaap:LetterOfCreditMemberus-gaap:LetterOfCreditMember2020-07-012020-09-300001429260fbio:TwoThousandNineteenNoteMember2020-07-012020-09-300001429260fbio:TwoThousandEighteenVentureNotesMember2020-07-012020-09-300001429260fbio:SubordinatedNoteFinancingOneMember2020-07-012020-09-300001429260fbio:OtherMember2020-07-012020-09-300001429260fbio:OaktreeNoteMember2020-07-012020-09-300001429260fbio:NscNotesPayableMember2020-07-012020-09-300001429260fbio:Mustang2019VentureNotesMember2020-07-012020-09-300001429260fbio:IdbNotePayableMember2020-07-012020-09-300001429260us-gaap:LetterOfCreditMember2020-01-012020-09-300001429260fbio:TwoThousandNineteenNoteMember2020-01-012020-09-300001429260fbio:TwoThousandEighteenVentureNotesMember2020-01-012020-09-300001429260fbio:SubordinatedNoteFinancingOneMember2020-01-012020-09-300001429260fbio:OtherMember2020-01-012020-09-300001429260fbio:NscNotesPayableMember2020-01-012020-09-300001429260fbio:Mustang2019VentureNotesMember2020-01-012020-09-300001429260fbio:IdbNotePayableMember2020-01-012020-09-300001429260us-gaap:LetterOfCreditMemberus-gaap:LetterOfCreditMember2019-07-012019-09-300001429260fbio:TwoThousandNineteenNoteMember2019-07-012019-09-300001429260fbio:TwoThousandEighteenVentureNotesMember2019-07-012019-09-300001429260fbio:SubordinatedNoteFinancingOneMember2019-07-012019-09-300001429260fbio:OtherMember2019-07-012019-09-300001429260fbio:OaktreeNoteMember2019-07-012019-09-300001429260fbio:NscNotesPayableMember2019-07-012019-09-300001429260fbio:Mustang2019VentureNotesMember2019-07-012019-09-300001429260fbio:IdbNotePayableMember2019-07-012019-09-300001429260us-gaap:LetterOfCreditMember2019-01-012019-09-300001429260fbio:TwoThousandNineteenNoteMember2019-01-012019-09-300001429260fbio:TwoThousandEighteenVentureNotesMember2019-01-012019-09-300001429260fbio:SubordinatedNoteFinancingOneMember2019-01-012019-09-300001429260fbio:OtherMember2019-01-012019-09-300001429260fbio:OaktreeNoteMember2019-01-012019-09-300001429260fbio:NscNotesPayableMember2019-01-012019-09-300001429260fbio:Mustang2019VentureNotesMember2019-01-012019-09-300001429260fbio:IdbNotePayableMember2019-01-012019-09-300001429260fbio:XiminoAgreementMember2020-01-012020-09-300001429260fbio:XiminoAgreementMember2019-01-012019-09-300001429260us-gaap:EmployeeStockOptionMemberus-gaap:EmployeeStockMember2020-07-012020-09-300001429260us-gaap:WarrantMember2020-07-012020-09-300001429260us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001429260us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001429260fbio:OtherMember2020-07-012020-09-300001429260fbio:NonEmployeeAwardsMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMember2020-07-012020-09-300001429260fbio:ExecutiveAwardsMember2020-07-012020-09-300001429260fbio:EmployeeAwardsMember2020-07-012020-09-300001429260fbio:CheckpointMember2020-07-012020-09-300001429260fbio:AvenueMember2020-07-012020-09-300001429260us-gaap:EmployeeStockOptionMemberus-gaap:EmployeeStockMember2020-01-012020-09-300001429260us-gaap:WarrantMember2020-01-012020-09-300001429260us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001429260us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001429260fbio:OtherMember2020-01-012020-09-300001429260fbio:NonEmployeeAwardsMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMember2020-01-012020-09-300001429260fbio:ExecutiveAwardsMember2020-01-012020-09-300001429260fbio:EmployeeAwardsMember2020-01-012020-09-300001429260fbio:CheckpointMember2020-01-012020-09-300001429260fbio:AvenueMember2020-01-012020-09-300001429260us-gaap:EmployeeStockOptionMemberus-gaap:EmployeeStockMember2019-07-012019-09-300001429260us-gaap:WarrantMember2019-07-012019-09-300001429260us-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-300001429260us-gaap:GeneralAndAdministrativeExpenseMember2019-07-012019-09-300001429260fbio:OtherMember2019-07-012019-09-300001429260fbio:NonEmployeeAwardsMember2019-07-012019-09-300001429260fbio:MustangTherapeuticsIncMember2019-07-012019-09-300001429260fbio:ExecutiveAwardsMember2019-07-012019-09-300001429260fbio:EmployeeAwardsMember2019-07-012019-09-300001429260fbio:CheckpointMember2019-07-012019-09-300001429260fbio:AvenueMember2019-07-012019-09-300001429260us-gaap:EmployeeStockOptionMemberus-gaap:EmployeeStockMember2019-01-012019-09-300001429260us-gaap:WarrantMember2019-01-012019-09-300001429260us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-300001429260us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-09-300001429260fbio:OtherMember2019-01-012019-09-300001429260fbio:NonEmployeeAwardsMember2019-01-012019-09-300001429260fbio:MustangTherapeuticsIncMember2019-01-012019-09-300001429260fbio:ExecutiveAwardsMember2019-01-012019-09-300001429260fbio:EmployeeAwardsMember2019-01-012019-09-300001429260fbio:CheckpointMember2019-01-012019-09-300001429260fbio:AvenueMember2019-01-012019-09-300001429260fbio:CustomerTwoMemberus-gaap:AccountsReceivableMember2019-09-300001429260fbio:CustomerOneMemberus-gaap:AccountsReceivableMember2019-09-300001429260us-gaap:TreasuryStockPreferredMember2020-01-012020-09-300001429260fbio:ThirdAnniversaryOfExecutionMemberfbio:LicenseAndSupplyAgreementMember2020-07-292020-07-290001429260fbio:SecondAnniversaryOfExecutionMemberfbio:LicenseAndSupplyAgreementMember2020-07-292020-07-290001429260fbio:FirstAnniversaryOfExecutionMemberfbio:LicenseAndSupplyAgreementMember2020-07-292020-07-290001429260fbio:CheckpointTherapeuticsIncMemberfbio:FoundersAgreementMemberus-gaap:CommonStockMemberfbio:MarketOfferingMember2020-01-012020-09-300001429260us-gaap:SeriesAPreferredStockMember2020-07-012020-09-300001429260us-gaap:SeriesAPreferredStockMember2020-01-012020-09-300001429260fbio:Oncogenuity.Member2020-05-012020-05-310001429260srt:MaximumMemberfbio:Oncogenuity.Member2020-05-310001429260fbio:Oncogenuity.Member2020-07-012020-09-300001429260fbio:MustangBioIncMember2020-07-012020-09-300001429260fbio:CellvationMember2020-07-012020-09-300001429260fbio:Oncogenuity.Member2020-01-012020-09-300001429260fbio:CellvationMember2020-01-012020-09-300001429260fbio:CellvationMember2019-07-012019-09-300001429260fbio:Oncogenuity.Member2019-01-012019-12-310001429260fbio:CellvationMember2019-01-012019-09-300001429260us-gaap:WarrantMember2020-01-012020-09-300001429260us-gaap:WarrantMember2020-09-300001429260us-gaap:WarrantMember2019-12-310001429260us-gaap:RestrictedStockMember2020-01-012020-09-300001429260fbio:MustangTherapeuticsIncMember2020-01-012020-09-300001429260fbio:AevitasTherapeuticsIncMember2020-01-012020-09-300001429260fbio:CaelumMember2019-01-012019-01-300001429260fbio:SirionTechnologyLicenseMemberus-gaap:LicensingAgreementsMemberfbio:DevelopmentMilestoneMember2020-09-302020-09-300001429260fbio:SirionTechnologyLicenseMemberus-gaap:LicensingAgreementsMemberfbio:AdditionalMilestonePaymentsMember2020-09-302020-09-300001429260fbio:ColumbiaLicenseMemberus-gaap:LicensingAgreementsMemberfbio:SaleMillstoneMember2020-01-012020-09-300001429260fbio:ColumbiaLicenseMemberus-gaap:LicensingAgreementsMemberfbio:ProductMilestoneMember2020-01-012020-09-300001429260fbio:ColumbiaLicenseMemberus-gaap:LicensingAgreementsMemberfbio:DevelopmentMilestoneMember2020-01-012020-09-300001429260srt:ChiefExecutiveOfficerMember2020-09-300001429260fbio:ExecutivesViceChairmanMember2020-09-300001429260fbio:CaelumWarrantLiabilitiesMember2020-07-012020-09-300001429260fbio:AlexionMember2019-01-012019-01-310001429260fbio:OaktreeWarrantsMember2020-08-292020-08-290001429260fbio:MustangBioIncMember2020-07-012020-09-300001429260fbio:SirionTechnologyLicenseMemberus-gaap:LicensingAgreementsMember2020-07-012020-09-300001429260fbio:MustangTherapeuticsIncMemberfbio:St.JudeXscidMember2020-07-012020-07-010001429260fbio:ColumbiaLicenseMemberus-gaap:LicensingAgreementsMember2020-05-062020-05-060001429260fbio:SirionTechnologyLicenseMemberus-gaap:LicensingAgreementsMember2020-01-012020-09-300001429260fbio:OaktreeNoteMember2020-01-012020-09-300001429260fbio:OaktreeNoteMember2020-08-272020-08-270001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2019-01-012019-09-300001429260fbio:ConsolidatedMember2019-01-012019-09-300001429260fbio:OaktreeWarrantsMember2020-08-290001429260fbio:SlabTwoMemberfbio:AvenueMembersrt:MinimumMemberus-gaap:SalesMember2020-01-012020-09-300001429260fbio:SlabTwoMemberfbio:AvenueMembersrt:MaximumMemberus-gaap:SalesMember2020-01-012020-09-300001429260fbio:SlabThreeMemberfbio:AvenueMemberus-gaap:SalesMember2020-01-012020-09-300001429260fbio:SlabOneMemberfbio:AvenueMemberus-gaap:SalesMember2020-01-012020-09-300001429260fbio:SlabOneMemberfbio:AvenueMemberfbio:SalesAfterJanuaryOneTwentyThousandTwentyNineMember2020-01-012020-09-300001429260fbio:AvenueMemberus-gaap:SalesMember2020-01-012020-09-300001429260fbio:ColumbiaLicenseMemberus-gaap:LicensingAgreementsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2020-07-012020-09-300001429260fbio:ColumbiaLicenseMemberus-gaap:LicensingAgreementsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2020-01-012020-09-300001429260fbio:TamidMember2020-09-300001429260fbio:Oncogenuity.Member2020-09-300001429260fbio:MustangTherapeuticsIncMember2020-09-300001429260fbio:JmcMember2020-09-300001429260fbio:HelocyteMember2020-09-300001429260fbio:CypriumMember2020-09-300001429260fbio:CoronadoSoCoIncMember2020-09-300001429260fbio:CheckpointTherapeuticsIncMember2020-09-300001429260fbio:CellvationMember2020-09-300001429260fbio:BaergicMember2020-09-300001429260fbio:AvenueMember2020-09-300001429260fbio:AevitasMember2020-09-300001429260fbio:TamidMember2019-12-310001429260fbio:MustangTherapeuticsIncMember2019-12-310001429260fbio:JmcMember2019-12-310001429260fbio:HelocyteMember2019-12-310001429260fbio:CypriumMember2019-12-310001429260fbio:CoronadoSoCoIncMember2019-12-310001429260fbio:CheckpointTherapeuticsIncMember2019-12-310001429260fbio:CellvationMember2019-12-310001429260fbio:BaergicMember2019-12-310001429260fbio:AvenueMember2019-12-310001429260fbio:AevitasMember2019-12-310001429260fbio:MustangBioIncMember2020-06-012020-06-300001429260fbio:SubordinatedNoteFinancing2017OneToFiveMember2020-01-012020-09-300001429260us-gaap:PreferredStockMemberus-gaap:IPOMember2020-08-282020-08-280001429260us-gaap:PreferredStockMemberus-gaap:IPOMember2020-05-292020-05-290001429260us-gaap:PreferredStockMemberus-gaap:IPOMember2020-02-142020-02-140001429260us-gaap:SeriesAPreferredStockMember2019-07-012019-09-300001429260us-gaap:SeriesAPreferredStockMember2019-01-012019-09-300001429260fbio:FoundersAgreementMemberfbio:MustangBioIncMemberus-gaap:CommonStockMemberfbio:MarketOfferingMember2020-01-012020-09-300001429260fbio:FoundersAgreementMemberfbio:MustangBioIncMemberus-gaap:CommonStockMemberfbio:MarketOfferingMember2019-01-012019-09-300001429260fbio:CaelumMember2020-01-012020-09-300001429260fbio:SlabTwoMemberfbio:AvenueMember2020-01-012020-09-300001429260fbio:SlabThreeMemberfbio:AvenueMember2020-01-012020-09-300001429260fbio:SlabOneMemberfbio:AvenueMember2020-01-012020-09-300001429260fbio:XiminoMemberfbio:JourneyMedicalCorporationMember2020-09-300001429260fbio:ExeldermMemberfbio:JourneyMedicalCorporationMember2020-09-300001429260fbio:JourneyMedicalCorporationMember2020-09-300001429260us-gaap:MeasurementInputSharePriceMemberfbio:CaelumMember2020-01-012020-09-300001429260us-gaap:MeasurementInputRiskFreeInterestRateMemberfbio:CaelumMember2020-01-012020-09-300001429260fbio:CaelumWarrantLiabilitiesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-01-012020-09-300001429260fbio:CaelumWarrantLiabilitiesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2019-01-012019-12-3100014292602019-01-012019-12-310001429260fbio:CaelumWarrantLiabilitiesMemberus-gaap:MeasurementInputPriceVolatilityMember2020-01-012020-09-300001429260fbio:CaelumWarrantLiabilitiesMemberus-gaap:MeasurementInputPriceVolatilityMember2019-01-012019-12-310001429260fbio:CaelumWarrantLiabilitiesMemberus-gaap:MeasurementInputExpectedTermMember2020-01-012020-09-300001429260fbio:CaelumWarrantLiabilitiesMemberus-gaap:MeasurementInputExpectedTermMember2019-01-012019-12-310001429260fbio:CaelumWarrantLiabilitiesMemberus-gaap:MeasurementInputExpectedDividendRateMember2020-01-012020-09-300001429260fbio:CaelumWarrantLiabilitiesMemberus-gaap:MeasurementInputExpectedDividendRateMember2019-01-012019-12-310001429260us-gaap:MeasurementInputPriceVolatilityMemberfbio:CaelumMember2020-01-012020-09-300001429260fbio:MeasurementInputInvestmentsMemberfbio:CaelumMember2019-01-012019-12-310001429260fbio:OaktreeWarrantsMember2020-08-272020-08-270001429260fbio:OaktreeWarrantsMember2020-01-012020-09-300001429260us-gaap:WarrantMember2020-01-012020-09-300001429260fbio:LicenseAndSupplyAgreementMember2020-01-012020-09-300001429260us-gaap:EmployeeStockOptionMemberus-gaap:EmployeeStockMember2020-09-300001429260fbio:Oncogenuity.Member2020-09-300001429260fbio:MustangBioIncMember2020-09-300001429260fbio:HelocyteIncMember2020-09-300001429260fbio:CypriumBioSciencesIncMember2020-09-300001429260fbio:CheckpointTherapeuticsIncMember2020-09-300001429260fbio:CellvationIncMember2020-09-300001429260fbio:CaelumMember2020-09-300001429260fbio:BaergicMember2020-09-300001429260fbio:AvenueMember2020-09-300001429260fbio:AevitasIncMember2020-09-300001429260fbio:Notes2019Member2019-09-132019-09-130001429260fbio:CreditFacilityProvidedMemberfbio:AvenueMember2020-06-122020-06-120001429260fbio:AvenueMemberfbio:SalesAfterJanuaryOneTwentyThousandTwentyNineMember2020-01-012020-09-300001429260fbio:ShelfTwoThousandTwentyMember2020-09-300001429260fbio:MustangBioIncMember2020-09-300001429260fbio:StockIncentivePlanTwoThousandThirteenMember2020-01-012020-09-300001429260us-gaap:CommonStockMember2020-07-012020-09-300001429260fbio:CommonSharesIssuableMember2020-07-012020-09-300001429260fbio:CommonSharesIssuableMember2020-01-012020-09-300001429260us-gaap:CommonStockMember2019-07-012019-09-300001429260us-gaap:CommonStockMember2019-01-012019-09-300001429260fbio:OpusCreditFacilityMember2019-01-012019-09-300001429260fbio:CommonSharesIssuableMember2019-07-012019-09-300001429260fbio:CheckpointTherapeuticsIncMemberus-gaap:CommonStockMemberfbio:MarketOfferingMember2020-09-012020-09-300001429260us-gaap:PreferredStockMemberus-gaap:IPOMember2020-08-262020-08-260001429260fbio:MustangBioIncMemberus-gaap:CommonStockMemberfbio:MarketOfferingMember2020-06-012020-06-300001429260us-gaap:PreferredStockMemberfbio:MarketOfferingMember2020-05-292020-05-290001429260us-gaap:PreferredStockMemberfbio:MarketOfferingMember2020-02-142020-02-140001429260us-gaap:CommonStockMemberfbio:MarketOfferingMember2020-01-012020-09-300001429260fbio:MustangBioIncMemberus-gaap:CommonStockMemberfbio:MarketOfferingMember2019-01-012019-09-300001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2020-09-300001429260fbio:DermatologyProductsSalesMember2020-09-300001429260fbio:ConsolidatedMember2020-09-300001429260fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember2019-09-300001429260fbio:DermatologyProductsSalesMember2019-09-300001429260fbio:ConsolidatedMember2019-09-300001429260fbio:XiminoAgreementMember2020-09-300001429260fbio:XiminoAgreementMember2019-12-310001429260fbio:LicenseAndSupplyAgreementMember2020-07-292020-07-290001429260fbio:LicenseAndSupplyAgreementMember2020-07-290001429260fbio:FortressBiotechIncMember2020-01-012020-09-300001429260fbio:Oncogenuity.Member2020-01-012020-09-300001429260fbio:MustangBioIncMember2020-01-012020-09-300001429260fbio:HelocyteIncMember2020-01-012020-09-300001429260fbio:CypriumBioSciencesIncMember2020-01-012020-09-300001429260fbio:CheckpointTherapeuticsIncMember2020-01-012020-09-300001429260fbio:CellvationIncMember2020-01-012020-09-300001429260fbio:BaergicMember2020-01-012020-09-300001429260fbio:AvenueMember2020-01-012020-09-300001429260fbio:AevitasIncMember2020-01-012020-09-300001429260fbio:CreditFacilityProvidedMemberfbio:AvenueMember2020-06-120001429260fbio:MustangBioIncMemberus-gaap:CommonStockMemberfbio:MarketOfferingMember2020-01-012020-09-300001429260fbio:CheckpointTherapeuticsIncMemberus-gaap:CommonStockMemberfbio:MarketOfferingMember2020-01-012020-09-3000014292602019-07-012019-09-300001429260fbio:CommonSharesIssuableMember2019-01-012019-09-3000014292602020-07-012020-09-3000014292602019-01-012019-09-300001429260us-gaap:RestrictedStockUnitsRSUMemberfbio:MustangBioIncMember2020-01-012020-09-300001429260us-gaap:RestrictedStockUnitsRSUMemberfbio:MustangBioIncMember2019-01-012019-09-300001429260us-gaap:NoncontrollingInterestMember2020-07-012020-09-300001429260us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001429260us-gaap:NoncontrollingInterestMember2020-01-012020-09-300001429260us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300001429260us-gaap:NoncontrollingInterestMember2019-07-012019-09-300001429260us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300001429260us-gaap:NoncontrollingInterestMember2019-01-012019-09-300001429260us-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-300001429260fbio:AlexionMemberfbio:CaelumMember2019-12-012019-12-3100014292602020-09-3000014292602019-12-310001429260us-gaap:CommonStockMember2020-01-012020-09-300001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2020-01-012020-09-300001429260us-gaap:CommonStockMember2020-11-050001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2020-11-0500014292602020-01-012020-09-30xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesfbio:Milestonefbio:itemiso4217:EURfbio:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from       to

Commission File Number 001-35366

FORTRESS BIOTECH, INC.

(Exact name of registrant as specified in its charter)

Delaware

20-5157386

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

2 Gansevoort Street, 9th Floor

New York, New York 10014

(Address including zip code of principal executive offices)

(781) 652-4500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Class

Trading Symbol(s)

Exchange Name

Common Stock

FBIO

Nasdaq Capital Market

9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

FBIOP

Nasdaq Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes     No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes     No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes     No  

Class of Stock

   

Outstanding Shares as of November 5, 2020

Common Stock, $0.001 par value

93,702,861

9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.001 par value

3,427,138

PART I.         FINANCIAL INFORMATION

Item 1.    Unaudited Condensed Consolidated Financial Statements

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

($ in thousands except for share and per share amounts)

September 30, 

December 31, 

2020

2019

 

(Unaudited)

ASSETS

 

  

 

  

Current assets

 

  

 

  

Cash and cash equivalents

$

218,389

$

136,858

Accounts receivable (net of allowance for doubtful accounts of $147 and $100 at September 30, 2020 and December 31, 2019, respectively)

 

15,653

 

13,539

Inventory

 

1,052

 

857

Other receivables - related party

 

939

 

865

Prepaid expenses and other current assets

 

1,704

 

4,133

Total current assets

 

237,737

 

156,252

Property and equipment, net

 

12,114

 

12,433

Operating lease right-of-use asset, net

 

20,265

 

21,480

Restricted cash

 

1,645

 

16,574

Long-term investment, at fair value

 

11,723

 

11,148

Intangible asset, net

 

11,039

 

7,377

Other assets

 

1,356

 

1,158

Total assets

$

295,879

$

226,422

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

  

 

  

Current liabilities

 

 

  

Accounts payable and accrued expenses

$

32,542

$

35,451

Accounts payable and accrued expenses - related party

 

19

 

Interest payable

 

23

 

1,042

Interest payable - related party

 

 

92

Notes payable, short-term

 

 

7,220

Operating lease liabilities – short-term

 

1,697

 

1,784

Derivative warrant liability

 

 

27

Other current liabilities

3,000

Total current liabilities

 

37,281

 

45,616

Notes payable, long-term (net of debt discount of $8,607 and $5,086 at September 30, 2020 and December 31, 2019, respectively)

 

51,393

 

77,436

Operating lease liabilities – long-term

 

22,855

 

23,712

Other long-term liabilities

 

8,205

 

7,126

Total liabilities

119,734

153,890

 

 

1

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

($ in thousands except for share and per share amounts)

September 30, 

December 31, 

2020

2019

    

(Unaudited)

    

Commitments and contingencies

 

  

 

  

Stockholders’ equity

 

  

 

  

Preferred stock, $.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 and 1,341,167 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively; liquidation value of $25.00 per share

 

3

 

1

Common stock, $.001 par value, 150,000,000 shares authorized, 93,748,374 and 74,027,425 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

 

94

 

74

Common stock issuable, 5,451 and 251,337 shares as of September 30, 2020 and December 31, 2019, respectively

 

18

 

500

Additional paid-in-capital

 

574,461

 

461,874

Accumulated deficit

 

(477,465)

 

(436,234)

Total stockholders' equity attributed to the Company

 

97,111

 

26,215

Non-controlling interests

 

79,034

 

46,317

Total stockholders' equity

 

176,145

 

72,532

Total liabilities and stockholders' equity

$

295,879

$

226,422

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

($ in thousands except for share and per share amounts)

(Unaudited)

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2020

    

2019

    

2020

    

2019

    

Revenue

 

  

 

  

 

  

 

  

 

Product revenue, net

$

9,447

$

9,492

$

30,808

$

23,816

Revenue - related party

 

28

 

280

 

1,042

 

1,683

Net revenue

 

9,475

 

9,772

 

31,850

 

25,499

Operating expenses

 

 

 

 

Cost of goods sold - product revenue

 

3,379

 

2,702

 

10,313

 

6,972

Research and development

 

13,298

 

14,571

 

43,868

 

56,355

Research and development - licenses acquired

 

458

 

700

 

2,278

 

1,350

General and administrative

 

15,383

 

14,339

 

45,358

 

41,260

Total operating expenses

 

32,518

 

32,312

 

101,817

 

105,937

Loss from operations

 

(23,043)

 

(22,540)

 

(69,967)

 

(80,438)

Other income (expense)

 

  

 

  

 

  

 

  

Interest income

 

265

 

738

 

1,228

 

1,955

Interest expense and financing fee

 

(6,958)

 

(3,168)

 

(13,142)

 

(8,743)

Change in fair value of derivative liability

 

(803)

 

 

(1,189)

 

Change in fair value of investments

 

575

 

 

575

 

Gain on deconsolidation of Caelum

 

 

 

 

18,521

Total other income (expense)

 

(6,921)

 

(2,430)

 

(12,528)

 

11,733

Net loss

 

(29,964)

 

(24,970)

 

(82,495)

 

(68,705)

Less: net loss attributable to non-controlling interests

 

14,417

 

12,208

 

41,264

 

44,237

Net loss attributable to common stockholders

$

(15,547)

$

(12,762)

$

(41,231)

$

(24,468)

Net loss per common share - basic and diluted

$

(0.39)

$

(0.44)

$

(1.19)

$

(1.29)

Net loss per common share attributable to non - controlling interests - basic and diluted

$

(0.19)

$

(0.21)

$

(0.59)

$

(0.83)

Net loss per common share attributable to common stockholders - basic and diluted

$

(0.20)

$

(0.22)

$

(0.59)

$

(0.46)

Weighted average common shares outstanding - basic and diluted

 

76,093,211

 

56,856,821

 

69,404,499

 

53,060,565

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Condensed Consolidated Statement of Changes in Stockholders’ Equity

($ in thousands)

(Unaudited)

For the Three Months Ended September 30, 2020

Total

Series A

Stockholders’

Preferred Stock

Common Stock

Shares

Treasury

Paid-In

Accumulated

Non-Controlling

Equity

    

Shares

    

Amount

    

Shares

    

Amount

    

Issuable

Stock

    

Capital

    

Deficit

    

Interests

    

(Deficit)

Balance at June 30, 2020

 

2,693,806

    

$

3

    

86,113,331

    

$

86

    

$

813

$

    

$

521,493

    

$

(461,918)

    

$

56,381

    

$

116,858

Stock-based compensation expense

 

 

 

 

 

 

3,171

 

 

 

3,171

Issuance of common stock related to equity plans

 

 

 

268,800

 

 

 

 

 

 

Issuance of common stock for at-the-market offering, net

 

 

7,064,214

 

7

 

 

21,110

 

 

 

21,117

Preferred A dividends declared and paid

 

 

 

 

 

 

(1,719)

 

 

 

(1,719)

Issuance of Series A preferred stock for cash, net

 

733,332

 

 

 

 

 

11,965

 

 

 

11,965

Partner company’s offering, net

 

 

 

 

 

 

18,774

 

 

 

18,774

Partner company’s at-the-market offering, net

 

 

 

 

 

 

23,053

 

 

 

23,053

Partner company’s preferred stock offering, net

7,088

7,088

Issuance of common stock under partner company’s ESPP

180

180

Partner company’s dividends declared and paid

 

 

 

 

 

 

(50)

 

 

 

(50)

Reclass partner company's warrants from liability to equity

 

 

 

 

 

 

1,216

 

 

 

1,216

Issuance of partner company’s common shares for research and development expenses

 

 

 

 

 

 

21

 

 

 

21

Common shares issued for 2017 Subordinated Note Financing interest expense

 

 

302,029

 

1

 

(500)

 

810

 

 

 

311

Write off common shares issuable for 2019 Notes interest expense

 

 

 

 

 

(313)

 

 

 

 

(313)

Common shares issuable for service

18

18

Issuance of warrants in conjunction with Oaktree Note

4,419

4,419

Non-controlling interest in partner companies

(37,070)

37,070

Net loss attributable to non-controlling interest

(14,417)

(14,417)

Net loss attributable to common stockholders

 

 

 

 

 

 

 

(15,547)

 

 

(15,547)

Balance at September 30, 2020

 

3,427,138

    

$

3

    

93,748,374

    

$

94

    

$

18

$

    

$

574,461

    

$

(477,465)

    

$

79,034

    

$

176,145

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Condensed Consolidated Statement of Changes in Stockholders’ Equity

($ in thousands)

(Unaudited)

For the Three Months Ended September 30, 2019

Series A

Total

Preferred Stock

Common Stock

Shares

Paid-In

Accumulated

Non-Controlling

Stockholders’

    

Shares

    

Amount

    

Shares

    

Amount

    

Issuable

Capital

    

Deficit

    

Interests

    

Equity

Balance at June 30, 2019

 

1,000,000

    

$

1

    

68,138,203

    

$

68

    

$

490

$

439,295

    

$

(407,980)

    

$

57,946

    

$

89,820

Stock-based compensation expense

 

 

 

 

 

3,741

 

 

 

3,741

Issuance of restricted stock

 

 

 

177,292

 

 

 

 

 

Issuance of common stock for at-the-market offering, net

1,213,643

1

1,930

1,931

Issuance of preferred A for at-the-market offering, net

26,111

523

523

Preferred A dividends declared and paid

 

 

 

 

(601)

 

 

 

(601)

Partner company’s offering, net

 

 

 

 

 

52

 

 

 

52

Partner company’s at-the-market offering, net

 

 

 

 

 

3,341

 

 

 

3,341

Common shares issuable for 2017 Subordinated Note Financing interest expense

 

 

 

 

500

 

 

 

500

Common shares issued for 2017 Subordinated Note Financing interest expense

317,804

1

(490)

489

Common shares issued for 2019 Notes interest expense

 

 

 

91,767

 

 

165

 

 

 

165

Common shares issued for 2019 Notes debt repayment

396,825

500

500

Non-controlling interest in subsidiaries

(3,467)

3,467

Write off of partner company note receivable

(2)

(2)

Net loss attributable to non-controlling interest

(12,208)

(12,208)

Net loss attributable to common stockholders

 

 

 

 

 

 

(12,762)

 

 

(12,762)

Balance at September 30, 2019

 

1,026,111

    

$

1

    

70,335,534

    

$

70

    

$

500

$

445,966

    

$

(420,742)

    

$

49,205

    

$

75,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Condensed Consolidated Statement of Changes in Stockholders’ Equity

($ in thousands)

(Unaudited)

For the Nine Months Ended September 30, 2020

Total

Series A

Stockholders’

Preferred Stock

Common Stock

Shares

Treasury

Paid-In

Accumulated

Non-Controlling

Equity

Shares

Amount

Shares

Amount

Issuable

Stock

Capital

Deficit

Interests

(Deficit)

Balance at December 31, 2019

    

1,341,167

    

$

1

    

74,027,425

    

$

74

    

$

500

    

$

$

461,874

    

$

(436,234)

    

$

46,317

    

$

72,532

Stock-based compensation expense

 

 

 

 

 

 

10,319

 

 

 

10,319

Issuance of common stock related to equity plans

 

 

 

2,307,231

 

2

 

 

(2)

 

 

 

Issuance of common stock under ESPP

 

 

53,268

 

 

 

90

 

 

 

90

Issuance of common stock for at-the-market offering, net

16,378,234

17

43,183

43,200

Preferred A dividends declared and paid

 

 

 

 

 

 

(4,507)

 

 

 

(4,507)

Repurchase of Series A preferred stock, net

 

(5,000)

 

 

 

 

 

(70)

(2)

 

 

 

(72)

Retirement of Series A preferred stock

 

 

 

 

 

 

70

(70)

 

 

 

Issuance of Series A preferred stock for cash, net

2,090,971

 

2

 

 

 

 

35,466

 

 

 

35,468

Partner company’s offering, net

 

 

 

 

 

 

53,698

 

 

 

53,698

Partner companies' at-the-market offering, net

 

 

 

 

 

 

33,500

 

 

 

33,500

Partner company’s preferred stock offering, net

 

 

 

 

 

 

7,088

 

 

 

7,088

Issuance of common stock under partner company’s ESPP

 

 

 

 

 

 

349

 

 

349

Partner company’s dividends declared and paid

 

 

 

 

 

 

(50)

 

 

 

(50)

Partner company’s exercise of warrants for cash

 

 

 

 

 

 

13

 

 

 

13

Reclass partner company's warrants from liability to equity

 

 

 

 

 

 

1,216

 

 

 

1,216

Issuance of partner company’s common shares for research and development expenses

 

 

 

 

 

 

42

 

 

 

42

Common shares issued for 2017 Subordinated Note Financing interest expense

982,216

1

(500)

1,816

1,317

Common shares issuable for service

18

18

Issuance of warrants in conjunction with Oaktree Note

4,419

4,419

Non-controlling interest in partner companies

(73,981)

73,981

Net loss attributable to non-controlling interest

(41,264)

(41,264)

Net loss attributable to common stockholders

(41,231)

(41,231)

Balance at September 30, 2020

 

3,427,138

$

3

 

93,748,374

$

94

$

18

$

$

574,461

$

(477,465)

$

79,034

$

176,145

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Condensed Consolidated Statement of Changes in Stockholders’ Equity

($ in thousands)

(Unaudited)

For the Nine Months Ended September 30, 2019

Series A

Common

Additional

Total

Preferred Stock

Common Stock

Shares

Paid-In

Accumulated

Non-Controlling

Stockholders’

Shares

Amount

Shares

Amount

Issuable

Capital

Deficit

Interests

Equity

Balance at December 31, 2018

    

1,000,000

    

$

1

    

57,845,447

    

$

58

    

$

659

    

$

397,408

$

(396,274)

    

$

17,891

    

$

19,743

Stock-based compensation expense

 

 

 

 

 

 

10,423

 

 

10,423

Issuance of restricted stock

 

 

 

1,842,034

 

2

 

 

(2)

 

 

Issuance of common stock under ESPP

 

 

54,221

 

 

 

60

 

 

60

Issuance of subsidiaries’ common shares for license expenses

 

 

 

 

 

(164)

 

164

 

 

Issuance of common stock for at-the-market offering, net

8,604,469

9

15,789

15,798

Issuance of Series A preferred stock for at-the-market offering, net

26,111

523

523

Preferred A dividends declared and paid

 

 

 

 

 

 

(1,773)

 

 

(1,773)

Partner company’s offering, net

 

 

 

 

 

 

61,036

 

 

61,036

Partner company’s at-the-market offering, net

 

 

 

 

 

 

29,680

 

 

29,680

Issuance of partner company warrants in conjunction with Horizon Notes

888

888

Common shares issuable for 2017 Subordinated Note Financing interest expense

 

 

 

 

500

 

 

 

500

Common shares issued for 2017 Subordinated Note Financing interest expense

 

 

 

1,330,450

 

1

 

(495)

 

1,468

 

 

974

Common shares issuable for 2019 Notes interest expense

 

 

 

 

 

281

 

 

 

281

Common shares issued for 2019 Notes interest expense

 

 

 

262,088

 

 

(281)

 

506

 

 

225

Common shares issued for 2019 Notes debt repayment

 

396,825

500

 

500

Non-controlling interest in subsidiaries

 

 

 

 

 

 

(70,702)

 

70,702

 

Write off of partner company note receivable

 

 

 

(2)

 

(2)

Deconsolidation of Caelum non-controlling interest

 

 

 

 

 

 

 

4,849

 

4,849

Net loss attributable to non-controlling interest

 

 

 

 

 

 

 

(44,237)

 

(44,237)

Net loss attributable to common stockholders

 

 

 

 

 

 

(24,468)

 

 

(24,468)

Balance at September 30, 2019

 

1,026,111

$

1

 

70,335,534

$

70

$

500

$

445,966

$

(420,742)

$

49,205

$

75,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

($ in thousands)

(Unaudited)

Nine Months Ended September 30, 

    

2020

    

2019

Cash Flows from Operating Activities:

 

  

 

  

Net loss

$

(82,495)

$

(68,705)

Reconciliation of net loss to net cash used in operating activities:

 

  

 

  

Depreciation expense

 

1,676

 

1,414

Bad debt expense

47

 

250

Amortization of debt discount

 

5,319

 

2,459

Non-cash interest

492

Amortization of product revenue license fee

 

1,065

 

820

Amortization of operating lease right-of-use assets

 

1,214

 

1,150

Stock-based compensation expense

 

10,319

 

10,423

Issuance of partner company’s common shares for research and development expenses

 

42

 

Common shares issuable for 2017 Subordinated Note Financing interest expense

 

 

500

Common shares issued for 2017 Subordinated Note Financing interest expense

1,317

974

Common shares issuable for 2019 Notes interest expense

281

Common shares issued for 2019 Notes interest expense

225

Common shares issuable for service

18

Change in fair value of derivative liability

 

1,189

 

Change in fair value of investment

 

(575)

 

Gain on deconsolidation of Caelum

 

 

(18,521)

Research and development-licenses acquired, expense

 

2,236

 

1,350

Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:

 

  

 

  

Accounts receivable

 

(2,161)

 

111

Inventory

 

(195)

 

(263)

Other receivables - related party

 

(74)

 

852

Prepaid expenses and other current assets

 

2,429

 

1,812

Other assets

 

(198)

 

(903)

Accounts payable and accrued expenses

 

(2,686)

 

(3,841)

Accounts payable and accrued expenses - related party

 

19

 

(149)

Interest payable

 

(1,019)

 

5

Interest payable - related party

 

(92)

 

(8)

Lease liabilities

 

(943)

 

(940)

Other long-term liabilities

 

(140)

 

795

Net cash used in operating activities

 

(63,196)

 

(69,909)

Cash Flows from Investing Activities:

    

  

    

  

Purchase of research and development licenses

 

(3,369)

 

(850)

Purchase of property and equipment

 

(1,228)

 

(1,455)

Purchase of intangible asset

(1,000)

(2,400)

Purchase of short-term investment (certificates of deposit)

(5,000)

Redemption of short-term investment (certificates of deposit)

 

 

17,604

Deconsolidation of Caelum

 

 

(1,201)

Net cash provided by (used in) continuing investing activities

 

(5,597)

 

6,698

Net cash provided by discontinued investing activities

 

 

13,089

Net cash provided by (used in) investing activities

 

(5,597)

 

19,787

8

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

($ in thousands)

(Unaudited)

Nine Months Ended September 30, 

2020

2019

Cash Flows from Financing Activities:

 

  

 

  

Payment of Series A preferred stock dividends

 

$

(4,507)

 

$

(1,773)

Purchase of treasury stock

(70)

Payment of costs related to purchase of treasury stock

 

(2)

 

Proceeds from issuance of Series A preferred stock

39,075

Payment of costs related to issuance of Series A preferred stock

(3,407)

Proceeds from issuance of common stock for at-the-market offering

44,796

16,099

Payment of costs related to issuance of common stock for at-the-market offering

 

(1,506)

 

(301)

Proceeds from issuance of Series A preferred stock for at-the-market offering

539

Payment of costs related to issuance of Series A preferred stock for at-the-market offering

(16)

Proceeds from issuance of common stock under ESPP

90

60

Proceeds from partner companies' ESPP

349

 

Partner company’s dividends declared and paid

(50)

 

Proceeds from partner companies' sale of stock

 

57,729

 

66,623

Payment of costs related to partner companies' sale of stock

 

(3,642)

 

(4,754)

Proceeds from partner companies' at-the-market offering

 

34,254

 

30,419

Payment of costs related to partner companies' at-the-market offering

 

(754)

 

(739)

Proceeds from partner company's preferred stock offering

8,000

Payment of costs related to partner company's preferred stock offering

(912)

Proceeds from exercise of partner company’s warrants

 

13

 

Payment of debt issuance costs associated with 2017 Subordinated Note Financing

 

(93)

 

(79)

Payment of debt issuance costs associated with 2018 Venture Notes

 

(58)

 

(126)

Proceeds from partner company's Horizon Notes

 

 

15,000

Payment of debt issuance costs associated with partner company's Horizon Notes

 

 

(1,393)

Proceeds from Oaktree Note

60,000

Payment of debt issuance costs associated with Oaktree Note

(4,239)

Repayment of 2017 Subordinated Note Financing

(28,356)

Repayment of 2018 Venture Notes

(21,707)

Repayment of 2019 Notes

(9,000)

Repayment of partner company's Horizon Notes

(15,750)

Repayment of IDB Note

 

(14,858)

 

Net cash provided by financing activities

 

135,395

 

119,559

Net increase in cash and cash equivalents and restricted cash

 

66,602

 

69,437

Cash and cash equivalents and restricted cash at beginning of period

 

153,432

 

81,582

Cash and cash equivalents and restricted cash at end of period

$

220,034

$

151,019

Supplemental disclosure of cash flow information:

 

 

Cash paid for interest

$

6,669

$

3,976

Cash paid for interest - related party

$

463

$

342

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

9

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

($ in thousands)

(Unaudited)

Nine Months Ended September 30, 

2020

2019

Supplemental disclosure of non-cash financing and investing activities:

 

  

 

  

Settlement of restricted stock units into common stock

$

2

$

2

Common shares issuable for license acquired

$

$

164

Issuance of partner company warrants in conjunction with Horizon Notes

$

$

888

Issuance of warrants in conjunction with Oaktree Note

$

4,419

$

Common shares issued from 2017 Subordinated Note Financing interest expense

$

500

$

Common shares issued for 2019 Notes

$

$

500

Unpaid fixed assets

$

317

$

288

Partner company's previous paid offering cost

$

$

833

Partner company's unpaid intangible assets

$

3,727

$

4,734

Reclass partner company's warrants from liability to equity

$

1,216

$

Unpaid debt offering cost

$

57

$

Unpaid at-the-market offering cost

$

96

$

Unpaid partner company’s offering cost

$

457

$

Unpaid Series A preferred stock offering cost

$

203

$

Unpaid research and development licenses acquired

$

117

$

Retirement of Series A preferred stock

$

70

$

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

10

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Organization and Description of Business

Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing pharmaceutical and biotechnology products and product candidates, which the Company does at the Fortress level, at its majority-owned and majority-controlled subsidiaries and joint ventures, and at entities the Company founded and in which it maintains significant minority ownership positions. Fortress has a talented and experienced business development team, comprising scientists, doctors and finance professionals, who identify and evaluate promising products and product candidates for potential acquisition by new or existing partner companies. Fortress through its partner companies has executed such arrangements in partnership with some of the world’s foremost universities, research institutes and pharmaceutical companies, including City of Hope National Medical Center, Fred Hutchinson Cancer Research Center, St. Jude Children’s Research Hospital, Dana-Farber Cancer Institute, Nationwide Children’s Hospital, Cincinnati Children’s Hospital Medical Center, Columbia University, the University of Pennsylvania, and AstraZeneca plc.

Following the exclusive license or other acquisition of the intellectual property underpinning a product or product candidate, Fortress leverages its business, scientific, regulatory, legal and finance expertise to help the partners achieve their goals. Partner companies then assess a broad range of strategic arrangements to accelerate and provide additional funding to support research and development, including joint ventures, partnerships, out-licensings, and public and private financings; to date, three partner companies are publicly-traded, and two have consummated strategic partnerships with industry leaders Alexion Pharmaceuticals, Inc. and InvaGen Pharmaceuticals, Inc. (“InvaGen”)(a subsidiary of Cipla Limited).

Several of our partner companies possess licenses to product candidate intellectual property, including Aevitas Therapeutics, Inc. (“Aevitas”), Avenue Therapeutics, Inc. (“Avenue”), Baergic Bio, Inc. (“Baergic”), Caelum Biosciences, Inc. (“Caelum”), Cellvation, Inc. (“Cellvation”), Checkpoint Therapeutics, Inc. (“Checkpoint”), Cyprium Therapeutics, Inc. (“Cyprium”), Helocyte, Inc. (“Helocyte”), Journey Medical Corporation (“Journey” or “JMC”), Mustang Bio, Inc. (“Mustang”) and Oncogenuity, Inc. (“Oncogenuity”).

Liquidity and Capital Resources

Since inception, the Company’s operations have been financed primarily through the sale of equity and debt securities, from the sale of partner companies, and the proceeds from the exercise of warrants and stock options. The Company has incurred losses from operations and negative cash flows from operating activities since inception and expects to continue to incur substantial losses for the next several years as it continues to fully develop and prepare regulatory filings and obtain regulatory approvals for its existing and new product candidates. The Company’s current cash and cash equivalents are sufficient to fund operations for at least the next 12 months. However, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, sale of a partner company, grants or other arrangements to fully develop and prepare regulatory filings and obtain regulatory approvals for the existing and new product candidates, fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for the potential products, sales and marketing capabilities.  If such funding is not available or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed. The Company also has the ability, subject to limitations imposed by Rule 144 of the Securities Act of 1933 and other applicable laws and regulations, to raise money from the sale of common stock of the public companies in which it has ownership positions. In addition to the foregoing, the Company does not expect any material impact on its development timelines, revenue levels and its liquidity due to the worldwide spread of COVID-19 (except as may be implicated by the Material Adverse Effect claimed by InvaGen in connection with their agreement with Avenue). However, the Company is continuing to assess the impact the spread of COVID-19 may have on its operations. Avenue will also continue to assess the alleged Material Adverse Effect claimed by InvaGen.

11

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.

The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited financial statements for the preceding fiscal year for each of the companies: Avenue, Checkpoint and Mustang. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2020, from which the Company derived the balance sheet data at December 31, 2019, as well as Checkpoint’s Form 10-K, filed with the SEC on March 11, 2020, Mustang’s Form 10-K, filed with the SEC on March 16, 2020, and Avenue’s Form 10-K, filed with the SEC on March 30, 2020.

The Company’s unaudited condensed consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company also consolidates subsidiaries in which it owns less than 50% of the subsidiary but maintains voting control. The Company continually assesses whether changes to existing relationships or future transactions may result in the consolidation or deconsolidation of partner companies.

The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period.

Use of Estimates

The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2019 Annual Report.

12

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Recently Adopted Accounting Pronouncements

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-13, Fair Value Measurement (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with the movement amongst or hierarchy associated with Level 1, Level 2 and Level 3 fair value measurements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. On January 1, 2020, the Company’s adoption of this guidance to did not have a material impact on its condensed consolidated  financial statements.

Recently Issued Accounting Pronouncements

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) (“ASU 470-20”) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 815-40”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. The ASU is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer and will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, for the Company as it is a smaller reporting company. Early adoption will be permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses”. The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. Recently, the FASB issued the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of the adoption of this ASU on its condensed consolidated  financial statements.

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

3. Discontinued Operations

The table below depicts the cash flows from the sale of the Company’s investment in National Holdings Corporation, a diversified independent brokerage company (together with its subsidiaries, herein referred to as “NHLD” or “National”) for the nine months ended September 30, 2019:

For the Nine Months Ended

September 30, 

($ in thousands)

    

2019

Investing activities

 

  

Proceeds from sale of National

$

13,089

Total cash provided by discontinued investing activities

$

13,089

At September 30, 2020 and 2019, the Company had no ownership interest in National.

13

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

4. Collaboration and Stock Purchase Agreements

Caelum

Agreement with Alexion

In January 2019, Caelum entered into a Development, Option and Stock Purchase Agreement (the “DOSPA”) and related documents by and among Caelum, Alexion Therapeutics, Inc. (“Alexion”), the Company and Caelum security holders as parties thereto (such security holders, including Fortress, the “Sellers”). Under the terms of the agreement, Alexion purchased a 19.9% minority equity interest in Caelum for $30 million. Additionally, Alexion has agreed to make potential payments to Caelum upon the achievement of certain developmental milestones, in exchange for which Alexion obtained a contingent exclusive option to acquire the remaining equity in Caelum. The agreement also provides for potential additional payments, in the event Alexion exercises the purchase option, for up to $500 million, which includes an upfront option exercise payment and potential regulatory and commercial milestone payments.

In December 2019, following the U.S. Food and Drug Administration (“FDA”) feedback which resulted in the redesign and expansion of Caelum’s planned clinical development program for its lead product candidate, CAEL-101, Caelum entered into an Amended and Restated DOSPA, which amended the terms of the existing agreement with Alexion. The amendment modified the terms of Alexion’s option to acquire the remaining equity in Caelum based on data from the expanded Phase 2/3 trials. The amendment also modified the development-related milestone events associated with the initial $30 million in contingent payments, provided for an additional $20 million in upfront funding, as well as funding of $60 million in exchange for an additional equity interest in Caelum at fair value upon achievement of a specific development-related milestone event.

In September 2020, following its Phase 2 open-label dose escalation study, Caelum announced the initiation of its Cardiac Amyloid Reaching for Extended Survival (“CARES”) Phase 3 clinical program to evaluate CAEL-101 a first-in-class amyloid fibril targeted therapy, in combination with standard-of-care (SoC) therapy in AL amyloidosis. The CARES clinical program includes two parallel Phase 3 studies – one in patients with Mayo stage 3a disease and one in patients with Mayo stage 3b disease – and will collectively enroll approximately 370 patients globally. Enrollment is underway in both studies. The primary objective of the clinical program is to assess overall survival.   The Phase 2 program continues with the addition of a study arm to evaluate CAEL-101 in combination with SoC therapy plus daratumumab.

Avenue

Agreement with InvaGen

On November 12, 2018, the Company’s partner company, Avenue, entered into a Stock Purchase and Merger Agreement (“Avenue SPMA”) with InvaGen Pharmaceuticals Inc. (“InvaGen”) and Madison Pharmaceuticals Inc., a newly formed, wholly-owned subsidiary of InvaGen. Pursuant to the Avenue SPMA, and following approval by Avenue’s stockholders on February 8, 2019, InvaGen purchased a number of shares of Avenue common stock representing 33.3% of Avenue’s fully diluted capital stock for net proceeds to Avenue of $31.5 million (after deducting fees and other offering-related costs).

Upon the achievement of certain closing conditions (including most notably FDA approval for IV Tramadol, Avenue’s product candidate), InvaGen will be obligated to acquire Avenue via reverse subsidiary merger (the “Merger Transaction”). Under the Merger Transaction, InvaGen will pay $180 million (subject to certain potential reductions) to the holders of Avenue’s capital stock (other than InvaGen itself). In October 2020, InvaGen communicated to Avenue that it believes a Material Adverse Effect (as defined in the Avenue SPMA) has occurred, due to the COVID-19 pandemic, which means that it is possible that InvaGen is attempting to avoid their obligations to consummate the second stage closing under the Avenue SPMA. Avenue disagrees with InvaGen’s assertion that a Material Adverse Effect has occurred, and Avenue has advised InvaGen of this position.

Subject to the terms and conditions described in the Avenue SPMA, InvaGen may also provide interim financing to Avenue in an amount of up to $7.0 million during the time period between February 8, 2019 and the Merger Transaction. Any amounts drawn on the interim financing will be deducted from the aggregate consideration payable to Company stockholders by virtue of the Merger Transaction.

14

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Prior to the closing of the Merger Transaction, Avenue will enter into a Contingent Value Rights Agreement (the “CVR Agreement”) with a trust company as rights agent, pursuant to which holders of common shares of Avenue, other than InvaGen (each, a “Holder”), will be entitled to receive on Contingent Value Right (“CVR”) for each share held immediately prior to the Merger Transaction.

Each CVR represents the right of its holder to receive a contingent cash payment pursuant to the CVR Agreement upon the achievement of certain milestones. If, during the period commencing on the day following the closing of the Merger Transaction until December 31, 2028, IV Tramadol generates at least $325 million or more in Net Sales (as defined in the CVR Agreement) in a calendar year, each Holder shall be entitled to receive their pro rata share of (i) if the product generated less than $400 million in Net Sales during such calendar year, 10% of Gross Profit (as defined in the CVR Agreement), (ii) if the product generated between $400 million and $500 million in Net Sales during such calendar year, 12.5% of Gross Profit, or (iii) if the product generated more than $500 million in Net Sales during such calendar year, 15% of Gross Profit. Additionally, at any time beginning on January 1, 2029 that IV Tramadol has generated at least $1.5 billion in aggregate Net Sales, then with respect to each calendar year in which IV Tramadol generates $100 million or more in Net Sales, each Holder shall be entitled to receive their pro rata share of an amount equal to 20% of the Gross Profit generated by IV Tramadol. These additional payments will terminate on the earlier of December 31, 2036 and the date (which may be extended by up to 6 months) that any person has received approval from the FDA for an Abbreviated New Drug Application (“NDA”) or an FDA AP-rated 505(b)(2) NDA using IV Tramadol.

On October 12, 2020, Avenue announced that it had received a Complete Response Letter (“CRL”) from the FDA regarding Avenue’s NDA for IV Tramadol.   The CRL cited deficiencies related to the terminal sterilization validation and stated that IV Tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population. Avenue requested a meeting with the FDA to resolve the issues described in the CRL and the meeting has been scheduled for the fourth quarter of 2020.

Also in October 2020, InvaGen Pharmaceuticals Inc. (“InvaGen”) communicated to Avenue that it believes a Material Adverse Effect (as defined in the Stock Purchase and Merger Agreement (“Avenue SPMA”)) has occurred, due to the COVID-19 pandemic, which means that it is possible that InvaGen is attempting to avoid their obligations to consummate the second stage closing under the Avenue SPMA. Avenue disagrees with InvaGen’s assertion that a Material Adverse Effect has occurred, and Avenue has advised InvaGen of this position.

5. Property and Equipment

Fortress’ property and equipment consisted of the following:

    

Useful Life

    

September 30, 

    

December 31, 

($ in thousands)

(Years)

2020

2019

(Unaudited)

Computer equipment

 

3

$

662

$

648

Furniture and fixtures

 

5

 

1,199

 

1,162

Machinery & equipment

 

5

 

5,014

 

4,594

Leasehold improvements

 

5-15

 

10,580

 

9,358

Construction in progress 1

 

N/A

 

821

 

1,157

Total property and equipment

 

18,276

 

16,919

Less: Accumulated depreciation

 

(6,162)

 

(4,486)

Property and equipment, net

$

12,114

$

12,433

Note 1:

Relates to the Mustang cell processing facility.

Fortress' depreciation expense for the three months ended September 30, 2020 and 2019 was approximately $0.6 million and $0.5 million, respectively, and was recorded in both research and development expense and general and administrative expense in the condensed consolidated statements of operations.

15

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Fortress' depreciation expense for the nine months ended September 30, 2020 and 2019 was approximately $1.7 million and $1.4 million, respectively, and was recorded in both research and development expense and general and administrative expense in the condensed consolidated statements of operations.

6. Fair Value Measurements

Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities.

Fair Value of Caelum

As of September 30, 2020, the Company valued its investment in Caelum in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, and estimated the fair value to be $11.7 million based on a per share value of $1.62. As of September 30, 2020, the following inputs were utilized to derive the value: risk free rate of return of 0.12%, volatility of 70% and a discount for lack of marketability of 28.6%.

As of December 31, 2019, the Company valued its investment in Caelum in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, and estimated the fair value to be $11.1 million based on a per share value of $1.54. As of December 31, 2019, the following inputs were utilized to derive the value: risk free rate of return of 1.6%, volatility of 70% and a discount for lack of marketability of 28.7%.

Cyprium Warrant Liability

During the quarter ended September 30, 2020, Cyprium raised approximately $8.0 million in Perpetual Preferred Shares (“Cyprium Offering,” see Note 14).  The Cyprium Offering coupled with the repayment of the 2018 Venture Debt (see Note 10), triggered the issuance of the Cyprium Warrant, in that a price per share could be established. As such these events resulted in Cyprium recording the Cyprium Warrant as issued rather than contingently issuable.

The fair value of the Cyprium Warrants in connection with the 2018 Venture Debt was determined by applying management’s estimate of the probability of issuance of the Contingently Issuable Warrants together with an option-pricing model, with the following key assumptions:

    

September 30, 2020

December 31, 2019

 

Risk-free interest rate

 

0.69

%

1.92

%

Expected dividend yield

 

Expected term in years

 

10.0

10.0

Expected volatility

 

85

%

93

%

Probability of issuance of the warrant

 

100

%

5

%

Cyprium

Contingently

Issuable Warrant

($ in thousands)

Liability

Beginning balance at January 1, 2020

$

27

Change in fair value

1,189

Reclass partner company's warrants from liability to equity

(1,216)

Ending balance at September 30, 2020

$

-

16

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The following tables classify into the fair value hierarchy of Fortress’ financial instruments, measured at fair value as of September 30, 2020 and December 31, 2019:

Fair Value Measurement as of  September 30, 2020

($ in thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets

 

  

 

  

 

  

 

  

Fair value of investment in Caelum

$

$

$

11,723

$

11,723

Total

$

$

$

11,723

$

11,723

Fair Value Measurement as of  December 31, 2019

($ in thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets

 

  

 

  

 

  

 

  

Fair value of investment in Caelum

 

$

 

$

 

$

11,148

 

$

11,148

Total

 

$

 

$

 

$

11,148

 

$

11,148

Fair Value Measurement as of  December 31, 2019

($ in thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Liabilities

 

  

 

  

 

  

 

  

Warrant liabilities

 

$

 

$

 

$

27

 

$

27

Total

 

$

 

$

 

$

27

 

$

27

The table below provides a roll-forward of the changes in fair value of Level 3 financial instruments as of September 30, 2020:

Investment in

Warrant

($ in thousands)

    

Caelum

    

 Liabilities

    

Total

Balance at December 31, 2019

$

11,148

$

27

$

11,175

Change in fair value

1,189

1,189

Reclass partner company's warrants from liability to equity

(1,216)

(1,216)

Change in fair value of investments

575

575

Balance at September 30, 2020

$

11,723

$

$

11,723

As of September 30, 2020, no transfers occurred between Level 1, Level 2 and Level 3 instruments.

7. Licenses Acquired

In accordance with ASC 730-10-25-1, Research and Development, costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use. The licenses purchased by Fortress and its partner companies require substantial completion of research and development, and regulatory and marketing approval efforts in order to reach technological feasibility. As such, for the three and nine months ended September 30, 2020 and 2019, the purchase price of licenses acquired was classified as research and development-licenses acquired in the condensed consolidated Statements of operations as reflected in the table below:

17

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Three Months Ended September 30, 

Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

    

Partner companies:

 

  

 

  

 

  

 

  

 

Mustang

$

287

$

700

$

1,837

$

1,350

Aevitas

162

162

Baergic

 

8

 

 

8

 

Oncogenuity

1

271

Total

$

458

$

700

$

2,278

$

1,350

Mustang

SIRION Biotech GmbH - LentiBOOSTTM (MB-207)

On September 30, 2020, Mustang entered into an exclusive, worldwide licensing agreement with SIRION Biotech (“SIRION”) for the rights to SIRION’s LentiBOOSTTM technology for the development of MB-207, Mustang’s lentiviral gene therapy for the treatment of previously transplanted patients with X-linked severe combined immunodeficiency (the “SIRION Technology License”). Pursuant to the SIRION Technology License, which requires payment in Euro, the Company paid SIRION a one-time upfront fee of $0.1 million (€0.1 million) during the three and nine months ended September 30, 2020. In addition, five future development milestone payments totaling up to approximately $5.6 million (€4.7 million) in the aggregate are due upon achievement of certain milestones. Additional milestone payments totaling up to $4.1 million (€3.5 million) in the aggregate are due in connection with the achievement of three commercial milestones and low- to mid-single digit royalties are due on aggregate cumulative worldwide net sales of licensed products.

For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for licenses acquired:

For the Three Months Ended September 30, 

For the Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

City of Hope National Medical Center

CD123 (MB-102)3

$

$

$

334

$

250

IL13Rα2 (MB-101) 3

333

HER2 (MB-103)1

250

CS1 (MB-104)

200

PSCA (Spacer)3

200

 

333

 

200

Fred Hutch - CD20 (MB-106)2

300

Nationwide Children’s Hospital - C134 (MB-108)

200

CSL Behring (Calimmune)

170

200

170

200

UCLA

300

300

SIRION LentiBOOSTTM

117

117

Total

$

287

$

700

$

1,837

$

1,350

Note 1:

Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-103 at COH, for the nine months ended September 30, 2020.

Note 2:

Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-106 at Fred Hutch, for the nine months ended September 30, 2020.

Note 3:

Represents a milestone payment to COH in connection with Mustang’s public underwritten offerings, for the nine months ended September 30, 2020.

18

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Oncogenuity

Effective May 6, 2020, Oncogenuity entered into a license agreement with the Trustees of Columbia University in the City of New York (“Columbia”) to develop novel oligonucleotides for the treatment of genetically driven cancers (the “Columbia License”). The proprietary platform produces oligomers, known as “ONCOlogues.”

As consideration for the Columbia License, Oncogenuity paid an upfront fee of $0.3 million, and Fortress transferred to Columbia 1,000,000 shares of Oncogenuity common stock, representing 10.00% ownership of Oncogenuity. In connection with the share transfer, Oncogenuity also provided Columbia with limited anti-dilution protection. Oncogenuity valued the stock grant to Columbia utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 41.7%, weighted average cost of capital of 20.5%, and net of debt utilized, resulting in a value of $0.021 per share or $21,000 for the three and nine months ended September 30, 2020. Since a portion of the acquisition of the license was settled through the transfer of shares of Oncogenuity's common stock, this transaction fell within the scope of ASC Topic 718, Compensation-Stock Compensation, since equity was transferred in exchange for goods (the license). Specifically, Oncogenuity recorded the cost of the license as a non-employee share based payment, measured at the grant date fair value of the common stock. The common shares were equity-classified. The anti-dilution provision was concluded to represent a performance condition tied to a future liquidity event, which was not considered as probable to occur at September 30, 2020, because it was deemed outside of Oncogenuity’s control.

Development milestone payments totaling up to approximately $18.0 million in the aggregate are due upon achievement of certain milestones in connection with the initial indication. Additional milestone payments totaling up to $15.3 million in the aggregate are due in connection with product development milestones for subsequent indications. A $15.0 million sales milestone is due upon the achievement of a licensed product sales threshold, and low- to mid-single digit royalties are due on aggregate cumulative worldwide net sales of licensed products.

For the three and nine months ended September 30, 2020, Oncogenuity recorded expense of nil and $0.3 million in research and development - licenses acquired in the Company’s condensed consolidated statements of operations.

8. Sponsored Research and Clinical Trial Agreements

Aevitas

For the three and nine months ended September 30, 2020 and 2019, Aevitas recorded the following expense in connection with its sponsored research and clinical trial agreements:

For the Three Months Ended September 30, 

For the Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

UMass - adeno-associated virus ("AAV")

163

218

UPenn - AAV

255

567

755

Duke - AAV

17

17

Total

$

163

$

272

$

785

$

772

Cellvation

For the three and nine months ended September 30, 2020 no expenses were incurred. For the three and nine months ended September 30 2019, Cellvation recorded expense of $0.1 million, in connection with its sponsored research arrangement with the University of Texas. The expense was recorded in research and development expense in the Company’s condensed consolidated statements of operations.

19

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Mustang

CS1(MB-104) Clinical Research and Support Agreement with COH

In June 2020, Mustang entered into a clinical research and support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: "Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients with CS1+ Multiple Myeloma." The CAR T being studied under this protocol has been designated by Mustang as MB-104. Under the terms of the agreement Mustang paid COH $0.8 million during the three months ended September 30, 2020 for costs incurred and will reimburse COH for costs associated with this trial, when incurred, not to exceed $2.4 million. The agreement will expire upon the delivery of the final study report or earlier.  Expense of $0.1 million an $0.8 million was incurred for the three and nine months ended September 30, 2020.

XSCID (MB-107) Data Transfer Agreement with St. Jude

In June 2020, Mustang entered into a Data Transfer Agreement with St. Jude under which Mustang will reimburse St. Jude for costs associated with St. Jude’s clinical trial for the treatment of infants with X-linked Severe Combined Immunodeficiency (“XSCID”).  Pursuant to the terms of this agreement Mustang paid an upfront fee of $1.1 million on July 1, 2020 and will continue to reimburse St. Jude for costs incurred in connection with this trial.

For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements:

For the Three Months Ended September 30, 

For the Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

City of Hope National Medical Center

$

$

500

$

500

$

1,500

CD123 (MB-102)

 

48

 

269

 

344

 

1,028

IL13Rα2 (MB-101)

 

96

 

244

 

422

 

811

Manufacturing

 

 

114

 

 

343

CS1 (MB-104)

65

835

Beth Israel Deaconess Medical Center - CRISPR

69

St. Jude Children's Research Hospital - XSCID (MB-107)

107

1,665

Fred Hutchinson Cancer Research Center - CD20 (MB-106)

418

49

1,134

690

Total

$

734

$

1,176

$

4,900

$

4,441

Oncogenuity

Pursuant to the terms of the Columbia License, Oncogenuity will pay up to $4.8 million to Columbia semiannually for five years ending in November 2024.

For the three and nine months ended September 30, 2020, Oncogenuity recorded expense of $0.2 million and $0.3 million, respectively, in research and development in the Company’s condensed consolidated statements of operations. No expense was recorded in 2019.

20

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

9. Intangibles, net

On July 29, 2020 Journey entered into a license and supply agreement with a third party for an oral acne treatment. Pursuant to the terms and conditions of the License and Supply Agreement (“LSA”), Journey agreed to pay $5.0 million, comprised of an upfront payment of $1.0 million paid upon execution with remaining payments due as follows: $1.0 million upon achievement of two marketing milestones and $3.0 million due in $1.0 million installments, commencing on the 18-month anniversary, the 24-month anniversary and the 36-month anniversary of execution of the LSA. Three additional milestone payments totaling $17.0 million are due upon the achievement of certain net sales milestones. Royalties in the mid, single digits based on net sales, subject to specified reductions are also due.

 

In accordance with ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, Journey determined the conditions of the LSA did not constitute the purchase of a business, and therefore recorded the consideration as an asset, to be amortized over the expected life of the product, which is deemed to be five years. In addition, Journey determined pursuant to ASC 450, Contingencies, that royalty payments in connection with the LSA will be recorded when they become payable with a corresponding charge to cost of goods sold.

  

In accordance with the installment payment terms of the LSA, Journey recorded a discount for imputed interest per ASC 835-30 Interest-Imputed Interest of $0.3 million. As of September 30, 2020, Journey recorded a net intangible asset related to this transaction of $4.7 million which was recorded on the Company’s condensed consolidated balance sheet.

The table below provides a summary of the Journey intangible assets as of September 30, 2020 and December 31, 2019, respectively:

Estimated Useful

($ in thousands)

    

Lives (Years)

    

September 30, 2020

    

December 31, 2019

(Unaudited)

Total Intangible assets – asset purchases

3 to 7

$

14,661

$

9,934

Accumulated amortization

 

  

 

(3,622)

 

(2,557)

Net intangible assets

 

  

$

11,039

$

7,377

The table below provides a summary for the nine months ended September 30, 2020, of Journey’s recognized expense related to its product licenses, which was recorded in costs of goods sold on the condensed consolidated statement of operations:

Intangible

($ in thousands)

    

Assets, Net

Beginning balance at January 1, 2020

$

7,377

Additions:

Oral acne treatment license acquisition1

4,727

Amortization expense

 

(1,065)

Ending balance at September 30, 2020

$

11,039

Note 1:  As of September 30, 2020, this asset has not yet been placed in service, therefore no amortization expense was recognized on this asset for the quarter ended September 30, 2020.  The Company expects the asset to be placed in service in the first half of 2021. Once the asset is placed in service the Company will amortize the asset over five years, which represents its expected useful life.

21

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The future amortization of these intangible assets is as follows:

Total

($ in thousands)

    

Ximino®

    

Exelderm®

    

Amortization

Three Months Ended December 31, 2020

$

254

$

100

$

354

Year Ended December 31, 2021

 

1,019

 

267

 

1,286

Year Ended December 31, 2022

1,019

1,019

Year Ended December 31, 2023

1,019

1,019

Year Ended December 31, 2024

 

1,019

 

 

1,019

Thereafter

1,615

1,615

Sub-total

$

5,945

$

367

$

6,312

Asset not yet placed in service

4,727

Total

$

5,945

$

367

$

11,039

10. Debt and Interest

Debt

During the quarter ended September 30, 2020 the Company entered into a new credit facility with Oaktree Fund Administration, LLC, as the administrative agent (in such capacity, the “Agent”), and the lenders from time to time party thereto (each a “Lender” or  “Oaktree” and collectively, the “Lenders”), as described below (the “Oaktree Note”).  The Company utilized the proceeds from the Oaktree Note to repay the 2017 Subordinated Notes, the 2018 Venture Notes and the 2019 Notes.  The Company also repaid the IDB Note utilizing the cash collateral securing the IDB Note, which was classified as restricted cash on the Company’s consolidated condensed balance sheet.  In addition, on September 30, 2020 Mustang repaid the Mustang Horizon Notes.  

Total debt consists of the following as of September 30, 2020 and December 31, 2019:

    

September 30, 

    

December 31,

    

    

($ in thousands)

2020

2019

Interest rate

Maturity

IDB Note

$

$

14,929

 

2.25

%  

Aug - 2021

2017 Subordinated Note Financing3

 

 

3,254

 

8.00

%

March - 2022

2017 Subordinated Note Financing3

 

 

13,893

 

8.00

%

May - 2022

2017 Subordinated Note Financing3

 

 

1,820

 

8.00

%

June - 2022

2017 Subordinated Note Financing3

 

 

3,018

 

8.00

%

August - 2022

2017 Subordinated Note Financing

 

 

6,371

 

8.00

%

September - 2022

2018 Venture Notes4

 

 

6,517

 

8.00

%  

August - 2021

2018 Venture Notes4

 

 

15,190

 

8.00

%  

September - 2021

2019 Notes1

 

 

9,000

 

12.00

%  

September - 2021

Mustang Horizon Notes2

 

 

15,750

 

9.00

%  

October - 2022

Oaktree Note

60,000

11.00

%

August - 2025

Total notes payable

 

60,000

 

89,742

 

  

 

  

Less: Discount on notes payable

 

8,607

 

5,086

 

  

 

  

Total notes payable

$

51,393

$

84,656

 

  

 

  

Note 1:

Formerly the Opus Credit Facility (see Note 16.)

Note 2:

Interest rate was 9.0% plus one-month LIBOR Rate in excess of 2.5%.

Note 3:

As a result of a one-year maturity date extension effective 2020, the interest rate increased by 1% to 9.0%.

Note 4:

At December 31, 2019, $6.0 million is included in Notes payable, short-term on the condensed consolidated balance sheet.

22

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Interest Expense

The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest; fees include amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan:

Three Months Ended September 30,

2020

2019

($ in thousands)

    

Interest

    

Fees

    

Total

    

Interest

    

Fees 

    

Total

IDB Note

$

77

$

$

77

$

86

$

$

86

2017 Subordinated Note Financing1

 

694

 

1,374

 

2,068

 

1,072

 

326

 

1,398

2019 Notes

172

172

275

 

104

379

2018 Venture Notes1

 

387

 

638

 

1,025

 

438

 

166

 

604

LOC Fees

 

14

 

 

14

 

14

 

 

14

Mustang Horizon Notes1,3

 

895

 

1,792

 

2,687

 

345

 

234

 

579

Oaktree Note1

624

108

732

Note Payable2

187

187

108

108

Other

 

(4)

 

 

(4)

 

 

 

Total Interest Expense and Financing Fee

$

3,046

$

3,912

$

6,958

$

2,230

$

938

$

3,168

Nine Months Ended September 30, 

2020

2019

($ in thousands)

    

Interest

    

Fees

    

Total

    

Interest

    

Fees

    

Total

IDB Note

$

246

$

$

246

$

254

$

-

$

254

2017 Subordinated Note Financing1

 

2,870

 

1,890

 

4,760

 

3,148

 

1,081

 

4,229

2019 Notes

 

710

 

 

710

 

840

336

 

1,176

2018 Venture Notes1

 

1,253

 

1,000

 

2,253

 

1,299

 

468

 

1,767

LOC Fees

 

45

 

 

45

 

45

 

 

45

Mustang Horizon Notes1,3

 

1,585

 

2,321

 

3,906

 

698

 

466

 

1,164

Oaktree Note1

624

108

732

Note Payable2

492

492

108

108

Other

 

(2)

 

 

(2)

 

Total Interest Expense and Financing Fee

$

7,823

$

5,319

$

13,142

$

6,284

$

2,459

$

8,743

Note 1:

For the three and nine months ended September 30, 2020, $1.2 million expense of unamortized debt discount fees for the 2017 Subordinated Note Financing, $0.3 million for the 2018 Venture Notes and $1.8 million for the Mustang Horizon Notes.

Note 2:

Imputed interest expense related to Journey’s agreements for Ximino and oral acne treatment.

Note 3:

Included in interest expense for the three and nine months ended September 30, 2020 was $0.6 million of prepayment penalties included in interest expense for the Mustang Horizon Notes.

Oaktree Note

On August 27, 2020 (the “Closing Date”), Fortress, as borrower, entered into a $60.0 million senior secured credit agreement (the “Agreement”) with Oaktree. The Company borrowed the full $60.0 million in connection with the terms of the Oaktree Note on the Closing Date and used the bulk of the proceeds to repay its outstanding debt to other lenders (2017 Subordinated Notes, 2018 Venture Notes and 2019 Notes (previously the “Opus Credit Facility”)).

The Oaktree Note bears interest at a fixed annual rate of 11.0%, payable quarterly and maturing on the fifth anniversary of the Closing Date, August 27, 2025, the (“Maturity Date”). The Company is required to make quarterly interest-only payments until the Maturity Date, at which point the outstanding principal amount is due. The Company may voluntarily prepay the Oaktree Note at any time subject to a Prepayment Fee as defined in the Terms section. The Company is required to make mandatory prepayments of the Oaktree Note under various circumstances as defined in the Terms section. No amounts paid or prepaid may be reborrowed without Oaktree consent.

23

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of permitted indebtedness, and dividends and other distributions, subject to certain exceptions. In addition, the Agreement contains certain financial covenants, including, among other things, (i) maintenance of minimum liquidity by the Company, and (ii) a minimum revenue test that is subject to certain exclusions. Failure by the Company to comply with the financial covenants will result in an event of default, subject to certain cure rights of the Company.  

The Agreement contains customary events of default, in certain circumstances subject to customary cure periods. Following an event of default and any cure period, if applicable, the Agent will have the right upon notice to accelerate all amounts outstanding under the Agreement, in addition to other remedies available to the lenders as secured creditors of the Company. The Agreement grants a security interest in favor of the Agent, for the benefit of the lenders, in substantially all of the Company’s assets as collateral securing the Company’s obligations under the Agreement, except for: (i) certain interests in controlled foreign corporation subsidiaries of the Company; (ii) the Company’s holdings in Avenue; and (iii) those portions of the Company’s holdings in certain subsidiaries (plus Caelum) that are encumbered by pre-existing equity pledges to certain of the Company’s officers.

Pursuant to the terms of the Agreement on the Closing Date the Company paid Oaktree an upfront commitment fee equal to 3% of the $60.0 million, or $1.8 million.  In addition, the Company paid a $35,000 Agency fee to the Agent which was due on the Closing Date and will be due annually, together with fees of $2.5 million directly to third parties involved in the transaction.  

In connection with the Oaktree Note, the Company issued warrants to Oaktree and certain of its affiliates to purchase up to 1,749,450 shares of common stock (see Note 14) with a relative fair value of $4.4 million.

As of September 30, 2020, the Company recorded the fees totaling $8.7 million ($1.8 million to Oaktree, $2.5 million of expenses paid to third-parties and $4.4 million representing the relative fair value of the Oaktree Warrants) to debt discount.  These costs will be amortized over the term of the Oaktree Note.

24

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

11. Accrued Liabilities and other Long-Term Liabilities

Accrued expenses and other long-term liabilities consisted of the following:

September 30, 

December 31,

($ in thousands)

    

2020

    

2019

Accrued expenses:

 

  

 

  

Professional fees

$

1,672

$

1,153

Salaries, bonus and related benefits

 

5,677

 

6,683

Accrued expense - related party

 

19

 

Research and development

 

4,604

 

4,215

Research and development - manufacturing

 

 

1,017

Research and development - license maintenance fees

 

629

 

361

Research and development - milestones

 

600

 

Accrued royalties payable

 

1,908

 

2,320

Accrued coupon expense

 

5,476

 

8,391

Other

 

547

 

1,259

Total accrued expenses

$

21,132

$

25,399

Other long-term liabilities:

 

  

 

  

Deferred rent and long-term lease abandonment charge1

$

1,996

$

2,136

Long-term notes payable, net (Journey)

Ximino agreement2

3,456

4,990

Oral acne treatment agreement3

2,753

Total other long-term liabilities

$

8,205

$

7,126

Note 1:

As of September 30, 2020, and December 31, 2019, the balance consists of deferred charges related to build-out of the New York facility.

Note 2:

As of September 30, 2020, and December 31, 2019, the imputed interest discount was $1.5 million and $2.0 million, respectively, in connection with its acquisition of Ximino in July 2019. Amortization of interest discount was $0.5 million for the nine months ended September 30, 2020, and $0.1 million for the nine months ended September 30, 2019. As of September 30, 2020, $2.0 million of note payable was classified as short-term.

Note 3:

As of September 30, 2020, the imputed discount balance was $0.2 million.  The imputed interest discount was calculated utilizing a 4.00% effective rate, which represents the market rate for an asset-backed three year loan, secured by receivables. As of September 30, 2020, $1.0 million of note payable was classified as short-term.

25

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

12. Non-Controlling Interests

Non-controlling interests in consolidated entities are as follows:

    

    

For the nine months ended

    

    

    

    

 

As of September 30, 2020

September 30, 2020

As of September 30, 2020

 

Net loss attributable to

Non-controlling interests

Non-controlling

 

($ in thousands)

    

NCI equity share

non-controlling interests

in consolidated entities

ownership

 

Aevitas

$

(2,297)

 

(680)

 

(2,977)

 

39.0

%

Avenue 2

 

5,709

 

(3,206)

 

2,503

 

77.4

%

Baergic

 

(1,605)

 

(68)

 

(1,673)

 

40.0

%

Cellvation

 

(1,072)

 

(145)

 

(1,217)

 

22.6

%

Checkpoint 1

 

37,963

 

(9,000)

 

28,963

 

80.0

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

784

 

(843)

 

(59)

 

28.4

%

Helocyte

 

(4,890)

 

(236)

 

(5,126)

 

18.8

%

JMC

 

123

 

257

 

380

 

6.9

%

Mustang 2

 

86,572

 

(27,035)

 

59,537

 

77.9

%

Oncogenuity

(47)

 

(268)

 

(315)

 

25.3

%

Tamid

 

(652)

 

(40)

 

(692)

 

22.8

%

Total

$

120,298

$

(41,264)

$

79,034

 

  

    

For the twelve months ended

    

    

 

As of December 31, 2019

December 31, 2019

As of December 31, 2019

 

Net loss attributable to 

Non-controlling interests 

Non-controlling 

 

($ in thousands)

    

NCI equity share

    

non-controlling interests

    

 in consolidated entities

    

 ownership

 

Aevitas

$

(1,249)

$

(694)

$

(1,943)

 

35.8

%

Avenue 2

 

24,269

 

(19,011)

 

5,258

 

77.3

%

Baergic

 

23

 

(1,162)

 

(1,139)

 

33.0

%

Cellvation

 

(732)

 

(158)

 

(890)

 

20.6

%

Checkpoint 1

 

29,389

 

(14,687)

 

14,702

 

78.0

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

(320)

 

(99)

 

(419)

 

10.6

%

Helocyte

 

(4,322)

 

(402)

 

(4,724)

 

19.3

%

JMC

 

(211)

 

325

 

114

 

6.9

%

Mustang 2

 

62,025

 

(25,727)

 

36,298

 

70.3

%

Tamid

 

(565)

 

(85)

 

(650)

 

22.8

%

Total

$

108,017

$

(61,700)

$

46,317

 

Note 1:

Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Note 2:

Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.

13. Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period.

26

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the nine months ended September 30, 2020:

Nine Months Ended September 30, 

2020

    

2019

Warrants to purchase Common Stock

 

3,026,693

 

2,745,364

Options to purchase Common Stock

 

1,187,600

 

1,169,293

Unvested Restricted Stock

 

14,305,949

 

12,622,881

Unvested Restricted Stock Units

 

434,215

 

791,610

Total

 

18,954,457

 

17,329,148

14. Stockholders’ Equity

Common Stock

At the Company’s 2020 Annual Meeting of Stockholders held on June 17, 2020, its stockholders approved an amendment to its certificate of incorporation to increase the number of authorized shares of common stock available to issue by 50,000,000 to 150,000,000 with a par value of $0.001 per share. The amendment was filed with the Secretary of State of the State of Delaware on June 18, 2020.

Stock-based Compensation

The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the three and nine months ended September 30, 2020 and 2019:

Three Months Ended September 30, 

Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

    

Employee awards

$

1,200

$

936

$

3,732

$

2,791

Executive awards of Fortress Companies' stock

 

369

 

358

 

1,136

 

1,065

Non-employee awards

 

31

 

15

 

136

 

84

Warrants

32

97

97

97

Partner Companies:

 

 

Avenue

 

161

 

298

 

592

 

1,585

Checkpoint

 

725

 

833

 

2,095

 

2,444

Mustang

 

606

 

1,120

 

2,368

 

2,174

Other

 

47

 

84

 

163

 

183

Total stock-based compensation expense

$

3,171

$

3,741

$

10,319

$

10,423

For the three months ended September 30, 2020 and 2019, approximately $0.7 million and $1.2 million, respectively, of stock-based compensation expense was included in research and development expenses in connection with equity grants made to employees and consultants and approximately $2.5 million and $2.5 million, respectively, was included in general and administrative expenses in connection with grants made to employees, members of the board of directors and consultants.

For the nine months ended September 30, 2020 and 2019, approximately $2.5 million and $2.6 million, respectively, of stock-based compensation expense was included in research and development expenses in connection with equity grants made to employees and consultants and approximately $7.8 million and $7.8 million, respectively, was included in general and administrative expenses in connection with grants made to employees, members of the board of directors and consultants.

27

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Equity Compensation Plans

At the Company’s 2020 Annual Meeting on June 30, 2020, the Company’s shareholders approved an amendment to the Company’s 2013 Stock Incentive Plan, as amended (“Stock Plan”) to increase common shares issuable under the Stock Plan by 3.0 million to 13.0 million.  For the nine months ended September 30, 2020, 4.2 million shares remain to be issued under the Stock Plan.

Stock Options

The following table summarizes Fortress stock option activities excluding activity related to Fortress partner companies:

Weighted average

Total

remaining

Weighted average

weighted average

contractual life

    

Number of shares

    

exercise price

    

intrinsic value

    

(years)

Options vested and expected to vest at December 31, 2019

 

1,410,501

$

4.30

$

684,752

 

2.33

Exercised

 

(100,000)

1.18

 

 

Forfeited

(247,011)

2.55

Options vested and expected to vest at September 30, 2020

 

1,063,490

$

5.00

$

1,044,218

 

2.87

As of September 30, 2020, Fortress had no unrecognized stock-based compensation expense related to options.

Restricted Stock and Restricted Stock Units

The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress Companies:

    

    

Weighted

average grant

Number of shares

price

Unvested balance at December 31, 2019

13,768,014

$

2.46

Restricted stock granted

1,873,072

2.57

Restricted stock vested

(1,549,564)

2.69

Restricted stock units granted

630,126

3.82

Restricted stock units forfeited

(106,250)

2.71

Restricted stock units vested

(368,290)

3.13

Unvested balance at September 30, 2020

14,247,108

$

2.49

As of September 30, 2020 and 2019, the Company had unrecognized stock-based compensation expense related to restricted stock and restricted stock unit awards of approximately $17.5 million and $12.7 million, respectively, which is expected to be recognized over the remaining weighted-average vesting period of 3.9 years and 5.0 years, respectively.

28

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Warrants

The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies:

Total weighted

Weighted average

average

remaining

Number of

Weighted average

 intrinsic

contractual life

    

shares

    

exercise price

    

value

    

(years)

Outstanding as of December 31, 2019

 

2,741,180

$

3.19

$

111,000

 

2.73

Granted

 

1,849,450

 

3.14

 

1,657,538

 

Forfeited

 

(9)

 

3.00

 

 

Outstanding as of September 30, 2020

 

4,590,621

$

3.17

$

4,111,018

 

5.10

Exercisable as of September 30, 2020

 

4,430,621

$

3.21

$

3,816,818

 

5.05

In connection with the Oaktree Note (see Note 10), the Company issued warrants to Oaktree and certain of its affiliates to purchase up to 1,749,450 shares of common stock at a purchase price of $3.20 per share (the “Oaktree Warrants”). Oaktree is entitled to additional warrants if at any time prior to the expiration of the Oaktree Warrants in event the Company issues equity, warrants or convertible notes (collectively known as “Security Instruments”) at a price that is less than 95% of the market price of the Company’s  Common Stock on the trading day prior to the issuance of the Security Instruments. The Warrants expire on August 27, 2030 and may be net exercised at the holder’s election. The Company also agreed to file a registration statement on Form S-3 to register for resale the shares of common stock issuable upon exercise of the Warrants.

The Company evaluated the accounting treatment of the Oaktree Warrants and determined that the Oaktree warrants met the scope exception of ASC 815-10-15-74(a) Derivatives and Hedging and therefore the warrants should be classified in stockholders’ equity.  As such the Company used a Black-Scholes model to value the Oaktree Warrants.  Utilizing the following inputs: term of 10 years, volatility of 86.8%, risk-free rate of return of 0.74% yielding a value of $4.8 million. ASC 470-20-25-2 Debt – Debt with Conversion and Other Options dictates that debt or stock issued with detachable warrants requires the proceeds to be allocated to the two instruments based on their relative fair values.  The relative fair value of the warrants was determined to be $4.4 million and was recorded as a component of Stockholders’ Equity in the Company’s condensed consolidated balance sheet at September 30, 2020.

Employee Stock Purchase Plan

Eligible employees can purchase the Company’s Common Stock at the end of a predetermined offering period at 85% of the lower of the fair market value at the beginning or end of the offering period. The ESPP is compensatory and results in stock-based compensation expense.

As of September 30, 2020, 507,783 shares have been purchased and 492,217 shares are available for future sale under the Company’s ESPP. Share-based compensation expense recorded was approximately $38,000 and $18,000, respectively, for the three months ended September 30, 2020 and 2019, and approximately $0.1 million and $0.1 million, respectively, for the nine months ended September 30, 2020 and 2019.

Capital Raises

9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Offering

On August 26, 2020, the Company closed on an underwritten public offering whereby it sold 666,666 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (Nasdaq: FBIOP) (the "Preferred Stock"), (plus a 45-day option to purchase up to an additional 66,666 shares, which was exercised in August 2020) at a price of $18.00 per share for gross proceeds of approximately $13.2 million, before deducting underwriting discounts and commissions and offering expenses of approximately $1.1 million.

29

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

On May 29, 2020, the Company closed on an underwritten public offering whereby it sold 555,556 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (Nasdaq: FBIOP) (the "Preferred Stock"), (plus a 45-day option to purchase up to an additional 83,333 shares, which was exercised in May 2020) at a price of $18.00 per share for gross proceeds of approximately $11.5 million, before deducting underwriting discounts and commissions and offering expenses of approximately $1.1 million.

On February 14, 2020, the Company announced the closing of an underwritten public offering, whereby it sold 625,000 shares of its Preferred Stock, (plus a 45-day option to purchase up to an additional 93,750 shares, which was exercised in February 2020) at a price of $20.00 per share for gross proceeds of approximately $14.4 million, before deducting underwriting discounts and commissions and offering expenses of approximately $1.3 million.

Cyprium 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Offering

On August 28, 2020, Cyprium closed on an underwritten public offering whereby it sold 255,400 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (“Cyprium Perpetual Preferred Stock” or “Cyprium PPS”), plus an overallotment of an additional 64,600 shares, which was exercised on September 18, 2020, at a price of $25.00 per share for gross proceeds of $8.0 million, before deducting underwriting discounts and commissions and offering expenses of approximately $0.9 million (the “Cyprium Offering”).

Pursuant to the terms of the Cyprium PPS, shareholders on the record date are entitled to receive a monthly cash dividend of $0.19531 per share which yields an annual dividend of $2.34375 per share. The Cyprium PPS will automatically be redeemed upon the first (and only the first) bona fide, arm’s-length sale of a Priority Review Voucher (a “PRV”) issued by the FDA in connection with the approval of CUTX-101, Cyprium’s lead product candidate.  Upon the P   R V Sale, each share of Cyprium PPS will be automatically redeemed in exchange for a payment equal to twice (2x) the $25.00 liquidation preference, plus accumulated and unpaid dividends to, but excluding, the redemption date.

An optional exchange to Company Preferred Stock is available after 24 months from the issuance date so long as a sale of the PRV has not occurred.  Additionally, if a PRV Sale has not occurred by September 30, 2024 the Cyprium PPS is either automatically exchanged for Company Preferred Stock or cash at the discretion of Fortress.  The Cyprium PPS is fully and unconditionally guaranteed by Fortress.

Cyprium paid an initial dividend of $49,883 ($0.19531 per share) to shareholders of record on September 30, 2020.

Checkpoint Underwritten Offering

In September 2020, Checkpoint completed an underwritten public offering in which it sold 7,321,429 shares of its common stock at a price of $2.80 per share for gross proceeds of approximately $20.5 million. Total net proceeds from the offering were approximately $18.9 million, net of underwriting discounts and offering expenses of approximately $1.6 million. The shares were sold under a shelf registration statement on Form S-3 that Checkpoint filed in November 2017 and was declared effective in December 2017 (“the Checkpoint S-3”).

Mustang Underwritten Offering

In June 2020, Mustang completed an underwritten public offering in which it sold 11,455,604 shares of its common stock at a price of $3.25 per share for gross proceeds of approximately $37.2 million. Total net proceeds from the offering were approximately $34.9 million, net of underwriting discounts and offering expenses of approximately $2.3 million. The shares were sold under Mustang’s S-3.

At-the-Market Offering

On June 28, 2019, the Company entered into an At Market Issuance Sales Agreement ("2019 Common ATM"), with Cantor Fitzgerald & Co., Oppenheimer & Co., Inc., H.C. Wainwright & Co. Inc., Jones Trading Institutional Services LLC and B. Riley, as selling agents, governing potential sales of the Company's common stock.

30

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The shares of common stock were sold under the Company’s shelf registration statement on Form S-3 originally filed on July 6, 2018 and declared effective July 23, 2019 (the “2019 Shelf”) through May 27, 2020.

On May 18, 2020, the Company filed a new shelf registration statement on Form S-3, which was declared effective on May 26, 2020 (the "2020 Shelf"). In connection with the 2020 Shelf, the Company entered into an At Market Issuance Sales Agreement ("2020 Common ATM"), with Cantor Fitzgerald & Co., Oppenheimer & Co., Inc., H.C. Wainwright & Co. Inc., B. Riley and Dawson James Securities, Inc., as selling agents, governing potential sales of the Company's common stock. ATM sales commencing on June 1, 2020 were made under the 2020 Shelf.

For the nine-month period ended September 30, 2020, the Company issued approximately 16.4 million shares of common stock at an average price of $2.74 per share for gross proceeds of $44.8 million.  In connection with these sales, the Company paid aggregate fees of approximately $1.6 million.  Approximately $29.5 million of securities remain available for sale under the 2020 Shelf at September 30, 2020.

Mustang At-the-Market Offering

On July 13, 2018, Mustang filed a shelf registration statement No. 333-226175 on Form S-3, as amended on July 20, 2018 (the "2018 Mustang S-3"), which was declared effective in August 2018. Under the 2018 Mustang S-3, Mustang may sell up to a total of $75.0 million of its securities. In connection with the 2018 Mustang S-3, Mustang entered into an At-the-Market Issuance Sales Agreement (the "Mustang ATM") with B. Riley FBR, Inc., Cantor Fitzgerald & Co., National Securities Corporation, and Oppenheimer & Co. Inc. (each an "Agent" and collectively, the "Agents"), relating to the sale of shares of common stock. Under the Mustang ATM, Mustang pays the Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of Mustang common stock.

On August 16, 2019, Mustang filed a shelf registration statement No. 333-233350 on Form S-3, (the "2019 Mustang S-3"), which was declared effective on September 30, 2019. Under the 2019 Mustang S-3, Mustang may sell up to a total of $75.0 million of its securities. On July 20, 2020, Mustang entered into Amendment No. 1 to the Mustang ATM with the Agents to reflect the new registration statement.

During the nine months ended September 30, 2020, Mustang issued approximately 7.2 million shares of common stock at an average price of $3.56 per share for gross proceeds of $25.6 million under the Mustang ATM. In connection with these sales, Mustang paid aggregate fees of approximately $0.5 million for net proceeds of approximately $25.1 million. During the nine months ended September 30, 2019, Mustang issued approximately 3.5 million shares of common stock at an average price of $6.42 per share for gross proceeds of $22.5 million under the Mustang ATM. In connection with these sales, Mustang paid aggregate fees of approximately $0.5 million for net proceeds of approximately $22.0 million. Pursuant to the Founders Agreement, Mustang issued 117,405 shares of common stock to Fortress at a weighted average price of $3.56 per share for the nine months ended September 30, 2020 for the Mustang ATM offering noted above. During the nine months ended September 30, 2019, Mustang issued 87,656 shares of common stock to Fortress at a weighted average price of $6.42 per share in connection with the Mustang ATM.

Approximately $32.6 million of the Mustang shelf remains available for sale under the 2019 Mustang S-3, following the offerings noted above. As of September 30, 2020, the 2018 Mustang S-3 is no longer available for sales of securities.

Checkpoint At-the-Market Offering

Under the Checkpoint S-3, Checkpoint may sell up to a total of $100 million of its securities. In connection with the Checkpoint S-3, Checkpoint entered into an At-the-Market Issuance Sales Agreement (the "Checkpoint ATM") with Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co., LLC (each a "Checkpoint Agent" and collectively, the "Checkpoint Agents"), relating to the sale of shares of common stock. Under the Checkpoint ATM, Checkpoint pays the Checkpoint Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of Checkpoint common stock.

During the nine months ended September 30, 2020, Checkpoint sold a total of 3,614,344 shares of common stock under the Checkpoint ATM for aggregate total gross proceeds of approximately $8.7 million at an average selling price of $2.40 per share, resulting in net proceeds of approximately $8.4 million after deducting commissions and other transaction costs.

31

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Pursuant to the Founders Agreement, Checkpoint issued 273,379 shares of common stock to Fortress at a weighted average price of $2.92 per share for the Checkpoint ATM offerings and the Checkpoint Underwritten Offering, both noted above.

Approximately $12.3 million of the Checkpoint shelf remains available for sale under the Checkpoint S-3, following the offerings noted above.

Share Repurchase Program

On March 23, 2020, the Company announced that its Board of Directors had approved a share repurchase program of the Company's outstanding Preferred Stock in an aggregate amount of up to $5.0 million. Repurchases under the program were made in the open market or through privately-negotiated transactions until the earlier to occur of the repurchase of $5.0 million of the Company's Preferred Stock or the close of trading on May 31, 2020, subject to applicable laws and regulations. The program did not commit the Company to repurchase any shares of Preferred Stock. As of September 30, 2020, 5,000 Preferred Stock shares were repurchased and retired under this program for total consideration of $0.1 million, net of fees of approximately $2,000.

15. Commitments and Contingencies

Most of the Company's lease liabilities result from the lease of its New York City, NY office, which expires in 2031, and Mustang's Worcester, MA cell processing facility lease, which expires in 2026. Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Certain of the Company's leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right of use assets as the Company is not reasonably certain to exercise the options. The Company does not act as a lessor or have any leases classified as financing leases. On September 30, 2020, the Company had operating lease liabilities of $24.6 million and right of use assets of $20.3 million, which were included in the Condensed Consolidated Balance Sheet.

During the three and nine months ended September 30, 2020 and 2019, the Company recorded the following as lease expense, which was recorded in general and administrative expense on the Company's Condensed Consolidated Statement of Operations:

    

Three Months Ended September 30, 

    

Nine Months Ended September 30, 

    

($in thousands)

2020

2019

2020

2019

Lease Cost

 

  

 

  

 

Operating lease cost

$

816

$

798

$

2,436

$

2,397

Shared lease costs

 

(469)

(479)

 

(1,409)

(1,408)

Variable lease cost

 

178

160

 

411

575

Total lease expense

$

525

$

479

$

1,438

$

1,564

The following tables summarize quantitative information about the Company's operating leases, under the adoption of Topic 842, Leases:

    

Nine Months Ended September 30, 

 

    

($in thousands)

2020

2019

 

Operating cash flows from operating leases

$

(2,127)

$

(2,185)

Weighted-average remaining lease term – operating leases (years)

 

5.9

 

6.4

Weighted-average discount rate – operating leases

 

6.2

%  

 

6.2

%

32

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

    

Future Lease

($ in thousands)

Liability

Three Months Ended December 31, 2020

$

839

Year Ended December 31, 2021

 

3,114

Year Ended December 31, 2022

 

3,084

Year Ended December 31, 2023

 

3,137

Year Ended December 31, 2024

 

3,190

Other

 

20,273

Total operating lease liabilities

 

33,637

Less: present value discount

 

(9,085)

Net operating lease liabilities, short-term and long-term

$

24,552

Indemnification

In accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has director and officer insurance to address such claims. Pursuant to agreements with clinical trial sites, the Company provides indemnification to such sites in certain conditions.

Legal Proceedings

In the ordinary course of business, the Company may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company’s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages.

16. Related Party Transactions

The Company’s Chairman, President and Chief Executive Officer, individually and through certain trusts over which he has voting and dispositive control, beneficially owned approximately 10.1% of the Company’s issued and outstanding Common Stock as of September 30, 2020. The Company’s Executive Vice Chairman, Strategic Development owns approximately 10.9% of the Company’s issued and outstanding Common Stock as of September 30, 2020.

Shared Services Agreement with TG Therapeutics, Inc

TG Therapeutics, Inc. ("TGTX") and the Company entered into an arrangement to share the cost of certain research and development employees. The Company’s Executive Vice Chairman, Strategic Development, is also the Executive Chairman and  Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX will reimburse the Company for the salary and benefit costs associated with these employees based upon actual hours worked on TGTX related projects. For the three months ended September 30, 2020 and 2019, the Company invoiced TGTX $0.1 million and $0.1 million, respectively. For the nine months ended September 30, 2020 and 2019, the Company invoiced TGTX $0.3 million and $0.3 million, respectively. On September 30, 2020, the amount due from TGTX related to this arrangement approximated $69,000.

Desk Space Agreements with TGTX and OPPM

In connection with the Company’s Desk Space Agreements with TGTX and Opus Point Partners Management, LLC (“OPPM”), for the three months ended September 30, 2020 and 2019, the Company had paid $0.7 million and $0.7 million in rent under the Desk Space Agreements. For the three months ended September 30, 2020 and 2019, the Company invoiced TGTX approximately $0.4 million and $0.4 million, respectively, and invoiced OPPM nil and approximately $24,000, respectively, for their prorated share of the rent base. On September 30, 2020, the amount due related to this arrangement from TGTX was nil and the amount due from OPPM approximated $0.4 million.

33

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

2019 Notes (formerly the Opus Credit Facility)

On September 13, 2019, the Company and Opus Point Healthcare Innovations Fund, LP (“OPHIF”) extended the maturity date of the 2019 Notes (formerly the “A&R Opus Credit Facility) from September 14, 2019 by two years to September 14, 2021. Terms of the 2019 Notes allows for the Company to make portions of interest and principal repayments in the form of shares of the Company’s common stock and/or in common stock of the Company’s publicly-traded subsidiaries, subject to certain conditions. Fortress retained the ability to prepay the Notes at any time without penalty. The notes payable under the A&R Opus Credit Facility bear interest at 12% per annum.

Effective December 31, 2019, OPHIF dissolved and distributed it assets among its limited partners. Following the distribution, the $9.0 million facility comprised of separate notes (collectively, the “2019 Notes”) held by DAK Capital Inc. ($3.8 million); Fortress’ Chairman, President and Chief Executive Officer Lindsay A. Rosenwald, M.D. ($0.3 million); Fortress's Executive Vice President, Strategic Development Michael S. Weiss ($2.0 million); and various entities and individuals affiliated with Dr. Rosenwald and Mr. Weiss ($2.9 million). The terms of the 2019 Notes did not change in connection with such reallocations.

During the quarter ended September 30, 2020, the Company used certain proceeds from the Oaktree Note to pay off the $9.0 million balance previously outstanding under the 2019 Notes (see Note 10).

For the nine months ended September 30, 2020, in connection with the 2019 Notes, the Company paid $0.5 million in interest on the portion of the 2019 Notes held by the Company's Chairman, President and Chief Executive Officer and the Company's Executive Vice President, Strategic Development. For the nine months ended September 30, 2019, the Company paid $0.2 million in common stock consisting of 91,767 shares at $1.80 per share.

Avenue Credit Facility Agreement

On June 12, 2020, Avenue, the Company and InvaGen entered into a Facility Agreement (“Avenue Facility Agreement”), under which, beginning on October 1, 2020, Avenue may borrow up to $2 million collectively from the Company and InvaGen, subject to certain conditions set forth therein. The Company’s commitment amount is $0.8 million, and InvaGen’s is $1.2 million , and a 7% per annum interest rate applies (payable on the last day of each fiscal quarter).  Repayment of the loan is due upon the earliest to occur of: (i) the Second Stage Closing Date, as defined in the SPMA; (ii) April 29, 2021; and (iii) the date that is 30 days following the termination of the Avenue SPMA.  As of September 30, 2020, there have been no amounts drawn by Avenue on the Avenue Facility Agreement.

34

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Founders Agreements

The Company has entered into Founders Agreements and, in some cases, Exchange Agreements with certain of its subsidiaries as described in the Company's Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. The following table summarizes, by partner company, the effective date of the Founders Agreements and PIK dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, Exchange Agreements, and the subsidiaries' certificates of incorporation:

PIK Dividend as

a % of fully

diluted

outstanding

Class of Stock

Fortress Partner Company

    

Effective Date 1

    

capitalization

    

Issued

Helocyte

March 20, 2015

 

2.5

%  

Common Stock

Avenue

February 17, 2015

 

0.0

%2  

Common Stock

Mustang

March 13, 2015

 

2.5

%  

Common Stock

Checkpoint

March 17, 2015

 

0.0

%3  

Common Stock

Cellvation

October 31, 2016

 

2.5

%  

Common Stock

Caelum

January 1, 2017

 

0.0

%4  

Common Stock

Baergic

December 17, 20195

2.5

%  

Common Stock

Cyprium

March 13, 2017

 

2.5

%  

Common Stock

Aevitas

July 28, 2017

 

2.5

%  

Common Stock

Oncogenuity

April 22, 2020 5

2.5

%

Common Stock

Note 1:

Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement or has since been amended to January 1 of each calendar year.

Note 2:

Concurrently with the execution and delivery of the Stock Purchase and Merger Agreement (“Avenue SPMA”) entered into between, Avenue, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”) (together, the “ SPMA Parties”), the SPMA Parties entered into a waiver agreement (the “Waiver Agreement”), pursuant to which the Company irrevocably waived its right to receive the annual dividend of Avenue’s common shares under the terms of the Class A preferred stock and any fees, payments, reimbursements or other distributions under the management services agreement between the Company and Avenue and the Founders Agreement, for the period from the effective date of the Waiver Agreement to the termination of InvaGen’s rights under the Avenue SPMA. Pursuant to the Waiver Agreement, immediately prior to the closing of the Merger Transaction contemplated under the Avenue SPMA, the Company will convert all of its preferred shares into common shares pursuant to the terms of the certificate of incorporation of Avenue, as amended from time to time.

Note 3:

Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.

Note 4:

Effective January 31, 2019 the Caelum Founders Agreement and MSA with Fortress were terminated in conjunction with the execution of the DOSPA between Caelum and Alexion (See Note 4).

Note 5:

Represents the Trigger Date, the date that the Fortress partner company first acquires, whether by license or otherwise, ownership rights in a product.

35

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Management Services Agreements

The Company has entered in Management Services Agreements (the “MSAs”) with certain of its partner companies as described in the Company’s Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. The following table summarizes the effective date of the MSA and the annual consulting fee payable by the partner company to the Company in quarterly installments:

Annual MSA Fee

Fortress partner company

    

Effective Date

    

(Income)/Expense

Helocyte

March 20, 2015

$

500

Avenue 1

February 17, 2015

 

Mustang

March 13, 2015

 

500

Checkpoint

March 17, 2015

 

500

Cellvation

October 31, 2016

 

500

Baergic

March 9, 2017

 

500

Cyprium

March 13, 2017

 

500

Aevitas

July 28, 2017

 

500

Oncogenuity

February 10, 2017

500

Fortress

 

(4,000)

Consolidated (Income)/Expense

$

Note 1:

Concurrently with the execution and delivery of the Avenue SPMA entered into among, Avenue, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”) (together, the “SPMA Parties”), the SPMA Parties entered into a waiver agreement (the “Waiver Agreement”), pursuant to which the Company irrevocably waived its right to receive the annual dividend of Avenue’s common shares under the terms of the Class A preferred stock and any fees, payments, reimbursements or other distributions under the management services agreement between the Company and Avenue and the Founders Agreement, for the period from the effective date of the Waiver Agreement to the termination of InvaGen’s rights under the Avenue SPMA. Pursuant to the Waiver Agreement, immediately prior to the closing of the Merger Transaction contemplated under the Avenue SPMA, the Company will convert all of its preferred shares into common shares pursuant to the terms of the certificate of incorporation of Avenue, as amended from time to time. (See Note 4).

17. Segment Information

The Company operates in two reportable segments, Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results from continued operations by reportable segment:

Pharmaceutical

    

and

($in thousands)

Dermatology

Biotechnology

Products

Product

Three Months Ended September 30, 2020

    

Sales

    

Development

    

Consolidated

Net revenue

$

9,447

$

28

$

9,475

Direct cost of goods

 

(3,379)

 

 

(3,379)

Sales and marketing costs

 

(4,649)

 

 

(4,649)

Research and development

 

 

(13,756)

 

(13,756)

General and administrative

(1,254)

(9,480)

(10,734)

Other expense

 

(113)

 

(6,808)

 

(6,921)

Segment income (loss)

$

52

(30,016)

$

(29,964)

Segment assets

Intangible assets, net

11,039

11,039

Tangible assets

21,108

263,732

284,840

Total segment assets

$

32,147

$

263,732

$

295,879

36

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Pharmaceutical

and

Dermatology

Biotechnology

($ in thousands)

Products

Product

Three Months Ended September 30, 2019

    

Sales

    

Development

    

Consolidated

Net revenue

$

9,492

$

280

$

9,772

Direct cost of goods

 

(2,702)

 

(2,702)

Sales and marketing costs

 

(4,370)

 

(4,370)

Research and development

 

 

(15,271)

(15,271)

General and administrative

 

(669)

 

(9,300)

(9,969)

Other expense

(108)

(2,322)

(2,430)

Segment income (loss)

$

1,643

$

(26,613)

$

(24,970)

Segment assets

Intangible assets, net

7,731

7,731

Tangible assets

10,966

202,891

213,857

Total segment assets

$

18,697

$

202,891

$

221,588

Pharmaceutical

  

and

Dermatology

Biotechnology

($in thousands)

Products

Product

  

Nine Months Ended September 30, 2020

    

Sales

    

Development

    

Consolidated

Net revenue

$

30,808

$

1,042

$

31,850

Direct cost of goods

 

(10,313)

 

 

(10,313)

Sales and marketing costs

 

(12,728)

 

 

(12,728)

Research and development

 

 

(46,146)

 

(46,146)

General and administrative

 

(3,556)

 

(29,074)

 

(32,630)

Other expense

 

(492)

 

(12,036)

 

(12,528)

Segment income (loss)

$

3,719

 

(86,214)

$

(82,495)

Segment assets

 

  

 

  

 

  

Intangible assets, net

 

11,039

11,039

Tangible assets

 

21,108

263,732

284,840

Total segment assets

$

32,147

$

263,732

$

295,879

Pharmaceutical

 and 

Dermatology

Biotechnology

($in thousands)

Products

Product

Nine Months Ended September 30, 2019

    

Sales

    

Development

    

Consolidated

Net revenue

$

23,816

$

1,683

$

25,499

Direct cost of goods

 

(6,972)

 

 

(6,972)

Sales and marketing costs

 

(12,064)

 

 

(12,064)

Research and development

 

 

(57,705)

 

(57,705)

General and administrative

 

(1,808)

 

(27,388)

 

(29,196)

Other expense

 

(108)

 

11,841

 

11,733

Segment income (loss)

$

2,864

$

(71,569)

$

(68,705)

Segment assets

Intangible assets, net

 

7,731

7,731

Tangible assets

 

10,966

202,891

213,857

Total segment assets

$

18,697

$

202,891

$

221,588

37

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

18. Revenues from Contracts and Significant Customers

Disaggregation of Total Revenue

Product revenue is comprised of Journey’s five marketed products: Targadox®, Luxamend®, Ceracade®, Exelderm® and Ximino®. Substantially all of the product revenue is recorded in the U.S. The Company’s related party revenue is from Checkpoint’s collaboration with TGTX. The table below summarizes the Company’s revenue for the three and nine months ending September 30, 2020 and 2019:

Three months ended September 30, 

Nine Months Ended September 30, 

    

2020

    

2019

    

2020

    

2019

    

Revenue

Product revenue, net

$

9,447

$

9,492

$

30,808

$

23,816

Revenue – related party

 

28

 

280

 

1,042

 

1,683

Net revenue

$

9,475

$

9,772

$

31,850

$

25,499

Significant Customers

For the three months ended September 30, 2020, none of the Company’s Dermatology Products customers accounted for more than 10% of its total gross product revenue.

For the nine months ended September 30, 2020, one of the Company’s Dermatology Products customers accounted for more than 10% of its total gross product revenue.

For the three and nine months ended September 30, 2019, gross product revenue under the 3PL Title Model accounted for approximately 60% and 76%, respectively.

At September 30, 2020, one of the Company’s Dermatology Products customers accounted for more than 10% of its total accounts receivable balance at 14.5%.

At September 30, 2019, two of the Company’s Dermatology Products customers accounted for more than 10% of its total accounts balance in the amounts of $3.5 million and $2.8 million.

19. Income taxes

In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer's social security payments, net operating loss utilization and carryback periods and modifications to the net interest deduction limitations. At this time, the Company does not believe that the CARES Act will have a material impact on its income tax provision for 2020. The Company will continue to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.

The Company and its subsidiaries are subject to US federal and state income taxes. Income tax expense is the total of the current year income tax due or refundable and the change in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of Management, it is more likely than not that some portion, or all, of the deferred tax asset will not be realized.

38

Table of Contents

FORTRESS BIOTECH, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The Company files a consolidated income tax return with subsidiaries for which the Company has an 80% or greater ownership interest. Subsidiaries for which the Company does not have an 80% or more ownership are not included in the Company’s consolidated income tax group and file their own separate income tax return. As a result, certain corporate entities included in these financial statements are not able to combine or offset their taxable income or losses with other entities’ tax attributes.

Income tax expense for the three and nine months ended September 30, 2020 and 2019 is based on the estimated annual effective tax rate.

39

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included elsewhere in this Form 10-Q. Our consolidated financial statements have been prepared in accordance with U.S. GAAP. The following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), including, without limitation, statements regarding our expectations, beliefs, intentions or future strategies that are signified by the words “expect,” “anticipate,” “intend,” “believe,” “may,” “plan”, “seek” or similar language. All forward-looking statements included in this document are based on information available to us on the date hereof and we assume no obligation to update any such forward-looking statements. For such forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Our business and financial performance are subject to substantial risks and uncertainties. Actual results could differ materially, from those projected in the forward-looking statements. In evaluating our business, you should carefully consider the information set forth under the heading “Risk Factors” herein and in our Annual Report on Form 10-K for the year ended December 31, 2019.

Overview

We are a biopharmaceutical company dedicated to acquiring, developing and commercializing pharmaceutical and biotechnology products and product candidates, which we do at the Fortress level, at our majority-owned and majority-controlled subsidiaries and joint ventures, and at entities we founded and in which we maintain significant minority ownership positions. Fortress has a talented and experienced business development team, comprising scientists, doctors, and finance professionals, who identify and evaluate promising products and product candidates for potential acquisition by new or existing partner companies. Through our partner companies, we have executed such arrangements in partnership with some of the world’s foremost universities, research institutes and pharmaceutical companies, including City of Hope National Medical Center, Fred Hutchinson Cancer Research Center, St. Jude Children’s Research Hospital, Dana-Farber Cancer Institute, Nationwide Children’s Hospital, Cincinnati Children’s Hospital Medical Center, Columbia University, the University of Pennsylvania, and AstraZeneca plc.

Following the exclusive license or other acquisition of the intellectual property underpinning a product or product candidate, we leverage our business, scientific, regulatory, legal and finance expertise to help our partners achieve their goals. Our partner companies then assess a broad range of strategic arrangements to accelerate and provide additional funding to support research and development, including joint ventures, partnerships, out-licensings, and public and private financings; to date, three partner companies are publicly-traded, and two have consummated strategic partnerships with industry leaders Alexion Pharmaceuticals, Inc. and InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Limited).

Recent Events

Marketed Dermatology Products

During the three and nine months ended September 30, 2020, through our partner company Journey Medical Corporation (“Journey” or “JMC”), our marketed products generated net revenue of $9.4 million and $30.8 million, respectively.

Late Stage Product Candidates

Intravenous (IV) Tramadol

IV Tramadol is currently in development with our partner company, Avenue Therapeutics, Inc. (“Avenue”) (NASDAQ: ATXI). Avenue submitted a new drug application (“NDA”) for IV Tramadol to treat moderate to moderately severe postoperative pain pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act (“FDCA”) in December 2019. On October 12, 2020, Avenue announced it received a Complete Response Letter (“CRL”) from the U.S Food and Drug Administration (“FDA”) regarding its New Drug Application (“NDA”) for IV tramadol.  The CRL cited deficiencies related to the terminal sterilization validation and stated that IV Tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population. Avenue has a meeting scheduled with the FDA for the fourth quarter of 2020 to discuss the issues cited in the CRL.

40

In October 2020, InvaGen Pharmaceuticals Inc. (“InvaGen”) communicated to Avenue that it believes a Material Adverse Effect (as defined in the Stock Purchase and Merger Agreement (“Avenue SPMA”)) has occurred, due to the COVID-19 pandemic, which means that it is possible that InvaGen is attempting to avoid their obligations to consummate the second stage closing under the Avenue SPMA. Avenue disagrees with InvaGen’s assertion that a Material Adverse Effect has occurred, and Avenue has advised InvaGen of this position.

CUTX-101 (Copper Histidinate)

In July 2020, Cyprium announced that the European Medicines Agency (“EMA”) Committee for Orphan Medicinal Products issued a positive opinion on Cyprium’s application for Orphan Drug Designation for Copper Histidinate, also referred to as CUTX-101, a potential treatment for Menkes disease. Menkes disease is a rare X-linked recessive pediatric disease caused by genetic mutations of the copper transporter, ATP7A. The FDA previously granted Orphan Drug and Fast Track Designations to CUTX-101 for the treatment of Menkes disease. The FDA grants Rare Pediatric Disease Designation for serious and life-threatening diseases that primarily affect children ages 18 years or younger and fewer than 200,000 people in the United States.

In August 2020, Cyprium reported positive topline clinical efficacy results for CUTX-101. The study demonstrated statistically significant improvement in overall survival for Menkes disease subjects who received early treatment (ET) with CUTX-101, compared to an untreated historical control (HC) cohort, with a nearly 80% reduction in the risk of death (Hazard Ratio = 0.21, p<0.0001). Median survival for the ET cohort was 14.8 years (177.1 months) compared to 1.3 years (15.9 months) for the untreated HC cohort. 

Cyprium intends to begin the rolling submission of the NDA for CUTX-101 to the FDA by the first quarter of 2021. If Cyprium’s NDA is approved, it may be eligible to receive a priority review voucher, which can be redeemed to obtain priority review for any subsequent marketing application and may be sold or transferred.

MB-107/MB-207 (Ex vivo Lentiviral Therapies for X-linked Severe Combined Immunodeficiency (XSCID))

In August 2020, Mustang announced that the FDA granted Rare Pediatric Disease Designation to MB-107,  a lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease, in newly-diagnosed infants, and to MB-207, a lentiviral gene therapy for the treatment of patients with XSCID who were previously treated with a hematopoietic stem cell transplantation (“HSCT”) and for whom re-treatment is indicated.

In September 2020, Mustang announced that the FDA granted Orphan Drug Designation to MB-107 for the treatment of XSCID in newly-diagnosed infants and to MB-207 for the treatment of patients with XSCID who were previously treated with a HSCT and for whom re-treatment is indicated.

Mustang had previously received Advanced Therapy Medicinal Product (“ATMP”) classification from the European Medicines Agency (“EMA”) for MB-107 in April 2020, as well as Regenerative Medicine Advanced Therapy (“RMAT”) designation from the FDA for MB-107 in August 2019.

In October 2020, Mustang licensed LentiBOOST™ technology from SIRION Biotech GmbH (“SIRION”) for the development of MB-207.

In May 2020, Mustang submitted an Investigational New Drug (“IND”) application with the FDA to initiate a registrational multicenter Phase 2 clinical trial of MB-107 in newly diagnosed infants with XSCID who are under the age of two. The trial is expected to enroll 10 patients who, together with 15 patients enrolled in the current multicenter trial led by St. Jude Children’s Research Hospital, will be compared with 25 matched historical control patients who have undergone HSCT. The primary efficacy endpoint will be event-free survival. The initiation of this trial is currently on hold pending CMC clearance by the FDA, and this clearance is expected in the first quarter of 2021. We are targeting topline data from the trial in the fourth quarter of 2022.

Mustang expects to file an IND in the first quarter of 2021 for a registrational multi-center Phase 2 clinical trial of its lentiviral gene therapy in previously transplanted XSCID patients (MB-207).  Mustang anticipates enrolling 20 patients and comparing them to matched historical control patients who have undergone a second HSCT. Mustang is targeting topline data for this trial in the fourth quarter of 2022.

41

Cosibelimab (anti-PD-L1 antibody (formerly CK-301))

In September 2020, Checkpoint announced updated interim results from the ongoing global, open-label, multicohort, Phase 1 clinical trial of its anti-PD-L1 antibody, cosibelimab, in patients with advanced cancers, including the registration-enabling cohort of patients with metastatic cutaneous squamous cell carcinoma (“mCSCC”). Cosibelimab demonstrated a 51.4% objective response rate (“ORR”) and 13.5% complete response rate, which is nearly double the complete response rate observed at the time of previous analysis.

The registration-enabling study in mCSCC is currently over 50% enrolled, with full enrollment anticipated in early 2021. Checkpoint is on track to report full top-line results in the second half of 2021. Additional information on the Phase 1 trial can be found on www.ClinicalTrials.gov using identifier NCT03212404.  

CAEL-101 (light chain fibril-reactive monoclonal antibody for AL amyloidosis)

In September 2020, Caelum announced the initiation of two Phase 3 studies of CAEL-101 for AL amyloidosis. The Phase 2 study met its primary objective, supporting initiation of the two parallel Phase 3 studies that will enroll ~370 AL amyloidosis patients.  The Phase 2 program continues with the addition of a study arm to evaluate CAEL-101 in combination with SoC therapy plus daratumumab.

Positive long-term Phase 1a/1b data presented at the International Symposium on Amyloidosis (ISA) 2020 demonstrated prolonged overall survival (78 percent at 37 months) and durable organ response.  CAEL-101 is currently in development at Caelum in collaboration with Alexion Pharmaceuticals, Inc.

Early Stage Product Candidates

MB-102 (CD123-targeted CAR T cell therapy)

In October 2020, Mustang announced that the first patient was been dosed in an open label, multicenter Phase 1/2 clinical trial to evaluate the safety and efficacy of MB-102 (CD123-targeted CAR T cell therapy) in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (“BPDCN”), acute myeloid leukemia (“AML”) and high-risk myelodysplastic syndrome (“hrMDS”).  Study sites include City of Hope, where the CAR T cell therapy was initially developed and where the clinical data were generated to support Mustang’s current multicenter trial, Dana-Farber Cancer Institute, Duke University and MD Anderson Cancer Center.  Additional information on the Phase 1/2 trial can be found on www.ClinicalTrials.gov using identifier NCT04109482.

ONCOlogues (proprietary platform technology using PNA oligonucleotides)

In May 2020, we entered into an exclusive worldwide licensing agreement with Columbia University to develop novel oligonucleotides for the treatment of genetically driven cancers. The proprietary platform produces oligomers, known as “ONCOlogues,” which are capable of binding gene sequences 1,000 times more effectively than complementary native DNA. ONCOlogues invade a DNA double helix and displace native mutated strands. This prevents the mRNA that antisense binds to from ever being created. It is active higher upstream than traditional antisense approaches as well as potentially more potent and broader in its utility.

In addition, we are exploring the potential of the platform to treat novel coronaviruses, such as COVID-19.

The ONCOlogues platform is currently in development at our partner company, Oncogenuity, Inc.

General Corporate

In August 2020, Fortress closed an underwritten public offering of 666,666 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (“Series A Preferred Stock”), (plus a 45-day option to purchase up to an additional 66,666 shares, which was exercised in August 2020) at a price of $18.00 per share for gross proceeds of approximately $13.2 million, before deducting underwriting discounts and commissions and offering expenses of $1.1 million.

Coupled with the February and May 2020 underwritten offerings of Series A Preferred Stock, Fortress has raised gross proceeds of approximately $39.1 million as of September 30, 2020 through the sale of its Series A Preferred Stock.

On June 28, 2019, Fortress entered into an At Market Issuance Sales Agreement (“2019 Common ATM”), with Cantor Fitzgerald & Co., Oppenheimer & Co., Inc., H.C. Wainwright & Co. Inc., Jones Trading Institutional Services LLC and B. Riley, as selling agents, governing potential sales of the Company’s common stock. From January 1, 2020 through November 5, 2020 the Company issued approximately 16.4 million shares of common stock for gross proceeds of $44.8 million at an average selling price of $2.74.

42

Also in August 2020, Fortress announced a $60 million loan agreement with Oaktree Capital Management (“Oaktree Note”).  The proceeds from this loan were used to pay off the balances outstanding under the 2017 Subordinated Note Financing, the 2018 Venture Notes, and the 2019 Notes.  The loan agreement will mature in August 2025.

Critical Accounting Policies and Use of Estimates

See Note 2 to the Condensed Consolidated Financial Statements.

Results of Operations

General

For the three and nine months ended September 30, 2020, we generated $9.5 million and $31.9 million, respectively, of net revenue, of which $9.4 million and $30.8 million, respectively, relates primarily to the sale of Journey branded and generic products and approximately $28,000 and $1.0 million, respectively, relates to Checkpoint’s collaborative agreements with TG Therapeutics Inc. (“TGTX”). As of September 30, 2020, we had an accumulated deficit of $477.5 million. While we may in the future generate revenue from a variety of sources, including license fees, milestone payments, research and development payments in connection with strategic partnerships and/or product sales, our and our subsidiaries’ current product candidates are at an early stage of development and may never be successfully developed or commercialized. Accordingly, we expect to continue to incur substantial losses from operations for the foreseeable future, and there can be no assurance that we will ever generate significant revenues.

For the three and nine months ended September 30, 2020, we had $3.4 million and $10.3 million, respectively, of costs of goods sold in connection with the sale of Journey’s marketed products, compared to $2.7 million and $7.0 million, respectively, for the three and nine months ended September 30, 2019. The increase is as a result of the amortization of license fees including the drug user fee related to the expansion of the marketed product portfolio as well as higher royalty fees attributed directly to the increase in net sales.

Research and Development Expenses

Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings and patents, laboratory costs and other supplies.

For the three months ended September 30, 2020 and 2019, research and development expenses were approximately $13.3 million and $14.6 million, respectively. Additionally, during the three months ended September 30, 2020 and 2019, we expensed approximately $0.5 million and $0.7 million, respectively, in costs related to the acquisition of licenses. Noncash, stock-based compensation expense included in research and development for the three months ended September 30, 2020 and 2019, was $0.7 million and $1.2 million, respectively.

The table below provides a summary of research and development costs associated with the development of our licenses by entity, for the quarter ended September 30, 2020 and 2019, by entity:

Three Months Ended September 30, 

% of total

($ in thousands)

    

2020

    

2019

    

2020

    

2019

 

Research & Development

 

  

 

  

 

  

 

  

Fortress

$

364

$

707

 

3

%

5

%

Partner Companies:

 

 

 

Avenue

 

466

 

1,706

 

4

%

12

%

Checkpoint

 

2,543

 

3,894

 

19

%

27

%

Mustang

 

7,925

 

7,247

 

60

%

50

%

Other1

 

2,000

 

1,017

 

14

%

6

%

Total Research & Development Expense

$

13,298

$

14,571

 

100

%

100

%

Note 1:

Includes the following partner companies: Aevitas, Baergic (2020 only), Cellvation, Cyprium, Helocyte, Oncogenuity (2020 only) and Tamid (2019 only).

43

General and Administrative Expenses

General and administrative expenses consist principally of sales and marketing costs, personnel-related costs, professional fees for legal, consulting, audit and tax services, rent and other general operating expenses not otherwise included in research and development expenses. For the three months ended September 30, 2020 and 2019, general and administrative expenses were approximately $15.4 million and $14.3 million, respectively. Noncash, stock-based compensation expense included in general and administrative expenses for the three months September 30, 2020 and 2019, was $2.5 million and $2.5 million, respectively.  

The table below provides a summary of general and administrative costs for the quarter ended September 30, 2020 and 2019, by entity:

 

Three Months Ended September 30, 

% of Total

($ in thousands)

    

2020

    

2019

    

    

2020

2019

 

General & Administrative

Fortress

$

5,289

$

4,994

 

34

%

35

%

Partner Companies:

 

 

 

Avenue

 

571

 

617

 

4

%

4

%

Checkpoint

 

1,573

 

1,403

 

10

%

10

%

JMC1

 

5,829

 

5,038

 

38

%

35

%

Mustang

 

1,640

 

1,924

 

11

%

13

%

Other2

 

481

 

363

 

3

%

3

%

Total General & Administrative Expense

$

15,383

$

14,339

 

100

%

100

%

Note 1:

Includes cost of outsourced sales force for the three months ended September 30, 2020 and 2019 of $2.9 million and $2.5 million, respectively.

Note 2:

Includes the following partner companies: Aevitas, Baergic (2020 only), Cellvation, Cyprium, Helocyte, Oncogenuity (2020 only) and Tamid (2019 only).

Comparison of three months ended September 30, 2020 and 2019

 

Three Months Ended September 30, 

Change

($ in thousands)

    

2020

    

2019

    

$

    

%

 

Revenue

Product revenue, net

$

9,447

$

9,492

$

(45)

 

0

%

Revenue – related party

 

28

 

280

 

(252)

 

(90)

%

Net revenue

 

9,475

 

9,772

 

(297)

 

(3)

%

Operating expenses

 

 

 

 

Cost of goods sold – product revenue

 

3,379

 

2,702

 

677

 

25

%

Research and development

 

13,298

 

14,571

 

(1,273)

 

(9)

%

Research and development – licenses acquired

 

458

 

700

 

(242)

 

(35)

%

General and administrative

 

15,383

 

14,339

 

1,044

 

7

%

Total operating expenses

 

32,518

 

32,312

 

206

 

1

%

Loss from operations

 

(23,043)

 

(22,540)

 

(503)

 

2

%

Other income (expense)

 

 

  

 

 

Interest income

 

265

 

738

 

(473)

 

(64)

%

Interest expense and financing fee

 

(6,958)

 

(3,168)

 

(3,790)

 

120

%

Change in fair value of derivative liability

 

(803)

 

 

(803)

 

100

%

Change in fair value of investment

575

 

 

575

 

100

%

Gain on deconsolidation of Caelum

 

 

 

 

100

%

Total other expense

 

(6,921)

 

(2,430)

 

(4,491)

 

185

%

Net Loss

 

(29,964)

 

(24,970)

 

(4,994)

 

20

%

Less: net loss attributable to non-controlling interest

 

14,417

 

12,208

 

2,209

 

18

%

Net loss attributable to common stockholders

$

(15,547)

$

(12,762)

$

(2,785)

 

22

%

44

Net revenues decreased $0.3 million or 3% from the three months ended September 30, 2019 to the three months ended September 30, 2020 due to a temporary supply shortage for Ximino in September 2020, which resulted in flat net revenue for Journey, as well as a decrease in collaboration revenue between Checkpoint and TGTX. Related party revenue for the three months ended September 30, 2019 included $0.2 million from TGTX for the purchase of clinical material of cosibelimab not replicated in the current quarter.

Cost of goods sold increased by $0.7 million or 25% from the three months ended September 30, 2019 to the three months ended September 30, 2020 due to the increase in the amortization of license fees including the drug user fee related to the expansion of Journey’s marketed product portfolio.

Research and development expenses decreased $1.3 million or 9% from the three months ended September 30, 2019 to the three months ended September 30, 2020. The following table shows the change in research and development spending by Fortress and its partner companies:

Three Months Ended September 30, 

September 30, 

Change

 

($in thousands)

    

2020

    

2019

    

$

    

%

    

Research & Development

Stock-based compensation

 

  

 

  

 

  

  

Fortress

$

207

$

158

$

49

31

%

Partner Companies:

 

  

 

  

 

  

Avenue

 

62

 

140

 

(78)

(56)

%

Checkpoint

 

156

 

179

 

(23)

(13)

%

Mustang

 

258

 

731

 

(473)

(65)

%

Other1

 

15

 

3

 

12

400

%

Sub-total stock-based compensation expense

 

698

 

1,211

 

(513)

(42)

%

Other Research & Development

 

  

 

  

 

  

Fortress

 

157

 

549

 

(392)

(71)

%

Partner Companies:

 

  

 

  

 

  

Avenue

 

404

 

1,566

 

(1,162)

(74)

%

Checkpoint

 

2,388

 

3,715

 

(1,327)

(36)

%

Mustang

 

7,667

 

6,516

 

1,151

18

%

Other1

 

1,984

 

1,014

 

970

96

%

Total Research & Development Expense

$

13,298

$

14,571

$

(1,273)

(9)

%

Note 1:

Includes the following partner companies: Aevitas, Baergic (2020 only), Cellvation, Cyprium, Helocyte, Oncogenuity (2020 only) and Tamid (2019 only).

The decrease in stock-based compensation for the quarter ended September 30, 2020 is primarily due to the effect of fully vested and forfeited equity grants to key employees and non-employees at Mustang.

The decrease in research and development expense of $1.2 million at Avenue is mainly due to NDA preparation costs and the completion of Avenue’s abdominoplasty and safety studies; the decreased spending at Checkpoint of $1.3 million is attributable primarily to reduced manufacturing and clinical costs related to Checkpoint’s product candidates. Mustang’s increase in research and development spending of $1.2 million is attributable to increased costs associated with third-party vector manufacturing and personnel related expenses. The increase in “Other” of $0.1 million is attributable to increased spend in the three months ended September 30, 2020 as compared to the three months ended September 30, 2019 Cyprium, as Cyprium prepares to file for its rolling NDA.

45

General and administrative expenses increased $1.0 million, or 7%, from the three months ended September 30, 2019 to the three months ended September 30, 2020. The following table shows the change in general and administrative spending by Fortress and its partner companies:

 

Three Months Ended September 30, 

Change

 

($in thousands)

    

2020

    

2019

    

$

    

%

 

General & Administrative

Stock-based compensation

 

  

 

  

 

  

  

Fortress

$

1,425

$

1,248

$

177

14

%

Partner Companies:

 

  

 

  

 

  

Avenue

 

99

 

158

 

(59)

(37)

%

Checkpoint

 

569

 

654

 

(85)

(13)

%

Mustang

 

348

 

389

 

(41)

(11)

%

Other2

 

32

 

81

 

(49)

(60)

%

Sub-total stock-based compensation expense

 

2,473

 

2,530

 

(57)

(2)

%

Other General & Administrative

 

  

 

  

 

  

Fortress

 

3,864

 

3,746

 

118

3

%

Partner Companies:

 

  

 

  

 

  

Avenue

 

472

 

459

 

13

3

%

Checkpoint

 

1,004

 

749

 

255

34

%

JMC1

 

5,797

 

5,038

 

759

15

%

Mustang

 

1,292

 

1,535

 

(243)

(16)

%

Other2

 

481

 

282

 

199

71

%

Total General & Administrative Expense

$

15,383

$

14,339

$

1,044

7

%

Note 1:

Includes cost of outsourced sales force for the three months ended September 30, 2020 and 2019 of $2.9 million and $2.5 million, respectively.

Note 2:

Includes the following partner companies: Aevitas, Baergic (2020 only), Cellvation, Cyprium, Helocyte, Oncogenuity (2020 only) and Tamid (2019 only). “Other” with regards to stock-based compensation expense includes JMC.

For the quarter ended September 30, 2020, the increase in general and administrative expenses of $1.0 million or 7% is primarily attributable to Journey’s increase in sales headcount, with 35 sales reps in the quarter ended September 30, 2019 vs. 40 in the quarter ended September 30, 2020, as well as Checkpoint’s increase in expenses related to professional fees and investor relations.

Total other expense increased $4.5 million, or 185%, from $2.4 million for the three months ended September 30, 2019 to $6.9 million for the three months ended September 30, 2020, primarily due to the interest expense and financing fee associated with the Oaktree Note and the debt payoff, and the change in fair value of derivative liabilities related to the warrants issued by Cyprium of $0.8 million recorded in the three months ended September 30, 2020.

46

Net loss attributable to common stockholders increased $2.9 million, or 22%, from a net loss of $12.8 million for the three months ended September 30, 2019 to a net loss of $15.5 million for the three months ended September 30, 2020.

Comparison of nine months ended September 30, 2020 and 2019

    

Nine Months Ended September 30, 

    

Change

($in thousands)

    

2020

    

2019

    

$

    

%

 

Revenue

Product revenue, net

$

30,808

$

23,816

$

6,992

29

%

Revenue – related party

 

1,042

 

1,683

 

(641)

(38)

%

Net revenue

 

31,850

 

25,499

 

6,351

25

%

Operating expenses

Cost of goods sold – product revenue

 

10,313

 

6,972

 

3,341

48

%

Research and development

 

43,868

 

56,355

 

(12,487)

(22)

%

Research and development – licenses acquired

 

2,278

 

1,350

 

928

69

%

General and administrative

 

45,358

 

41,260

 

4,098

10

%

Total operating expenses

 

101,817

 

105,937

 

(4,120)

(4)

%

Loss from operations

 

(69,967)

 

(80,438)

 

10,471

(13)

%

Other income (expense)

 

 

  

 

  

Interest income

 

1,228

 

1,955

 

(727)

(37)

%

Interest expense and financing fee

 

(13,142)

 

(8,743)

 

(4,399)

50

%

Change in fair value of derivative liability

 

(1,189)

 

 

(1,189)

100

%

Change in fair value of investment

575

 

 

575

100

%

Gain on deconsolidation of Caelum

 

 

18,521

 

(18,521)

(100)

%

Total other (expense) income

 

(12,528)

 

11,733

 

(24,261)

(207)

%

Net loss

 

(82,495)

 

(68,705)

 

(13,790)

20

%

Less: net loss attributable to non-controlling interest

 

41,264

 

44,237

 

(2,973)

(7)

%

Net loss attributable to common stockholders

$

(41,231)

$

(24,468)

$

(16,763)

69

%

Net revenues increased $6.4 million or 25% from the nine months ended September 30, 2019 to the nine months ended September 30, 2020. The increase in net revenue is related to an increase in product revenue of $7.0 million associated with Journey’s marketed products driven by the expansion of its product lines and overall sales growth, offset by a decrease of $0.6 million in collaboration revenue between Checkpoint and TGTX.

Cost of goods sold increased by $3.3 million or 48% from the nine months ended September 30, 2019 to the nine months ended September 30, 2020 due to the increase in Journey marketed products revenue in the current nine-month period as compared to the prior period.

47

Research and development expenses decreased $12.5 million or 22% from the nine months ended September 30, 2019 to the nine months ended September 30, 2020. The following table shows the change in research and development spending by Fortress and its partner companies:

 

Nine Months Ended September 30, 

Change

($ in thousands)

    

2020

    

2019

    

$

    

%

 

Research & Development

Stock-based compensation

 

  

 

  

 

  

 

  

Fortress

$

611

$

447

$

164

 

37

%

Partner Companies:

 

 

 

 

Avenue

 

231

 

505

 

(274)

 

(54)

%

Checkpoint

 

462

 

559

 

(97)

 

(17)

%

Mustang

 

1,156

 

1,116

 

40

 

4

%

Other1

 

26

 

8

 

18

 

225

%

Sub-total stock-based compensation expense

 

2,486

 

2,635

 

(149)

 

(6)

%

Other Research & Development

 

 

 

 

Fortress

 

775

 

1,454

 

(679)

 

(47)

%

Partner Companies:

 

 

 

 

Avenue

 

2,151

 

17,834

 

(15,683)

 

(88)

%

Checkpoint

 

7,745

 

12,036

 

(4,291)

 

(36)

%

Mustang

 

25,788

 

19,789

 

5,999

 

30

%

Other1

 

4,923

 

2,607

 

2,316

 

89

%

Total Research & Development Expense

$

43,868

$

56,355

$

(12,487)

 

(22)

%

Note 1:

Includes the following partner companies: Aevitas, Baergic (2020 only), Cellvation, Cyprium, Helocyte, Oncogenuity (2020 only) and Tamid (2019 only).

The increase in stock-based compensation for the nine months ended September 30, 2020 is primarily due to additional equity grants to key employees and non-employees at Fortress and Mustang.

The decrease in research and development expense of $15.7 million at Avenue is due to the completion of Avenue’s abdominoplasty and safety studies; the decreased spending at Checkpoint of $4.3 million is attributable primarily to manufacturing costs related to cosibelimab incurred in the nine months ended September 30, 2019 and were not replicated in the current nine month period and a reduction in clinical costs for CK-101. Mustang’s increase in research and development spending of $6.0 million is attributable to personnel costs due to increased headcount and increased spending on third-party vector manufacturing, third-party contract research organizations, as well as consulting and sponsored research and clinical trial agreements. The increase in “Other” of $2.3 million is attributable to increased spend in the nine months ended September 30, 2020 as compared to the nine months ended September 30, 2019 primarily attributable to development costs associated with our partner company Cyprium, as Cyprium prepares to file for its rolling NDA.

48

General and administrative expenses increased $4.1 million, or 10%, from the nine months ended September 30, 2019 to the nine months ended September 30, 2020. The following table shows the change in general and administrative spending by Fortress and its partner companies:

 

Nine Months Ended September 30, 

Change

($ in thousands)

    

2020

    

2019

    

$

    

%

 

General & Administrative

 

  

 

  

 

  

  

Stock-based compensation

 

  

 

  

 

  

  

Fortress

$

4,490

$

3,590

$

900

25

%

Partner Companies:

 

 

 

Avenue

 

361

 

1,079

 

(718)

(67)

%

Checkpoint

 

1,633

 

1,885

 

(252)

(13)

%

Mustang

 

1,212

 

1,058

 

154

15

%

Other2

 

137

 

176

 

(39)

(22)

%

Sub-total stock-based compensation expense

 

7,833

 

7,788

 

45

1

%

Other General & Administrative

 

 

 

Fortress

 

11,639

 

10,165

 

1,474

15

%

Partner Companies:

 

 

 

Avenue

 

1,471

 

1,373

 

98

7

%

Checkpoint

 

2,989

 

2,623

 

366

14

%

JMC1

 

16,284

 

13,872

 

2,412

17

%

Mustang

 

4,119

 

4,613

 

(494)

(11)

%

Other2

 

1,023

 

826

 

197

24

%

Total General & Administrative Expense

$

45,358

$

41,260

$

4,098

10

%

Note 1:

Includes cost of outsourced sales force for the nine months ended September 30, 2020 and 2019 of $7.5 million and $7.4 million, respectively.

Note 2:

Includes the following partner companies: Aevitas, Baergic (2020 only), Cellvation, Cyprium, Helocyte, Oncogenuity (2020 only) and Tamid (2019 only). “Other” with regards to stock-based compensation expense includes JMC.

For the nine months ended September 30, 2020, the increase in general and administrative expenses of $4.1 million or 10% is primarily attributable to Journey’s sales and marketing cost increases due to the increased sales headcount as well as the product portfolio, and Fortress’ increase due to increased headcount-related costs, professional fees for ongoing business development activities as well as legal expenses, accounting fees, and costs associated with investor relations.

Total other income (expense) decreased $24.3 million, or 207%, from income of $11.7 million for the nine months ended September 30, 2019 to expense of $12.5 million for the nine months ended September 30, 2020, primarily due to the gain on deconsolidation of Caelum of $18.5 million recorded in the nine months ended September 30, 2019 as well as an increase in financing fees of $4.4 million attributable to the repayment of debt.

Net loss attributable to common stockholders increased $16.8 million, or 69%, from a net loss of $24.5 million for the nine months ended September 30, 2019 to a net loss of $41.2 million for the nine months ended September 30, 2020.

Liquidity and Capital Resources

We will require additional financing to fully develop and prepare regulatory filings and obtain regulatory approvals for our existing and new product candidates, fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for our potential products, and sales and marketing capabilities. We have funded our operations to date primarily through the sale of equity and debt securities. We believe that our current cash and cash equivalents is sufficient to fund operations for at least the next twelve months. Our failure to raise capital as and when needed would have a material adverse impact on our financial condition and our ability to pursue our business strategies. We may seek funds through equity or debt financings, collaborative or other arrangements with corporate sources, sales of stakes in partner companies, the contingent acquisitions of Avenue and Caelum, or through other sources of financing.

49

In addition to the foregoing, based on the Company’s current assessment, the Company does not expect any material impact on its long-term development timeline and its liquidity due to the worldwide spread of the COVID-19 virus. However, the Company is continuing to assess the effect on its operations by monitoring the spread of COVID-19 and the actions implemented to combat the virus throughout the world.

Cash Flows for the Nine Months Ended September 30, 2020 and 2019

Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

Statement of cash flows data:

 

  

 

  

Total cash (used in)/provided by:

 

  

 

  

Operating activities

$

(63,196)

$

(69,909)

Investing activities

 

(5,597)

 

19,787

Financing activities

 

135,395

 

119,559

Net increase in cash and cash equivalents and restricted cash

$

66,602

$

69,437

Components of cash flows from publicly-traded partner companies are comprised of:

For the Nine Months Ended September 30, 2020

($ in thousands)

    

Fortress1

    

Avenue

    

Checkpoint

    

Mustang

 

Total

Statement of cash flows data:

 

  

 

  

 

  

 

  

  

Total cash (used in)/provided by:

 

  

 

  

 

  

 

  

  

Operating activities

$

(20,315)

$

(3,420)

$

(11,617)

$

(27,844)

$

(63,196)

Investing activities

 

(1,649)

 

(1,000)

 

 

(2,948)

 

(5,597)

Financing activities

 

63,196

 

 

27,569

 

44,630

 

135,395

Net increase in cash and cash equivalents and restricted cash

$

41,232

$

(4,420)

$

15,952

$

13,838

$

66,602

For the Nine Months Ended September 30, 2019

($ in thousands)

    

Fortress1

    

Avenue

    

Checkpoint

    

Mustang

    

Total

Statement of cash flows data:

 

  

 

  

 

  

 

  

 

  

Total cash (used in)/provided by:

 

  

 

  

 

  

 

  

 

  

Operating activities

$

(7,911)

$

(21,263)

$

(16,644)

$

(24,091)

$

(69,909)

Investing activities

 

9,487

 

(5,000)

 

 

15,300

 

19,787

Financing activities

 

14,401

 

32,333

 

7,709

 

65,116

 

119,559

Net increase in cash and cash equivalents and restricted cash

$

15,977

$

6,070

$

(8,935)

$

56,325

$

69,437

Note 1:

Includes Fortress and non-public partner companies, with the exception of Caelum, which was deconsolidated in the quarter ended March 31, 2019.  Operating activities are offset by a gain of $18.5 million related to the deconsolidation of Caelum for the nine months ended September 30, 2019.

Operating Activities

Net cash used in operating activities decreased $6.7 million from the nine months ended September 30, 2019, compared to the nine months ended September 30, 2020. The decrease is due to the decrease of $18.5 million in the gain recognized on the deconsolidation of Caelum, offset by the $2.6 million increase in cash used from the changes in operating assets and liabilities as well as the $13.8 million increase in net loss.

Investing Activities

Net cash provided by investing activities for the nine months ended September 30, 2019 of $19.8 million, as compared to net cash used in investing activities of $5.6 million for the nine months ended September 30, 2020 is a $25.4 million change in cash flows from investing activities. The change is primarily due to $17.4 million decrease in the redemption of certificates of deposit, an increase in the purchase of research and development licenses of $2.5 million, offset by  the $13.1 million decrease in cash from discontinued investing activities due to the deconsolidation of Caelum.

50

Financing Activities

Net cash provided by financing activities was $119.6 million for the nine months ended September 30, 2019, compared to $135.4 million of net cash provided by financing activities for the nine months ended September 30, 2020, an increase of $15.9 million. During the nine months ended September 30, 2020, net proceeds the issuance of Series A preferred stock was $35.7 million, net proceeds from at-the-market offerings for both the Company and its partners was $76.8 million, and net proceeds from partner company sale of stock was $54.1 million, offset by $4.5 million paid in Series A Preferred dividends. During the nine months ended September 30, 2019, net proceeds from partners’ offerings were $61.0 million, net proceeds from partner companies’ at-the-market offerings were $29.7 million, and net proceeds from Mustang’s Horizon Notes was $13.6 million.

Off-Balance Sheet Arrangements

We are not party to any off-balance sheet transactions. We have no guarantees or obligations other than those which arise out of normal business operations.

Item 3.      Quantitative and Qualitative Disclosures About Market Risks

Market risk represents the risk of loss that may result from the change in value of financial instruments due to fluctuations in their market price. Market risk is inherent in all financial instruments. Market risk may be exacerbated in times of trading illiquidity when market participants refrain from transacting in normal quantities and/or at normal bid-offer spreads. Our exposure to market risk is directly related to derivatives, debt and equity linked instruments related to our financing activities.

Our assets and liabilities are denominated in U.S. dollars. Consequently, we have not considered it necessary to use foreign currency contracts or other derivative instruments to manage changes in currency rates. We do not know, nor do we plan to, use derivative financial instruments for speculative or trading purposes. However, these circumstances might change.

The primary quantifiable market risk associated with our financial instruments is sensitivity to changes in interest rates. Interest rate risk represents the potential loss from adverse changes in market interest rates. We use an interest rate sensitivity simulation to assess our interest rate risk exposure. For purposes of presenting the possible earnings effect of a hypothetical, adverse change in interest rates over the 12-month period from our reporting date, we assume that all interest rate sensitive financial instruments will be impacted by a hypothetical, immediate 100 basis point increase in interest rates as of the beginning of the period. The sensitivity is based upon the hypothetical assumption that all relevant types of interest rates that affect our results would increase instantaneously, simultaneously and to the same degree. We do not believe that our cash and equivalents have significant risk of default or illiquidity.

The sensitivity analyses of the interest rate sensitive financial instruments are hypothetical and should be used with caution. Changes in fair value based on a 1% or 2% variation in an estimate generally cannot be extrapolated because the relationship of the change in the estimate to the change in fair value may not be linear. Also, the effect of a variation in a particular estimate on the fair value of financial instruments is calculated independent of changes in any other estimate; in practice, changes in one factor may result in changes in another factor, which might magnify or counteract the sensitivities. In addition, the sensitivity analyses do not consider any action that we may take to mitigate the impact of any adverse changes in the key estimates.

Based on our analysis, for the years ended December 31, 2018 and December 31, 2019, and for the interim period through September 30, 2020, we determined the effect of a 100+1- basis point change in interest rates on the value of our financial instruments and the resultant effect on our net loss to be immaterial.

51

Item 4.      Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of September 30, 2020, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations, which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Item 1.      Legal Proceedings

None.

Item 1A.      Risk Factors

Investing in our Common Stock, Series A Preferred Stock or any other type of equity or debt securities (together our “Securities”) involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K including the consolidated financial statements and the related notes, as well as the risks, uncertainties and other information set forth in the reports and other materials filed or furnished by our partners and affiliates Checkpoint, Mustang, and Avenue with the SEC, before deciding to invest in our Securities. If any of the following risks or the risks included in the public filings of Checkpoint, Mustang or Avenue were to materialize, our business, financial condition, results of operations, and future growth prospects could be materially and adversely affected. In that event, the market price of our Securities could decline, and you could lose part of or all of your investment in our Securities. In addition, you should be aware that the below stated risks should be read as being applicable to our partners and affiliates such that, if any of the negative outcomes associated with any such risk is experienced by one of our partners or affiliates, the value of Fortress’ holdings in such partner or affiliate (if any) may decline.

The below risks are grouped into nine broad categories:

(1)Risks Inherent in Drug Development
(2)Risks Pertaining to the Need for and Impact of Existing and Additional Financing Activities
(3)Risks Pertaining to Our Existing Revenue Stream from Journey Medical
(4)Risks Pertaining to our Business Strategy, Structure and Organization
(5)Risks Pertaining to Reliance on Third Parties
(6)Risks Pertaining to Intellectual Property and Potential Disputes with Licensors Thereof
(7)Risks Pertaining to the Commercialization of Product Candidates
(8)Risks Pertaining to Legislation and Regulation Affecting the Biopharmaceutical and Other Industries
(9)General Risks

The above categories are broadly stated, and you should review each of the individual sub-headings and detailed descriptions thereunder for a more comprehensive understanding of the risks posed by investing in our Securities.

52

Risks Inherent in Drug Development

Most of our product candidates are at early stages of development and may not be successfully developed or commercialized; the product candidates that we do advance into clinical trials may not receive regulatory approval.

Most of our existing product candidates remain in the early stages of development and will require substantial further capital expenditures, development, testing and regulatory clearances/approvals prior to commercialization. The development and regulatory approval processes take several years, and it is not likely that our product candidates, even if successfully developed and approved by the FDA and/or foreign equivalent regulatory bodies, would be commercially available for several years. Of the large number of drugs in development, only a small percentage successfully obtain regulatory approval and are commercialized. Accordingly, even if we are able to obtain the requisite financing to fund development programs, we cannot assure you that any of our product candidates will be successfully developed or commercialized, which could result in the failure of our business and a loss of your investment in our Company.

Pharmaceutical development has inherent risks. We will be required to demonstrate through well-controlled clinical trials that product candidates are effective with a favorable benefit-risk profile for use in their target indications before seeking regulatory approvals for their commercial sale. Success in early clinical trials does not mean that later clinical trials will be successful, as product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through initial clinical testing. Also, we may need to conduct additional clinical trials that are not currently anticipated. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. As a result, product candidates that we advance into clinical trials may not receive regulatory approval.

In addition, even if our product candidates were to obtain approval, regulatory authorities may approve any such product candidates or any future product candidate for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. The regulatory authority may also require the label to contain warnings, contraindications, or precautions that limit the commercialization of the product. In addition, the Drug Enforcement Agency (or foreign equivalent) may classify one or more of our product candidates in scheduling under the Controlled Substances Act (or its foreign equivalent) that could impede such product’s commercial viability. Any of these scenarios could compromise the commercial prospects for one or more of our current or future product candidates.

Our product candidates currently under clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays and/or prevent the receipt of the required approvals to commercialize product candidates.

The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of any product candidate, including our product candidates, is subject to extensive regulation by the FDA in the United States and by comparable health authorities in foreign markets. In the United States, we are not permitted to market a product candidate until such product candidate’s Biologics License Application (“BLA”) or New Drug Application (“NDA”) is approved by the FDA. The process of obtaining approval is expensive, often takes many years, and can vary substantially based upon the type, complexity and novelty of the products involved. In addition to significant clinical testing requirements, our ability to obtain marketing approval for product candidates depends on obtaining the final results of required non-clinical testing, including characterization of the manufactured components of our product candidates and validation of our manufacturing processes. The FDA may determine that our product manufacturing processes, testing procedures or facilities are inadequate to justify approval. Approval policies or regulations may change, and the FDA has substantial discretion in the pharmaceutical approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in the clinical development of product candidates, regulatory approval is never guaranteed.

The FDA and other regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including, but not limited to:

the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
our inability to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for an indication;

53

the FDA may not accept clinical data from trials conducted by individual investigators or in countries where the standard of care is potentially different from that of the United States;
the results of clinical trials may not meet the level of statistical significance required by the FDA for approval;
the FDA may disagree with the interpretation of data from preclinical studies or clinical trials;
the FDA may not approve the manufacturing processes or facilities or those of third-party manufacturers with which we or our respective collaborators currently contract for clinical supplies and plan to contract for commercial supplies; or
the approval policies or regulations of the FDA may significantly change in a manner rendering the clinical data insufficient for approval or the product characteristics or benefit-risk profile unfavorable for approval.

With respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, recent events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new pharmaceuticals based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us from commercializing our product candidates.

Delays in the commencement of our clinical trials (or suspensions or terminations of such trials) could result in increased costs and/or delay our ability to pursue regulatory approvals.

The commencement or resumption of clinical trials can be delayed for a variety of reasons, including, but not necessarily limited to, delays in:

obtaining regulatory clearance/approval to commence a clinical trial;
identifying, recruiting and training suitable clinical investigators;
reaching and preserving agreements on acceptable terms with prospective clinical research organizations (“CROs”) and trial sites, the terms of which can be subject to extensive negotiation, may be subject to modification from time to time and may vary significantly among different CROs and trial sites;
obtaining sufficient quantities of a product candidate for use in clinical trials;
obtaining Institutional Review Board (“IRB”) or ethics committee approval to conduct a clinical trial at a prospective site;
developing and validating companion diagnostics on a timely basis, if required;
adding new clinical sites once a trial has begun;
the death, disability, departure or other change to the principal investigator or other staff overseeing the clinical trial at a given site;
identifying, recruiting and enrolling patients to participate in a clinical trial; or
retaining (or replacing) patients who have initiated a clinical trial but who may withdraw due to adverse events from the therapy, insufficient efficacy, fatigue with the clinical trial process, personal issues, or other reasons.

Any delays in the commencement of our clinical trials will delay our ability to pursue regulatory approval for product candidates. In addition, many of the factors that cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate.

54

Additionally, unacceptable adverse safety events caused by any of our product candidates that we advance into clinical trials could cause regulatory authorities to interrupt, delay or stop clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications and markets. This, in turn, could prevent us from commercializing the affected product candidate and generating revenues from its sale. If any of our product candidates causes unacceptable adverse safety events in clinical trials, we may not be able to obtain regulatory approval or commercialize such products, or, if such product candidates are approved for marketing, future adverse events could cause us to withdraw such products from the market.

Suspensions or delays in the completion of clinical testing could result in increased costs and delay or prevent our ability to complete development of that product or generate product revenues.

Once a clinical trial has begun, patient recruitment and enrollment may be slower than we anticipate. Clinical trials may also be delayed as a result of ambiguous or negative interim results or difficulties in obtaining sufficient quantities of product manufactured in accordance with regulatory requirements and on a timely basis. Further, a clinical trial may be modified, suspended or terminated by us, an IRB, an ethics committee or a data safety monitoring committee overseeing the clinical trial, any clinical trial site with respect to that site, or the FDA or other regulatory authorities, due to a number of factors, including, but not necessarily limited to:

failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;
inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;
stopping rules contained in the protocol;
unforeseen safety issues or any determination that the clinical trial presents unacceptable health risks; and
lack of adequate funding to continue the clinical trial.

Changes in regulatory requirements and guidance also may occur, and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit clinical trial protocols to IRBs for re-examination, which may in turn impact the costs and timing of, and the likelihood of successfully completing, a clinical trial. If we experience delays in the completion of, or if we must suspend or terminate, any clinical trial of any product candidate, our ability to obtain regulatory approval for that product candidate will be delayed, and the commercial prospects, if any, for the product candidate may suffer as a result. In addition, many of these factors may also ultimately lead to the denial of regulatory approval of a product candidate.

If our competitors develop treatments for any of the target indications for which our product candidates are being developed and those competitor products are approved more quickly, marketed more successfully or demonstrated to be more effective, the commercial opportunity with respect to that product candidate will be reduced or eliminated.

The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. There can be no assurance that developments by others will not render one or more of our product candidates obsolete or noncompetitive. Furthermore, new developments, including the development of other drug technologies and methods of preventing the incidence of disease, occur in the pharmaceutical industry at a rapid pace. These developments may render one or more of our product candidates obsolete or noncompetitive.

Competitors may seek to develop alternative formulations that do not directly infringe on our in-licensed patent rights. The commercial opportunity for one or more of our product candidates could be significantly harmed if competitors are able to develop alternative formulations outside the scope of our in-licensed patents. Compared to us, many of our potential competitors have substantially greater:

capital resources;
development resources, including personnel and technology;
clinical trial experience;

55

regulatory experience;
expertise in prosecution of intellectual property rights; and
manufacturing, distribution and sales and marketing experience.

As a result of these factors, our competitors may obtain regulatory approval of their products more rapidly than we are able to or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize one or more of our product candidates. Our competitors may also develop drugs that are more effective, safe, useful and less costly than ours and may be more successful than us in manufacturing and marketing their products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We will also face competition from these third parties in establishing clinical trial sites, in patient registration for clinical trials, and in identifying and in-licensing new product candidates.

Negative public opinion and increased regulatory scrutiny of the therapies that underpin many of our product candidates may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.

Public perception may be influenced by claims that one or more of the therapies underpinning our product candidates, including without limitation gene therapy, is unsafe, and such therapy may not gain the acceptance of the public or the medical community. In particular, the success of our gene therapy platforms will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity, could lead to increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product candidates that do obtain approval and/or a decrease in demand for any such product candidates. Concern about environmental spread of our products, whether real or anticipated, may also hinder the commercialization of our products.

Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.

Any regulatory approval is limited to those specific diseases and indications for which a product is deemed to be safe and effective by the FDA. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain FDA approval for any desired future indications for our products, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.

While physicians may choose to prescribe drugs for uses that are not described in the product’s labeling and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, our ability to promote the products is limited to those indications that are specifically approved by the FDA. These “off-label” uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the US generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject of off-label use. If our promotional activities fail to comply with these regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines relating to promotion and advertising may cause the FDA to suspend or withdraw an approved product from the market, require a recall or institute fines, or could result in disgorgement of money, operating restrictions, corrective advertising, injunctions or criminal prosecution, any of which could harm our business.

56

Risks Pertaining to the Need for and Impact of Existing and Additional Financing Activities

We have historically financed a significant portion of our growth and operations in part through the assumption of debt; should an event of default occur under any applicable loan documents, our business would be materially adversely affected. Also, our current credit arrangement with Oaktree Capital contains restrictive covenants that inhibit our and certain of our partner companies’ abilities to take certain actions.

At September 30, 2020, the total amount of debt outstanding, net of the debt discount was $51.4 million. If we default on our obligations, the holders of our debt may declare the outstanding amounts immediately payable together with accrued interest, and/or take possession of pledged collateral, if any. If an event of default occurs, we may not be able to cure it within any applicable cure period, if at all. If the maturity of our indebtedness is accelerated, we may not have sufficient funds available for repayment or we may not have the ability to borrow or obtain sufficient funds to replace the accelerated indebtedness on terms acceptable to us, or at all. In addition, current or future debt obligations may limit our ability to finance future operations or satisfy capital needs or to engage in, expand or pursue our business activities. Such restrictive covenants may also prevent us from engaging in activities that could be beneficial to our business and our stockholders unless we repay the outstanding debt, which may not be desirable or possible.

On August 27, 2020, we entered into a $60.0 million senior secured credit agreement with Oaktree Fund Administration, LLC and the lenders from time to time party thereto (collectively, “Oaktree”). The Oaktree credit agreement contains certain affirmative and negative covenants restricting our and certain of our partner companies’ abilities to take certain actions, especially as pertains indebtedness, liens, investments, affiliate transactions, dispositions, prepayment of other indebtedness, dividends and other distributions (subject in each case to exceptions). The Oaktree credit agreement also contains financial covenants obligating us to maintain a minimum liquidity amount and a minimum amount of revenue, in both cases subject to exceptions. The breach of any such provisions (even, potentially, in an immaterial manner) could result in an event of default under the Oaktree credit agreement, and the restrictions imposed by such provisions may inhibit our and certain of our partner companies’ ability to enter into certain transactions or arrangements that management otherwise believes would be in our or such partner companies’ best interests.

We have a history of operating losses that is expected to continue, and we are unable to predict the extent of future losses, whether we will generate significant or any revenues or whether we will achieve or sustain profitability.

We are an early-stage company and our prospects must be considered in light of the uncertainties, risks, expenses and difficulties frequently encountered by companies in their early stages of operations. We continue to generate operating losses in all periods including losses from continuing operations of approximately $101.7 million and $130.8 million for the years ended December 31, 2019 and 2018, respectively, and a loss from continuing operations of $70.0 million for the nine months ended September 30, 2020. At September 30, 2020, we had an accumulated deficit of approximately $477.5 million. We expect to make substantial expenditures and incur increasing operating costs and interest expense in the future, and our accumulated deficit will increase significantly as we expand development and clinical trial activities for our product candidates and finance investments in certain of our existing and new partners and affiliates in accordance with our growth strategy. Our losses have had, and are expected to continue to have, an adverse impact on our working capital, total assets and stockholders’ equity.

Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the timing or amount of increased expenses or when or if, we will be able to achieve profitability. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if:

one or more of our product candidates is approved for commercial sale, due to our ability to establish the necessary commercial infrastructure to launch this product candidate without substantial delays, including hiring sales and marketing personnel and contracting with third parties for warehousing, distribution, cash collection and related commercial activities;
we are required by the FDA or foreign regulatory authorities, to perform studies in addition to those currently expected;
there are any delays in completing our clinical trials or the development of any of our product candidates;
we execute other collaborative, licensing or similar arrangements and the timing of payments we may make or receive under these arrangements;
there are variations in the level of expenses related to our future development programs;

57

there are any product liability or intellectual property infringement lawsuits in which we may become involved;
there are any regulatory developments affecting product candidates of our competitors; and
one or more of our product candidates receives regulatory approval.

Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our development stage products, and we do not know when, or if, we will generate any revenue. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:

obtain regulatory approval for one or more of our product candidates, or any future product candidate that we may license or acquire;
manufacture commercial quantities of one or more of our product candidates or any future product candidate, if approved, at acceptable cost levels; and
develop a commercial organization and the supporting infrastructure required to successfully market and sell one or more of our product candidates or any future product candidate, if approved.

Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.

To fund our operations and service our debt securities, which may be deemed to include our Series A Preferred Stock, we will be required to generate a significant amount of cash. Our ability to generate cash depends on a number of factors, some of which are beyond our control, and any failure to meet our debt obligations would have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common stock and/or preferred stock to decline.

Prevailing economic conditions and financial, business and other factors, many of which are beyond our control, may affect our ability to make payments on our debt. If we do not generate sufficient cash flow to satisfy our debt obligations, we may have to undertake alternative financing plans, such as refinancing or restructuring our debt, selling assets, reducing or delaying capital investments or seeking to raise additional capital. Alternatively, as we have done in the past, we may also elect to refinance certain of our debt, for example, to extend maturities. Our ability to restructure or refinance our debt will depend on the capital markets and our financial condition at such time. If we are unable to access the capital markets, whether because of the condition of those capital markets or our own financial condition or reputation within such capital markets, we may be unable to refinance our debt. In addition, any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. Our inability to generate sufficient cash flow to satisfy our debt obligations or to refinance our obligations on commercially reasonable terms, or at all, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common stock and/or debt securities to decline.

Repayment of our indebtedness is dependent in part on the generation of cash flow by Journey and its ability to make such cash available to us, by dividend, debt repayment or otherwise. Journey may not be able to, or may not be permitted to, make distributions to enable us to make payments in respect of our indebtedness. Each of our subsidiaries, including Journey, is a distinct legal entity and, under certain circumstances, legal and contractual restrictions may limit our ability to obtain cash from our subsidiaries.

Our ability to continue to reduce our indebtedness will depend upon factors including our future operating performance, our ability to access the capital markets to refinance existing debt and prevailing economic conditions and financial, business and other factors, many of which are beyond our control. We can provide no assurance of the amount by which we will reduce our debt, if at all. In addition, servicing our debt will result in a reduction in the amount of our cash flow available for other purposes, including operating costs and capital expenditures that could improve our competitive position and results of operations.

58

If we cannot continue to fund our research and development programs, we may be required to reduce product development, which will adversely impact our growth strategy.

Our research and development (“R&D”) programs will require substantial additional capital to conduct research, preclinical testing and clinical trials, establish pilot scale and commercial scale manufacturing processes and facilities, and establish and develop quality control, regulatory, marketing, sales, and administrative capabilities to support these programs. We expect to fund our R&D activities from a combination of cash generated from royalties and milestones from our partners in various past, ongoing, and future collaborations, and through additional equity or debt financings from third parties. These financings could depress the stock prices of our securities. If additional funds are required to support our operations and such funds cannot be obtained on favorable terms, we may not be able to develop products, which will adversely impact our growth strategy.

We may not be able to generate returns for our investors if our partners, several of which have limited or no operating history, no commercialized revenue generating products, and are not yet profitable, cannot obtain additional third-party financing.

As part of our growth strategy, we have made and will likely continue to make substantial financial and operational commitments in our partners, which often have limited or no operating history, no commercialized revenue generating products, and require additional third-party financing to fund product and services development or acquisitions. Our business depends in large part on the ability of one or more of our partner companies to innovate, in-license, develop or acquire successful biopharmaceutical products and/or acquire companies in increasingly competitive and highly regulated markets. If certain of our partner companies do not successfully obtain additional third-party financing to commercialize products or successfully acquire companies, as applicable, the value of our businesses and our ownership stakes in our partner companies may be materially adversely affected.

We may need substantial additional funding and may be unable to raise capital when needed, which may force us to delay, curtail or eliminate one or more of our R&D programs, commercialization efforts or planned acquisitions and potentially change our growth strategy.

Our operations have consumed substantial amounts of cash since inception. During the years ended December 31, 2019 and 2018 we incurred R&D expenses of approximately $75.2 million and $83.3 million, respectively, and $43.9 million for the nine months ended September 30, 2020. We expect to continue to spend significant amounts on our growth strategy. We believe that our current cash and cash equivalents will enable us to continue to fund operations in the normal course of business for at least the next 12 months. Until such time, if ever, as we can generate a sufficient amount of product revenue and achieve profitability, we expect to seek to finance potential cash needs. Our ability to obtain additional funding when needed, changes to our operating plans, our existing and anticipated working capital needs, the acceleration or modification of our planned R&D activities, expenditures, acquisitions and growth strategy, increased expenses or other events may affect our need for additional capital in the future and require us to seek additional funding sooner or on different terms than anticipated. In addition, if we are unable to raise additional capital when needed, we might have to delay, curtail or eliminate one or more of our R&D programs and commercialization efforts and potentially change our growth strategy.

Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.

To the extent that we raise additional capital by issuing common stock (or preferred stock that is convertible into common stock), the share ownership of existing stockholders will be diluted. Any future debt financings may involve covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, redeem our stock, make certain financial commitments and engage in certain merger, consolidation or asset sale transactions, among other restrictions. In addition, if we raise additional funds through licensing or sublicensing arrangements, it may be necessary to relinquish potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.

59

Risks Pertaining to Our Existing Operating Revenue Stream

Future revenue based on sales of our dermatology products, especially Ximino, Targadox and Exelderm, may be lower than expected or lower than in previous periods.

The vast majority of our operating income for the foreseeable future is expected to come from the sale of dermatology products through our partner company Journey Medical Corporation. Any setback that may occur with respect to such products, in particular Ximino, Targadox and Exelderm, could significantly impair our operating results and/or reduce our revenue and the market prices of our Securities. Setbacks for such products could include, but are not necessarily limited to, problems with shipping, distribution, demand, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, competition with existing or new products, physician or patient acceptance of the products, as well as higher than expected total rebates, returns or recalls. These products also are or may become subject to third party generic competition.

Any disruptions to the capabilities, composition, size or existence of Journey’s sales force may have a significant adverse impact on our existing revenue stream. Also, with respect to future potential product candidates, if we are unable to establish and/or maintain sales and marketing capabilities or fail to enter into agreements with third parties to market, distribute and sell products that may be successfully developed, we may not be able to effectively market and sell such products and generate product revenue.

Journey’s sales force has been and is expected to continue to be an important contributor to its commercial success; any disruptions to Journey’s relationship with such sales force or the third-party contractor through which they are engaged could materially adversely affect Journey’s product sales.  

Apart from Journey, we do not currently have the infrastructure for the sales, marketing and distribution of any of our product candidates, and we must build and maintain such infrastructures or make arrangements with third parties to perform these functions in order to commercialize any products that we may successfully develop. The establishment and development of a sales force, either by us or certain of our partners, or the establishment of a contract sales force, to market any products for which we may receive marketing approval is expensive and time-consuming and could delay any such product launch or compromise the successful commercialization of such products. If we are unable to establish and maintain sales and marketing capabilities or any other non-technical capabilities necessary to commercialize any products that may be successfully developed, we will need to contract with third parties to market and sell such products. We may not be able to establish arrangements with third parties on commercially reasonable terms, or at all.

Failure to be included in formularies developed by managed care organizations and coverage by other organizations may negatively impact the utilization of our products, which could harm our market shares and could have a material adverse effect on our business and financial condition.

Managed care organizations and other third-party payors try to negotiate the pricing of medical services and products to control their costs. Managed care organizations and pharmacy benefit managers typically develop formularies to reduce their cost for medications. Formularies can be based on the prices and therapeutic benefits of the available products. Due to their lower costs, generic products are often favored. The breadth of the products covered by formularies varies considerably from one managed care organization to another, and many formularies include alternative and competitive products for treatment of particular medical conditions. Failure to be included in such formularies or to achieve favorable formulary status may negatively impact the utilization and market share of our products. If our products are not included within an adequate number of formularies or adequate reimbursement levels are not provided, or if those policies increasingly favor generic products, this could have a material adverse effect on our business and financial condition.

Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.

We intend to seek approval to market our future products in both the United States and in countries and territories outside the United States. If we obtain approval in one or more foreign countries, we will be subject to rules and regulations in those countries relating to such products. In some foreign countries, particularly in the European Union, the pricing of prescription pharmaceuticals and biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for any of our product candidates and may be affected by existing and future healthcare reform measures.

60

Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which pharmaceuticals they will pay for and establish reimbursement levels. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor’s determination that use of a product is:

a covered benefit under its health plan;
safe, effective and medically necessary;
appropriate for the specific patient;
cost-effective; and
experimental or investigational.

Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require that we provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Additionally, while we may seek approval of our products in combination with each other, there can be no guarantee that we will obtain coverage and reimbursement for any of our products together, or that such reimbursement will incentivize the use of our products in combination with each other as opposed to in combination with other agents which may be priced more favorably to the medical community.

In both the United States and certain foreign countries, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably. In particular, the Medicare Modernization Act of 2003 revised the payment methodology for many products reimbursed by Medicare, resulting in lower rates of reimbursement for many types of drugs, and added a prescription drug benefit to the Medicare program that involves commercial plans negotiating drug prices for their members. Since 2003, there have been a number of other legislative and regulatory changes to the coverage and reimbursement landscape for pharmaceuticals.

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the “Affordable Care Act” or “ACA,” was enacted in 2010 and made significant changes to the United States’ healthcare system. The ACA and any revisions or replacements of that Act, any substitute legislation, and other changes in the law or regulatory framework could have a material adverse effect on our business.

Among the provisions of the ACA of importance to our potential product candidates are:

an annual, nondeductible fee on any entity that manufactures, or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;
expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance;
a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer’s outpatient drugs to be covered under Medicare Part D;
extension of a manufacturer’s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;

61

expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 138% of the federal poverty level, thereby potentially increasing a manufacturer’s Medicaid rebate liability;
expansion of the entities eligible for discounts under the 340B Drug Pricing Program;
new requirements under the federal Open Payments program and its implementing regulations;
a new requirement to annually report drug samples that manufacturers and distributors provide to physicians;
a new regulatory pathway for the approval of biosimilar biological products, all of which will impact existing government healthcare programs and will result in the development of new programs; and
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.

The Supreme Court upheld the ACA in the main challenge to the constitutionality of the law in 2012. Specifically, the Supreme Court held that the individual mandate and corresponding penalty was constitutional because it would be considered a tax by the federal government. The Supreme Court also upheld federal subsidies for purchasers of insurance through federally facilitated exchanges in a decision released in June 2015.

President Trump ran for office on a platform that supported the repeal of the ACA, and one of his first actions after his inauguration was to sign an Executive Order instructing federal agencies to waive or delay requirements of the ACA that impose economic or regulatory burdens on states, families, the health-care industry and others.

In January 2017, Congress voted to adopt a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation of legislation that would repeal portions of the ACA. The Budget Resolution is not a law. However, it is widely viewed as the first step toward the passage of legislation that would repeal certain aspects of the ACA. In March 2017, following the passage of the budget resolution for fiscal year 2017, the United States House of Representatives passed legislation known as the American Health Care Act of 2017, which, if enacted, would amend or repeal significant portions of the ACA. Attempts in the Senate in 2017 to pass ACA repeal legislation, including the Better Care Reconciliation Act of 2017, were unsuccessful.

At the end of 2017, Congress passed the Tax Cuts and Jobs Act, which repealed the penalty for individuals who fail to maintain minimum essential health coverage as required by the ACA. Following this legislation, Texas and 19 other states filed a lawsuit alleging that the ACA is unconstitutional as the individual mandate was repealed, undermining the legal basis for the Supreme Court’s prior decision. On December 14, 2018, a Texas federal district court judge issued a ruling declaring that the ACA in its entirety is unconstitutional. Upon appeal, the Fifth Circuit upheld the district court’s ruling that the individual mandate is unconstitutional. However, the Fifth Circuit remanded the case back to the district court to conduct a more thorough assessment of the constitutionality of the entire ACA despite the individual mandate being unconstitutional. While this decision has no immediate legal effect on the ACA and its provisions, this lawsuit is ongoing and the outcome may have a significant impact on our business.

The Bipartisan Budget Act of 2018, the “BBA,” which set government spending levels for Fiscal Years 2018 and 2019, revised certain provisions of the ACA. Specifically, beginning in 2019, the BBA increased manufacturer point-of-sale discounts off negotiated prices of applicable brand drugs in the Medicare Part D coverage gap from 50% to 70%, ultimately increasing the liability for brand drug manufacturers. Further, this mandatory manufacturer discount applies to biosimilars beginning in 2019.

The 116th Congress has explored legislation intended to address the cost of prescription drugs. Notably, the major committees of jurisdiction in the Senate (Finance Committee, Health, Education, Labor and Pensions Committee, and Judiciary Committee), have marked up legislation intended to address various elements of the prescription drug supply chain. Proposals include a significant overhaul of the Medicare Part D benefit design, addressing patent “loopholes”, and efforts to cap the increase in drug prices. The House Energy and Commerce Committee approved drug-related legislation intended to increase transparency of drug prices and also curb anti-competitive behavior in the pharmaceutical supply chain. In addition, the House Ways & Means Committee approved legislation intended to improve drug price transparency, including for drug manufacturers to justify certain price increases. While we cannot predict what proposals may ultimately become law, the elements under consideration could significantly change the landscape in which the pharmaceutical market operates.

62

The Senate Committee on Health, Education, Labor, and Pensions (HELP) advanced the Lower Health Care Costs Act of 2019. Among other things, the bill is intended to reduce costs in the United States health sector. The bill revises certain requirements to expedite the approval of generics and biosimilars. It also limits prices that pharmacy benefit managers may charge health insurers or enrollees for prescription drugs. Although this bill still needs to pass the full Senate and House of Representatives, it is worth noting the wide-ranging effects it could have on the health care sector.

On December 12, 2019, the House of Representatives passed broad legislation (H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act) that would, among other provisions, require HHS to negotiate drug prices and impose price caps and restructure the Medicare Part D benefit, imposing more financial responsibility on certain drug manufacturers. Failure by a manufacturer to reach an agreement with HHS on the negotiated price could result in significant penalties for prescription drug manufacturers. In addition, S. 2543, the Prescription Drug Pricing Reduction Act would also, among other provisions, restructure the Medicare Part D benefit, but it would not authorize direct negotiation by the federal government. While we cannot predict what proposals may ultimately become law, the elements under consideration could significantly change the landscape in which the pharmaceutical market operates.

The Trump Administration has also taken several regulatory steps to redirect ACA implementation. The Department of Health and Human Services, the HHS, finalized a Medicare hospital payment reduction for Part B drugs acquired through the 340B Drug Pricing Program. The courts have since overturned this payment reduction, but the lawsuit is ongoing on appeal and HHS continues to implement the payment cuts. HHS also has signaled its intent to continue to pursue reimbursement policy changes for all Medicare Part B drugs that likely would reduce hospital and physician reimbursement for these drugs.

HHS has made numerous other proposals aimed at lowering drug prices for Medicare beneficiaries and increasing price transparency. While many of the proposals have been withdrawn or struck down by the courts, it appears the Trump Administration will continue to explore its authority to make regulatory changes to the pharmaceutical industry. For example, the Trump Administration released an Advance Notice of Proposed Rulemaking related to an international price index model. It is unclear what eventually will be proposed, but the President has alluded to the concept of most favored nation pricing with regard to U.S. drug purchasing. In addition, HHS, in conjunction with the FDA, released two pharmaceutical importation models in December 2019: (1) a Notice of Proposed Rulemaking to permit importation of pharmaceuticals from Canada, and (2) draft FDA guidance permitting manufacturers to import their own pharmaceuticals that were originally intended for marketing in other countries.

HHS also has taken steps to increase the availability of cheaper health insurance options, typically with fewer benefits and less generous coverage. The Administration has also signaled its intention to address drug prices and to increase competition, including by increasing the availability of biosimilars and generic drugs. As these are regulatory actions, a new administration could undo or modify these efforts.

There likely will continue to be legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare products and services. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:

the demand for any products for which we may obtain regulatory approval;
our ability to set a price that we believe is fair for our products;
our ability to generate revenues and achieve or maintain profitability;
the level of taxes that we are required to pay; and
the availability of capital.

In addition, governments may impose price controls, which may adversely affect our future profitability. In January 2020, President Trump signed into law the U.S.-Mexico-Canada (USMCA) trade deal into law. As enacted, there are no commitments with respect to biologic product intellectual property rights or data protection, which may create an unfavorable environment across these three countries.

63

Risks Pertaining to our Business Strategy, Structure and Organization

We have in the past and are likely in the future to undergo collaborations and/or divestitures with respect to certain of our assets and subsidiaries, some of which may be material and/or transformative, which could adversely affect our business, prospects and opportunities for growth.

We have in the past completed a number of partnerships and/or contingent sales of our assets and subsidiaries, including an equity investment and contingent sale between Avenue and InvaGen and an equity investment and contingent option transaction between Caelum and Alexion Pharmaceuticals, Inc. Each of these transactions has been time-consuming and has diverted management’s attention. As a result of these contingent sales (and other similar transactions we may in the future complete), we may experience a reduction in the size or scope of our business, our market share in particular markets, our opportunities with respect to certain markets, products or therapeutic categories or our ability to compete in certain markets and therapeutic categories. For example, in connection with execution of the Avenue SPMA, we signed a Restrictive Covenant Agreement, which prohibits us from, directly or indirectly, engaging in the business of hospital administered pain management anywhere in the world other than Canada, Central America or South America for a period of five years after the earlier of the termination of the Avenue SPMA or consummation of the Merger Transaction (as defined in the Avenue SPMA).

In addition, in connection with any such transaction that involves a (contingent or non-contingent) sale of one of our assets or subsidiaries, we may surrender our ability to realize long-term value from such asset or subsidiary, in the form of foregone royalties, milestone payments, sublicensing revenue or otherwise, in exchange for upfront and/or other payments. In the event, for instance, that a product candidate underpinning any such asset or subsidiary is granted FDA approval for commercialization following the execution of documentation governing the sale by us of such asset or subsidiary, the transferee of such asset or subsidiary may realize tremendous value from commercializing such product, which we would have realized for ourselves had we not executed such sale transaction and been able to achieve applicable approvals independently.

Should we seek to enter into collaborations or divestitures with respect to other assets or subsidiaries, we may be unable to consummate such arrangements on satisfactory or commercially reasonable terms within our anticipated timelines. In addition, our ability to identify, enter into and/or consummate collaborations and/or divestitures may be limited by competition we face from other companies in pursuing similar transactions in the biotechnology and pharmaceutical industries. Any collaboration or divestiture we pursue, whether we are able to complete it or not, may be complex, time consuming and expensive, may divert the management’s attention, have a negative impact on our customer relationships, cause us to incur costs associated with maintaining the business of the targeted collaboration or divestiture during the transaction process and also to incur costs of closing and disposing the affected business or transferring the operations of the business to other facilities. In addition, if such transactions are not completed for any reason, the market price of our common stock may reflect a market assumption that such transactions will occur, and a failure to complete such transactions could result in a negative perception by the market of us generally and a decline in the market price of our common stock. For example, consummation of the Avenue-InvaGen merger contemplated by the Avenue SPMA is conditioned on, inter alia: (i) final FDA approval of IV tramadol (Avenue’s lead product candidate); (ii) labeling for IV tramadol containing an indication as moderate to moderately severe (post-operative) pain, not restricted to any specific type of surgery; (iii) classification of IV tramadol by the DEA as a Schedule IV drug; and (iv) there being no Risk Evaluation and Mitigation Strategy from the FDA applicable to IV tramadol. If one or more of these conditions is not satisfied, InvaGen will not be obligated to consummate the Avenue-InvaGen merger, which could materially adversely affect our business.

On October 12, 2020, Avenue announced that it had received a Complete Response Letter (the “CRL") from the FDA regarding Avenue’s New Drug Application for IV Tramadol. The CRL cited deficiencies related to the terminal sterilization validation and stated that IV Tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population. Avenue’s ability to potentially commercialize IV Tramadol, and the timing of potential commercialization, is dependent on the FDA's review of Avenue’s response to the CRL and its NDA for IV Tramadol, and other items such as timely and successful completion of the terminal sterilization validation, ultimate FDA approval, and potentially additional capital.

In October 2020, InvaGen communicated to Avenue that it believes a Material Adverse Effect (as defined in the SPMA) has occurred due to the impact of the COVID-19 pandemic on potential commercialization and projected sales of IV Tramadol, which means it is possible InvaGen could attempt to avoid its obligation to consummate the second stage closing under the SPMA. Avenue disagrees with InvaGen’s assertion that a Material Adverse Effect has occurred and has advised InvaGen of this position.

64

As a result of these factors, any collaboration or divestiture (whether or not completed) could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common stock and/or preferred stock to decline.

We have in the past acted, do currently act, and are likely to continue in the future to act as guarantor and/or indemnitor of the obligations, actions or inactions of certain of our subsidiaries and affiliated companies; depending on the terms of such arrangements, we may be contractually obligated to pay substantial amounts to third parties based on the actions or inactions of our subsidiaries and/or affiliates.

We have in the past acted, do currently act, and are likely to continue in the future to act as guarantor of the debt obligations of several of our subsidiaries and/or affiliates, including Aevitas, Baergic, Cellvation and Cyprium. Depending on the terms of such guaranty arrangements, we may be contractually obligated to pay substantial amounts to third party lenders based on the actions or inactions of such subsidiaries and/or affiliates, which would result in a reduction of the amount of our cash available for other purposes and may have a material adverse effect on the price of our Securities.

We also have in the past acted, do currently act, and are likely to continue in the future to act as indemnitor of potential losses that may be experienced by one or more of our affiliated companies and/or their partners or investors. In particular, under that certain Indemnification Agreement, dated as of November 12, 2018 (the “Indemnification Agreement”), we indemnify InvaGen Pharmaceuticals Inc. (“InvaGen”) and its affiliates for any losses they may sustain in connection with inaccuracies that may appear in the representations and warranties that our partner company Avenue made to InvaGen in that certain Stock Purchase and Merger Agreement, dated as of November 12, 2018 (the “Avenue SPMA”). The maximum amount of indemnification we may have to provide under the Indemnification Agreement is $35.0 million, and such obligation terminates upon the consummation of the Merger Transaction (as defined in the Avenue SPMA). In the event of payment by us of any such indemnification amount, we would be able to recoup such amounts (other than our pro rata share of the indemnification as a shareholder in Avenue) from the Merger Transaction proceeds, but if the Merger Transaction never occurs, we would have no means of recouping such previously-paid indemnification amounts. If we become obligated to pay all or a portion of such indemnification amounts (regardless of whether or not we are partially reimbursed out of the proceeds of the Merger Transaction), our business and the market value of our common stock and/or debt securities may be materially adversely impacted.

Our future growth depends in part on our ability to identify and acquire or in-license products and product candidates, and if we are unable to do so, or to integrate acquired products into our operations, we may have limited growth opportunities.

An important part of our business strategy is to continue to develop a pipeline of product candidates by acquiring or in-licensing products, businesses or technologies. Future in-licenses or acquisitions, however, may entail numerous operational and financial risks, including, but not necessarily limited to:

exposure to unknown liabilities;
disruption of our business and diversion of our management’s time and attention to develop acquired products or technologies;
difficulty or inability to secure financing to fund development activities for such acquired or in-licensed technologies in the current economic environment;
incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;
higher than expected acquisition and integration costs;
increased amortization expenses;
difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;
impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and
inability to retain key employees of any acquired businesses.

65

We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. In particular, we may compete with larger pharmaceutical companies and other competitors in our efforts to establish new collaborations and in-licensing opportunities. These competitors likely will have access to greater financial resources than us and may have greater expertise in identifying and evaluating new opportunities. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts.

Certain of our officers and directors serve in similar roles at our partners, affiliates, related parties and/or other entities with which we transact business or in which we hold significant minority ownership positions; ongoing and future relationships and transactions between these parties could result in conflicts of interest.

We share directors and/or officers with certain of our partners, and other entities with which we transact business or in which we hold significant minority ownership positions, and such arrangements could create conflicts of interest in the future, including with respect to the allocation of corporate opportunities. While we believe that we have put in place policies and procedures to identify and mitigate such conflicts, and that any existing agreements that may give rise to such conflicts and any such policies or procedures were negotiated at arm’s length in conformity with fiduciary duties, such conflicts of interest may nonetheless arise. The existence and consequences of such potential conflicts could expose us to lost profits, claims by our investors and creditors, and harm to our results of operations.

Some of our executives, directors and principal stockholders can control our direction and policies, and their interests may be adverse to the interests of our other stockholders.

At September 30, 2020, Lindsay A. Rosenwald, M.D., our Chairman, President and Chief Executive Officer, beneficially owned 10.1% of our issued and outstanding capital stock. At September 30, 2020, Michael S. Weiss, our Executive Vice Chairman, Strategic Development, beneficially owned 10.9% of our issued and outstanding capital stock. By virtue of their holdings and membership on our Board of Directors, Dr. Rosenwald and Mr. Weiss may individually influence our management and our affairs and may make it difficult for us to consummate corporate transactions such as mergers, consolidations or the sale of all or substantially all of our assets that may be favorable from our standpoint or that of our other stockholders.

If we acquire, enter into joint ventures with or obtain a controlling interest in companies in the future, it could adversely affect our operating results and the value of our Securities, thereby diluting stockholder value, disrupting our business and/or diminishing the value of our holdings in our partner companies.

As part of our growth strategy, we might acquire, enter into joint ventures with, or obtain significant ownership stakes in other companies. Acquisitions of, joint ventures with and investments in other companies involve numerous risks, including, but not necessarily limited to:

risk of entering new markets in which we have little to no experience;
diversion of financial and managerial resources from existing operations;
successfully negotiating a proposed acquisition or investment timely and at a price or on terms and conditions favorable to us;
the impact of regulatory reviews on a proposed acquisition or investment;
the outcome of any legal proceedings that may be instituted with respect to the proposed acquisitions or investment;
with respect to an acquisition, difficulties in integrating operations, technologies, services and personnel; and
potential inability to maintain relationships with customers of the companies we may acquire or invest in.

If we fail to properly evaluate potential acquisitions, joint ventures or other transaction opportunities, we might not achieve the anticipated benefits of any such transaction, we might incur higher costs than anticipated, and management resources and attention might be diverted from other necessary or valuable activities.

66

Risks Pertaining to Reliance on Third Parties

We currently rely predominantly on third parties to manufacture our preclinical and clinical pharmaceutical supplies and expect to continue to rely heavily on them and other contractors to produce commercial supplies of our products, and our dependence on third-party suppliers could adversely impact our businesses. We also rely solely on third parties to manufacture Journey’s commercialized products, which dependence may also adversely impact our businesses.

We depend heavily on third party manufacturers for product supply. If our contract manufacturers cannot successfully manufacture material that conforms to applicable specifications and with FDA regulatory requirements, we will not be able to secure and/or maintain FDA approval for those products. Our third-party suppliers will be required to maintain compliance with cGMPs and will be subject to inspections by the FDA and comparable agencies and authorities in other jurisdictions to confirm such compliance. In the event that the FDA or such other authorities determine that our third-party suppliers have not complied with cGMPs or comparable regulations, the relevant clinical trials could be terminated or subjected to a clinical hold until such time as we are able to obtain appropriate replacement material and/or applicable compliance, and commercial product could be unfit for sale, or if distributed, could be recalled from the market. Any delay, interruption or other issues that arise in the manufacture, testing, packaging, labeling, storage, or distribution of our products as a result of a failure of the facilities or operations of our third-party suppliers to comply with regulatory requirements or pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products and product candidates. In addition, several of our currently commercialized products, sold through our partner company Journey, are produced by a single manufacturer, and, although we closely monitor inventory prophylactically, disruptions to such supply arrangements could adversely affect our ability to meet product demand and therefore diminish revenues.

We also rely on third-party manufacturers to purchase from third-party suppliers the materials necessary to produce product candidates for anticipated clinical trials. There are a small number of suppliers for certain capital equipment and raw materials that are used to manufacture those products. We do not have any control over the process or timing of the acquisition of these raw materials by our third-party manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Any significant delay in the supply of raw material components related to an ongoing clinical trial could considerably delay completion of our clinical trials, product testing and potential regulatory approval.

We do not expect to have the resources or capacity to commercially manufacture our product candidates internally, if approved, and would likely continue to be heavily dependent upon third-party manufacturers. Our dependence on third parties to manufacture and supply clinical trial materials, as well as our planned dependence on third party manufacturers for any products that may be approved, may adversely affect our ability to develop and commercialize products in a timely or cost-effective manner, or at all.

We rely heavily on third parties for the development and manufacturing of products and product candidates.

Certain our partner companies, on whose successes we largely rely, are early-stage biopharmaceutical companies with limited operating histories. To date, we have engaged primarily in acquisition, evaluative and R&D activities and have not generated any revenues from product sales (except through Journey). We have incurred significant net losses since our inception. As of September 30, 2020, we had an accumulated deficit of approximately $477.5 million. We may need to rely on third parties for activities critical to the product candidate development process, including but not necessarily limited to:

identifying and evaluating product candidates;
negotiating, drafting and entering into licensing and other arrangements with product development partners; and
continuing to undertake pre-clinical development and designing and executing clinical trials.

We have also not demonstrated the ability to perform the functions necessary for the successful commercialization of any of our pre-market product candidates, should any of them be approved for marketing. If we were to have any such product candidates approved, the successful commercialization of such products would require us to perform or contract with third parties for performance of a variety of critical functions, including, but not necessarily limited to:

advising and participating in regulatory approval processes;
formulating and manufacturing products for clinical development programs and commercial sale; and

67

conducting sales and marketing activities.

Our operations have been limited to acquiring, developing and securing the proprietary rights for, and undertaking pre-clinical development and clinical trials of, product candidates, both at the Fortress level and via our partner companies. These operations provide a limited basis for our stockholders and prospective investors to assess our ability to develop and commercialize potential product candidates, as well as for you to assess the advisability of investing in our securities.

We rely on third parties to conduct clinical trials. If these third parties do not meet agreed-upon deadlines or otherwise conduct the trials as required, our clinical development programs could be delayed or unsuccessful, and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.

We rely on third-party contract research organizations and site management organizations to conduct most of our preclinical studies and all of our clinical trials for our product candidates. We expect to continue to rely on third parties, such as contract research organizations, site management organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct some of our preclinical studies and all of our clinical trials. These CROs, investigators, and other third parties will and do play a significant role in the conduct of our trials and the subsequent collection and analysis of data from the clinical trials.

There is no guarantee that any CROs, investigators and other third parties upon which we rely for administration and conduct of our clinical trials will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, or fails to adhere to our clinical protocols or otherwise perform in a substandard manner, our clinical trials may be extended, delayed or terminated. If any of the clinical trial sites terminates for any reason, we may lose follow-up information on patients enrolled in our ongoing clinical trials unless the care of those patients is transferred to another qualified clinical trial site. In addition, principal investigators for our clinical trials may serve as scientific advisers or consultants to us from time to time and receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site, or the FDA’s willingness to accept such data, may be jeopardized.

Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial and for ensuring that our preclinical studies are conducted in accordance with good laboratory practice (“GLP”) as appropriate. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices (“GCPs”) for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of our clinical research organizations fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

If any of our relationships with these third-party contract research organizations or site management organizations terminates, we may not be able to enter into arrangements with alternative contract research organizations or site management organizations or to do so on commercially reasonable terms. Switching or adding additional contract research organizations or site management organizations involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new contract research organization or site management organization commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. Though we carefully manage our relationships with our contract research organizations or site management organizations, there can be no assurance that we will not encounter similar challenges or delays in the future.

68

We rely on clinical and pre-clinical data and results obtained by third parties that could ultimately prove to be inaccurate or unreliable.

As part of the strategy we implement to mitigate development risk, we seek to develop product candidates with well-studied mechanisms of action, and we intend to utilize biomarkers to assess potential clinical efficacy early in the development process. This strategy necessarily relies upon clinical and pre-clinical data and other results produced or obtained by third parties, which may ultimately prove to be inaccurate or unreliable. If the third-party data and results we rely upon prove to be inaccurate, unreliable or not applicable to our product candidates, we could make inaccurate assumptions and conclusions about our product candidates, and our research and development efforts could be compromised or called into question during the review of any marketing applications that we submit.

Collaborative relationships with third parties could cause us to expend significant resources and incur substantial business risk with no assurance of financial return.

We anticipate substantial reliance upon strategic collaborations for marketing and commercializing our existing product candidates and we may rely even more on strategic collaborations for R&D of other product candidates. We may sell product offerings through strategic partnerships with pharmaceutical and biotechnology companies. If we are unable to establish or manage such strategic collaborations on terms favorable to us in the future, our revenue and drug development may be limited.

If we enter into R&D collaborations during the early phases of drug development, success will, in part, depend on the performance of research collaborators. We may not directly control the amount or timing of resources devoted by research collaborators to activities related to product candidates. Research collaborators may not commit sufficient resources to our R&D programs. If any research collaborator fails to commit sufficient resources, the preclinical or clinical development programs related to the collaboration could be delayed or terminated. Also, collaborators may pursue existing or other development-stage products or alternative technologies in preference to those being developed in collaboration with us. Finally, if we fail to make required milestone or royalty payments to collaborators or to observe other obligations in agreements with them, the collaborators may have the right to terminate or stop performance of those agreements.

Establishing strategic collaborations is difficult and time-consuming. Our discussions with potential collaborators may not lead to the establishment of collaborations on favorable terms, if at all. Potential collaborators may reject collaborations based upon their assessment of our financial, regulatory or intellectual property positions. Even if we successfully establish new collaborations, these relationships may never result in the successful development or commercialization of product candidates or the generation of sales revenue. To the extent that we enter into collaborative arrangements, the related product revenues that might follow are likely to be lower than if we directly marketed and sold products. Such collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on, and such collaborations could be more attractive than the one with us for any future product candidate.

Management of our relationships with collaborators will require:

significant time and effort from our management team;
coordination of our marketing and R&D programs with the respective marketing and R&D priorities of our collaborators; and
effective allocation of our resources to multiple projects.

69

Risks Pertaining to Intellectual Property and Potential Disputes with Licensors Thereof

If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.

Our success depends, in large part, on our ability to obtain patent protection for product candidates and their formulations and uses. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our partners will be successful in obtaining patents or what the scope of an issued patent may ultimately be. These risks and uncertainties include, but are not necessarily limited to, the following:

patent applications may not result in any patents being issued, or the scope of issued patents may not extend to competitive product candidates and their formulations and uses developed or produced by others;
our competitors, many of which have substantially greater resources than us or our partners, and many of which have made significant investments in competing technologies, may seek, or may already have obtained, patents that may limit or interfere with our abilities to make, use, and sell potential product candidates, file new patent applications, or may affect any pending patent applications that we may have;
there may be significant pressure on the U.S. government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful as a matter of public policy regarding worldwide health concerns; and
countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.

In addition, patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or otherwise may not provide any competitive advantage. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the US Patent and Trademark Office (“PTO”), or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority of invention would be unsuccessful, resulting in a material adverse effect on our US patent positions. An adverse determination in any such submission, patent office trial, proceeding or litigation could reduce the scope of, render unenforceable, or invalidate, our patent rights, allow third parties to commercialize our technologies or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Third parties are often responsible for maintaining patent protection for our product candidates, at our and their expense. If that party fails to appropriately prosecute and maintain patent protection for a product candidate, our abilities to develop and commercialize products may be adversely affected, and we may not be able to prevent competitors from making, using and selling competing products. Such a failure to properly protect intellectual property rights relating to any of our product candidates could have a material adverse effect on our financial condition and results of operations. In addition, U.S. patent laws may change, which could prevent or limit us from filing patent applications or patent claims to protect products and/or technologies or limit the exclusivity periods that are available to patent holders, as well as affect the validity, enforceability, or scope of issued patents.

We and our licensors also rely on trade secrets and proprietary know-how to protect product candidates. Although we have taken steps to protect our and their trade secrets and unpatented know-how, including entering into confidentiality and non-use agreements with third parties, and proprietary information and invention assignment agreements with employees, consultants and advisers, third parties may still come upon this same or similar information independently. Despite these efforts, any of these parties may also breach the agreements and may unintentionally or willfully disclose our or our licensors’ proprietary information, including our trade secrets, and we may not be able to identify such breaches or obtain adequate remedies. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, if any of our or our licensors’ trade secrets were to be lawfully obtained or independently developed by a competitor, we and our licensors would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our or our licensors’ trade secrets were to be disclosed to or independently developed by a competitor, our competitive positions would be harmed.

70

The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify any patentable aspects of our research and development output and methodology, and, even if we do, an opportunity to obtain patent protection may have passed. Given the uncertain and time-consuming process of filing patent applications and prosecuting them, it is possible that our product(s) or process(es) originally covered by the scope of the patent application may have changed or been modified, leaving our product(s) or process(es) without patent protection. If our licensors or we fail to obtain or maintain patent protection or trade secret protection for one or more product candidates or any future product candidate we may license or acquire, third parties may be able to leverage our proprietary information and products without risk of infringement, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and achieve profitability. Moreover, should we enter into other collaborations we may be required to consult with or cede control to collaborators regarding the prosecution, maintenance and enforcement of licensed patents. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, no consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology patents has emerged to date in the US. The patent situation outside the US is even more uncertain. The laws of foreign countries may not protect our rights to the same extent as the laws of the US, and we may fail to seek or obtain patent protection in all major markets. For example, European patent law restricts the patentability of methods of treatment of the human body more than US law does. We might also become involved in derivation proceedings in an event that a third party misappropriates one or more of our inventions and files their own patent application directed to such one or more inventions. The costs of these proceedings could be substantial and it is possible that our efforts to establish priority of invention (or that a third party derived an invention from us) would be unsuccessful, resulting in a material adverse effect on our US patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the US and other countries may diminish the value of our patents or narrow the scope of our patent protection. For example, the federal courts of the US have taken an increasingly dim view of the patent eligibility of certain subject matter, such as naturally occurring nucleic acid sequences, amino acid sequences and certain methods of utilizing same, which include their detection in a biological sample and diagnostic conclusions arising from their detection. Such subject matter, which had long been a staple of the biotechnology and biopharmaceutical industry to protect their discoveries, is now considered, with few exceptions, ineligible in the first instance for protection under the patent laws of the US. Accordingly, we cannot predict the breadth of claims that may be allowed and remain enforceable in our patents or in those licensed from a third party.

Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include changes to transition from a “first-to-invent” system to a “first inventor-to-file” system and to the way issued patents are challenged. The formation of the Patent Trial and Appeal Board now provides a less burdensome, quicker and less expensive process for challenging issued patents. The PTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first inventor-to-file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.

Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.

We also may rely on the regulatory period of market exclusivity for any of our biologic product candidates that are successfully developed and approved for commercialization. Although this period in the United States is generally 12 years from the date of marketing approval (depending on the nature of the specific product), there is a risk that the U.S. Congress could amend laws to significantly shorten this exclusivity period. Once any regulatory period of exclusivity expires, depending on the status of our patent coverage and the nature of the product, we may not be able to prevent others from marketing products that are biosimilar to or interchangeable with our products, which would materially adversely affect our business.

71

If we or our licensors are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.

Our success also depends on our ability, and the abilities of any of our respective current or future collaborators, to develop, manufacture, market and sell product candidates without infringing the proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products, some of which may be directed at claims that overlap with the subject matter of our or our licensors’ intellectual property. Because patent applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that our product candidates or proprietary technologies may infringe. Similarly, there may be issued patents relevant to our product candidates of which we or our licensors are not aware. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the US and other jurisdictions are typically not published until 18 months after a first filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or such licensors were the first to make the inventions claimed in patents or pending patent applications that we own or licensed, or that we and our licensors were the first to file for patent protection of such inventions. In the event that a third party has also filed a US patent application relating to our product candidates or a similar invention, depending upon the priority dates claimed by the competing parties, we may have to participate in interference proceedings declared by the PTO to determine priority of invention in the US. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority of invention would be unsuccessful, resulting in a material adverse effect on our U.S. patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our or any of our licensors’ patent rights are highly uncertain.

There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we or any of our licensors, suppliers or collaborators infringe the third party’s intellectual property rights, we may have to, among other things:

obtain additional licenses, which may not be available on commercially reasonable terms, if at all;
abandon an infringing product candidate or redesign products or processes to avoid infringement, which may demand substantial funds, time and resources and which may result in inferior or less desirable processes and/or products;
pay substantial damages, including the possibility of treble damages and attorneys’ fees, if a court decides that the product or proprietary technology at issue infringes on or violates the third party’s rights;
pay substantial royalties, fees and/or grant cross-licenses to our product candidates; and/or

defend litigation or administrative proceedings which may be costly regardless of outcome, and which could result in a substantial diversion of financial and management resources.

We may be involved in lawsuits to protect or enforce our patents or the patents of licensors, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our or our licensors’ patents. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against accused infringers could provoke these parties to assert counterclaims against us alleging invalidity of our or our licensors’ patents or that we infringe their patents; or provoke those parties to petition the PTO to institute inter partes review against the asserted patents, which may lead to a finding that all or some of the claims of the patent are invalid. In addition, in a patent infringement proceeding, a court may decide that a patent of ours or our licensor’s is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our or our licensors’ patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, found to be unenforceable, or interpreted narrowly and could likewise put pending patent applications at risk of not issuing. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

72

Because we in-license the intellectual property needed to develop and commercialize products and product candidates from third parties, any dispute with the licensors or the non-performance of such license agreements may adversely affect our ability to develop and commercialize the applicable product candidates.

The patents, patent applications and other intellectual property rights underpinning all of our existing product candidates were in-licensed from third parties. Under the terms of such license agreements, the licensors generally have the right to terminate such agreements in the event of a material breach. The licenses require us to make annual, milestone or other payments prior to commercialization of any product and our ability to make these payments depends on the ability to generate cash in the future. These license agreements also generally require the use of diligent and reasonable efforts to develop and commercialize product candidates.

If there is any conflict, dispute, disagreement or issue of non-performance between us or one of our partners, on the one hand, and the respective licensing partner, on the other hand, regarding the rights or obligations under the license agreements, including any conflict, dispute or disagreement arising from a failure to satisfy payment obligations under such agreements, the ability to develop and commercialize the affected product candidate may be adversely affected.

The types of disputes that may arise between us and the third parties from whom we license intellectual property include, but are not necessarily limited to:

the scope of rights granted under such license agreements and other interpretation-related issues;
the extent to which our technologies and processes infringe on intellectual property of the licensor that is not subject to such license agreements;
the scope and interpretation of the representations and warranties made to us by our licensors, including those pertaining to the licensors’ right title and interest in the licensed technology and the licensors’ right to grant the licenses contemplated by such agreements;
the sublicensing of patent and other rights under our license agreements and/or collaborative development relationships, and the rights and obligations associated with such sublicensing, including whether or not a given transaction constitutes a sublicense under such license agreement;
the diligence and development obligations under license agreements (which may include specific diligence milestones) and what activities or achievements satisfy those diligence obligations;
whether or not the milestones associated with certain milestone payment obligations have been achieved or satisfied;
the applicability or scope of indemnification claims or obligations under such license agreements;
the permissibility and advisability of, and strategy regarding, the pursuit of potential third-party infringers of the intellectual property that is the subject of such license agreements;
the calculation of royalty, milestone, sublicense revenue and other payment obligations under such license agreements;
the extent to which rights, if any, are retained by licensors under such license agreements;
whether or not a material breach has occurred under such license agreements and the extent to which such breach, if deemed to have occurred, is or can be cured within applicable cure periods, if any;
disputes regarding patent filing and prosecution decisions, as well as payment obligations regarding past and ongoing patent expenses;
intellectual property rights resulting from the joint creation or use of intellectual property (including improvements made to licensed intellectual property) by our and our partners’ licensors and us and our partners; and
the priority of invention of patented technology.

73

In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations or may conflict in such a way that puts us in breach of one or more agreements, which would make us susceptible to lengthy and expensive disputes with one or more of such third-party licensing partners. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreements, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.

Risks Pertaining to the Commercialization of Product Candidates

If any of our product candidates that may be successfully developed do not achieve broad market acceptance among physicians, patients, healthcare payors and the medical community, the revenues that any such product candidates generate from sales will be limited.

Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors and the medical community. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally would also be necessary for commercial success. The degree of market acceptance of any approved products would depend on a number of factors, including, but not necessarily limited to:

the efficacy and safety as demonstrated in clinical trials;
the timing of market introduction of such product candidate as well as competitive products;
the clinical indications for which the product is approved;
acceptance by physicians, major operators of hospitals and clinics and patients of the product as a safe and effective treatment;
the potential and perceived advantages of product candidates over alternative treatments;
the safety of product candidates in a broader patient group (i.e., based on actual use);
the cost of treatment in relation to alternative treatments;
the availability of adequate reimbursement and pricing by third parties and government authorities;
changes in regulatory requirements by government authorities for our product candidates;
relative convenience and ease of administration;
the prevalence and severity of side effects and adverse events;
the effectiveness of our sales and marketing efforts; and
unfavorable publicity relating to the product.

If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate sufficient revenue from these products and in turn we may not become or remain profitable.

74

Even if approved, any product candidates that we may develop and market may be later withdrawn from the market or subject to promotional limitations.

We may not be able to obtain the labeling claims or scheduling classifications necessary or desirable for the promotion of our marketed products (or our product candidates if approved). We may also be required to undertake post-marketing clinical trials. If the results of such post-marketing studies are not satisfactory or if adverse events or other safety issues arise after approval, the FDA or a comparable regulatory authority in another jurisdiction may withdraw marketing authorization or may condition continued marketing on commitments from us that may be expensive and/or time consuming to complete. In addition, if we or others identify adverse side effects after any of our products are on the market, or if manufacturing problems occur, regulatory approval may be withdrawn and reformulation of our products, additional clinical trials, changes in labeling of our products and additional marketing applications may be required. Any reformulation or labeling changes may limit the marketability of such products if approved.

We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for one or more of our product candidates or a future product candidate we may license or acquire and may have to limit their commercialization.

The use of one or more of our product candidates and any future product candidate we may license or acquire in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Product liability claims might be brought against us by consumers, health care providers or others using, administering or selling our products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

withdrawal of clinical trial participants;
suspension or termination of clinical trial sites or entire trial programs;
decreased demand for any product candidates or products that we may develop;
initiation of investigations by regulators;
impairment of our business reputation;
costs of related litigation;
substantial monetary awards to patients or other claimants;
loss of revenues;
reduced resources of our management to pursue our business strategy; and
the inability to commercialize our product candidate or future product candidates.

We will obtain limited product liability insurance coverage for any and all of our upcoming clinical trials. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. When needed we intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for one or more of our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.

75

Additionally, we have entered into various agreements under which we indemnify third parties for certain claims relating to product candidates. These indemnification obligations may require us to pay significant sums of money for claims that are covered by these indemnifications.

Any product for which we obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with products, when and if any of them are approved.

Any product for which we obtain marketing approval, along with the manufacturing processes and facilities, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of, and review by, the FDA and comparable regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping, and requirements regarding company presentations and interactions with healthcare professionals. Even if we obtain regulatory approval for a product, the approval may be subject to limitations on the indicated uses for which the product may be marketed or subject to conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. We also may be subject to state laws and registration requirements covering the distribution of drug products. Later discovery of previously unknown problems with products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:

restrictions on product manufacturing, distribution or use;
restrictions on the labeling or marketing of a product;
requirements to conduct post-marketing studies or clinical trials;
warning letters;
withdrawal of the products from the market;
refusal to approve pending applications or supplements to approved applications that we submit;
recalls;
fines;
suspension or withdrawal of marketing or regulatory approvals;
refusal to permit the import or export of products;
product seizure or detentions;
injunctions or the imposition of civil or criminal penalties; and
adverse publicity.

If we or our suppliers, third-party contractors, clinical investigators or collaborators are slow to adapt, or are unable to adapt, to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, we or our collaborators may be subject to the actions listed above, including losing marketing approval for products when and if any of them are approved, resulting in decreased revenue from milestones, product sales or royalties.

76

We will need to obtain FDA approval of any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business.

A pharmaceutical product cannot be marketed in the US or other countries until it has completed a rigorous and extensive regulatory review processes, including approval of a brand name. Any brand names we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark registration from the PTO. The FDA typically conducts a review of proposed product brand names, including an evaluation of potential for confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.

Risks Pertaining to Legislation and Regulation Affecting the Biopharmaceutical and Other Industries

We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad.

We cannot predict the likelihood, nature or extent of how government regulation that may arise from future legislation or administrative or executive action taken by the U.S. presidential administration may impact our business and industry. In particular, the U.S. President has taken several executive actions, specifically through rulemaking and guidance, that could impact the pharmaceutical business and industry. A few of the major administrative actions include:

1.On October 9, 2019, the Centers for Medicare & Medicaid Services (“CMS”) issued a proposed rule entitled, Modernizing and Clarifying the Physician Self-Referral Regulations and on the same day the HHS Office of Inspector General issued a similar rule, entitled Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary penalty Rules Regarding Beneficiary Inducements. The proposed rules are an effort to reform regulations dealing with anti-kickback and self-referral laws. The proposals are attempting to allow certain financial arrangements that would otherwise violate anti-kickback and self-referral laws for providers that are participating in value-based payment arrangements. The proposed rule could impact drug purchasing behavior to ensure providers are within their budget and/or restructure existing payment structures between providers and manufacturers.
2.On October 30, 2019, the Administration issued an advanced notice of proposed rulemaking (“ANPRM”) entitled, International Pricing Index Model for Medicare Part B Drugs. This ANPRM is soliciting feedback on a potential proposal to align United States drug prices in the Medicare Part B program with international prices. It also solicits public feedback on a policy that would allowing private-sector vendors to negotiate prices, take title to drugs, and improve competition for hospital and physician business. Although this is only a notice for a potential rule, it signals the Administration’s desire to regulatorily influence the United States drug pricing system that could adversely affect the industry.
3.On November 15, 2019, CMS issued a proposed rule entitled, Transparency in Coverage and finalized the Calendar Year (“CY”) 2020 Outpatient Prospective Payment System (“OPPS”) & Ambulatory Surgical Center Price Transparency Requirements for Hospitals to Make Standard Charges Rule. Together the rules would increase price transparency through health plans and in hospitals. The affects may influence consumer purchasing habits in the health care sector as a whole. Although the transparency provisions are not yet in effect and the hospital price transparency requirements are subject to litigation, there could be implications for the industry related to drug pricing if or when it is enacted.
4.On November 18, 2019, CMS issued a proposed rule entitled, Medicaid Fiscal Accountability Regulation (“MFAR”). The proposed rule would significantly impact states’ ability to finance their Medicaid programs. If finalized, the MFAR could force states to restructure their Medicaid financing that could disincentivize or change state prescription drug purchasing behavior that would adversely impact the industry.

77

5.On December 18, 2019, the FDA issued a proposed rule entitled, Importation of Prescription Drugs. The proposed rule would allow the importation of certain prescription drugs from Canada. If finalized, states or other non-federal government entities would be able to submit importation program proposals to FDA for review and authorization. This proposed rule could also influence pricing practices in the United States.
6.On January 30, 2020, CMS issued a state waiver option entitled, Health Adult Opportunity (“HAO”). The HAO would allow states to restructure benefits and coverage policies for their Medicaid programs. The HAO will provide states administrative flexibilities in exchange for a capped federal share. The cap on the federal share is commonly referred to as a “block grant.” Importantly, the HAO allows states to set formularies that align with Essential Health Benefit requirements while still requiring manufacturers to participate in the Medicaid Rebate Program. Depending on utilization of the HAO by states, it could impact the industry – especially if states elect to use a formulary.

It is also possible that the Trump Administration will include drug pricing proposals in annual rulemaking throughout the year. As noted above, it is impossible to predict whether these policies will be included in future rulemaking; however, it is possible and worth noting.

Our current and future relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.

Healthcare providers, physicians and third-party payors in the U.S. and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which we sell, market and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by the federal and state governments and by governments in foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not necessarily limited to:

the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid;
federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

78

the federal Open Payments program, which requires manufacturers of certain drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare & Medicaid Services, or CMS, information related to “payments or other transfers of value” made to “covered recipients,” which include physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals) and applicable manufacturers. Applicable group purchasing organizations also are required to report annually to CMS the ownership and investment interests held by the physicians and their immediate family members. The SUPPORT for Patients and Communities Act added to the definition of covered recipient practitioners including physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse-midwives effective in 2022. Data collection began on August 1, 2013 with requirements for manufacturers to submit reports to CMS by March 31, 2014 and 90 days after the end of each subsequent calendar year. Disclosure of such information was made by CMS on a publicly available website beginning in September 2014; and
analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could have a material adverse effect on our businesses. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including our collaborators, is found not to be in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our businesses.

As we continue to execute our growth strategy, we may be subject to further government regulation which could adversely affect our financial results, including without limitation the Investment Company Act of 1940.

If we engage in business combinations and other transactions that result in holding minority or non-control investment interests in a number of entities, we may become subject to regulation under the Investment Company Act of 1940, as amended (the “Investment Company Act”). If we do become subject to the Investment Company Act, we would be required to register as an investment company and could be expected to incur significant registration and compliance costs in the future.

General Risks

Major public health issues, and specifically the pandemic caused by the coronavirus COVID-19 outbreak, could have an adverse effect on the clinical trials of our partner companies, and as a result, have an adverse impact on our financial condition and results of operations and other aspects of our business.

In December 2019, a novel strain of coronavirus which causes a disease referred to as COVID-19, was first detected in Wuhan, China, and has since spread worldwide. On March 11, 2020, the World Health Organization declared that the rapidly spreading COVID-19 outbreak had evolved into a pandemic. In response to the pandemic, many governments around the world are implementing a variety of control measures to reduce the spread of COVID-19, including travel restrictions and bans, instructions to residents to practice social distancing, quarantine advisories, shelter-in-place orders and required closures of non-essential businesses.

79

The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains, and created significant volatility and disruption of financial markets. The extent to which the COVID-19 pandemic impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning the virus and the actions to contain it or treat its impact, among others.

Some factors from the COVID-19 outbreak that may delay or otherwise adversely affect our or our partner companies’ clinical trial programs, as well as adversely impact our business generally, include:

delays or difficulties in clinical site initiation, including difficulties in recruiting clinical sites, and delays enrolling patients in our clinical trials or increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19, being forced to quarantine, or not otherwise being able to complete study assessments, particularly for older patients or others with a higher risk of contracting COVID-19;
missed study visits or study procedures which could lead to an abundance of protocol deviations that have the potential to interfere with the interpretability of trial results;
impacts to clinical results, including an increased number of observed adverse events, as a result of participants enrolled in our clinical trials contracting COVID-19;
diversion of healthcare resources, including clinical trial investigators and staff, away from the conduct of clinical trials to focus on pandemic concerns which could result in delays to our partner companies’ clinical trials;
limitations on travel, including limitations on domestic and international travel, and government-imposed quarantines or restrictions imposed by key third parties that could interrupt key trial activities, such as clinical trial site initiations and monitoring;
interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, or production slowdowns or stoppages;
disruptions and delays caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home across the healthcare system; and
disruptions in or delays to regulatory approvals, inspections, reviews or other regulatory activities, including review of NDAs and approvals of protocol changes or amendments to SPAs, as a result of the spread of COVID-19 affecting the operations of the FDA or other regulatory authorities.

The disruptions discussed above and other consequences of COVID-19 pandemic could result in missed study visits or study procedures in our clinical trials, which could lead to an abundance of protocol deviations that impact the interpretability of the trial results. A significant number of deviations may call into question whether the execution of a clinical trial was consistent with the protocol, which is of particular importance where study designs were agreed to as part of a Special Protocol Assessment (SPA). In extreme cases, significant deviations from the protocol may be considered a violation of a SPA and result in potential rescindment of an SPA agreement.

We and our partner companies currently rely on third parties for certain functions or services in support of our clinical trials and key areas of our operations. These third parties include contract research organizations (CROs), medical institutions and clinical investigators, contract manufacturing organizations, suppliers, and external business partners supporting our preparations for commercialization. If these third parties themselves are adversely impacted by restrictions resulting from the COVID-19 outbreak, we will likely experience delays and/or realize additional costs. As a result, our or our partner companies’ efforts to obtain regulatory approvals for, and to commercialize, our or our partner companies’ product candidates may be delayed or disrupted.

In addition, as a result of government directives on social distancing and to protect the health of our workforce, we have asked our office-based employees to work remotely and have restricted domestic and international travel indefinitely.

80

We restricted on-site staff to only those personnel and contractors who must perform essential activities that must be completed on-site. Third parties on which we rely may also increase their use of remote working arrangements in response to COVID-19. Our increased reliance on personnel working remotely may negatively impact productivity, including our ability to monitor clinical trials, prepare regulatory applications, and conduct data analysis, or disrupt, delay, or otherwise adversely impact our business. In addition, remote working could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors.

The ability of the Company’s employees and consultants to work may be significantly impacted by the coronavirus.

The Company’s employees and consultants are being affected by the COVID-19 pandemic. Substantially all of our office and management personnel are working remotely, and the Company may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the coronavirus. COVID-19 may also compromise the ability of independent contractors who perform consulting services for us to deliver services or deliverables in a satisfactory or timely manner.  Further, our management team is focused on mitigating the adverse effects of the COVID-19 pandemic, which has required and will continue to require a large investment of time and resources, thereby diverting their attention from other priorities that existed prior to the outbreak of the pandemic. If these conditions worsen, or last for an extended period of time, the Company’s ability to manage its business may be impaired, and operational risks, cybersecurity risks and other risks facing the Company even prior to the pandemic may be elevated.

We may not be able to hire or retain key officers or employees needed to implement our business strategy and develop products and businesses.

Our success depends on the continued contributions of our executive officers, financial, scientific, and technical personnel and consultants, and on our ability to attract additional personnel as we continue to implement growth strategies and acquire and invest in companies with varied businesses. During our operating history, many essential responsibilities have been assigned to a relatively small number of individuals. However, as we continue to implement our growth strategy, the demands on our key employees will expand, and we will need to recruit additional qualified employees. The competition for such qualified personnel is intense, and the loss of services of certain key personnel, or our inability to attract additional personnel to fill critical positions, could adversely affect our business.

We currently depend heavily upon the efforts and abilities of our management team and the management teams of our partners. The loss or unavailability of the services of any of these individuals could have a material adverse effect on our business, prospects, financial condition and results. In addition, we have not obtained, do not own, and are not the beneficiary of key-person life insurance for any of our key personnel. We only maintain a limited amount of directors’ and officers’ liability insurance coverage. There can be no assurance that this coverage will be sufficient to cover the costs of the events that may occur, in which case, there could be a substantial impact on our ability to continue operations.

Our employees, consultants, or third-party partners may engage in misconduct or other improper activities, including but not necessarily limited to noncompliance with regulatory standards and requirements or internal procedures, policies or agreements to which such employees, consultants and partners are subject, any of which could have a material adverse effect on our business.

We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, consultants, or third-party partners could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with current good manufacturing practices (“cGMPs”), comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately, comply with internal procedures, policies or agreements to which such employees, consultants or partners are subject, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee, consultant, or third-party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation, as well as civil and criminal liability. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other civil and/or criminal sanctions.

81

We receive a large amount of proprietary information from potential or existing licensors of intellectual property and potential acquisition target companies, all pursuant to confidentiality agreements. The confidentiality and proprietary invention assignment agreements that we have in place with each of our employees and consultants prohibit the unauthorized disclosure of such information, but such employees or consultants may nonetheless disclose such information through negligence or willful misconduct. Any such unauthorized disclosures could subject us to monetary damages and/or injunctive or equitable relief. The notes, analyses and memoranda that we have generated based on such information are also valuable to our businesses, and the unauthorized disclosure or misappropriation of such materials by our employees and consultants could significantly harm our strategic initiatives – especially if such disclosures are made to our competitor companies.

We may be subject to claims that our employees and/or consultants have wrongfully used or disclosed to us alleged trade secrets of their former employers or other clients.

As is common in the biopharmaceutical industry, we rely on employees and consultants to assist in the development of product candidates, many of whom were previously employed at, or may have previously been or are currently providing consulting services to, other biopharmaceutical companies, including our competitors or potential competitors. We may become subject to claims related to whether these individuals have inadvertently or otherwise used, disclosed or misappropriated trade secrets or other proprietary information of their former employers or their former or current clients. Litigation may be necessary to defend against these claims. Even if we are successful in defending these claims, litigation could result in substantial costs and be a distraction to management and/or the employees or consultants that are implicated.

The market price of our securities may be volatile and may fluctuate in a way that is disproportionate to our operating performance.

The stock prices of our securities may experience substantial volatility as a result of a number of factors, including, but not necessarily limited to:

announcements we make regarding our current product candidates, acquisition of potential new product candidates and companies and/or in-licensing through multiple partners/affiliates;
sales or potential sales of substantial amounts of our Common Stock;
issuance of debt or other securities;
our delay or failure in initiating or completing pre-clinical or clinical trials or unsatisfactory results of any of these trials;
announcements about us or about our competitors, including clinical trial results, regulatory approvals or new product introductions;
developments concerning our licensors and/or product manufacturers;
litigation and other developments relating to our patents or other proprietary rights or those of our competitors;
conditions in the pharmaceutical or biotechnology industries;
governmental regulation and legislation;
unstable regional political and economic conditions;
variations in our anticipated or actual operating results; and
change in securities analysts’ estimates of our performance, or our failure to meet analysts’ expectations.

82

Many of these factors are beyond our control. The stock markets in general, and the market for pharmaceutical and biotechnological companies in particular, have historically experienced extreme price and volume fluctuations. These fluctuations often have been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors could reduce the market prices of our securities, regardless of our actual operating performance.

Sales of a substantial number of shares of our Common Stock, or the perception that such sales may occur, may adversely impact the price of our Common Stock.

Almost all of the 99.7 million outstanding shares of our Common Stock, inclusive of outstanding equity awards, as of September 30, 2020 are available for sale in the public market, either pursuant to Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), or an effective registration statement. In addition, pursuant to our current shelf registration statement on Form S-3, from time to time we may issue and sell shares of our Common Stock or Preferred Stock having an aggregate offering price of up to $29.5 million as of September 30, 2020. Any sale of a substantial number of shares of our Common Stock or our Preferred Stock could cause a drop in the trading price of our Common Stock or Preferred Stock on the Nasdaq Stock Market.

We may not be able to manage our anticipated growth, which may in turn adversely impact our business.

We will need to continue to expend capital on improving our infrastructure to address our anticipated growth. Acquisitions of companies or products could place a strain on our management, and administrative, operational and financial systems. In addition, we may need to hire, train, and manage more employees, focusing on their integration with us and corporate culture. Integration and management issues associated with increased acquisitions may require a disproportionate amount of our management’s time and attention and distract our management from other activities related to running our business.

The occurrence of a catastrophic disaster could damage our facilities beyond insurance limits or we could lose key data which could cause us to curtail or cease operations.

We are vulnerable to damage and/or loss of vital data from natural disasters, such as earthquakes, tornadoes, power loss, fire, health epidemics and pandemics, floods and similar events, as well as from accidental loss or destruction. If any disaster were to occur, our ability to operate our businesses could be seriously impaired. We have property, liability and business interruption insurance that may not be adequate to cover losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business, financial condition and prospects. Any of the aforementioned circumstances, including without limitation the COVID-19 virus, may also impede our employees’ and consultants’ abilities to provide services in-person and/or in a timely manner; hinder our ability to raise funds to finance our operations on favorable terms or at all; and trigger effectiveness of “force majeure” clauses under agreements with respect to which we receive goods and services, or under which we are obligated to achieve developmental milestones on certain timeframes. Disputes with third parties over the applicability of such “force majeure” clauses, or the enforceability of developmental milestones and related extension mechanisms in light of such business interruptions, may arise and may become expensive and time-consuming.

Our ability to use our pre-change NOLs and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.

We may, from time to time, carry net operating loss carryforwards (“NOLs”) as deferred tax assets on our balance sheet.  Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50-percentage- point cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation’s ability to use its pre-change NOLs and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership, some of which changes are outside our control. As a result, our ability to use our pre-change NOLs and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.

83

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.

We, and/or third parties on our behalf, may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations may also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property and casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or penalized with fines in an amount exceeding our respective resources, and clinical trials or regulatory approvals could be suspended.

Although we maintain workers’ compensation insurance to cover costs and expenses incurred due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted in connection with the storage or disposal of biological or hazardous materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

We have never paid and currently do not intend to pay cash dividends in the near future, except for the dividend we pay on our Series A Preferred Stock. As a result, capital appreciation, if any, will be the sole source of gain for our Common Stockholders.

We have never paid cash dividends on our Common Stock, or made stock dividends, except for the dividend we pay on shares of our Series A Preferred Stock, and we currently intend to retain future earnings, if any, to fund the development and growth of our businesses, and retain our stock positions. In addition, the terms of existing and future debt agreements may preclude us from paying cash or stock dividends. Equally, each of our partners is governed by its own board of directors with individual governance and decision-making regimes and mandates to oversee such entities in accordance with their respective fiduciary duties. As a result, we alone cannot determine the acts that could maximize value to you of such partners in which we maintain ownership positions, such as declaring cash or stock dividends. As a result, capital appreciation, if any, of our Common Stock will be the sole source of gain for our Common Stockholders for the foreseeable future.

Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business or the business of our partners.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, ability to accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business or the business of our partners. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough nonessential FDA employees and stop routine activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. If the timing of FDA’s review and approval of new products is delayed, the timing of our or our partners’ development process may be delayed, which could result in delayed milestone revenues and materially harm our operations or business.

84

We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. Also, if we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors’ views of us and, as a result, the value of our Securities.

As a public company, we incur significant legal, accounting and other expenses under the Sarbanes-Oxley Act (“SOX”), as well as rules subsequently implemented by the SEC, and the rules of the Nasdaq Stock Exchange. These rules impose various requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and appropriate corporate governance practices. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

SOX requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. As a result, we are required to periodically perform an evaluation of our internal controls over financial reporting to allow management to report on the effectiveness of those controls, as required by Section 404 of SOX. Additionally, our independent auditors are required to perform a similar evaluation and report on the effectiveness of our internal controls over financial reporting. These efforts to comply with Section 404 and related regulations have required, and continue to require, the commitment of significant financial and managerial resources. While we anticipate maintaining the integrity of our internal controls over financial reporting and all other aspects of Section 404, we cannot be certain that a material weakness will not be identified when we test the effectiveness of our control systems in the future. If a material weakness is identified, we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources, costly litigation or a loss of public confidence in our internal controls, which could have an adverse effect on the market price of our stock.

Provisions in our certificate of incorporation, our bylaws and Delaware law might discourage, delay or prevent a change in control of our Company or changes in our management and, therefore, depress the trading price of our Common Stock or other Securities.

Provisions of our certificate of incorporation, our bylaws and Delaware law may have the effect of deterring unsolicited takeovers and/or delaying or preventing a change in control of our Company or changes in our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then-current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interests. These provisions include:

the inability of stockholders to call special meetings; and
the ability of our Board of Directors to designate the terms of and issue new series of preferred stock without stockholder approval, which could include the right to approve an acquisition or other change in our control or could be used to institute a rights plan, also known as a poison pill, that would work to dilute the stock ownership of a potential hostile acquirer, likely preventing acquisitions that have not been approved by our Board of Directors.

In addition, the Delaware General Corporation Law prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.

The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our Common Stock. They could also deter potential acquirers of our Company, thereby reducing the likelihood that you would receive a premium for your ownership of our Securities through an acquisition.

Item 2.      Unregistered Sales of Equity Securities and Use of Proceeds

None.

85

Item 3.      Defaults Upon Senior Securities

None.

Item 4.      Mine Safety Disclosures

None.

Item 5.      Other Information

None.

Item 6.      Exhibits

Exhibit Index

Exhibit
Number

    

Exhibit Title

 

 

 

10.1

Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020. (*+)

31.1

 

Certification of Chairman, President and Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

 

Certification of the Chairman, President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2

 

Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

Inline XBRL Instance Document.(*)

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document.(*)

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.(*)

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.(*)

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document.(*)

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.(*)

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*  Filed herewith.

+  Certain confidential portions of this exhibit have been omitted pursuant to Item 601(b) of Regulation S-K.

86

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

November 9, 2020

FORTRESS BIOTECH, INC.

 

 

 

 

By: 

/s/ Lindsay A. Rosenwald, M.D.

 

 

Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer (Principal Executive Officer)

 

 

 

November 9, 2020

By:

/s/ Robyn M. Hunter

 

 

Robyn M. Hunter Chief Financial Officer (Principal Financial Officer)

87

EX-10.1 2 fbio-20200930xex10d1.htm EX-10.1

Certain identified information has been excluded from the document because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

August 27, 2020

Exhibit 10.1

CREDIT AGREEMENT

dated as of August 27, 2020

by and among

FORTRESS BIOTECH, INC.,

as the Borrower,

THE LENDERS FROM TIME TO TIME PARTY HERETO

as the Lenders, and

OAKTREE FUND ADMINISTRATION, LLC,

as the Administrative Agent

  

U.S. $60,000,000

-i-

­SC1:5266419.14


TABLE OF CONTENTS

Section 1. DEFINITIONS1

1.01Certain Defined Terms1

1.02Accounting Terms and Principles24

1.03Interpretation24

1.04Division25

Section 2. THE COMMITMENT AND THE LOANS25

2.01Loans25

2.02Borrowing Procedures26

2.03Notes26

2.04Use of Proceeds26

Section 3. PAYMENTS OF PRINCIPAL AND INTEREST, ETC.26

3.01Scheduled Repayments and Prepayments Generally; Application26

3.02Interest27

3.03Prepayments27

Section 4. PAYMENTS, ETC.29

4.01Payments29

4.02Computations30

4.03Set-Off31

Section 5. YIELD PROTECTION, TAXES, ETC.31

5.01Additional Costs31

5.02Illegality33

5.03Taxes33

5.04Mitigation Obligations37

5.05Survival38

Section 6. CONDITIONS38

6.01Conditions to the Borrowing of the Loans38

Section 7. REPRESENTATIONS AND WARRANTIES42

7.01Power and Authority42

7.02Authorization; Enforceability42

7.03Governmental and Other Approvals; No Conflicts42

-ii-

­SC1:5266419.14


7.04Financial Statements; Material Adverse Change43

7.05Properties43

7.06No Actions or Proceedings44

7.07Compliance with Laws and Agreements45

7.08Taxes45

7.09Full Disclosure45

7.10Investment Company Act and Margin Stock Regulation45

7.11Solvency46

7.12Subsidiaries46

7.13Indebtedness and Liens46

7.14Material Agreements46

7.15Restrictive Agreements46

7.16Real Property46

7.17Pension Matters46

7.18Transactions with Affiliates47

7.19OFAC; Anti-Terrorism Laws47

7.20Anti-Corruption47

7.21Priority of Obligations48

Section 8. AFFIRMATIVE COVENANTS48

8.01Financial Statements and Other Information48

8.02Notices of Material Events50

8.03Existence51

8.04Payment of Obligations51

8.05Insurance51

8.06Books and Records; Inspection Rights52

8.07Compliance with Laws and Other Obligations52

8.08Maintenance of Properties, Etc.52

8.09Licenses53

8.10Use of Proceeds53

8.11Further Assurances53

8.12Termination of Non-Permitted Liens54

-iii-

­SC1:5266419.14


8.13Board Materials; Oaktree Lender Board Observer54

8.14ERISA Compliance54

8.15Cash Management54

8.16Post-Closing Obligations55

Section 9. NEGATIVE COVENANTS56

9.01Indebtedness56

9.02Liens57

9.03Fundamental Changes and Acquisitions58

9.04Lines of Business59

9.05Investments59

9.06Restricted Payments60

9.07Payments of Indebtedness62

9.08Change in Fiscal Year62

9.09Sales of Assets, Etc.62

9.10Transactions with Affiliates63

9.11Restrictive Agreements63

9.12Modifications and Terminations of Organic Documents63

9.13Sales and Leasebacks63

9.14Hazardous Material64

9.15Accounting Changes64

9.16Compliance with ERISA64

9.17Restriction of Amendments to Certain Documents64

9.18Sanctions; Anti-Corruption Use of Proceeds64

9.19Closing Date Equity Interests.65

9.20Margin Stock. .65

Section 10. FINANCIAL COVENANTS65

10.01Minimum Liquidity65

10.02Minimum Revenue65

Section 11. EVENTS OF DEFAULT66

11.01Events of Default66

11.02Remedies68

-iv-

­SC1:5266419.14


11.03[Reserved]69

11.04Minimum Revenue Covenant Cure69

11.05Payment of Prepayment Fee and Specified Return Shortfall70

Section 12. THE ADMINISTRATIVE AGENT71

12.01Appointment and Duties71

12.02Binding Effect72

12.03Use of Discretion72

12.04Delegation of Rights and Duties73

12.05Reliance and Liability73

12.06Administrative Agent Individually74

12.07Lender Credit Decision75

12.08Expenses; Indemnities75

12.09Resignation of the Administrative Agent76

12.10Release of Collateral or Guarantors76

12.11Additional Secured Parties77

Section 13. MISCELLANEOUS78

13.01No Waiver78

13.02Notices78

13.03Expenses, Indemnification, Etc.78

13.04Amendments, Etc.79

13.05Successors and Assigns80

13.06Survival83

13.07Captions83

13.08Counterparts, Effectiveness83

13.09Governing Law83

13.10Jurisdiction, Service of Process and Venue83

13.11Waiver of Jury Trial84

13.12Waiver of Immunity84

13.13Entire Agreement84

13.14Severability84

13.15No Fiduciary Relationship84

-v-

­SC1:5266419.14


13.16Confidentiality85

13.17Interest Rate Limitation85

13.18Judgment Currency86

13.19USA PATRIOT Act86

13.20Acknowledgement and Consent to Bail-In of EEA Financial Institutions86

SCHEDULES AND EXHIBITS

Schedule 1-Loans Schedule

Schedule 3-Minimum Revenue

Schedule 7.05(b)-Certain Intellectual Property

Schedule 7.08-Taxes

Schedule 7.12-Information Regarding Subsidiaries

Schedule 7.13(a)-Existing Indebtedness

Schedule 7.13(b)-Existing Liens

Schedule 7.14-Material Agreements

Schedule 7.15-Restrictive Agreements

Schedule 7.16-Real Property Owned or Leased by Borrower

Schedule 7.18-Transactions with Affiliates

Schedule 9.05-Existing Investments

Schedule 9.09(a)-Sale of Assets

Schedule 9.09(b)Qualifying Avenue Sale

Schedule 9.09(c)Qualifying [*] Sale

Schedule 9.19-Closing Date Equity Interests

  

Exhibit A-Form of Note

Exhibit B-Form of Borrowing Notice

Exhibit C-1-Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)

Exhibit C-2-Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)

Exhibit C-3-Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)

Exhibit C-4-Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)

Exhibit D-Form of Compliance Certificate

Exhibit E-Form of Assignment and Assumption

Exhibit F-Form of Warrant

Exhibit G-Form of Solvency Certificate

Exhibit H-Form of Funding Date Certificate

-vi-

­SC1:5266419.14


-vii-

­SC1:5266419.14


CREDIT AGREEMENT

CREDIT AGREEMENT, dated as of August 27, 2020 (this “Agreement”), among FORTRESS BIOTECH, INC., a Delaware corporation (the “Borrower”), the lenders from time to time party hereto (each a “Lender” and collectively, the “Lenders”), and OAKTREE FUND ADMINISTRATION, LLC, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”).

WITNESSETH:

WHEREAS, the Borrower has requested that the Lenders provide a senior secured term loan facility to the Borrower in an aggregate principal amount of $60,000,000 to be extended on the Closing Date; and

WHEREAS, the Lenders are willing, on the terms and subject to the conditions set forth herein, to provide such senior secured term loan facility.

NOW, THEREFORE, the parties hereto agree as follows:

Section 1.
DEFINITIONS
1.01Certain Defined Terms. As used herein, the following terms have the following respective meanings:

Account Control Agreement Completion Date” has the meaning set forth in Section 8.16(a).

Acquisition” means any transaction, or any series of related transactions, by which any Person (for purposes of this definition, an “acquirer”) directly or indirectly, by means of amalgamation, merger, purchase of assets, purchase of Equity Interests, or otherwise, (i) acquires all or substantially all of the assets of any other Person, (ii) acquires an entire business line or unit or division of any other Person, (iii) with respect to any other Person that is managed or governed by a Board, acquires control of Equity Interests of such other Person representing more than fifty percent (50%) of the ordinary voting power (determined on a fully-diluted basis) for the election of directors of such Person’s Board, or (iv) acquires control of more than fifty percent (50%) of the Equity Interests in any other Person (determined on a fully-diluted basis) that is not managed by a Board.

Administrative Agent” has the meaning set forth in the preamble hereto.

Affiliate” means, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified.

Agreement” has the meaning set forth in the preamble hereto.

­SC1:5266419.14


Anti-Terrorism Laws” means any laws relating to terrorism or money laundering, including, without limitation, (i) the Money Laundering Control Act of 1986 (e.g., 18 U.S.C. §§ 1956 and 1957), (ii) the Bank Secrecy Act of 1970 (e.g., 31 U.S.C. §§ 5311 – 5330), as amended by the Patriot Act, (iii) the laws, regulations and Executive Orders administered by the United States Department of the Treasury’s Office of Foreign Assets Control (“OFAC”), (iv) the Comprehensive Iran Sanctions, Accountability, and Divestment Act of 2010 and implementing regulations by the United States Department of the Treasury, (v) any law prohibiting or directed against terrorist activities or the financing of terrorist activities (e.g., 18 U.S.C. §§ 2339A and 2339B), or (vi) any similar laws enacted in the United States, European Union or any other jurisdictions in which the parties to this agreement operate, and all other present and future legal requirements of any Governmental Authority governing, addressing, relating to, or attempting to eliminate, terrorist acts and acts of war.

Applicable Prepayment Percentage” means 20.0%.

Arm’s Length Transaction” means, with respect to any transaction, the terms of such transaction shall not be less favorable to the Borrower or any of its Subsidiaries than commercially reasonable terms that would be obtained in a transaction with a Person that is an unrelated third party.

Asset Sale” has the meaning set forth in Section 9.09.

Assignment and Assumption” means an assignment and assumption entered into by a Lender and an assignee of such Lender substantially in the form of Exhibit E, or such other form as is acceptable to the Administrative Agent.

Bail-In Action” means the exercise of any Write-Down and Conversion Powers by the applicable EEA Resolution Authority in respect of any liability of an EEA Financial Institution.

Bail-In Legislation” means, with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule.

Bankruptcy Code” means Title 11 of the United States Code entitled “Bankruptcy.”

Beneficial Ownership Certification” means a certification regarding beneficial ownership as required by the Beneficial Ownership Regulation.

Beneficial Ownership Regulation” means 31 C.F.R. § 1010.230.

Benefit Plan” means any employee benefit plan as defined in Section 3(3) of ERISA (whether governed by the laws of the United States or otherwise) to which the Borrower or any Subsidiary thereof incurs or otherwise has any obligation or liability, contingent or otherwise.

-2-

­SC1:5266419.14


Board” means, with respect to any Person, the board of directors or equivalent management or oversight body of such Person or any committee thereof authorized to act on behalf of such board (or equivalent body).

Board Observer” has the meaning set forth in Section 8.13(b).

Borrower” has the meaning set forth in the preamble hereto.

Borrower Party” has the meaning set forth in Section 13.03(b).

Borrowing” means the borrowing of the Loans on the Closing Date.

Borrowing Notice” means a written notice substantially in the form of Exhibit B.

Business Day” means a day (other than a Saturday or Sunday) on which commercial banks are not authorized or required to close in New York City.

Capital Lease Obligations” means, as to any Person, the obligations of such Person to pay rent or other amounts under a lease of (or other agreement conveying the right to use) real and/or personal property, which obligations are required to be classified and accounted for as a capital lease on a balance sheet of such Person under GAAP and, for purposes of this Agreement, the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP.

Casualty Event” means the damage, destruction or condemnation, as the case may be, of property of the Borrower or any of its Subsidiaries in excess of $2,000,000.

CFC” means a Subsidiary that is a “controlled foreign corporation” within the meaning of Section 957 of the Code.

CFC Holding Company” means any Domestic Subsidiary that owns no material assets (directly or indirectly) other than Equity Interests, or Equity Interests and debt, of one or more CFCs or Domestic Subsidiaries that are themselves CFC Holding Companies.

Change of Control” means an event or series of events (i) as a result of which any “person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the Securities Act, but excluding any of such person or its Subsidiaries, and any Person acting in its capacity as trustee, agent or other fiduciary or administrator of any such Plan) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act, except that a person or group shall be deemed to have “beneficial ownership” of all Equity Interests that such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage of time (such right, an “option right”)), directly or indirectly, of thirty-five percent (35%) or more of the Equity Interests of the Borrower entitled to vote for members of the Board of the Borrower on a fully-diluted basis (and taking into account all such Equity Interests that such person or group has the right to acquire pursuant to any option right); or (ii) as a result of which, during any period of twelve (12) consecutive months, a majority of the members of the Board of the Borrower cease to be composed of individuals (x) who were members of such

-3-

­SC1:5266419.14


Board on the first day of such period, (y) whose election or nomination to such Board was approved by individuals referred to in clause (x) above constituting at the time of such election or nomination at least a majority of such Board or equivalent governing body or (z) whose election or nomination to such Board was approved by individuals referred to in clauses (x) and (y) above constituting at the time of such election or nomination at least a majority of such Board; or (iii) that results in the sale of all or substantially all of the assets or businesses of the Borrower and its Subsidiaries, taken as a whole.

Claims” means (and includes) any claim, demand, complaint, grievance, action, application, suit, cause of action, order, charge, indictment, prosecution, judgement or other similar process, whether in respect of assessments or reassessments, debts, liabilities, expenses, costs, damages or losses, contingent or otherwise, whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of legal counsel, and all costs incurred in investigating or pursuing any of the foregoing or any proceeding relating to any of the foregoing.

Closing Date” means the date on which the conditions precedent specified in Section 6.01 are satisfied (or waived in accordance with Section 13.04) and on which the Loans are to be made to the Borrower.

Closing Date Equity Interests” has the meaning set forth in Section 9.19.

Code” means the Internal Revenue Code of 1986, as amended from time to time, and the rules and regulations promulgated thereunder from time to time.

Collateral” means any real, personal and mixed property (including Equity Interests), whether tangible or intangible, in which Liens are granted or purported to be granted to the Administrative Agent as security for the Obligations under any Loan Document on or after the Closing Date, including future acquired or created assets or property (or collectively, all such real, personal and mixed property, as the context may require).

Commitment” means, with respect to each Lender, the obligation of such Lender to make Loans to the Borrower on the Closing Date in accordance with the terms and conditions of this Agreement, which commitment is in the amount set forth opposite such Lender’s name on Schedule 1 under the caption “Commitment”, as such Schedule may be amended from time to time pursuant to an Assignment and Assumption or otherwise. The aggregate amount of Commitments on the date of this Agreement equals $60,000,000.

Compliance Certificate” has the meaning set forth in Section 8.01(c).

Connection Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.

Contracts” means any contract, license, lease, agreement, obligation, promise, undertaking, understanding, arrangement, document, commitment, entitlement or engagement under which a Person has, or will have, any liability or contingent liability (in each case, whether

-4-

­SC1:5266419.14


written or oral, express or implied, and whether in respect of monetary or payment obligations, performance obligations or otherwise).

Control” means, in respect of a particular Person, the possession by one or more other Persons, directly or indirectly, of the power to direct or cause the direction of the management or policies of such particular Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative thereto.

Controlled Account” has the meaning set forth in Section 8.15(a).

Copyright” means all copyrights, copyright registrations and applications for copyright registrations, including all renewals and extensions thereof and all other rights whatsoever accruing thereunder or pertaining thereto throughout the world.

Cyprium” means Cyprium Therapeutics, Inc.

Cyprium Financing” has the meaning set forth on Schedule 7.18.

Default” means any Event of Default and any event that, upon the giving of notice, the lapse of time or both, would constitute an Event of Default.

Default Rate” has the meaning set forth in Section 3.02(b).

Designated Jurisdiction” means any country or territory to the extent that such country or territory is the subject of country- or territory-wide Sanctions.

Disqualified Equity Interests” means, with respect to any Person, any Equity Interest of such Person that, by its terms (or by the terms of any security or other Equity Interest into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition (i) matures or is mandatorily redeemable (other than solely for Qualified Equity Interests), including pursuant to a sinking fund obligation or otherwise, (ii) is redeemable at the option of the holder thereof (other than solely for Qualified Equity Interests), in whole or in part, (iii) provides for the scheduled payments of dividends or other distributions in cash or other securities that would constitute Disqualified Equity Interests, or (iv) is or becomes convertible into or exchangeable for Indebtedness or any other Equity Interests that would constitute Disqualified Equity Interests, in each case, prior to the date that is ninety-one (91) days after the Maturity Date.

Division” has the meaning set forth in Section 1.04.

Dollars” and “$” means lawful money of the United States of America.

Domestic Subsidiary” means any Subsidiary that is a corporation, limited liability company, partnership or similar business entity incorporated, formed or organized under the laws of the United States, any state of the United States or the District of Columbia.

DOSPA” has the meaning set forth in Section 8.16(e).

-5-

­SC1:5266419.14


EEA Financial Institution” means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.

EEA Member Country” means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.

EEA Resolution Authority” means any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.

Eligible Transferee” means and includes (i) any commercial bank, (ii) any insurance company, (iii) any finance company, (iv) any financial institution, (v) any Person that is a bona fide debt fund primarily engaged in the making, purchasing, holding or other investing in commercial loans, notes, bonds or similar extensions of credit or securities in the Ordinary Course, (vi) with respect to any Lender, any of its Affiliates or such Lender’s or Affiliate’s managed funds or accounts, and (vii) any other “accredited investor” (as defined in Regulation D of the Securities Act) that is principally in the business of managing investments or holding assets for investment purposes.

Environmental Claims” means any investigation, notice, notice of violation, claim, action, suit, proceeding, demand, information request, abatement order or other order or directive (conditional or otherwise), by any Governmental Authority or any other Person, arising (i) pursuant to or in connection with any actual or alleged violation of any Environmental Law; (ii) in connection with any Hazardous Material or any actual or alleged Hazardous Materials Activity; or (iii) in connection with any actual or alleged damage, injury, threat or harm to health, safety, natural resources or the environment, arising out of a violation of Environmental Law or any Hazardous Materials Activity.

Environmental Law” means all laws (including common law and any federal, state, provincial or local governmental law), rule, regulation, order, writ, judgment, notice, requirement, binding agreement, injunction or decree, whether U.S. or non-U.S., relating in any way to (i) environmental matters, including those relating to any Hazardous Materials Activity; (ii) the generation, use, storage, transportation or disposal of Hazardous Materials; or (iii) to the extent related to Hazardous Materials Activity, occupational safety and health, industrial hygiene, land use, natural resources or the protection of human, plant or animal health or welfare, in any manner applicable to the Borrower or any of its Subsidiaries or any Facility.

Environmental Liability” means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of the Borrower or any of its Subsidiaries directly or indirectly resulting from or based upon (i) violation of any Environmental Law, (ii) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (iii) exposure to any Hazardous Materials,

-6-

­SC1:5266419.14


(iv) the release or threatened release of any Hazardous Materials into the environment or (v) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing.

Equity Interests” means, with respect to any Person (for purposes of this defined term, an “issuer”), all shares of, interests or participations in, or other equivalents in respect of such issuer’s capital stock, including all membership interests, partnership interests or equivalent, and all debt or other securities directly or indirectly exchangeable, exercisable or otherwise convertible into, such issuer’s capital stock, whether now outstanding or issued after the Closing Date, and in each case, however designated and whether voting or non-voting.

Equivalent Amount” means, with respect to an amount denominated in one currency, the amount in another currency that could be purchased by the amount in the first currency determined by reference to the Exchange Rate at the time of determination.

ERISA” means the United States Employee Retirement Income Security Act of 1974, as amended.

ERISA Affiliate” means, collectively, the Borrower, any Subsidiary thereof, and any Person under common control, or treated as a single employer, with the Borrower or any Subsidiary thereof, within the meaning of Section 414(b) or (c) of the Code and solely for purposes of Section 412 of the Code and Section 302 of ERISA, Section 414(m) or (o) of the Code.

ERISA Event” means (i) a reportable event as defined in Section 4043 of ERISA with respect to a Title IV Plan, excluding, however, such events for which the 30-day notice requirement has been waived; (ii) a withdrawal by the Borrower or any ERISA Affiliate thereof from a Title IV Plan during a plan year in which such entity was a “substantial employer” as defined in Section 4001(a)(2) of ERISA or a cessation of operations that is treated as such a withdrawal under Section 4062(e) of ERISA or the termination of any Title IV Plan with at least two or more contributing sponsors that are not ERISA Affiliates resulting in liability under Section 4064 of ERISA; (iii) the withdrawal of the Borrower or any ERISA Affiliate thereof in a complete or partial withdrawal (within the meaning of Section 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefore, or the receipt by the Borrower or any ERISA Affiliate thereof of notice from any Multiemployer Plan that it is insolvent pursuant to Section 4245 of ERISA; (iv) the filing of a notice of intent to terminate, the treatment of a plan amendment as a termination under Section 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Title IV Plan or Multiemployer Plan; (v) the imposition of liability on the Borrower or any ERISA Affiliate thereof pursuant to Sections 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA; (vi) the failure by the Borrower or any ERISA Affiliate thereof to make any required contribution to a Plan, or the failure to meet the minimum funding standard of Section 412 of the Code with respect to any Title IV Plan (whether or not waived in accordance with Section 412(c) of the Code) or the failure to make by its due date a required installment under Section 430 of the Code with respect to any Title IV Plan or the failure to make any required contribution to a Multiemployer Plan; (vii) the determination that any Title IV Plan is considered an at-risk plan

-7-

­SC1:5266419.14


or a plan in endangered to critical status within the meaning of Sections 430, 431 and 432 of the Code or Sections 303, 304 and 305 of ERISA; (viii) the imposition of any liability under Title I or Title IV of ERISA, other than PBGC premiums due but not delinquent under Section 4007 of ERISA, upon the Borrower or any ERISA Affiliate thereof; (ix) an application for a funding waiver under Section 303 of ERISA or an extension of any amortization period pursuant to Section 412 of the Code with respect to any Title IV Plan; or (x) the imposition of any lien (or the fulfillment of the conditions for the imposition of any lien) on any of the rights, properties or assets of the Borrower or any ERISA Affiliate thereof, in either case pursuant to Title I or IV, including Section 302(f) or 303(k) of ERISA or to Section 401(a)(29) or 430(k) of the Code.

ERISA Funding Rules” means the rules regarding minimum required contributions (including any installment payment thereof) to Title IV Plans, as set forth in Sections 412, 430, 431, 432 and 436 of the Code and Sections 302, 303, 304 and 305 of ERISA.

EU Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time.

Event of Default” has the meaning set forth in Section 11.01.

Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

Exchange Rate” means, as of any date, the rate at which any currency may be exchanged into another currency, as set forth on the relevant Bloomberg screen at or about 11:00 a.m. (Eastern time) on such date. In the event that such rate does not appear on the Bloomberg screen, the “Exchange Rate” shall be determined by reference to such other publicly available service for displaying exchange rates as may be reasonably designated by the Administrative Agent.

Excluded Taxes” means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient: (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes and branch profits Taxes, in each case, (x) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivisions thereof) or (y) that are Other Connection Taxes, (ii) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law in effect on the date on which (1) such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Borrower under Section 5.04) or (2) such Lender changes its lending office, except in each case to the extent that, pursuant to Section 5.03, amounts with respect to such Taxes were payable either to such Lender’s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient’s failure to comply with Section 5.03(f), and (iv) any U.S. federal withholding Taxes imposed under FATCA.

-8-

­SC1:5266419.14


Facility” means any real property (including all buildings, fixtures or other improvements located thereon) now, hereafter or heretofore owned, leased or operated by the Borrower or any of its Subsidiaries.

FATCA” means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code.

Federal Funds Effective Rate” means, for any day, the rate calculated by the Federal Reserve Bank of New York based on such day’s federal funds transactions by depositary institutions (as determined in such manner as the Federal Reserve Bank of New York shall set forth on its public website from time to time) and published on the next succeeding Business Day by the Federal Reserve Bank of New York as the federal funds effective rate; provided that if such rate is not so published for any day which is a Business Day, the average of the quotations for such day on such transactions received by the Administrative Agent from three (3) major banks of recognized standing selected by it; and provided further, that if the Federal Funds Effective Rate as so determined would be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.

Fee Letter” means the Fee Letter, dated as of the date of this Agreement, among the Borrower, the Lenders and the Administrative Agent.

Foreign Lender” means a Lender that is not a U.S. Person.

Foreign Subsidiary” means any Subsidiary that is not a Domestic Subsidiary.

Funding Date Certificate” means a certificate substantially in the form of Exhibit H.

GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time, set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants, in the statements and pronouncements of the Financial Accounting Standards Board and in such other statements by such other entity as may be in general use by significant segments of the accounting profession that are applicable to the circumstances as of the date of determination. All references to “GAAP” shall be to GAAP applied consistently with the principles used in the preparation of the financial statements delivered pursuant to Section 6.01(f)(i).

Governmental Approval” means any consent, authorization, approval, order, license, franchise, permit, certification, accreditation, registration, clearance or exemption that is issued or granted by or from (or pursuant to any act of) any Governmental Authority, including any application or submission related to any of the foregoing.

Governmental Authority” means any nation, government, branch of power (whether executive, legislative or judicial), state, province or municipality or other political subdivision

-9-

­SC1:5266419.14


thereof and any entity exercising executive, legislative, judicial, monetary, regulatory or administrative functions of or pertaining to government, including without limitation regulatory authorities, governmental departments, agencies, commissions, bureaus, officials, ministers, courts, bodies, boards, tribunals and dispute settlement panels, and other law-, rule- or regulation-making organizations or entities of any state, territory, county, city or other political subdivision of any country, in each case whether U.S. or non-U.S.

Guarantee” of or by any Person (the “guarantor”) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (ii) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation or (iv) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; provided, that the term Guarantee shall not include (x) endorsements for collection or deposit and (y) guarantees of operating leases, in each case, in the ordinary course of business.

Hazardous Material” means any chemical, material or substance, exposure to which is prohibited, limited or regulated by any Governmental Authority or which may or would reasonably be expected to pose a hazard to the health and safety of the owners, occupants or any Persons in the vicinity of any Facility or to the indoor or outdoor environment.

Hazardous Materials Activity” means any past, current, proposed or threatened activity, event or occurrence involving any Hazardous Materials, including the use, manufacture, possession, storage, holding, presence, existence, location, release, threatened release, discharge, placement, generation, transportation, processing, construction, treatment, abatement, removal, remediation, disposal, recycling, disposition or handling of any Hazardous Materials, and any investigation, monitoring, corrective action or response action with respect to any of the foregoing.

Hedging Agreement” means any interest rate exchange agreement, foreign currency exchange agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement.

Immaterial Subsidiary” means any Subsidiary of the Borrower that (i) individually constitutes or holds less than five percent (5%) of the Borrower’s consolidated total assets or generates less than five percent (5%) of the Borrower’s consolidated total revenue, and (ii) when taken together with all then existing Immaterial Subsidiaries, such Subsidiary and such Immaterial Subsidiaries, in the aggregate, would constitute or hold less than fifteen percent (15%) of the Borrower’s consolidated total assets or generate less than fifteen percent (15%) of the Borrower’s consolidated total revenue, in each case as pursuant to the most recent fiscal

-10-

­SC1:5266419.14


period for which financial statements were required to have been delivered pursuant to Sections 8.01(a) or (b).

Indebtedness” of any Person means, without duplication, (i) all obligations of such Person for borrowed money, (ii) all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or similar instruments, (iii) all obligations of such Person upon which interest charges are customarily paid, (iv) all obligations of such Person under conditional sale or other title retention agreements relating to property acquired by such Person, (v) all obligations of such Person in respect of the deferred purchase price of property or services (excluding accounts payable incurred in the ordinary course of business and not overdue by more than ninety (90) days), (vi) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (vii) all Guarantees by such Person of Indebtedness of others, (viii) all Capital Lease Obligations of such Person, (ix) all obligations, contingent or otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty, (x) obligations under any Hedging Agreement, currency swaps, forwards, futures or derivatives transactions, (xi) all obligations, contingent or otherwise, of such Person in respect of bankers’ acceptances, (xii) all guaranteed minimum payments of such Person under any license or other agreements, (xiii) any Disqualified Equity Interests of such Person, and (xiv) all other obligations required to be classified as indebtedness of such Person under GAAP; provided that, notwithstanding the foregoing, Indebtedness shall not include accrued expenses, deferred rent, deferred taxes, deferred compensation or customary obligations under employment agreements. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person’s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor.

Indemnified Party” has the meaning set forth in Section 13.03(b).

Indemnified Taxes” means (i) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any Obligation and (ii) to the extent not otherwise described in clause (i), Other Taxes.

Information Certificate” means the Information Certificate delivered pursuant to Section 6.01(c).

Insolvency Proceeding” means (i) any case, action or proceeding before any court or other Governmental Authority relating to bankruptcy, reorganization, insolvency, liquidation, receivership, dissolution, winding-up or relief of debtors, or (ii) any general assignment for the benefit of creditors, composition, marshaling of assets for creditors, or other, similar arrangement in respect of any Person’s creditors generally or any substantial portion of such Person’s creditors, in each case undertaken under U.S. federal, state or foreign law, including the Bankruptcy Code.

-11-

­SC1:5266419.14


Intellectual Property” means, collectively, all rights, priorities and privileges relating to intellectual property, whether arising under the laws of the U.S. or any other jurisdiction or political subdivision thereof (including any multinational laws or otherwise), including all inventions (whether patentable or unpatentable and whether or not reduced to practice) and discoveries, and all improvements thereto, and all know-how, confidential or proprietary information, trade secrets, data, Patents, Trademarks, Copyrights and internet domain names, together with all common law rights and moral rights therein, and all goodwill associated therewith, and all rights of the same or similar effect or nature in any jurisdiction corresponding to such Intellectual Property throughout the world.

Interest Rate” means 11.0% per annum, as may be increased pursuant to Section 3.02(b).

Invention” means any novel, inventive or useful art, apparatus, method, process, machine (including any article or device), manufacture or composition of matter, or any novel, inventive and useful improvement in any art, method, process, machine (including article or device), manufacture or composition of matter.

Investment” means, for any Person: (i) the acquisition (whether for cash, property, services or securities or otherwise) of any debt or Equity Interests, bonds, notes, debentures, partnership or other ownership interests or other securities of any other Person or any agreement to make any such acquisition (including any “short sale” or any sale of any securities at a time when such securities are not owned by the Person entering into such sale); (ii) the making of any deposit with, or advance, loan, assumption of debt or other extension of credit to, or capital contribution in any other Person (including the purchase of property from another Person subject to an understanding or agreement, contingent or otherwise, to resell such property to such Person), but excluding any such advance, loan or extension of credit having a term not exceeding ninety (90) days arising in connection with the sale of inventory or supplies by such Person in the Ordinary Course; or (iii) the entering into of any Guarantee of, or other contingent obligation with respect to, Indebtedness or other liability of any other Person and (without duplication) any amount committed to be advanced, lent or extended to such Person. The amount of an Investment will be determined at the time the Investment is made without giving effect to any subsequent changes in value.

IRS” means the U.S. Internal Revenue Service or any successor agency, and to the extent relevant, the U.S. Department of the Treasury.

JMC” means Journey Medical Corporation, a Delaware corporation.

Law” means, collectively, all U.S. or non-U.S. federal, state, provincial, territorial, municipal or local statute, treaty, rule, guideline, regulation, ordinance, code or administrative or judicial precedent or authority, including any interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.

-12-

­SC1:5266419.14


Lenders” has the meaning set forth in the preamble hereto.

Lien” means (a) any mortgage, lien, pledge, hypothecation, charge, security interest, or other encumbrance of any kind or character whatsoever, whether or not filed, recorded or otherwise perfected under applicable law, or any lease, title retention agreement, mortgage, restriction, easement, right-of-way, option or adverse claim (of ownership or possession) (including any conditional sale or other title retention agreement, any lease in the nature thereof, and any other encumbrance on title to real property, any option or other agreement to sell, or give a security interest in, such asset and any filing of or agreement to give any financing statement under the Uniform Commercial Code (or equivalent statutes of any jurisdiction)) or any preferential arrangement that has the practical effect of creating a security interest and (b) in the case of Equity Interests, any purchase option, call or similar right of a third party with respect to such Equity Interests.

Loan” means each loan advanced by a Lender pursuant to Section 2.01.

Loan Documents” means, collectively, this Agreement, the Notes, the Security Documents, the Warrant, the Fee Letter and any subordination agreement, intercreditor agreement or other present or future document, instrument, agreement or certificate delivered to the Administrative Agent (for itself or for the benefit of any other Secured Party) in connection with this Agreement or any of the other Loan Documents, in each case, as amended or otherwise modified.

Loss” means judgments, debts, liabilities, expenses, costs, damages or losses, contingent or otherwise, whether liquidated or unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees and disbursements of legal counsel on a full indemnity basis, and all costs incurred in investigating or pursuing any Claim or any proceeding relating to any Claim.

Majority Lenders” means, at any time, Lenders having at such time in excess of fifty percent (50%) of the aggregate Commitments (or, if such Commitments are terminated, the outstanding principal amount of the Loans) then in effect.

Margin Stock” means “margin stock” within the meaning of Regulations U and X.

Material Adverse Change” and “Material Adverse Effect” mean a material adverse change in or effect on (i) the business, financial performance, operations, condition of the assets or liabilities of the Borrower and its Subsidiaries taken as a whole, (ii) the ability of the Borrower to perform its obligations under the Loan Documents, as and when due, or (iii) the legality, validity, binding effect or enforceability of the Loan Documents or the rights, remedies and benefits available to, or conferred upon, the Administrative Agent or the Secured Parties under any of the Loan Documents.

Material Agreement” means any Contract required to be disclosed (including amendments thereto) under regulations promulgated under the Securities Act of 1933 or Securities Exchange Act of 1934, as may be amended. For the avoidance of doubt, employment and management contracts shall not be Material Agreements.

-13-

­SC1:5266419.14


Material Indebtedness” means, at any time, any Indebtedness of the Borrower or any Subsidiary thereof, the outstanding principal amount of which, individually or in the aggregate, exceeds $5,000,000 (or the Equivalent Amount in other currencies).

Material Subsidiary” means any Subsidiary of the Borrower that is not an Immaterial Subsidiary and in which the Borrower owns more than fifty percent (50%) of the outstanding Equity Interests.

Maturity Date” means August 27, 2025.

Maximum Rate” has the meaning set forth in Section 13.17.

Minimum Liquidity Amount” means (i) from the Closing Date to but not including the earliest date following the Closing Date on which the Borrower consummates a Permitted Acquisition, $20,000,000 and (ii) from the earliest date following the Closing Date on which the Borrower consummates a Permitted Acquisition, $25,000,000; provided that, notwithstanding the foregoing, the Minimum Liquidity Amount shall be permanently reduced to $15,000,000 on the first date on which the outstanding principal amount of the Loans is less than $40,000,000.

Minimum Revenue Covenant” has the meaning set forth in Section 10.02.

Minimum Revenue Cure Right” has the meaning set forth in Section 11.04(a).

Monetization Event” means the occurrence of any of the following events: (i) an Asset Sale (other than a Qualifying Avenue Sale or a Qualifying [*] Sale), (ii) the sale of any priority review voucher by Cyprium; (iii) the sale of any priority review voucher by Mustang Bio, Inc.; and (iv) the receipt by the Borrower of any dividend or other distribution (other than royalty payments received based on customary revenue or sales payments, but excluding any such payments relating to milestones or regulatory developments) in cash from any of its Subsidiaries in excess of $5,000,000 other than in connection with an event referred to in clauses (i) through (iii) above, a Qualifying Avenue Sale or a Qualifying [*] Sale.

Multiemployer Plan” means any multiemployer plan, as defined in Section 400l(a)(3) of ERISA, to which any ERISA Affiliate incurs or otherwise has any obligation or liability, contingent or otherwise.

Net Proceeds” means, (i) with respect to any Casualty Event experienced or suffered by the Borrower or any of its Subsidiaries, the amount of cash proceeds received (directly or indirectly) from time to time by or on behalf of such Person after deducting therefrom only (x) costs and expenses related thereto incurred by the Borrower or such Subsidiary in connection therewith, and (y) Taxes (including transfer Taxes or net income Taxes) paid or payable in connection therewith; and (ii) with respect to any Monetization Event, Qualifying Avenue Sale or Qualifying [*] Sale the amount of total consideration (including but not limited to consideration in the form of cash and Equity Interests) received (directly or indirectly) from time to time (including any contingent consideration, including but not limited to milestone payments and royalty payments) by or on behalf of such Person after deducting therefrom only (x) costs and expenses related thereto incurred by the Borrower or such Subsidiary in connection

-14-

­SC1:5266419.14


therewith, and (y) Taxes (including transfer Taxes or net income Taxes) paid or payable in connection therewith; provided that, in each case of clauses (i) and (ii), costs and expenses shall only be deducted to the extent, that the amounts so deducted are (x) actually paid to a Person that is not an Affiliate of the Borrower or any of its Subsidiaries and (y) properly attributable to such Casualty Event, Asset Sale or other Monetization Event, as the case may be.

Note” means a promissory note, in substantially the form of Exhibit A hereto, executed and delivered by the Borrower to any Lender in accordance with Section 2.03.

Notice of Intent to Cure Revenue Covenant” has the meaning set forth in Section 11.04(b).

NY UCC” means the UCC as in effect from time to time in New York.

Oaktree Lender” means any Lender that is an Affiliate or managed fund or account of Oaktree Capital Management, L.P.

Obligations” means, with respect to the Borrower, all amounts, obligations, liabilities, covenants and duties of every type and description owing by the Borrower to any Secured Party (including all Warrant Obligations) any other indemnitee hereunder or any participant, arising out of, under, or in connection with, any Loan Document, whether direct or indirect (regardless of whether acquired by assignment), absolute or contingent, due or to become due, whether liquidated or not, now existing or hereafter arising and however acquired, and whether or not evidenced by any instrument or for the payment of money, including, without duplication, (i) all Loans, (ii) all interest, whether or not accruing after the filing of any petition in bankruptcy or after the commencement of any insolvency, reorganization or similar proceeding, and whether or not a claim for post-filing or post-petition interest is allowed in any such proceeding, and (iii) all other fees, expenses (including fees, charges and disbursement of counsel), interest, Prepayment Fee, Specified Return Shortfall, commissions, charges, costs, disbursements, indemnities and reimbursement of amounts paid and other sums chargeable to the Borrower under any Loan Document.

OFAC” has the meaning assigned to such term in the definition of “Anti-Terrorism Laws.”

Ordinary Course” means ordinary course of business or ordinary trade activities that are customary for similar businesses in the normal course of their ordinary operations and not while in financial distress.

Organic Document” means, for any Person, such Person’s formation documents, including, as applicable, its certificate of incorporation, by-laws, certificate of partnership, partnership agreement, certificate of formation, limited liability agreement, operating agreement and all shareholder agreements, voting trusts and similar arrangements applicable to such Person’s Equity Interests, or any equivalent document of any of the foregoing.

Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing

-15-

­SC1:5266419.14


such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).

Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 5.03(g)).

Participant” has the meaning set forth in Section 13.05(e).

Participant Register” has the meaning set forth in Section 13.05(e).

Patents” means all patents and patent applications, including (i) the Inventions and improvements described and claimed therein, (ii) the reissues, divisions, continuations, renewals, extensions, and continuations in part thereof, and (iii) all rights whatsoever accruing thereunder or pertaining thereto throughout the world.

Patriot Act” has the meaning set forth in Section 13.19.

Payment Date” means (i) March 31, June 30, September 30 and December 31 of each year, commencing on the first such date to occur after the Closing Date; and (ii) the Maturity Date.

PBGC” means the United States Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing similar functions.

Permitted Acquisition” means any Acquisition by the Borrower or any of its Subsidiaries, whether by purchase, merger or otherwise; provided that:

(a)immediately prior to, and immediately after giving effect thereto, no Default or Event of Default shall have occurred and be continuing or could reasonably be expected to result therefrom;

(b)such Acquisition shall comply in all material respects with all applicable Laws and all applicable Governmental Approvals;

(c)in the case of any Acquisition of Equity Interests of another Person, after giving effect to such Acquisition, all Equity Interests of such other Person acquired by the Borrower or any of its Subsidiaries shall be owned, directly or indirectly, beneficially and of record, by the Borrower or any of its Subsidiaries, and, the Borrower shall satisfy each of the actions set forth in Section 8.11 as required by such Section;

-16-

­SC1:5266419.14


(d)on a Pro Forma Basis after giving effect to such Acquisition, the Borrower shall have at least $25,000,000 in cash in one or more Controlled Accounts that is free and clear of all Liens, other than Liens granted hereunder in favor of the Administrative Agent;

(e)to the extent that the purchase price for any such Acquisition is paid in cash, the amount thereof does not exceed $10,000,000 (or the Equivalent Amount in other currencies) in any fiscal year;

(f)to the extent that the purchase price for any such Acquisition is paid in Equity Interests, all such Equity Interests shall be Qualified Equity Interests;

(g)promptly upon request by the Administrative Agent in the case of any such Acquisition, the Borrower shall provide to the Administrative Agent (i) at least ten (10) Business Day’s prior written notice of any such Acquisition, together with summaries, prepared in reasonable detail, of all due diligence conducted by or on behalf of the Borrower or the applicable Subsidiary, as applicable, prior to such Acquisition, in each case subject to customary confidentiality restrictions, (ii) subject to customary confidentiality restrictions, a copy of the draft purchase agreement related to the proposed Acquisition (and any related documents requested by the Administrative Agent), (iii) pro forma financial statements of the Borrower and its Subsidiaries (as of the last day of the most recently ended fiscal quarter prior to the date of consummation of such Acquisition for which financial statements are required to be delivered pursuant to Sections 8.01(a) or (b)) after giving effect to such Acquisition, and (iv) subject to customary confidentiality restrictions, any other information reasonably requested (to the extent available), by the Administrative Agent and available to the Borrower; and

(h)neither the Borrower nor any of its Subsidiaries (including any acquired Person) shall, in connection with any such Acquisition, assume or remain liable with respect to (x) any Indebtedness of the related seller or the business, Person or assets acquired, (y) any Lien on any business, Person or assets acquired, except to the extent permitted pursuant to Section 9.02 or (z) any other liabilities (including Tax, ERISA and environmental liabilities), except to the extent the assumption of such liability could not reasonably be expected to result in a Material Adverse Effect. Any other such Indebtedness, liabilities or Liens not permitted to be assumed, continued or otherwise supported by the Borrower or Subsidiary thereof hereunder shall be paid in full or released within sixty (60) days of the acquisition date.

Permitted Cash Equivalent Investments” means (i) marketable direct obligations issued or unconditionally guaranteed by the United States or any member states of the European Union or any agency or any state thereof having maturities of not more than one (1) year from the date of acquisition, (ii) commercial paper maturing no more than two hundred seventy (270) days after the date of acquisition thereof and having the highest rating from either Standard & Poor’s Ratings Group or Moody’s Investors Service, Inc., and (iii) funds held in ICS and CDARS programs.

-17-

­SC1:5266419.14


Permitted Indebtedness” means any Indebtedness permitted under Section 9.01.

Permitted Liens” means any Liens permitted under Section 9.02.

Permitted Refinancing” means, with respect to any Indebtedness permitted to be refinanced, extended, renewed or replaced hereunder, any refinancings, extensions, renewals and replacements of such Indebtedness; provided that such refinancing, extension, renewal or replacement shall not (i) increase the outstanding principal amount of the Indebtedness being refinanced, extended, renewed or replaced, except by an amount equal to accrued interest and a reasonable premium or other reasonable amount paid, and fees and expenses reasonably incurred in connection therewith, (ii) contain terms relating to outstanding principal amount, amortization, maturity, collateral security (if any) or subordination (if any), or other material terms that, taken as a whole, are less favorable in any material respect to the Borrower and its Subsidiaries or the Secured Parties than the terms of any agreement or instrument governing such existing Indebtedness, (iii) have an applicable interest rate which does not exceed the greater of (A) the rate of interest of the Indebtedness being replaced and (B) the then applicable market interest rate, (iv) contain any new requirement to grant any Lien or to give any Guarantee that was not an existing requirement of such Indebtedness and (v) after giving effect to such refinancing, extension, renewal or replacement, no Default shall have occurred (or could reasonably be expected to occur) as a result thereof.

Person” means any individual, corporation, company, voluntary association, partnership, limited liability company, joint venture, trust, unincorporated organization or Governmental Authority or other entity of whatever nature.

Plan” means any employee pension benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of the Code or Section 302 of ERISA, and in respect of which the Borrower or any ERISA Affiliate is (or, if such plan were terminated, would under Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of ERISA.

Prepayment Fee” means (a) with respect to any prepayment of all or any portion of the Loans, whether by optional or mandatory prepayment, acceleration, payment of a Revenue Cure Payment or otherwise (other than by mandatory prepayment in connection with a Monetization Event, a Qualifying Avenue Sale or a Qualifying [*] Sale), occurring (i) on or prior to the second anniversary of the Closing Date, an amount equal to the amount of interest that would have been paid on the principal amount of the Loans being so repaid or prepaid for the period from and including the date of such repayment or prepayment to but excluding the date that is the two (2) year anniversary of the Closing Date, plus three percent (3%) of the principal amount of the Loans being so repaid or prepaid, (ii) at any time after the second anniversary of the Closing Date but on or prior to the third anniversary of the Closing Date, an amount equal to three percent (3%) of the aggregate outstanding principal amount of the Loans being so repaid or prepaid, (iii) at any time after the third anniversary of the Closing Date but on or prior to the fourth anniversary of the Closing Date, an amount equal to two percent (2%) of the aggregate outstanding principal amount of the Loans being so repaid or prepaid and (iv) if the prepayment is made after the fourth anniversary of the Closing Date, 0% and (b) with respect to any

-18-

­SC1:5266419.14


mandatory prepayment of all or any portion of the Loans in connection with a Monetization Event (which shall not include, for the avoidance of doubt, any Qualifying Avenue Sale or Qualifying [*] Sale), occurring (i) on or prior to the first anniversary of the Closing Date, an amount equal to six percent (6%) of the aggregate outstanding principal amount of the Loans being so repaid or prepaid, (ii) at any time after the first anniversary of the Closing Date but on or prior to the second anniversary of the Closing Date, an amount equal to four and a half percent (4.5%) of the aggregate outstanding principal amount of the Loans being so repaid or prepaid, (iii) at any time after the second anniversary of the Closing Date but on or prior to the third anniversary of the Closing Date, an amount equal to three percent (3%) of the aggregate outstanding principal amount of the Loans being so repaid or prepaid, (iv) at any time after the third anniversary of the Closing Date but on or prior to the fourth anniversary of the Closing Date, an amount equal to two percent (2%) of the aggregate outstanding principal amount of the Loans being so repaid or prepaid and (v) if the prepayment is made after the fourth anniversary of the Closing Date, 0%.

Prepayment Price” has the meaning set forth in Section 3.03(a)(i).

“Private Subsidiary” is any Subsidiary that is not a Public Subsidiary.

Pro Forma Basis” shall mean, with respect to the calculation of any financial ratio, as of any date, that pro forma effect will be given to the Transactions, any Permitted Acquisition, any issuance, incurrence, assumption or permanent repayment of Indebtedness (including Indebtedness issued, incurred or assumed as a result of, or to finance, any relevant transaction and for which any such financial ratio is being calculated) and all sales, transfers and other dispositions or discontinuance of any subsidiary, line of business or division, in each case that have occurred during the four consecutive fiscal quarter period of the Borrower being used to calculate such financial ratio (the “Reference Period”), or subsequent to the end of the Reference Period but prior to such date or prior to or simultaneously with the event for which a determination under this definition is made, as if each such event occurred on the first day of the Reference Period.

Prohibited Payment” means any bribe, rebate, payoff, influence payment, kickback or other payment or gift of money or anything of value (including meals or entertainment) to any officer, employee or ceremonial office holder of any government or instrumentality thereof, political party or supra-national organization (such as the United Nations), any political candidate, any royal family member or any other person who is connected or associated personally with any of the foregoing that is prohibited under any Law for the purpose of influencing any act or decision of such payee in his official capacity, inducing such payee to do or omit to do any act in violation of his lawful duty, securing any improper advantage or inducing such payee to use his influence with a government or instrumentality thereof to affect or influence any act or decision of such government or instrumentality.

Proportionate Share” means, with respect to any Lender, the percentage obtained by dividing (i) the Commitment (or, if the Commitments are terminated, the outstanding principal amount of the Loans) of such Lender then in effect by (ii) the sum of the Commitments (or, if the

-19-

­SC1:5266419.14


Commitments are terminated, the outstanding principal amount of the Loans) of all Lenders then in effect.

“Public Subsidiary” is any Subsidiary the Equity Interests of which are traded on any public market or exchange.

Qualified Equity Interest” means, with respect to any Person, any Equity Interest of such Person that is not a Disqualified Equity Interest.

Qualified Plan” means an employee benefit plan (as defined in Section 3(3) of ERISA) other than a Multiemployer Plan (i) that is or was at any time maintained or sponsored by the Borrower or any ERISA Affiliate thereof or to which the Borrower or any ERISA Affiliate thereof has ever made, or was ever obligated to make, contributions, and (ii) that is intended to be tax qualified under Section 401(a) of the Code.

Qualifying Avenue Sale” has the meaning set forth on Schedule 9.09(b).

Qualifying [*] Sale” has the meaning set forth on Schedule 9.09(c).

Recipient” means the Administrative Agent or any Lender.

Refinanced Indebtedness” means the Indebtedness incurred under (a) the Amended and Restated Credit Facility Agreement, dated as of March 12, 2018, by and among Borrower, Opus Point Healthcare Innovations Fund, LP and each other lender from time to time party thereto (the “Opus Debt”), (b) those Notes issued pursuant to that certain Confidential Private Placement Memorandum, dated as of January 16, 2018 (the “Venture Debt”), and (c) those Notes issued pursuant to that certain Confidential Private Placement Memorandum, dated as of March 24, 2017 (the “2017 Subordinated Debt”).

Register” has the meaning set forth in Section 13.05(d).

Regulation T” means Regulation T of the Board of Governors of the Federal Reserve System, as amended.

Regulation U” means Regulation U of the Board of Governors of the Federal Reserve System, as amended.

Regulation X” means Regulation X of the Board of Governors of the Federal Reserve System, as amended.

Reinvestment” has the meaning set forth in Section 3.01.

Reinvestment Period” has the meaning set forth in Section 3.03(b).

Related Parties” has the meaning set forth in Section 13.16.

Resignation Effective Date” has the meaning set forth in Section 12.09.

-20-

­SC1:5266419.14


Responsible Officer” of any Person means each of the president, chief executive officer, chief financial officer and similar officer of such Person.

Restricted Payment” means any dividend or other distribution (whether in cash, Equity Interests or other property) with respect to any Equity Interests of the Borrower or any of its Subsidiaries, or any payment (whether in cash, Equity Interests or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such Equity Interests of the Borrower or any of its Subsidiaries, any payment of interest, principal or fees in respect of any Indebtedness owed by the Borrower or any of its Subsidiaries to any holder of any Equity Interests of the Borrower or any of its Subsidiaries, or any option, warrant or other right to acquire any such Equity Interests of the Borrower or any of its Subsidiaries.

Restrictive Agreement” means any Contract or other arrangement that prohibits, restricts or imposes any condition upon (i) the ability of the Borrower or any of its Subsidiaries to create, incur or permit to exist any Lien upon any of its properties or assets (other than customary provisions in Contracts (including without limitation leases and in-bound licenses of Intellectual Property) restricting the assignment thereof), or (ii) the ability of the Borrower or any of its Subsidiaries to make Restricted Payments with respect to any of their respective Equity Interests or to make or repay loans or advances to the Borrower or any of its Subsidiaries or to Guarantee Indebtedness of the Borrower or any of its Subsidiaries.

Revenue” means, with respect to any Person for any relevant fiscal period, the consolidated total revenues of such Person for such fiscal period, as recognized on the income statement of such Person, determined on a consolidated basis in accordance with GAAP.

Revenue Cure Payment” means, with respect to any fiscal quarter of the Borrower in which the Minimum Revenue Covenant applies, a payment of $6,000,000 in cash.

Sanction” means any international economic or financial sanction or trade embargo imposed, administered or enforced from time to time by the United States Government (including, without limitation, OFAC), the United Nations Security Council, the European Union or its Member States, Her Majesty’s Treasury or other relevant sanctions authority where the Borrower is located or conducts business.

Secured Parties” means the Lenders, the Administrative Agent and any of their respective permitted transferees or assigns.

Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

Security Agreement” means the Security Agreement, delivered pursuant to Section 6.01(h), between the Borrower and the Administrative Agent, granting a security interest in the Borrower’s personal property in favor of the Administrative Agent, for the benefit of the Secured Parties.

-21-

­SC1:5266419.14


Security Documents” means, collectively, the Security Agreement, each Short-Form IP Security Agreement, and each other security document, control agreement or financing statement required or recommended to perfect Liens in favor of the Secured Parties for purposes of securing the Obligations.

Short-Form IP Security Agreements” means short-form copyright, patent or trademark (as the case may be) security agreements, substantially in the form of Exhibit C, D and E to the Security Agreement, entered into by the Borrower in favor of the Secured Parties, each in form and substance satisfactory to the Administrative Agent (and as amended, modified or replaced from time to time).

Solvent” means, as to any Person as of any date of determination, that on such date (i) the fair value of the property of such Person is greater than the total amount of liabilities, including contingent liabilities, of such Person, (ii) the present fair saleable value of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured, (iii) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person’s ability to pay such debts and liabilities as they mature and (iv) such Person is not engaged in a business or transaction, and is not about to engage in a business or transaction, for which such Person’s property would constitute an unreasonably small capital. The amount of any contingent liability at any time shall be computed as the amount that, in light of all of the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.

Specified Return Shortfall” has the meaning set forth in the Fee Letter.

Subsidiary” means, with respect to any Person (the “parent”) at any date, any corporation, limited liability company, partnership, association or other entity the accounts of which would be consolidated with those of the parent in the parent’s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of such date, as well as any other corporation, limited liability company, partnership, association or other entity (i) of which securities or other ownership interests representing more than fifty percent (50%) of the equity or more than fifty percent (50%) of the ordinary voting power or, in the case of a partnership, more than fifty percent (50%) of the general partnership interests are, as of such date, owned, controlled or held, directly or indirectly, or (ii) that is, as of such date, otherwise Controlled, by the parent or one or more direct or indirect subsidiaries of the parent or by the parent and one or more direct or indirect subsidiaries of the parent. Unless otherwise specified, all references herein to a “Subsidiary” or to “Subsidiaries” shall refer to a Subsidiary or Subsidiaries of the Borrower.

Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

Title IV Plan” means an employee benefit plan (as defined in Section 3(3) of ERISA) other than a Multiemployer Plan (i) that is or was at any time maintained or sponsored by the

-22-

­SC1:5266419.14


Borrower or any ERISA Affiliate thereof or to which the Borrower or any ERISA Affiliate thereof has ever made, or was obligated to make, contributions, and (ii) that is or was subject to Section 412 of the Code, Section 302 of ERISA or Title IV of ERISA.

Trademarks” means all trade names, trademarks and service marks, logos, trademark and service mark registrations, and applications for trademark and service mark registrations, including (i) all renewals of trademark and service mark registrations and (ii) all rights whatsoever accruing thereunder or pertaining thereto throughout the world, together, in each case, with the goodwill of the business connected with the use thereof.

Transactions” means (a) the negotiation, preparation, execution, delivery and performance by the Borrower of this Agreement and the other Loan Documents, the making of the Loans hereunder, and all other transactions contemplated pursuant to this Agreement and the other Loan Documents, including the creation of the Liens pursuant to the Security Documents, (b) the repayment in full and termination of the Refinanced Indebtedness and (c) the payment of all fees and expenses incurred or paid by the Borrower in connection with the foregoing.

UCC” means, with respect to any applicable jurisdictions, the Uniform Commercial Code as in effect in such jurisdiction, as may be modified from time to time.

United States” or “U.S.” means the United States of America, its fifty states and the District of Columbia.

U.S. Person” means a “United States Person” within the meaning of Section 7701(a)(30) of the Code.

U.S. Tax Compliance Certificate” has the meaning set forth in Section 5.03(f)(ii)(B)(3).

VWAP” has the meaning set forth in the Warrant.

Warrant” means that certain Warrant, dated as of the Closing Date and delivered pursuant to Section 6.01(k), evidenced by an instrument substantially the form of Exhibit F hereto, as amended, replaced or otherwise modified pursuant to the terms thereof.

Warrant Obligations” means all Obligations of Borrower arising out of, under or in connection with the Warrant.

Withdrawal Liability” means, at any time, any liability incurred (whether or not assessed) by any ERISA Affiliate and not yet satisfied or paid in full at such time with respect to any Multiemployer Plan pursuant to Section 4201 of ERISA.

Withholding Agent” means the Borrower or the Administrative Agent.

Write-Down and Conversion Powers” means, with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule.

-23-

­SC1:5266419.14


1.02Accounting Terms and Principles. Unless otherwise specified, all accounting terms used in each Loan Document shall be interpreted, and all accounting determinations and computations thereunder (including under Section 10 and any definitions used in such calculations) shall be made, in accordance with GAAP. Unless otherwise expressly provided, all financial covenants and defined financial terms shall be computed on a consolidated basis for the Borrower and its Subsidiaries, in each case without duplication. If the Borrower requests an amendment to any provision hereof to eliminate the effect of (a) any change in GAAP or the application thereof or (b) the issuance of any new accounting rule or guidance or in the application thereof, in each case, occurring after the date of this Agreement, then the Lenders and Borrower agree that they will negotiate in good faith amendments to the provisions of this Agreement that are directly affected by such change or issuance with the intent of having the respective positions of the Lenders and Borrower after such change or issuance conform as nearly as possible to their respective positions as of the date of this Agreement and, until any such amendments have been agreed upon, (i) the provisions in this Agreement shall be calculated as if no such change or issuance has occurred and (ii) the Borrower shall provide to the Lenders a written reconciliation in form and substance reasonably satisfactory to the Lenders, between calculations of any baskets and other requirements hereunder before and after giving effect to such change or issuance.
1.03Interpretation. For all purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires,
(a)the terms defined in this Agreement include the plural as well as the singular and vice versa;
(b)words importing gender include all genders;
(c)any reference to a Section, Annex, Schedule or Exhibit refers to a Section of, or Annex, Schedule or Exhibit to, this Agreement;
(d)any reference to “this Agreement” refers to this Agreement, including all Annexes, Schedules and Exhibits hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its Annexes, Schedules and Exhibits as a whole and not to any particular Section, Annex, Schedule, Exhibit or any other subdivision;
(e)references to days, months and years refer to calendar days, months and years, respectively;
(f)all references herein to “include” or “including” shall be deemed to be followed by the words “without limitation”;
(g)the word “from” when used in connection with a period of time means “from and including” and the word “until” means “to but not including”;
(h)the words “asset” and “property” shall be construed to have the same meaning and effect and to refer broadly to any and all assets and properties, whether tangible or

-24-

­SC1:5266419.14


intangible, real or personal, including cash, securities, rights under contractual obligations and permits and any right or interest in any such assets or property;
(i)accounting terms not specifically defined herein (other than “property” and “asset”) shall be construed in accordance with GAAP;
(j)the word “will” shall have the same meaning as the word “shall”;
(k)where any provision in this Agreement or any other Loan Document refers to an action to be taken by any Person, or an action which such Person is prohibited from taking, such provision shall be applicable whether such action is taken directly or, to the knowledge of such Person, indirectly; and
(l)references to any Lien granted or created hereunder or pursuant to any other Loan Document securing any Obligations shall deemed to be a Lien for the benefit of the Secured Parties.

Unless otherwise expressly provided herein, references to organizational documents, agreements (including the Loan Documents) and other contractual instruments shall be deemed to include all subsequent amendments, restatements, extensions, supplements and other modifications thereto permitted by the Loan Documents. Any definition or reference to any Law shall include all statutory and regulatory provisions consolidating, amending, replacing, supplementing or interpreting such Law.

If any payment required to be made pursuant to the terms and conditions of any Loan Document falls due on a day which is not a Business Day, then such required payment date shall be extended to the immediately following Business Day. For purposes of determining compliance with any covenant (including the computation of any financial covenant) contained herein, Indebtedness of the Borrower and its Subsidiaries will be deemed to be equal to 100% of the outstanding principal amount thereof or payment obligations with respect thereto at the time of determination thereof.

1.04Division. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction’s laws) (a “Division”), if (a) any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its equity interests at such time.
Section 2.
THE COMMITMENT AND THE LOANS
2.01Loans.

-25-

­SC1:5266419.14


(a)On the terms and subject to the conditions of this Agreement, each Lender agrees to make Loans to the Borrower in a principal amount equal to the amount of such Lender’s Commitment on the Closing Date.
(b)No amounts paid or prepaid with respect to any Loan may be reborrowed.
(c)Any term or provision hereof (or of any other Loan Document) to the contrary notwithstanding, Loans made to the Borrower will be denominated solely in Dollars and will be repayable solely in Dollars and no other currency.
2.02Borrowing Procedures. At least one (1) Business Day prior to the Closing Date (or such shorter period agreed by the Administrative Agent), the Borrower shall deliver to the Administrative Agent an irrevocable Borrowing Notice in the form of Exhibit B signed by a duly authorized representative of the Borrower (which notice, if received by the Administrative Agent on a day that is not a Business Day or after 10:00 A.M. (Eastern time) on a Business Day, shall be deemed to have been delivered on the next Business Day). Each Borrowing Notice shall be for the full amount of the Commitments and no Borrowing Notice for less than such full amount shall be permitted.
2.03Notes. If requested by any Lender, the Loan of such Lender shall be evidenced by one or more Notes. The Borrower shall prepare, execute and deliver to the Lender such promissory note(s) substantially in the form attached hereto as Exhibit A.
2.04Use of Proceeds. The Borrower shall use the proceeds of the Loans (i) for repaying the Refinanced Indebtedness and (ii) for working capital and general corporate purposes, including the payment of fees and expenses associated with this Agreement.
Section 3.
PAYMENTS OF PRINCIPAL AND INTEREST, ETC.
3.01Scheduled Repayments and Prepayments Generally; Application. The Borrower hereby promises to pay to the Administrative Agent for the account of each Lender (as such amounts may in each case be reduced from time to time in accordance with Section 3.03) on the Maturity Date, all outstanding Obligations in full (together with accrued and unpaid interest and any other accrued and unpaid charges thereon and all other obligations due and payable by the Borrower under this Agreement, including any Specified Return Shortfall). Except as otherwise provided in this Agreement, each payment (including each repayment and prepayment) by the Borrower (other than fees payable pursuant to the Fee Letter) will be deemed to be made ratably in accordance with the Lenders’ Proportionate Shares. On any date occurring prior to the Maturity Date that payment or prepayment in full of the Loans hereunder occurs, the Borrower shall pay in full all outstanding Obligations, which shall include the Prepayment Fee, if applicable, and any Specified Return Shortfall.

-26-

­SC1:5266419.14


3.02Interest.
(a)Interest Generally. The outstanding principal amount of the Loans shall accrue interest from the date made to repayment (whether by acceleration or otherwise and whether voluntary or mandatory) at the Interest Rate.
(b)Default Interest. Notwithstanding the foregoing, upon the occurrence and during the continuance of any Event of Default, the Interest Rate shall increase automatically by two and a half percent (2.5%) per annum (the Interest Rate, as increased pursuant to this Section 3.02(b), being the “Default Rate”). If any Obligation (other than Warrant Obligations but including, without limitation, fees, costs and expenses payable hereunder) is not paid when due (giving effect to any applicable grace period) under any applicable Loan Document, the amount thereof shall accrue interest at the Default Rate.
(c)Interest Payment Dates. Accrued interest on the Loans shall be payable in arrears on each Payment Date in cash, and upon the payment or prepayment of the Loans (on the principal amount being so paid or prepaid); provided that interest payable at the Default Rate shall also be payable in cash from time to time on demand by the Administrative Agent.
3.03Prepayments.
(a)Optional Prepayments.
(i)Subject to prior written notice pursuant to clause (ii) below, the Borrower shall have the right to optionally prepay in whole or in part the outstanding principal amount of the Loans on any Business Day for an amount equal to the sum of (A) the aggregate principal amount of the Loans being prepaid, (B) any accrued but unpaid interest on the principal amount of the Loans being prepaid, (C) any applicable Prepayment Fee and (D) if applicable, other unpaid amounts then due and owing pursuant to this Agreement and the other Loan Documents (such aggregate amount, the “Prepayment Price”); provided that each partial prepayment of principal of Loans shall be in an aggregate amount at least equal to $5,000,000 and integral multiples of $1,000,000 in excess thereof.
(ii)A notice of optional prepayment shall be effective only if received by the Administrative Agent not later than 2:00 p.m. (Eastern time) on a date not less than three (3) (nor more than five (5)) Business Days prior to the proposed prepayment date. Each notice of optional prepayment shall specify the proposed prepayment date, the Prepayment Price, the principal amount to be prepaid and any conditions to prepayment (if applicable).
(b)Mandatory Prepayments for Casualty Events and Monetization Events. Within five (5) Business Days following Borrower’s receipt of Net Proceeds from any Casualty Event or Monetization Event (other than an Asset Sale permitted pursuant to Sections 9.09(a), (b), (c), (d) or (h) or any Asset Sale related to the Equity Interests in, or assets of, [*] that is not a Qualifying [*] Sale), the Borrower shall make a mandatory prepayment of the Loans in an amount equal to the sum of (i) the Applicable Prepayment Percentage of the Net Proceeds received by the Borrower with respect to such Monetization Event or insurance proceeds or condemnation awards in respect of such Casualty Event, as the case may be, (ii) any accrued but

-27-

­SC1:5266419.14


unpaid interest on any principal amount of the Loans being prepaid and (iii) any applicable Prepayment Fee; provided that, so long as no Default has occurred and is continuing or shall result therefrom, if, within five (5) Business Days following Borrower’s receipt of Net Proceeds from any such Casualty Event or Monetization Event as a result of which the Borrower receives Net Proceeds in an aggregate amount less than $5,000,000, a Responsible Officer of the Borrower delivers to the Administrative Agent a notice to the effect that the Borrower intends to apply the Net Proceeds from such Monetization Event or insurance proceeds or condemnation awards in respect of such Casualty Event, to reinvest in the business of the Borrower (a “Reinvestment”), then such Net Proceeds of such Monetization Event or insurance proceeds or condemnation awards in respect of such Casualty Event may be applied for such purpose in lieu of such mandatory prepayment to the extent such Net Proceeds of such Monetization Event or insurance proceeds or condemnation awards in respect of such Casualty Event are actually applied for such purpose; provided, further, that, in the event that Net Proceeds have not been so applied within three hundred sixty-five (365) days (the “Reinvestment Period”) following the occurrence of such Casualty Event or Monetization Event, the Borrower shall no later than the end of such period make a mandatory prepayment of the Loans in an aggregate amount equal to the sum of (i) the Applicable Prepayment Percentage of the unused balance of such Net Proceeds received by the Borrower with respect to such Monetization Event or insurance proceeds or condemnation awards in respect of such Casualty Event, (ii) any accrued but unpaid interest on any principal amount of the Loans being prepaid and (iii) any applicable Prepayment Fee; provided, further, that other than as provided in clause (d) below, Borrower shall not be required to prepay more than $10 million of principal amount of the Loans in the aggregate with respect to any Asset Sale(s) and/or other Monetization Event(s) related to the Equity Interests in, or assets of, any individual Subsidiary.
(c)Mandatory Prepayments for Debt Issuances. Immediately upon receipt by the Borrower or any of its Subsidiaries of proceeds from any issuance, incurrence or assumption of Indebtedness other than Indebtedness permitted by Section 9.01, on or after the Closing Date, the Borrower shall prepay the Loans and other Obligations in an amount equal to 100% of the cash proceeds received, plus the Prepayment Fee, if applicable.
(d)Other Mandatory Prepayments. Within five (5) Business Days following Borrower’s receipt of Net Proceeds from any Qualifying Avenue Sale or Qualifying [*] Sale, the Borrower shall make a mandatory prepayment of the Loans in an amount equal to the sum of (i) the Net Proceeds received by the Borrower with respect to such Qualifying Avenue Sale or Qualifying [*] Sale, as the case may be; provided Borrower shall not be required to prepay more than $7.5 million of principal amount of the Loans under this clause (d) from any Qualifying Avenue Sale or more than $12.5 million of principal amount of the Loans under this clause (d) from any Qualifying [*] Sale, (ii) any accrued but unpaid interest on any principal amount of the Loans being prepaid and (iii) an amount equal to six percent (6%) of the aggregate outstanding principal amount of the Loans being so repaid or prepaid. Within five (5) Business Days following Borrower’s receipt of Net Proceeds from any Asset Sale related to the Equity Interests in, or assets of, [*] that is not a Qualifying [*] Sale, the Borrower shall make a mandatory prepayment of the Loans in an amount equal to the sum of (i) $15.0 million of principal amount of the Loans, (ii) any accrued but unpaid interest on the principal amount of the Loans being prepaid and (iii) any applicable Prepayment Fee.

-28-

­SC1:5266419.14


(e)General. The Borrower shall notify the Administrative Agent not later than 12:00 p.m. (Eastern time) on a date not less than two (2) Business Days (but not more than three (3) Business Days) prior to any mandatory prepayment. Notwithstanding anything in this Section 3.03 to the contrary, any Lender may elect, by written notice to the Administrative Agent no later than 12:00 p.m. (Eastern time), one (1) Business Day prior to the prepayment date (or such later time as the Administrative Agent may agree), to decline all or any portion of any mandatory prepayment of its Loans pursuant to this Section 3.03. Any Lender that fails to deliver such notice to the Administrative Agent in the time frame set forth above shall be deemed to have accepted its share of any mandatory prepayment. The aggregate amount of the prepayment that would have been applied to prepay Loans but was so declined may be retained by the Borrower and used for any general corporate purpose not prohibited by this Agreement. If any Lender declines all or any portion of any mandatory prepayment of its Loans in connection with a Monetization Event, Qualifying Avenue Sale or Qualifying [*] Sale, the Borrower shall grant such Lender warrants in an amount equal to 2.50% of the principal amount of mandatory prepayment so declined, with an exercise price equal to the VWAP of the Borrower’s common stock for the period beginning on the trading day that is 30 days prior to the issuance date and ending on the last trading day immediately preceding the issuance date. For the avoidance of doubt, the issuance of any warrants pursuant to this clause (e) shall not be deemed to be a prepayment and shall not reduce the Borrower’s obligations to make any mandatory prepayment required under clause (b) or clause (d) above with respect to any Monetization Event, Qualifying Avenue Sale or Qualifying [*] Sale occurring after the issuance of such warrants.
(f)Prepayment Fee. Without limiting the foregoing, whenever the Prepayment Fee is in effect and payable pursuant to the terms hereof or any other Loan Document, such Prepayment Fee shall be payable on each prepayment of all or any portion of the Loans, whether by optional or mandatory prepayment, acceleration or otherwise (other than any prepayment pursuant to Section 5.02).
(g)Partial Prepayments. Prepayments shall be accompanied by accrued interest to the extent required by Section 3.02.
Section 4.
PAYMENTS, ETC.
4.01Payments.
(a)Payments Generally. Each payment of principal, interest and other amounts to be made by the Borrower under this Agreement or any other Loan Document shall be made (i) in Dollars, in immediately available funds, without deduction, set off or counterclaim, to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, to the deposit account of the Administrative Agent designated by the Administrative Agent by notice to the Borrower, and (ii) not later than 2:00 p.m. (Eastern time) on the date on which such payment is due (each such payment made after such time on such due date may in the Administrative Agent’s discretion be deemed to have been made on the next succeeding Business Day).

-29-

­SC1:5266419.14


(b)Application of Payments. Notwithstanding anything herein to the contrary, following the occurrence and continuance of an Event of Default, all payments shall be applied as follows:
(A)first, to the payment of that portion of the Obligations constituting unpaid fees, indemnities, expenses or other amounts (including fees and disbursements and other charges of counsel payable under Section 13.03) payable to the Administrative Agent in its capacity as such;
(B)second, to the payment of that portion of the Obligations constituting unpaid fees, indemnities, costs, expenses and other amounts (other than principal and interest, but including fees and disbursements and other charges of counsel payable under Section 13.03 and any Prepayment Fees) payable to the Lenders arising under the Loan Documents (other than the Warrant), ratably among them in proportion to the respective amounts described in this clause (B) payable to them;
(C)third, to the payment of that portion of the Obligations constituting accrued and unpaid interest on the Loans, ratably among the Lenders in proportion to the respective amounts described in this clause (C) payable to them;
(D)fourth, to the payment of that portion of the Obligations constituting unpaid principal of the Loans, ratably among the Lenders in proportion to the respective amounts described in this clause (D) payable to them;
(E)fifth, in reduction of any other Obligation then due and owing, ratably among the Administrative Agent and the Lenders based upon the respective aggregate amount of all such Obligations owing to them in accordance with the respective amounts thereof then due and payable; and
(F)sixth, the balance, if any, after all Obligations have been indefeasibly paid in full, to the Borrower or such other Person as may be lawfully entitled to or directed by the Borrower to receive the remainder.
(c)Non-Business Days. If the due date of any payment under this Agreement (whether in respect of principal, interest, fees, costs or otherwise) would otherwise fall on a day that is not a Business Day, such date shall be extended to the next succeeding Business Day, unless such Business Day falls in another calendar month, in which case such Interest Period shall end on the immediately preceding Business Day and, in the case of any payment accruing interest, interest thereon shall continue to accrue and be payable for the period of such extension; provided that if such next succeeding Business Day would fall after the Maturity Date, payment shall be made on the immediately preceding Business Day.
4.02Computations. All computations of interest and fees hereunder shall be computed on the basis of a year of three hundred and sixty (360) days and actual days elapsed during the period for which payable. Interest is calculated from and including the date of the Borrowing of each Loan to, but excluding, the date of repayment or prepayment of such Loan.

-30-

­SC1:5266419.14


4.03Set-Off.
(a)Set-Off Generally. Upon the occurrence and during the continuance of any Event of Default, the Administrative Agent, each of the Lenders and each of their Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by the Administrative Agent, any Lender and any of their Affiliates to or for the credit or the account of the Borrower against any and all of the Obligations, whether or not such Person shall have made any demand and although such obligations may be unmatured. Any Person exercising rights of set off hereunder agrees promptly to notify the Borrower after any such set-off and application; provided that the failure to give such notice shall not affect the validity of such set-off and application. The rights of the Administrative Agent, the Lenders and each of their Affiliates under this Section 4.03 are in addition to other rights and remedies (including other rights of set-off) that such Persons may have.
(b)Exercise of Rights Not Required. Nothing contained in Section 4.03(a) shall require the Administrative Agent, any Lender or any of their Affiliates to exercise any such right or shall affect the right of such Persons to exercise, and retain the benefits of exercising, any such right with respect to any other indebtedness or obligation of the Borrower.
(c)Payments Set Aside. To the extent that any payment by or on behalf of the Borrower is made to the Administrative Agent or any Lender, or the Administrative Agent, any Lender or any Affiliate of the foregoing exercises its right of setoff pursuant to this Section 4.03, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent, such Lender or such Affiliate in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any Insolvency Proceeding or otherwise, then (i) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and (ii) each Lender severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Federal Funds Effective Rate from time to time in effect.
Section 5.
YIELD PROTECTION, TAXES, ETC.
5.01Additional Costs.
(a)Change in Law Generally. If, on or after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), the adoption of any Law, or any change in any Law, or any change in the interpretation or administration thereof by any court or other Governmental Authority charged with the interpretation or

-31-

­SC1:5266419.14


administration thereof, or compliance by the Administrative Agent or any of the Lenders (or its lending office) with any request or directive (whether or not having the force of law) of any such Governmental Authority, shall (i) impose, modify or deem applicable any reserve (including any such requirement imposed by the Board of Governors of the Federal Reserve System), special deposit, contribution, insurance assessment or similar requirement, in each case that becomes effective after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), against assets of, deposits with or for the account of, or credit extended by, a Lender (or its lending office), (ii) impose on a Lender (or its lending office) any other condition (other than Taxes) affecting the Loans or the Commitment, or (iii) subject any Lender to any Taxes on its Loan, Commitment or other obligations, or its deposits, reserves, other liabilities or capital (if any) attributable thereto (other than (A) Indemnified Taxes, (B) Taxes described in clauses (ii) through (iv) of the definition of Excluded Taxes and (C) Connection Income Taxes) and the result of any of the foregoing is to increase the cost to such Lender of making or maintaining the Loans, or to reduce the amount of any sum received or receivable by such Lender under this Agreement or any other Loan Document, by an amount reasonably deemed by such Lender in good faith to be material, then the Borrower shall pay to such Lender on demand such additional amount or amounts as will compensate such Lender for such increased cost or reduction.
(b)Change in Capital Requirements. If a Lender shall have determined that, on or after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), the adoption of any Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any Governmental Authority charged with the interpretation or administration thereof, or any request or directive regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, in each case that becomes effective after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), has or would have the effect of reducing the rate of return on capital of a Lender (or its parent) as a consequence of a Lender’s obligations hereunder or the Loans to a level below that which a Lender (or its parent) could have achieved but for such adoption, change, request or directive by an amount reasonably deemed by it to be material, then the Borrower shall pay to such Lender on demand such additional amount or amounts as will compensate such Lender (or its parent) for such reduction.
(c)Notification by Lender. Each Lender promptly will notify the Borrower of any event of which it has knowledge, occurring after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement), which will entitle such Lender to compensation pursuant to this Section 5.01. Before giving any such notice pursuant to this Section 5.01(c) such Lender shall designate a different lending office if such designation (x) will, in the reasonable judgment of such Lender, avoid the need for, or reduce the amount of, such compensation and (y) will not, in the reasonable judgment of such Lender, be materially disadvantageous to such Lender. A certificate of such Lender claiming compensation under this Section 5.01, setting forth the additional amount or amounts to be paid to it hereunder, shall be conclusive and binding on the Borrower in the absence of manifest error.

-32-

­SC1:5266419.14


(d)Notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to constitute a change in Law for all purposes of this Section 5.01, regardless of the date enacted, adopted or issued.
(e)Delay in Requests. Failure or delay on the part of any Lender to demand compensation pursuant to this Section 5.1 shall not constitute a waiver of such Lender’s right to demand such compensation; provided that the Borrower shall not be required to compensate a Lender pursuant to this Section 5.1 for any increased costs incurred or reductions suffered more than nine months prior to the date that such Lender Section 5.1 notifies the Borrower of the event giving rise to such increased costs or reductions, and of such Lender’s intention to claim compensation therefor (except that, if the event giving rise to such increased costs or reductions is retroactive, then the nine-month period referred to above shall be extended to include the period of retroactive effect thereof).
5.02Illegality. Notwithstanding any other provision of this Agreement, in the event that on or after the date hereof (or, with respect to any Lender, such later date on which such Lender becomes a party to this Agreement) the adoption of or any change in any Law or in the interpretation or application thereof by any competent Governmental Authority shall make it unlawful for a Lender or its lending office to make or maintain the Loans (and, in the opinion of such Lender, the designation of a different lending office would either not avoid such unlawfulness or would be disadvantageous to such Lender), then such Lender shall promptly notify the Borrower thereof, following which if such Law shall so mandate, the Loans shall be prepaid by the Borrower on or before such date as shall be mandated by such Law in an amount equal to the Prepayment Price (notwithstanding anything herein to the contrary, without any Prepayment Fee) applicable on such prepayment date in accordance with Section 3.03(a).
5.03Taxes. For purposes of this Section 5.03, the term “applicable Law” includes FATCA.
(a)Payments Free of Taxes. Any and all payments by or on account of any Obligation shall be made without deduction or withholding for any Taxes, except as required by any applicable Law. If any applicable Law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable Laws and, if such Tax is an Indemnified Tax, then the sum payable by the Borrower shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 5.03) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.

-33-

­SC1:5266419.14


(b)Payment of Other Taxes by the Borrower. The Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable Laws, or at the option of the Administrative Agent or each Lender, timely reimburse it for the payment of any Other Taxes.
(c)Evidence of Payments. As soon as practicable after any payment of Taxes by the Borrower to a Governmental Authority pursuant to this Section 5.03, the Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.
(d)Indemnification by the Borrower. The Borrower shall reimburse and indemnify each Recipient, within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 5.03) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender shall be conclusive absent manifest error.
(e)Indemnification by the Lender. Each Lender shall severally indemnify the Administrative Agent, within ten (10) days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), and (ii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to the Lender from any other source against any amount due to the Administrative Agent under this Section 5.03(e).
(f)Status of Lenders.
(i)Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding; provided that, other than in the case of U.S. federal withholding Taxes, such Lender has received written notice from the Borrower advising it of the availability of such exemption or reduction and containing all

-34-

­SC1:5266419.14


applicable documentation. In addition, any Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by Law as reasonably requested by the Borrower as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two (2) sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Section 5.03(f)(ii)(A), (ii)(B), and (ii)(D)) shall not be required if in such Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.
(ii)Without limiting the generality of the foregoing, in the event that the Borrower is a U.S. Person:
(A)any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of IRS Form W-9 (or successor form) certifying that such Lender is exempt from U.S. federal backup withholding tax;
(B)any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable:
(1)in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty;
(2)executed copies of IRS Form W-8ECI (or successor form);
(3)in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit C-1 to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, or a “controlled foreign corporation” related to the Borrower as described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E as applicable (or successor forms); or

-35-

­SC1:5266419.14


(4)to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY (or successor form), accompanied by IRS Form W-8ECI (or successor form), IRS Form W-8BEN or IRS Form W-8BEN-E (or successor form), a U.S. Tax Compliance Certificate, substantially in the form of Exhibit C-2 or C-3, IRS Form W-9 (or successor form), and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit C-4 on behalf of each such direct and indirect partner.
(C)any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable Laws as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable Laws to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and
(D)if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this clause (D), “FATCA” shall include any amendments made to FATCA after the date of this Agreement.
(iii)The Administrative Agent (including any successor Administrative Agent) shall deliver to Borrower on or prior to the date on which it becomes an Administrative Agent under this Agreement (and from time to time thereafter upon the reasonable request of Borrower), executed copies of IRS Form W-9 certifying that it is exempt from U.S. federal backup withholding tax.

Each Lender and the Administrative Agent agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.

-36-

­SC1:5266419.14


(g)Treatment of Certain Tax Benefits. If any party to this Agreement determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 5 (including by the payment of additional amounts pursuant to this Section 5), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section 5 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this Section 5.03(g) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this Section 5.03(g), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 5.03(g) the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This Section 5.03(g) shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.
(h)Each party hereto hereby acknowledges and agrees that the Loans made on the Closing Date are part of an investment unit within the meaning of Section 1273(c)(2) of the Code, which includes the Warrant. For federal income tax purposes, pursuant to Treasury Regulations § 1.1273-2(h), the Borrower, the Administrative Agent and the Lenders acknowledge that the “issue price” of the Loans is 97% of the stated principal amount of the Loans minus the fair market value and purchase price of the Warrants (as determined in accordance with the terms of the Warrants) . Each of the Borrower, the Administrative Agent and the Lenders agree to use the foregoing issue price, fair market value and purchase price for U.S. federal income tax purposes with respect to the transactions contemplated hereby (unless otherwise required by a final determination by the IRS or a court of competent jurisdiction).
5.04Mitigation Obligations. (a)If the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or to any Governmental Authority for the account of any Lender pursuant to Section 5.01 or Section 5.03, then such Lender shall (at the request of the Borrower) use commercially reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign and delegate its rights and obligations hereunder to another of its offices, branches or Affiliates if, in the sole reasonable judgment of such Lender, such designation or assignment and delegation would (i) eliminate or reduce amounts payable pursuant to Section 5.01 or Section 5.03, as the case may be, in the future, (ii) not subject such Lender to any unreimbursed cost or expense and (iii) not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment and delegation.

-37-

­SC1:5266419.14


(b)If any Lender requests compensation under Section 5.01, or if the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 5.03 and, in each case, such Lender has declined or is unable to designate a different lending office in accordance with paragraph (a) of this Section 5.04, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 13.05), all of its interests, rights (other than its existing rights to payments pursuant to Section 5.01 or Section 5.03) and obligations under this Agreement and the related Loan Documents to an Eligible Transferee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment); provided that:
(i)such Lender shall have received payment of an amount equal to the outstanding principal of its Loans, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Loan Documents from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts);
(ii)in the case of any such assignment resulting from a claim for compensation under Section 5.01 or payments required to be made pursuant to Section 5.03, such assignment will result in a reduction in such compensation or payments thereafter; and
(iii)such assignment does not conflict with applicable Law;

A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply.

5.05Survival. Each party’s obligations under this Section 5 shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all Obligations under any Loan Document.
Section 6.
CONDITIONS
6.01Conditions to the Borrowing of the Loans. The obligation of each Lender to make its Loans shall be subject to the delivery of a Borrowing Notice as required pursuant to Section 2.02, and the prior or concurrent satisfaction or waiver of each of the conditions precedent set forth below in this Section 6.01.
(a)Loan Documents. The Administrative Agent shall have received each Loan Document required to be executed by the Borrower on the Closing Date and delivered by the Borrower (which may be delivered by facsimile or other electronic means for the purposes of satisfying this clause (a) on the Closing Date) and such Loan Documents shall be in form and substance satisfactory to the Administrative Agent and the Lenders and their respective counsels.

-38-

­SC1:5266419.14


(b)Secretary’s Certificate, Etc. The Administrative Agent shall have received from the Borrower (x) a copy of a good standing certificate, dated a date reasonably close to the Closing Date and (y) a certificate, dated as of the Closing Date, duly executed and delivered by the Borrower’s Responsible Officer, as to:
(i)resolutions of the Borrower’s Board then in full force and effect authorizing the execution, delivery and performance of each Loan Document to be executed by the Borrower and the Transactions;
(ii)the incumbency and signatures of Responsible Officers authorized to execute and deliver each Loan Document to be executed by the Borrower; and
(iii)the full force and validity of each Organic Document of the Borrower and copies thereof;

upon which certificates shall be in form and substance reasonably satisfactory to the Administrative Agent and upon which the Administrative Agent and the Lenders may conclusively rely until they shall have received a further certificate of the Responsible Officer of any such Person cancelling or amending the prior certificate of such Person.

(c)Information Certificate. The Administrative Agent shall have received a fully completed Information Certificate in form and substance reasonably satisfactory to the Administrative Agent, dated as of the Closing Date, duly executed and delivered by a Responsible Officer of the Borrower. All documents and agreements required to be appended to the Information Certificate, shall be in form and substance reasonably satisfactory to the Administrative Agent, shall have been executed and delivered by the requisite parties and shall be in full force and effect.
(d)Funding Date Certificate. The Administrative Agent shall have received a Funding Date Certificate, dated as of the Closing Date and in form and substance reasonably satisfactory to the Administrative Agent, duly executed and delivered by a Responsible Officer of the Borrower.
(e)Delivery of Notes. The Administrative Agent shall have received a Note to the extent requested by any Lender pursuant to Section 2.03 for the Loans duly executed and delivered by a Responsible Officer of the Borrower.
(f)Financial Information, Etc. The Administrative Agent shall have received:
(i)audited consolidated financial statements of the Borrower and its Subsidiaries for the fiscal year ended December 31, 2019; and
(ii)unaudited consolidated balance sheets of the Borrower and its Subsidiaries for the fiscal quarters ended March 31, 2020 and June 30, 2020, together with the related consolidated statement of operations, shareholder’s equity and cash flows for such fiscal quarters.

-39-

­SC1:5266419.14


(g)Solvency. The Administrative Agent shall have received a solvency certificate, substantially in the form of Exhibit G, duly executed and delivered by the chief financial officer of the Borrower, dated as of the Closing Date, in form and substance reasonably satisfactory to the Administrative Agent.
(h)Security Documents. The Administrative Agent shall have received executed counterparts of a Security Agreement, in form and substance reasonably acceptable to the Administrative Agent, dated as of the Closing Date, duly executed and delivered by the Borrower, together with all documents (including share certificates, transfers and stock transfer forms, notices or any other instruments) required to be delivered or filed under the Security Documents and evidence satisfactory to it that arrangements have been made with respect to all registrations, notices or actions required under the Security Documents to be effected, given or made in order to establish a valid and perfected first priority security interest in the Collateral in accordance with the terms of the Security Documents, including:
(i)delivery of all certificates (in the case of Equity Interests that are certificated securities (as defined in the UCC)) evidencing the issued and outstanding capital securities owned by the Borrower that are required to be pledged and so delivered under the Security Agreement, which certificates in each case shall be accompanied by undated instruments of transfer duly executed in blank, or, in the case of Equity Interests that are uncertificated securities (as defined in the UCC), confirmation and evidence reasonably satisfactory to the Administrative Agent and the Lenders that the security interest required to be pledged therein under the Security Agreement has been transferred to and perfected by the Administrative Agent and the Lenders in accordance with Articles 8 and 9 of the NY UCC and all laws otherwise applicable to the perfection of the pledge of such Equity Interests;
(ii)financing statements naming the Borrower as a debtor and the Administrative Agent as the secured party, or other similar instruments or documents, in each case suitable for filing, filed under the UCC (or equivalent law) of all jurisdictions as may be necessary or, in the opinion of the Administrative Agent, desirable to perfect the Liens of the Secured Parties pursuant to the Security Agreement; and
(iii)UCC-3 termination statements, if any, necessary to release all Liens and other rights of any Person in any collateral described in the Security Agreement previously granted by any Person.
(i)Lien Searches. The Administrative Agent shall be satisfied with Lien searches regarding the Borrower made as of a date reasonably close to the Closing Date.
(j)Warrant. The Administrative Agent shall have received an executed counterpart of the Warrant.
(k)Insurance. The Administrative Agent shall have received certified copies of the insurance policies (or binders in respect thereof), from one or more insurance companies satisfactory to the Administrative Agent, evidencing coverage required to be maintained pursuant to each Loan Document.

-40-

­SC1:5266419.14


(l)Opinions of Counsel. The Administrative Agent shall have received an opinion, dated as of the Closing Date and addressed to the Administrative Agent and the Lenders, from independent legal counsel to the Borrower, in form and substance reasonably acceptable to the Administrative Agent.
(m)Fee Letter. The Administrative Agent shall have received an executed counterpart of the Fee Letter, duly executed and delivered by the Borrower.
(n)Closing Fees, Expenses, Etc. Each of the Administrative Agent and each Lender shall have received for its own account, (i) the upfront fee as set forth in the Fee Letter, which shall be paid by way of the Administrative Agent retaining such amount from the proceeds of the Loan and (ii) all fees, costs and expenses due and payable to it pursuant to the Fee Letter and Section 13.03, including all reasonable closing costs and fees and all unpaid reasonable expenses of the Administrative Agent and the Lenders incurred in connection with the Transactions (including the Administrative Agent’s and the Lenders’ legal fees and expenses) in each case, to the extent invoiced (or as to which a good faith estimate has been provided to the Borrower) at least two (2) Business Days prior to the Closing Date.
(o)Material Adverse Change. Since December 31, 2019, no event, circumstance or change has occurred that has caused or could reasonably be expected to cause, either individually or in the aggregate, a Material Adverse Change, both before and after giving effect to the Loans to be made on the Closing Date.
(p)Know Your Customer. The Administrative Agent shall have received, a duly executed W-9 (or other applicable tax form) of the Borrower, and, as applicable, all documentation and other information required by bank regulatory authorities under applicable “know your customer” and Anti-Terrorism Laws, including, without limitation, the Patriot Act.
(q)No Default. No event shall have occurred or be continuing or would result from the making of the Loans that would constitute a Default or Event of Default.
(r)Representations and Warranties. The representations and warranties contained in this Agreement and in the other Loan Documents delivered pursuant to 6.01(a) shall be true and correct in all material respects (unless such representations are already qualified by reference to materiality, Material Adverse Effect or similar language, in which case such representations and warranties shall be true and correct in all respects) on and as of the Closing Date, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties shall have been true and correct in all respects on and as of such earlier date.
(s)Payoff of Existing Indebtedness. The Opus Debt and 2017 Subordinated Debt (other than contingent obligations (including indemnification obligations) that by their terms are to survive the termination of the relevant loan documentation and debt instruments evidencing the Opus Debt and 2017 Subordinated Debt, as applicable) shall have been (or substantially concurrently with the making of the Loans on the Closing Date shall be) repaid or satisfied and

-41-

­SC1:5266419.14


discharged, and in connection therewith all guarantees and liens shall have been released, on or prior to the Closing Date.
(t)Beneficial Ownership Certificate. To the extent requested by any Lender or the Administrative Agent, the Borrower shall have provided to such Lender and the Administrative Agent all documentation and other information so requested, including a duly executed W-9 of the Borrower (or such other applicable tax form), in connection with applicable “know your customer” and anti-money laundering rules and regulations, including the Patriot Act, and if the Borrower qualifies as a “legal entity customer” under the Beneficial Ownership Regulation, a Beneficial Ownership Certification, in each case prior to the Closing Date.
Section 7.
REPRESENTATIONS AND WARRANTIES

The Borrower hereby represents and warrants to the Administrative Agent and each Lender on the Closing Date, and any other date such representation and warranty is required to be made under the Loan Documents, as set forth below:

7.01Power and Authority. The Borrower and each of its Subsidiaries (i) is duly organized and validly existing under the laws of its jurisdiction of organization, (ii) has all requisite corporate or other power, and has all Governmental Approvals necessary to own its assets and carry on its business as now being or as proposed to be conducted, except to the extent that failure to have the same could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, (iii) is qualified to do business and is in good standing in all jurisdictions in which the nature of the business conducted by it makes such qualification necessary except where failure so to qualify could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, and (iv) has full power, authority and legal right to enter into and perform its obligations under each of the Loan Documents and to borrow the Loans hereunder.
7.02Authorization; Enforceability. Each Transaction is within the Borrower’s corporate or other organizational powers and have been duly authorized by all necessary corporate or other organizational action including, if required, approval by all necessary holders of Equity Interests. This Agreement has been duly executed and delivered by the Borrower and constitutes, and each of the other Loan Documents when executed and delivered by the Borrower will constitute, a legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights and (ii) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).
7.03Governmental and Other Approvals; No Conflicts. None of the execution, delivery and performance by the Borrower of the Loan Documents or the consummation by the Borrower of the Transactions (i) requires any Governmental Approval of, registration or filing with, or any other action by, any Governmental Authority or any other Person, except for (x) such as have been obtained or made and are in full force and effect and (y) filings and recordings in respect of

-42-

­SC1:5266419.14


perfecting or recording the Liens created pursuant to the Security Documents, (ii) will violate (1) any Law, (2) any Organic Document of the Borrower or any of its Subsidiaries or (3) any order of any Governmental Authority, that in the case of clause (ii)(1) or clause (ii)(3), individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect, (iii) will violate or result in a default under any Material Agreement binding upon the Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect or (iv) will result in the creation or imposition of any Lien (other than Permitted Liens) on any asset of the Borrower or any of its Subsidiaries.

7.04Financial Statements; Material Adverse Change.
(a)Financial Statements. The Borrower has heretofore furnished to the Administrative Agent (who shall forward to the Lenders) certain consolidated financial statements as provided for in Section 6.01(f). Such financial statements, and all other financial statements delivered by the Borrower pursuant to this Agreement present fairly, in all material respects, the consolidated financial position and results of operations and cash flows of the Borrower and its Subsidiaries as of such dates and for such periods in accordance with GAAP, subject to year-end audit adjustments and the absence of footnotes in the case of the statements of the type described in Section 8.01(a). Neither the Borrower nor any of its Subsidiaries has any material contingent liabilities or unusual forward or long-term commitments not disclosed in the aforementioned financial statements.
(b)No Material Adverse Change. Since December 31, 2019, no event, circumstance or change has occurred that has caused or could reasonably be expected to cause, individually or in the aggregate, a Material Adverse Change.
7.05Properties.
(a)Property Generally. The Borrower and each of its Subsidiaries has good and marketable fee simple title to, or valid leasehold interests in, all its real and personal property material to its business, subject only to Permitted Liens and except for minor defects in title that do not interfere with its ability to conduct its business as currently conducted or to utilize such properties for their intended purposes.
(b)Intellectual Property.
(i)The Borrower is the sole and exclusive beneficial owner of all right, title and interest in and to all Intellectual Property that is owned or purported to be owned by the Borrower, free and clear of any Liens or Claims other than Permitted Liens. Without limiting the foregoing, and except as set forth in Schedule 7.05(b)(i):
(A)to the knowledge of the Borrower, the operation and conduct of the business of the Borrower or any of its Subsidiaries, including the use of their respective material Intellectual Property in such Person’s Ordinary Course does not violate, infringe or constitute a misappropriation of any valid rights arising under any Intellectual Property of any other Person in a manner that has resulted in, or would reasonably be expected to result in, a Material Adverse Effect;

-43-

­SC1:5266419.14


(B)Except as has not resulted in and would not be expected to result in a Material Adverse Effect, neither the Borrower nor any of its Subsidiaries has received any notice from, or Claim by, any Person that the operation and conduct of the business of the Borrower or any of its Subsidiaries (including their respective use of material Intellectual Property) infringes upon, violates or constitutes a misappropriation of, any Intellectual Property of any other Person in any material respect;
(C)the Borrower does not have knowledge that any material Intellectual Property is being infringed, violated, or misappropriated by any other Person in a manner that has resulted in, or is reasonably expected to result in, a Material Adverse Effect;
(D)except as would not reasonably be expected to result in a Material Adverse Effect, the Borrower owns or has a valid and enforceable license or right to use all material Intellectual Property used in or necessary for the conduct of its business as conducted as of the date hereof; and
(E)all current and former employees and contractors that have developed material Intellectual Property for or on behalf of the Borrower or any of its Subsidiaries have executed written confidentiality and invention assignment Contracts with the Borrower or such Subsidiary, as applicable, that irrevocably and presently assign to the Borrower or such Subsidiary, as applicable, or its designee all rights of such employees and contractors to any such material Intellectual Property, except as would vest initially in the Borrower or its Subsidiary by operation of Law.
7.06No Actions or Proceedings.
(a)Litigation. There is no litigation, investigation or proceeding pending or, to the knowledge of the Borrower or any of its Subsidiaries threatened in writing, with respect to the Borrower or any such Subsidiaries by or before any Governmental Authority or arbitrator that, (i) if adversely determined, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect or (ii) involves this Agreement or any other Loan Document.
(b)Environmental Matters. Except with respect to any matters that (either individually or in the aggregate) could not reasonably be expected to result in a Material Adverse Effect, neither the Borrower nor any of its Subsidiaries (i) has failed to comply with any Environmental Law or to obtain, maintain or comply with any permit, license or other approval required under any Environmental Law, (ii) has become subject to any Environmental Liability, (iii) has received any Environmental Claim, or has knowledge that any is threatened, (iv) has entered into any agreement in which the Borrower or any of its Subsidiaries has assumed or undertaken responsibility or obligations of any other person with respect to any Environmental Liability or (v) has knowledge of any basis for any other Environmental Liability.
(c)Labor Matters. Neither the Borrower nor any of its Subsidiaries has engaged in unfair labor practices as defined in 29 U.S.C. § §152(8) and 158 of the National Labor Relations Act and there are no pending or threatened in writing labor actions, disputes, grievances,

-44-

­SC1:5266419.14


arbitration proceedings, or similar Claims or actions involving the employees of the Borrower or any of its Subsidiaries, in each case that could reasonably be expected to have a Material Adverse Effect. There are no strike or work stoppages in existence or threatened in writing against the Borrower and to the knowledge of the Borrower, no union organizing activity is taking place. There are no collective bargaining agreements covering employees of the Borrower or any of its Subsidiaries.
7.07Compliance with Laws and Agreements. The Borrower is in compliance with (i) all Laws binding on it and orders of any Governmental Authority applicable to it, its operations or its property and (ii) and all obligations binding upon it, its operations or its property pursuant to any Contract, in each case except for such failures to comply which would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. No Default has occurred and is continuing.
7.08Taxes. Except as set forth on Schedule 7.08, the Borrower and its Subsidiaries have timely filed or caused to be filed all tax returns and reports required to have been filed and have paid or caused to be paid all taxes required to have been paid by it, except (a) taxes that are being contested in good faith by appropriate proceedings and for which the Borrower or such Subsidiary, as applicable, has set aside on its books adequate reserves with respect thereto in accordance with GAAP or (b) to the extent that the failure to do so would not reasonably be expected to have a Material Adverse Effect.
7.09Full Disclosure. None of the reports, financial statements, certificates or other written information furnished by or on behalf of the Borrower or any of its Subsidiaries to the Administrative Agent (on behalf of itself and the Lenders) in connection with the negotiation of this Agreement and the other Loan Documents or delivered hereunder or thereunder (as modified or supplemented by other information so furnished) contains any material misstatement of material fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that, with respect to projected financial information, the Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time, and it being understood that such projected financial information and all other forward looking information are not to be viewed as facts and that actual results during the period or periods covered thereby may differ from such projected results and that the differences may be material.
7.10Investment Company Act and Margin Stock Regulation.
(a)Investment Company Act. Neither the Borrower nor any of its Subsidiaries is an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940, as amended.
(b)Margin Stock. The Borrower is not engaged principally, or as one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock, and the Borrower and its Subsidiaries do not own or hold any Margin Stock, with the exception of Equity Interests held by the Borrower in Avenue Therapeutics, Inc., Checkpoint Therapeutics, Inc. and Mustang Bio, Inc..

-45-

­SC1:5266419.14


The Borrowing of the Loans by the Borrower, and the use of the proceeds thereof, will not violate Regulation U or X.
7.11Solvency. The Borrower is and, immediately after giving effect to the making of the Loans, the use of proceeds thereof, and the consummation of the Transactions, will be, Solvent.
7.12Subsidiaries. Set forth on Schedule 7.12 is a complete and correct list of all direct and indirect Subsidiaries of the Borrower. Each such Subsidiary is duly organized and validly existing under the jurisdiction of its organization shown in said Schedule 7.12, and the percentage ownership by the Borrower in each such Subsidiary thereof on an issued and outstanding basis is as shown in said Schedule 7.12.
7.13Indebtedness and Liens. Set forth on Schedule 7.13(a) is a complete and correct list of all Indebtedness of the Borrower and each of its Subsidiaries outstanding as of the Closing Date. Set forth on Schedule 7.13(b) is a complete and correct list of all Liens granted by the Borrower and each of its Subsidiaries with respect to their respective property and outstanding as of the Closing Date.
7.14Material Agreements. Except as set forth on Schedule 7.14, neither the Borrower nor any Subsidiary is in material default under any Material Agreement, nor does the Borrower have any knowledge of (i) any Claim against it or any of its Subsidiaries for any material breach of any such Material Agreement or (ii) any material default by any party to any such Material Agreement.
7.15Restrictive Agreements. Except as set forth in Schedule 7.15, as of the Closing Date, neither the Borrower nor any of its Subsidiaries is subject to any Restrictive Agreement, except (i) those permitted under Section 9.11, (ii) restrictions and conditions imposed by Law or by this Agreement, (iii) any stockholder agreement, charter, by-laws, or other organizational documents of the Borrower or any of its Subsidiaries as in effect on the date hereof and (iv) limitations associated with Permitted Liens.
7.16Real Property. Schedule 7.16 correctly sets forth all real property that is owned or leased by the Borrower, indicating in each case whether the respective property is owned or leased, the identity of the owner and lessee (if applicable) and the location of the respective property. Except as set forth in Schedule 7.16, the Borrower does not own or lease (as tenant thereof) any real property as of the Closing Date.
7.17Pension Matters. To Borrower’s knowledge, each Benefit Plan, and each trust thereunder, intended to qualify for tax exempt status under Section 401 or 501 of the Code or other Laws so qualifies. Except for those that could not, in the aggregate, reasonably be expected to result in a Material Adverse Effect, (x) each Benefit Plan is in compliance with applicable provisions of ERISA, the Code and other Laws, (y) there are no existing or pending (or to the knowledge of the Borrower or any of its Subsidiaries, threatened) claims (other than routine claims for benefits in the normal course), sanctions, actions, lawsuits or other proceedings or investigation involving any Benefit Plan to which the Borrower or Subsidiary thereof incurs or otherwise has or could have an obligation or any liability or Claim and (z) no ERISA Event has

-46-

­SC1:5266419.14


occurred. The Borrower and each of its ERISA Affiliates has met all applicable requirements under the ERISA Funding Rules with respect to each Title IV Plan, and no waiver of the minimum funding standards under the ERISA Funding Rules has been applied for or obtained. As of the most recent valuation date for any Title IV Plan, the funding target attainment percentage (as defined in Section 430(d)(2) of the Code) is at least sixty percent (60%), and neither the Borrower nor any of its ERISA Affiliates knows of any facts or circumstances that could reasonably be expected to cause the funding target attainment percentage to fall below sixty percent (60%) as of the most recent valuation date. As of the Closing Date, no ERISA Event has occurred in connection with which obligations and liabilities (contingent or otherwise) remain outstanding. No ERISA Affiliate has incurred any Withdrawal Liability as a result of a complete withdrawal from any Multiemployer Plan on the date this representation is made.

7.18Transactions with Affiliates. Except as set forth on Schedule 7.18 and for Arm’s Length Transactions, neither the Borrower nor any of its Subsidiaries has entered into, renewed, extended or been a part to, any transaction (including the purchase, sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any Affiliate.
7.19OFAC; Anti-Terrorism Laws.
(a)Neither the Borrower nor any of its Subsidiaries is in violation of any Anti-Terrorism Law or engages in or conspires to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the Anti-Terrorism Laws.
(b)Neither the Borrower nor any of its Subsidiaries, nor, to the knowledge of the Borrower, any of their respective directors, officers, or employees (i) is currently the target of any Sanctions, (ii) is located, organized or residing in any Designated Jurisdiction in violation of Sanctions, or (iii) is or has been (within the previous five (5) years) engaged in any transaction with, or for the benefit of, any Person who is now or was then the target of Sanctions or who is located, organized or residing in any Designated Jurisdiction, in violation of Sanctions. No Loan, nor the proceeds from any Loan, has been or will be used, directly or, to the knowledge of the Borrower, indirectly, to lend, contribute or provide to, or has been or will be otherwise made available for the purpose of funding, any activity or business in any Designated Jurisdiction in violation of Sanctions or for the purpose of funding any activity or business of any Person located, organized or residing in any Designated Jurisdiction or who is the subject of any Sanctions, in violation of Sanctions, or in any other manner that will result in any violation by any party to this Agreement of Sanctions.
7.20Anti-Corruption. Neither the Borrower nor any of its Subsidiaries, nor, to the knowledge of the Borrower, any of their respective directors, officers or employees, directly or, to the knowledge of the Borrower, indirectly, has (i) materially violated or is in material violation of any applicable anti-corruption Law, or (ii) made, offered to make, promised to make or authorized the payment or giving of, directly or, to the knowledge of the Borrower, indirectly, any Prohibited Payment.

-47-

­SC1:5266419.14


7.21Priority of Obligations. The Obligations constitute unsubordinated obligations of the Borrower, and except for any obligations which have priority under applicable Law, rank at least pari passu in right of payment with all other unsubordinated Indebtedness of the Borrower.

Section 8.
AFFIRMATIVE COVENANTS

The Borrower covenants and agrees with the Administrative Agent and the Lenders that, until the Commitments have expired or been terminated and all Obligations (other than Warrant Obligations and inchoate indemnification and expense reimbursement obligations for which no claim has been made) including the Prepayment Fee, if applicable, have been indefeasibly paid in full in cash:

8.01Financial Statements and Other Information. The Borrower will furnish to the Administrative Agent:
(a)as soon as available and in any event within forty-five (45) days after the end of the first three (3) fiscal quarters of each fiscal year (i) the consolidated balance sheets of the Borrower and its Subsidiaries as of the end of such fiscal quarter and (ii) the related consolidated statements of income, shareholders’ equity and cash flows of the Borrower and its Subsidiaries for such quarter and the portion of the fiscal year through the end of such fiscal quarter, in each case prepared in accordance with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the corresponding period in the preceding fiscal year, together with (iii) a certificate of a Responsible Officer of the Borrower stating that (x) such financial statements fairly present in all material respects the financial condition of the Borrower and its Subsidiaries as at such date and (y) the results of operations of the Borrower and its Subsidiaries for the period ended on such date have been prepared in accordance with GAAP consistently applied, subject to changes resulting from normal, year-end audit adjustments and except for the absence of notes; provided that documents required to be furnished pursuant to this Section 8.01(a) shall be deemed furnished on the date that such documents are publicly available on “EDGAR” (with the related certificate separately delivered);
(b)as soon as available and in any event within ninety (90) days after the end of each fiscal year (i) the consolidated balance sheets of the Borrower and its Subsidiaries as of the end of such fiscal year and (ii) the related consolidated statements of income, shareholders’ equity and cash flows of the Borrower and its Subsidiaries for such fiscal year, in each case prepared in accordance with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the previous fiscal year, accompanied by a report and opinion thereon of BDO USA, LLP or another firm of independent certified public accountants of recognized national standing reasonably acceptable to the Administrative Agent, which report and opinion shall be prepared in accordance with generally accepted auditing standards and shall not be subject to any “going concern” or like qualification or exception or emphasis of matter of going concern footnote or any qualification or exception as to the scope of such audit; provided that documents required to be furnished pursuant to this Section 8.01(b) shall be deemed furnished on the date that such documents are publicly available on “EDGAR”;

-48-

­SC1:5266419.14


(c)together with the financial statements required pursuant to 8.01(a) and (b), a compliance certificate signed by the chief financial or accounting Responsible Officer of the Borrower as of the end of the applicable accounting period (which delivery may be by electronic communication including fax or email and shall be deemed to be an original, authentic counterpart thereof for all purposes) substantially in the form of Exhibit D (a “Compliance Certificate”) including (i) details of any issues that are material that are raised by auditors and any occurrence or existence of any event, circumstance, act or omission that would cause any representation or warranty contained in Section 7.07 to be incorrect in any material respect (or in any respect if such representation or warranty is qualified by materiality or by reference to Material Adverse Effect or Material Adverse Change) if such representation or warranty were to be made at the time of delivery of a Compliance Certificate and (ii) for any fiscal period when the Minimum Revenue Covenant is in effect, a certification that the Borrower is in compliance with the Minimum Revenue Covenant as of the last day of such period.;
(d)after being prepared by the Borrower and approved by its Board, and promptly following the Administrative Agent’s request therefor, a consolidated financial forecast for the Borrower and its Subsidiaries for the fiscal year to which such forecast relates; provided that, for each fiscal year, on or before the sixtieth (60th) day following the beginning of such fiscal year, the Borrower shall prepare, and its Board shall approve such consolidated financial forecast for such fiscal year, and the Borrower shall notify the Administrative Agent promptly after the Board has given such approval;
(e)promptly after the same are released, copies of all press releases; provided that documents required to be furnished pursuant to this Section 8.01(e) shall be deemed furnished on the date that such documents are publicly available on “EDGAR”;
(f)promptly, and in any event within five (5) Business Days after receipt thereof by the Borrower, copies of each notice or other correspondence received from any securities regulator or exchange to the authority of which the Borrower may become subject from time to time concerning any investigation or possible investigation or other inquiry by such agency regarding financial or other operational results of the Borrower; provided that documents required to be furnished pursuant to this Section 8.01(f) shall be deemed furnished on the date that such documents are publicly available on “EDGAR”;
(g)promptly after the same are available, copies of each annual report, proxy or financial statement or other report or communication sent to the stockholders of the Borrower and its Subsidiaries, and copies of all annual, regular, periodic and special reports and registration statements which the Borrower or its Subsidiaries may file or be required to file with any securities regulator or exchange to the authority of which the Borrower or such Subsidiary, as applicable, may become subject from time to time; provided that documents required to be furnished pursuant to this Section 8.01(g) shall be deemed furnished on the date that such documents are publicly available on “EDGAR”;
(h)the information regarding insurance maintained by the Borrower and its Subsidiaries as required under Section 8.05;

-49-

­SC1:5266419.14


(i)together with the delivery of the Compliance Certificate, evidence satisfactory to the Administrative Agent, based upon the Borrower’s bank account statements that the Borrower has met its minimum liquidity requirement set out in Section 10.01; and
(j)such other information respecting the businesses, financial performance, operations condition of the assets or liabilities of the Borrower (including with respect to the Collateral), taken as a whole, as the Administrative Agent may from time to time reasonably request.
8.02Notices of Material Events. The Borrower will furnish to the Administrative Agent written notice of the following (x) with respect to clause (a) below within three (3) Business Days and (y) with respect to clause (b) through (j) below, within five (5) Business Days:
(a)the occurrence of any Default or Event of Default;
(b)the occurrence of any event with respect to the property or assets of the Borrower or any of its Subsidiaries resulting in an actual loss in excess of insurance or for which the insurer has denied coverage, in an aggregate amount of $2,000,000 (or the Equivalent Amount in other currencies) or more;
(c)(i) any proposed acquisition of stock, assets or property by the Borrower or any of its Subsidiaries that could reasonably be expected to result in material Environmental Liability, and (ii) any spillage, leakage, discharge, disposal, leaching, migration or release of any Hazardous Material by the Borrower or any of its Subsidiaries required to be reported to any Governmental Authority and that could reasonably be expected to result in material Environmental Liability;
(d)the assertion of any Claim under any Environmental Law by any Person against, or with respect to the activities of, the Borrower or any of its Subsidiaries and any alleged liability or non-compliance with any Environmental Laws or any permits, licenses or authorizations issued pursuant to Environmental Laws which could reasonably be expected to involve damages in excess of $2,000,000 (or the Equivalent Amount in other currencies) other than any such Claim or alleged violation that, if adversely determined, could not (either individually or in the aggregate) reasonably be expected to have a Material Adverse Effect;
(e)the filing or commencement of any action, suit or proceeding by or before any arbitrator or Governmental Authority against or affecting the Borrower or any of its Affiliates that could reasonably be expected to result in a Material Adverse Effect;
(f)(i) the intention of any ERISA Affiliate to file any notice of intent to terminate any Title IV Plan, a copy of such notice and (ii) the filing by any ERISA Affiliate of a request for a minimum funding waiver under Section 412 of the Code with respect to any Title IV Plan, in writing and in reasonable detail (including a description of any action that any ERISA Affiliate proposes to take with respect thereto, together with a copy of any notice filed with the PBGC or the IRS pertaining thereto);

-50-

­SC1:5266419.14


(g)any material change in accounting policies or financial reporting practices by the Borrower or any of its Subsidiaries;
(h)any labor controversy resulting in or threatening to result in any strike, work stoppage, boycott, shutdown or other material labor disruption against or involving the Borrower;
(i)any change to the Borrower’s or any of its Subsidiaries’ ownership of any Controlled Account, by delivering the Administrative Agent a notice setting forth a complete and correct list of all such accounts as of the date of such change; and
(j)any other development that results in, or could reasonably be expected to result in, a Material Adverse Effect.

Each notice delivered under this Section 8.02 shall be accompanied by a statement of a Responsible Officer of the Borrower setting forth the details of the event or development requiring such notice and any action taken or proposed to be taken with respect thereto. Nothing in this Section 8.02 is intended to waive, consent to or otherwise permit any action or omission that is otherwise prohibited by this Agreement or any other Loan Document.

8.03Existence. The Borrower shall, and shall cause each of its Subsidiaries to, preserve, renew and maintain in full force and effect its legal existence; provided that the foregoing shall not prohibit any merger, amalgamation, consolidation, liquidation or dissolution permitted under Section 9.03.
8.04Payment of Obligations. The Borrower will, and will cause each of its Subsidiaries to, pay and discharge its obligations, including (i) all Taxes, fees, assessments and governmental charges or levies imposed upon it or upon its properties or assets prior to the date on which penalties attach thereto, and all lawful claims for labor, materials and supplies which, if unpaid, might become a Lien upon any properties or assets of the Borrower or any of its Subsidiaries, except (A) to the extent such Taxes, fees, assessments or governmental charges or levies or such claims are being contested in good faith by appropriate proceedings and are adequately reserved against in accordance with GAAP or (B) to the extent that the failure to do so would not reasonably be expected to have a Material Adverse Effect, and (ii) all lawful claims which, if unpaid, would by law become a Lien upon its property not constituting a Permitted Lien.
8.05Insurance. The Borrower will, and will cause each of its Subsidiaries to maintain, with financially sound and reputable insurance companies, insurance in such amounts and against such risks as are customarily maintained by companies engaged in the same or similar businesses. Upon the request of the Administrative Agent, the Borrower shall furnish the Administrative Agent from time to time with (i) material information as to the insurance carried by it and, if so requested, copies of all such insurance policies and (ii) a certificate from the Borrower’s insurance broker or other insurance specialist stating that all premiums then due on the policies relating to insurance on the Collateral have been paid and that such policies are in full force and effect. Receipt of notice of termination or cancellation of any such insurance policies or reduction of coverages or amounts thereunder shall entitle the Secured Parties to

-51-

­SC1:5266419.14


renew any such policies, cause the coverages and amounts thereof to be maintained at levels required pursuant to the first sentence of this Section 8.05 or otherwise to obtain similar insurance in place of such policies, in each case, the Borrower will be responsible for the reasonable and documented cost of such insurance (to be payable on demand). The amount of any such reasonable and documented expenses shall accrue interest at the Default Rate if not paid on demand and shall constitute “Obligations.”

8.06Books and Records; Inspection Rights. The Borrower will, and will cause each of its Subsidiaries to, keep proper books of record and account in which full, true and correct (in all material respects) entries are made of all dealings and transactions in relation to its business and activities. The Borrower will, and for so long as JMC is a Subsidiary will cause JMC to, permit any representatives designated by the Administrative Agent or the Lenders, upon reasonable prior notice, to visit and inspect its properties, to examine and make extracts from its books and records, and to discuss its affairs, finances and condition (financial or otherwise) with its officers and independent accountants, during normal business hours (but not more often than twice per year unless an Event of Default has occurred and is continuing) as the Administrative Agent or the Lenders may request; provided that such representative shall use its commercially reasonable efforts to minimize disruption to the business and affairs of the Borrower or JMC, as applicable, as a result of any such visit, inspection, examination or discussion. Notwithstanding anything to the contrary contained herein, neither the Borrower nor JMC will be required to disclose or permit the inspection or discussion of, any document, information or other matter (i) that constitutes trade secrets or proprietary information, (ii) in respect of which disclosure to any Lender (or their respective representatives or contractors) is prohibited by any applicable Law or any binding agreement with a third party (so long as such agreement is not entered into in contemplation of this Agreement) or (iii) that is subject to attorney-client or similar privilege, which could reasonably be expected to be lost or forfeited if disclosed to the Administrative Agent or any Lender. The Borrower shall pay all reasonable and documented costs of all such inspections.
8.07Compliance with Laws and Other Obligations. The Borrower will, and will cause each of its Subsidiaries to, (i) comply with all Laws (including Anti-Terrorism Laws, Sanctions and Environmental Laws) applicable to it and its business activities, (ii) comply in all material respects with all Governmental Approvals applicable to it and its business activities and (iii) maintain in full force and effect, remain in compliance with, and perform all obligations under all Material Agreement to which it is a party, except, in the case of clause (i) and (iii) above, where the failure to do so could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The Borrower shall maintain in effect and enforce policies and procedures reasonably designed to promote compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Terrorism Laws and Sanctions.
8.08Maintenance of Properties, Etc. The Borrower shall, and shall cause each of its Subsidiaries to, maintain and preserve all of its assets and properties, necessary or useful in the conduct of its business in good working order and condition in accordance with the general practice of other Persons of similar character and size, ordinary wear and tear and damage from

-52-

­SC1:5266419.14


casualty or condemnation excepted and except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.

8.09Licenses. The Borrower shall, and shall cause each of its Subsidiaries to, obtain and maintain all Governmental Approvals necessary in connection with the execution, delivery and performance of the Loan Documents, the consummation of the Transactions or the operation and conduct of its business and ownership of its properties, except where the failure to do so could not reasonably be expected to have a Material Adverse Effect.
8.10Use of Proceeds. The proceeds of the Loans will be used only as provided in Section 2.04. No part of the proceeds of the Loans will be used, whether directly or indirectly, for any purpose that entails a violation of any of the Regulations of the Board of Governors of the Federal Reserve System, including Regulations T, U and X.
8.11Further Assurances.
(a)Subject to clauses (b) and (c) below:
(i)the Borrower will take such action from time to time as shall reasonably be requested by the Administrative Agent to effectuate the purposes and objectives of this Agreement and the Security Agreement; and
(ii)without limiting the generality of the foregoing, the Borrower will take such action from time to time (including delivering shares of stock together with undated transfer powers executed in blank, applicable control agreements and other instruments) as shall be reasonably requested by the Administrative Agent to create, in favor of the Secured Parties, perfected security interests and Liens in substantially all of the personal property (other than Excluded Assets (as defined in the Security Agreement)) of the Borrower as collateral security for the Obligations; provided that any such security interest or Lien shall be subject to the relevant requirements of the Security Documents; provided, further that, without limiting the right of the Administrative Agent to require a Lien or security interest in any newly acquired or created Subsidiary or asset, upon the prior written request of the Borrower, the Borrower and the Administrative Agent shall consult, in good faith, as to whether the cost of obtaining a Lien or security interest thereon would be unreasonably excessive relative to the benefit thereof.
(b)CFCs, etc.Any term or provision of this Section 8.11 to the contrary notwithstanding, the Borrower shall not be required to pledge (or cause to be pledged) to the Administrative Agent, for the benefit of the Secured Parties, Equity Interests of any Subsidiary representing, in the aggregate, more than sixty-five percent (65%) of the Equity Interests of any CFC or CFC Holding Company; provided, that the above restrictions shall apply only to the extent the Borrower reasonably determines (after consultation with the Administrative Agent) that the failure to impose such restrictions could reasonably be expected to generate a current or future income inclusion, or other adverse tax consequence, to the Borrower or any of its Subsidiaries (as determined in good faith from time to time).
(c)Limitations on Certain Obligations. Notwithstanding anything to the contrary contained in this Agreement or any other Loan Document, the Borrower shall not be required to

-53-

­SC1:5266419.14


enter into or obtain any mortgage, deed of trust, leasehold mortgage or any similar agreement in respect to any fee interest or leasehold interest in real property.
8.12Termination of Non-Permitted Liens. In the event that the Borrower shall become aware of, or be notified by the Administrative Agent or any Lender of the existence of, any outstanding Lien against any assets or property of the Borrower or any of its Private Subsidiaries, which Lien is not a Permitted Lien, the Borrower shall use its commercially reasonable efforts to promptly terminate or cause the termination of such Lien.
8.13Board Materials; Oaktree Lender Board Observer.
(a)The Borrower shall deliver to the Administrative Agent copies of any agenda and other written materials provided to the board of directors (or any committee thereof) of the Borrower prior to any meeting of the board of directors (or such committee thereof), at or promptly after such materials are furnished to the members of the board of directors (or such committee thereof), (b) copies of all minutes of meetings of the board of directors (or any committee thereof) of the Borrower at or promptly after such minutes are furnished to the members of the board of directors (or such committee thereof), (c) copies of all material written consents duly passed by the board of directors (or any committee thereof) of the Borrower and (d) promptly upon presentation of any regular periodic materials to the board of directors (or any committee thereof) of the Borrower reporting on the current, past or future financial performance and business and operations of the Borrower or any of its Subsidiaries (which shall include, among other things, updates with respect to material events relating to other Material Agreements), copies of such materials shall be delivered to the Administrative Agent; provided that any such material may be redacted by the Borrower to exclude information that directly relates to either the Lenders in their capacities as debt lenders or future debt refinancing transactions.
(b)Upon the request of the Oaktree Lender, the Borrower shall permit a single designee of the Oaktree Lender to be an observer to the board of directors of the Borrower (the “Board Observer”). In such capacity, the Board Observer shall be entitled to attend all meetings of the board of directors of the Borrower. The Borrower shall ensure that the Board Observer is invited to each such meeting at the same time as each other member of the board of directors and that such Board Observer receives all board materials at the same time as each other member of the board of directors; provided that any such material may be redacted by the Borrower, and the Borrower may exclude the Board Observer from meetings of the board of directors, in order to prevent the Board Observer from receiving or learning information that directly relates to either the Oaktree Lender in its capacity as a debt lender or future debt refinancing transactions. If appointed, the Board Observer may resign or withdraw at any time, or, at the request of the Oaktree Lender, be replaced by a designee of the Oaktree Lender.
8.14ERISA Compliance. The Borrower shall comply, and shall cause each of its Subsidiaries to comply, with the provisions of ERISA with respect to any Plans to which the Borrower or such Subsidiary is a party as an employer in all material respects.
8.15Cash Management. The Borrower shall:

-54-

­SC1:5266419.14


(a)maintain at all times an aggregate amount of cash of the Borrower equal to the Minimum Liquidity Amount in deposit accounts, disbursement accounts, investment accounts (and other similar accounts) and lockboxes with a bank or financial institution within the U.S. that has executed and delivered to the Administrative Agent an account control agreement, in form and substance reasonably acceptable to the Administrative Agent (each such deposit account, disbursement account, investment account (or similar account) and lockbox, a “Controlled Account”); each such Controlled Account shall be a cash collateral account, with all cash, checks and other similar items of payment in such account securing payment of the Obligations, and the Borrower shall have granted a Lien to the Administrative Agent, for the benefit of the Secured Parties, over such Controlled Accounts; and
(b)deposit promptly, and in any event no later than five (5) Business Days after the date of receipt thereof, all cash, checks, drafts or other similar items of payment relating to or constituting payments made in respect of any and all accounts and other rights and interests into Controlled Accounts.
8.16Post-Closing Obligations.
(a)Controlled Accounts. Within sixty (60) days following the Closing Date (or such longer period of time as agreed by the Administrative Agent in its sole discretion) (the “Account Control Agreement Completion Date”), the Administrative Agent shall have received evidence that (i) all deposit accounts, lockboxes, disbursement accounts, investment accounts or other similar accounts of the Borrower located within the U.S. are Controlled Accounts and (ii) such Controlled Accounts are subject to one or more account control agreements, in favor of, and satisfactory in form and substance to, the Administrative Agent that (A) ensures, to the extent necessary under applicable law, the perfection of a first priority security interest in favor of the Administrative Agent on such Controlled Account, (B) provides that, upon written notice from the Administrative Agent, such bank or financial institution shall comply with instructions originated by the Administrative Agent directing disposition of the funds in such Controlled Account without further consent by the Borrower, and (C) may not be terminated without the prior written consent of the Administrative Agent.
(b)Financial Covenant Compliance. On the Account Control Agreement Completion Date, the Administrative Agent shall have received written evidence reasonably satisfactory to it that, as of the Account Control Agreement Completion Date, the Borrower is in compliance with Section 10.01 and Section 8.15(a).
(c)Insurance. Within thirty (30) days following the Closing Date (or such longer period of time as agreed by the Administrative Agent in its sole discretion), all such insurance policies required to be maintained by the Borrower pursuant to the Loan Documents shall name the Administrative Agent (for its benefit and the benefit of the Lenders) loss payee or additional insured, as applicable, and provide that no cancellation of the policies will be made without at least ten (10) days prior written notice to the Administrative Agent and the Administrative Agent shall have received certified copies of such insurance policies (or binders in respect thereof).

-55-

­SC1:5266419.14


(d)Payoff of Venture Debt. The Venture Debt (other than contingent obligations (including indemnification obligations) that by their terms are to survive the termination of the relevant loan documentation and debt instruments evidencing the Venture Debt) shall be repaid or satisfied and discharged, and in connection therewith all guarantees and liens shall have been released, as soon as permitted under the terms thereof, and in no event later than September 29, 2020. The Borrower shall provide evidence of the payoff of the Venture Debt to the Administrative Agent, in form and substance satisfactory to the Administrative Agent, promptly after the repayment thereof.
(e)Stockholder Rights and Other Waivers. Within sixty (60) days following the Closing Date (or such longer period of time as agreed by the Administrative Agent in its sole discretion), the Administrative Agent shall have received evidence of Borrower’s receipt of (i) the waiver by its Subsidiaries and/or the requisite stockholders of its Subsidiaries of any option, right of first refusal, or rights under any stockholders or similar agreement that would prohibit, impair, delay or otherwise affect the pledge of the Pledged Collateral under the Security Agreement, the sale or disposition thereof pursuant thereto or the exercise by the Administrative Agent of rights and remedies thereunder and (ii) the waiver by Alexion Pharmaceuticals, Inc. of the restrictions set forth in Section 9.7 of the Amended and Restated Development, Option and Stock Purchase Agreement (the “DOSPA”), dated as of December 31, 2019, by and among Alexion Pharmaceuticals, Inc., Caelum Biosciences, Inc., the Sellers (as defined therein) and the Borrower, in substantially the form agreed to between the Administrative Agent and the Borrower prior to the Closing Date.
Section 9.
NEGATIVE COVENANTS

The Borrower covenants and agrees with the Administrative Agent and the Lenders that, until the Commitments have expired or been terminated and all Obligations (other than Warrant Obligations and inchoate indemnification and expense reimbursement obligations for which no claim has been made), including the Prepayment Fee, if applicable, have been indefeasibly paid in full in cash:

9.01Indebtedness. The Borrower will not, and will not permit any of its Private Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, whether directly or indirectly, except:
(a)the Obligations;
(b)Indebtedness existing on the date hereof and set forth on Schedule 7.13(a) and Permitted Refinancings thereof;
(c)accounts payable to trade creditors for goods and services and current operating liabilities (not the result of the borrowing of money) incurred in the ordinary course of the Borrower’s or such Subsidiary’s business in accordance with customary terms and paid within the specified time, unless contested in good faith by appropriate proceedings and reserved for in accordance with GAAP;

-56-

­SC1:5266419.14


(d)Indebtedness consisting of guarantees resulting from the endorsement of negotiable instruments for collection in the ordinary course of business;
(e)Indebtedness in respect of working capital facilities of the Borrower (which Indebtedness is secured by accounts receivable of JMC) in an aggregate outstanding principal amount not to exceed $7,500,000 (or the Equivalent Amount in other currencies) and an all-in-yield not to exceed at any time 7% per annum (provided that, if the interest rate for such Indebtedness is a floating rate, the 7% limitation shall not be deemed to be exceeded solely as a result of an increase in the applicable benchmark rate or the application of the benchmark rate floor, if any, set forth in the documentation governing such Indebtedness, in each case, following the incurrence of such Indebtedness); provided that the documentation governing such Indebtedness shall be in form and substance reasonably satisfactory to the Administrative Agent in its sole discretion;
(f)Indebtedness of any Subsidiary permitted under Section 9.05(f);
(g)other Indebtedness in an aggregate outstanding principal amount not to exceed $5,000,000 (or the Equivalent Amount in other currencies).
9.02Liens. The Borrower will not, and will not permit any of its Private Subsidiaries to, create, incur, assume or permit to exist any Lien on any property now owned by it or such Private Subsidiary, except:
(a)Liens securing the Obligations;
(b)any Lien on any property or asset of the Borrower or any of its Subsidiaries existing on the date hereof and set forth on Schedule 7.13(b) and renewals and extensions thereof in connection with Permitted Refinancings of the Indebtedness being secured by such Lien; provided that (i) no such Lien (including any renewal or extension thereof) shall extend to any other property or asset of the Borrower or any of its Subsidiaries and (ii) any such Lien shall secure only those obligations which it secures on the date hereof and renewals, extensions and replacements thereof in connection with Permitted Refinancings of the Indebtedness being secured by such Lien that do not increase the outstanding principal amount thereof;
(c)Liens imposed by any Law arising in the ordinary course of business, including (but not limited to) carriers’, warehousemen’s, landlords’, and mechanics’ liens, liens relating to leasehold improvements and other similar Liens arising in the ordinary course of business and which (x) do not in the aggregate materially detract from the value of the property subject thereto or materially impair the use thereof in the operations of the business of such Person or (y) are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing the forfeiture or sale of the property subject to such Liens and for which adequate reserves have been made if required in accordance with GAAP;
(d)pledges or deposits made in the Ordinary Course in connection with bids, contract leases, appeal bonds, workers’ compensation, unemployment insurance or other similar social security legislation;

-57-

­SC1:5266419.14


(e)Liens securing Taxes, assessments and other governmental charges, the payment of which is not yet due or is being contested in good faith by appropriate proceedings promptly initiated and diligently conducted and for which such reserve or other appropriate provisions, if any, as shall be required by GAAP shall have been made;
(f)servitudes, easements, rights of way, restrictions and other similar encumbrances on real property imposed by any Law and Liens consisting of zoning or building restrictions, easements, licenses, restrictions on the use of property or minor imperfections in title thereto which, in the aggregate, are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Borrower or any of its Subsidiaries; and
(g)with respect to any real property, (i) such defects or encroachments as might be revealed by an up-to-date survey of such real property; (ii) the reservations, limitations, provisos and conditions expressed in the original grant, deed or patent of such property by the original owner of such real property pursuant to all applicable Laws; and (iii) rights of expropriation, access or user or any similar right conferred or reserved by or in any Law, which, in the aggregate for clauses (i), (ii) and (iii), are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any of the Borrower or its Subsidiaries;
(h)bankers liens, rights of setoff and similar Liens incurred on deposits made in the Ordinary Course;
(i)Liens on accounts receivable of JMC securing Indebtedness permitted under Section 9.01(e);
(j)Any judgment lien or lien arising from decrees or attachments not constituting an Event of Default;
(k)Liens arising from precautionary UCC financing statement filings regarding operating leases of personal property and consignment arrangements entered into in the Ordinary Course in an Arm’s-Length Transaction;
(l)Liens in connection with the financing of insurance premiums; and
(m)other Liens, which secure obligations in an aggregate amount not to exceed $2,500,000 (or the Equivalent Amount in other currencies) at any time outstanding.

Notwithstanding anything in this Agreement to the contrary, the Borrower shall not create, incur, assume or permit to exist any Lien on any Equity Interests owned by it in any other Person, except such as are set forth on Schedule 9.02.

9.03Fundamental Changes and Acquisitions. The Borrower will not, and will not permit any of its Private Subsidiaries to, (i) enter into any transaction of merger, amalgamation or consolidation, (ii) liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution), (iii) sell or issue any Equity Interests (other than common Equity Interests), or (iv) other than

-58-

­SC1:5266419.14


Permitted Acquisitions, make any Acquisition or otherwise acquire any business or substantially all the property from, or Equity Interests of, or be a party to any Acquisition of, any Person, except:

(a)the merger, amalgamation or consolidation of (i) any Subsidiary with or into the Borrower; provided that with respect to any such transaction involving the Borrower, the Borrower must be the surviving or successor entity of such transaction or (ii) any Subsidiary with or into any other Subsidiary;
(b)the sale, lease, transfer or other disposition by any Subsidiary of any or all of its property (upon voluntary liquidation or otherwise) to the Borrower or any other Subsidiary;
(c)the sale, transfer or other disposition of the Equity Interests of any Subsidiary (1) to the Borrower, and (2) in accordance with Section 9.09;
(d)the sale or issuance of (i) preferred Equity Interests by the Borrower in an amount in the aggregate no greater than $30,000,000 minus the amount of preferred Equity Interests issued pursuant to subclause (ii) and (ii) preferred Equity Interests in connection with the Cyprium Financing in an amount no greater than $8,000,000; and
(e)in connection with any Monetization Event.
9.04Lines of Business. The Borrower will not, and will not permit any of its Subsidiaries to, engage in any business other than the business engaged in on the date hereof by such Persons or a business reasonably related, incidental or complementary thereto or reasonable extensions thereof.
9.05Investments. The Borrower will not, and will not permit any of its Subsidiaries to, make, directly or indirectly, or permit to remain outstanding any Investments except:
(a)Investments outstanding on the date hereof and identified in Schedule 9.05 and any renewals, amendments and replacements thereof that do not increase the amount thereof of any such Investment or require that any additional Investment be made (unless otherwise permitted hereunder);
(b)operating deposit accounts with banks (or similar deposit-taking institutions) that, in the case maintained by the Borrower, are Controlled Accounts;
(c)extensions of credit in the nature of accounts receivable or notes receivable arising from the sales of goods or services in the Ordinary Course in an Arm’s-Length Transaction;
(d)Permitted Cash Equivalent Investments that, in the case maintained by the Borrower, are in Controlled Accounts;
(e)Investments by the Borrower in connection with a Permitted Acquisition;

-59-

­SC1:5266419.14


(f)Investments (i) by the Borrower (x) in any Subsidiary in the form of advances, loans or other extensions of credit, in each case, in the ordinary course of business consistent with past practice, (y) in any Public Subsidiary in the form of capital contributions, or (z) in any Private Subsidiary in the form of capital contributions in an amount not to exceed $20,000,000 in the aggregate; provided, in each case, that at the time of any such Investment, (A) the Borrower shall have, on a Pro Forma Basis and after giving effect to any cash interest payments on Indebtedness and dividend payments on preferred equity payable by the Borrower in the ninety (90) days following such Investment, at least $25,000,000 in cash in one or more Controlled Accounts that are free and clear of all Liens, other than Liens granted hereunder in favor of the Administrative Agent and (B) such Investments shall be pledged to the Administrative Agent, and provided, further, that, notwithstanding any of the foregoing or any other provision hereof, any Indebtedness owed to the Borrower by any Subsidiary (or accrued Management Services Agreement fees owed to the Borrower by any Subsidiary) that is incurred in compliance with this Agreement may be subsequently converted into such Subsidiary’s common stock in connection with a bona fide, third party common equity financing of such Subsidiary, or (ii) by a Subsidiary in any other Subsidiary;
(g)Investments consisting of prepaid expenses, negotiable instruments held for collection or deposit, security deposits with utilities, landlords and other like Persons and deposits in connection with workers’ compensation and similar deposits, in each case, made in the Ordinary Course;
(h)employee loans, travel advances and guarantees in accordance with the Borrower’s usual and customary practices with respect thereto (if permitted by applicable Laws) which in the aggregate shall not exceed $1,000,000 outstanding at any time (or the Equivalent Amount in other currencies);
(i)Investments received in connection with any Insolvency Proceedings in respect of any customers, suppliers or clients and in settlement of delinquent obligations of, and other disputes with, customers, suppliers or clients;
(j)the increase in value of any Investment otherwise permitted pursuant to this Section 9.05;
(k)other Investments (other than Investments by the Borrower in any Subsidiary) in an aggregate amount not to exceed $2,500,000 (or the Equivalent Amount in other currencies);
(l)Investments permitted under Section 9.03; and
(m)Investments of any Person in existence at the time such Person becomes a Subsidiary; provided such Investment was not made in connection with or in anticipation of such Person becoming a Subsidiary and any modification, replacement, renewal or extension thereof.
9.06Restricted Payments. The Borrower will not, and will not permit any of its Private Subsidiaries to, declare or make, or agree to pay or make, directly or indirectly, any Restricted Payment; provided that the following Restricted Payments shall be permitted so long as no Event

-60-

­SC1:5266419.14


of Default has occurred and is continuing or could reasonably be expected to occur or result from such Restricted Payment:

(a)dividends with respect to the Borrower’s Equity Interests payable solely in shares of its Qualified Equity Interests (or the equivalent thereof);
(b)the Borrower’s purchase, redemption, retirement, or other acquisition of shares of its Equity Interests with the proceeds received from a substantially concurrent issue of new shares of its Qualified Equity Interests;
(c)dividends or other distributions paid by any Subsidiary to the Borrower and dividends paid by any Subsidiary ratably (or less than ratably) to each other holder of Equity Interests of such Subsidiary (including, without limitation, as part of, or immediately following, a Monetization Event);
(d)any purchase, redemption, retirement or other acquisition of Equity Interests of the Borrower held by officers, directors and employees or former officers, directors or employees (or their transferees, estates, or beneficiaries under their estates) of Borrower and its Subsidiaries not to exceed $1,000,000 (or the Equivalent Amount in other currencies) in any fiscal year;
(e)cashless exercises of options and warrants;
(f)cash payments made by the Borrower to redeem, purchase, repurchase or retire its obligations under warrants issued by it (in the nature of cash payments in lieu of fractional shares) in accordance with the terms thereof;
(g)dividends with respect to shares of the Borrower’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock outstanding as of the date hereof pursuant to the terms thereof as in effect as of the date hereof;
(h)dividends paid in cash with respect to preferred Equity Interests issued pursuant to Section 9.03(d), in an aggregate amount not to exceed $2,500,000 in any fiscal year;
(i)cash payments made to redeem, purchase, repurchase or retire any preferred Equity Interest in Cyprium issued pursuant to Section 9.03(d), provided that, after giving effect to any such payment, the Borrower shall have on a Pro Forma Basis at least $25,000,000 in cash in one or more Controlled Accounts that are free and clear of all Liens, other than Liens granted hereunder in favor of the Administrative Agent; and
(j)other Restricted Payments in an aggregate amount not to exceed $1,000,000 (or the Equivalent Amount in other currencies) in any fiscal year.

Notwithstanding anything in this Agreement to the contrary, (i) the Borrower shall not declare or make, or agree to pay or make, directly or indirectly, any Restricted Payment in the form of Equity Interests owned by the Borrower in any other Person, (ii) any dividends paid in cash with respect to preferred Equity Interests issued pursuant to Section 9.03(d) shall only be made

-61-

­SC1:5266419.14


pursuant to clause (h) above (and not any other clause of this Section 9.06) and (iii) any cash payments made to redeem, purchase, repurchase or retire any Equity Interest in Cyprium issued pursuant to the Cyprium Financing shall only be made pursuant to clause (i) above (and not any other clause of this Section 9.06).

9.07Payments of Indebtedness. The Borrower will not, and will not permit any of its Private Subsidiaries to, make any payments in respect of any Indebtedness other than (i) payments of the Obligations, and (ii) scheduled payments of other Indebtedness to the extent permitted to be incurred pursuant to Section 9.01.
9.08Change in Fiscal Year. The Borrower will not, and will not permit any of its Subsidiaries to, change the last day of its fiscal year from that in effect on the date hereof, except to change the fiscal year of a Subsidiary acquired in connection with an Acquisition to conform its fiscal year to that of the Borrower.
9.09Sales of Assets, Etc. The Borrower will not, and will not permit any of its Private Subsidiaries to, sell, lease or sublease (as lessor or sub-lessor), sale and leaseback, assign, convey, exclusively license (in terms of geography or field of use), transfer, or otherwise dispose of any of its businesses, assets or property of any kind, whether real, personal, or mixed and whether tangible or intangible, whether now owned or hereafter acquired (including accounts receivable and Equity Interests of Subsidiaries), or forgive, release or compromise any amount owed to the Borrower or any of its Subsidiaries, in each case, in one transaction or series of transactions (any thereof, an “Asset Sale”), except:
(a)sales, transfers and other dispositions of receivables in connection with the compromise, settlement or collection thereof in the Ordinary Course;
(b)sales of inventory or licenses of Intellectual Property in the Ordinary Course in an Arm’s-Length Transaction;
(c)the forgiveness, release or compromise of any amount owed to the Borrower or any of its Subsidiaries in the Ordinary Course;
(d)dispositions (including by way of abandonment or cancellation) of any equipment and other tangible property that is obsolete or worn out or no longer used or useful in the Business disposed of in the Ordinary Course in an Arm’s-Length Transaction;
(e)dispositions resulting from Casualty Events;
(f)in connection with any transaction permitted under Section 9.03 or 9.05;
(g)dispositions identified in Schedule 9.09(a);
(h)any Qualifying [*] Sale or Qualifying Avenue Sale; and
(i)so long as no Event of Default has occurred and is continuing, (1) other Asset Sales with a fair market value not in excess of $5,000,000 (or the Equivalent Amount in other

-62-

­SC1:5266419.14


currencies) in the aggregate in any fiscal year, and (2) other Asset Sales by Borrower with a fair market value in excess of $5,000,000 (or the Equivalent Amount in other currencies) in the aggregate in any fiscal year and as to which Borrower has complied with the mandatory prepayment provisions of Section 3.03(b), so long as the consideration for any such Asset Sale is at least equal to the fair market value of the assets being sold and the Borrower has sufficient cash on hand to comply with the mandatory prepayment provisions of Section 3.03(b).

Notwithstanding anything in this Agreement to the contrary, the Borrower shall not sell or otherwise dispose of any Equity Interests owned by it in another Person unless the consideration for such sale or disposition is at least equal to the fair market value of such Equity Interests being sold.

9.10Transactions with Affiliates. The Borrower will not, and will not permit any of its Private Subsidiaries to, directly or indirectly, enter into or permit to exist any transaction to sell, lease, license or otherwise transfer any assets to, or purchase, lease, license or otherwise acquire any assets from, or otherwise engage in any other transactions with, any of its Affiliates, unless such arrangement or transaction (i) is an Arm’s-Length Transaction that is of the kind which would be entered into by a prudent Person in the position of the Borrower with another Person that is not an Affiliate, (ii) is permitted under Section 9.01, 9.03, 9.05, 9.06, 9.07 or 9.09, (iii) constitutes customary compensation and indemnification of, and other employment arrangements with, directors, officers, and employees of the Borrower or its Subsidiaries in the ordinary course of business, (iv) constitutes payment of customary fees, reimbursement of expenses, and payment of indemnification to officers and directors and customary payment of insurance premiums on behalf of officers and directors by the Borrower or its Subsidiaries, in each case, in the ordinary course of business or (v) are the transactions set forth on Schedule 7.18. Notwithstanding the foregoing or any other provision hereof, the Borrower may, without the Lenders’ or Administrative Agent’s prior written consent, but with notice to the Administrative Agent, terminate its Founders Agreement or Management Services Agreement with any Private Subsidiary in connection with the offering or potential offering of common stock by such Private Subsidiary.
9.11Restrictive Agreements. The Borrower will not, and will not permit any of its Private Subsidiaries to, directly or indirectly, enter into, incur or permit to exist any Restrictive Agreement other than (i) restrictions and conditions imposed by applicable Laws or by the Loan Documents, (ii) Restrictive Agreements listed on Schedule 7.15 or (iii) limitations associated with Permitted Liens.
9.12Modifications and Terminations of Organic Documents. The Borrower will not, and will not permit any of its Private Subsidiaries to, waive, amend, terminate, replace or otherwise modify any term or provision of any Organic Document in any way or manner materially adverse to the interests of the Lenders in their capacities as Lenders hereunder.
9.13Sales and Leasebacks. The Borrower will not, and will not permit any of its Private Subsidiaries to, become liable, directly or indirectly, with respect to any lease, whether an operating lease or a Capital Lease Obligation, of any property (whether real, personal, or mixed), whether now owned or hereafter acquired, (i) which such Person has sold or transferred or is to

-63-

­SC1:5266419.14


sell or transfer to any other Person and (ii) which the Borrower or such Subsidiary intends to use for substantially the same purposes as property which has been or is to be sold or transferred.

9.14Hazardous Material. The Borrower will not, and will not permit any of its Subsidiaries to, use, generate, manufacture, install, treat, release, store or dispose of any Hazardous Material, except in compliance with all applicable Environmental Laws or where the failure to comply could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. If the Administrative Agent at any time has a reasonable basis to believe that there is any material violation by the Borrower of any Environmental Law or the presence or release of any Hazardous Material which could result in material Environmental Liability, the Borrower shall, and shall cause each Subsidiary to, (i) cause the performance of such environmental audits and testing, and preparation of such environmental reports, at the Borrower’s sole cost and expense, as the Administrative Agent may from time to time reasonably request with respect to any parcel of real property subject to a Collateral Document that is a mortgage, deed of trust or similar instrument, which shall be conducted by Persons reasonably acceptable to the Administrative Agent and shall be in form and substance reasonably acceptable to the Administrative Agent, and (ii) permit the Administrative Agent or its representatives to have access to all such real property for the purpose of conducting, at the Borrower’s sole cost and expense, such environmental audits and testing as the Administrative Agent shall reasonably deem appropriate.
9.15Accounting Changes. The Borrower will not, and will not permit any of its Subsidiaries to, make any significant change in accounting treatment or reporting practices, except as required or permitted by GAAP.
9.16Compliance with ERISA. No ERISA Affiliate shall cause or suffer to exist (i) any event that could result in the imposition of a Lien with respect to any Title IV Plan or Multiemployer Plan or (ii) any other ERISA Event that could, in the aggregate, reasonably be expected to result in a Material Adverse Effect. Neither the Borrower nor any of its Subsidiaries shall cause or suffer to exist any event that could result in the imposition of a Lien with respect to any Benefit Plan.
9.17Restriction of Amendments to Certain Documents. The Borrower will not, nor will it permit any of its Private Subsidiaries to, amend or otherwise modify, or waive any rights under, any other Contract if, in any case, such amendment, modification or waiver could reasonably be expected to be materially adverse to, a Lien on any Collateral securing the Obligations.
9.18Sanctions; Anti-Corruption Use of Proceeds.
(a)Neither the Borrower or any of its Subsidiaries or their respective agents shall (i) conduct any business or engage in any transaction or dealing with any Sanctioned Person, including the making or receiving any contribution of funds, goods or services to or for the benefit of any Sanctioned Person; (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to any Sanctions; or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or

-64-

­SC1:5266419.14


avoiding, or attempts to violate, any of the prohibitions set forth any Sanctions, the Patriot Act or any other Anti-Terrorism Law.
(b)The Borrower will not, directly or, to the knowledge of the Borrower, indirectly, use the proceeds of the Loans, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person, (i) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any applicable anti-corruption Law, or (ii) (A) for the purpose of funding any activities or business of or with any Person, or in any country or territory, that, at the time of such funding, is, or whose government is, the subject of country- or territory-wide Sanctions, in violation of Sanctions or (B) in any other manner that would result in a violation of Sanctions by any party to this Agreement.
9.19Closing Date Equity Interests. The Borrower will not, at any time, cease to directly own the Equity Interests that it owns as of the date hereof as set forth on Schedule 9.19 (the “Closing Date Equity Interests”); provided, however, that the Borrower may sell or otherwise dispose of such Closing Date Equity Interests in a transaction permitted under Section 9.09 so long as the consideration for such sale or disposition is at least equal to the fair market value of the Closing Date Equity Interests being sold and the Borrower has sufficient cash on hand to comply with the mandatory prepayment provisions of Section 3.03.

9.20Margin Stock. The Borrower shall not, nor shall it permit any of its Subsidiaries to, purchase or carry Margin Stock, with the exception of the Equity Interests held by the Borrower in Avenue Therapeutics, Inc., Checkpoint Therapeutics, Inc., Mustang Bio, Inc. or any Private Subsidiary that becomes a Public Subsidiary from time to time.

Section 10.
FINANCIAL COVENANTS
10.01Minimum Liquidity. The Borrower shall at all times maintain the Minimum Liquidity Amount in cash and, after the Account Control Agreement Completion Date, in one or more Controlled Accounts that is free and clear of all Liens, other than Liens granted hereunder in favor of the Administrative Agent.
10.02Minimum Revenue. Beginning with the fiscal quarter of the Borrower ending on March 31, 2021, as of the last day of each fiscal quarter of the Borrower, and for so long as JMC is a Subsidiary of Borrower, the Revenue of JMC for the twelve (12) consecutive month period ending on the last day of such fiscal quarter, shall not be less than the corresponding amount set forth opposite such fiscal quarter on Schedule 3 (the “Minimum Revenue Covenant”).

-65-

­SC1:5266419.14


Section 11.
EVENTS OF DEFAULT
11.01Events of Default. Each of the following events shall constitute an “Event of Default”:
(a)Principal or Interest Payment Default. The Borrower shall fail to pay any principal of or interest on the Loan, when and as the same shall become due and payable, whether at the due date thereof, at a date fixed for prepayment thereof or otherwise.
(b)Other Payment Defaults. The Borrower shall fail to pay any Obligation (other than an amount referred to in Section 11.01(a)) when and as the same shall become due and payable, and such failure shall continue unremedied for a period of three (3) Business Days.
(c)Representations and Warranties. Any representation or warranty made or deemed made by or on behalf of the Borrower or any of its Subsidiaries in or in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof, shall: (i) prove to have been incorrect when made or deemed made to the extent that such representation or warranty contains any materiality or Material Adverse Effect qualifier; or (ii) prove to have been incorrect in any material respect when made or deemed made to the extent that such representation or warranty does not otherwise contain any materiality or Material Adverse Effect qualifier.
(d)Certain Covenants. The Borrower shall fail to observe or perform any covenant, condition or agreement contained in 8.02, 8.03 (with respect to the Borrower’s existence), 8.10, 8.11, 8.13, 8.15, 8.16, Section 9 or Section 10.
(e)Other Covenants. The Borrower shall fail to observe or perform any covenant, condition or agreement contained in this Agreement (other than those specified in Section 11.01(a), (b) or (d)) or any other Loan Document, and, in the case of any failure that is capable of cure, such failure shall continue unremedied for a period of thirty (30) or more days.
(f)Payment Default on Other Indebtedness. The Borrower or any of its Private Subsidiaries shall fail to make any payment (whether of principal or interest and regardless of amount) in respect of any Material Indebtedness, when and as the same shall become due and payable after giving effect to any applicable grace or cure period as originally provided by the terms of such Indebtedness.
(g)Other Defaults on Other Indebtedness. (i) Any material breach of, or “event of default” or similar event under, any Contract governing any Material Indebtedness shall occur and such breach or “event of default” or similar event shall continue unremedied, uncured or unwaived after the expiration of any grace or cure period thereunder, or (ii) any event or condition occurs (x) that results in any Material Indebtedness becoming due prior to its scheduled maturity or (y) that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of such Material Indebtedness or any trustee or agent on its or their behalf to cause such Material Indebtedness to become due, or to require the prepayment,

-66-

­SC1:5266419.14


repurchase, redemption or defeasance thereof, prior to its scheduled maturity; provided that this Section 11.01(g) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the property or assets securing such Material Indebtedness.
(h)Insolvency, Bankruptcy, Etc.
(i)The Borrower or any of its Material Subsidiaries becomes insolvent, or generally does not or becomes unable to pay its debts or meet its liabilities as the same become due, or admits in writing its inability to pay its debts generally, or declares any general moratorium on its indebtedness, or proposes a compromise or arrangement or deed of company arrangement between it and any class of its creditors.
(ii)The Borrower or any of its Material Subsidiaries commits an act of bankruptcy or makes an assignment of its property for the general benefit of its creditors or makes a proposal (or files a notice of its intention to do so).
(iii)The Borrower or any of its Material Subsidiaries institutes any proceeding seeking to adjudicate it an insolvent, or seeking liquidation, dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection, moratorium, relief, stay of proceedings of creditors generally (or any class of creditors), or composition of it or its debts or any other relief, under any Law, whether U.S. or non-U.S., now or hereafter in effect relating to bankruptcy, winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law or in equity, or files an answer admitting the material allegations of a petition filed against it in any such proceeding.
(iv)The Borrower or any of its Material Subsidiaries applies for the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager, sequestrator, conservator, custodian, administrator, trustee, liquidator, voluntary administrator, receiver and manager or other similar official for it or any substantial part of its property.
(v)Any petition is filed, application made or other proceeding instituted against or in respect of the Borrower or any of its Material Subsidiaries:
(A)seeking to adjudicate it as insolvent;
(B)seeking a receiving order against it;
(C)seeking liquidation, dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection, moratorium, relief, stay of proceedings of creditors generally (or any class of creditors), deed of company arrangement or composition of it or its debts or any other relief under any Law, whether U.S. or non-U.S., now or hereafter in effect relating to bankruptcy, winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law or in equity; or
(D)seeking the entry of an order for relief or the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager, sequestrator, conservator,

-67-

­SC1:5266419.14


custodian, administrator, trustee, liquidator, voluntary administrator, receiver and manager or other similar official for it or any substantial part of its property,

and such petition, application or proceeding continues undismissed, or unstayed and in effect, for a period of forty-five (45) days after the institution thereof; provided that if an order, decree or judgment is granted or entered (whether or not entered or subject to appeal) against the Borrower or such Subsidiary thereunder in the interim, such grace period will cease to apply; provided, further, that if the Borrower or Material Subsidiary files an answer admitting the material allegations of a petition filed against it in any such proceeding, such grace period will cease to apply.

(vi)Any other event occurs which, under the Laws of any applicable jurisdiction, has an effect equivalent to any of the events referred to in this Section 11.01(h).
(i)Judgments. One or more judgments for the payment of money in an aggregate amount in excess of $5,000,000 (or the Equivalent Amount in other currencies) (except to the extent fully covered (other than to the extent of customary deductibles) by insurance pursuant to which the insurer has not denied coverage) shall be rendered against the Borrower or any of its Subsidiaries or any combination thereof and the same shall remain undischarged for a period of forty-five (45) calendar days during which execution shall not be effectively stayed, or any action shall be legally taken by a judgment creditor to attach or levy upon any assets of the Borrower to enforce any such judgment.
(j)ERISA. An ERISA Event shall have occurred that when taken together with all other ERISA Events that have occurred, could reasonably be expected to result in liability of the Borrower and its Subsidiaries in an aggregate amount in excess of $5,000,000 (or the Equivalent Amount in other currencies).
(k)Change of Control. A Change of Control shall have occurred.
(l)[Reserved].
(m)Impairment of Security, Etc. If any of the following events occurs: (i) Any Lien created by any of the Security Documents shall at any time not constitute a valid and perfected Lien on the applicable Collateral in favor of the Secured Parties, free and clear of all other Liens (other than Permitted Liens) except due to the action or inaction of the Administrative Agent, (ii) except for expiration in accordance with its terms, any of the Security Documents shall for whatever reason cease to be in full force and effect or (iii) the Borrower shall, directly or indirectly, contest in any manner such effectiveness, validity, binding nature or enforceability of any such Lien or any Loan Document.
11.02Remedies.
(a)Defaults Other Than Bankruptcy Defaults. Upon the occurrence of any Event of Default, then, and in every such event (other than an Event of Default described in Section 11.01(h)), and at any time thereafter during the continuance of such event, the Administrative Agent may, by notice to the Borrower, declare the Loans then outstanding to be due and payable

-68-

­SC1:5266419.14


in whole (or in part, in which case any principal not so declared to be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and all fees and other Obligations, including any applicable Prepayment Fee, shall become due and payable immediately (in the case of the Loans, at the Prepayment Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower.
(b)Bankruptcy Defaults. In case of an Event of Default described in Section 11.01(h), the principal of the Loans then outstanding, together with accrued interest thereon and all fees and other Obligations, including any applicable Prepayment Fee, shall automatically become due and payable immediately (in the case of the Loans, at the Prepayment Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower.
11.03[Reserved].
11.04Minimum Revenue Covenant Cure.
(a)Notwithstanding anything to the contrary contained in Section 11.02, in the event the Borrower fails to comply with the requirements of the Minimum Revenue Covenant, during the period from the end of the relevant fiscal quarter until the expiration of the tenth Business Day subsequent to the date the financial statements are required to be delivered pursuant to Section 8.01(a) or 8.01(b), the Borrower shall have the right to make a Revenue Cure Payment (the “Minimum Revenue Cure Right”); provided, that the Borrower may exercise the Minimum Revenue Cure Right on a maximum of two (2) occasions while the Obligations remain outstanding. Upon the Administrative Agent’s receipt of the applicable Revenue Cure Payment, the Borrower shall then be in compliance with the requirements of the Minimum Revenue Covenant and the Borrower shall be deemed to have satisfied the requirements of the Minimum Revenue Covenant as of the relevant date of determination with the same effect as though there had been no failure to comply therewith at such date, and the applicable breach of the Minimum Revenue Covenant and any related default that had occurred shall be deemed cured for the purposes of this Agreement. Any Revenue Cure Payment shall be applied to the prepayment of the Loans.
(b)Upon the Administrative Agent’s receipt of a notice from the Borrower that it intends to exercise the Minimum Revenue Cure Right (a “Notice of Intent to Cure Revenue Covenant”), until the tenth Business Day subsequent to the date the financial statements are required to be delivered pursuant to Section 8.01(a) or 8.01(b) to which such Notice of Intent to Cure Revenue Covenant relates, neither the Administrative Agent nor any Lender shall exercise the right to accelerate payment of the Loans or terminate the Commitments and neither the Administrative Agent nor any other Lender shall exercise any right to foreclose on or take possession of the Collateral solely on the basis of an allegation of an Event of Default having occurred and being continuing under Section 11.01(d) due to failure by the Borrower to comply with the requirements of the Minimum Revenue Covenant for the applicable period but no Lender shall be required to extend any credit pursuant to its Commitment during such period. If within such ten Business Day period, the Oaktree Lender declines the exercise by the Borrower

-69-

­SC1:5266419.14


of the Minimum Revenue Cure Right by written notice to the Administrative Agent and the Borrower to that effect, then the Borrower shall be deemed to have satisfied the requirements of the Minimum Revenue Covenant as of the relevant date of determination with the same effect as though there had been no failure to comply therewith at such date, and the applicable breach of the Minimum Revenue Covenant and any related default that had occurred shall be deemed cured for the purposes of this Agreement.
11.05Payment of Prepayment Fee and Specified Return Shortfall. Notwithstanding anything in this Agreement to the contrary, the Prepayment Fee and Specified Return Shortfall shall automatically be due and payable at any time the Obligations become due and payable prior to the Maturity Date in accordance with the terms hereof as though such Indebtedness was voluntarily prepaid and shall constitute part of the Obligations, whether due to acceleration pursuant to the terms of this Agreement (in which case it shall be due immediately, upon the giving of notice to Borrower in accordance with Section 11.02(a), or automatically, in accordance with Section 11.02(b)), by operation of law or otherwise (including, without limitation, on account of any bankruptcy filing), in view of the impracticability and extreme difficulty of ascertaining the actual amount of damages to the Lenders or profits lost by the Lenders as a result of such acceleration, and by mutual agreement of the parties as to a reasonable estimation and calculation of the lost profits or damages of the Lenders as a result thereof. Any Prepayment Fee payable pursuant to this Agreement and Specified Return Shortfall payable pursuant to the Fee Letter shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination, acceleration or prepayment and the Borrower agrees that such Prepayment Fee and Specified Return Shortfall are reasonable under the circumstances currently existing. The Prepayment Fee and Specified Return Shortfall shall also be payable in the event the Obligations (and/or this Agreement) are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure or by any other means. The Borrower hereby waives the provisions of any present or future statute or law that prohibits or may prohibit the collection of the prepayment fee OR Specified Return Shortfall and any defense to payment, whether such defense may be based in public policy, ambiguity, or otherwise. The Borrower, the Administrative Agent and the Lenders acknowledge and agree that any Prepayment Fee and Specified Return Shortfall due and payable in accordance with this Agreement shall not constitute unmatured interest, whether under Section 5.02(b)(3) of the Bankruptcy Code or otherwise. The Borrower further acknowledges and agrees, and waives any argument to the contrary, that payment of such amount does not constitute a penalty or an otherwise unenforceable or invalid obligation. The Borrower expressly agrees that (i) the Prepayment Fee and Specified Return Shortfall are reasonable and is the product of an arm’s-length transaction between sophisticated business people, ably represented by counsel, (ii) the Prepayment Fee and Specified Return Shortfall shall be payable notwithstanding the then prevailing market rates at the time payment is made, (iii) there has been a course of conduct between the Lenders and the Borrower giving specific consideration in this transaction for such agreement to pay the Prepayment Fee and Specified Return Shortfall, (iv) the Borrower shall be estopped hereafter from claiming differently than as agreed to in this Section 11.05, (v) their agreement to pay the Prepayment Fee and Specified Return Shortfall is a material inducement to the Lenders to make the Loans, and (vi) the Prepayment Fee and Specified Return Shortfall represent a good faith, reasonable estimate and

-70-

­SC1:5266419.14


calculation of the lost profits, losses or other damages of the Lenders and that it would be impractical and extremely difficult to ascertain the actual amount of damages to the Lenders or profits lost by the Lenders as a result of such event.

Section 12.
THE ADMINISTRATIVE AGENT
12.01Appointment and Duties. Subject in all cases to clause (c) below:
(a)Appointment of the Administrative Agent. Each of the Lenders hereby irrevocably appoints Oaktree Fund Administration, LLC (together with any successor Administrative Agent pursuant to Section 12.09) as the Administrative Agent hereunder and authorizes the Administrative Agent to (i) execute and deliver the Loan Documents and accept delivery thereof on its behalf from the Borrower or any of its Subsidiaries, (ii) take such action on its behalf and to exercise all rights, powers and remedies and perform the duties as are expressly delegated to the Administrative Agent under such Loan Documents and (iii) exercise such powers as are reasonably incidental thereto. Except as expressly set forth herein, the provisions of this Section 12 are solely for the benefit of the Administrative Agent and the Lenders, and neither the Borrower nor any Affiliate thereof shall have rights as a third-party beneficiary of any such provisions.
(b)Duties as Collateral and Disbursing Agent. Without limiting the generality of Section 12.01(a), the Administrative Agent shall have the sole and exclusive right and authority (to the exclusion of the Lenders), and is hereby authorized, to (i) act as the disbursing and collecting agent for the Lenders with respect to all payments and collections arising in connection with the Loan Documents (including in any proceeding described in Section 11.01(h) or any other bankruptcy, insolvency or similar proceeding), and each Person making any payment in connection with any Loan Document to any Secured Party is hereby authorized to make such payment to the Administrative Agent, (ii) file and prove claims and file other documents necessary or desirable to allow the claims of the Secured Parties with respect to any Obligation in any proceeding described in Section 11.01(h) or any other bankruptcy, insolvency or similar proceeding (but not to vote, consent or otherwise act on behalf of such Secured Party), (iii) act as collateral agent for each Secured Party for purposes of acquiring, holding, enforcing and perfecting all Liens created by the Loan Documents and all other purposes stated therein, (iv) manage, supervise and otherwise deal with the Collateral, (v) take such other action as is necessary or desirable to maintain the perfection and priority of the Liens created or purported to be created by the Loan Documents, (vi) except as may be otherwise specified in any Loan Document, exercise all remedies given to the Administrative Agent and the other Secured Parties with respect to the Collateral, whether under the Loan Documents, applicable Laws or otherwise and (vii) execute any amendment, consent or waiver under the Loan Documents on behalf of any Lender that has consented in writing to such amendment, consent or waiver; provided that the Administrative Agent hereby appoints, authorizes and directs each Lender to act as collateral sub-agent for the Administrative Agent and the Lenders for purposes of the perfection of all Liens with respect to the Collateral, including any deposit account maintained by the Borrower with, and cash and Permitted Cash Equivalents Investments held by, such Lender, and may further authorize and direct the Lenders to take further actions as collateral sub-agents for

-71-

­SC1:5266419.14


purposes of enforcing such Liens or otherwise to transfer the Collateral subject thereto to the Administrative Agent, and each Lender hereby agrees to take such further actions to the extent, and only to the extent, so authorized and directed.
(c)Limited Duties. The Lenders and the Borrower hereby each acknowledge and agree that the Administrative Agent (i) has undertaken its role hereunder purely as an accommodation to the parties hereto and the Transactions, (ii) is receiving no compensation for undertaking such role and (iii) subject only to the notice provisions set forth in Section 12.09, may resign from such role at any time for any reason or no reason whatsoever. Without limiting the foregoing, the parties hereto further acknowledge and agree that under the Loan Documents, the Administrative Agent (i) is acting solely on behalf of the Lenders (except to the limited extent provided in Section 12.11), with duties that are entirely administrative in nature, notwithstanding the use of the defined term “the Administrative Agent”, the terms “agent”, “administrative agent” and “collateral agent” and similar terms in any Loan Document to refer to the Administrative Agent, which terms are used for title purposes only, (ii) is not assuming any duty or obligation under any Loan Document other than as expressly set forth therein or any role as agent, fiduciary or trustee of or for any Lender or any other Secured Party and (iii) shall have no implied functions, responsibilities, duties, obligations or other liabilities under any Loan Document (fiduciary or otherwise), in each case, regardless of whether a Default has occurred and is continuing, and each Lender hereby waives and agrees not to assert any claim against the Administrative Agent based on the roles, duties and legal relationships expressly disclaimed in this clause (c). Without in any way limiting the foregoing, the Administrative Agent shall not, except as expressly set forth in this Agreement and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.
12.02Binding Effect. Each Lender agrees that (i) any action taken by the Administrative Agent or the Majority Lenders (or, if expressly required hereby, a greater proportion of the Lenders) in accordance with the provisions of the Loan Documents, (ii) any action taken by the Administrative Agent in reliance upon the instructions of the Majority Lenders (or, where so required, such greater proportion) and (iii) the exercise by the Administrative Agent or the Majority Lenders (or, where so required, such greater proportion) of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of the Secured Parties.
12.03Use of Discretion.
(a)No Action without Instructions. The Administrative Agent shall not be required to exercise any discretion or take, or to omit to take, any action, including with respect to enforcement or collection, except (subject to clause (b) below) any action it is required to take or omit to take (i) under any Loan Document or (ii) pursuant to written instructions from the Majority Lenders (or, where expressly required by the terms of this Agreement, a greater proportion of the Lenders).

-72-

­SC1:5266419.14


(b)Right Not to Follow Certain Instructions. Notwithstanding Section 12.03(a) or any other term or provision of this Section 12, the Administrative Agent shall not be required to take, or to omit to take, any action (i) unless, upon demand, the Administrative Agent receives an indemnification satisfactory to it from the Lenders (or, to the extent applicable and acceptable to the Administrative Agent, any other Secured Party) against all liabilities that, by reason of such action or omission, may be imposed on, incurred by or asserted against the Administrative Agent or any Related Party thereof or (ii) that is, in the opinion of the Administrative Agent, in its sole and absolute discretion, contrary to any Loan Document, Law or the best interests of the Administrative Agent or any of its Affiliates or Related Parties, including, for the avoidance of doubt, any action that may be in violation of the automatic stay in connection with any Insolvency Proceeding.
12.04Delegation of Rights and Duties. The Administrative Agent may, upon any term or condition it specifies, delegate or exercise any of its rights, powers and remedies under, and delegate or perform any of its duties or any other action with respect to, any Loan Document by or through any trustee, co-agent, employee, attorney-in-fact and any other Person (including any Secured Party). The Administrative Agent and any such Person may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. Any such Person and its Related Parties shall benefit from this Section 12 to the extent provided by the Administrative Agent; provided, however, that the exculpatory provisions of this Section 12 shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and of any such sub-agent, and shall apply to their respective activities in connection with their activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and non-appealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.
12.05Reliance and Liability.
(a)the Administrative Agent may, without incurring any liability hereunder, (i) consult with any of its Related Parties and, whether or not selected by it, any other advisors, accountants and other experts (including advisors to, and accountants and experts engaged by, the Borrower) and (ii) rely and act upon any notice, request, certificate, consent, statement, instrument, document or other writing (including and electronic message, Internet or intranet website posting or other distribution), telephone message or conversation or oral conversation, in each case believed by it to be genuine and transmitted, signed or otherwise authenticated by the appropriate parties. In determining compliance with any condition hereunder to the making of a Loan that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative Agent may presume that such condition is satisfactory to such Lender unless the Administrative Agent shall have received written notice to the contrary from such Lender prior to the making of such Loan.
(b)Neither the Administrative Agent nor any of its Related Parties shall be liable for any action taken or omitted to be taken by any of them under or in connection with any Loan Document, and each Lender and the Borrower hereby waive and shall not assert any right, claim or cause of action based thereon, except to the extent of liabilities resulting primarily from the

-73-

­SC1:5266419.14


fraudulent conduct or behavior of the Administrative Agent or, as the case may be, such Related Party (each as determined in a final, non-appealable judgment or order by a court of competent jurisdiction) in connection with the duties expressly set forth herein. Without limiting the foregoing, the Administrative Agent:
(i)shall not be responsible or otherwise incur liability for any action or omission taken in reliance upon the instructions of, or with the consent of, the Majority Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith to be necessary, under the circumstances as provided in Section 13.04) or for the actions or omissions of any of its Related Parties selected with reasonable care (other than employees, officers and directors of the Administrative Agent, when acting on behalf of the Administrative Agent);
(ii)shall not be responsible to any Secured Party for the (a) validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document, or (b) due execution, legality, validity, enforceability, effectiveness, genuineness, sufficiency or value of, or the attachment, perfection or priority of any Lien created or purported to be created under or in connection with, any Loan Document;
(iii)makes no warranty or representation, and shall not be responsible, to any Secured Party for, and shall not have any duty to ascertain or inquire into, any statement, document, information, certificate, report, representation or warranty made or furnished by or on behalf of any Related Party, in or in connection with any Loan Document or any transaction contemplated therein, whether or not transmitted by the Administrative Agent, including as to completeness, accuracy, scope or adequacy thereof, or for the scope, nature or results of any due diligence performed by the Administrative Agent in connection with the Loan Documents, including, for the avoidance of doubt, the satisfaction of any condition set forth in Section 6 of this Agreement or elsewhere herein (other than to confirm receipt of items expressly required to be delivered to the Administrative Agent); and
(iv)shall not have any duty to ascertain or to inquire as to the performance or observance of any provision of any Loan Document or whether any condition set forth in any Loan Document is satisfied or waived, including, without limiting the generality of the foregoing, as to the financial condition of the Borrower or as to the existence or continuation or possible occurrence or continuation of any Default or Event of Default and shall not be deemed to have notice or knowledge of such occurrence or continuation unless it has received a notice from the Borrower, any Lender describing such Default or Event of Default clearly labeled “notice of default” (in which case the Administrative Agent shall promptly give notice of such receipt to all Lenders);

and, for each of the items set forth in clauses (i) through (iv) above, each Lender and the Borrower hereby waives and agrees not to assert any right, claim or cause of action it might have against the Administrative Agent based thereon.

12.06Administrative Agent Individually. The Administrative Agent and its Affiliates may make loans and other extensions of credit to, acquire stock and stock equivalents of, accept

-74-

­SC1:5266419.14


deposits from, act as the financial advisor for or in any other advisory capacity for, or engage in any kind of business with, the Borrower or Affiliate thereof as though it were not acting as the Administrative Agent and may receive separate fees and other payments therefor. To the extent the Administrative Agent or any of its Affiliates makes any Loan or otherwise becomes a Lender hereunder, it shall have and may exercise the same rights and powers hereunder and shall be subject to the same obligations and liabilities as any other Lender and the terms “Lender”, “Majority Lender”, and any similar terms shall, except where otherwise expressly provided in any Loan Document, include, without limitation, the Administrative Agent or such Affiliate, as the case may be, in its individual capacity as Lender or as one of the Majority Lenders, respectively.

12.07Lender Credit Decision. Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent, any Lender or any of their Related Parties or upon any document solely or in part because such document was transmitted by the Administrative Agent or any of its Related Parties, conducted its own independent investigation of the financial condition and affairs of the Borrower and has made and continues to make its own credit decisions in connection with entering into, and taking or not taking any action under, any Loan Document or with respect to any transaction contemplated in any Loan Document, in each case based on such documents and information as it shall deem appropriate.
12.08Expenses; Indemnities.
(a)Each Lender agrees to reimburse the Administrative Agent and each of its Related Parties (to the extent not reimbursed by the Borrower) promptly upon demand for such Lender’s Proportionate Share of any costs and expenses (including fees, charges and disbursements of financial, legal and other advisors and Other Taxes paid in the name of, or on behalf of, the Borrower) that may be incurred by the Administrative Agent or any of its Related Parties in connection with the preparation, syndication, execution, delivery, administration, modification, consent, waiver or enforcement (whether through negotiations, through any work-out, bankruptcy, restructuring or other legal or other proceeding or otherwise) of, or legal advice in respect of its rights or responsibilities under, any Loan Document.
(b)Each Lender further agrees to indemnify the Administrative Agent (or any sub-agent thereof) and any Related Parties of the Administrative Agent (or any such sub-agent) (to the extent not indefeasibly paid by the Borrower), from and against such Lender’s aggregate Proportionate Share of the liabilities (including taxes, interests and penalties imposed for not properly withholding or backup withholding on payments made to on or for the account of any Lender) that may be imposed on, incurred by or asserted against the Administrative Agent (or any sub-agent thereof) or any Related Parties of the Administrative Agent (or any such sub-agent) in any matter relating to or arising out of, in connection with or as a result of any Loan Document, any Related Document or any other act, event or transaction related, contemplated in or attendant to any such document, or, in each case, any action taken or omitted to be taken by the Administrative Agent (or any sub-agent thereof) or any Related Parties of the Administrative Agent (or any such sub-agent) under or with respect to any of the foregoing; provided that no Lender shall be liable to the Administrative Agent (or any sub-agent thereof) or any Related Parties of the Administrative Agent (or any such sub-agent) to the extent such liability has

-75-

­SC1:5266419.14


resulted primarily from the gross negligence or willful misconduct of the Administrative Agent (or any sub-agent thereof) or, as the case may be, such Related Parties of the Administrative Agent (or any sub-agent thereof), as determined by a court of competent jurisdiction in a final non-appealable judgment or order.
12.09Resignation of the Administrative Agent.
(a)At any time upon not less than 30 days’ prior written notice, the Administrative Agent may resign as the “the Administrative Agent” hereunder, in whole or in part (in the sole and absolute discretion of the Administrative Agent). If the Administrative Agent delivers any such notice, the Majority Lenders shall have the right, in consultation with the Borrower, to appoint a successor, which shall be (i) a Lender holding at least thirty percent (30%) of the outstanding principal amount of the Loans or any Affiliate thereof or (ii) any other financial institution consented to by the Borrower (provided that the consent of the Borrower shall not be required to the extent an Event of Default has occurred and is continuing). If a successor Administrative Agent has not been appointed on or before the effectiveness of the resignation of the resigning Administrative Agent (or such earlier date as shall be agreed by the Majority Lenders) (the “Resignation Effective Date”), then the resigning Administrative Agent may (but shall not be obligated to), on behalf of the Lenders, appoint any Person reasonably chosen by it as the successor Administrative Agent, notwithstanding whether the Majority Lenders have appointed a successor or the Borrower has consented to such successor. Whether or not a successor has been appointed, such resignation shall become effective on the Resignation Effective Date.
(b)Effective from the Resignation Effective Date, (i) the resigning Administrative Agent shall be discharged from its duties and obligations under the Loan Documents to the extent set forth in the applicable resignation notice, (ii) the Lenders shall assume and perform all of the duties of the Administrative Agent until a successor Administrative Agent shall have accepted a valid appointment hereunder, (iii) the resigning Administrative Agent and its Related Parties shall no longer have the benefit of any provision of any Loan Document other than with respect to (x) any actions taken or omitted to be taken while such resigning Administrative Agent was, or because the Administrative Agent had been, validly acting as the Administrative Agent under the Loan Documents or (y) any continuing duties such resigning Administrative Agent will continue to perform, and (iv) subject to its rights under Section 12.04, the resigning Administrative Agent shall take such action as may be reasonably necessary to assign to the successor Administrative Agent its rights as the Administrative Agent under the Loan Documents. Effective immediately upon its acceptance of a valid appointment as the Administrative Agent, a successor Administrative Agent shall succeed to, and become vested with, all the rights, powers, privileges and duties of the resigning Administrative Agent under the Loan Documents.
12.10Release of Collateral or Guarantors. Each Lender hereby consents to the release and hereby directs the Administrative Agent to release any Lien held by the Administrative Agent for the benefit of the Secured Parties against (i) any Collateral that is disposed of by the Borrower in an Asset Sale permitted by the Loan Documents (including pursuant to a valid waiver or consent), and (ii) all of the Collateral, upon (x) termination of the Commitments and (y) payment

-76-

­SC1:5266419.14


and satisfaction in full of all Loans and all other Obligations that the Administrative Agent has been notified in writing are then due and payable (other than Warrant Obligations and inchoate indemnification and expense reimbursement obligations for which no claim has been made).

Each Lender hereby directs the Administrative Agent, and the Administrative Agent hereby agrees, upon receipt of reasonable advance notice from the Borrower, to execute and deliver or file such documents and to perform other actions reasonably necessary to release the guarantees and Liens when and as directed in this Section 12.10.

12.11Additional Secured Parties. The benefit of the provisions of the Loan Documents directly relating to the Collateral or any Lien granted thereunder shall extend to and be available to any Secured Party that is not a Lender as long as, by accepting such benefits, such Secured Party agrees, as among the Administrative Agent and all other Secured Parties, that such Secured Party is bound by (and, if requested by the Administrative Agent, shall confirm such agreement in a writing in form and substance acceptable to the Administrative Agent) this Section 12 and the decisions and actions of the Administrative Agent and the Majority Lenders (or, where expressly required by the terms of this Agreement, a greater proportion of the Lenders) to the same extent a Lender is bound; provided that, notwithstanding the foregoing, (i) such Secured Party shall be bound by Section 12.08 only to the extent of Liabilities, costs and expenses with respect to or otherwise relating to the Collateral held for the benefit of such Secured Party, in which case the obligations of such Secured Party thereunder shall not be limited by any concept of pro rata share or similar concept, (ii) each of the Administrative Agent and each Lender shall be entitled to act at its sole discretion, without regard to the interest of such Secured Party, regardless of whether any Obligation to such Secured Party thereafter remains outstanding, is deprived of the benefit of the Collateral, becomes unsecured or is otherwise affected or put in jeopardy thereby, and without any duty or liability to such Secured Party or any such Obligation and (iii) such Secured Party shall not have any right to be notified of, consent to, direct, require or be heard with respect to, any action taken or omitted in respect of the Collateral or under any Loan Document.

12.12Agent May File Proofs of Claim. In case of the pendency of any Insolvency Proceeding or any other judicial proceeding relating to the Borrower, the Administrative Agent (irrespective of whether the principal of any Loan shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered (but not obligated) by intervention or such proceeding or otherwise:

(a)to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent under Section 13.03) allowed in such judicial proceeding; and

-77-

­SC1:5266419.14


(b)to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same;

and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due to the Administrative Agent under Section 13.03.

Section 13.
MISCELLANEOUS
13.01No Waiver. No failure on the part of the Administrative Agent or the Lenders to exercise and no delay in exercising, and no course of dealing with respect to, any right, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege under any Loan Document preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.
13.02Notices. All notices, requests, instructions, directions and other communications provided for herein (including any modifications of, or waivers, requests or consents under, this Agreement) or in the other Loan Documents shall be given or made in writing (including by telecopy or email) delivered, if to the Borrower, the Administrative Agent or any Lender, to its address specified on the signature pages hereto or at such other address as shall be designated by such party in a written notice to the other parties. Except as otherwise provided in this Agreement or therein, all such communications shall be deemed to have been duly given upon receipt of a legible copy thereof, in each case given or addressed as aforesaid. All such communications provided for herein by telecopy shall be confirmed in writing promptly after the delivery of such communication (it being understood that non-receipt of written confirmation of such communication shall not invalidate such communication).
13.03Expenses, Indemnification, Etc.
(a)Expenses. The Borrower agrees to pay or reimburse (i) the Administrative Agent and the Lenders and their respective Affiliates for all of their reasonable and documented out of pocket costs and expenses (including the reasonable and documented out of pocket fees, expenses, charges and disbursements of Sullivan & Cromwell LLP, counsel to the Lenders, the fees (if necessary) of local counsel for both of the Administrative Agent and the Lenders in each relevant material jurisdiction, and any sales, goods and services or other similar taxes applicable thereto, and reasonable and documented printing, reproduction, document delivery, communication and travel costs) in connection with (x) the negotiation, preparation, execution and delivery of this Agreement and the other Loan Documents and the making of the Loans (exclusive of post-closing costs), (y) post-closing costs (including, without limitation, costs of the administration of this Agreement and the other Loan Documents) and (z) the negotiation or

-78-

­SC1:5266419.14


preparation of any modification, supplement or waiver of any of the terms of this Agreement or any of the other Loan Documents (whether or not consummated) and (ii) each of the Administrative Agent and the Lenders for all of their documented out of pocket costs and expenses (including the fees and expenses of any legal counsel) in connection with the enforcement, exercise or protection of their rights in connection with this Agreement and the other Loan Documents, including their rights under this Section 13.03, or in connection with the Loans made hereunder, including such out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans.
(b)Indemnification. The Borrower hereby agrees to indemnify the Administrative Agent (and any sub-agent thereof), the Lenders and their respective Affiliates, directors, officers, employees, attorneys, agents, advisors and controlling parties (each, an “Indemnified Party”) from and against, and agrees to hold them harmless against, any and all Claims and Losses of any kind including reasonable and documented out of pocket fees and disbursements of any counsel for each Indemnified Party, joint or several, that may be incurred by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection with or relating to (i) this Agreement or any of the other Loan Documents or the Transactions, (ii) any use made or proposed to be made with the proceeds of the Loans, (ii) any actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by the Borrower or any of its Subsidiaries, or (iv) any actual or prospective claim, investigation, litigation or proceeding relating to any of the foregoing, whether based on contract, tort, or any other theory, whether or not such investigation, litigation or proceeding is brought by the Borrower, any of its Subsidiaries, shareholders or creditors, an Indemnified Party or any other Person, or an Indemnified Party is otherwise a party thereto, and whether or not any of the conditions precedent set forth in Section 6 are satisfied or the other transactions contemplated by this Agreement are consummated, except to the extent such Claim or Loss is found in a final, non-appealable judgment by a court of competent jurisdiction to have resulted from such Indemnified Party’s gross negligence or willful misconduct. The Borrower shall not assert any claim against any Indemnified Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the Transactions or the actual or proposed use of the proceeds of the Loans. The Borrower, its Subsidiaries and Affiliates and their respective directors, officers, employees, attorneys, agents, advisors and controlling parties are each sometimes referred to in this Agreement as a “Borrower Party”. No Lender shall assert any claim against any Borrower Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the Transactions or the actual or proposed use of the proceeds of the Loans. This Section shall not apply to Taxes other than Taxes relating to a non-Tax Claim or Loss governed by this Section 13.03(b).
13.04Amendments, Etc. Except as otherwise expressly provided in this Agreement, any provision of this Agreement and any other Loan Document (except for the Warrant, which may be amended, waived or supplemented in accordance with the terms thereof) may be modified or supplemented only by an instrument in writing signed by the Borrower, the Administrative Agent and the Majority Lenders; provided that:

-79-

­SC1:5266419.14


(a)any such modification or supplement that is disproportionately adverse to any Lender as compared to other Lenders or subjects any Lender to any additional obligation shall not be effective without the consent of such affected Lender;
(b)the consent of all of the Lenders shall be required to:
(i)amend, modify, discharge, terminate or waive any of the terms of this Agreement or any other Loan Document if such amendment, modification, discharge, termination or waiver would increase the amount of the Loans or Commitment, reduce the fees payable hereunder, reduce interest rates or other amounts payable with respect to the Loans, extend any date fixed for payment of principal (it being understood that the waiver of any prepayment of Loans shall not constitute an extension of any date fixed for payment of principal), interest or other amounts payable relating to the Loans or extend the repayment dates of the Loans; provided, for the avoidance of doubt, that any waiver or amendment relating to an Event of Default or Default arising out of breach or prospective breach of the Minimum Revenue Covenant shall only require the consent of the Majority Lenders;
(ii)amend, modify, discharge, terminate or waive any Security Document if the effect is to release all or substantially all of the Collateral subject thereto other than pursuant to the terms hereof or thereof; or
(iii)amend this Section 13.04 or the definition of “Majority Lenders”.
13.05Successors and Assigns.
(a)General. The provisions of this Agreement and the other Loan Documents shall be binding upon and inure to the benefit of the parties hereto or thereto and their respective successors and assigns permitted hereby or thereby, except that the Borrower may not assign or otherwise transfer any of its rights or obligations hereunder (except in connection with an event permitted under Section 9.03) without the prior written consent of the Administrative Agent. Any Lender may assign or otherwise transfer any of its rights or obligations hereunder or under any of the other Loan Documents (i) to an assignee in accordance with the provisions of Section 13.05(b), (ii) by way of participation in accordance with the provisions of Section 13.05(e), or (iii) by way of pledge or assignment of a security interest subject to the restrictions of Section 13.05(f). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in Section 13.05(e) and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement.
(b)Assignments by Lender. Any Lender may at any time assign to one or more Persons all or a portion of its rights and obligations under this Agreement (including all or a portion of the Loans at the time owing to it) and the other Loan Documents; provided that (i) no such assignment shall be made to the Borrower, any Affiliate of the Borrower, any employees or directors of the Borrower at any time and (ii) no such assignment shall be made without the prior written consent of the Administrative Agent. The consent of the Borrower (such consent not to

-80-

­SC1:5266419.14


be unreasonably withheld, conditioned or delayed) shall be required unless (x) a Default or Event of Default has occurred and is continuing at the time of such assignment or (y) such assignment is to an Eligible Transferee; provided that the Borrower shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within five (5) Business Days after having received written notice thereof. Subject to the recording thereof by the Lender pursuant to Section 13.05(d), from and after the recordation date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of the Lender under this Agreement and the other Loan Documents, and correspondingly the assigning Lender shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) and the other Loan Documents but shall continue to be entitled to the benefits of Section 5 and Section 13.03. Any assignment or transfer by the Lender of rights or obligations under this Agreement that does not comply with this Section 13.05(b) shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with Section 13.05(e). The parties to each such Assignment and Assumption shall execute and deliver to the Administrative Agent, for the Administrative Agent’s acceptance, an Assignment and Assumption, together with (i) a processing and recordation fee of $3,500, and (ii) all “know your customer” documentation and Patriot Act documentation requested by the Administrative Agent.
(c)Amendments to Loan Documents. Each of the Administrative Agent, the Lenders and the Borrower agrees to enter into such amendments to the Loan Documents, and such additional Security Documents and other instruments and agreements, in each case in form and substance reasonably acceptable to the Administrative Agent, the Lenders and the Borrower, as shall reasonably be necessary to implement and give effect to any assignment made under this Section 13.05.
(d)Register. The Administrative Agent, acting solely for this purpose as a non-fiduciary agent of the Borrower, shall maintain at one of its offices in the United States a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior written notice.
(e)Participations. Any Lender may at any time, without the consent of, or notice to, the Borrower, sell participations to any Eligible Transferee (other than a natural person or the Borrower or any of its Affiliates or Subsidiaries) (each, a “Participant”) in all or a portion of the Lender’s rights and/or obligations under this Agreement (including all or a portion of the Commitment and/or the Loans owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other

-81-

­SC1:5266419.14


parties hereto for the performance of such obligations and (iii) the Borrower shall continue to deal solely and directly with such Lender in connection therewith. Any agreement or instrument pursuant to which any Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce the Loan Documents and to approve any amendment, modification or waiver of any provision of the Loan Documents; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver that would (i) increase or extend the term of such Lender’s Commitment, (ii) extend the date fixed for the payment of principal of or interest on the Loans or any portion of any fee hereunder payable to the Participant, (iii) reduce the amount of any such payment of principal, or (iv) reduce the rate at which interest is payable thereon to a level below the rate at which the Participant is entitled to receive such interest. Subject to Section 13.05(f), the Borrower agrees that each Participant shall be entitled to the benefits of Section 5.01 or 5.03 (subject to the requirements and limitations therein, including the requirements under Section 5.03(f) (it being understood that the documentation required under Section 5.03(f) shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section 13.05(b); provided that such Participant (a) agrees to be subject to the provisions of Section 5.04 as if it were an assignee under Section 13.05(b) and (b) shall not be entitled to receive any greater payment under Section 5.01 or 5.03, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a change in Law that occurs after the Participant acquired the applicable participation. Each Lender that sells a participation agrees, at the Borrower's request and expense, to use reasonable efforts to cooperate with the Borrower to effectuate the provisions of Section 5.04(b) with respect to any Participant. To the extent permitted by Law, each Participant also shall be entitled to the benefits of Section 4.03(a) as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under the Loan Documents (the “Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant’s interest in any commitments, loans or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.
(f)Limitations on Rights of Participants. A Participant shall not be entitled to receive any greater payment under Section 5.01 or 5.03 than such Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the Borrower’s prior written consent.

-82-

­SC1:5266419.14


(g)Certain Pledges. Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under the Loan Documents to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.
13.06Survival. The obligations of the Borrower under Sections 5.01, 5.02, 5.03, 13.03, 13.05, 13.06, 13.09, 13.10, 13.11, 13.12, 13.13 and 13.14 shall survive the repayment of the Obligations and the termination of the Commitments and, in the case of the Lenders’ assignment of any interest in the Commitments or the Loans hereunder, shall survive, in the case of any event or circumstance that occurred prior to the effective date of such assignment, the making of such assignment, notwithstanding that the Lenders may cease to be “Lenders” hereunder. In addition, each representation and warranty made, or deemed to be made by a Borrowing Notice, herein or pursuant hereto shall survive the making of such representation and warranty.
13.07Captions. The table of contents and captions and section headings appearing herein are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this Agreement.
13.08Counterparts, Effectiveness. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof. This Agreement shall become effective when counterparts hereof executed on behalf of the Borrower, the Administrative Agent and the Lender shall have been received by the Administrative Agent.
13.09Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York.
13.10Jurisdiction, Service of Process and Venue.
(a)Submission to Jurisdiction. Each party hereby irremovably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or tort or otherwise, against such other party in any way relating to this Agreement or any Loan Document or the transactions relating hereto or thereto, in any forum other than the courts of the State of New York sitting in New York County, and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally submits to the jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by applicable Law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action, litigation or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.

-83-

­SC1:5266419.14


(b)Waiver of Venue, Etc. Each party hereto irrevocably waives to the fullest extent permitted by law any objection that it may now or hereafter have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Loan Document and hereby further irrevocably waives to the fullest extent permitted by law any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals has elapsed) in any such suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of which such party is or may be subject, by suit upon judgment.
13.11Waiver of Jury Trial. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.
13.12Waiver of Immunity. To the extent that the Borrower may be or become entitled to claim for itself or its property or revenues any immunity on the ground of sovereignty or the like from suit, court jurisdiction, attachment prior to judgment, attachment in aid of execution of a judgment or execution of a judgment, and to the extent that in any such jurisdiction there may be attributed such an immunity (whether or not claimed), the Borrower hereby irrevocably agrees not to claim and hereby irrevocably waives such immunity with respect to its obligations under this Agreement and the other Loan Documents.
13.13Entire Agreement. This Agreement and the other Loan Documents constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof, including any confidentiality (or similar) agreements. THE BORROWER ACKNOWLEDGES, REPRESENTS AND WARRANTS THAT IN DECIDING TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS OR IN TAKING OR NOT TAKING ANY ACTION HEREUNDER OR THEREUNDER, IT HAS NOT RELIED, AND WILL NOT RELY, ON ANY STATEMENT, REPRESENTATION, WARRANTY, COVENANT, AGREEMENT OR UNDERSTANDING, WHETHER WRITTEN OR ORAL, OF OR WITH ADMINISTRATIVE AGENT OR THE LENDERS OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS.
13.14Severability. If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by any Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof.
13.15No Fiduciary Relationship. The Borrower acknowledges that the Administrative Agent and the Lenders have no fiduciary relationship with, or fiduciary duty to, the Borrower arising out of or in connection with this Agreement or the other Loan Documents, and the relationship between the Lenders and the Borrower is solely that of creditor and debtor. This Agreement and the other Loan Documents do not create a joint venture among the parties.

-84-

­SC1:5266419.14


13.16Confidentiality. All information received from the Borrower or any Subsidiary relating to the Borrower or any Subsidiary or any of their respective businesses (the “Information”) shall be deemed non-public information for purposes of this Section 13.16 unless marked “Public.” Each of the Administrative Agent and the Lenders acknowledges that (i) the Information may include material non-public information concerning Borrower or a Subsidiary, as the case may be, (ii) it has developed compliance procedures regarding the use of material non-public information and (iii) it will handle such material non-public information in accordance with applicable Law, including United States federal and state securities Laws. The Administrative Agent and each Lender agree to keep confidential all non-public information provided to them by the Borrower pursuant to this Agreement in accordance with its customary procedures for handling material non-public information; provided that nothing herein shall prevent the Administrative Agent or any Lender from disclosing any such information (i) to the Administrative Agent, any other Lender, any Affiliate of a Lender or any Eligible Transferee or other assignee permitted under Section 13.05(b), (ii) to its employees, officers, directors, agents, attorneys, accountants, trustees and other professional advisors or those of any of its affiliates (collectively, its “Related Parties”), (iii) upon the request or demand of any Governmental Authority purporting to have jurisdiction over such Person or its Related Parties (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (iv) in response to any order of any court or other Governmental Authority or as may otherwise be required pursuant to any Law, (v) if requested or required to do so in connection with any litigation or similar proceeding, (vi) that has been publicly disclosed (other than as a result of a disclosure in violation of this Section 13.16), (vii) to the extent necessary in connection with the exercise of any remedy hereunder or under any other Loan Document, (viii) on a confidential basis to (A) any rating agency in connection with rating the Borrower or its Subsidiaries or the Loans or (B) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers of other market identifiers with respect to the Loans or (ix) to any other party hereto; provided that, in the case of disclosure pursuant to clause (iii), (iv) and (v) above, the Administrative Agent or applicable Lender, as applicable, shall promptly provide notice to the Borrower to the extent reasonable and not prohibited by Law or any applicable Governmental Authority, so that Borrower may seek a protective order.
13.17Interest Rate Limitation. Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to any Loan, together with all fees, charges and other amounts that are treated as interest on such Loan under applicable Law (collectively, “charges”), shall exceed the maximum lawful rate (the “Maximum Rate”) that may be contracted for, charged, taken, received or reserved by the Administrative Agent and the Lender holding such Loan in accordance with applicable Law, the rate of interest payable in respect of such Loan hereunder, together with all charges payable in respect thereof, shall be limited to the Maximum Rate. To the extent lawful, the interest and charges that would have been paid in respect of such Loan but were not paid as a result of the operation of this Section shall be cumulated and the interest and charges payable to such Lender in respect of other Loans or periods shall be increased (but not above the amount collectible at the Maximum Rate therefor) until such cumulated amount, together with interest thereon at the Federal Funds Effective Rate for each day to the date of repayment, shall have been received by such Lender. Any amount collected by such Lender that exceeds the maximum amount collectible at the Maximum Rate shall be applied to the reduction

-85-

­SC1:5266419.14


of the principal balance of such Loan so that at no time shall the interest and charges paid or payable in respect of such Loan exceed the maximum amount collectible at the Maximum Rate.

13.18Judgment Currency.
(a)If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder in Dollars into another currency, the parties hereto agree, to the fullest extent permitted by Law, that the rate of exchange used shall be that at which, in accordance with normal banking procedures, the Administrative Agent could purchase Dollars with such other currency at the buying spot rate of exchange in the New York foreign exchange market on the Business Day immediately preceding that on which any such judgment, or any relevant part thereof, is given.
(b)The obligations of the Borrower in respect of any sum due to the Administrative Agent hereunder and under the other Loan Documents shall, notwithstanding any judgment in a currency other than Dollars, be discharged only to the extent that on the Business Day following receipt by the Administrative Agent of any sum adjudged to be so due in such other currency the Administrative Agent may, in accordance with normal banking procedures, purchase Dollars with such other currency. If the amount of Dollars so purchased is less than the sum originally due to the Administrative Agent in Dollars, the Borrower agrees, to the fullest extent that it may effectively do so, as a separate obligation and notwithstanding any such judgment, to indemnify the Administrative Agent against such loss. If the amount of Dollars so purchased exceeds the sum originally due to the Administrative Agent in Dollars, the Administrative Agent shall remit such excess to the Borrower.
13.19USA PATRIOT Act. The Administrative Agent and the Lenders hereby notify the Borrower that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Patriot Act”), they are required to obtain, verify and record information that identifies the Borrower, which information includes the name and address of the Borrower and other information that will allow such Person to identify the Borrower in accordance with the Patriot Act.
13.20Acknowledgement and Consent to Bail-In of EEA Financial Institutions. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any EEA Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the Write-Down and Conversion Powers of an EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:
(a)the application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an EEA Financial Institution; and
(b)the effects of any Bail-In Action on any such liability, including, if applicable:

(i)

a reduction in full or in part or cancellation of any such liability;

-86-

­SC1:5266419.14


(ii)a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such EEA Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or

(i)the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of any EEA Resolution Authority.

[Signature Pages Follow]

-87-

­SC1:5266419.14


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first above written.

BORROWER:

FORTRESS BIOTECH, INC.

By:

/s/ Robyn Hunter

Name:

Robyn Hunter

Title:

Chief Financial Officer

Address for Notices:
Fortress Biotech, Inc
95 Sawyer Road, Suite 110
Waltham MA 02453
Attn: Chief Financial Officer

Phone: 781.652.4507

Email: rhunter@fortressbiotech.com

[Signature Page to Credit Agreement]

­SC1:5266419.14


ADMINISTRATIVE AGENT:

OAKTREE FUND ADMINISTRATION, LLC

By:

Oaktree Capital Management, L.P.

Its:

Managing Member

By:

/s/ Brian Price

Name: Brian Price

Title: Senior Vice President

By:

/s/ Peter Boos

Name: Peter Boos

Title: Assistant Vice President

Address for Notices:
Oaktree Fund Administration, LLC

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071
Attn:Oaktree Agency

Email:Oaktreeagency@alterdomus.com

With a copy to:
Oaktree Capital Management, L.P.

333 S. Grand Avenue, 28th Fl.

Los Angeles, CA 90071
Attn:Aman Kumar

Email:AmKumar@oaktreecapital.com

[Signature Page to Credit Agreement]

­SC1:5266419.14


LENDER:

By:

/s/

By:

/s/

Name:

Title:

By:

/s/

Name:

Title:

Address for Notices:

Attn:

Email:

[Signature Page to Credit Agreement]

­SC1:5266419.14


­SC1:5266419.14


EX-31.1 3 fbio-20200930xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Lindsay A. Rosenwald, M.D., certify that:

(1)          I have reviewed this Quarterly Report on Form 10-Q of Fortress Biotech, Inc. (the “Registrant”);

(2)          Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)          Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

(4)         The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15 (f)) for the Registrant and have:

a.           designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.           designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.           evaluated the effectiveness of Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.           disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

(5)          The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

a.           all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

b.            any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal controls over financial reporting.

Dated: November 9, 2020

By:

/s/ Lindsay A. Rosenwald, M.D.

Lindsay A. Rosenwald, M.D.

Chairman, President and Chief Executive Officer

(Principal Executive Officer)


EX-31.2 4 fbio-20200930xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Robyn M. Hunter, certify that:

(1)          I have reviewed this Quarterly Report on Form 10-Q of Fortress Biotech, Inc. (the “Registrant”);

(2)          Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)          Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

(4)         The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15 (f)) for the Registrant and have:

a.            designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.           designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.            evaluated the effectiveness of Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.            disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

(5)          The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

a.            all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

b.            any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal controls over financial reporting.

Dated: November 9, 2020

By:

/s/ Robyn M. Hunter

Robyn M. Hunter

Chief Financial Officer

(Principal Financial Officer)


EX-32.1 5 fbio-20200930xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Fortress Biotech, Inc. (the “Company”) for the quarterly period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lindsay A. Rosenwald, M.D., Chairman, President, and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)          The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company, as of, and for, the periods presented in the Report.

Dated: November 9, 2020

By:

/s/ Lindsay A. Rosenwald, M.D.

Lindsay A. Rosenwald, M.D.

Chairman, President and Chief Executive Officer

(Principal Executive Officer)


EX-32.2 6 fbio-20200930xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Fortress Biotech, Inc. (the “Company”) for the quarterly period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robyn M. Hunter, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)          The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company, as of, and for, the periods presented in the Report.

Dated: November 9, 2020

By:

/s/ Robyn M. Hunter

Robyn M. Hunter

Chief Financial Officer

(Principal Financial Officer)


EX-101.SCH 7 fbio-20200930.xsd EX-101.SCH 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Discontinued Operations- Cash flows from the transaction (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Property and Equipment - Components of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Intangibles, net - Summary Of The JMC Intangible Asset (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Intangibles, net - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Debt and Interest - Long-term debt (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Accrued Liabilities and other Long-Term Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Commitments and Contingencies - Lease expense (Details) link:presentationLink link:calculationLink link:definitionLink 41502 - Disclosure - Commitments and Contingencies - Future minimum lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Sponsored Research and Clinical Trial Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Collaboration and Stock Purchase Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Property and Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Fair Value Measurements - Contingently Issuable Warrants with option pricing model (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Fair Value Measurements - Derivative Contingently Issuable Warrant liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Fair Value Measurements - Exclusive of National Financial Instruments Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 40604 - Disclosure - Fair Value Measurements - Changes in fair value (Details) link:presentationLink link:calculationLink link:definitionLink 40605 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Licenses Acquired - License as recorded in the Condensed Consolidated Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Licenses Acquired - Mustang expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Licenses Acquired - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Sponsored Research and Clinical Trial Agreements - Summary of Aevitas expense related to its sponsored research agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Sponsored Research and Clinical Trial Agreements - Summary of Mustang expense related to its sponsored research agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Sponsored Research and Clinical Trial Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Intangibles, net - Cost Of Goods Sold (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Intangibles, net - Amortization Of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Debt and Interest- Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Accrued Liabilities and other Long-Term Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Non-Controlling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41402 - Disclosure - Stockholders' Equity - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41403 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41404 - Disclosure - Stockholders' Equity - Warrant activities (Details) link:presentationLink link:calculationLink link:definitionLink 41405 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41503 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Related Party Transactions - Founders Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 41602 - Disclosure - Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41603 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41801 - Disclosure - Revenues from Contracts and Significant Customers - Company's product revenue (Details) link:presentationLink link:calculationLink link:definitionLink 41802 - Disclosure - Revenues from Contracts and Significant Customers - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Collaboration and Stock Purchase Agreements link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Licenses Acquired link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Sponsored Research and Clinical Trial Agreements link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Intangibles, net link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Debt and Interest link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Accrued Liabilities and other Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Non-Controlling Interests link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 11801 - Disclosure - Revenues from Contracts and Significant Customers link:presentationLink link:calculationLink link:definitionLink 11901 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Licenses Acquired (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Intangibles, net (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Debt and Interest (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Accrued Liabilities and other Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Non-Controlling Interests (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 31603 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 31703 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 31803 - Disclosure - Revenues from Contracts and Significant Customers (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 fbio-20200930_cal.xml EX-101.CAL EX-101.DEF 9 fbio-20200930_def.xml EX-101.DEF EX-101.LAB 10 fbio-20200930_lab.xml EX-101.LAB EX-101.PRE 11 fbio-20200930_pre.xml EX-101.PRE XML 12 fbio-20200930x10q_htm.xml IDEA: XBRL DOCUMENT 0001429260 2020-05-31 0001429260 2020-03-23 0001429260 us-gaap:NoncontrollingInterestMember 2020-09-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-09-30 0001429260 fbio:CommonSharesIssuableMember 2020-09-30 0001429260 us-gaap:NoncontrollingInterestMember 2020-06-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-06-30 0001429260 fbio:CommonSharesIssuableMember 2020-06-30 0001429260 2020-06-30 0001429260 us-gaap:NoncontrollingInterestMember 2019-12-31 0001429260 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-12-31 0001429260 fbio:CommonSharesIssuableMember 2019-12-31 0001429260 us-gaap:NoncontrollingInterestMember 2019-09-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-09-30 0001429260 fbio:CommonSharesIssuableMember 2019-09-30 0001429260 us-gaap:NoncontrollingInterestMember 2019-06-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-06-30 0001429260 fbio:CommonSharesIssuableMember 2019-06-30 0001429260 2019-06-30 0001429260 us-gaap:NoncontrollingInterestMember 2018-12-31 0001429260 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2018-12-31 0001429260 fbio:CommonSharesIssuableMember 2018-12-31 0001429260 us-gaap:SeriesAPreferredStockMember 2020-09-30 0001429260 us-gaap:CommonStockMember 2020-09-30 0001429260 us-gaap:SeriesAPreferredStockMember 2020-06-30 0001429260 us-gaap:CommonStockMember 2020-06-30 0001429260 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001429260 us-gaap:CommonStockMember 2019-12-31 0001429260 us-gaap:SeriesAPreferredStockMember 2019-09-30 0001429260 us-gaap:CommonStockMember 2019-09-30 0001429260 us-gaap:SeriesAPreferredStockMember 2019-06-30 0001429260 us-gaap:CommonStockMember 2019-06-30 0001429260 us-gaap:SeriesAPreferredStockMember 2018-12-31 0001429260 us-gaap:CommonStockMember 2018-12-31 0001429260 fbio:MustangBioIncMember 2019-09-30 0001429260 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001429260 us-gaap:RestrictedStockMember 2020-09-30 0001429260 us-gaap:RestrictedStockMember 2019-12-31 0001429260 fbio:TgTherapeuticsIncMember fbio:SharedServicesAgreementMember 2020-07-01 2020-09-30 0001429260 fbio:TgTherapeuticsIncMember fbio:DeskShareAgreementsMember 2020-07-01 2020-09-30 0001429260 fbio:OpusPointPartnersManagementLlcMember fbio:DeskShareAgreementsMember 2020-07-01 2020-09-30 0001429260 fbio:TgTherapeuticsIncMember fbio:SharedServicesAgreementMember 2020-01-01 2020-09-30 0001429260 fbio:TgTherapeuticsIncMember fbio:DeskShareAgreementsMember 2020-01-01 2020-09-30 0001429260 fbio:TgTherapeuticsIncMember fbio:SharedServicesAgreementMember 2019-07-01 2019-09-30 0001429260 fbio:OpusPointPartnersManagementLlcMember fbio:DeskShareAgreementsMember 2019-07-01 2019-09-30 0001429260 fbio:TgTherapeuticsIncMember fbio:SharedServicesAgreementMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:St.JudeChildrenSResearchHospitalXscidMb107Member 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:FredHutchinsonCancerResearchCenterCd20Mb106Member 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CohIl13raaMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeNationalMedicalCenterMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeManufacturingMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeCs1Member 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeCD123Member 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:BIDMCCRISPRMember 2020-07-01 2020-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:UpennAavMember 2020-07-01 2020-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:UmassAavMember 2020-07-01 2020-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:DukeAavMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:UclaMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:SirionLentiboostMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:NationwideChildrensHospitalMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:FredHutchCd20CarTMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CslBehringCalimmuneMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CohHer2Member 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohSpacerMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohIl13r2CarTMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohCsiCarTMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopecohCd123Member 2020-07-01 2020-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember 2020-07-01 2020-09-30 0001429260 fbio:OncogenuityMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember 2020-07-01 2020-09-30 0001429260 fbio:BaergicMember 2020-07-01 2020-09-30 0001429260 fbio:AevitasMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:St.JudeChildrenSResearchHospitalXscidMb107Member 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:FredHutchinsonCancerResearchCenterCd20Mb106Member 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CohIl13raaMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeNationalMedicalCenterMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeManufacturingMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeCs1Member 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeCD123Member 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:BIDMCCRISPRMember 2020-01-01 2020-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:UpennAavMember 2020-01-01 2020-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:UmassAavMember 2020-01-01 2020-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:DukeAavMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:UclaMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:SirionLentiboostMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:NationwideChildrensHospitalMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:FredHutchCd20CarTMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CslBehringCalimmuneMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CohHer2Member 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohSpacerMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohIl13r2CarTMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohCsiCarTMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopecohCd123Member 2020-01-01 2020-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember 2020-01-01 2020-09-30 0001429260 fbio:OncogenuityMember 2020-01-01 2020-09-30 0001429260 fbio:BaergicMember 2020-01-01 2020-09-30 0001429260 fbio:AevitasMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:St.JudeChildrenSResearchHospitalXscidMb107Member 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:FredHutchinsonCancerResearchCenterCd20Mb106Member 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CohIl13raaMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeNationalMedicalCenterMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeManufacturingMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeCs1Member 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeCD123Member 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:BIDMCCRISPRMember 2019-07-01 2019-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:UpennAavMember 2019-07-01 2019-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:UmassAavMember 2019-07-01 2019-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:DukeAavMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:UclaMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:SirionLentiboostMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:NationwideChildrensHospitalMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:FredHutchCd20CarTMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CslBehringCalimmuneMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CohHer2Member 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohSpacerMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohIl13r2CarTMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohCsiCarTMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopecohCd123Member 2019-07-01 2019-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:St.JudeChildrenSResearchHospitalXscidMb107Member 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:FredHutchinsonCancerResearchCenterCd20Mb106Member 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CohIl13raaMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeNationalMedicalCenterMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeManufacturingMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeCs1Member 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:CityOfHopeCD123Member 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:BIDMCCRISPRMember 2019-01-01 2019-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:UpennAavMember 2019-01-01 2019-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:UmassAavMember 2019-01-01 2019-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember fbio:DukeAavMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:UclaMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:SirionLentiboostMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:NationwideChildrensHospitalMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:FredHutchCd20CarTMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CslBehringCalimmuneMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CohHer2Member 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohSpacerMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohIl13r2CarTMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopeCohCsiCarTMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:CityOfHopecohCd123Member 2019-01-01 2019-09-30 0001429260 fbio:AevitasTherapeuticsIncMember fbio:ResearchAndClinicalTrialAgreementsMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember 2019-01-01 2019-09-30 0001429260 fbio:Notes2019Member 2020-07-01 2020-09-30 0001429260 fbio:VentureNotesThreeMember 2019-01-01 2019-09-30 0001429260 srt:MinimumMember us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2020-01-01 2020-09-30 0001429260 srt:MaximumMember us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2020-01-01 2020-09-30 0001429260 us-gaap:MachineryAndEquipmentMember 2020-01-01 2020-09-30 0001429260 us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-09-30 0001429260 us-gaap:ComputerEquipmentMember 2020-01-01 2020-09-30 0001429260 us-gaap:LeaseholdsAndLeaseholdImprovementsMember fbio:FortressBiotechIncMember 2020-09-30 0001429260 us-gaap:MachineryAndEquipmentMember 2020-09-30 0001429260 us-gaap:FurnitureAndFixturesMember 2020-09-30 0001429260 us-gaap:ConstructionInProgressMember 2020-09-30 0001429260 us-gaap:ComputerEquipmentMember 2020-09-30 0001429260 us-gaap:LeaseholdsAndLeaseholdImprovementsMember fbio:FortressBiotechIncMember 2019-12-31 0001429260 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001429260 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001429260 us-gaap:ConstructionInProgressMember 2019-12-31 0001429260 us-gaap:ComputerEquipmentMember 2019-12-31 0001429260 us-gaap:PreferredStockMember fbio:SeriesCumulativeRedeemablePerpetualPreferredStock9.375Member 2020-05-29 2020-05-29 0001429260 us-gaap:PreferredStockMember fbio:SeriesCumulativeRedeemablePerpetualPreferredStock9.375Member 2020-02-14 2020-02-14 0001429260 us-gaap:PreferredStockMember us-gaap:IPOMember 2020-08-28 0001429260 us-gaap:CommonStockMember fbio:MarketOfferingMember 2020-05-29 2020-05-29 0001429260 us-gaap:CommonStockMember fbio:MarketOfferingMember 2020-02-14 2020-02-14 0001429260 fbio:Notes2019Member 2019-01-01 2019-09-30 0001429260 fbio:HorizonNotesMember 2020-01-01 2020-09-30 0001429260 fbio:VentureNoteMember 2019-01-01 2019-09-30 0001429260 fbio:HorizonNotesMember 2019-01-01 2019-09-30 0001429260 fbio:DeskShareAgreementsMember 2020-07-01 2020-09-30 0001429260 fbio:DeskShareAgreementsMember 2019-07-01 2019-09-30 0001429260 fbio:TamidMember 2020-01-01 2020-09-30 0001429260 fbio:Oncogenuity.Member 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember 2020-01-01 2020-09-30 0001429260 fbio:JmcMember 2020-01-01 2020-09-30 0001429260 fbio:HelocyteMember 2020-01-01 2020-09-30 0001429260 fbio:CypriumMember 2020-01-01 2020-09-30 0001429260 fbio:CoronadoSoCoIncMember 2020-01-01 2020-09-30 0001429260 fbio:CheckpointTherapeuticsIncMember 2020-01-01 2020-09-30 0001429260 fbio:CellvationMember 2020-01-01 2020-09-30 0001429260 fbio:BaergicMember 2020-01-01 2020-09-30 0001429260 fbio:AvenueMember 2020-01-01 2020-09-30 0001429260 fbio:AevitasMember 2020-01-01 2020-09-30 0001429260 fbio:TamidMember 2019-01-01 2019-12-31 0001429260 fbio:MustangTherapeuticsIncMember 2019-01-01 2019-12-31 0001429260 fbio:JmcMember 2019-01-01 2019-12-31 0001429260 fbio:HelocyteMember 2019-01-01 2019-12-31 0001429260 fbio:CypriumMember 2019-01-01 2019-12-31 0001429260 fbio:CoronadoSoCoIncMember 2019-01-01 2019-12-31 0001429260 fbio:CheckpointTherapeuticsIncMember 2019-01-01 2019-12-31 0001429260 fbio:CellvationMember 2019-01-01 2019-12-31 0001429260 fbio:BaergicMember 2019-01-01 2019-12-31 0001429260 fbio:AvenueMember 2019-01-01 2019-12-31 0001429260 fbio:AevitasMember 2019-01-01 2019-12-31 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-07-01 2020-09-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-01-01 2020-09-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-07-01 2019-09-30 0001429260 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2019-01-01 2019-09-30 0001429260 fbio:MustangBioIncMember 2019-08-16 0001429260 fbio:MustangBioIncMember 2018-07-13 0001429260 fbio:CheckpointTherapeuticsIncMember 2017-11-30 0001429260 fbio:OralAcneTreatmentAgreementMember 2020-09-30 0001429260 fbio:OralAcneTreatmentAgreementMember 2019-12-31 0001429260 fbio:Notes2019Member fbio:MichealS.WeissMember 2019-12-31 0001429260 fbio:Notes2019Member fbio:DrRosenwaldMember 2019-12-31 0001429260 fbio:Notes2019Member fbio:DrRosenwaldAndMrWeissMember 2019-12-31 0001429260 fbio:Notes2019Member fbio:DakCapitalIncMember 2019-12-31 0001429260 fbio:VentureNotesTwoMember 2019-12-31 0001429260 fbio:VentureNotesThreeMember 2019-12-31 0001429260 fbio:VentureNoteMember 2019-12-31 0001429260 fbio:SubordinatedNoteFinancingTwoMember 2019-12-31 0001429260 fbio:SubordinatedNoteFinancingThreeMember 2019-12-31 0001429260 fbio:SubordinatedNoteFinancingOneMember 2019-12-31 0001429260 fbio:SubordinatedNoteFinancingFourMember 2019-12-31 0001429260 fbio:SubordinatedNoteFinancingFiveMember 2019-12-31 0001429260 fbio:Notes2019Member 2019-12-31 0001429260 fbio:Mustang2019VentureDebtMember 2019-12-31 0001429260 fbio:IdbNotePayableMember 2019-12-31 0001429260 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2019-12-31 0001429260 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember 2019-12-31 0001429260 us-gaap:FairValueInputsLevel1Member us-gaap:WarrantMember 2019-12-31 0001429260 us-gaap:WarrantMember 2019-12-31 0001429260 us-gaap:FairValueInputsLevel3Member fbio:CaelumConvertibleNotesMember 2020-09-30 0001429260 us-gaap:FairValueInputsLevel2Member fbio:CaelumConvertibleNotesMember 2020-09-30 0001429260 us-gaap:FairValueInputsLevel1Member fbio:CaelumConvertibleNotesMember 2020-09-30 0001429260 fbio:MeasurementInputInvestmentsMember fbio:CaelumMember 2020-09-30 0001429260 fbio:CaelumConvertibleNotesMember 2020-09-30 0001429260 us-gaap:FairValueInputsLevel3Member fbio:CaelumConvertibleNotesMember 2019-12-31 0001429260 us-gaap:FairValueInputsLevel2Member fbio:CaelumConvertibleNotesMember 2019-12-31 0001429260 us-gaap:FairValueInputsLevel1Member fbio:CaelumConvertibleNotesMember 2019-12-31 0001429260 fbio:MeasurementInputInvestmentsMember fbio:CaelumMember 2019-12-31 0001429260 fbio:CaelumConvertibleNotesMember 2019-12-31 0001429260 fbio:Notes2019Member 2020-01-01 2020-09-30 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2020-01-01 2020-09-30 0001429260 srt:MinimumMember us-gaap:FiniteLivedIntangibleAssetsMember fbio:JourneyMedicalCorpMember 2020-01-01 2020-09-30 0001429260 srt:MaximumMember us-gaap:FiniteLivedIntangibleAssetsMember fbio:JourneyMedicalCorpMember 2020-01-01 2020-09-30 0001429260 fbio:LicenseAndSupplyAgreementMember 2020-09-30 0001429260 fbio:JourneyMedicalCorporationMember 2019-12-31 0001429260 fbio:JourneyMedicalCorpMember 2020-09-30 0001429260 fbio:JourneyMedicalCorpMember 2019-12-31 0001429260 us-gaap:WarrantMember 2020-09-30 0001429260 fbio:CaelumMember 2020-09-30 0001429260 us-gaap:WarrantMember 2019-12-31 0001429260 fbio:CaelumMember 2019-12-31 0001429260 us-gaap:WarrantMember fbio:CaelumMember 2020-01-01 2020-09-30 0001429260 us-gaap:RestrictedStockMember 2020-09-30 0001429260 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 0001429260 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001429260 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001429260 fbio:TgTherapeuticsIncMember fbio:SharedServicesAgreementMember 2020-09-30 0001429260 fbio:TgTherapeuticsIncMember fbio:DeskShareAgreementsMember 2020-09-30 0001429260 fbio:OpusPointPartnersManagementLlcMember fbio:DeskShareAgreementsMember 2020-09-30 0001429260 fbio:CreditFacilityProvidedMember fbio:AvenueMember 2020-09-30 0001429260 us-gaap:PreferredStockMember us-gaap:IPOMember 2020-01-01 2020-09-30 0001429260 fbio:CaelumMember 2020-01-01 2020-09-30 0001429260 fbio:TwoThousandEighteenVentureNotesMember 2020-09-30 0001429260 fbio:Mustang2019VentureNotesMember 2020-09-30 0001429260 fbio:VentureNotesTwoMember 2020-01-01 2020-09-30 0001429260 fbio:VentureNotesThreeMember 2020-01-01 2020-09-30 0001429260 fbio:VentureNoteMember 2020-01-01 2020-09-30 0001429260 fbio:SubordinatedNoteFinancingTwoMember 2020-01-01 2020-09-30 0001429260 fbio:SubordinatedNoteFinancingThreeMember 2020-01-01 2020-09-30 0001429260 fbio:SubordinatedNoteFinancingFourMember 2020-01-01 2020-09-30 0001429260 fbio:SubordinatedNoteFinancingFiveMember 2020-01-01 2020-09-30 0001429260 fbio:Mustang2019VentureDebtMember 2020-01-01 2020-09-30 0001429260 us-gaap:LondonInterbankOfferedRateLIBORMember 2020-09-30 0001429260 fbio:VentureNotesTwoMember 2020-09-30 0001429260 fbio:VentureNotesThreeMember 2020-09-30 0001429260 fbio:VentureNoteMember 2020-09-30 0001429260 fbio:SubordinatedNoteFinancingTwoMember 2020-09-30 0001429260 fbio:SubordinatedNoteFinancingThreeMember 2020-09-30 0001429260 fbio:SubordinatedNoteFinancingOneMember 2020-09-30 0001429260 fbio:SubordinatedNoteFinancingFourMember 2020-09-30 0001429260 fbio:SubordinatedNoteFinancingFiveMember 2020-09-30 0001429260 fbio:SubordinatedNoteFinancing2017OneToFiveMember 2020-09-30 0001429260 fbio:OaktreeNoteMember 2020-09-30 0001429260 fbio:Notes2019Member 2020-09-30 0001429260 fbio:Mustang2019VentureDebtMember 2020-09-30 0001429260 fbio:IdbNotePayableMember 2020-09-30 0001429260 fbio:OaktreeNoteMember 2020-08-27 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2020-07-01 2020-09-30 0001429260 fbio:DermatologyProductsSalesMember 2020-07-01 2020-09-30 0001429260 fbio:ConsolidatedMember 2020-07-01 2020-09-30 0001429260 fbio:DermatologyProductsSalesMember 2020-01-01 2020-09-30 0001429260 fbio:ConsolidatedMember 2020-01-01 2020-09-30 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2019-07-01 2019-09-30 0001429260 fbio:DermatologyProductsSalesMember 2019-07-01 2019-09-30 0001429260 fbio:ConsolidatedMember 2019-07-01 2019-09-30 0001429260 fbio:DermatologyProductsSalesMember 2019-01-01 2019-09-30 0001429260 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001429260 fbio:ThreePlTitleModelMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001429260 fbio:ThreePlTitleModelMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001429260 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember 2020-07-01 2020-09-30 0001429260 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember 2020-01-01 2020-09-30 0001429260 us-gaap:AccountsReceivableMember 2020-01-01 2020-09-30 0001429260 us-gaap:AccountsReceivableMember 2019-01-01 2019-09-30 0001429260 fbio:StockIncentivePlanTwoThousandThirteenMember 2020-06-30 0001429260 fbio:StockIncentivePlanTwoThousandThirteenMember 2020-06-29 0001429260 2019-06-16 0001429260 2019-06-17 0001429260 us-gaap:PreferredStockMember us-gaap:OverAllotmentOptionMember 2020-08-28 0001429260 fbio:OaktreeWarrantsMember 2020-08-27 0001429260 us-gaap:PreferredStockMember us-gaap:IPOMember 2020-08-26 0001429260 us-gaap:PreferredStockMember us-gaap:IPOMember 2020-05-29 0001429260 us-gaap:PreferredStockMember us-gaap:IPOMember 2020-02-14 0001429260 2019-09-30 0001429260 2018-12-31 0001429260 srt:MinimumMember 2020-09-30 0001429260 srt:MaximumMember 2020-09-30 0001429260 fbio:SPMMember fbio:FirstStageMemberMember 2019-01-09 2019-02-08 0001429260 fbio:SPMMember 2019-01-09 2019-02-08 0001429260 2018-11-12 0001429260 us-gaap:FairValueInputsLevel3Member 2020-09-30 0001429260 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001429260 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001429260 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001429260 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001429260 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001429260 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001429260 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001429260 fbio:UnvestedRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001429260 fbio:UnvestedRestrictedStockMember 2020-01-01 2020-09-30 0001429260 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001429260 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001429260 fbio:UnvestedRestrictedStockUnitsMember 2019-01-01 2019-09-30 0001429260 fbio:UnvestedRestrictedStockMember 2019-01-01 2019-09-30 0001429260 fbio:JourneyMedicalCorporationMember 2020-01-01 2020-09-30 0001429260 us-gaap:LetterOfCreditMember us-gaap:LetterOfCreditMember 2020-07-01 2020-09-30 0001429260 fbio:TwoThousandNineteenNoteMember 2020-07-01 2020-09-30 0001429260 fbio:TwoThousandEighteenVentureNotesMember 2020-07-01 2020-09-30 0001429260 fbio:SubordinatedNoteFinancingOneMember 2020-07-01 2020-09-30 0001429260 fbio:OtherMember 2020-07-01 2020-09-30 0001429260 fbio:OaktreeNoteMember 2020-07-01 2020-09-30 0001429260 fbio:NscNotesPayableMember 2020-07-01 2020-09-30 0001429260 fbio:Mustang2019VentureNotesMember 2020-07-01 2020-09-30 0001429260 fbio:IdbNotePayableMember 2020-07-01 2020-09-30 0001429260 us-gaap:LetterOfCreditMember 2020-01-01 2020-09-30 0001429260 fbio:TwoThousandNineteenNoteMember 2020-01-01 2020-09-30 0001429260 fbio:TwoThousandEighteenVentureNotesMember 2020-01-01 2020-09-30 0001429260 fbio:SubordinatedNoteFinancingOneMember 2020-01-01 2020-09-30 0001429260 fbio:OtherMember 2020-01-01 2020-09-30 0001429260 fbio:NscNotesPayableMember 2020-01-01 2020-09-30 0001429260 fbio:Mustang2019VentureNotesMember 2020-01-01 2020-09-30 0001429260 fbio:IdbNotePayableMember 2020-01-01 2020-09-30 0001429260 us-gaap:LetterOfCreditMember us-gaap:LetterOfCreditMember 2019-07-01 2019-09-30 0001429260 fbio:TwoThousandNineteenNoteMember 2019-07-01 2019-09-30 0001429260 fbio:TwoThousandEighteenVentureNotesMember 2019-07-01 2019-09-30 0001429260 fbio:SubordinatedNoteFinancingOneMember 2019-07-01 2019-09-30 0001429260 fbio:OtherMember 2019-07-01 2019-09-30 0001429260 fbio:OaktreeNoteMember 2019-07-01 2019-09-30 0001429260 fbio:NscNotesPayableMember 2019-07-01 2019-09-30 0001429260 fbio:Mustang2019VentureNotesMember 2019-07-01 2019-09-30 0001429260 fbio:IdbNotePayableMember 2019-07-01 2019-09-30 0001429260 us-gaap:LetterOfCreditMember 2019-01-01 2019-09-30 0001429260 fbio:TwoThousandNineteenNoteMember 2019-01-01 2019-09-30 0001429260 fbio:TwoThousandEighteenVentureNotesMember 2019-01-01 2019-09-30 0001429260 fbio:SubordinatedNoteFinancingOneMember 2019-01-01 2019-09-30 0001429260 fbio:OtherMember 2019-01-01 2019-09-30 0001429260 fbio:OaktreeNoteMember 2019-01-01 2019-09-30 0001429260 fbio:NscNotesPayableMember 2019-01-01 2019-09-30 0001429260 fbio:Mustang2019VentureNotesMember 2019-01-01 2019-09-30 0001429260 fbio:IdbNotePayableMember 2019-01-01 2019-09-30 0001429260 fbio:XiminoAgreementMember 2020-01-01 2020-09-30 0001429260 fbio:XiminoAgreementMember 2019-01-01 2019-09-30 0001429260 us-gaap:EmployeeStockOptionMember us-gaap:EmployeeStockMember 2020-07-01 2020-09-30 0001429260 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001429260 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001429260 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001429260 fbio:OtherMember 2020-07-01 2020-09-30 0001429260 fbio:NonEmployeeAwardsMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember 2020-07-01 2020-09-30 0001429260 fbio:ExecutiveAwardsMember 2020-07-01 2020-09-30 0001429260 fbio:EmployeeAwardsMember 2020-07-01 2020-09-30 0001429260 fbio:CheckpointMember 2020-07-01 2020-09-30 0001429260 fbio:AvenueMember 2020-07-01 2020-09-30 0001429260 us-gaap:EmployeeStockOptionMember us-gaap:EmployeeStockMember 2020-01-01 2020-09-30 0001429260 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001429260 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001429260 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001429260 fbio:OtherMember 2020-01-01 2020-09-30 0001429260 fbio:NonEmployeeAwardsMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember 2020-01-01 2020-09-30 0001429260 fbio:ExecutiveAwardsMember 2020-01-01 2020-09-30 0001429260 fbio:EmployeeAwardsMember 2020-01-01 2020-09-30 0001429260 fbio:CheckpointMember 2020-01-01 2020-09-30 0001429260 fbio:AvenueMember 2020-01-01 2020-09-30 0001429260 us-gaap:EmployeeStockOptionMember us-gaap:EmployeeStockMember 2019-07-01 2019-09-30 0001429260 us-gaap:WarrantMember 2019-07-01 2019-09-30 0001429260 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001429260 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001429260 fbio:OtherMember 2019-07-01 2019-09-30 0001429260 fbio:NonEmployeeAwardsMember 2019-07-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember 2019-07-01 2019-09-30 0001429260 fbio:ExecutiveAwardsMember 2019-07-01 2019-09-30 0001429260 fbio:EmployeeAwardsMember 2019-07-01 2019-09-30 0001429260 fbio:CheckpointMember 2019-07-01 2019-09-30 0001429260 fbio:AvenueMember 2019-07-01 2019-09-30 0001429260 us-gaap:EmployeeStockOptionMember us-gaap:EmployeeStockMember 2019-01-01 2019-09-30 0001429260 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001429260 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001429260 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001429260 fbio:OtherMember 2019-01-01 2019-09-30 0001429260 fbio:NonEmployeeAwardsMember 2019-01-01 2019-09-30 0001429260 fbio:MustangTherapeuticsIncMember 2019-01-01 2019-09-30 0001429260 fbio:ExecutiveAwardsMember 2019-01-01 2019-09-30 0001429260 fbio:EmployeeAwardsMember 2019-01-01 2019-09-30 0001429260 fbio:CheckpointMember 2019-01-01 2019-09-30 0001429260 fbio:AvenueMember 2019-01-01 2019-09-30 0001429260 fbio:CustomerTwoMember us-gaap:AccountsReceivableMember 2019-09-30 0001429260 fbio:CustomerOneMember us-gaap:AccountsReceivableMember 2019-09-30 0001429260 us-gaap:TreasuryStockPreferredMember 2020-01-01 2020-09-30 0001429260 fbio:ThirdAnniversaryOfExecutionMember fbio:LicenseAndSupplyAgreementMember 2020-07-29 2020-07-29 0001429260 fbio:SecondAnniversaryOfExecutionMember fbio:LicenseAndSupplyAgreementMember 2020-07-29 2020-07-29 0001429260 fbio:FirstAnniversaryOfExecutionMember fbio:LicenseAndSupplyAgreementMember 2020-07-29 2020-07-29 0001429260 fbio:FoundersAgreementMember us-gaap:CommonStockMember fbio:MarketOfferingMember fbio:CheckpointTherapeuticsIncMember 2020-01-01 2020-09-30 0001429260 us-gaap:SeriesAPreferredStockMember 2020-07-01 2020-09-30 0001429260 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-09-30 0001429260 fbio:Oncogenuity.Member 2020-05-01 2020-05-31 0001429260 srt:MaximumMember fbio:Oncogenuity.Member 2020-05-31 0001429260 fbio:Oncogenuity.Member 2020-07-01 2020-09-30 0001429260 fbio:MustangBioIncMember 2020-07-01 2020-09-30 0001429260 fbio:CellvationMember 2020-07-01 2020-09-30 0001429260 fbio:Oncogenuity.Member 2020-01-01 2020-09-30 0001429260 fbio:CellvationMember 2020-01-01 2020-09-30 0001429260 fbio:CellvationMember 2019-07-01 2019-09-30 0001429260 fbio:Oncogenuity.Member 2019-01-01 2019-12-31 0001429260 fbio:CellvationMember 2019-01-01 2019-09-30 0001429260 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001429260 us-gaap:WarrantMember 2020-09-30 0001429260 us-gaap:WarrantMember 2019-12-31 0001429260 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember 2020-01-01 2020-09-30 0001429260 fbio:AevitasTherapeuticsIncMember 2020-01-01 2020-09-30 0001429260 fbio:CaelumMember 2019-01-01 2019-01-30 0001429260 fbio:SirionTechnologyLicenseMember us-gaap:LicensingAgreementsMember fbio:DevelopmentMilestoneMember 2020-09-30 2020-09-30 0001429260 fbio:SirionTechnologyLicenseMember us-gaap:LicensingAgreementsMember fbio:AdditionalMilestonePaymentsMember 2020-09-30 2020-09-30 0001429260 fbio:ColumbiaLicenseMember us-gaap:LicensingAgreementsMember fbio:SaleMillstoneMember 2020-01-01 2020-09-30 0001429260 fbio:ColumbiaLicenseMember us-gaap:LicensingAgreementsMember fbio:ProductMilestoneMember 2020-01-01 2020-09-30 0001429260 fbio:ColumbiaLicenseMember us-gaap:LicensingAgreementsMember fbio:DevelopmentMilestoneMember 2020-01-01 2020-09-30 0001429260 srt:ChiefExecutiveOfficerMember 2020-09-30 0001429260 fbio:ExecutivesViceChairmanMember 2020-09-30 0001429260 fbio:CaelumWarrantLiabilitiesMember 2020-07-01 2020-09-30 0001429260 fbio:AlexionMember 2019-01-01 2019-01-31 0001429260 fbio:OaktreeWarrantsMember 2020-08-29 2020-08-29 0001429260 fbio:MustangBioIncMember 2020-07-01 2020-09-30 0001429260 fbio:SirionTechnologyLicenseMember us-gaap:LicensingAgreementsMember 2020-07-01 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember fbio:St.JudeXscidMember 2020-07-01 2020-07-01 0001429260 fbio:ColumbiaLicenseMember us-gaap:LicensingAgreementsMember 2020-05-06 2020-05-06 0001429260 fbio:SirionTechnologyLicenseMember us-gaap:LicensingAgreementsMember 2020-01-01 2020-09-30 0001429260 fbio:OaktreeNoteMember 2020-01-01 2020-09-30 0001429260 fbio:OaktreeNoteMember 2020-08-27 2020-08-27 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2019-01-01 2019-09-30 0001429260 fbio:ConsolidatedMember 2019-01-01 2019-09-30 0001429260 fbio:OaktreeWarrantsMember 2020-08-29 0001429260 fbio:AvenueMember srt:MinimumMember us-gaap:SalesMember fbio:SlabTwoMember 2020-01-01 2020-09-30 0001429260 fbio:AvenueMember srt:MaximumMember us-gaap:SalesMember fbio:SlabTwoMember 2020-01-01 2020-09-30 0001429260 fbio:AvenueMember us-gaap:SalesMember fbio:SlabThreeMember 2020-01-01 2020-09-30 0001429260 fbio:AvenueMember us-gaap:SalesMember fbio:SlabOneMember 2020-01-01 2020-09-30 0001429260 fbio:AvenueMember fbio:SalesAfterJanuaryOneTwentyThousandTwentyNineMember fbio:SlabOneMember 2020-01-01 2020-09-30 0001429260 fbio:AvenueMember us-gaap:SalesMember 2020-01-01 2020-09-30 0001429260 fbio:ColumbiaLicenseMember us-gaap:LicensingAgreementsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2020-07-01 2020-09-30 0001429260 fbio:ColumbiaLicenseMember us-gaap:LicensingAgreementsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2020-01-01 2020-09-30 0001429260 fbio:TamidMember 2020-09-30 0001429260 fbio:Oncogenuity.Member 2020-09-30 0001429260 fbio:MustangTherapeuticsIncMember 2020-09-30 0001429260 fbio:JmcMember 2020-09-30 0001429260 fbio:HelocyteMember 2020-09-30 0001429260 fbio:CypriumMember 2020-09-30 0001429260 fbio:CoronadoSoCoIncMember 2020-09-30 0001429260 fbio:CheckpointTherapeuticsIncMember 2020-09-30 0001429260 fbio:CellvationMember 2020-09-30 0001429260 fbio:BaergicMember 2020-09-30 0001429260 fbio:AvenueMember 2020-09-30 0001429260 fbio:AevitasMember 2020-09-30 0001429260 fbio:TamidMember 2019-12-31 0001429260 fbio:MustangTherapeuticsIncMember 2019-12-31 0001429260 fbio:JmcMember 2019-12-31 0001429260 fbio:HelocyteMember 2019-12-31 0001429260 fbio:CypriumMember 2019-12-31 0001429260 fbio:CoronadoSoCoIncMember 2019-12-31 0001429260 fbio:CheckpointTherapeuticsIncMember 2019-12-31 0001429260 fbio:CellvationMember 2019-12-31 0001429260 fbio:BaergicMember 2019-12-31 0001429260 fbio:AvenueMember 2019-12-31 0001429260 fbio:AevitasMember 2019-12-31 0001429260 fbio:MustangBioIncMember 2020-06-01 2020-06-30 0001429260 fbio:SubordinatedNoteFinancing2017OneToFiveMember 2020-01-01 2020-09-30 0001429260 us-gaap:PreferredStockMember us-gaap:IPOMember 2020-08-28 2020-08-28 0001429260 us-gaap:PreferredStockMember us-gaap:IPOMember 2020-05-29 2020-05-29 0001429260 us-gaap:PreferredStockMember us-gaap:IPOMember 2020-02-14 2020-02-14 0001429260 us-gaap:SeriesAPreferredStockMember 2019-07-01 2019-09-30 0001429260 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-09-30 0001429260 fbio:FoundersAgreementMember fbio:MustangBioIncMember us-gaap:CommonStockMember fbio:MarketOfferingMember 2020-01-01 2020-09-30 0001429260 fbio:FoundersAgreementMember fbio:MustangBioIncMember us-gaap:CommonStockMember fbio:MarketOfferingMember 2019-01-01 2019-09-30 0001429260 fbio:CaelumMember 2020-01-01 2020-09-30 0001429260 fbio:AvenueMember fbio:SlabTwoMember 2020-01-01 2020-09-30 0001429260 fbio:AvenueMember fbio:SlabThreeMember 2020-01-01 2020-09-30 0001429260 fbio:AvenueMember fbio:SlabOneMember 2020-01-01 2020-09-30 0001429260 fbio:XiminoMember fbio:JourneyMedicalCorporationMember 2020-09-30 0001429260 fbio:ExeldermMember fbio:JourneyMedicalCorporationMember 2020-09-30 0001429260 fbio:JourneyMedicalCorporationMember 2020-09-30 0001429260 us-gaap:MeasurementInputSharePriceMember fbio:CaelumMember 2020-01-01 2020-09-30 0001429260 us-gaap:MeasurementInputRiskFreeInterestRateMember fbio:CaelumMember 2020-01-01 2020-09-30 0001429260 fbio:CaelumWarrantLiabilitiesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-01-01 2020-09-30 0001429260 fbio:CaelumWarrantLiabilitiesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-01-01 2019-12-31 0001429260 2019-01-01 2019-12-31 0001429260 fbio:CaelumWarrantLiabilitiesMember us-gaap:MeasurementInputPriceVolatilityMember 2020-01-01 2020-09-30 0001429260 fbio:CaelumWarrantLiabilitiesMember us-gaap:MeasurementInputPriceVolatilityMember 2019-01-01 2019-12-31 0001429260 fbio:CaelumWarrantLiabilitiesMember us-gaap:MeasurementInputExpectedTermMember 2020-01-01 2020-09-30 0001429260 fbio:CaelumWarrantLiabilitiesMember us-gaap:MeasurementInputExpectedTermMember 2019-01-01 2019-12-31 0001429260 fbio:CaelumWarrantLiabilitiesMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-01-01 2020-09-30 0001429260 fbio:CaelumWarrantLiabilitiesMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-01-01 2019-12-31 0001429260 us-gaap:MeasurementInputPriceVolatilityMember fbio:CaelumMember 2020-01-01 2020-09-30 0001429260 fbio:MeasurementInputInvestmentsMember fbio:CaelumMember 2019-01-01 2019-12-31 0001429260 fbio:OaktreeWarrantsMember 2020-08-27 2020-08-27 0001429260 fbio:OaktreeWarrantsMember 2020-01-01 2020-09-30 0001429260 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001429260 fbio:LicenseAndSupplyAgreementMember 2020-01-01 2020-09-30 0001429260 us-gaap:EmployeeStockOptionMember us-gaap:EmployeeStockMember 2020-09-30 0001429260 fbio:Oncogenuity.Member 2020-09-30 0001429260 fbio:MustangBioIncMember 2020-09-30 0001429260 fbio:HelocyteIncMember 2020-09-30 0001429260 fbio:CypriumBioSciencesIncMember 2020-09-30 0001429260 fbio:CheckpointTherapeuticsIncMember 2020-09-30 0001429260 fbio:CellvationIncMember 2020-09-30 0001429260 fbio:CaelumMember 2020-09-30 0001429260 fbio:BaergicMember 2020-09-30 0001429260 fbio:AvenueMember 2020-09-30 0001429260 fbio:AevitasIncMember 2020-09-30 0001429260 fbio:Notes2019Member 2019-09-13 2019-09-13 0001429260 fbio:CreditFacilityProvidedMember fbio:AvenueMember 2020-06-12 2020-06-12 0001429260 fbio:AvenueMember fbio:SalesAfterJanuaryOneTwentyThousandTwentyNineMember 2020-01-01 2020-09-30 0001429260 fbio:ShelfTwoThousandTwentyMember 2020-09-30 0001429260 fbio:MustangBioIncMember 2020-09-30 0001429260 fbio:StockIncentivePlanTwoThousandThirteenMember 2020-01-01 2020-09-30 0001429260 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001429260 fbio:CommonSharesIssuableMember 2020-07-01 2020-09-30 0001429260 fbio:CommonSharesIssuableMember 2020-01-01 2020-09-30 0001429260 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001429260 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001429260 fbio:OpusCreditFacilityMember 2019-01-01 2019-09-30 0001429260 fbio:CommonSharesIssuableMember 2019-07-01 2019-09-30 0001429260 us-gaap:CommonStockMember fbio:MarketOfferingMember fbio:CheckpointTherapeuticsIncMember 2020-09-01 2020-09-30 0001429260 us-gaap:PreferredStockMember us-gaap:IPOMember 2020-08-26 2020-08-26 0001429260 fbio:MustangBioIncMember us-gaap:CommonStockMember fbio:MarketOfferingMember 2020-06-01 2020-06-30 0001429260 us-gaap:PreferredStockMember fbio:MarketOfferingMember 2020-05-29 2020-05-29 0001429260 us-gaap:PreferredStockMember fbio:MarketOfferingMember 2020-02-14 2020-02-14 0001429260 us-gaap:CommonStockMember fbio:MarketOfferingMember 2020-01-01 2020-09-30 0001429260 fbio:MustangBioIncMember us-gaap:CommonStockMember fbio:MarketOfferingMember 2019-01-01 2019-09-30 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2020-09-30 0001429260 fbio:DermatologyProductsSalesMember 2020-09-30 0001429260 fbio:ConsolidatedMember 2020-09-30 0001429260 fbio:PharmaceuticalAndBiotechnologyProductDevelopmentMember 2019-09-30 0001429260 fbio:DermatologyProductsSalesMember 2019-09-30 0001429260 fbio:ConsolidatedMember 2019-09-30 0001429260 fbio:XiminoAgreementMember 2020-09-30 0001429260 fbio:XiminoAgreementMember 2019-12-31 0001429260 fbio:LicenseAndSupplyAgreementMember 2020-07-29 2020-07-29 0001429260 fbio:LicenseAndSupplyAgreementMember 2020-07-29 0001429260 fbio:FortressBiotechIncMember 2020-01-01 2020-09-30 0001429260 fbio:Oncogenuity.Member 2020-01-01 2020-09-30 0001429260 fbio:MustangBioIncMember 2020-01-01 2020-09-30 0001429260 fbio:HelocyteIncMember 2020-01-01 2020-09-30 0001429260 fbio:CypriumBioSciencesIncMember 2020-01-01 2020-09-30 0001429260 fbio:CheckpointTherapeuticsIncMember 2020-01-01 2020-09-30 0001429260 fbio:CellvationIncMember 2020-01-01 2020-09-30 0001429260 fbio:BaergicMember 2020-01-01 2020-09-30 0001429260 fbio:AvenueMember 2020-01-01 2020-09-30 0001429260 fbio:AevitasIncMember 2020-01-01 2020-09-30 0001429260 fbio:CreditFacilityProvidedMember fbio:AvenueMember 2020-06-12 0001429260 fbio:MustangBioIncMember us-gaap:CommonStockMember fbio:MarketOfferingMember 2020-01-01 2020-09-30 0001429260 us-gaap:CommonStockMember fbio:MarketOfferingMember fbio:CheckpointTherapeuticsIncMember 2020-01-01 2020-09-30 0001429260 2019-07-01 2019-09-30 0001429260 fbio:CommonSharesIssuableMember 2019-01-01 2019-09-30 0001429260 2020-07-01 2020-09-30 0001429260 2019-01-01 2019-09-30 0001429260 us-gaap:RestrictedStockUnitsRSUMember fbio:MustangBioIncMember 2020-01-01 2020-09-30 0001429260 us-gaap:RestrictedStockUnitsRSUMember fbio:MustangBioIncMember 2019-01-01 2019-09-30 0001429260 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001429260 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-09-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001429260 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001429260 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-09-30 0001429260 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001429260 fbio:CaelumMember fbio:AlexionMember 2019-12-01 2019-12-31 0001429260 2020-09-30 0001429260 2019-12-31 0001429260 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2020-01-01 2020-09-30 0001429260 us-gaap:CommonStockMember 2020-11-05 0001429260 fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember 2020-11-05 0001429260 2020-01-01 2020-09-30 shares iso4217:USD pure iso4217:USD shares fbio:Milestone fbio:item iso4217:EUR fbio:segment August 1, 2021 March 2, 2022 May 1, 2022 June 1, 2022 August 1, 2022 September 1, 2022 August 1, 2021 September 1, 2021 September 1, 2021 October 1, 2022 August 1, 2025 Accelerated Filer 0001429260 --12-31 2020 Q3 false false Fortress Biotech, Inc. 74027425 93748374 3427138 1341167 P5Y 1000000 1000000 P15Y 10-Q true 2020-09-30 false 001-35366 DE 20-5157386 2 Gansevoort Street, 9th Floor New York NY 10014 781 652-4500 Common Stock FBIO NASDAQ 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock FBIOP NASDAQ Yes Yes true false false 93702861 3427138 218389000 136858000 147000 100000 15653000 13539000 1052000 857000 939000 865000 1704000 4133000 237737000 156252000 12114000 12433000 20265000 21480000 1645000 16574000 11723000 11148000 11039000 7377000 1356000 1158000 295879000 226422000 32542000 35451000 19000 0 23000 1042000 0 92000 0 7220000 1697000 1784000 0 27000 3000000 0 37281000 45616000 8607000 5086000 51393000 77436000 22855000 23712000 8205000 7126000 119734000 153890000 0.001 0.001 15000000 15000000 5000000 5000000 3427138 1341167 25.00 25.00 3000 1000 0.001 0.001 150000000 150000000 93748374 74027425 94000 74000 5451 251337 18000 500000 574461000 461874000 -477465000 -436234000 97111000 26215000 79034000 46317000 176145000 72532000 295879000 226422000 9447000 9492000 30808000 23816000 28000 280000 1042000 1683000 9475000 9772000 31850000 25499000 3379000 2702000 10313000 6972000 13298000 14571000 43868000 56355000 458000 700000 2278000 1350000 15383000 14339000 45358000 41260000 32518000 32312000 101817000 105937000 -23043000 -22540000 -69967000 -80438000 265000 738000 1228000 1955000 6958000 3168000 13142000 8743000 803000 0 1189000 0 575000 0 575000 0 0 0 0 18521000 -6921000 -2430000 -12528000 11733000 -29964000 -24970000 -82495000 -68705000 -14417000 -12208000 -41264000 -44237000 -15547000 -12762000 -41231000 -24468000 -0.39 -0.44 -1.19 -1.29 -0.19 -0.21 -0.59 -0.83 -0.20 -0.22 -0.59 -0.46 76093211 56856821 69404499 53060565 2693806 3000 86113331 86000 813000 521493000 -461918000 56381000 116858000 3171000 3171000 268800 7064214 7000 21110000 21117000 1719000 1719000 733332 -11965000 -11965000 18774000 18774000 23053000 23053000 7088000 7088000 180000 180000 50000 50000 1216000 1216000 21000 21000 302029 1000 -500000 810000 311000 313000 313000 18000 18000 4419000 4419000 37070000 -37070000 14417000 14417000 -15547000 -15547000 3427138 3000 93748374 94000 18000 574461000 -477465000 79034000 176145000 1000000 1000 68138203 68000 490000 439295000 -407980000 57946000 89820000 3741000 3741000 177292 1213643 1000 1930000 1931000 26111 523000 523000 601000 601000 52000 52000 3341000 3341000 500000 500000 317804 1000 -490000 489000 91767 165000 165000 396825 500000 500000 3467000 -3467000 2000 2000 12208000 12208000 -12762000 -12762000 1026111 1000 70335534 70000 500000 445966000 -420742000 49205000 75000000 1341167 1000 74027425 74000 500000 461874000 -436234000 46317000 72532000 10319000 10319000 2307231 2000 -2000 53268 90000 90000 16378234 17000 43183000 43200000 4507000 4507000 5000 70000 2000 72000 70000 70000 2090971 -2000 -35466000 -35468000 53698000 53698000 33500000 33500000 7088000 7088000 349000 349000 50000 50000 13000 13000 1216000 1216000 42000 42000 982216 1000 -500000 1816000 1317000 18000 18000 4419000 4419000 73981000 -73981000 41264000 41264000 -41231000 -41231000 3427138 3000 93748374 94000 18000 574461000 -477465000 79034000 176145000 1000000 1000 57845447 58000 659000 397408000 -396274000 17891000 19743000 10423000 10423000 1842034 2000 -2000 54221 60000 60000 -164000 164000 8604469 9000 15789000 15798000 26111 523000 523000 1773000 1773000 61036000 61036000 29680000 29680000 888000 888000 500000 500000 1330450 1000 -495000 1468000 974000 281000 281000 262088 -281000 506000 225000 396825 500000 500000 70702000 -70702000 2000 2000 4849000 4849000 44237000 44237000 -24468000 -24468000 1026111 1000 70335534 70000 500000 445966000 -420742000 49205000 75000000 -82495000 -68705000 1676000 1414000 47000 250000 5319000 2459000 492000 0 1065000 820000 1214000 1150000 10319000 10423000 42000 0 0 500000 1317000 974000 0 281000 0 225000 18000 0 1189000 0 575000 0 0 18521000 2236000 1350000 2161000 -111000 195000 263000 74000 -852000 -2429000 -1812000 198000 903000 -2686000 -3841000 19000 -149000 -1019000 5000 -92000 -8000 -943000 -940000 -140000 795000 -63196000 -69909000 3369000 850000 1228000 1455000 1000000 2400000 0 5000000 0 17604000 0 1201000 -5597000 6698000 0 13089000 -5597000 19787000 4507000 1773000 70000 0 2000 0 39075000 0 3407000 0 44796000 16099000 1506000 301000 0 539000 0 16000 90000 60000 349000 0 50000 0 57729000 66623000 3642000 4754000 34254000 30419000 754000 739000 -8000000 0 912000 0 13000 0 93000 79000 58000 126000 0 15000000 0 1393000 60000000 0 4239000 0 28356000 0 21707000 0 9000000 0 15750000 0 14858000 0 135395000 119559000 66602000 69437000 153432000 81582000 220034000 151019000 6669000 3976000 463000 342000 2000 2000 0 164000 0 888000 4419000 0 500000 0 0 500000 317000 288000 0 833000 3727000 4734000 1216000 0 57000 0 96000 0 457000 0 203000 0 117000 0 70000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization and Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing pharmaceutical and biotechnology products and product candidates, which the Company does at the Fortress level, at its majority-owned and majority-controlled subsidiaries and joint ventures, and at entities the Company founded and in which it maintains significant minority ownership positions. Fortress has a talented and experienced business development team, comprising scientists, doctors and finance professionals, who identify and evaluate promising products and product candidates for potential acquisition by new or existing partner companies. Fortress through its partner companies has executed such arrangements in partnership with some of the world’s foremost universities, research institutes and pharmaceutical companies, including City of Hope National Medical Center, Fred Hutchinson Cancer Research Center, St. Jude Children’s Research Hospital, Dana-Farber Cancer Institute, Nationwide Children’s Hospital, Cincinnati Children’s Hospital Medical Center, Columbia University, the University of Pennsylvania, and AstraZeneca plc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following the exclusive license or other acquisition of the intellectual property underpinning a product or product candidate, Fortress leverages its business, scientific, regulatory, legal and finance expertise to help the partners achieve their goals. Partner companies then assess a broad range of strategic arrangements to accelerate and provide additional funding to support research and development, including joint ventures, partnerships, out-licensings, and public and private financings; to date, three partner companies are publicly-traded, and two have consummated strategic partnerships with industry leaders Alexion Pharmaceuticals, Inc. and InvaGen Pharmaceuticals, Inc. (“InvaGen”)(a subsidiary of Cipla Limited).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Several of our partner companies possess licenses to product candidate intellectual property, including Aevitas Therapeutics, Inc. (“Aevitas”), Avenue Therapeutics, Inc. (“Avenue”), Baergic Bio, Inc. (“Baergic”), Caelum Biosciences, Inc. (“Caelum”), Cellvation, Inc. (“Cellvation”), Checkpoint Therapeutics, Inc. (“Checkpoint”), Cyprium Therapeutics, Inc. (“Cyprium”), Helocyte, Inc. (“Helocyte”), Journey Medical Corporation (“Journey” or “JMC”), Mustang Bio, Inc. (“Mustang”) and Oncogenuity, Inc. (“Oncogenuity”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:12pt;margin:0pt;">Liquidity and Capital Resources</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Since inception, the Company’s operations have been financed primarily through the sale of equity and debt securities, from the sale of partner companies, and the proceeds from the exercise of warrants and stock options. The Company has incurred losses from operations and negative cash flows from operating activities since inception and expects to continue to incur substantial losses for the next several years as it continues to fully develop and prepare regulatory filings and obtain regulatory approvals for its existing and new product candidates. The Company’s current cash and cash equivalents are sufficient to fund operations for at least the next 12 months. However, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, sale of a partner company, grants or other arrangements to fully develop and prepare regulatory filings and obtain regulatory approvals for the existing and new product candidates, fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for the potential products, sales and marketing capabilities.  If such funding is not available or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed. The Company also has the ability, subject to limitations imposed by Rule 144 of the Securities Act of 1933 and other applicable laws and regulations, to raise money from the sale of common stock of the public companies in which it has ownership positions. In addition to the foregoing, the Company does not expect any material impact on its development timelines, revenue levels and its liquidity due to the worldwide spread of COVID-19 (except as may be implicated by the Material Adverse Effect claimed by InvaGen in connection with their agreement with Avenue). However, the Company is continuing to assess the impact the spread of COVID-19 may have on its operations. Avenue will also continue to assess the alleged Material Adverse Effect claimed by InvaGen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited financial statements for the preceding fiscal year for each of the companies: Avenue, Checkpoint and Mustang. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2020, from which the Company derived the balance sheet data at December 31, 2019, as well as Checkpoint’s Form 10-K, filed with the SEC on March 11, 2020, Mustang’s Form 10-K, filed with the SEC on March 16, 2020, and Avenue’s Form 10-K, filed with the SEC on March 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s unaudited condensed consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company also consolidates subsidiaries in which it owns less than 50% of the subsidiary but maintains voting control. The Company continually assesses whether changes to existing relationships or future transactions may result in the consolidation or deconsolidation of partner companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2019 Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Adopted Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-13, <i style="font-style:italic;">Fair Value Measurement (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</i>, which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with the movement amongst or hierarchy associated with Level 1, Level 2 and Level 3 fair value measurements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. On January 1, 2020, the Company’s adoption of this guidance to did not have a material impact on its condensed consolidated  financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In August 2020, the FASB issued ASU No. 2020-06, </span><i style="font-style:italic;font-weight:normal;">Debt—Debt with Conversion and Other Options (Subtopic 470-20) </i><span style="font-weight:normal;">(“ASU 470-20”)</span><span style="font-style:italic;"> </span><i style="font-style:italic;font-weight:normal;">and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity </i><span style="font-weight:normal;">(“ASU 815-40”)</span><span style="font-weight:normal;">, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. The ASU is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer and will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, for the Company as it is a smaller reporting company. Early adoption will be permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In June 2016, the FASB issued ASU 2016-13, </span><i style="font-style:italic;font-weight:normal;">“Financial Instruments – Credit Losses”</i><span style="font-weight:normal;">. The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. Recently, the FASB issued the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of the adoption of this ASU on its condensed consolidated  financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In December 2019, the FASB issued ASU No. 2019-12, “</span><i style="font-style:italic;font-weight:normal;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i><span style="font-weight:normal;"> (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited financial statements for the preceding fiscal year for each of the companies: Avenue, Checkpoint and Mustang. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2020, from which the Company derived the balance sheet data at December 31, 2019, as well as Checkpoint’s Form 10-K, filed with the SEC on March 11, 2020, Mustang’s Form 10-K, filed with the SEC on March 16, 2020, and Avenue’s Form 10-K, filed with the SEC on March 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s unaudited condensed consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company also consolidates subsidiaries in which it owns less than 50% of the subsidiary but maintains voting control. The Company continually assesses whether changes to existing relationships or future transactions may result in the consolidation or deconsolidation of partner companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2019 Annual Report.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Adopted Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-13, <i style="font-style:italic;">Fair Value Measurement (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</i>, which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with the movement amongst or hierarchy associated with Level 1, Level 2 and Level 3 fair value measurements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. On January 1, 2020, the Company’s adoption of this guidance to did not have a material impact on its condensed consolidated  financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In August 2020, the FASB issued ASU No. 2020-06, </span><i style="font-style:italic;font-weight:normal;">Debt—Debt with Conversion and Other Options (Subtopic 470-20) </i><span style="font-weight:normal;">(“ASU 470-20”)</span><span style="font-style:italic;"> </span><i style="font-style:italic;font-weight:normal;">and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity </i><span style="font-weight:normal;">(“ASU 815-40”)</span><span style="font-weight:normal;">, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. The ASU is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer and will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, for the Company as it is a smaller reporting company. Early adoption will be permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In June 2016, the FASB issued ASU 2016-13, </span><i style="font-style:italic;font-weight:normal;">“Financial Instruments – Credit Losses”</i><span style="font-weight:normal;">. The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. Recently, the FASB issued the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of the adoption of this ASU on its condensed consolidated  financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In December 2019, the FASB issued ASU No. 2019-12, “</span><i style="font-style:italic;font-weight:normal;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i><span style="font-weight:normal;"> (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">3. Discontinued Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below depicts the cash flows from the sale of the Company’s investment in National Holdings Corporation, a diversified independent brokerage company (together with its subsidiaries, herein referred to as “NHLD” or “National”) for the nine months ended September 30, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:79.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:top;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from sale of National</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,089</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash provided by discontinued investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,089</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At September 30, 2020 and 2019, the Company had no ownership interest in National.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below depicts the cash flows from the sale of the Company’s investment in National Holdings Corporation, a diversified independent brokerage company (together with its subsidiaries, herein referred to as “NHLD” or “National”) for the nine months ended September 30, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:79.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:top;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from sale of National</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,089</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:79.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash provided by discontinued investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,089</p></td></tr></table> 13089000 13089000 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">4. Collaboration and Stock Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Caelum</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;">Agreement with Alexion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2019, Caelum entered into a Development, Option and Stock Purchase Agreement (the “DOSPA”) and related documents by and among Caelum, Alexion Therapeutics, Inc. (“Alexion”), the Company and Caelum security holders as parties thereto (such security holders, including Fortress, the “Sellers”). Under the terms of the agreement, Alexion purchased a 19.9% minority equity interest in Caelum for $30 million. Additionally, Alexion has agreed to make potential payments to Caelum upon the achievement of certain developmental milestones, in exchange for which Alexion obtained a contingent exclusive option to acquire the remaining equity in Caelum. The agreement also provides for potential additional payments, in the event Alexion exercises the purchase option, for up to $500 million, which includes an upfront option exercise payment and potential regulatory and commercial milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2019, following the U.S. Food and Drug Administration (“FDA”) feedback which resulted in the redesign and expansion of Caelum’s planned clinical development program for its lead product candidate, CAEL-101, Caelum entered into an Amended and Restated DOSPA, which amended the terms of the existing agreement with Alexion. The amendment modified the terms of Alexion’s option to acquire the remaining equity in Caelum based on data from the expanded Phase 2/3 trials. The amendment also modified the development-related milestone events associated with the initial $30 million in contingent payments, provided for an additional $20 million in upfront funding, as well as funding of $60 million in exchange for an additional equity interest in Caelum at fair value upon achievement of a specific development-related milestone event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In September 2020, following its Phase 2 open-label dose escalation study, Caelum announced the initiation of its Cardiac Amyloid Reaching for Extended Survival (“CARES”) Phase 3 clinical program to evaluate CAEL-101<span style="font-size:13.5pt;"> </span>a first-in-class amyloid fibril targeted therapy, in combination with standard-of-care (SoC) therapy in AL amyloidosis. The CARES clinical program includes two parallel Phase 3 studies – one in patients with Mayo stage 3a disease and one in patients with Mayo stage 3b disease – and will collectively enroll approximately 370 patients globally. Enrollment is underway in both studies. The primary objective of the clinical program is to assess overall survival.   The Phase 2 program continues with the addition of a study arm to evaluate CAEL-101 in combination with SoC therapy plus daratumumab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Avenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;">Agreement with InvaGen</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 12, 2018, the Company’s partner company, Avenue, entered into a Stock Purchase and Merger Agreement (“Avenue SPMA”) with InvaGen Pharmaceuticals Inc. (“InvaGen”) and Madison Pharmaceuticals Inc., a newly formed, wholly-owned subsidiary of InvaGen. Pursuant to the Avenue SPMA, and following approval by Avenue’s stockholders on February 8, 2019, InvaGen purchased a number of shares of Avenue common stock representing 33.3% of Avenue’s fully diluted capital stock for net proceeds to Avenue of $31.5 million (after deducting fees and other offering-related costs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upon the achievement of certain closing conditions (including most notably FDA approval for IV Tramadol, Avenue’s product candidate), InvaGen will be obligated to acquire Avenue via reverse subsidiary merger (the “Merger Transaction”). Under the Merger Transaction, InvaGen will pay $180 million (subject to certain potential reductions) to the holders of Avenue’s capital stock (other than InvaGen itself). In October 2020, InvaGen communicated to Avenue that it believes a Material Adverse Effect (as defined in the Avenue SPMA) has occurred, due to the COVID-19 pandemic, which means that it is possible that InvaGen is attempting to avoid their obligations to consummate the second stage closing under the Avenue SPMA. Avenue disagrees with InvaGen’s assertion that a Material Adverse Effect has occurred, and Avenue has advised InvaGen of this position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subject to the terms and conditions described in the Avenue SPMA, InvaGen may also provide interim financing to Avenue in an amount of up to $7.0 million during the time period between February 8, 2019 and the Merger Transaction. Any amounts drawn on the interim financing will be deducted from the aggregate consideration payable to Company stockholders by virtue of the Merger Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to the closing of the Merger Transaction, Avenue will enter into a Contingent Value Rights Agreement (the “CVR Agreement”) with a trust company as rights agent, pursuant to which holders of common shares of Avenue, other than InvaGen (each, a “Holder”), will be entitled to receive on Contingent Value Right (“CVR”) for each share held immediately prior to the Merger Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Each CVR represents the right of its holder to receive a contingent cash payment pursuant to the CVR Agreement upon the achievement of certain milestones. If, during the period commencing on the day following the closing of the Merger Transaction until December 31, 2028, IV Tramadol generates at least $325 million or more in Net Sales (as defined in the CVR Agreement) in a calendar year, each Holder shall be entitled to receive their pro rata share of (i) if the product generated less than $400 million in Net Sales during such calendar year, 10% of Gross Profit (as defined in the CVR Agreement), (ii) if the product generated between $400 million and $500 million in Net Sales during such calendar year, 12.5% of Gross Profit, or (iii) if the product generated more than $500 million in Net Sales during such calendar year, 15% of Gross Profit. Additionally, at any time beginning on January 1, 2029 that IV Tramadol has generated at least $1.5 billion in aggregate Net Sales, then with respect to each calendar year in which IV Tramadol generates $100 million or more in Net Sales, each Holder shall be entitled to receive their pro rata share of an amount equal to 20% of the Gross Profit generated by IV Tramadol. These additional payments will terminate on the earlier of December 31, 2036 and the date (which may be extended by up to 6 months) that any person has received approval from the FDA for an Abbreviated New Drug Application (“NDA”) or an FDA AP-rated 505(b)(2) NDA using IV Tramadol.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:3.29pt 0pt 3.29pt 0pt;">On October 12, 2020, Avenue announced that it had received a Complete Response Letter (“CRL”) from the FDA regarding Avenue’s NDA for IV Tramadol.   The CRL cited deficiencies related to the terminal sterilization validation and stated that IV Tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population. Avenue requested a meeting with the FDA to resolve the issues described in the CRL and the meeting has been scheduled for the fourth quarter of 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:3.29pt 0pt 3.29pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Also in October 2020, InvaGen Pharmaceuticals Inc. (“InvaGen”) communicated to Avenue that it believes a Material Adverse Effect (as defined in the Stock Purchase and Merger Agreement (“Avenue SPMA”)) has occurred, due to the COVID-19 pandemic, which means that it is possible that InvaGen is attempting to avoid their obligations to consummate the second stage closing under the Avenue SPMA. Avenue disagrees with InvaGen’s assertion that a Material Adverse Effect has occurred, and Avenue has advised InvaGen of this position.</p> 0.199 30000000 500000000 30000000 20000000 60000000 0.333 31500000 180000000 7000000.0 325000000 400000000 0.10 400000000 500000000 0.125 500000000 0.15 1500000000 100000000 0.20 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">5. Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fortress’ property and equipment consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Useful Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 662</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 648</p></td></tr><tr><td style="vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,162</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery &amp; equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,014</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,594</p></td></tr><tr><td style="vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_kKPabswYEEaAdUbLTYZaAQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">5</span></span><span style="-sec-ix-hidden:Hidden_R0gBYmYNg0OuWrfgVVP6Iw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">-15</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,358</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 821</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,157</p></td></tr><tr><td style="vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,919</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,162)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,486)</p></td></tr><tr><td style="vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,433</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">Note 1:</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">Relates to the Mustang cell processing facility.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Fortress' depreciation expense for the three months ended September 30, 2020 and 2019 was approximately </span><span style="font-weight:normal;">$0.6</span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$0.5</span><span style="font-weight:normal;"> million, respectively, and was recorded in both research and development expense and general and administrative expense in the condensed consolidated statements of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fortress' depreciation expense for the nine months ended September 30, 2020 and 2019 was approximately $1.7 million and $1.4 million, respectively, and was recorded in both research and development expense and general and administrative expense in the condensed consolidated statements of operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fortress’ property and equipment consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Useful Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 662</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 648</p></td></tr><tr><td style="vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,162</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery &amp; equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,014</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,594</p></td></tr><tr><td style="vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_kKPabswYEEaAdUbLTYZaAQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">5</span></span><span style="-sec-ix-hidden:Hidden_R0gBYmYNg0OuWrfgVVP6Iw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">-15</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,358</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">N/A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 821</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,157</p></td></tr><tr><td style="vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,919</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,162)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,486)</p></td></tr><tr><td style="vertical-align:top;width:67.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,433</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">Note 1:</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">Relates to the Mustang cell processing facility.</span></p></td></tr></table> P3Y 662000 648000 P5Y 1199000 1162000 P5Y 5014000 4594000 10580000 9358000 821000 1157000 18276000 16919000 6162000 4486000 12114000 12433000 600000 500000 1700000 1400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">6. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;">Fair Value of Caelum</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, the Company valued its investment in Caelum in accordance with ASC Topic 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>, and estimated the fair value to be $11.7 million based on a per share value of $1.62. As of September 30, 2020, the following inputs were utilized to derive the value: risk free rate of return of 0.12%, volatility of 70% and a discount for lack of marketability of 28.6%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of December 31, 2019, the Company valued its investment in Caelum in accordance with ASC Topic 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>, and estimated the fair value to be $11.1 million based on a per share value of $1.54. As of December 31, 2019, the following inputs were utilized to derive the value: risk free rate of return of 1.6%, volatility of 70% and a discount for lack of marketability of 28.7%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Cyprium Warrant Liability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the quarter ended September 30, 2020, Cyprium raised approximately $8.0 million in Perpetual Preferred Shares (“Cyprium Offering,” see Note 14).  The Cyprium Offering coupled with the repayment of the 2018 Venture Debt (see Note 10), triggered the issuance of the Cyprium Warrant, in that a price per share could be established. As such these events resulted in Cyprium recording the Cyprium Warrant as issued rather than contingently issuable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of the Cyprium Warrants in connection with the 2018 Venture Debt was determined by applying management’s estimate of the probability of issuance of the Contingently Issuable Warrants together with an option-pricing model, with the following key assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.92</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term in years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of issuance of the warrant</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cyprium</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contingently</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuable Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning balance at January 1, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,189</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclass partner company's warrants from liability to equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,216)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending balance at September 30, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables classify into the fair value hierarchy of Fortress’ financial instruments, measured at fair value as of September 30, 2020 and December 31, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement as of  September 30, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:top;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of investment in Caelum</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement as of  December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of investment in Caelum</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,148</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,148</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,148</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement as of  December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below provides a roll-forward of the changes in fair value of Level 3 financial instruments as of September 30, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Investment in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Caelum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,148</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,175</p></td></tr><tr><td style="vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,189</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclass partner company's warrants from liability to equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,216)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,216)</p></td></tr><tr><td style="vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value of investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 575</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at September 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2020, no transfers occurred between Level 1, Level 2 and Level 3 instruments.</p> 11700000 1.62 0.0012 0.70 0.286 11100000 1.54 0.016 0.70 0.287 8000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.92</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term in years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Probability of issuance of the warrant</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table> 0.0069 0.0192 0 0 P10Y P10Y 0.85 0.93 1 0.05 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cyprium</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contingently</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuable Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning balance at January 1, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td></tr><tr><td style="vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,189</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclass partner company's warrants from liability to equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,216)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending balance at September 30, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr></table> 27000 1189000 1216000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables classify into the fair value hierarchy of Fortress’ financial instruments, measured at fair value as of September 30, 2020 and December 31, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement as of  September 30, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:top;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of investment in Caelum</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement as of  December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of investment in Caelum</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,148</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,148</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,148</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement as of  December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td></tr></table> 0 0 11723000 11723000 0 0 11723000 11723000 0 0 11148000 11148000 0 0 11148000 11148000 0 0 27000 27000 0 0 27000 27000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below provides a roll-forward of the changes in fair value of Level 3 financial instruments as of September 30, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Investment in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Caelum</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,148</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,175</p></td></tr><tr><td style="vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,189</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclass partner company's warrants from liability to equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,216)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,216)</p></td></tr><tr><td style="vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value of investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 575</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at September 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,723</p></td></tr></table> 11148000 27000 11175000 1189000 1189000 1216000 1216000 575000 575000 11723000 0 11723000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">7. Licenses Acquired</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with ASC 730-10-25-1, <i style="font-style:italic;">Research and Development</i>, costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use. The licenses purchased by Fortress and its partner companies require substantial completion of research and development, and regulatory and marketing approval efforts in order to reach technological feasibility. As such, for the three and nine months ended September 30, 2020 and 2019, the purchase price of licenses acquired was classified as research and development-licenses acquired in the condensed consolidated Statements of operations as reflected in the table below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Partner companies:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#ff0000;">  </span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#ff0000;">  </span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Mustang</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Aevitas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 162</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 162</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Baergic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Oncogenuity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 271</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Mustang</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">SIRION Biotech GmbH - LentiBOOST</span><sup style="font-size:7.5pt;line-height:100%;text-decoration:underline;text-decoration-color:#000000;top:0pt;vertical-align:top;">TM</sup><span style="text-decoration:underline;text-decoration-color:#000000;"> (MB-207)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On September 30, 2020, Mustang entered into an exclusive, worldwide licensing agreement with SIRION Biotech (“SIRION”) for the rights to SIRION’s LentiBOOST<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> technology for the development of MB-207, Mustang’s lentiviral gene therapy for the treatment of previously transplanted patients with X-linked severe combined immunodeficiency (the “SIRION Technology License”). Pursuant to the SIRION Technology License, which requires payment in Euro, the Company paid SIRION a one-time upfront fee of $0.1 million (€0.1 million) during the three and nine months ended September 30, 2020. In addition, five future development milestone payments totaling up to approximately $5.6 million (€4.7 million) in the aggregate are due upon achievement of certain milestones. Additional milestone payments totaling up to $4.1 million (€3.5 million) in the aggregate are due in connection with the achievement of three commercial milestones and low- to mid-single digit royalties are due on aggregate cumulative worldwide net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;"><span style="font-style:normal;">For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for licenses acquired:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">City of Hope National Medical Center</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CD123 (MB-102)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">IL13Rα2 (MB-101)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> 3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">HER2 (MB-103)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CS1 (MB-104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">PSCA (Spacer)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 333</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fred Hutch - CD20 (MB-106)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nationwide Children’s Hospital - C134 (MB-108)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CSL Behring (Calimmune)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">UCLA</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">SIRION LentiBOOST<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 287</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,837</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,350</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-103 at COH, for the nine months ended September 30, 2020.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-106 at Fred Hutch, for the nine months ended September 30, 2020.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Note 3:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Represents a milestone payment to COH in connection with Mustang’s public underwritten offerings, for the nine months ended September 30, 2020.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Oncogenuity </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective May 6, 2020, Oncogenuity entered into a license agreement with the Trustees of Columbia University in the City of New York (“Columbia”) to develop novel oligonucleotides for the treatment of genetically driven cancers (the “Columbia License”). The proprietary platform produces oligomers, known as “ONCOlogues.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As consideration for the Columbia License, Oncogenuity paid an upfront fee of $0.3 million, and Fortress transferred to Columbia 1,000,000 shares of Oncogenuity common stock, representing 10.00% ownership of Oncogenuity. In connection with the share transfer, Oncogenuity also provided Columbia with limited anti-dilution protection. Oncogenuity valued the stock grant to Columbia utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 41.7%, weighted average cost of capital of 20.5%, and net of debt utilized, resulting in a value of $0.021 per share or $21,000 for the three and nine months ended September 30, 2020. Since a portion of the acquisition of the license was settled through the transfer of shares of Oncogenuity's common stock, this transaction fell within the scope of <i style="font-style:italic;">ASC Topic 718, Compensation-Stock Compensation</i>, since equity was transferred in exchange for goods (the license). Specifically, Oncogenuity recorded the cost of the license as a non-employee share based payment, measured at the grant date fair value of the common stock. The common shares were equity-classified. The anti-dilution provision was concluded to represent a performance condition tied to a future liquidity event, which was not considered as probable to occur at September 30, 2020, because it was deemed outside of Oncogenuity’s control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Development milestone payments totaling up to approximately $18.0 million in the aggregate are due upon achievement of certain milestones in connection with the initial indication. Additional milestone payments totaling up to $15.3 million in the aggregate are due in connection with product development milestones for subsequent indications. A $15.0 million sales milestone is due upon the achievement of a licensed product sales threshold, and low- to mid-single digit royalties are due on aggregate cumulative worldwide net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three and nine months ended September 30, 2020, Oncogenuity recorded expense of nil and $0.3 million in research and development - licenses acquired in the Company’s condensed consolidated statements of operations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Partner companies:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#ff0000;">  </span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#ff0000;">  </span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Mustang</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Aevitas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 162</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 162</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Baergic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Oncogenuity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 271</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:36.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 287000 700000 1837000 1350000 162000 162000 8000 8000 1000 271000 458000 700000 2278000 1350000 100000 100000 100000 100000 5600000 4700000 4100000 3500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;"><span style="font-style:normal;">For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for licenses acquired:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">City of Hope National Medical Center</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CD123 (MB-102)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">IL13Rα2 (MB-101)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> 3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">HER2 (MB-103)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CS1 (MB-104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">PSCA (Spacer)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 333</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fred Hutch - CD20 (MB-106)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nationwide Children’s Hospital - C134 (MB-108)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CSL Behring (Calimmune)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">UCLA</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td></tr><tr><td style="vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">SIRION LentiBOOST<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 287</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,837</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,350</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-103 at COH, for the nine months ended September 30, 2020.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-106 at Fred Hutch, for the nine months ended September 30, 2020.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Note 3:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Represents a milestone payment to COH in connection with Mustang’s public underwritten offerings, for the nine months ended September 30, 2020.</p></td></tr></table> 0 0 334000 250000 0 0 333000 0 0 0 250000 0 0 0 0 200000 0 200000 333000 200000 0 0 300000 0 0 0 0 200000 170000 200000 170000 200000 0 300000 0 300000 117000 0 117000 0 287000 700000 1837000 1350000 300000 1000000 0.1000 0.417 0.417 0.205 0.205 0.021 0.021 21000 21000 18000000.0 15300000 15000000.0 0 300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">8. Sponsored Research and Clinical Trial Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Aevitas </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three and nine months ended September 30, 2020 and 2019, Aevitas recorded the following expense in connection with its sponsored research and clinical trial agreements:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:35.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">UMass - adeno-associated virus ("AAV")</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 218</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">UPenn - AAV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 755</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Duke - AAV</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 772</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cellvation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the three and nine months ended September 30, 2020 no expenses were incurred. For the three and nine months ended September 30 2019, Cellvation recorded expense of $0.1 million, in connection with its sponsored research arrangement with the University of Texas. The expense was recorded in research and development expense in the Company’s condensed consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Mustang</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">CS1(MB-104) Clinical Research and Support Agreement with COH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2020, Mustang entered into a clinical research and support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: "Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients with CS1+ Multiple Myeloma." The CAR T being studied under this protocol has been designated by Mustang as MB-104. Under the terms of the agreement Mustang paid COH $0.8 million during the three months ended September 30, 2020 for costs incurred and will reimburse COH for costs associated with this trial, when incurred, not to exceed $2.4 million. The agreement will expire upon the delivery of the final study report or earlier.  Expense of $0.1 million an $0.8 million was incurred for the three and nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">XSCID (MB-107) Data Transfer Agreement with St. Jude</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, Mustang entered into a Data Transfer Agreement with St. Jude under which Mustang will reimburse St. Jude for costs associated with St. Jude’s clinical trial for the treatment of infants with X-linked Severe Combined Immunodeficiency (“XSCID”).  Pursuant to the terms of this agreement Mustang paid an upfront fee of $1.1 million on July 1, 2020 and will continue to reimburse St. Jude for costs incurred in connection with this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:39.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">City of Hope National Medical Center</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,500</p></td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CD123 (MB-102)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,028</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">IL13Rα2 (MB-101)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 244</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 422</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 811</p></td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 343</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CS1 (MB-104)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 835</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beth Israel Deaconess Medical Center - CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">St. Jude Children's Research Hospital - XSCID (MB-107)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,665</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Fred Hutchinson Cancer Research Center - CD20 (MB-106)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 690</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,176</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,900</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,441</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Oncogenuity </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Columbia License, Oncogenuity will pay up to $4.8 million to Columbia semiannually for five years ending in November 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three and nine months ended September 30, 2020, Oncogenuity recorded expense of $0.2 million and $0.3 million, respectively, in research and development in the Company’s condensed consolidated statements of operations. No expense was recorded in 2019.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three and nine months ended September 30, 2020 and 2019, Aevitas recorded the following expense in connection with its sponsored research and clinical trial agreements:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:35.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">UMass - adeno-associated virus ("AAV")</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 218</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">UPenn - AAV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 755</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Duke - AAV</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:35.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 772</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 163000 0 218000 0 0 255000 567000 755000 0 17000 0 17000 163000 272000 785000 772000 0 0 100000 100000 800000 2400000 100000 800000 1100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:39.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">City of Hope National Medical Center</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,500</p></td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CD123 (MB-102)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,028</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">IL13Rα2 (MB-101)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 244</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 422</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 811</p></td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 343</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CS1 (MB-104)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 835</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beth Israel Deaconess Medical Center - CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">St. Jude Children's Research Hospital - XSCID (MB-107)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,665</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Fred Hutchinson Cancer Research Center - CD20 (MB-106)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 690</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 734</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,176</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,900</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,441</p></td></tr></table> 0 500000 500000 1500000 48000 269000 344000 1028000 96000 244000 422000 811000 0 114000 0 343000 65000 0 835000 0 0 0 0 69000 107000 0 1665000 0 418000 49000 1134000 690000 734000 1176000 4900000 4441000 4800000 P5Y 200000 300000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">9. Intangibles, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 29, 2020 Journey entered into a license and supply agreement with a third party for an oral acne treatment. Pursuant to the terms and conditions of the License and Supply Agreement (“LSA”), Journey agreed to pay $5.0 million, comprised of an upfront payment of $1.0 million paid upon execution with remaining payments due as follows: $1.0 million upon achievement of two marketing milestones and $3.0 million due <span style="-sec-ix-hidden:Hidden_gjCjFwYtvEKXX9bSO45slQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">in</span></span> $1.0 <span style="-sec-ix-hidden:Hidden_eWaAHK0KREqf7RzCrbYzrQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">million</span></span> installments, commencing on the 18-month anniversary, the 24-month anniversary and the 36-month anniversary of execution of the LSA. Three additional milestone payments totaling $17.0 million are due upon the achievement of certain net sales milestones. Royalties in the mid, single digits based on net sales, subject to specified reductions are also due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with ASU 2017-01, <i style="font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</i>, Journey determined the conditions of the LSA did not constitute the purchase of a business, and therefore recorded the consideration as an asset, to be amortized over the expected life of the product, which is deemed to be five years. In addition, Journey determined pursuant to ASC 450, <i style="font-style:italic;">Contingencies,</i> that royalty payments in connection with the LSA will be recorded when they become payable with a corresponding charge to cost of goods sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accordance with the installment payment terms of the LSA, Journey recorded a discount for imputed interest per ASC 835-30 <i style="font-style:italic;">Interest-Imputed Interest </i>of <i style="font-style:italic;">$</i>0.3 million<i style="font-style:italic;">. </i>As of September 30, 2020, Journey recorded a net intangible asset related to this transaction of $4.7 million which was recorded on the Company’s condensed consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below provides a summary of the Journey intangible assets as of September 30, 2020 and December 31, 2019, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lives (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Intangible assets – asset purchases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3 to 7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,661</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,934</p></td></tr><tr><td style="vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,622)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,557)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net intangible assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,039</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,377</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below provides a summary for the nine months ended September 30, 2020, of Journey’s recognized expense related to its product licenses, which was recorded in costs of goods sold on the condensed consolidated statement of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intangible</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets, Net</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning balance at January 1, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,377</p></td></tr><tr><td style="vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Oral acne treatment license acquisition<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,727</p></td></tr><tr><td style="vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,065)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending balance at September 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,039</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Note 1:  As of September 30, 2020, this asset has not yet been placed in service, therefore no amortization expense was recognized on this asset for the quarter ended September 30, 2020.  The Company expects the asset to be placed in service in the first half of 2021. Once the asset is placed in service the Company will amortize the asset over five years, which represents its expected useful life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The future amortization of these intangible assets is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;"> ($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ximino®</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exelderm®</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 354</p></td></tr><tr><td style="vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,286</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td></tr><tr><td style="vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td></tr><tr><td style="vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,615</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,945</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,312</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asset not yet placed in service</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,727</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,945</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,039</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 5000000.0 1000000.0 1000000.0 2 3000000.0 1000000.0 P18M P24M P36M 3 17000000.0 P5Y 300000 4700000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below provides a summary of the Journey intangible assets as of September 30, 2020 and December 31, 2019, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lives (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Intangible assets – asset purchases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3 to 7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,661</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,934</p></td></tr><tr><td style="vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,622)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,557)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net intangible assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,039</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,377</p></td></tr></table> P3Y P7Y 14661000 9934000 3622000 2557000 11039000 7377000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below provides a summary for the nine months ended September 30, 2020, of Journey’s recognized expense related to its product licenses, which was recorded in costs of goods sold on the condensed consolidated statement of operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intangible</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets, Net</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning balance at January 1, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,377</p></td></tr><tr><td style="vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Oral acne treatment license acquisition<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,727</p></td></tr><tr><td style="vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,065)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending balance at September 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,039</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Note 1:  As of September 30, 2020, this asset has not yet been placed in service, therefore no amortization expense was recognized on this asset for the quarter ended September 30, 2020.  The Company expects the asset to be placed in service in the first half of 2021. Once the asset is placed in service the Company will amortize the asset over five years, which represents its expected useful life.</p> 7377000 4727000 1065000 11039000 P5Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The future amortization of these intangible assets is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;"> ($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ximino®</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exelderm®</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 354</p></td></tr><tr><td style="vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,286</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td></tr><tr><td style="vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019</p></td></tr><tr><td style="vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,615</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,945</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,312</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asset not yet placed in service</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,727</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,945</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,039</p></td></tr></table> 254000 100000 354000 1019000 267000 1286000 1019000 0 1019000 1019000 0 1019000 1019000 0 1019000 1615000 0 1615000 5945000 367000 6312000 4727000 5945000 367000 11039000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">10. Debt and Interest</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the quarter ended September 30, 2020 the Company entered into a new credit facility with Oaktree Fund Administration, LLC, as the administrative agent (in such capacity, the “Agent”), and the lenders from time to time party thereto (each a “Lender” or  “Oaktree” and collectively, the “Lenders”), as described below (the “Oaktree Note”).  The Company utilized the proceeds from the Oaktree Note to repay the 2017 Subordinated Notes, the 2018 Venture Notes and the 2019 Notes.  The Company also repaid the IDB Note utilizing the cash collateral securing the IDB Note, which was classified as restricted cash on the Company’s consolidated condensed balance sheet.  In addition, on September 30, 2020 Mustang repaid the Mustang Horizon Notes.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total debt consists of the following as of September 30, 2020 and December 31, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IDB Note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,929</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.25</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_5JJ7DdbLWEC34RPHYraHlQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">Aug - 2021</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bLyBg7nTVUSLH6Y1Rnhv-A"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">March - 2022</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,893</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_xGZp3eLSsUGs9vSkdIjk1Q"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">May - 2022</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__uUSTUVsTU-ST9w6EWuWrw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">June - 2022</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_fIDDogVajkqjB69XzOqVVg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">August - 2022</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">% </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_in5sqaFo4UCVko9eURxUHQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">September - 2022</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2018 Venture Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">4</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,517</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_GkkzFOSYpkiQpJybAmK5kg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">August - 2021</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2018 Venture Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">4</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__sryfuZMZkq0cydJRkLcWw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">September - 2021</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2019 Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_IgEJOAWNM0yHJ43yNzRiRA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">September - 2021</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang Horizon Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bljwSLBjyU-2Lrf9ESoUUg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">October - 2022</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oaktree Note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0-jWaeKoEkW_6eQpvVTfCg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">August - 2025</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 89,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: Discount on notes payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,607</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,086</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Formerly the Opus Credit Facility (see Note 16.)</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Interest rate was 9.0% plus one-month LIBOR Rate in excess of 2.5%.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 3:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">As a result of a one-year maturity date extension effective 2020, the interest rate increased by 1% to 9.0%. </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Note 4:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">At December 31, 2019, $6.0 million is included in Notes payable, short-term on the condensed consolidated balance sheet.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest; fees include amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:56.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fees </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fees </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IDB Note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,398</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2019 Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 172</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 172</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 275</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 379</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2018 Venture Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 604</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LOC Fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang Horizon Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1,3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 579</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oaktree Note<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 624</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Note Payable<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Interest Expense and Financing Fee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,168</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:56.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fees </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fees </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IDB Note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,229</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2019 Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 840</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 336</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,176</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2018 Venture Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,767</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LOC Fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang Horizon Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1,3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,164</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oaktree Note<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 624</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Note Payable<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Interest Expense and Financing Fee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,743</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">For the three and nine months ended September 30, 2020, $1.2 million expense of unamortized debt discount fees for the 2017 Subordinated Note Financing, $0.3 million for the 2018 Venture Notes and $1.8 million for the Mustang Horizon Notes.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Imputed interest expense related to Journey’s agreements for Ximino and oral acne treatment.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Note 3: </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Included in interest expense for the three and nine months ended September 30, 2020 was $0.6 million of prepayment penalties included in interest expense for the Mustang Horizon Notes.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><i style="font-style:italic;">Oaktree Note</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 27, 2020 (the “Closing Date”), Fortress, as borrower, entered into a $60.0 million senior secured credit agreement (the “Agreement”) with Oaktree. The Company borrowed the full $60.0 million in connection with the terms of the Oaktree Note on the Closing Date and used the bulk of the proceeds to repay its outstanding debt to other lenders (2017 Subordinated Notes, 2018 Venture Notes and 2019 Notes (previously the “Opus Credit Facility”)). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Oaktree Note bears interest at a fixed annual rate of 11.0%, payable quarterly and maturing on the fifth anniversary of the Closing Date, August 27, 2025, the (“Maturity Date”). The Company is required to make quarterly interest-only payments until the Maturity Date, at which point the outstanding principal amount is due. The Company may voluntarily prepay the Oaktree Note at any time subject to a Prepayment Fee as defined in the Terms section. The Company is required to make mandatory prepayments of the Oaktree Note under various circumstances as defined in the Terms section. No amounts paid or prepaid may be reborrowed without Oaktree consent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of permitted indebtedness, and dividends and other distributions, subject to certain exceptions. In addition, the Agreement contains certain financial covenants, including, among other things, (i) maintenance of minimum liquidity by the Company, and (ii) a minimum revenue test that is subject to certain exclusions. Failure by the Company to comply with the financial covenants will result in an event of default, subject to certain cure rights of the Company.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Agreement contains customary events of default, in certain circumstances subject to customary cure periods. Following an event of default and any cure period, if applicable, the Agent will have the right upon notice to accelerate all amounts outstanding under the Agreement, in addition to other remedies available to the lenders as secured creditors of the Company. The Agreement grants a security interest in favor of the Agent, for the benefit of the lenders, in substantially all of the Company’s assets as collateral securing the Company’s obligations under the Agreement, except for: (i) certain interests in controlled foreign corporation subsidiaries of the Company; (ii) the Company’s holdings in Avenue; and (iii) those portions of the Company’s holdings in certain subsidiaries (plus Caelum) that are encumbered by pre-existing equity pledges to certain of the Company’s officers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the terms of the Agreement on the Closing Date the Company paid Oaktree an upfront commitment fee equal to 3% of the $60.0 million, or $1.8 million.  In addition, the Company paid a $35,000 Agency fee to the Agent which was due on the Closing Date and will be due annually, together with fees of $2.5 million directly to third parties involved in the transaction.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the Oaktree Note, the Company issued warrants to Oaktree and certain of its affiliates to purchase up to 1,749,450 shares of common stock (see Note 14) with a relative fair value of $4.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, the Company recorded the fees totaling $8.7 million ($1.8 million to Oaktree, $2.5 million of expenses paid to third-parties and $4.4 million representing the relative fair value of the Oaktree Warrants) to debt discount.  These costs will be amortized over the term of the Oaktree Note.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total debt consists of the following as of September 30, 2020 and December 31, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Maturity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IDB Note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,929</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.25</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_5JJ7DdbLWEC34RPHYraHlQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">Aug - 2021</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bLyBg7nTVUSLH6Y1Rnhv-A"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">March - 2022</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,893</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_xGZp3eLSsUGs9vSkdIjk1Q"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">May - 2022</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__uUSTUVsTU-ST9w6EWuWrw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">June - 2022</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_fIDDogVajkqjB69XzOqVVg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">August - 2022</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">% </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_in5sqaFo4UCVko9eURxUHQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">September - 2022</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2018 Venture Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">4</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,517</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_GkkzFOSYpkiQpJybAmK5kg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">August - 2021</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2018 Venture Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">4</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__sryfuZMZkq0cydJRkLcWw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">September - 2021</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2019 Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_IgEJOAWNM0yHJ43yNzRiRA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">September - 2021</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang Horizon Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bljwSLBjyU-2Lrf9ESoUUg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">October - 2022</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oaktree Note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0-jWaeKoEkW_6eQpvVTfCg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">August - 2025</span></span></p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 89,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: Discount on notes payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,607</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,086</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:top;width:46.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,656</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Formerly the Opus Credit Facility (see Note 16.)</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Interest rate was 9.0% plus one-month LIBOR Rate in excess of 2.5%.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 3:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">As a result of a one-year maturity date extension effective 2020, the interest rate increased by 1% to 9.0%. </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Note 4:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">At December 31, 2019, $6.0 million is included in Notes payable, short-term on the condensed consolidated balance sheet.</p></td></tr></table> 0 14929000 0.0225 0 3254000 0.0800 0 13893000 0.0800 0 1820000 0.0800 0 3018000 0.0800 0 6371000 0.0800 0 6517000 0.0800 0 15190000 0.0800 0 9000000 0.1200 0 15750000 0.0900 60000000 0.1100 60000000 89742000 8607000 5086000 51393000 84656000 0.090 0.025 P1Y 0.01 0.090 6000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest; fees include amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:56.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fees </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fees </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IDB Note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,398</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2019 Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 172</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 172</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 275</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 379</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2018 Venture Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 604</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LOC Fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang Horizon Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1,3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 234</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 579</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oaktree Note<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 624</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Note Payable<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Interest Expense and Financing Fee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,168</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:56.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fees </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fees </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IDB Note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2017 Subordinated Note Financing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,229</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2019 Notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 710</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 840</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 336</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,176</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2018 Venture Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,767</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LOC Fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang Horizon Notes<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1,3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,164</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oaktree Note<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 624</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Note Payable<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:41.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Interest Expense and Financing Fee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,743</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">For the three and nine months ended September 30, 2020, $1.2 million expense of unamortized debt discount fees for the 2017 Subordinated Note Financing, $0.3 million for the 2018 Venture Notes and $1.8 million for the Mustang Horizon Notes.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Imputed interest expense related to Journey’s agreements for Ximino and oral acne treatment.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Note 3: </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Included in interest expense for the three and nine months ended September 30, 2020 was $0.6 million of prepayment penalties included in interest expense for the Mustang Horizon Notes.</p></td></tr></table> 77000 0 77000 86000 0 86000 694000 1374000 2068000 1072000 326000 1398000 172000 0 172000 275000 104000 379000 387000 638000 1025000 438000 166000 604000 14000 0 14000 14000 0 14000 895000 1792000 2687000 345000 234000 579000 624000 108000 732000 0 0 0 187000 0 187000 0 108000 108000 -4000 0 -4000 0 0 0 3046000 3912000 6958000 2230000 938000 3168000 246000 0 246000 254000 254000 2870000 1890000 4760000 3148000 1081000 4229000 710000 0 710000 840000 336000 1176000 1253000 1000000 2253000 1299000 468000 1767000 45000 0 45000 45000 0 45000 1585000 2321000 3906000 698000 466000 1164000 624000 108000 732000 0 0 0 492000 0 492000 0 108000 108000 -2000 0 -2000 0 0 0 7823000 5319000 13142000 6284000 2459000 8743000 1200000 1200000 300000 300000 1800000 1800000 600000 600000 60000000.0 60000000.0 0.110 0.03 60000000.0 1800000 35000 2500000 1749450 4400000 8700000 1800000 2500000 4400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">11. Accrued Liabilities and other Long-Term Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses and other long-term liabilities consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,153</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Salaries, bonus and related benefits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,677</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,683</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expense - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,604</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,215</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development - manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,017</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development - license maintenance fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 629</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 361</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development - milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued royalties payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,908</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,320</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued coupon expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,391</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 547</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,259</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,399</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred rent and long-term lease abandonment charge<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,996</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,136</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Long-term notes payable, net (Journey)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Ximino agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,456</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,990</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Oral acne treatment agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other long-term liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,205</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,126</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">As of September 30, 2020, and December 31, 2019, the balance consists of deferred charges related to build-out of the New York facility.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">As of September 30, 2020, and December 31, 2019, the imputed interest discount was $1.5 million and $2.0 million, respectively, in connection with its acquisition of Ximino in July 2019. Amortization of interest discount was $0.5 million for the nine months ended September 30, 2020, and $0.1 million for the nine months ended September 30, 2019. As of September 30, 2020, $2.0 million of note payable was classified as short-term.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 3:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">As of September 30, 2020, the imputed discount balance was $0.2 million.  The imputed interest discount was calculated utilizing a 4.00% effective rate, which represents the market rate for an asset-backed three year loan, secured by receivables. As of September 30, 2020, $1.0 million of note payable was classified as short-term.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses and other long-term liabilities consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,153</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Salaries, bonus and related benefits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,677</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,683</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expense - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,604</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,215</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development - manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,017</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development - license maintenance fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 629</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 361</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development - milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued royalties payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,908</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,320</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued coupon expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,391</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 547</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,259</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,399</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred rent and long-term lease abandonment charge<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,996</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,136</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Long-term notes payable, net (Journey)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Ximino agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,456</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,990</p></td></tr><tr><td style="vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Oral acne treatment agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other long-term liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,205</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,126</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">As of September 30, 2020, and December 31, 2019, the balance consists of deferred charges related to build-out of the New York facility.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">As of September 30, 2020, and December 31, 2019, the imputed interest discount was $1.5 million and $2.0 million, respectively, in connection with its acquisition of Ximino in July 2019. Amortization of interest discount was $0.5 million for the nine months ended September 30, 2020, and $0.1 million for the nine months ended September 30, 2019. As of September 30, 2020, $2.0 million of note payable was classified as short-term.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 3:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">As of September 30, 2020, the imputed discount balance was $0.2 million.  The imputed interest discount was calculated utilizing a 4.00% effective rate, which represents the market rate for an asset-backed three year loan, secured by receivables. As of September 30, 2020, $1.0 million of note payable was classified as short-term.</p></td></tr></table> 1672000 1153000 5677000 6683000 19000 0 4604000 4215000 0 1017000 629000 361000 600000 0 1908000 2320000 5476000 8391000 547000 1259000 21132000 25399000 1996000 2136000 3456000 4990000 2753000 0 8205000 7126000 1500000 2000000.0 500000 100000 2000000.0 200000 0.0400 P3Y 1000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">12. Non-Controlling Interests</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Non-controlling interests in consolidated entities are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the nine months ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-controlling interests</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-controlling</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NCI equity share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">non-controlling interests</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in consolidated entities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Aevitas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,297)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (680)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,977)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Avenue <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,206)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Baergic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,605)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,673)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cellvation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,072)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (145)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,217)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Checkpoint<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> 1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,963</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,963</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coronado SO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (290)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (290)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cyprium</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 784</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (843)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (59)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Helocyte</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,890)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (236)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">JMC</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,035)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oncogenuity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (268)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (315)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tamid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (652)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (692)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120,298</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (41,264)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,034</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the twelve months ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-controlling interests </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-controlling </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;"> ($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NCI equity share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">non-controlling interests</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <b style="font-weight:bold;">in consolidated entities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <b style="font-weight:bold;">ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Aevitas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,249)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (694)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,943)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Avenue <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,011)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 77.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Baergic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,162)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,139)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cellvation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (158)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (890)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Checkpoint <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,389</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,687)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,702</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 78.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coronado SO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (290)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (290)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cyprium</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (320)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (99)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (419)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10.6</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Helocyte</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,322)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (402)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,724)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">JMC</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (211)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 325</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 114</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 62,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,727)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 36,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 70.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tamid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (565)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (85)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (650)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 22.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 108,017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (61,700)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights. </p></td></tr></table> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Non-controlling interests in consolidated entities are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the nine months ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-controlling interests</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-controlling</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NCI equity share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">non-controlling interests</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in consolidated entities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Aevitas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,297)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (680)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,977)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Avenue <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,206)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Baergic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,605)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,673)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cellvation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,072)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (145)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,217)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Checkpoint<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> 1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,963</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,963</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coronado SO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (290)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (290)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cyprium</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 784</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (843)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (59)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Helocyte</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,890)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (236)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">JMC</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,035)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oncogenuity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (268)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (315)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tamid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (652)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (692)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120,298</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (41,264)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79,034</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the twelve months ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-controlling interests </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-controlling </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;"> ($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NCI equity share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">non-controlling interests</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <b style="font-weight:bold;">in consolidated entities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <b style="font-weight:bold;">ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Aevitas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,249)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (694)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,943)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 35.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Avenue <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,011)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 77.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Baergic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,162)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,139)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cellvation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (158)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (890)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Checkpoint <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,389</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,687)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 14,702</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 78.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coronado SO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (290)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (290)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cyprium</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (320)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (99)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (419)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10.6</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Helocyte</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,322)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (402)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,724)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">JMC</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (211)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 325</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 114</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 62,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,727)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 36,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 70.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tamid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (565)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (85)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (650)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 22.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:31.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 108,017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (61,700)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 46,317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights. </p></td></tr></table> -2297000 -680000 -2977000 0.390 5709000 -3206000 2503000 0.774 -1605000 -68000 -1673000 0.400 -1072000 -145000 -1217000 0.226 37963000 -9000000 28963000 0.800 -290000 0 -290000 0.130 784000 -843000 -59000 0.284 -4890000 -236000 -5126000 0.188 123000 257000 380000 0.069 86572000 -27035000 59537000 0.779 -47000 -268000 -315000 0.253 -652000 -40000 -692000 0.228 120298000 -41264000 79034000 -1249000 -694000 -1943000 0.358 24269000 -19011000 5258000 0.773 23000 -1162000 -1139000 0.330 -732000 -158000 -890000 0.206 29389000 -14687000 14702000 0.780 -290000 0 -290000 0.130 -320000 -99000 -419000 0.106 -4322000 -402000 -4724000 0.193 -211000 325000 114000 0.069 62025000 -25727000 36298000 0.703 -565000 -85000 -650000 0.228 108017000 -61700000 46317000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">13. Net Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the nine months ended September 30, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase Common Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,026,693</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,745,364</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,187,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,169,293</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested Restricted Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,305,949</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,622,881</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested Restricted Stock Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 434,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 791,610</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,954,457</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,329,148</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the nine months ended September 30, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase Common Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,026,693</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,745,364</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,187,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,169,293</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested Restricted Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,305,949</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,622,881</p></td></tr><tr><td style="vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested Restricted Stock Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 434,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 791,610</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,954,457</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,329,148</p></td></tr></table> 3026693 2745364 1187600 1169293 14305949 12622881 434215 791610 18954457 17329148 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">14. Stockholders’ Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">At the Company’s 2020 Annual Meeting of Stockholders held on June 17, 2020, its stockholders approved an amendment to its certificate of incorporation to increase the number of authorized shares of common stock available to issue by </span><span style="font-weight:normal;">50,000,000 </span><span style="font-weight:normal;">to </span><span style="font-weight:normal;">150,000,000 </span><span style="font-weight:normal;">with a par value of </span><span style="font-weight:normal;">$0.001</span><span style="font-weight:normal;"> per share. The amendment was filed with the Secretary of State of the State of Delaware on June 18, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the three and nine months ended September 30, 2020 and 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 936</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,791</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Executive awards of Fortress Companies' stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-employee awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 136</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Partner Companies:</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Avenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Checkpoint</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 725</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 833</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,095</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,444</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Mustang</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 606</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 183</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended September 30, 2020 and 2019, approximately $0.7 million and $1.2 million, respectively, of stock-based compensation expense was included in research and development expenses in connection with equity grants made to employees and consultants and approximately $2.5 million and $2.5 million, respectively, was included in general and administrative expenses in connection with grants made to employees, members of the board of directors and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2020 and 2019, approximately $2.5 million and $2.6 million, respectively, of stock-based compensation expense was included in research and development expenses in connection with equity grants made to employees and consultants and approximately $7.8 million and $7.8 million, respectively, was included in general and administrative expenses in connection with grants made to employees, members of the board of directors and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the Company’s 2020 Annual Meeting on June 30, 2020, the Company’s shareholders approved an amendment to the Company’s 2013 Stock Incentive Plan, as amended (“Stock Plan”) to increase common shares issuable under the Stock Plan by 3.0 million to 13.0 million.  For the nine months ended September 30, 2020, 4.2 million shares remain to be issued under the Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes Fortress stock option activities excluding activity related to Fortress partner companies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual life</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">intrinsic value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and expected to vest at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,410,501</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.30</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 684,752</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.33</p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (100,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (247,011)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and expected to vest at September 30, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,063,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,044,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.87</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, Fortress had no unrecognized stock-based compensation expense related to options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Restricted Stock and Restricted Stock Units</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress Companies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,768,014</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.46</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,873,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.57</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,549,564)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.69</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 630,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.82</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (106,250)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.71</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (368,290)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.13</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at September 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,247,108</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.49</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020 and 2019, the Company had unrecognized stock-based compensation expense related to restricted stock and restricted stock unit awards of approximately $17.5 million and $12.7 million, respectively, which is expected to be recognized over the remaining weighted-average vesting period of 3.9 years and 5.0 years, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual life</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,741,180</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.73</p></td></tr><tr><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,849,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,657,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of September 30, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,590,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,111,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.10</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of September 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,430,621</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,816,818</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.05</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the Oaktree Note (see Note 10), the Company issued warrants to Oaktree and certain of its affiliates to purchase up to 1,749,450 shares of common stock at a purchase price of $3.20 per share (the “Oaktree Warrants”). Oaktree is entitled to additional warrants if at any time prior to the expiration of the Oaktree Warrants in event the Company issues equity, warrants or convertible notes (collectively known as “Security Instruments”) at a price that is less than 95% of the market price of the Company’s  Common Stock on the trading day prior to the issuance of the Security Instruments. The Warrants expire on August 27, 2030 and may be net exercised at the holder’s election. The Company also agreed to file a registration statement on Form S-3 to register for resale the shares of common stock issuable upon exercise of the Warrants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company evaluated the accounting treatment of the Oaktree Warrants and determined that the Oaktree warrants met the scope exception of <i style="font-style:italic;">ASC 815-10-15-74(a) Derivatives and Hedging </i>and therefore the warrants should be classified in stockholders’ equity.  As such the Company used a Black-Scholes model to value the Oaktree Warrants.  Utilizing the following inputs: term of 10 years, volatility of 86.8%, risk-free rate of return of 0.74% yielding a value of $4.8 million. <i style="font-style:italic;">ASC 470-20-25-2 Debt – Debt with Conversion and Other Options</i> dictates that debt or stock issued with detachable warrants requires the proceeds to be allocated to the two instruments based on their relative fair values.  The relative fair value of the warrants was determined to be $4.4 million and was recorded as a component of Stockholders’ Equity in the Company’s condensed consolidated balance sheet at September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Employee Stock Purchase Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Eligible employees can purchase the Company’s Common Stock at the end of a predetermined offering period at 85% of the lower of the fair market value at the beginning or end of the offering period. The ESPP is compensatory and results in stock-based compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, 507,783 shares have been purchased and 492,217 shares are available for future sale under the Company’s ESPP. Share-based compensation expense recorded was approximately $38,000 and $18,000, respectively, for the three months ended September 30, 2020 and 2019, and approximately $0.1 million and $0.1 million, respectively, for the nine months ended September 30, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Capital Raises</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 26, 2020, the Company closed on an underwritten public offering whereby it sold 666,666 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (Nasdaq: FBIOP) (the "Preferred Stock"), (plus a 45-day option to purchase up to an additional 66,666 shares, which was exercised in August 2020) at a price of $18.00 per share for gross proceeds of approximately $13.2 million, before deducting underwriting discounts and commissions and offering expenses of approximately $1.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 29, 2020, the Company closed on an underwritten public offering whereby it sold 555,556 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (Nasdaq: FBIOP) (the "Preferred Stock"), (plus a 45-day option to purchase up to an additional 83,333 shares, which was exercised in May 2020) at a price of $18.00 per share for gross proceeds of approximately $11.5 million, before deducting underwriting discounts and commissions and offering expenses of approximately $1.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 14, 2020, the Company announced the closing of an underwritten public offering, whereby it sold 625,000 shares of its Preferred Stock, (plus a 45-day option to purchase up to an additional 93,750 shares, which was exercised in February 2020) at a price of $20.00 per share for gross proceeds of approximately $14.4 million, before deducting underwriting discounts and commissions and offering expenses of approximately $1.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cyprium 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 28, 2020, Cyprium closed on an underwritten public offering whereby it sold 255,400 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (“Cyprium Perpetual Preferred Stock” or “Cyprium PPS”), plus an overallotment of an additional 64,600 shares, which was exercised on September 18, 2020, at a price of $25.00 per share for gross proceeds of $8.0 million, before deducting underwriting discounts and commissions and offering expenses of approximately $0.9 million (the “Cyprium Offering”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Cyprium PPS, shareholders on the record date are entitled to receive a monthly cash dividend of $0.19531 per share which yields an annual dividend of $2.34375 per share. The Cyprium PPS will automatically be redeemed upon the first (and only the first) bona fide, arm’s-length sale of a Priority Review Voucher (a “<span style="font-style:italic;font-weight:bold;">PRV</span>”) issued by the FDA in connection with the approval of CUTX-101, Cyprium’s lead product candidate.  Upon the <span style="letter-spacing:-2pt;">P   R V</span> Sale,<span style="letter-spacing:-0.5pt;"> </span>each<span style="letter-spacing:-0.55pt;"> </span>share<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.55pt;"> Cyprium </span>PPS<span style="letter-spacing:-0.5pt;"> </span>will<span style="letter-spacing:-0.45pt;"> </span>be<span style="letter-spacing:-0.6pt;"> </span>automatically redeemed<span style="letter-spacing:-0.8pt;"> </span>in<span style="letter-spacing:-0.75pt;"> </span>exchange<span style="letter-spacing:-0.75pt;"> </span>for<span style="letter-spacing:-0.7pt;"> </span>a<span style="letter-spacing:-0.8pt;"> </span>payment<span style="letter-spacing:-0.75pt;"> </span>equal<span style="letter-spacing:-0.8pt;"> </span>to<span style="letter-spacing:-0.75pt;"> </span>twice<span style="letter-spacing:-0.75pt;"> </span>(2x)<span style="letter-spacing:-0.75pt;"> </span>the<span style="letter-spacing:-0.8pt;"> </span>$25.00 liquidation preference, <i style="font-style:italic;">plus </i>accumulated and unpaid dividends to, but excluding, the redemption<span style="letter-spacing:-0.2pt;"> </span>date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An optional exchange to Company Preferred Stock is available after 24 months from the issuance date so long as a sale of the PRV has not occurred.  Additionally, if a PRV Sale has not occurred by September 30, 2024 the Cyprium PPS is either automatically exchanged for Company Preferred Stock or cash at the discretion of Fortress.  The Cyprium PPS is fully and unconditionally guaranteed by Fortress.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cyprium paid an initial dividend of $49,883 ($0.19531 per share) to shareholders of record on September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Checkpoint Underwritten Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2020, Checkpoint completed an underwritten public offering in which it sold 7,321,429 shares of its common stock at a price of $2.80 per share for gross proceeds of approximately $20.5 million. Total net proceeds from the offering were approximately $18.9 million, net of underwriting discounts and offering expenses of approximately $1.6 million. The shares were sold under a shelf registration statement on Form S-3 that Checkpoint filed in November 2017 and was declared effective in December 2017 (“the Checkpoint S-3”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mustang Underwritten Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, Mustang completed an underwritten public offering in which it sold 11,455,604 shares of its common stock at a price of $3.25 per share for gross proceeds of approximately $37.2 million. Total net proceeds from the offering were approximately $34.9 million, net of underwriting discounts and offering expenses of approximately $2.3 million. The shares were sold under Mustang’s S-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-the-Market Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 28, 2019, the Company entered into an At Market Issuance Sales Agreement ("2019 Common ATM"), with Cantor Fitzgerald &amp; Co., Oppenheimer &amp; Co., Inc., H.C. Wainwright &amp; Co. Inc., Jones Trading Institutional Services LLC and B. Riley, as selling agents, governing potential sales of the Company's common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The shares of common stock were sold under the Company’s shelf registration statement on Form S-3 originally filed on July 6, 2018 and declared effective July 23, 2019 (the “2019 Shelf”) through May 27, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 18, 2020, the Company filed a new shelf registration statement on Form S-3, which was declared effective on May 26, 2020 (the "2020 Shelf"). In connection with the 2020 Shelf, the Company entered into an At Market Issuance Sales Agreement ("2020 Common ATM"), with Cantor Fitzgerald &amp; Co., Oppenheimer &amp; Co., Inc., H.C. Wainwright &amp; Co. Inc., B. Riley and Dawson James Securities, Inc., as selling agents, governing potential sales of the Company's common stock. ATM sales commencing on June 1, 2020 were made under the 2020 Shelf. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the nine-month period ended September 30, 2020, the Company issued approximately 16.4 million shares of common stock at an average price of $2.74 per share for gross proceeds of $44.8 million.  In connection with these sales, the Company paid aggregate fees of approximately $1.6 million.  Approximately $29.5 million of securities remain available for sale under the 2020 Shelf at September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mustang At-the-Market Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 13, 2018, Mustang filed a shelf registration statement No. 333-226175 on Form S-3, as amended on July 20, 2018 (the "2018 Mustang S-3"), which was declared effective in August 2018. Under the 2018 Mustang S-3, Mustang may sell up to a total of $75.0 million of its securities. In connection with the 2018 Mustang S-3, Mustang entered into an At-the-Market Issuance Sales Agreement (the "Mustang ATM") with B. Riley FBR, Inc., Cantor Fitzgerald &amp; Co., National Securities Corporation, and Oppenheimer &amp; Co. Inc. (each an "Agent" and collectively, the "Agents"), relating to the sale of shares of common stock. Under the Mustang ATM, Mustang pays the Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of Mustang common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 16, 2019, Mustang filed a shelf registration statement No. 333-233350 on Form S-3, (the "2019 Mustang S-3"), which was declared effective on September 30, 2019. Under the 2019 Mustang S-3, Mustang may sell up to a total of $75.0 million of its securities. On July 20, 2020, Mustang entered into Amendment No. 1 to the Mustang ATM with the Agents to reflect the new registration statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2020, Mustang issued approximately 7.2 million shares of common stock at an average price of $3.56 per share for gross proceeds of $25.6 million under the Mustang ATM. In connection with these sales, Mustang paid aggregate fees of approximately $0.5 million for net proceeds of approximately $25.1 million. During the nine months ended September 30, 2019, Mustang issued approximately 3.5 million shares of common stock at an average price of $6.42 per share for gross proceeds of $22.5 million under the Mustang ATM. In connection with these sales, Mustang paid aggregate fees of approximately $0.5 million for net proceeds of approximately $22.0 million. Pursuant to the Founders Agreement, Mustang issued 117,405 shares of common stock to Fortress at a weighted average price of $3.56 per share for the nine months ended September 30, 2020 for the Mustang ATM offering noted above. During the nine months ended September 30, 2019, Mustang issued 87,656 shares of common stock to Fortress at a weighted average price of $6.42 per share in connection with the Mustang ATM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Approximately $32.6 million of the Mustang shelf remains available for sale under the 2019 Mustang S-3, following the offerings noted above. As of September 30, 2020, the 2018 Mustang S-3 is no longer available for sales of securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Checkpoint At-the-Market Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Checkpoint S-3, Checkpoint may sell up to a total of $100 million of its securities. In connection with the Checkpoint S-3, Checkpoint entered into an At-the-Market Issuance Sales Agreement (the "Checkpoint ATM") with Cantor Fitzgerald &amp; Co., Ladenburg Thalmann &amp; Co. Inc. and H.C. Wainwright &amp; Co., LLC (each a "Checkpoint Agent" and collectively, the "Checkpoint Agents"), relating to the sale of shares of common stock. Under the Checkpoint ATM, Checkpoint pays the Checkpoint Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of Checkpoint common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2020, Checkpoint sold a total of 3,614,344 shares of common stock under the Checkpoint ATM for aggregate total gross proceeds of approximately $8.7 million at an average selling price of $2.40 per share, resulting in net proceeds of approximately $8.4 million after deducting commissions and other transaction costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Founders Agreement, Checkpoint issued 273,379 shares of common stock to Fortress at a weighted average price of $2.92 per share for the Checkpoint ATM offerings and the Checkpoint Underwritten Offering, both noted above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Approximately $12.3 million of the Checkpoint shelf remains available for sale under the Checkpoint S-3, following the offerings noted above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Share Repurchase Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 23, 2020, the Company announced that its Board of Directors had approved a share repurchase program of the Company's outstanding Preferred Stock in an aggregate amount of up to $5.0 million. Repurchases under the program were made in the open market or through privately-negotiated transactions until the earlier to occur of the repurchase of $5.0 million of the Company's Preferred Stock or the close of trading on May 31, 2020, subject to applicable laws and regulations. The program did not commit the Company to repurchase any shares of Preferred Stock. As of September 30, 2020, 5,000 Preferred Stock shares were repurchased and retired under this program for total consideration of $0.1 million, net of fees of approximately $2,000.</p> 50000000 50000000 150000000 150000000 0.001 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the three and nine months ended September 30, 2020 and 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 936</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,791</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Executive awards of Fortress Companies' stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-employee awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 136</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Partner Companies:</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Avenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Checkpoint</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 725</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 833</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,095</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,444</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Mustang</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 606</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 183</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 1200000 936000 3732000 2791000 369000 358000 1136000 1065000 31000 15000 136000 84000 32000 97000 97000 97000 161000 298000 592000 1585000 725000 833000 2095000 2444000 606000 1120000 2368000 2174000 47000 84000 163000 183000 3171000 3741000 10319000 10423000 700000 1200000 2500000 2500000 2500000 2600000 7800000 7800000 3000000.0 13000000.0 4200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes Fortress stock option activities excluding activity related to Fortress partner companies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual life</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">intrinsic value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and expected to vest at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,410,501</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.30</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 684,752</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.33</p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (100,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (247,011)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and expected to vest at September 30, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,063,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,044,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.87</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 1410501 4.30 684752 P2Y3M29D 100000 1.18 0 247011 2.55 0 1063490 5.00 1044218 P2Y10M13D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress Companies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,768,014</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.46</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,873,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.57</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,549,564)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.69</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 630,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.82</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (106,250)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.71</p></td></tr><tr><td style="vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Restricted stock units vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (368,290)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.13</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at September 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,247,108</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.49</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 13768014 2.46 1873072 2.57 1549564 2.69 630126 3.82 106250 2.71 368290 3.13 14247108 2.49 17500000 12700000 P3Y10M24D P5Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual life</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,741,180</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.73</p></td></tr><tr><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,849,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,657,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of September 30, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,590,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,111,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.10</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:37.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of September 30, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,430,621</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,816,818</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.05</p></td></tr></table> 2741180 3.19 111000 P2Y8M23D 1849450 3.14 1657538 -9 3.00 0 4590621 3.17 4111018 P5Y1M6D 4430621 3.21 3816818 P5Y18D 1749450 3.20 0.95 P10Y 0.00868 0.0074 4800000 2 4400000 0.85 507783 492217 38000 18000 100000 100000 666666 0.09375 66666 18.00 13200000 1100000 555556 0.09375 83333 18.00 11500000 1100000 625000 93750 20.00 14400000 1300000 255400 0.09375 64600 25.00 8000000.0 900000 0.19531 2.34375 25.00 P24M 49883000 0.19531 7321429 2.80 20500000 18900000 1600000 11455604 3.25 37200000 34900000 2300000 16400000 2.74 44800000 1600000 29500000 75000000.0 0.030 75000000.0 7200000 3.56 25600000 500000 25100000 3500000 6.42 22500000 500000 22000000.0 117405 3.56 87656 6.42 32600000 100000000 0.030 3614344 8700000 2.40 8400000 273379 2.92 12300000 5000000.0 5000000.0 5000 100000 2000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">15. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Most of the Company's lease liabilities result from the lease of its New York City, NY office, which expires in 2031, and Mustang's Worcester, MA cell processing facility lease, which expires in 2026. Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Certain of the Company's leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right of use assets as the Company is not reasonably certain to exercise the options. The Company does not act as a lessor or have any leases classified as financing leases. On September 30, 2020, the Company had operating lease liabilities of $24.6 million and right of use assets of $20.3 million, which were included in the Condensed Consolidated Balance Sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three and nine months ended September 30, 2020 and 2019, the Company recorded the following as lease expense, which was recorded in general and administrative expense on the Company's Condensed Consolidated Statement of Operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease Cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shared lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (469)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (479)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,409)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,408)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 525</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,438</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,564</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables summarize quantitative information about the Company's operating leases, under the adoption of <i style="font-style:italic;">Topic 842, Leases</i>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,127)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,185)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term – operating leases (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate – operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Future Lease</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 839</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,114</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,084</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,137</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,190</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,273</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,637</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,085)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating lease liabilities, short-term and long-term</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,552</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indemnification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has director and officer insurance to address such claims. Pursuant to agreements with clinical trial sites, the Company provides indemnification to such sites in certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the ordinary course of business, the Company may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company’s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages.</p> 24600000 20300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three and nine months ended September 30, 2020 and 2019, the Company recorded the following as lease expense, which was recorded in general and administrative expense on the Company's Condensed Consolidated Statement of Operations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease Cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Shared lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (469)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (479)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,409)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,408)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 525</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,438</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,564</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables summarize quantitative information about the Company's operating leases, under the adoption of <i style="font-style:italic;">Topic 842, Leases</i>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,127)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,185)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term – operating leases (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate – operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 816000 798000 2436000 2397000 469000 479000 1409000 1408000 -178000 160000 -411000 575000 525000 479000 1438000 1564000 2127000 2185000 P5Y10M24D P6Y4M24D 0.062 0.062 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Future Lease</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 839</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,114</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,084</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,137</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year Ended December 31, 2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,190</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,273</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,637</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,085)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating lease liabilities, short-term and long-term</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,552</p></td></tr></table> 839000 3114000 3084000 3137000 3190000 20273000 33637000 9085000 24552000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">16. Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s Chairman, President and Chief Executive Officer, individually and through certain trusts over which he has voting and dispositive control, beneficially owned approximately 10.1% of the Company’s issued and outstanding Common Stock as of September 30, 2020. The Company’s Executive Vice Chairman, Strategic Development owns approximately 10.9% of the Company’s issued and outstanding Common Stock as of September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Shared Services Agreement with TG Therapeutics, Inc</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">TG Therapeutics, Inc. ("TGTX") and the Company entered into an arrangement to share the cost of certain research and development employees. The Company’s Executive Vice Chairman, Strategic Development, is also the Executive Chairman and  Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX will reimburse the Company for the salary and benefit costs associated with these employees based upon actual hours worked on TGTX related projects. For the three months ended September 30, 2020 and 2019, the Company invoiced TGTX $0.1 million and $0.1 million, respectively. For the nine months ended September 30, 2020 and 2019, the Company invoiced TGTX $0.3 million and $0.3 million, respectively. On September 30, 2020, the amount due from TGTX related to this arrangement approximated $69,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Desk Space Agreements with TGTX and OPPM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Company’s Desk Space Agreements with TGTX and Opus Point Partners Management, LLC (“OPPM”), for the three months ended September 30, 2020 and 2019, the Company had paid $0.7 million and $0.7 million in rent under the Desk Space Agreements. For the three months ended September 30, 2020 and 2019, the Company invoiced TGTX approximately $0.4 million and $0.4 million, respectively, and invoiced OPPM nil and approximately $24,000, respectively, for their prorated share of the rent base. On September 30, 2020, the amount due related to this arrangement from TGTX was nil and the amount due from OPPM approximated $0.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2019 Notes (formerly the Opus Credit Facility)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 13, 2019, the Company and Opus Point Healthcare Innovations Fund, LP (“OPHIF”) extended the maturity date of the 2019 Notes (formerly the “A&amp;R Opus Credit Facility) from September 14, 2019 by two years to September 14, 2021. Terms of the 2019 Notes allows for the Company to make portions of interest and principal repayments in the form of shares of the Company’s common stock and/or in common stock of the Company’s publicly-traded subsidiaries, subject to certain conditions. Fortress retained the ability to prepay the Notes at any time without penalty. The notes payable under the A&amp;R Opus Credit Facility bear interest at 12% per annum. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective December 31, 2019, OPHIF dissolved and distributed it assets among its limited partners. Following the distribution, the $9.0 million facility comprised of separate notes (collectively, the “2019 Notes”) held by DAK Capital Inc. ($3.8 million); Fortress’ Chairman, President and Chief Executive Officer Lindsay A. Rosenwald, M.D. ($0.3 million); Fortress's Executive Vice President, Strategic Development Michael S. Weiss ($2.0 million); and various entities and individuals affiliated with Dr. Rosenwald and Mr. Weiss ($2.9 million). The terms of the 2019 Notes did not change in connection with such reallocations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the quarter ended September 30, 2020, the Company used certain proceeds from the Oaktree Note to pay off the $9.0 million balance previously outstanding under the 2019 Notes (see Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2020, in connection with the 2019 Notes, the Company paid $0.5 million in interest on the portion of the 2019 Notes held by the Company's Chairman, President and Chief Executive Officer and the Company's Executive Vice President, Strategic Development. For the nine months ended September 30, 2019, the Company paid $0.2 million in common stock consisting of 91,767 shares at $1.80 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Avenue Credit Facility Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 12, 2020, Avenue, the Company and InvaGen entered into a Facility Agreement (“Avenue Facility Agreement”), under which, beginning on October 1, 2020, Avenue may borrow up to $2 million collectively from the Company and InvaGen, subject to certain conditions set forth therein. The Company’s commitment amount is $0.8 million, and InvaGen’s is $1.2 million , and a 7% per annum interest rate applies (payable on the last day of each fiscal quarter).  Repayment of the loan is due upon the earliest to occur of: (i) the Second Stage Closing Date, as defined in the SPMA; (ii) April 29, 2021; and (iii) the date that is 30 days following the termination of the Avenue SPMA.  As of September 30, 2020, there have been no amounts drawn by Avenue on the Avenue Facility Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Founders Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has entered into Founders Agreements and, in some cases, Exchange Agreements with certain of its subsidiaries as described in the Company's Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. The following table summarizes, by partner company, the effective date of the Founders Agreements and PIK dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, Exchange Agreements, and the subsidiaries' certificates of incorporation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PIK Dividend as</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">a % of fully</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">diluted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class of Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fortress Partner Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective Date </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capitalization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Helocyte</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 20, 2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Avenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">February 17, 2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 13, 2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Checkpoint</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 17, 2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cellvation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">October 31, 2016</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Caelum</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">January 1, 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">4</sup>  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Baergic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 17, 2019<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cyprium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 13, 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Aevitas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">July 28, 2017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oncogenuity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">April 22, 2020 <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement or has since been amended to January 1 of each calendar year.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Concurrently with the execution and delivery of the Stock Purchase and Merger Agreement (“Avenue SPMA”) entered into between, Avenue, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”) (together, the “ SPMA Parties”), the SPMA Parties entered into a waiver agreement (the “Waiver Agreement”), pursuant to which the Company irrevocably waived its right to receive the annual dividend of Avenue’s common shares under the terms of the Class A preferred stock and any fees, payments, reimbursements or other distributions under the management services agreement between the Company and Avenue and the Founders Agreement, for the period from the effective date of the Waiver Agreement to the termination of InvaGen’s rights under the Avenue SPMA. Pursuant to the Waiver Agreement, immediately prior to the closing of the Merger Transaction contemplated under the Avenue SPMA, the Company will convert all of its preferred shares into common shares pursuant to the terms of the certificate of incorporation of Avenue, as amended from time to time.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 3:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 4:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Effective January 31, 2019 the Caelum Founders Agreement and MSA with Fortress were terminated in conjunction with the execution of the DOSPA between Caelum and Alexion (See Note 4).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Note 5:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Represents the Trigger Date, the date that the Fortress partner company first acquires, whether by license or otherwise, ownership rights in a product.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Management Services Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has entered in Management Services Agreements (the “MSAs”) with certain of its partner companies as described in the Company’s Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. The following table summarizes the effective date of the MSA and the annual consulting fee payable by the partner company to the Company in quarterly installments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Annual MSA Fee</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fortress partner company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Income)/Expense</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Helocyte</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 20, 2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Avenue <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">February 17, 2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 13, 2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Checkpoint</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 17, 2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cellvation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">October 31, 2016</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Baergic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 9, 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cyprium</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 13, 2017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Aevitas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">July 28, 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oncogenuity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">February 10, 2017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fortress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consolidated (Income)/Expense</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Concurrently with the execution and delivery of the Avenue SPMA entered into among, Avenue, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”) (together, the “SPMA Parties”), the SPMA Parties entered into a waiver agreement (the “Waiver Agreement”), pursuant to which the Company irrevocably waived its right to receive the annual dividend of Avenue’s common shares under the terms of the Class A preferred stock and any fees, payments, reimbursements or other distributions under the management services agreement between the Company and Avenue and the Founders Agreement, for the period from the effective date of the Waiver Agreement to the termination of InvaGen’s rights under the Avenue SPMA. Pursuant to the Waiver Agreement, immediately prior to the closing of the Merger Transaction contemplated under the Avenue SPMA, the Company will convert all of its preferred shares into common shares pursuant to the terms of the certificate of incorporation of Avenue, as amended from time to time. (See Note 4).</p></td></tr></table> 0.101 0.109 100000 100000 300000 300000 69000 700000 700000 400000 400000 0 24000 0 400000 P2Y 0.12 9000000.0 3800000 300000 2000000.0 2900000 9000000.0 500000 200000 91767 1.80 2000000 800000 1200000 0.07 P30D 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has entered into Founders Agreements and, in some cases, Exchange Agreements with certain of its subsidiaries as described in the Company's Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. The following table summarizes, by partner company, the effective date of the Founders Agreements and PIK dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, Exchange Agreements, and the subsidiaries' certificates of incorporation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PIK Dividend as</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">a % of fully</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">diluted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class of Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fortress Partner Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective Date </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capitalization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Helocyte</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 20, 2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Avenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">February 17, 2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 13, 2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Checkpoint</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 17, 2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cellvation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">October 31, 2016</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Caelum</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">January 1, 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">4</sup>  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Baergic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December 17, 2019<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cyprium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 13, 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Aevitas</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">July 28, 2017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr><tr><td style="vertical-align:top;width:44.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oncogenuity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">April 22, 2020 <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Common Stock</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement or has since been amended to January 1 of each calendar year.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Concurrently with the execution and delivery of the Stock Purchase and Merger Agreement (“Avenue SPMA”) entered into between, Avenue, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”) (together, the “ SPMA Parties”), the SPMA Parties entered into a waiver agreement (the “Waiver Agreement”), pursuant to which the Company irrevocably waived its right to receive the annual dividend of Avenue’s common shares under the terms of the Class A preferred stock and any fees, payments, reimbursements or other distributions under the management services agreement between the Company and Avenue and the Founders Agreement, for the period from the effective date of the Waiver Agreement to the termination of InvaGen’s rights under the Avenue SPMA. Pursuant to the Waiver Agreement, immediately prior to the closing of the Merger Transaction contemplated under the Avenue SPMA, the Company will convert all of its preferred shares into common shares pursuant to the terms of the certificate of incorporation of Avenue, as amended from time to time.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 3:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 4:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Effective January 31, 2019 the Caelum Founders Agreement and MSA with Fortress were terminated in conjunction with the execution of the DOSPA between Caelum and Alexion (See Note 4).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Note 5:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Represents the Trigger Date, the date that the Fortress partner company first acquires, whether by license or otherwise, ownership rights in a product.</p></td></tr></table> 2015-03-20 0.025 2015-02-17 0.000 2015-03-13 0.025 2015-03-17 0.000 2016-10-31 0.025 2017-01-01 0.000 2019-12-17 0.025 2017-03-13 0.025 2017-07-28 0.025 2020-04-22 0.025 0.025 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has entered in Management Services Agreements (the “MSAs”) with certain of its partner companies as described in the Company’s Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. The following table summarizes the effective date of the MSA and the annual consulting fee payable by the partner company to the Company in quarterly installments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Annual MSA Fee</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fortress partner company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Effective Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Income)/Expense</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Helocyte</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 20, 2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Avenue <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">February 17, 2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mustang</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 13, 2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Checkpoint</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 17, 2015</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cellvation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">October 31, 2016</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Baergic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 9, 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cyprium</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March 13, 2017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Aevitas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">July 28, 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oncogenuity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">February 10, 2017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fortress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consolidated (Income)/Expense</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Note 1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Concurrently with the execution and delivery of the Avenue SPMA entered into among, Avenue, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”) (together, the “SPMA Parties”), the SPMA Parties entered into a waiver agreement (the “Waiver Agreement”), pursuant to which the Company irrevocably waived its right to receive the annual dividend of Avenue’s common shares under the terms of the Class A preferred stock and any fees, payments, reimbursements or other distributions under the management services agreement between the Company and Avenue and the Founders Agreement, for the period from the effective date of the Waiver Agreement to the termination of InvaGen’s rights under the Avenue SPMA. Pursuant to the Waiver Agreement, immediately prior to the closing of the Merger Transaction contemplated under the Avenue SPMA, the Company will convert all of its preferred shares into common shares pursuant to the terms of the certificate of incorporation of Avenue, as amended from time to time. (See Note 4).</p></td></tr></table> 2015-03-20 500 2015-02-17 2015-03-13 500 2015-03-17 500 2016-10-31 500 2017-03-09 500 2017-03-13 500 2017-07-28 500 2017-02-10 500 -4000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">17. Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company operates in two reportable segments, Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results from continued operations by reportable segment:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pharmaceutical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dermatology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Biotechnology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Products</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Sales</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net revenue</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,447</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,475</p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Direct cost of goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,379)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,379)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,649)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,649)</p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,756)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,756)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,254)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,480)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,734)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,808)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,921)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment income (loss) </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (30,016)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,964)</p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Segment assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,039</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,039</p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 284,840</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total segment assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,147</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263,732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 295,879</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pharmaceutical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dermatology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Biotechnology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Products</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sales</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net revenue</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,492</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 280</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,772</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct cost of goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,702)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,702)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,370)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,370)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,271)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,271)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (669)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,300)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,969)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,322)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,430)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment income (loss)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,643</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26,613)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,970)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Segment assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,731</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,731</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 213,857</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,697</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202,891</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,588</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pharmaceutical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dermatology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Biotechnology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Products</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sales</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net revenue</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,808</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,042</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,850</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct cost of goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,313)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,313)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,728)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,728)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,146)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,556)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,074)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,630)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,036)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,528)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment income (loss)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,719</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86,214)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (82,495)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Segment assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,039</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,039</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,840</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,147</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263,732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295,879</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pharmaceutical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">and</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dermatology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Biotechnology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Products</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sales</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net revenue</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,816</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,683</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,499</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct cost of goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,972)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,972)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,064)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,064)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,705)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,705)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,808)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,388)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,196)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,733</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment income (loss)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,864</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,569)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (68,705)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Segment assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,731</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,731</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 213,857</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,697</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202,891</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,588</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company operates in two reportable segments, Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results from continued operations by reportable segment:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pharmaceutical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dermatology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Biotechnology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Products</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Sales</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net revenue</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,447</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,475</p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Direct cost of goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,379)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,379)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,649)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,649)</p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,756)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,756)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,254)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,480)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,734)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,808)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,921)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment income (loss) </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (30,016)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,964)</p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Segment assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,039</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,039</p></td></tr><tr><td style="vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 284,840</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total segment assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,147</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263,732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 295,879</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pharmaceutical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dermatology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Biotechnology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Products</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sales</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net revenue</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,492</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 280</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,772</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct cost of goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,702)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,702)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,370)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,370)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,271)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,271)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (669)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,300)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,969)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,322)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,430)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment income (loss)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,643</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26,613)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,970)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Segment assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,731</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,731</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 213,857</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,697</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202,891</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,588</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pharmaceutical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dermatology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> Biotechnology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Products</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sales</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net revenue</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,808</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,042</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,850</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct cost of goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,313)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,313)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,728)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,728)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,146)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,556)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,074)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,630)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,036)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,528)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment income (loss)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,719</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86,214)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (82,495)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Segment assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">  </p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,039</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,039</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,840</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,147</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 263,732</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295,879</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pharmaceutical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">and</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dermatology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Biotechnology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Products</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Sales</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net revenue</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,816</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,683</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,499</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct cost of goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,972)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,972)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,064)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,064)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,705)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,705)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,808)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,388)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,196)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,733</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Segment income (loss)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,864</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,569)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (68,705)</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Segment assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,731</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,731</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 213,857</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total segment assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,697</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202,891</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,588</p></td></tr></table> 2 9447000 28000 9475000 3379000 0 3379000 4649000 0 4649000 0 13756000 13756000 1254000 9480000 10734000 113000 6808000 6921000 52000 -30016000 -29964000 11039000 0 11039000 21108000 263732000 284840000 32147000 263732000 295879000 9492000 280000 9772000 2702000 0 2702000 4370000 0 4370000 0 15271000 15271000 669000 9300000 9969000 108000 2322000 2430000 1643000 -26613000 -24970000 7731000 0 7731000 10966000 202891000 213857000 18697000 202891000 221588000 30808000 1042000 31850000 10313000 10313000 12728000 12728000 46146000 46146000 3556000 29074000 32630000 492000 12036000 12528000 3719000 -86214000 -82495000 11039000 11039000 21108000 263732000 284840000 32147000 263732000 295879000 23816000 1683000 25499000 6972000 6972000 12064000 12064000 57705000 57705000 1808000 27388000 29196000 108000 -11841000 -11733000 2864000 -71569000 -68705000 7731000 7731000 10966000 202891000 213857000 18697000 202891000 221588000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">18. Revenues from Contracts and Significant Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;">Disaggregation of Total Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Product revenue is comprised of Journey’s five marketed products: Targadox®, Luxamend®, Ceracade®, Exelderm® and Ximino®. Substantially all of the product revenue is recorded in the U.S. The Company’s related party revenue is from Checkpoint’s collaboration with TGTX. The table below summarizes the Company’s revenue for the three and nine months ending September 30, 2020 and 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Product revenue, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,447</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,492</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,808</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,816</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Revenue – related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,475</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,772</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,850</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,499</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Significant Customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the three months ended September 30, 2020, none of the Company’s Dermatology Products customers accounted for more than 10% of its total gross product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the nine months ended September 30, 2020, one of the Company’s Dermatology Products customers accounted for more than 10% of its total gross product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 10pt 0pt;">For the three and nine months ended September 30, 2019, gross product revenue under the 3PL Title Model accounted for approximately 60% and 76%, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">At September 30, 2020, one of the Company’s Dermatology Products customers accounted for more than 10% of its total accounts receivable balance at 14.5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At September 30, 2019, two of the Company’s Dermatology Products customers accounted for more than 10% of its total accounts balance in the amounts of $3.5 million and $2.8 million.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Product revenue is comprised of Journey’s five marketed products: Targadox®, Luxamend®, Ceracade®, Exelderm® and Ximino®. Substantially all of the product revenue is recorded in the U.S. The Company’s related party revenue is from Checkpoint’s collaboration with TGTX. The table below summarizes the Company’s revenue for the three and nine months ending September 30, 2020 and 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Product revenue, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,447</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,492</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,808</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,816</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Revenue – related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,475</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,772</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,850</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,499</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 9447000 9492000 30808000 23816000 28000 280000 1042000 1683000 9475000 9772000 31850000 25499000 none of the Company’s Dermatology Products customers accounted for more than 10% of its total gross product revenue one of the Company’s Dermatology Products customers accounted for more than 10% of its total gross product revenue 0.60 0.76 one of the Company’s Dermatology Products customers accounted for more than 10% of its total accounts receivable balance at 14.5% 0.145 two of the Company’s Dermatology Products customers accounted for more than 10% of its total accounts balance in the amounts of $3.5 million and $2.8 million 3500000 2800000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 10pt 0pt;">19. Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer's social security payments, net operating loss utilization and carryback periods and modifications to the net interest deduction limitations. At this time, the Company does not believe that the CARES Act will have a material impact on its income tax provision for 2020. The Company will continue to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company and its subsidiaries are subject to US federal and state income taxes. Income tax expense is the total of the current year income tax due or refundable and the change in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of Management, it is more likely than not that some portion, or all, of the deferred tax asset will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company files a consolidated income tax return with subsidiaries for which the Company has an 80% or greater ownership interest. Subsidiaries for which the Company does not have an 80% or more ownership are not included in the Company’s consolidated income tax group and file their own separate income tax return. As a result, certain corporate entities included in these financial statements are not able to combine or offset their taxable income or losses with other entities’ tax attributes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Income tax expense for the three and nine months ended September 30, 2020 and 2019 is based on the estimated annual effective tax rate.</p> XML 13 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2020
Nov. 05, 2020
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 001-35366  
Entity Registrant Name Fortress Biotech, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 20-5157386  
Entity Address, Address Line One 2 Gansevoort Street, 9th Floor  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10014  
City Area Code 781  
Local Phone Number 652-4500  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Central Index Key 0001429260  
Document Fiscal Year Focus 2020  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q3  
Common Stock [Member]    
Document Information [Line Items]    
Title of 12(b) Security Common Stock  
Trading Symbol FBIO  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   93,702,861
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock    
Document Information [Line Items]    
Title of 12(b) Security 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock  
Trading Symbol FBIOP  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   3,427,138
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets    
Cash and cash equivalents $ 218,389 $ 136,858
Accounts receivable (net of allowance for doubtful accounts of $147 and $100 at September 30, 2020 and December 31, 2019, respectively) 15,653 13,539
Inventory 1,052 857
Other receivables - related party 939 865
Prepaid expenses and other current assets 1,704 4,133
Total current assets 237,737 156,252
Property and equipment, net 12,114 12,433
Operating lease right-of-use asset, net 20,265 21,480
Restricted cash 1,645 16,574
Long-term investment, at fair value 11,723 11,148
Intangible asset, net 11,039 7,377
Other assets 1,356 1,158
Total assets 295,879 226,422
Current liabilities    
Accounts payable and accrued expenses 32,542 35,451
Accounts payable and accrued expenses - related party 19 0
Interest payable 23 1,042
Interest payable - related party 0 92
Notes payable, short-term 0 7,220
Operating lease liabilities - short-term 1,697 1,784
Derivative warrant liability 0 27
Other current liabilities 3,000 0
Total current liabilities 37,281 45,616
Notes payable, long-term (net of debt discount of $8,607 and $5,086 at September 30, 2020 and December 31, 2019, respectively) 51,393 77,436
Operating lease liabilities - long-term 22,855 23,712
Other long-term liabilities 8,205 7,126
Total liabilities 119,734 153,890
Commitments and contingencies
Stockholders' equity    
Preferred stock, $.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 and 1,341,167 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively; liquidation value of $25.00 per share 3 1
Common stock, $.001 par value, 150,000,000 shares authorized, 93,748,374 and 74,027,425 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively 94 74
Common stock issuable, 5,451 and 251,337 shares as of September 30, 2020 and December 31, 2019, respectively 18 500
Additional paid-in-capital 574,461 461,874
Accumulated deficit (477,465) (436,234)
Total stockholders' equity attributed to the Company 97,111 26,215
Non-controlling interests 79,034 46,317
Total stockholders' equity 176,145 72,532
Total liabilities and stockholders' equity $ 295,879 $ 226,422
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Condensed Consolidated Balance Sheets    
Allowance for Doubtful Accounts Receivable, Current $ 147 $ 100
Debt Instrument, Unamortized Discount, Noncurrent $ 8,607 $ 5,086
Preferred Stock, par value $ 0.001 $ 0.001
Preferred Stock, shares authorized 15,000,000 15,000,000
Preferred Stock Shares Designated 5,000,000 5,000,000
Preferred Stock, shares issued 3,427,138 1,341,167
Preferred Stock, shares outstanding 3,427,138 1,341,167
Preferred Stock, Liquidation Preference Per Share $ 25.00 $ 25.00
Common Stock, par value $ 0.001 $ 0.001
Common Stock, shares authorized 150,000,000 150,000,000
Common Stock, shares issued 93,748,374 74,027,425
Common Stock, shares outstanding 93,748,374 74,027,425
Common Stock, Shares Subscribed but Unissued 5,451 251,337
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue        
Product revenue, net $ 9,447 $ 9,492 $ 30,808 $ 23,816
Revenue - related party 28 280 1,042 1,683
Net revenue 9,475 9,772 31,850 25,499
Operating expenses        
Cost of goods sold - product revenue 3,379 2,702 10,313 6,972
Research and development 13,298 14,571 43,868 56,355
Research and development - licenses acquired 458 700 2,278 1,350
General and administrative 15,383 14,339 45,358 41,260
Total operating expenses 32,518 32,312 101,817 105,937
Income (loss) from operations (23,043) (22,540) (69,967) (80,438)
Other income (expense)        
Interest income 265 738 1,228 1,955
Interest expense and financing fee (6,958) (3,168) (13,142) (8,743)
Change in fair value of derivative liability (803) 0 (1,189) 0
Change in fair value of investments 575 0 575 0
Gain on deconsolidation of Caelum 0 0 0 18,521
Total other income (expense) (6,921) (2,430) (12,528) 11,733
Net loss (29,964) (24,970) (82,495) (68,705)
Less: net loss attributable to non-controlling interests 14,417 12,208 41,264 44,237
Net loss attributable to common stockholders $ (15,547) $ (12,762) $ (41,231) $ (24,468)
Net loss per common share - basic and diluted $ (0.39) $ (0.44) $ (1.19) $ (1.29)
Net loss per common share attributable to non - controlling interests - basic and diluted (0.19) (0.21) (0.59) (0.83)
Net loss per common share attributable to common stockholders - basic and diluted $ (0.20) $ (0.22) $ (0.59) $ (0.46)
Weighted average common shares outstanding - basic and diluted 76,093,211 56,856,821 69,404,499 53,060,565
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Series A Preferred Stock [Member]
Common Stock [Member]
Shares Issuable [Member]
Treasury Stock [Member]
Paid-In Capital [Member]
Accumulated Deficit [Member]
Non-Controlling Interests [Member]
Total
Balance at Dec. 31, 2018 $ 1 $ 58 $ 659   $ 397,408 $ (396,274) $ 17,891 $ 19,743
Balance (in shares) at Dec. 31, 2018 1,000,000 57,845,447            
Stock-based compensation expense         10,423     10,423
Issuance of restricted stock   $ 2     (2)      
Issuance of restricted stock (in shares)   1,842,034            
Issuance of common stock under ESPP         60     60
Issuance of common stock under ESPP (in shares)   54,221            
Issuance of subsidiaries' common shares for license expenses     (164)   164      
Issuance of common stock for at-the-market offering, net   $ 9     15,789     15,798
Issuance of common stock for at-the-market offering, net (in shares)   8,604,469            
Preferred A dividends declared and paid         (1,773)     (1,773)
Partner company's sale of stock, net         61,036     61,036
Partner company's at-the-market offering, net         29,680     29,680
Issuance of partner company warrants in conjunction with Horizon Notes         888     888
Common shares issuable for 2017 Subordinated Note Financing interest expense     500         500
Common shares issued for 2017 Subordinated Note Financing interest expense   $ 1 (495)   1,468     974
Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)   1,330,450            
Common shares issuable for 2019 Notes interest expense     281         281
Common shares issued for 2019 Notes interest expense     (281)   506     225
Common shares issued for 2019 Notes interest expense (in shares)   262,088            
Common shares issued for Opus debt         500     500
Common shares issued for Opus debt (in shares)   396,825            
Non-controlling interest in subsidiaries         (70,702)   70,702  
Deconsolidation of Caelum non-controlling interest             4,849 4,849
Net loss attributable to non-controlling interest             (44,237) (44,237)
Net loss attributable to common stockholders           (24,468)   (24,468)
Issuance of preferred A for at-the-market offering, net         523     523
Issuance of preferred A for at-the-market offering, net (in shares) 26,111              
Write off of Partner company note receivable         (2)     (2)
Balance at Sep. 30, 2019 $ 1 $ 70 500   445,966 (420,742) 49,205 75,000
Balance (in shares) at Sep. 30, 2019 1,026,111 70,335,534            
Balance at Jun. 30, 2019 $ 1 $ 68 490   439,295 (407,980) 57,946 89,820
Balance (in shares) at Jun. 30, 2019 1,000,000 68,138,203            
Stock-based compensation expense         3,741     3,741
Issuance of restricted stock (in shares)   177,292            
Issuance of common stock for at-the-market offering, net   $ 1     1,930     1,931
Issuance of common stock for at-the-market offering, net (in shares)   1,213,643            
Preferred A dividends declared and paid         (601)     (601)
Partner company's offering, net         52     52
Partner company's at-the-market offering, net         3,341     3,341
Common shares issuable for 2017 Subordinated Note Financing interest expense     500         500
Common shares issued for 2017 Subordinated Note Financing interest expense   $ 1 (490)   489      
Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)   317,804            
Common shares issued for Opus interest expense (in shares)   91,767            
Common shares issuable for Opus interest expense         165     165
Common shares issued for Opus debt         500     500
Common shares issued for Opus debt (in shares)   396,825            
Non-controlling interest in subsidiaries         (3,467)   3,467  
Net loss attributable to non-controlling interest             (12,208) (12,208)
Net loss attributable to common stockholders           (12,762)   (12,762)
Issuance of preferred A for at-the-market offering, net         523     523
Issuance of preferred A for at-the-market offering, net (in shares) 26,111              
Write off of Partner company note receivable         (2)     (2)
Balance at Sep. 30, 2019 $ 1 $ 70 500   445,966 (420,742) 49,205 75,000
Balance (in shares) at Sep. 30, 2019 1,026,111 70,335,534            
Balance at Dec. 31, 2019 $ 1 $ 74 500   461,874 (436,234) 46,317 72,532
Balance (in shares) at Dec. 31, 2019 1,341,167 74,027,425            
Stock-based compensation expense         10,319     10,319
Issuance of common stock related to equity plans   $ 2     (2)      
Issuance of common stock related to equity plans (in shares)   2,307,231            
Issuance of common stock under ESPP         90     90
Issuance of common stock under ESPP (in shares)   53,268            
Issuance of common stock for at-the-market offering, net   $ 17     43,183     43,200
Issuance of common stock for at-the-market offering, net (in shares)   16,378,234            
Preferred A dividends declared and paid         (4,507)     (4,507)
Repurchase of Series A preferred stock, net       $ (70) (2)     (72)
Repurchase of Series A preferred stock (in shares) (5,000)              
Retirement of Series A preferred stock       $ 70        
Retirement of Series A preferred stock         (70)      
Issuance of Series A preferred stock for cash, net $ 2       35,466     35,468
Issuance of Series A preferred stock for cash, net (in shares) 2,090,971              
Partner company's offering, net         53,698     53,698
Partner company's at-the-market offering, net         33,500     33,500
Partner company's preferred stock offering, net         7,088     7,088
Partner company's dividends declared and paid         50     50
Reclass partner company's warrants from liability to equity         1,216     1,216
Issuance of partner company's common shares for research and development expenses         42     42
Partner company's exercise of warrants for cash         13     13
Partner company's ESPP         349     349
Issuance of partner company warrants in conjunction with Horizon Notes               0
Common shares issued for 2017 Subordinated Note Financing interest expense   $ 1 (500)   1,816     1,317
Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)   982,216            
Common shares issuable for service     18         18
Issuance of warrants in conjunction with Oaktree Note         4,419     4,419
Non-controlling interest in subsidiaries         (73,981)   73,981  
Net loss attributable to non-controlling interest             (41,264) (41,264)
Net loss attributable to common stockholders           (41,231)   (41,231)
Balance at Sep. 30, 2020 $ 3 $ 94 18   574,461 (477,465) 79,034 176,145
Balance (in shares) at Sep. 30, 2020 3,427,138 93,748,374            
Balance at Jun. 30, 2020 $ 3 $ 86 813   521,493 (461,918) 56,381 116,858
Balance (in shares) at Jun. 30, 2020 2,693,806 86,113,331            
Stock-based compensation expense         3,171     3,171
Issuance of common stock related to equity plans (in shares)   268,800            
Issuance of common stock under ESPP         180     180
Issuance of common stock for at-the-market offering, net   $ 7     21,110     21,117
Issuance of common stock for at-the-market offering, net (in shares)   7,064,214            
Preferred A dividends declared and paid         (1,719)     (1,719)
Issuance of Series A preferred stock for cash, net         11,965     11,965
Issuance of Series A preferred stock for cash, net (in shares) 733,332              
Partner company's offering, net         18,774     18,774
Partner company's at-the-market offering, net         23,053     23,053
Partner company's preferred stock offering, net         7,088     7,088
Partner company's dividends declared and paid         50     50
Reclass partner company's warrants from liability to equity         1,216     1,216
Issuance of partner company's common shares for research and development expenses         21     21
Common shares issued for 2017 Subordinated Note Financing interest expense   $ 1 (500)   810     311
Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)   302,029            
Write off common shares issuable for 2019 Notes interest expense     (313)         (313)
Common shares issuable for service     18         18
Issuance of warrants in conjunction with Oaktree Note         4,419     4,419
Non-controlling interest in subsidiaries         (37,070)   37,070  
Net loss attributable to non-controlling interest             (14,417) (14,417)
Net loss attributable to common stockholders           (15,547)   (15,547)
Balance at Sep. 30, 2020 $ 3 $ 94 $ 18   $ 574,461 $ (477,465) $ 79,034 $ 176,145
Balance (in shares) at Sep. 30, 2020 3,427,138 93,748,374            
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Cash Flows from Operating Activities:          
Net loss $ (29,964,000) $ (24,970,000) $ (82,495,000) $ (68,705,000)  
Reconciliation of net loss to net cash used in operating activities:          
Depreciation expense 600,000 500,000 1,676,000 1,414,000  
Bad debt expense     47,000 250,000  
Amortization of debt discount     5,319,000 2,459,000  
Non-cash interest     492,000 0  
Amortization of product revenue license fee     1,065,000 820,000  
Amortization of operating lease right-of-use assets     1,214,000 1,150,000  
Stock-based compensation expense     10,319,000 10,423,000  
Issuance of partner company's common shares for research and development expenses     42,000 0  
Common shares issuable for 2017 Subordinated Note Financing interest expense     0 500,000  
Common shares issued for 2017 Subordinated Note Financing interest expense     1,317,000 974,000  
Common shares issuable for 2019 Notes interest expense     0 281,000  
Common shares issued for 2019 Notes interest expense     0 225,000  
Common shares issuable for service     18,000 0  
Change in fair value of derivative liability     1,189,000 0  
Change in fair value of investment (575,000) 0 (575,000) 0  
Gain on deconsolidation of Caelum     0 (18,521,000)  
Research and development-licenses acquired, expense     2,236,000 1,350,000  
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:          
Accounts receivable     (2,161,000) 111,000  
Inventory     (195,000) (263,000)  
Other receivables - related party     (74,000) 852,000  
Prepaid expenses and other current assets     2,429,000 1,812,000  
Other assets     (198,000) (903,000)  
Accounts payable and accrued expenses     (2,686,000) (3,841,000)  
Accounts payable and accrued expenses - related party     19,000 (149,000)  
Interest payable     (1,019,000) 5,000  
Interest payable - related party     (92,000) (8,000)  
Lease liabilities     (943,000) (940,000)  
Other long-term liabilities     (140,000) 795,000  
Net cash used in operating activities     (63,196,000) (69,909,000)  
Cash Flows from Investing Activities:          
Purchase of research and development licenses     (3,369,000) (850,000)  
Purchase of property and equipment     (1,228,000) (1,455,000)  
Purchase of intangible asset     (1,000,000) (2,400,000)  
Purchase of short-term investment (certificates of deposit)     0 (5,000,000)  
Redemption of short-term investment (certificates of deposit)     0 17,604,000  
Deconsolidation of Caelum     0 (1,201,000)  
Net cash provided by (used in) continuing investing activities     (5,597,000) 6,698,000  
Net cash provided by discontinued investing activities     0 13,089,000 $ 0
Net cash provided by (used in) investing activities     (5,597,000) 19,787,000  
Cash Flows from Financing Activities:          
Payment of Series A preferred stock dividends     (4,507,000) (1,773,000)  
Purchase of treasury stock     (70,000) 0  
Payment of costs related to purchase of treasury stock     (2,000) 0  
Proceeds from issuance of Series A preferred stock     39,075,000 0  
Payment of cost related to issuance of Series A preferred stock     (3,407,000) 0  
Proceeds from issuance of common stock for at-the-market offering     44,796,000 16,099,000  
Payment of cost related to issuance of common stock for at-the-market offering     (1,506,000) (301,000)  
Proceeds from issuance of Series A preferred stock for at-the-market offering     0 539,000  
Payment of cost related to issuance of Series A preferred stock for at-the-market offering     0 (16,000)  
Proceeds from issuance of common stock under ESPP     90,000 60,000  
Proceeds from partner companies' ESPP     349,000 0  
Partner company's dividends declared and paid     (50,000) 0  
Proceeds from partner companies' sale of stock     57,729,000 66,623,000  
Payment of costs related to partner companies' sale of stock     (3,642,000) (4,754,000)  
Proceeds from partner companies' at-the-market offering     34,254,000 30,419,000  
Payment of costs related to partner companies' at-the-market offering     (754,000) (739,000)  
Proceeds from partner company's preferred stock offering     (8,000,000) 0  
Payment of costs related to partner company's preferred stock offering     (912,000) 0  
Proceeds from exercise of partner company's warrants     13,000 0  
Repayment of IDB Note     (14,858,000) 0  
Net cash provided by financing activities     135,395,000 119,559,000  
Net increase in cash and cash equivalents and restricted cash     66,602,000 69,437,000  
Cash and cash equivalents and restricted cash at beginning of period     153,432,000 81,582,000 81,582,000
Cash and cash equivalents and restricted cash at end of period $ 220,034,000 $ 151,019,000 220,034,000 151,019,000 $ 153,432,000
Supplemental disclosure of cash flow information:          
Cash paid for interest     6,669,000 3,976,000  
Cash paid for interest - related party     463,000 342,000  
Supplemental disclosure of non-cash financing and investing activities:          
Settlement of restricted stock units into common stock     2,000 2,000  
Common shares issuable for license acquired     0 164,000  
Issuance of partner company warrants in conjunction with Horizon Notes     0 888,000  
Issuance of warrants in conjunction with Oaktree debt     4,419,000 0  
Common shares issued from 2017 Subordinated Note Financing interest expense     500,000 0  
Common shares issued for 2019 Notes     0 500,000  
Unpaid fixed assets     317,000 288,000  
Partner company's previous paid offering cost     0 833,000  
Reclass partner company's warrants from liability to equity     1,216,000 0  
Unpaid debt offering cost     57,000 0  
Unpaid at-the-market offering cost     96,000 0  
Unpaid partner company's offering cost     457,000 0  
Partner company's unpaid intangible assets     3,727,000 4,734,000  
Unpaid Series A preferred stock offering cost     203,000 0  
Unpaid research and development licenses acquired     117,000 0  
Retirement of Series A preferred stock     70,000 0  
2017 Subordinated Note Financing One [Member]          
Cash Flows from Financing Activities:          
Payment of debt issuance costs     (93,000) (79,000)  
Repayments of debt     (28,356,000) 0  
2018 Venture Notes One [Member]          
Cash Flows from Financing Activities:          
Payment of debt issuance costs     (58,000) (126,000)  
Repayments of debt     (21,707,000) 0  
2019 Notes [Member]          
Cash Flows from Financing Activities:          
Repayments of debt     (9,000,000) 0  
Oaktree Note [Member]          
Reconciliation of net loss to net cash used in operating activities:          
Amortization of debt discount     4,400,000    
Cash Flows from Financing Activities:          
Payment of debt issuance costs     (4,239,000) 0  
Proceeds from issuance of Notes     60,000,000 0  
Horizon Notes [Member]          
Cash Flows from Financing Activities:          
Payment of debt issuance costs     0 (1,393,000)  
Proceeds from issuance of Notes     0 15,000,000  
Repayments of debt     $ (15,750,000) $ 0  
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Description of Business
9 Months Ended
Sep. 30, 2020
Organization and Description of Business  
Organization and Description of Business

1. Organization and Description of Business

Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing pharmaceutical and biotechnology products and product candidates, which the Company does at the Fortress level, at its majority-owned and majority-controlled subsidiaries and joint ventures, and at entities the Company founded and in which it maintains significant minority ownership positions. Fortress has a talented and experienced business development team, comprising scientists, doctors and finance professionals, who identify and evaluate promising products and product candidates for potential acquisition by new or existing partner companies. Fortress through its partner companies has executed such arrangements in partnership with some of the world’s foremost universities, research institutes and pharmaceutical companies, including City of Hope National Medical Center, Fred Hutchinson Cancer Research Center, St. Jude Children’s Research Hospital, Dana-Farber Cancer Institute, Nationwide Children’s Hospital, Cincinnati Children’s Hospital Medical Center, Columbia University, the University of Pennsylvania, and AstraZeneca plc.

Following the exclusive license or other acquisition of the intellectual property underpinning a product or product candidate, Fortress leverages its business, scientific, regulatory, legal and finance expertise to help the partners achieve their goals. Partner companies then assess a broad range of strategic arrangements to accelerate and provide additional funding to support research and development, including joint ventures, partnerships, out-licensings, and public and private financings; to date, three partner companies are publicly-traded, and two have consummated strategic partnerships with industry leaders Alexion Pharmaceuticals, Inc. and InvaGen Pharmaceuticals, Inc. (“InvaGen”)(a subsidiary of Cipla Limited).

Several of our partner companies possess licenses to product candidate intellectual property, including Aevitas Therapeutics, Inc. (“Aevitas”), Avenue Therapeutics, Inc. (“Avenue”), Baergic Bio, Inc. (“Baergic”), Caelum Biosciences, Inc. (“Caelum”), Cellvation, Inc. (“Cellvation”), Checkpoint Therapeutics, Inc. (“Checkpoint”), Cyprium Therapeutics, Inc. (“Cyprium”), Helocyte, Inc. (“Helocyte”), Journey Medical Corporation (“Journey” or “JMC”), Mustang Bio, Inc. (“Mustang”) and Oncogenuity, Inc. (“Oncogenuity”).

Liquidity and Capital Resources

Since inception, the Company’s operations have been financed primarily through the sale of equity and debt securities, from the sale of partner companies, and the proceeds from the exercise of warrants and stock options. The Company has incurred losses from operations and negative cash flows from operating activities since inception and expects to continue to incur substantial losses for the next several years as it continues to fully develop and prepare regulatory filings and obtain regulatory approvals for its existing and new product candidates. The Company’s current cash and cash equivalents are sufficient to fund operations for at least the next 12 months. However, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, sale of a partner company, grants or other arrangements to fully develop and prepare regulatory filings and obtain regulatory approvals for the existing and new product candidates, fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for the potential products, sales and marketing capabilities.  If such funding is not available or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed. The Company also has the ability, subject to limitations imposed by Rule 144 of the Securities Act of 1933 and other applicable laws and regulations, to raise money from the sale of common stock of the public companies in which it has ownership positions. In addition to the foregoing, the Company does not expect any material impact on its development timelines, revenue levels and its liquidity due to the worldwide spread of COVID-19 (except as may be implicated by the Material Adverse Effect claimed by InvaGen in connection with their agreement with Avenue). However, the Company is continuing to assess the impact the spread of COVID-19 may have on its operations. Avenue will also continue to assess the alleged Material Adverse Effect claimed by InvaGen.

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2020
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.

The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited financial statements for the preceding fiscal year for each of the companies: Avenue, Checkpoint and Mustang. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2020, from which the Company derived the balance sheet data at December 31, 2019, as well as Checkpoint’s Form 10-K, filed with the SEC on March 11, 2020, Mustang’s Form 10-K, filed with the SEC on March 16, 2020, and Avenue’s Form 10-K, filed with the SEC on March 30, 2020.

The Company’s unaudited condensed consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company also consolidates subsidiaries in which it owns less than 50% of the subsidiary but maintains voting control. The Company continually assesses whether changes to existing relationships or future transactions may result in the consolidation or deconsolidation of partner companies.

The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period.

Use of Estimates

The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2019 Annual Report.

Recently Adopted Accounting Pronouncements

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-13, Fair Value Measurement (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with the movement amongst or hierarchy associated with Level 1, Level 2 and Level 3 fair value measurements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. On January 1, 2020, the Company’s adoption of this guidance to did not have a material impact on its condensed consolidated  financial statements.

Recently Issued Accounting Pronouncements

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) (“ASU 470-20”) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 815-40”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. The ASU is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer and will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, for the Company as it is a smaller reporting company. Early adoption will be permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses”. The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. Recently, the FASB issued the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of the adoption of this ASU on its condensed consolidated  financial statements.

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Discontinued Operations
9 Months Ended
Sep. 30, 2020
Discontinued Operations  
Discontinued Operations

3. Discontinued Operations

The table below depicts the cash flows from the sale of the Company’s investment in National Holdings Corporation, a diversified independent brokerage company (together with its subsidiaries, herein referred to as “NHLD” or “National”) for the nine months ended September 30, 2019:

For the Nine Months Ended

September 30, 

($ in thousands)

    

2019

Investing activities

 

  

Proceeds from sale of National

$

13,089

Total cash provided by discontinued investing activities

$

13,089

At September 30, 2020 and 2019, the Company had no ownership interest in National.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and Stock Purchase Agreements
9 Months Ended
Sep. 30, 2020
Collaboration and Stock Purchase Agreements  
Collaboration and Stock Purchase Agreements

4. Collaboration and Stock Purchase Agreements

Caelum

Agreement with Alexion

In January 2019, Caelum entered into a Development, Option and Stock Purchase Agreement (the “DOSPA”) and related documents by and among Caelum, Alexion Therapeutics, Inc. (“Alexion”), the Company and Caelum security holders as parties thereto (such security holders, including Fortress, the “Sellers”). Under the terms of the agreement, Alexion purchased a 19.9% minority equity interest in Caelum for $30 million. Additionally, Alexion has agreed to make potential payments to Caelum upon the achievement of certain developmental milestones, in exchange for which Alexion obtained a contingent exclusive option to acquire the remaining equity in Caelum. The agreement also provides for potential additional payments, in the event Alexion exercises the purchase option, for up to $500 million, which includes an upfront option exercise payment and potential regulatory and commercial milestone payments.

In December 2019, following the U.S. Food and Drug Administration (“FDA”) feedback which resulted in the redesign and expansion of Caelum’s planned clinical development program for its lead product candidate, CAEL-101, Caelum entered into an Amended and Restated DOSPA, which amended the terms of the existing agreement with Alexion. The amendment modified the terms of Alexion’s option to acquire the remaining equity in Caelum based on data from the expanded Phase 2/3 trials. The amendment also modified the development-related milestone events associated with the initial $30 million in contingent payments, provided for an additional $20 million in upfront funding, as well as funding of $60 million in exchange for an additional equity interest in Caelum at fair value upon achievement of a specific development-related milestone event.

In September 2020, following its Phase 2 open-label dose escalation study, Caelum announced the initiation of its Cardiac Amyloid Reaching for Extended Survival (“CARES”) Phase 3 clinical program to evaluate CAEL-101 a first-in-class amyloid fibril targeted therapy, in combination with standard-of-care (SoC) therapy in AL amyloidosis. The CARES clinical program includes two parallel Phase 3 studies – one in patients with Mayo stage 3a disease and one in patients with Mayo stage 3b disease – and will collectively enroll approximately 370 patients globally. Enrollment is underway in both studies. The primary objective of the clinical program is to assess overall survival.   The Phase 2 program continues with the addition of a study arm to evaluate CAEL-101 in combination with SoC therapy plus daratumumab.

Avenue

Agreement with InvaGen

On November 12, 2018, the Company’s partner company, Avenue, entered into a Stock Purchase and Merger Agreement (“Avenue SPMA”) with InvaGen Pharmaceuticals Inc. (“InvaGen”) and Madison Pharmaceuticals Inc., a newly formed, wholly-owned subsidiary of InvaGen. Pursuant to the Avenue SPMA, and following approval by Avenue’s stockholders on February 8, 2019, InvaGen purchased a number of shares of Avenue common stock representing 33.3% of Avenue’s fully diluted capital stock for net proceeds to Avenue of $31.5 million (after deducting fees and other offering-related costs).

Upon the achievement of certain closing conditions (including most notably FDA approval for IV Tramadol, Avenue’s product candidate), InvaGen will be obligated to acquire Avenue via reverse subsidiary merger (the “Merger Transaction”). Under the Merger Transaction, InvaGen will pay $180 million (subject to certain potential reductions) to the holders of Avenue’s capital stock (other than InvaGen itself). In October 2020, InvaGen communicated to Avenue that it believes a Material Adverse Effect (as defined in the Avenue SPMA) has occurred, due to the COVID-19 pandemic, which means that it is possible that InvaGen is attempting to avoid their obligations to consummate the second stage closing under the Avenue SPMA. Avenue disagrees with InvaGen’s assertion that a Material Adverse Effect has occurred, and Avenue has advised InvaGen of this position.

Subject to the terms and conditions described in the Avenue SPMA, InvaGen may also provide interim financing to Avenue in an amount of up to $7.0 million during the time period between February 8, 2019 and the Merger Transaction. Any amounts drawn on the interim financing will be deducted from the aggregate consideration payable to Company stockholders by virtue of the Merger Transaction.

Prior to the closing of the Merger Transaction, Avenue will enter into a Contingent Value Rights Agreement (the “CVR Agreement”) with a trust company as rights agent, pursuant to which holders of common shares of Avenue, other than InvaGen (each, a “Holder”), will be entitled to receive on Contingent Value Right (“CVR”) for each share held immediately prior to the Merger Transaction.

Each CVR represents the right of its holder to receive a contingent cash payment pursuant to the CVR Agreement upon the achievement of certain milestones. If, during the period commencing on the day following the closing of the Merger Transaction until December 31, 2028, IV Tramadol generates at least $325 million or more in Net Sales (as defined in the CVR Agreement) in a calendar year, each Holder shall be entitled to receive their pro rata share of (i) if the product generated less than $400 million in Net Sales during such calendar year, 10% of Gross Profit (as defined in the CVR Agreement), (ii) if the product generated between $400 million and $500 million in Net Sales during such calendar year, 12.5% of Gross Profit, or (iii) if the product generated more than $500 million in Net Sales during such calendar year, 15% of Gross Profit. Additionally, at any time beginning on January 1, 2029 that IV Tramadol has generated at least $1.5 billion in aggregate Net Sales, then with respect to each calendar year in which IV Tramadol generates $100 million or more in Net Sales, each Holder shall be entitled to receive their pro rata share of an amount equal to 20% of the Gross Profit generated by IV Tramadol. These additional payments will terminate on the earlier of December 31, 2036 and the date (which may be extended by up to 6 months) that any person has received approval from the FDA for an Abbreviated New Drug Application (“NDA”) or an FDA AP-rated 505(b)(2) NDA using IV Tramadol.

On October 12, 2020, Avenue announced that it had received a Complete Response Letter (“CRL”) from the FDA regarding Avenue’s NDA for IV Tramadol.   The CRL cited deficiencies related to the terminal sterilization validation and stated that IV Tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population. Avenue requested a meeting with the FDA to resolve the issues described in the CRL and the meeting has been scheduled for the fourth quarter of 2020.

Also in October 2020, InvaGen Pharmaceuticals Inc. (“InvaGen”) communicated to Avenue that it believes a Material Adverse Effect (as defined in the Stock Purchase and Merger Agreement (“Avenue SPMA”)) has occurred, due to the COVID-19 pandemic, which means that it is possible that InvaGen is attempting to avoid their obligations to consummate the second stage closing under the Avenue SPMA. Avenue disagrees with InvaGen’s assertion that a Material Adverse Effect has occurred, and Avenue has advised InvaGen of this position.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment
9 Months Ended
Sep. 30, 2020
Property and Equipment  
Property and Equipment

5. Property and Equipment

Fortress’ property and equipment consisted of the following:

    

Useful Life

    

September 30, 

    

December 31, 

($ in thousands)

(Years)

2020

2019

(Unaudited)

Computer equipment

 

3

$

662

$

648

Furniture and fixtures

 

5

 

1,199

 

1,162

Machinery & equipment

 

5

 

5,014

 

4,594

Leasehold improvements

 

5-15

 

10,580

 

9,358

Construction in progress 1

 

N/A

 

821

 

1,157

Total property and equipment

 

18,276

 

16,919

Less: Accumulated depreciation

 

(6,162)

 

(4,486)

Property and equipment, net

$

12,114

$

12,433

Note 1:

Relates to the Mustang cell processing facility.

Fortress' depreciation expense for the three months ended September 30, 2020 and 2019 was approximately $0.6 million and $0.5 million, respectively, and was recorded in both research and development expense and general and administrative expense in the condensed consolidated statements of operations.

Fortress' depreciation expense for the nine months ended September 30, 2020 and 2019 was approximately $1.7 million and $1.4 million, respectively, and was recorded in both research and development expense and general and administrative expense in the condensed consolidated statements of operations.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements
9 Months Ended
Sep. 30, 2020
Fair Value Measurements  
Fair Value Measurements

6. Fair Value Measurements

Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities.

Fair Value of Caelum

As of September 30, 2020, the Company valued its investment in Caelum in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, and estimated the fair value to be $11.7 million based on a per share value of $1.62. As of September 30, 2020, the following inputs were utilized to derive the value: risk free rate of return of 0.12%, volatility of 70% and a discount for lack of marketability of 28.6%.

As of December 31, 2019, the Company valued its investment in Caelum in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, and estimated the fair value to be $11.1 million based on a per share value of $1.54. As of December 31, 2019, the following inputs were utilized to derive the value: risk free rate of return of 1.6%, volatility of 70% and a discount for lack of marketability of 28.7%.

Cyprium Warrant Liability

During the quarter ended September 30, 2020, Cyprium raised approximately $8.0 million in Perpetual Preferred Shares (“Cyprium Offering,” see Note 14).  The Cyprium Offering coupled with the repayment of the 2018 Venture Debt (see Note 10), triggered the issuance of the Cyprium Warrant, in that a price per share could be established. As such these events resulted in Cyprium recording the Cyprium Warrant as issued rather than contingently issuable.

The fair value of the Cyprium Warrants in connection with the 2018 Venture Debt was determined by applying management’s estimate of the probability of issuance of the Contingently Issuable Warrants together with an option-pricing model, with the following key assumptions:

    

September 30, 2020

December 31, 2019

 

Risk-free interest rate

 

0.69

%

1.92

%

Expected dividend yield

 

Expected term in years

 

10.0

10.0

Expected volatility

 

85

%

93

%

Probability of issuance of the warrant

 

100

%

5

%

Cyprium

Contingently

Issuable Warrant

($ in thousands)

Liability

Beginning balance at January 1, 2020

$

27

Change in fair value

1,189

Reclass partner company's warrants from liability to equity

(1,216)

Ending balance at September 30, 2020

$

-

The following tables classify into the fair value hierarchy of Fortress’ financial instruments, measured at fair value as of September 30, 2020 and December 31, 2019:

Fair Value Measurement as of  September 30, 2020

($ in thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets

 

  

 

  

 

  

 

  

Fair value of investment in Caelum

$

$

$

11,723

$

11,723

Total

$

$

$

11,723

$

11,723

Fair Value Measurement as of  December 31, 2019

($ in thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets

 

  

 

  

 

  

 

  

Fair value of investment in Caelum

 

$

 

$

 

$

11,148

 

$

11,148

Total

 

$

 

$

 

$

11,148

 

$

11,148

Fair Value Measurement as of  December 31, 2019

($ in thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Liabilities

 

  

 

  

 

  

 

  

Warrant liabilities

 

$

 

$

 

$

27

 

$

27

Total

 

$

 

$

 

$

27

 

$

27

The table below provides a roll-forward of the changes in fair value of Level 3 financial instruments as of September 30, 2020:

Investment in

Warrant

($ in thousands)

    

Caelum

    

 Liabilities

    

Total

Balance at December 31, 2019

$

11,148

$

27

$

11,175

Change in fair value

1,189

1,189

Reclass partner company's warrants from liability to equity

(1,216)

(1,216)

Change in fair value of investments

575

575

Balance at September 30, 2020

$

11,723

$

$

11,723

As of September 30, 2020, no transfers occurred between Level 1, Level 2 and Level 3 instruments.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Licenses Acquired
9 Months Ended
Sep. 30, 2020
Licenses Acquired  
Licenses Acquired

7. Licenses Acquired

In accordance with ASC 730-10-25-1, Research and Development, costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use. The licenses purchased by Fortress and its partner companies require substantial completion of research and development, and regulatory and marketing approval efforts in order to reach technological feasibility. As such, for the three and nine months ended September 30, 2020 and 2019, the purchase price of licenses acquired was classified as research and development-licenses acquired in the condensed consolidated Statements of operations as reflected in the table below:

Three Months Ended September 30, 

Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

    

Partner companies:

 

  

 

  

 

  

 

  

 

Mustang

$

287

$

700

$

1,837

$

1,350

Aevitas

162

162

Baergic

 

8

 

 

8

 

Oncogenuity

1

271

Total

$

458

$

700

$

2,278

$

1,350

Mustang

SIRION Biotech GmbH - LentiBOOSTTM (MB-207)

On September 30, 2020, Mustang entered into an exclusive, worldwide licensing agreement with SIRION Biotech (“SIRION”) for the rights to SIRION’s LentiBOOSTTM technology for the development of MB-207, Mustang’s lentiviral gene therapy for the treatment of previously transplanted patients with X-linked severe combined immunodeficiency (the “SIRION Technology License”). Pursuant to the SIRION Technology License, which requires payment in Euro, the Company paid SIRION a one-time upfront fee of $0.1 million (€0.1 million) during the three and nine months ended September 30, 2020. In addition, five future development milestone payments totaling up to approximately $5.6 million (€4.7 million) in the aggregate are due upon achievement of certain milestones. Additional milestone payments totaling up to $4.1 million (€3.5 million) in the aggregate are due in connection with the achievement of three commercial milestones and low- to mid-single digit royalties are due on aggregate cumulative worldwide net sales of licensed products.

For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for licenses acquired:

For the Three Months Ended September 30, 

For the Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

City of Hope National Medical Center

CD123 (MB-102)3

$

$

$

334

$

250

IL13Rα2 (MB-101) 3

333

HER2 (MB-103)1

250

CS1 (MB-104)

200

PSCA (Spacer)3

200

 

333

 

200

Fred Hutch - CD20 (MB-106)2

300

Nationwide Children’s Hospital - C134 (MB-108)

200

CSL Behring (Calimmune)

170

200

170

200

UCLA

300

300

SIRION LentiBOOSTTM

117

117

Total

$

287

$

700

$

1,837

$

1,350

Note 1:

Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-103 at COH, for the nine months ended September 30, 2020.

Note 2:

Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-106 at Fred Hutch, for the nine months ended September 30, 2020.

Note 3:

Represents a milestone payment to COH in connection with Mustang’s public underwritten offerings, for the nine months ended September 30, 2020.

Oncogenuity

Effective May 6, 2020, Oncogenuity entered into a license agreement with the Trustees of Columbia University in the City of New York (“Columbia”) to develop novel oligonucleotides for the treatment of genetically driven cancers (the “Columbia License”). The proprietary platform produces oligomers, known as “ONCOlogues.”

As consideration for the Columbia License, Oncogenuity paid an upfront fee of $0.3 million, and Fortress transferred to Columbia 1,000,000 shares of Oncogenuity common stock, representing 10.00% ownership of Oncogenuity. In connection with the share transfer, Oncogenuity also provided Columbia with limited anti-dilution protection. Oncogenuity valued the stock grant to Columbia utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 41.7%, weighted average cost of capital of 20.5%, and net of debt utilized, resulting in a value of $0.021 per share or $21,000 for the three and nine months ended September 30, 2020. Since a portion of the acquisition of the license was settled through the transfer of shares of Oncogenuity's common stock, this transaction fell within the scope of ASC Topic 718, Compensation-Stock Compensation, since equity was transferred in exchange for goods (the license). Specifically, Oncogenuity recorded the cost of the license as a non-employee share based payment, measured at the grant date fair value of the common stock. The common shares were equity-classified. The anti-dilution provision was concluded to represent a performance condition tied to a future liquidity event, which was not considered as probable to occur at September 30, 2020, because it was deemed outside of Oncogenuity’s control.

Development milestone payments totaling up to approximately $18.0 million in the aggregate are due upon achievement of certain milestones in connection with the initial indication. Additional milestone payments totaling up to $15.3 million in the aggregate are due in connection with product development milestones for subsequent indications. A $15.0 million sales milestone is due upon the achievement of a licensed product sales threshold, and low- to mid-single digit royalties are due on aggregate cumulative worldwide net sales of licensed products.

For the three and nine months ended September 30, 2020, Oncogenuity recorded expense of nil and $0.3 million in research and development - licenses acquired in the Company’s condensed consolidated statements of operations.

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Sponsored Research and Clinical Trial Agreements
9 Months Ended
Sep. 30, 2020
Sponsored Research and Clinical Trial Agreements  
Sponsored Research and Clinical Trial Agreements

8. Sponsored Research and Clinical Trial Agreements

Aevitas

For the three and nine months ended September 30, 2020 and 2019, Aevitas recorded the following expense in connection with its sponsored research and clinical trial agreements:

For the Three Months Ended September 30, 

For the Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

UMass - adeno-associated virus ("AAV")

163

218

UPenn - AAV

255

567

755

Duke - AAV

17

17

Total

$

163

$

272

$

785

$

772

Cellvation

For the three and nine months ended September 30, 2020 no expenses were incurred. For the three and nine months ended September 30 2019, Cellvation recorded expense of $0.1 million, in connection with its sponsored research arrangement with the University of Texas. The expense was recorded in research and development expense in the Company’s condensed consolidated statements of operations.

Mustang

CS1(MB-104) Clinical Research and Support Agreement with COH

In June 2020, Mustang entered into a clinical research and support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: "Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients with CS1+ Multiple Myeloma." The CAR T being studied under this protocol has been designated by Mustang as MB-104. Under the terms of the agreement Mustang paid COH $0.8 million during the three months ended September 30, 2020 for costs incurred and will reimburse COH for costs associated with this trial, when incurred, not to exceed $2.4 million. The agreement will expire upon the delivery of the final study report or earlier.  Expense of $0.1 million an $0.8 million was incurred for the three and nine months ended September 30, 2020.

XSCID (MB-107) Data Transfer Agreement with St. Jude

In June 2020, Mustang entered into a Data Transfer Agreement with St. Jude under which Mustang will reimburse St. Jude for costs associated with St. Jude’s clinical trial for the treatment of infants with X-linked Severe Combined Immunodeficiency (“XSCID”).  Pursuant to the terms of this agreement Mustang paid an upfront fee of $1.1 million on July 1, 2020 and will continue to reimburse St. Jude for costs incurred in connection with this trial.

For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements:

For the Three Months Ended September 30, 

For the Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

City of Hope National Medical Center

$

$

500

$

500

$

1,500

CD123 (MB-102)

 

48

 

269

 

344

 

1,028

IL13Rα2 (MB-101)

 

96

 

244

 

422

 

811

Manufacturing

 

 

114

 

 

343

CS1 (MB-104)

65

835

Beth Israel Deaconess Medical Center - CRISPR

69

St. Jude Children's Research Hospital - XSCID (MB-107)

107

1,665

Fred Hutchinson Cancer Research Center - CD20 (MB-106)

418

49

1,134

690

Total

$

734

$

1,176

$

4,900

$

4,441

Oncogenuity

Pursuant to the terms of the Columbia License, Oncogenuity will pay up to $4.8 million to Columbia semiannually for five years ending in November 2024.

For the three and nine months ended September 30, 2020, Oncogenuity recorded expense of $0.2 million and $0.3 million, respectively, in research and development in the Company’s condensed consolidated statements of operations. No expense was recorded in 2019.

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Intangibles, net
9 Months Ended
Sep. 30, 2020
Intangibles, net  
Intangibles, net

9. Intangibles, net

On July 29, 2020 Journey entered into a license and supply agreement with a third party for an oral acne treatment. Pursuant to the terms and conditions of the License and Supply Agreement (“LSA”), Journey agreed to pay $5.0 million, comprised of an upfront payment of $1.0 million paid upon execution with remaining payments due as follows: $1.0 million upon achievement of two marketing milestones and $3.0 million due in $1.0 million installments, commencing on the 18-month anniversary, the 24-month anniversary and the 36-month anniversary of execution of the LSA. Three additional milestone payments totaling $17.0 million are due upon the achievement of certain net sales milestones. Royalties in the mid, single digits based on net sales, subject to specified reductions are also due.

 

In accordance with ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, Journey determined the conditions of the LSA did not constitute the purchase of a business, and therefore recorded the consideration as an asset, to be amortized over the expected life of the product, which is deemed to be five years. In addition, Journey determined pursuant to ASC 450, Contingencies, that royalty payments in connection with the LSA will be recorded when they become payable with a corresponding charge to cost of goods sold.

  

In accordance with the installment payment terms of the LSA, Journey recorded a discount for imputed interest per ASC 835-30 Interest-Imputed Interest of $0.3 million. As of September 30, 2020, Journey recorded a net intangible asset related to this transaction of $4.7 million which was recorded on the Company’s condensed consolidated balance sheet.

The table below provides a summary of the Journey intangible assets as of September 30, 2020 and December 31, 2019, respectively:

Estimated Useful

($ in thousands)

    

Lives (Years)

    

September 30, 2020

    

December 31, 2019

(Unaudited)

Total Intangible assets – asset purchases

3 to 7

$

14,661

$

9,934

Accumulated amortization

 

  

 

(3,622)

 

(2,557)

Net intangible assets

 

  

$

11,039

$

7,377

The table below provides a summary for the nine months ended September 30, 2020, of Journey’s recognized expense related to its product licenses, which was recorded in costs of goods sold on the condensed consolidated statement of operations:

Intangible

($ in thousands)

    

Assets, Net

Beginning balance at January 1, 2020

$

7,377

Additions:

Oral acne treatment license acquisition1

4,727

Amortization expense

 

(1,065)

Ending balance at September 30, 2020

$

11,039

Note 1:  As of September 30, 2020, this asset has not yet been placed in service, therefore no amortization expense was recognized on this asset for the quarter ended September 30, 2020.  The Company expects the asset to be placed in service in the first half of 2021. Once the asset is placed in service the Company will amortize the asset over five years, which represents its expected useful life.

The future amortization of these intangible assets is as follows:

Total

($ in thousands)

    

Ximino®

    

Exelderm®

    

Amortization

Three Months Ended December 31, 2020

$

254

$

100

$

354

Year Ended December 31, 2021

 

1,019

 

267

 

1,286

Year Ended December 31, 2022

1,019

1,019

Year Ended December 31, 2023

1,019

1,019

Year Ended December 31, 2024

 

1,019

 

 

1,019

Thereafter

1,615

1,615

Sub-total

$

5,945

$

367

$

6,312

Asset not yet placed in service

4,727

Total

$

5,945

$

367

$

11,039

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and Interest
9 Months Ended
Sep. 30, 2020
Debt and Interest  
Debt and Interest

10. Debt and Interest

Debt

During the quarter ended September 30, 2020 the Company entered into a new credit facility with Oaktree Fund Administration, LLC, as the administrative agent (in such capacity, the “Agent”), and the lenders from time to time party thereto (each a “Lender” or  “Oaktree” and collectively, the “Lenders”), as described below (the “Oaktree Note”).  The Company utilized the proceeds from the Oaktree Note to repay the 2017 Subordinated Notes, the 2018 Venture Notes and the 2019 Notes.  The Company also repaid the IDB Note utilizing the cash collateral securing the IDB Note, which was classified as restricted cash on the Company’s consolidated condensed balance sheet.  In addition, on September 30, 2020 Mustang repaid the Mustang Horizon Notes.  

Total debt consists of the following as of September 30, 2020 and December 31, 2019:

    

September 30, 

    

December 31,

    

    

($ in thousands)

2020

2019

Interest rate

Maturity

IDB Note

$

$

14,929

 

2.25

%  

Aug - 2021

2017 Subordinated Note Financing3

 

 

3,254

 

8.00

%

March - 2022

2017 Subordinated Note Financing3

 

 

13,893

 

8.00

%

May - 2022

2017 Subordinated Note Financing3

 

 

1,820

 

8.00

%

June - 2022

2017 Subordinated Note Financing3

 

 

3,018

 

8.00

%

August - 2022

2017 Subordinated Note Financing

 

 

6,371

 

8.00

%

September - 2022

2018 Venture Notes4

 

 

6,517

 

8.00

%  

August - 2021

2018 Venture Notes4

 

 

15,190

 

8.00

%  

September - 2021

2019 Notes1

 

 

9,000

 

12.00

%  

September - 2021

Mustang Horizon Notes2

 

 

15,750

 

9.00

%  

October - 2022

Oaktree Note

60,000

11.00

%

August - 2025

Total notes payable

 

60,000

 

89,742

 

  

 

  

Less: Discount on notes payable

 

8,607

 

5,086

 

  

 

  

Total notes payable

$

51,393

$

84,656

 

  

 

  

Note 1:

Formerly the Opus Credit Facility (see Note 16.)

Note 2:

Interest rate was 9.0% plus one-month LIBOR Rate in excess of 2.5%.

Note 3:

As a result of a one-year maturity date extension effective 2020, the interest rate increased by 1% to 9.0%.

Note 4:

At December 31, 2019, $6.0 million is included in Notes payable, short-term on the condensed consolidated balance sheet.

Interest Expense

The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest; fees include amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan:

Three Months Ended September 30,

2020

2019

($ in thousands)

    

Interest

    

Fees

    

Total

    

Interest

    

Fees 

    

Total

IDB Note

$

77

$

$

77

$

86

$

$

86

2017 Subordinated Note Financing1

 

694

 

1,374

 

2,068

 

1,072

 

326

 

1,398

2019 Notes

172

172

275

 

104

379

2018 Venture Notes1

 

387

 

638

 

1,025

 

438

 

166

 

604

LOC Fees

 

14

 

 

14

 

14

 

 

14

Mustang Horizon Notes1,3

 

895

 

1,792

 

2,687

 

345

 

234

 

579

Oaktree Note1

624

108

732

Note Payable2

187

187

108

108

Other

 

(4)

 

 

(4)

 

 

 

Total Interest Expense and Financing Fee

$

3,046

$

3,912

$

6,958

$

2,230

$

938

$

3,168

Nine Months Ended September 30, 

2020

2019

($ in thousands)

    

Interest

    

Fees

    

Total

    

Interest

    

Fees

    

Total

IDB Note

$

246

$

$

246

$

254

$

-

$

254

2017 Subordinated Note Financing1

 

2,870

 

1,890

 

4,760

 

3,148

 

1,081

 

4,229

2019 Notes

 

710

 

 

710

 

840

336

 

1,176

2018 Venture Notes1

 

1,253

 

1,000

 

2,253

 

1,299

 

468

 

1,767

LOC Fees

 

45

 

 

45

 

45

 

 

45

Mustang Horizon Notes1,3

 

1,585

 

2,321

 

3,906

 

698

 

466

 

1,164

Oaktree Note1

624

108

732

Note Payable2

492

492

108

108

Other

 

(2)

 

 

(2)

 

Total Interest Expense and Financing Fee

$

7,823

$

5,319

$

13,142

$

6,284

$

2,459

$

8,743

Note 1:

For the three and nine months ended September 30, 2020, $1.2 million expense of unamortized debt discount fees for the 2017 Subordinated Note Financing, $0.3 million for the 2018 Venture Notes and $1.8 million for the Mustang Horizon Notes.

Note 2:

Imputed interest expense related to Journey’s agreements for Ximino and oral acne treatment.

Note 3:

Included in interest expense for the three and nine months ended September 30, 2020 was $0.6 million of prepayment penalties included in interest expense for the Mustang Horizon Notes.

Oaktree Note

On August 27, 2020 (the “Closing Date”), Fortress, as borrower, entered into a $60.0 million senior secured credit agreement (the “Agreement”) with Oaktree. The Company borrowed the full $60.0 million in connection with the terms of the Oaktree Note on the Closing Date and used the bulk of the proceeds to repay its outstanding debt to other lenders (2017 Subordinated Notes, 2018 Venture Notes and 2019 Notes (previously the “Opus Credit Facility”)).

The Oaktree Note bears interest at a fixed annual rate of 11.0%, payable quarterly and maturing on the fifth anniversary of the Closing Date, August 27, 2025, the (“Maturity Date”). The Company is required to make quarterly interest-only payments until the Maturity Date, at which point the outstanding principal amount is due. The Company may voluntarily prepay the Oaktree Note at any time subject to a Prepayment Fee as defined in the Terms section. The Company is required to make mandatory prepayments of the Oaktree Note under various circumstances as defined in the Terms section. No amounts paid or prepaid may be reborrowed without Oaktree consent.

The Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of permitted indebtedness, and dividends and other distributions, subject to certain exceptions. In addition, the Agreement contains certain financial covenants, including, among other things, (i) maintenance of minimum liquidity by the Company, and (ii) a minimum revenue test that is subject to certain exclusions. Failure by the Company to comply with the financial covenants will result in an event of default, subject to certain cure rights of the Company.  

The Agreement contains customary events of default, in certain circumstances subject to customary cure periods. Following an event of default and any cure period, if applicable, the Agent will have the right upon notice to accelerate all amounts outstanding under the Agreement, in addition to other remedies available to the lenders as secured creditors of the Company. The Agreement grants a security interest in favor of the Agent, for the benefit of the lenders, in substantially all of the Company’s assets as collateral securing the Company’s obligations under the Agreement, except for: (i) certain interests in controlled foreign corporation subsidiaries of the Company; (ii) the Company’s holdings in Avenue; and (iii) those portions of the Company’s holdings in certain subsidiaries (plus Caelum) that are encumbered by pre-existing equity pledges to certain of the Company’s officers.

Pursuant to the terms of the Agreement on the Closing Date the Company paid Oaktree an upfront commitment fee equal to 3% of the $60.0 million, or $1.8 million.  In addition, the Company paid a $35,000 Agency fee to the Agent which was due on the Closing Date and will be due annually, together with fees of $2.5 million directly to third parties involved in the transaction.  

In connection with the Oaktree Note, the Company issued warrants to Oaktree and certain of its affiliates to purchase up to 1,749,450 shares of common stock (see Note 14) with a relative fair value of $4.4 million.

As of September 30, 2020, the Company recorded the fees totaling $8.7 million ($1.8 million to Oaktree, $2.5 million of expenses paid to third-parties and $4.4 million representing the relative fair value of the Oaktree Warrants) to debt discount.  These costs will be amortized over the term of the Oaktree Note.

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Liabilities and other Long-Term Liabilities
9 Months Ended
Sep. 30, 2020
Accrued Liabilities and other Long-Term Liabilities  
Accrued Liabilities and other Long-Term Liabilities

11. Accrued Liabilities and other Long-Term Liabilities

Accrued expenses and other long-term liabilities consisted of the following:

September 30, 

December 31,

($ in thousands)

    

2020

    

2019

Accrued expenses:

 

  

 

  

Professional fees

$

1,672

$

1,153

Salaries, bonus and related benefits

 

5,677

 

6,683

Accrued expense - related party

 

19

 

Research and development

 

4,604

 

4,215

Research and development - manufacturing

 

 

1,017

Research and development - license maintenance fees

 

629

 

361

Research and development - milestones

 

600

 

Accrued royalties payable

 

1,908

 

2,320

Accrued coupon expense

 

5,476

 

8,391

Other

 

547

 

1,259

Total accrued expenses

$

21,132

$

25,399

Other long-term liabilities:

 

  

 

  

Deferred rent and long-term lease abandonment charge1

$

1,996

$

2,136

Long-term notes payable, net (Journey)

Ximino agreement2

3,456

4,990

Oral acne treatment agreement3

2,753

Total other long-term liabilities

$

8,205

$

7,126

Note 1:

As of September 30, 2020, and December 31, 2019, the balance consists of deferred charges related to build-out of the New York facility.

Note 2:

As of September 30, 2020, and December 31, 2019, the imputed interest discount was $1.5 million and $2.0 million, respectively, in connection with its acquisition of Ximino in July 2019. Amortization of interest discount was $0.5 million for the nine months ended September 30, 2020, and $0.1 million for the nine months ended September 30, 2019. As of September 30, 2020, $2.0 million of note payable was classified as short-term.

Note 3:

As of September 30, 2020, the imputed discount balance was $0.2 million.  The imputed interest discount was calculated utilizing a 4.00% effective rate, which represents the market rate for an asset-backed three year loan, secured by receivables. As of September 30, 2020, $1.0 million of note payable was classified as short-term.

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Non-Controlling Interests
9 Months Ended
Sep. 30, 2020
Non-Controlling Interests  
Non-Controlling Interests

12. Non-Controlling Interests

Non-controlling interests in consolidated entities are as follows:

    

    

For the nine months ended

    

    

    

    

 

As of September 30, 2020

September 30, 2020

As of September 30, 2020

 

Net loss attributable to

Non-controlling interests

Non-controlling

 

($ in thousands)

    

NCI equity share

non-controlling interests

in consolidated entities

ownership

 

Aevitas

$

(2,297)

 

(680)

 

(2,977)

 

39.0

%

Avenue 2

 

5,709

 

(3,206)

 

2,503

 

77.4

%

Baergic

 

(1,605)

 

(68)

 

(1,673)

 

40.0

%

Cellvation

 

(1,072)

 

(145)

 

(1,217)

 

22.6

%

Checkpoint 1

 

37,963

 

(9,000)

 

28,963

 

80.0

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

784

 

(843)

 

(59)

 

28.4

%

Helocyte

 

(4,890)

 

(236)

 

(5,126)

 

18.8

%

JMC

 

123

 

257

 

380

 

6.9

%

Mustang 2

 

86,572

 

(27,035)

 

59,537

 

77.9

%

Oncogenuity

(47)

 

(268)

 

(315)

 

25.3

%

Tamid

 

(652)

 

(40)

 

(692)

 

22.8

%

Total

$

120,298

$

(41,264)

$

79,034

 

  

    

For the twelve months ended

    

    

 

As of December 31, 2019

December 31, 2019

As of December 31, 2019

 

Net loss attributable to 

Non-controlling interests 

Non-controlling 

 

($ in thousands)

    

NCI equity share

    

non-controlling interests

    

 in consolidated entities

    

 ownership

 

Aevitas

$

(1,249)

$

(694)

$

(1,943)

 

35.8

%

Avenue 2

 

24,269

 

(19,011)

 

5,258

 

77.3

%

Baergic

 

23

 

(1,162)

 

(1,139)

 

33.0

%

Cellvation

 

(732)

 

(158)

 

(890)

 

20.6

%

Checkpoint 1

 

29,389

 

(14,687)

 

14,702

 

78.0

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

(320)

 

(99)

 

(419)

 

10.6

%

Helocyte

 

(4,322)

 

(402)

 

(4,724)

 

19.3

%

JMC

 

(211)

 

325

 

114

 

6.9

%

Mustang 2

 

62,025

 

(25,727)

 

36,298

 

70.3

%

Tamid

 

(565)

 

(85)

 

(650)

 

22.8

%

Total

$

108,017

$

(61,700)

$

46,317

 

Note 1:

Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Note 2:

Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss per Common Share
9 Months Ended
Sep. 30, 2020
Net Loss per Common Share  
Net Loss per Common Share

13. Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period.

The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the nine months ended September 30, 2020:

Nine Months Ended September 30, 

2020

    

2019

Warrants to purchase Common Stock

 

3,026,693

 

2,745,364

Options to purchase Common Stock

 

1,187,600

 

1,169,293

Unvested Restricted Stock

 

14,305,949

 

12,622,881

Unvested Restricted Stock Units

 

434,215

 

791,610

Total

 

18,954,457

 

17,329,148

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity
9 Months Ended
Sep. 30, 2020
Stockholders' Equity  
Stockholders' Equity

14. Stockholders’ Equity

Common Stock

At the Company’s 2020 Annual Meeting of Stockholders held on June 17, 2020, its stockholders approved an amendment to its certificate of incorporation to increase the number of authorized shares of common stock available to issue by 50,000,000 to 150,000,000 with a par value of $0.001 per share. The amendment was filed with the Secretary of State of the State of Delaware on June 18, 2020.

Stock-based Compensation

The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the three and nine months ended September 30, 2020 and 2019:

Three Months Ended September 30, 

Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

    

Employee awards

$

1,200

$

936

$

3,732

$

2,791

Executive awards of Fortress Companies' stock

 

369

 

358

 

1,136

 

1,065

Non-employee awards

 

31

 

15

 

136

 

84

Warrants

32

97

97

97

Partner Companies:

 

 

Avenue

 

161

 

298

 

592

 

1,585

Checkpoint

 

725

 

833

 

2,095

 

2,444

Mustang

 

606

 

1,120

 

2,368

 

2,174

Other

 

47

 

84

 

163

 

183

Total stock-based compensation expense

$

3,171

$

3,741

$

10,319

$

10,423

For the three months ended September 30, 2020 and 2019, approximately $0.7 million and $1.2 million, respectively, of stock-based compensation expense was included in research and development expenses in connection with equity grants made to employees and consultants and approximately $2.5 million and $2.5 million, respectively, was included in general and administrative expenses in connection with grants made to employees, members of the board of directors and consultants.

For the nine months ended September 30, 2020 and 2019, approximately $2.5 million and $2.6 million, respectively, of stock-based compensation expense was included in research and development expenses in connection with equity grants made to employees and consultants and approximately $7.8 million and $7.8 million, respectively, was included in general and administrative expenses in connection with grants made to employees, members of the board of directors and consultants.

Equity Compensation Plans

At the Company’s 2020 Annual Meeting on June 30, 2020, the Company’s shareholders approved an amendment to the Company’s 2013 Stock Incentive Plan, as amended (“Stock Plan”) to increase common shares issuable under the Stock Plan by 3.0 million to 13.0 million.  For the nine months ended September 30, 2020, 4.2 million shares remain to be issued under the Stock Plan.

Stock Options

The following table summarizes Fortress stock option activities excluding activity related to Fortress partner companies:

Weighted average

Total

remaining

Weighted average

weighted average

contractual life

    

Number of shares

    

exercise price

    

intrinsic value

    

(years)

Options vested and expected to vest at December 31, 2019

 

1,410,501

$

4.30

$

684,752

 

2.33

Exercised

 

(100,000)

1.18

 

 

Forfeited

(247,011)

2.55

Options vested and expected to vest at September 30, 2020

 

1,063,490

$

5.00

$

1,044,218

 

2.87

As of September 30, 2020, Fortress had no unrecognized stock-based compensation expense related to options.

Restricted Stock and Restricted Stock Units

The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress Companies:

    

    

Weighted

average grant

Number of shares

price

Unvested balance at December 31, 2019

13,768,014

$

2.46

Restricted stock granted

1,873,072

2.57

Restricted stock vested

(1,549,564)

2.69

Restricted stock units granted

630,126

3.82

Restricted stock units forfeited

(106,250)

2.71

Restricted stock units vested

(368,290)

3.13

Unvested balance at September 30, 2020

14,247,108

$

2.49

As of September 30, 2020 and 2019, the Company had unrecognized stock-based compensation expense related to restricted stock and restricted stock unit awards of approximately $17.5 million and $12.7 million, respectively, which is expected to be recognized over the remaining weighted-average vesting period of 3.9 years and 5.0 years, respectively.

Warrants

The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies:

Total weighted

Weighted average

average

remaining

Number of

Weighted average

 intrinsic

contractual life

    

shares

    

exercise price

    

value

    

(years)

Outstanding as of December 31, 2019

 

2,741,180

$

3.19

$

111,000

 

2.73

Granted

 

1,849,450

 

3.14

 

1,657,538

 

Forfeited

 

(9)

 

3.00

 

 

Outstanding as of September 30, 2020

 

4,590,621

$

3.17

$

4,111,018

 

5.10

Exercisable as of September 30, 2020

 

4,430,621

$

3.21

$

3,816,818

 

5.05

In connection with the Oaktree Note (see Note 10), the Company issued warrants to Oaktree and certain of its affiliates to purchase up to 1,749,450 shares of common stock at a purchase price of $3.20 per share (the “Oaktree Warrants”). Oaktree is entitled to additional warrants if at any time prior to the expiration of the Oaktree Warrants in event the Company issues equity, warrants or convertible notes (collectively known as “Security Instruments”) at a price that is less than 95% of the market price of the Company’s  Common Stock on the trading day prior to the issuance of the Security Instruments. The Warrants expire on August 27, 2030 and may be net exercised at the holder’s election. The Company also agreed to file a registration statement on Form S-3 to register for resale the shares of common stock issuable upon exercise of the Warrants.

The Company evaluated the accounting treatment of the Oaktree Warrants and determined that the Oaktree warrants met the scope exception of ASC 815-10-15-74(a) Derivatives and Hedging and therefore the warrants should be classified in stockholders’ equity.  As such the Company used a Black-Scholes model to value the Oaktree Warrants.  Utilizing the following inputs: term of 10 years, volatility of 86.8%, risk-free rate of return of 0.74% yielding a value of $4.8 million. ASC 470-20-25-2 Debt – Debt with Conversion and Other Options dictates that debt or stock issued with detachable warrants requires the proceeds to be allocated to the two instruments based on their relative fair values.  The relative fair value of the warrants was determined to be $4.4 million and was recorded as a component of Stockholders’ Equity in the Company’s condensed consolidated balance sheet at September 30, 2020.

Employee Stock Purchase Plan

Eligible employees can purchase the Company’s Common Stock at the end of a predetermined offering period at 85% of the lower of the fair market value at the beginning or end of the offering period. The ESPP is compensatory and results in stock-based compensation expense.

As of September 30, 2020, 507,783 shares have been purchased and 492,217 shares are available for future sale under the Company’s ESPP. Share-based compensation expense recorded was approximately $38,000 and $18,000, respectively, for the three months ended September 30, 2020 and 2019, and approximately $0.1 million and $0.1 million, respectively, for the nine months ended September 30, 2020 and 2019.

Capital Raises

9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Offering

On August 26, 2020, the Company closed on an underwritten public offering whereby it sold 666,666 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (Nasdaq: FBIOP) (the "Preferred Stock"), (plus a 45-day option to purchase up to an additional 66,666 shares, which was exercised in August 2020) at a price of $18.00 per share for gross proceeds of approximately $13.2 million, before deducting underwriting discounts and commissions and offering expenses of approximately $1.1 million.

On May 29, 2020, the Company closed on an underwritten public offering whereby it sold 555,556 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (Nasdaq: FBIOP) (the "Preferred Stock"), (plus a 45-day option to purchase up to an additional 83,333 shares, which was exercised in May 2020) at a price of $18.00 per share for gross proceeds of approximately $11.5 million, before deducting underwriting discounts and commissions and offering expenses of approximately $1.1 million.

On February 14, 2020, the Company announced the closing of an underwritten public offering, whereby it sold 625,000 shares of its Preferred Stock, (plus a 45-day option to purchase up to an additional 93,750 shares, which was exercised in February 2020) at a price of $20.00 per share for gross proceeds of approximately $14.4 million, before deducting underwriting discounts and commissions and offering expenses of approximately $1.3 million.

Cyprium 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Offering

On August 28, 2020, Cyprium closed on an underwritten public offering whereby it sold 255,400 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (“Cyprium Perpetual Preferred Stock” or “Cyprium PPS”), plus an overallotment of an additional 64,600 shares, which was exercised on September 18, 2020, at a price of $25.00 per share for gross proceeds of $8.0 million, before deducting underwriting discounts and commissions and offering expenses of approximately $0.9 million (the “Cyprium Offering”).

Pursuant to the terms of the Cyprium PPS, shareholders on the record date are entitled to receive a monthly cash dividend of $0.19531 per share which yields an annual dividend of $2.34375 per share. The Cyprium PPS will automatically be redeemed upon the first (and only the first) bona fide, arm’s-length sale of a Priority Review Voucher (a “PRV”) issued by the FDA in connection with the approval of CUTX-101, Cyprium’s lead product candidate.  Upon the P   R V Sale, each share of Cyprium PPS will be automatically redeemed in exchange for a payment equal to twice (2x) the $25.00 liquidation preference, plus accumulated and unpaid dividends to, but excluding, the redemption date.

An optional exchange to Company Preferred Stock is available after 24 months from the issuance date so long as a sale of the PRV has not occurred.  Additionally, if a PRV Sale has not occurred by September 30, 2024 the Cyprium PPS is either automatically exchanged for Company Preferred Stock or cash at the discretion of Fortress.  The Cyprium PPS is fully and unconditionally guaranteed by Fortress.

Cyprium paid an initial dividend of $49,883 ($0.19531 per share) to shareholders of record on September 30, 2020.

Checkpoint Underwritten Offering

In September 2020, Checkpoint completed an underwritten public offering in which it sold 7,321,429 shares of its common stock at a price of $2.80 per share for gross proceeds of approximately $20.5 million. Total net proceeds from the offering were approximately $18.9 million, net of underwriting discounts and offering expenses of approximately $1.6 million. The shares were sold under a shelf registration statement on Form S-3 that Checkpoint filed in November 2017 and was declared effective in December 2017 (“the Checkpoint S-3”).

Mustang Underwritten Offering

In June 2020, Mustang completed an underwritten public offering in which it sold 11,455,604 shares of its common stock at a price of $3.25 per share for gross proceeds of approximately $37.2 million. Total net proceeds from the offering were approximately $34.9 million, net of underwriting discounts and offering expenses of approximately $2.3 million. The shares were sold under Mustang’s S-3.

At-the-Market Offering

On June 28, 2019, the Company entered into an At Market Issuance Sales Agreement ("2019 Common ATM"), with Cantor Fitzgerald & Co., Oppenheimer & Co., Inc., H.C. Wainwright & Co. Inc., Jones Trading Institutional Services LLC and B. Riley, as selling agents, governing potential sales of the Company's common stock.

The shares of common stock were sold under the Company’s shelf registration statement on Form S-3 originally filed on July 6, 2018 and declared effective July 23, 2019 (the “2019 Shelf”) through May 27, 2020.

On May 18, 2020, the Company filed a new shelf registration statement on Form S-3, which was declared effective on May 26, 2020 (the "2020 Shelf"). In connection with the 2020 Shelf, the Company entered into an At Market Issuance Sales Agreement ("2020 Common ATM"), with Cantor Fitzgerald & Co., Oppenheimer & Co., Inc., H.C. Wainwright & Co. Inc., B. Riley and Dawson James Securities, Inc., as selling agents, governing potential sales of the Company's common stock. ATM sales commencing on June 1, 2020 were made under the 2020 Shelf.

For the nine-month period ended September 30, 2020, the Company issued approximately 16.4 million shares of common stock at an average price of $2.74 per share for gross proceeds of $44.8 million.  In connection with these sales, the Company paid aggregate fees of approximately $1.6 million.  Approximately $29.5 million of securities remain available for sale under the 2020 Shelf at September 30, 2020.

Mustang At-the-Market Offering

On July 13, 2018, Mustang filed a shelf registration statement No. 333-226175 on Form S-3, as amended on July 20, 2018 (the "2018 Mustang S-3"), which was declared effective in August 2018. Under the 2018 Mustang S-3, Mustang may sell up to a total of $75.0 million of its securities. In connection with the 2018 Mustang S-3, Mustang entered into an At-the-Market Issuance Sales Agreement (the "Mustang ATM") with B. Riley FBR, Inc., Cantor Fitzgerald & Co., National Securities Corporation, and Oppenheimer & Co. Inc. (each an "Agent" and collectively, the "Agents"), relating to the sale of shares of common stock. Under the Mustang ATM, Mustang pays the Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of Mustang common stock.

On August 16, 2019, Mustang filed a shelf registration statement No. 333-233350 on Form S-3, (the "2019 Mustang S-3"), which was declared effective on September 30, 2019. Under the 2019 Mustang S-3, Mustang may sell up to a total of $75.0 million of its securities. On July 20, 2020, Mustang entered into Amendment No. 1 to the Mustang ATM with the Agents to reflect the new registration statement.

During the nine months ended September 30, 2020, Mustang issued approximately 7.2 million shares of common stock at an average price of $3.56 per share for gross proceeds of $25.6 million under the Mustang ATM. In connection with these sales, Mustang paid aggregate fees of approximately $0.5 million for net proceeds of approximately $25.1 million. During the nine months ended September 30, 2019, Mustang issued approximately 3.5 million shares of common stock at an average price of $6.42 per share for gross proceeds of $22.5 million under the Mustang ATM. In connection with these sales, Mustang paid aggregate fees of approximately $0.5 million for net proceeds of approximately $22.0 million. Pursuant to the Founders Agreement, Mustang issued 117,405 shares of common stock to Fortress at a weighted average price of $3.56 per share for the nine months ended September 30, 2020 for the Mustang ATM offering noted above. During the nine months ended September 30, 2019, Mustang issued 87,656 shares of common stock to Fortress at a weighted average price of $6.42 per share in connection with the Mustang ATM.

Approximately $32.6 million of the Mustang shelf remains available for sale under the 2019 Mustang S-3, following the offerings noted above. As of September 30, 2020, the 2018 Mustang S-3 is no longer available for sales of securities.

Checkpoint At-the-Market Offering

Under the Checkpoint S-3, Checkpoint may sell up to a total of $100 million of its securities. In connection with the Checkpoint S-3, Checkpoint entered into an At-the-Market Issuance Sales Agreement (the "Checkpoint ATM") with Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co., LLC (each a "Checkpoint Agent" and collectively, the "Checkpoint Agents"), relating to the sale of shares of common stock. Under the Checkpoint ATM, Checkpoint pays the Checkpoint Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of Checkpoint common stock.

During the nine months ended September 30, 2020, Checkpoint sold a total of 3,614,344 shares of common stock under the Checkpoint ATM for aggregate total gross proceeds of approximately $8.7 million at an average selling price of $2.40 per share, resulting in net proceeds of approximately $8.4 million after deducting commissions and other transaction costs.

Pursuant to the Founders Agreement, Checkpoint issued 273,379 shares of common stock to Fortress at a weighted average price of $2.92 per share for the Checkpoint ATM offerings and the Checkpoint Underwritten Offering, both noted above.

Approximately $12.3 million of the Checkpoint shelf remains available for sale under the Checkpoint S-3, following the offerings noted above.

Share Repurchase Program

On March 23, 2020, the Company announced that its Board of Directors had approved a share repurchase program of the Company's outstanding Preferred Stock in an aggregate amount of up to $5.0 million. Repurchases under the program were made in the open market or through privately-negotiated transactions until the earlier to occur of the repurchase of $5.0 million of the Company's Preferred Stock or the close of trading on May 31, 2020, subject to applicable laws and regulations. The program did not commit the Company to repurchase any shares of Preferred Stock. As of September 30, 2020, 5,000 Preferred Stock shares were repurchased and retired under this program for total consideration of $0.1 million, net of fees of approximately $2,000.

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2020
Commitments and Contingencies  
Commitments and Contingencies

15. Commitments and Contingencies

Most of the Company's lease liabilities result from the lease of its New York City, NY office, which expires in 2031, and Mustang's Worcester, MA cell processing facility lease, which expires in 2026. Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Certain of the Company's leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right of use assets as the Company is not reasonably certain to exercise the options. The Company does not act as a lessor or have any leases classified as financing leases. On September 30, 2020, the Company had operating lease liabilities of $24.6 million and right of use assets of $20.3 million, which were included in the Condensed Consolidated Balance Sheet.

During the three and nine months ended September 30, 2020 and 2019, the Company recorded the following as lease expense, which was recorded in general and administrative expense on the Company's Condensed Consolidated Statement of Operations:

    

Three Months Ended September 30, 

    

Nine Months Ended September 30, 

    

($in thousands)

2020

2019

2020

2019

Lease Cost

 

  

 

  

 

Operating lease cost

$

816

$

798

$

2,436

$

2,397

Shared lease costs

 

(469)

(479)

 

(1,409)

(1,408)

Variable lease cost

 

178

160

 

411

575

Total lease expense

$

525

$

479

$

1,438

$

1,564

The following tables summarize quantitative information about the Company's operating leases, under the adoption of Topic 842, Leases:

    

Nine Months Ended September 30, 

 

    

($in thousands)

2020

2019

 

Operating cash flows from operating leases

$

(2,127)

$

(2,185)

Weighted-average remaining lease term – operating leases (years)

 

5.9

 

6.4

Weighted-average discount rate – operating leases

 

6.2

%  

 

6.2

%

    

Future Lease

($ in thousands)

Liability

Three Months Ended December 31, 2020

$

839

Year Ended December 31, 2021

 

3,114

Year Ended December 31, 2022

 

3,084

Year Ended December 31, 2023

 

3,137

Year Ended December 31, 2024

 

3,190

Other

 

20,273

Total operating lease liabilities

 

33,637

Less: present value discount

 

(9,085)

Net operating lease liabilities, short-term and long-term

$

24,552

Indemnification

In accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has director and officer insurance to address such claims. Pursuant to agreements with clinical trial sites, the Company provides indemnification to such sites in certain conditions.

Legal Proceedings

In the ordinary course of business, the Company may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company’s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages.

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions
9 Months Ended
Sep. 30, 2020
Related Party Transactions  
Related Party Transactions

16. Related Party Transactions

The Company’s Chairman, President and Chief Executive Officer, individually and through certain trusts over which he has voting and dispositive control, beneficially owned approximately 10.1% of the Company’s issued and outstanding Common Stock as of September 30, 2020. The Company’s Executive Vice Chairman, Strategic Development owns approximately 10.9% of the Company’s issued and outstanding Common Stock as of September 30, 2020.

Shared Services Agreement with TG Therapeutics, Inc

TG Therapeutics, Inc. ("TGTX") and the Company entered into an arrangement to share the cost of certain research and development employees. The Company’s Executive Vice Chairman, Strategic Development, is also the Executive Chairman and  Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX will reimburse the Company for the salary and benefit costs associated with these employees based upon actual hours worked on TGTX related projects. For the three months ended September 30, 2020 and 2019, the Company invoiced TGTX $0.1 million and $0.1 million, respectively. For the nine months ended September 30, 2020 and 2019, the Company invoiced TGTX $0.3 million and $0.3 million, respectively. On September 30, 2020, the amount due from TGTX related to this arrangement approximated $69,000.

Desk Space Agreements with TGTX and OPPM

In connection with the Company’s Desk Space Agreements with TGTX and Opus Point Partners Management, LLC (“OPPM”), for the three months ended September 30, 2020 and 2019, the Company had paid $0.7 million and $0.7 million in rent under the Desk Space Agreements. For the three months ended September 30, 2020 and 2019, the Company invoiced TGTX approximately $0.4 million and $0.4 million, respectively, and invoiced OPPM nil and approximately $24,000, respectively, for their prorated share of the rent base. On September 30, 2020, the amount due related to this arrangement from TGTX was nil and the amount due from OPPM approximated $0.4 million.

2019 Notes (formerly the Opus Credit Facility)

On September 13, 2019, the Company and Opus Point Healthcare Innovations Fund, LP (“OPHIF”) extended the maturity date of the 2019 Notes (formerly the “A&R Opus Credit Facility) from September 14, 2019 by two years to September 14, 2021. Terms of the 2019 Notes allows for the Company to make portions of interest and principal repayments in the form of shares of the Company’s common stock and/or in common stock of the Company’s publicly-traded subsidiaries, subject to certain conditions. Fortress retained the ability to prepay the Notes at any time without penalty. The notes payable under the A&R Opus Credit Facility bear interest at 12% per annum.

Effective December 31, 2019, OPHIF dissolved and distributed it assets among its limited partners. Following the distribution, the $9.0 million facility comprised of separate notes (collectively, the “2019 Notes”) held by DAK Capital Inc. ($3.8 million); Fortress’ Chairman, President and Chief Executive Officer Lindsay A. Rosenwald, M.D. ($0.3 million); Fortress's Executive Vice President, Strategic Development Michael S. Weiss ($2.0 million); and various entities and individuals affiliated with Dr. Rosenwald and Mr. Weiss ($2.9 million). The terms of the 2019 Notes did not change in connection with such reallocations.

During the quarter ended September 30, 2020, the Company used certain proceeds from the Oaktree Note to pay off the $9.0 million balance previously outstanding under the 2019 Notes (see Note 10).

For the nine months ended September 30, 2020, in connection with the 2019 Notes, the Company paid $0.5 million in interest on the portion of the 2019 Notes held by the Company's Chairman, President and Chief Executive Officer and the Company's Executive Vice President, Strategic Development. For the nine months ended September 30, 2019, the Company paid $0.2 million in common stock consisting of 91,767 shares at $1.80 per share.

Avenue Credit Facility Agreement

On June 12, 2020, Avenue, the Company and InvaGen entered into a Facility Agreement (“Avenue Facility Agreement”), under which, beginning on October 1, 2020, Avenue may borrow up to $2 million collectively from the Company and InvaGen, subject to certain conditions set forth therein. The Company’s commitment amount is $0.8 million, and InvaGen’s is $1.2 million , and a 7% per annum interest rate applies (payable on the last day of each fiscal quarter).  Repayment of the loan is due upon the earliest to occur of: (i) the Second Stage Closing Date, as defined in the SPMA; (ii) April 29, 2021; and (iii) the date that is 30 days following the termination of the Avenue SPMA.  As of September 30, 2020, there have been no amounts drawn by Avenue on the Avenue Facility Agreement.

Founders Agreements

The Company has entered into Founders Agreements and, in some cases, Exchange Agreements with certain of its subsidiaries as described in the Company's Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. The following table summarizes, by partner company, the effective date of the Founders Agreements and PIK dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, Exchange Agreements, and the subsidiaries' certificates of incorporation:

PIK Dividend as

a % of fully

diluted

outstanding

Class of Stock

Fortress Partner Company

    

Effective Date 1

    

capitalization

    

Issued

Helocyte

March 20, 2015

 

2.5

%  

Common Stock

Avenue

February 17, 2015

 

0.0

%2  

Common Stock

Mustang

March 13, 2015

 

2.5

%  

Common Stock

Checkpoint

March 17, 2015

 

0.0

%3  

Common Stock

Cellvation

October 31, 2016

 

2.5

%  

Common Stock

Caelum

January 1, 2017

 

0.0

%4  

Common Stock

Baergic

December 17, 20195

2.5

%  

Common Stock

Cyprium

March 13, 2017

 

2.5

%  

Common Stock

Aevitas

July 28, 2017

 

2.5

%  

Common Stock

Oncogenuity

April 22, 2020 5

2.5

%

Common Stock

Note 1:

Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement or has since been amended to January 1 of each calendar year.

Note 2:

Concurrently with the execution and delivery of the Stock Purchase and Merger Agreement (“Avenue SPMA”) entered into between, Avenue, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”) (together, the “ SPMA Parties”), the SPMA Parties entered into a waiver agreement (the “Waiver Agreement”), pursuant to which the Company irrevocably waived its right to receive the annual dividend of Avenue’s common shares under the terms of the Class A preferred stock and any fees, payments, reimbursements or other distributions under the management services agreement between the Company and Avenue and the Founders Agreement, for the period from the effective date of the Waiver Agreement to the termination of InvaGen’s rights under the Avenue SPMA. Pursuant to the Waiver Agreement, immediately prior to the closing of the Merger Transaction contemplated under the Avenue SPMA, the Company will convert all of its preferred shares into common shares pursuant to the terms of the certificate of incorporation of Avenue, as amended from time to time.

Note 3:

Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.

Note 4:

Effective January 31, 2019 the Caelum Founders Agreement and MSA with Fortress were terminated in conjunction with the execution of the DOSPA between Caelum and Alexion (See Note 4).

Note 5:

Represents the Trigger Date, the date that the Fortress partner company first acquires, whether by license or otherwise, ownership rights in a product.

Management Services Agreements

The Company has entered in Management Services Agreements (the “MSAs”) with certain of its partner companies as described in the Company’s Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. The following table summarizes the effective date of the MSA and the annual consulting fee payable by the partner company to the Company in quarterly installments:

Annual MSA Fee

Fortress partner company

    

Effective Date

    

(Income)/Expense

Helocyte

March 20, 2015

$

500

Avenue 1

February 17, 2015

 

Mustang

March 13, 2015

 

500

Checkpoint

March 17, 2015

 

500

Cellvation

October 31, 2016

 

500

Baergic

March 9, 2017

 

500

Cyprium

March 13, 2017

 

500

Aevitas

July 28, 2017

 

500

Oncogenuity

February 10, 2017

500

Fortress

 

(4,000)

Consolidated (Income)/Expense

$

Note 1:

Concurrently with the execution and delivery of the Avenue SPMA entered into among, Avenue, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”) (together, the “SPMA Parties”), the SPMA Parties entered into a waiver agreement (the “Waiver Agreement”), pursuant to which the Company irrevocably waived its right to receive the annual dividend of Avenue’s common shares under the terms of the Class A preferred stock and any fees, payments, reimbursements or other distributions under the management services agreement between the Company and Avenue and the Founders Agreement, for the period from the effective date of the Waiver Agreement to the termination of InvaGen’s rights under the Avenue SPMA. Pursuant to the Waiver Agreement, immediately prior to the closing of the Merger Transaction contemplated under the Avenue SPMA, the Company will convert all of its preferred shares into common shares pursuant to the terms of the certificate of incorporation of Avenue, as amended from time to time. (See Note 4).

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information
9 Months Ended
Sep. 30, 2020
Segment Information  
Segment Information

17. Segment Information

The Company operates in two reportable segments, Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results from continued operations by reportable segment:

Pharmaceutical

    

and

($in thousands)

Dermatology

Biotechnology

Products

Product

Three Months Ended September 30, 2020

    

Sales

    

Development

    

Consolidated

Net revenue

$

9,447

$

28

$

9,475

Direct cost of goods

 

(3,379)

 

 

(3,379)

Sales and marketing costs

 

(4,649)

 

 

(4,649)

Research and development

 

 

(13,756)

 

(13,756)

General and administrative

(1,254)

(9,480)

(10,734)

Other expense

 

(113)

 

(6,808)

 

(6,921)

Segment income (loss)

$

52

(30,016)

$

(29,964)

Segment assets

Intangible assets, net

11,039

11,039

Tangible assets

21,108

263,732

284,840

Total segment assets

$

32,147

$

263,732

$

295,879

Pharmaceutical

and

Dermatology

Biotechnology

($ in thousands)

Products

Product

Three Months Ended September 30, 2019

    

Sales

    

Development

    

Consolidated

Net revenue

$

9,492

$

280

$

9,772

Direct cost of goods

 

(2,702)

 

(2,702)

Sales and marketing costs

 

(4,370)

 

(4,370)

Research and development

 

 

(15,271)

(15,271)

General and administrative

 

(669)

 

(9,300)

(9,969)

Other expense

(108)

(2,322)

(2,430)

Segment income (loss)

$

1,643

$

(26,613)

$

(24,970)

Segment assets

Intangible assets, net

7,731

7,731

Tangible assets

10,966

202,891

213,857

Total segment assets

$

18,697

$

202,891

$

221,588

Pharmaceutical

  

and

Dermatology

Biotechnology

($in thousands)

Products

Product

  

Nine Months Ended September 30, 2020

    

Sales

    

Development

    

Consolidated

Net revenue

$

30,808

$

1,042

$

31,850

Direct cost of goods

 

(10,313)

 

 

(10,313)

Sales and marketing costs

 

(12,728)

 

 

(12,728)

Research and development

 

 

(46,146)

 

(46,146)

General and administrative

 

(3,556)

 

(29,074)

 

(32,630)

Other expense

 

(492)

 

(12,036)

 

(12,528)

Segment income (loss)

$

3,719

 

(86,214)

$

(82,495)

Segment assets

 

  

 

  

 

  

Intangible assets, net

 

11,039

11,039

Tangible assets

 

21,108

263,732

284,840

Total segment assets

$

32,147

$

263,732

$

295,879

Pharmaceutical

 and 

Dermatology

Biotechnology

($in thousands)

Products

Product

Nine Months Ended September 30, 2019

    

Sales

    

Development

    

Consolidated

Net revenue

$

23,816

$

1,683

$

25,499

Direct cost of goods

 

(6,972)

 

 

(6,972)

Sales and marketing costs

 

(12,064)

 

 

(12,064)

Research and development

 

 

(57,705)

 

(57,705)

General and administrative

 

(1,808)

 

(27,388)

 

(29,196)

Other expense

 

(108)

 

11,841

 

11,733

Segment income (loss)

$

2,864

$

(71,569)

$

(68,705)

Segment assets

Intangible assets, net

 

7,731

7,731

Tangible assets

 

10,966

202,891

213,857

Total segment assets

$

18,697

$

202,891

$

221,588

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Revenues from Contracts and Significant Customers
9 Months Ended
Sep. 30, 2020
Revenues from Contracts and Significant Customers  
Revenues from Contracts and Significant Customers

18. Revenues from Contracts and Significant Customers

Disaggregation of Total Revenue

Product revenue is comprised of Journey’s five marketed products: Targadox®, Luxamend®, Ceracade®, Exelderm® and Ximino®. Substantially all of the product revenue is recorded in the U.S. The Company’s related party revenue is from Checkpoint’s collaboration with TGTX. The table below summarizes the Company’s revenue for the three and nine months ending September 30, 2020 and 2019:

Three months ended September 30, 

Nine Months Ended September 30, 

    

2020

    

2019

    

2020

    

2019

    

Revenue

Product revenue, net

$

9,447

$

9,492

$

30,808

$

23,816

Revenue – related party

 

28

 

280

 

1,042

 

1,683

Net revenue

$

9,475

$

9,772

$

31,850

$

25,499

Significant Customers

For the three months ended September 30, 2020, none of the Company’s Dermatology Products customers accounted for more than 10% of its total gross product revenue.

For the nine months ended September 30, 2020, one of the Company’s Dermatology Products customers accounted for more than 10% of its total gross product revenue.

For the three and nine months ended September 30, 2019, gross product revenue under the 3PL Title Model accounted for approximately 60% and 76%, respectively.

At September 30, 2020, one of the Company’s Dermatology Products customers accounted for more than 10% of its total accounts receivable balance at 14.5%.

At September 30, 2019, two of the Company’s Dermatology Products customers accounted for more than 10% of its total accounts balance in the amounts of $3.5 million and $2.8 million.

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Income taxes
9 Months Ended
Sep. 30, 2020
Income taxes  
Income taxes

19. Income taxes

In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer's social security payments, net operating loss utilization and carryback periods and modifications to the net interest deduction limitations. At this time, the Company does not believe that the CARES Act will have a material impact on its income tax provision for 2020. The Company will continue to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.

The Company and its subsidiaries are subject to US federal and state income taxes. Income tax expense is the total of the current year income tax due or refundable and the change in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of Management, it is more likely than not that some portion, or all, of the deferred tax asset will not be realized.

The Company files a consolidated income tax return with subsidiaries for which the Company has an 80% or greater ownership interest. Subsidiaries for which the Company does not have an 80% or more ownership are not included in the Company’s consolidated income tax group and file their own separate income tax return. As a result, certain corporate entities included in these financial statements are not able to combine or offset their taxable income or losses with other entities’ tax attributes.

Income tax expense for the three and nine months ended September 30, 2020 and 2019 is based on the estimated annual effective tax rate.

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2020
Summary of Significant Accounting Policies  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.

The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited financial statements for the preceding fiscal year for each of the companies: Avenue, Checkpoint and Mustang. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2020, from which the Company derived the balance sheet data at December 31, 2019, as well as Checkpoint’s Form 10-K, filed with the SEC on March 11, 2020, Mustang’s Form 10-K, filed with the SEC on March 16, 2020, and Avenue’s Form 10-K, filed with the SEC on March 30, 2020.

The Company’s unaudited condensed consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company also consolidates subsidiaries in which it owns less than 50% of the subsidiary but maintains voting control. The Company continually assesses whether changes to existing relationships or future transactions may result in the consolidation or deconsolidation of partner companies.

The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period.

Use of Estimates

Use of Estimates

The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.

Significant Accounting Policies

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2019 Annual Report.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-13, Fair Value Measurement (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with the movement amongst or hierarchy associated with Level 1, Level 2 and Level 3 fair value measurements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. On January 1, 2020, the Company’s adoption of this guidance to did not have a material impact on its condensed consolidated  financial statements.

Recently Issued Accounting Pronouncements

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) (“ASU 470-20”) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 815-40”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. The ASU is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer and will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, for the Company as it is a smaller reporting company. Early adoption will be permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses”. The ASU sets forth a “current expected credit loss” (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. Recently, the FASB issued the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of the adoption of this ASU on its condensed consolidated  financial statements.

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Discontinued Operations (Tables)
9 Months Ended
Sep. 30, 2020
Discontinued Operations  
Schedule of cash flows statement

The table below depicts the cash flows from the sale of the Company’s investment in National Holdings Corporation, a diversified independent brokerage company (together with its subsidiaries, herein referred to as “NHLD” or “National”) for the nine months ended September 30, 2019:

For the Nine Months Ended

September 30, 

($ in thousands)

    

2019

Investing activities

 

  

Proceeds from sale of National

$

13,089

Total cash provided by discontinued investing activities

$

13,089

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Tables)
9 Months Ended
Sep. 30, 2020
Property and Equipment  
Schedule of property and equipment

Fortress’ property and equipment consisted of the following:

    

Useful Life

    

September 30, 

    

December 31, 

($ in thousands)

(Years)

2020

2019

(Unaudited)

Computer equipment

 

3

$

662

$

648

Furniture and fixtures

 

5

 

1,199

 

1,162

Machinery & equipment

 

5

 

5,014

 

4,594

Leasehold improvements

 

5-15

 

10,580

 

9,358

Construction in progress 1

 

N/A

 

821

 

1,157

Total property and equipment

 

18,276

 

16,919

Less: Accumulated depreciation

 

(6,162)

 

(4,486)

Property and equipment, net

$

12,114

$

12,433

Note 1:

Relates to the Mustang cell processing facility.

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2020
Schedule of financial instruments, measured at fair value

The following tables classify into the fair value hierarchy of Fortress’ financial instruments, measured at fair value as of September 30, 2020 and December 31, 2019:

Fair Value Measurement as of  September 30, 2020

($ in thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets

 

  

 

  

 

  

 

  

Fair value of investment in Caelum

$

$

$

11,723

$

11,723

Total

$

$

$

11,723

$

11,723

Fair Value Measurement as of  December 31, 2019

($ in thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets

 

  

 

  

 

  

 

  

Fair value of investment in Caelum

 

$

 

$

 

$

11,148

 

$

11,148

Total

 

$

 

$

 

$

11,148

 

$

11,148

Fair Value Measurement as of  December 31, 2019

($ in thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Liabilities

 

  

 

  

 

  

 

  

Warrant liabilities

 

$

 

$

 

$

27

 

$

27

Total

 

$

 

$

 

$

27

 

$

27

Schedule of changes in fair value of financial instruments

The table below provides a roll-forward of the changes in fair value of Level 3 financial instruments as of September 30, 2020:

Investment in

Warrant

($ in thousands)

    

Caelum

    

 Liabilities

    

Total

Balance at December 31, 2019

$

11,148

$

27

$

11,175

Change in fair value

1,189

1,189

Reclass partner company's warrants from liability to equity

(1,216)

(1,216)

Change in fair value of investments

575

575

Balance at September 30, 2020

$

11,723

$

$

11,723

Warrants [Member] | Caelum [Member]  
Schedule of weighted average (in aggregate) significant unobservable inputs

    

September 30, 2020

December 31, 2019

 

Risk-free interest rate

 

0.69

%

1.92

%

Expected dividend yield

 

Expected term in years

 

10.0

10.0

Expected volatility

 

85

%

93

%

Probability of issuance of the warrant

 

100

%

5

%

Schedule of fair value of derivative warrant liability

Cyprium

Contingently

Issuable Warrant

($ in thousands)

Liability

Beginning balance at January 1, 2020

$

27

Change in fair value

1,189

Reclass partner company's warrants from liability to equity

(1,216)

Ending balance at September 30, 2020

$

-

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Licenses Acquired (Tables)
9 Months Ended
Sep. 30, 2020
Licenses Acquired  
Schedule of research and development-licenses

Three Months Ended September 30, 

Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

    

Partner companies:

 

  

 

  

 

  

 

  

 

Mustang

$

287

$

700

$

1,837

$

1,350

Aevitas

162

162

Baergic

 

8

 

 

8

 

Oncogenuity

1

271

Total

$

458

$

700

$

2,278

$

1,350

Schedule of research and development for licenses acquired

For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for licenses acquired:

For the Three Months Ended September 30, 

For the Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

City of Hope National Medical Center

CD123 (MB-102)3

$

$

$

334

$

250

IL13Rα2 (MB-101) 3

333

HER2 (MB-103)1

250

CS1 (MB-104)

200

PSCA (Spacer)3

200

 

333

 

200

Fred Hutch - CD20 (MB-106)2

300

Nationwide Children’s Hospital - C134 (MB-108)

200

CSL Behring (Calimmune)

170

200

170

200

UCLA

300

300

SIRION LentiBOOSTTM

117

117

Total

$

287

$

700

$

1,837

$

1,350

Note 1:

Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-103 at COH, for the nine months ended September 30, 2020.

Note 2:

Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-106 at Fred Hutch, for the nine months ended September 30, 2020.

Note 3:

Represents a milestone payment to COH in connection with Mustang’s public underwritten offerings, for the nine months ended September 30, 2020.

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Sponsored Research and Clinical Trial Agreements (Tables)
9 Months Ended
Sep. 30, 2020
Aevitas  
Schedule of research and development for sponsored research and clinical trial agreements

For the three and nine months ended September 30, 2020 and 2019, Aevitas recorded the following expense in connection with its sponsored research and clinical trial agreements:

For the Three Months Ended September 30, 

For the Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

UMass - adeno-associated virus ("AAV")

163

218

UPenn - AAV

255

567

755

Duke - AAV

17

17

Total

$

163

$

272

$

785

$

772

Mustang [Member]  
Schedule of research and development for sponsored research and clinical trial agreements

For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements:

For the Three Months Ended September 30, 

For the Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

City of Hope National Medical Center

$

$

500

$

500

$

1,500

CD123 (MB-102)

 

48

 

269

 

344

 

1,028

IL13Rα2 (MB-101)

 

96

 

244

 

422

 

811

Manufacturing

 

 

114

 

 

343

CS1 (MB-104)

65

835

Beth Israel Deaconess Medical Center - CRISPR

69

St. Jude Children's Research Hospital - XSCID (MB-107)

107

1,665

Fred Hutchinson Cancer Research Center - CD20 (MB-106)

418

49

1,134

690

Total

$

734

$

1,176

$

4,900

$

4,441

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Intangibles, net (Tables)
9 Months Ended
Sep. 30, 2020
Intangibles, net  
Schedule of JMC intangible asset

The table below provides a summary of the Journey intangible assets as of September 30, 2020 and December 31, 2019, respectively:

Estimated Useful

($ in thousands)

    

Lives (Years)

    

September 30, 2020

    

December 31, 2019

(Unaudited)

Total Intangible assets – asset purchases

3 to 7

$

14,661

$

9,934

Accumulated amortization

 

  

 

(3,622)

 

(2,557)

Net intangible assets

 

  

$

11,039

$

7,377

Schedule of JMC recognized expense related to its product licenses

The table below provides a summary for the nine months ended September 30, 2020, of Journey’s recognized expense related to its product licenses, which was recorded in costs of goods sold on the condensed consolidated statement of operations:

Intangible

($ in thousands)

    

Assets, Net

Beginning balance at January 1, 2020

$

7,377

Additions:

Oral acne treatment license acquisition1

4,727

Amortization expense

 

(1,065)

Ending balance at September 30, 2020

$

11,039

Note 1:  As of September 30, 2020, this asset has not yet been placed in service, therefore no amortization expense was recognized on this asset for the quarter ended September 30, 2020.  The Company expects the asset to be placed in service in the first half of 2021. Once the asset is placed in service the Company will amortize the asset over five years, which represents its expected useful life.

Schedule of future amortization of intangible assets

The future amortization of these intangible assets is as follows:

Total

($ in thousands)

    

Ximino®

    

Exelderm®

    

Amortization

Three Months Ended December 31, 2020

$

254

$

100

$

354

Year Ended December 31, 2021

 

1,019

 

267

 

1,286

Year Ended December 31, 2022

1,019

1,019

Year Ended December 31, 2023

1,019

1,019

Year Ended December 31, 2024

 

1,019

 

 

1,019

Thereafter

1,615

1,615

Sub-total

$

5,945

$

367

$

6,312

Asset not yet placed in service

4,727

Total

$

5,945

$

367

$

11,039

XML 45 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and Interest (Tables)
9 Months Ended
Sep. 30, 2020
Debt and Interest  
Schedule of debt

Total debt consists of the following as of September 30, 2020 and December 31, 2019:

    

September 30, 

    

December 31,

    

    

($ in thousands)

2020

2019

Interest rate

Maturity

IDB Note

$

$

14,929

 

2.25

%  

Aug - 2021

2017 Subordinated Note Financing3

 

 

3,254

 

8.00

%

March - 2022

2017 Subordinated Note Financing3

 

 

13,893

 

8.00

%

May - 2022

2017 Subordinated Note Financing3

 

 

1,820

 

8.00

%

June - 2022

2017 Subordinated Note Financing3

 

 

3,018

 

8.00

%

August - 2022

2017 Subordinated Note Financing

 

 

6,371

 

8.00

%

September - 2022

2018 Venture Notes4

 

 

6,517

 

8.00

%  

August - 2021

2018 Venture Notes4

 

 

15,190

 

8.00

%  

September - 2021

2019 Notes1

 

 

9,000

 

12.00

%  

September - 2021

Mustang Horizon Notes2

 

 

15,750

 

9.00

%  

October - 2022

Oaktree Note

60,000

11.00

%

August - 2025

Total notes payable

 

60,000

 

89,742

 

  

 

  

Less: Discount on notes payable

 

8,607

 

5,086

 

  

 

  

Total notes payable

$

51,393

$

84,656

 

  

 

  

Note 1:

Formerly the Opus Credit Facility (see Note 16.)

Note 2:

Interest rate was 9.0% plus one-month LIBOR Rate in excess of 2.5%.

Note 3:

As a result of a one-year maturity date extension effective 2020, the interest rate increased by 1% to 9.0%.

Note 4:

At December 31, 2019, $6.0 million is included in Notes payable, short-term on the condensed consolidated balance sheet.

Schedule of interest expense for all debt arrangements

The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest; fees include amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan:

Three Months Ended September 30,

2020

2019

($ in thousands)

    

Interest

    

Fees

    

Total

    

Interest

    

Fees 

    

Total

IDB Note

$

77

$

$

77

$

86

$

$

86

2017 Subordinated Note Financing1

 

694

 

1,374

 

2,068

 

1,072

 

326

 

1,398

2019 Notes

172

172

275

 

104

379

2018 Venture Notes1

 

387

 

638

 

1,025

 

438

 

166

 

604

LOC Fees

 

14

 

 

14

 

14

 

 

14

Mustang Horizon Notes1,3

 

895

 

1,792

 

2,687

 

345

 

234

 

579

Oaktree Note1

624

108

732

Note Payable2

187

187

108

108

Other

 

(4)

 

 

(4)

 

 

 

Total Interest Expense and Financing Fee

$

3,046

$

3,912

$

6,958

$

2,230

$

938

$

3,168

Nine Months Ended September 30, 

2020

2019

($ in thousands)

    

Interest

    

Fees

    

Total

    

Interest

    

Fees

    

Total

IDB Note

$

246

$

$

246

$

254

$

-

$

254

2017 Subordinated Note Financing1

 

2,870

 

1,890

 

4,760

 

3,148

 

1,081

 

4,229

2019 Notes

 

710

 

 

710

 

840

336

 

1,176

2018 Venture Notes1

 

1,253

 

1,000

 

2,253

 

1,299

 

468

 

1,767

LOC Fees

 

45

 

 

45

 

45

 

 

45

Mustang Horizon Notes1,3

 

1,585

 

2,321

 

3,906

 

698

 

466

 

1,164

Oaktree Note1

624

108

732

Note Payable2

492

492

108

108

Other

 

(2)

 

 

(2)

 

Total Interest Expense and Financing Fee

$

7,823

$

5,319

$

13,142

$

6,284

$

2,459

$

8,743

Note 1:

For the three and nine months ended September 30, 2020, $1.2 million expense of unamortized debt discount fees for the 2017 Subordinated Note Financing, $0.3 million for the 2018 Venture Notes and $1.8 million for the Mustang Horizon Notes.

Note 2:

Imputed interest expense related to Journey’s agreements for Ximino and oral acne treatment.

Note 3:

Included in interest expense for the three and nine months ended September 30, 2020 was $0.6 million of prepayment penalties included in interest expense for the Mustang Horizon Notes.

XML 46 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Liabilities and other Long-Term Liabilities (Tables)
9 Months Ended
Sep. 30, 2020
Accrued Liabilities and other Long-Term Liabilities  
Schedule of accrued expenses and other long-term liabilities

Accrued expenses and other long-term liabilities consisted of the following:

September 30, 

December 31,

($ in thousands)

    

2020

    

2019

Accrued expenses:

 

  

 

  

Professional fees

$

1,672

$

1,153

Salaries, bonus and related benefits

 

5,677

 

6,683

Accrued expense - related party

 

19

 

Research and development

 

4,604

 

4,215

Research and development - manufacturing

 

 

1,017

Research and development - license maintenance fees

 

629

 

361

Research and development - milestones

 

600

 

Accrued royalties payable

 

1,908

 

2,320

Accrued coupon expense

 

5,476

 

8,391

Other

 

547

 

1,259

Total accrued expenses

$

21,132

$

25,399

Other long-term liabilities:

 

  

 

  

Deferred rent and long-term lease abandonment charge1

$

1,996

$

2,136

Long-term notes payable, net (Journey)

Ximino agreement2

3,456

4,990

Oral acne treatment agreement3

2,753

Total other long-term liabilities

$

8,205

$

7,126

Note 1:

As of September 30, 2020, and December 31, 2019, the balance consists of deferred charges related to build-out of the New York facility.

Note 2:

As of September 30, 2020, and December 31, 2019, the imputed interest discount was $1.5 million and $2.0 million, respectively, in connection with its acquisition of Ximino in July 2019. Amortization of interest discount was $0.5 million for the nine months ended September 30, 2020, and $0.1 million for the nine months ended September 30, 2019. As of September 30, 2020, $2.0 million of note payable was classified as short-term.

Note 3:

As of September 30, 2020, the imputed discount balance was $0.2 million.  The imputed interest discount was calculated utilizing a 4.00% effective rate, which represents the market rate for an asset-backed three year loan, secured by receivables. As of September 30, 2020, $1.0 million of note payable was classified as short-term.

XML 47 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Non-Controlling Interests (Tables)
9 Months Ended
Sep. 30, 2020
Non-Controlling Interests  
Schedule of non-controlling interests in consolidated entities

Non-controlling interests in consolidated entities are as follows:

    

    

For the nine months ended

    

    

    

    

 

As of September 30, 2020

September 30, 2020

As of September 30, 2020

 

Net loss attributable to

Non-controlling interests

Non-controlling

 

($ in thousands)

    

NCI equity share

non-controlling interests

in consolidated entities

ownership

 

Aevitas

$

(2,297)

 

(680)

 

(2,977)

 

39.0

%

Avenue 2

 

5,709

 

(3,206)

 

2,503

 

77.4

%

Baergic

 

(1,605)

 

(68)

 

(1,673)

 

40.0

%

Cellvation

 

(1,072)

 

(145)

 

(1,217)

 

22.6

%

Checkpoint 1

 

37,963

 

(9,000)

 

28,963

 

80.0

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

784

 

(843)

 

(59)

 

28.4

%

Helocyte

 

(4,890)

 

(236)

 

(5,126)

 

18.8

%

JMC

 

123

 

257

 

380

 

6.9

%

Mustang 2

 

86,572

 

(27,035)

 

59,537

 

77.9

%

Oncogenuity

(47)

 

(268)

 

(315)

 

25.3

%

Tamid

 

(652)

 

(40)

 

(692)

 

22.8

%

Total

$

120,298

$

(41,264)

$

79,034

 

  

    

For the twelve months ended

    

    

 

As of December 31, 2019

December 31, 2019

As of December 31, 2019

 

Net loss attributable to 

Non-controlling interests 

Non-controlling 

 

($ in thousands)

    

NCI equity share

    

non-controlling interests

    

 in consolidated entities

    

 ownership

 

Aevitas

$

(1,249)

$

(694)

$

(1,943)

 

35.8

%

Avenue 2

 

24,269

 

(19,011)

 

5,258

 

77.3

%

Baergic

 

23

 

(1,162)

 

(1,139)

 

33.0

%

Cellvation

 

(732)

 

(158)

 

(890)

 

20.6

%

Checkpoint 1

 

29,389

 

(14,687)

 

14,702

 

78.0

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

(320)

 

(99)

 

(419)

 

10.6

%

Helocyte

 

(4,322)

 

(402)

 

(4,724)

 

19.3

%

JMC

 

(211)

 

325

 

114

 

6.9

%

Mustang 2

 

62,025

 

(25,727)

 

36,298

 

70.3

%

Tamid

 

(565)

 

(85)

 

(650)

 

22.8

%

Total

$

108,017

$

(61,700)

$

46,317

 

Note 1:

Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Note 2:

Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.

XML 48 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss per Common Share (Tables)
9 Months Ended
Sep. 30, 2020
Net Loss per Common Share  
Schedule of diluted weighted average shares outstanding

The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the nine months ended September 30, 2020:

Nine Months Ended September 30, 

2020

    

2019

Warrants to purchase Common Stock

 

3,026,693

 

2,745,364

Options to purchase Common Stock

 

1,187,600

 

1,169,293

Unvested Restricted Stock

 

14,305,949

 

12,622,881

Unvested Restricted Stock Units

 

434,215

 

791,610

Total

 

18,954,457

 

17,329,148

XML 49 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2020
Stockholders' Equity  
Schedule of stock-based compensation expense

The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the three and nine months ended September 30, 2020 and 2019:

Three Months Ended September 30, 

Nine Months Ended September 30, 

($ in thousands)

    

2020

    

2019

    

2020

    

2019

    

Employee awards

$

1,200

$

936

$

3,732

$

2,791

Executive awards of Fortress Companies' stock

 

369

 

358

 

1,136

 

1,065

Non-employee awards

 

31

 

15

 

136

 

84

Warrants

32

97

97

97

Partner Companies:

 

 

Avenue

 

161

 

298

 

592

 

1,585

Checkpoint

 

725

 

833

 

2,095

 

2,444

Mustang

 

606

 

1,120

 

2,368

 

2,174

Other

 

47

 

84

 

163

 

183

Total stock-based compensation expense

$

3,171

$

3,741

$

10,319

$

10,423

Schedule of Stock option activities

The following table summarizes Fortress stock option activities excluding activity related to Fortress partner companies:

Weighted average

Total

remaining

Weighted average

weighted average

contractual life

    

Number of shares

    

exercise price

    

intrinsic value

    

(years)

Options vested and expected to vest at December 31, 2019

 

1,410,501

$

4.30

$

684,752

 

2.33

Exercised

 

(100,000)

1.18

 

 

Forfeited

(247,011)

2.55

Options vested and expected to vest at September 30, 2020

 

1,063,490

$

5.00

$

1,044,218

 

2.87

Schedule of Restricted stock awards and restricted stock units

The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress Companies:

    

    

Weighted

average grant

Number of shares

price

Unvested balance at December 31, 2019

13,768,014

$

2.46

Restricted stock granted

1,873,072

2.57

Restricted stock vested

(1,549,564)

2.69

Restricted stock units granted

630,126

3.82

Restricted stock units forfeited

(106,250)

2.71

Restricted stock units vested

(368,290)

3.13

Unvested balance at September 30, 2020

14,247,108

$

2.49

Schedule of Warrant activities

The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies:

Total weighted

Weighted average

average

remaining

Number of

Weighted average

 intrinsic

contractual life

    

shares

    

exercise price

    

value

    

(years)

Outstanding as of December 31, 2019

 

2,741,180

$

3.19

$

111,000

 

2.73

Granted

 

1,849,450

 

3.14

 

1,657,538

 

Forfeited

 

(9)

 

3.00

 

 

Outstanding as of September 30, 2020

 

4,590,621

$

3.17

$

4,111,018

 

5.10

Exercisable as of September 30, 2020

 

4,430,621

$

3.21

$

3,816,818

 

5.05

XML 50 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies (Tables)
9 Months Ended
Sep. 30, 2020
Commitments and Contingencies  
Schedule of lease expense

During the three and nine months ended September 30, 2020 and 2019, the Company recorded the following as lease expense, which was recorded in general and administrative expense on the Company's Condensed Consolidated Statement of Operations:

    

Three Months Ended September 30, 

    

Nine Months Ended September 30, 

    

($in thousands)

2020

2019

2020

2019

Lease Cost

 

  

 

  

 

Operating lease cost

$

816

$

798

$

2,436

$

2,397

Shared lease costs

 

(469)

(479)

 

(1,409)

(1,408)

Variable lease cost

 

178

160

 

411

575

Total lease expense

$

525

$

479

$

1,438

$

1,564

The following tables summarize quantitative information about the Company's operating leases, under the adoption of Topic 842, Leases:

    

Nine Months Ended September 30, 

 

    

($in thousands)

2020

2019

 

Operating cash flows from operating leases

$

(2,127)

$

(2,185)

Weighted-average remaining lease term – operating leases (years)

 

5.9

 

6.4

Weighted-average discount rate – operating leases

 

6.2

%  

 

6.2

%

Schedule of Future Minimum Rental Payments for Operating Leases

    

Future Lease

($ in thousands)

Liability

Three Months Ended December 31, 2020

$

839

Year Ended December 31, 2021

 

3,114

Year Ended December 31, 2022

 

3,084

Year Ended December 31, 2023

 

3,137

Year Ended December 31, 2024

 

3,190

Other

 

20,273

Total operating lease liabilities

 

33,637

Less: present value discount

 

(9,085)

Net operating lease liabilities, short-term and long-term

$

24,552

XML 51 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions (Tables)
9 Months Ended
Sep. 30, 2020
Related Party Transactions  
Schedule of effective date and PIK dividend or equity fee payable

The Company has entered into Founders Agreements and, in some cases, Exchange Agreements with certain of its subsidiaries as described in the Company's Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. The following table summarizes, by partner company, the effective date of the Founders Agreements and PIK dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, Exchange Agreements, and the subsidiaries' certificates of incorporation:

PIK Dividend as

a % of fully

diluted

outstanding

Class of Stock

Fortress Partner Company

    

Effective Date 1

    

capitalization

    

Issued

Helocyte

March 20, 2015

 

2.5

%  

Common Stock

Avenue

February 17, 2015

 

0.0

%2  

Common Stock

Mustang

March 13, 2015

 

2.5

%  

Common Stock

Checkpoint

March 17, 2015

 

0.0

%3  

Common Stock

Cellvation

October 31, 2016

 

2.5

%  

Common Stock

Caelum

January 1, 2017

 

0.0

%4  

Common Stock

Baergic

December 17, 20195

2.5

%  

Common Stock

Cyprium

March 13, 2017

 

2.5

%  

Common Stock

Aevitas

July 28, 2017

 

2.5

%  

Common Stock

Oncogenuity

April 22, 2020 5

2.5

%

Common Stock

Note 1:

Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement or has since been amended to January 1 of each calendar year.

Note 2:

Concurrently with the execution and delivery of the Stock Purchase and Merger Agreement (“Avenue SPMA”) entered into between, Avenue, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”) (together, the “ SPMA Parties”), the SPMA Parties entered into a waiver agreement (the “Waiver Agreement”), pursuant to which the Company irrevocably waived its right to receive the annual dividend of Avenue’s common shares under the terms of the Class A preferred stock and any fees, payments, reimbursements or other distributions under the management services agreement between the Company and Avenue and the Founders Agreement, for the period from the effective date of the Waiver Agreement to the termination of InvaGen’s rights under the Avenue SPMA. Pursuant to the Waiver Agreement, immediately prior to the closing of the Merger Transaction contemplated under the Avenue SPMA, the Company will convert all of its preferred shares into common shares pursuant to the terms of the certificate of incorporation of Avenue, as amended from time to time.

Note 3:

Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.

Note 4:

Effective January 31, 2019 the Caelum Founders Agreement and MSA with Fortress were terminated in conjunction with the execution of the DOSPA between Caelum and Alexion (See Note 4).

Note 5:

Represents the Trigger Date, the date that the Fortress partner company first acquires, whether by license or otherwise, ownership rights in a product.

Schedule of effective date and annual consulting fee payable by the subsidiary to the Company

The Company has entered in Management Services Agreements (the “MSAs”) with certain of its partner companies as described in the Company’s Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. The following table summarizes the effective date of the MSA and the annual consulting fee payable by the partner company to the Company in quarterly installments:

Annual MSA Fee

Fortress partner company

    

Effective Date

    

(Income)/Expense

Helocyte

March 20, 2015

$

500

Avenue 1

February 17, 2015

 

Mustang

March 13, 2015

 

500

Checkpoint

March 17, 2015

 

500

Cellvation

October 31, 2016

 

500

Baergic

March 9, 2017

 

500

Cyprium

March 13, 2017

 

500

Aevitas

July 28, 2017

 

500

Oncogenuity

February 10, 2017

500

Fortress

 

(4,000)

Consolidated (Income)/Expense

$

Note 1:

Concurrently with the execution and delivery of the Avenue SPMA entered into among, Avenue, the Company and InvaGen Pharmaceuticals Inc. (“InvaGen”) (together, the “SPMA Parties”), the SPMA Parties entered into a waiver agreement (the “Waiver Agreement”), pursuant to which the Company irrevocably waived its right to receive the annual dividend of Avenue’s common shares under the terms of the Class A preferred stock and any fees, payments, reimbursements or other distributions under the management services agreement between the Company and Avenue and the Founders Agreement, for the period from the effective date of the Waiver Agreement to the termination of InvaGen’s rights under the Avenue SPMA. Pursuant to the Waiver Agreement, immediately prior to the closing of the Merger Transaction contemplated under the Avenue SPMA, the Company will convert all of its preferred shares into common shares pursuant to the terms of the certificate of incorporation of Avenue, as amended from time to time. (See Note 4).

XML 52 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information (Tables)
9 Months Ended
Sep. 30, 2020
Segment Information  
Schedule of continued operations by reportable segment

The Company operates in two reportable segments, Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results from continued operations by reportable segment:

Pharmaceutical

    

and

($in thousands)

Dermatology

Biotechnology

Products

Product

Three Months Ended September 30, 2020

    

Sales

    

Development

    

Consolidated

Net revenue

$

9,447

$

28

$

9,475

Direct cost of goods

 

(3,379)

 

 

(3,379)

Sales and marketing costs

 

(4,649)

 

 

(4,649)

Research and development

 

 

(13,756)

 

(13,756)

General and administrative

(1,254)

(9,480)

(10,734)

Other expense

 

(113)

 

(6,808)

 

(6,921)

Segment income (loss)

$

52

(30,016)

$

(29,964)

Segment assets

Intangible assets, net

11,039

11,039

Tangible assets

21,108

263,732

284,840

Total segment assets

$

32,147

$

263,732

$

295,879

Pharmaceutical

and

Dermatology

Biotechnology

($ in thousands)

Products

Product

Three Months Ended September 30, 2019

    

Sales

    

Development

    

Consolidated

Net revenue

$

9,492

$

280

$

9,772

Direct cost of goods

 

(2,702)

 

(2,702)

Sales and marketing costs

 

(4,370)

 

(4,370)

Research and development

 

 

(15,271)

(15,271)

General and administrative

 

(669)

 

(9,300)

(9,969)

Other expense

(108)

(2,322)

(2,430)

Segment income (loss)

$

1,643

$

(26,613)

$

(24,970)

Segment assets

Intangible assets, net

7,731

7,731

Tangible assets

10,966

202,891

213,857

Total segment assets

$

18,697

$

202,891

$

221,588

Pharmaceutical

  

and

Dermatology

Biotechnology

($in thousands)

Products

Product

  

Nine Months Ended September 30, 2020

    

Sales

    

Development

    

Consolidated

Net revenue

$

30,808

$

1,042

$

31,850

Direct cost of goods

 

(10,313)

 

 

(10,313)

Sales and marketing costs

 

(12,728)

 

 

(12,728)

Research and development

 

 

(46,146)

 

(46,146)

General and administrative

 

(3,556)

 

(29,074)

 

(32,630)

Other expense

 

(492)

 

(12,036)

 

(12,528)

Segment income (loss)

$

3,719

 

(86,214)

$

(82,495)

Segment assets

 

  

 

  

 

  

Intangible assets, net

 

11,039

11,039

Tangible assets

 

21,108

263,732

284,840

Total segment assets

$

32,147

$

263,732

$

295,879

Pharmaceutical

 and 

Dermatology

Biotechnology

($in thousands)

Products

Product

Nine Months Ended September 30, 2019

    

Sales

    

Development

    

Consolidated

Net revenue

$

23,816

$

1,683

$

25,499

Direct cost of goods

 

(6,972)

 

 

(6,972)

Sales and marketing costs

 

(12,064)

 

 

(12,064)

Research and development

 

 

(57,705)

 

(57,705)

General and administrative

 

(1,808)

 

(27,388)

 

(29,196)

Other expense

 

(108)

 

11,841

 

11,733

Segment income (loss)

$

2,864

$

(71,569)

$

(68,705)

Segment assets

Intangible assets, net

 

7,731

7,731

Tangible assets

 

10,966

202,891

213,857

Total segment assets

$

18,697

$

202,891

$

221,588

XML 53 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Revenues from Contracts and Significant Customers (Tables)
9 Months Ended
Sep. 30, 2020
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Product revenue is comprised of Journey’s five marketed products: Targadox®, Luxamend®, Ceracade®, Exelderm® and Ximino®. Substantially all of the product revenue is recorded in the U.S. The Company’s related party revenue is from Checkpoint’s collaboration with TGTX. The table below summarizes the Company’s revenue for the three and nine months ending September 30, 2020 and 2019:

Three months ended September 30, 

Nine Months Ended September 30, 

    

2020

    

2019

    

2020

    

2019

    

Revenue

Product revenue, net

$

9,447

$

9,492

$

30,808

$

23,816

Revenue – related party

 

28

 

280

 

1,042

 

1,683

Net revenue

$

9,475

$

9,772

$

31,850

$

25,499

XML 54 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Discontinued Operations- Cash flows from the transaction (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Investing activities      
Proceeds from sale of National   $ 13,089  
Total cash provided by discontinued investing activities $ 0 $ 13,089 $ 0
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and Stock Purchase Agreements (Details) - USD ($)
$ in Millions
1 Months Ended 9 Months Ended
Dec. 31, 2019
Feb. 08, 2019
Jan. 31, 2019
Jan. 30, 2019
Sep. 30, 2020
Nov. 12, 2018
Business Acquisition, Percentage of Voting Interests Acquired           33.30%
Business Combination, Contingent Consideration, Liability           $ 180.0
Caelum [Member]            
Sale of Stock Percentage of Shares Transferred on Transaction       19.90%    
Sale of Stock, Consideration Received on Transaction       $ 30.0    
Alexion [Member]            
Potential Additional Payments, Maximum     $ 500.0      
Alexion [Member] | Caelum [Member]            
Initial contingent payments $ 30.0          
Additional upfront funding 20.0          
Funding for additional equity interest $ 60.0          
Sales [Member] | Avenue [Member]            
Net sales threshold         $ 325.0  
Sales After January 1. 2029 [Member] | Avenue [Member]            
Gross Profit Percentage To Net Sales         20.00%  
Contingent Earn Out Payments Measurement Second Model         $ 1,500.0  
Slab One [Member] | Avenue [Member]            
Gross Profit Percentage To Net Sales         10.00%  
Slab One [Member] | Sales [Member] | Avenue [Member]            
Net sales threshold         $ 400.0  
Slab One [Member] | Sales After January 1. 2029 [Member] | Avenue [Member]            
Net sales threshold         $ 100.0  
Slab Two [Member] | Avenue [Member]            
Gross Profit Percentage To Net Sales         12.50%  
Slab Two [Member] | Sales [Member] | Avenue [Member] | Minimum [Member]            
Net sales threshold         $ 400.0  
Slab Two [Member] | Sales [Member] | Avenue [Member] | Maximum [Member]            
Net sales threshold         $ 500.0  
Slab Three [Member] | Avenue [Member]            
Gross Profit Percentage To Net Sales         15.00%  
Slab Three [Member] | Sales [Member] | Avenue [Member]            
Net sales threshold         $ 500.0  
SPMA [Member]            
Business Combination, Consideration Transferred   $ 7.0        
First Stage [Member] | SPMA [Member]            
Business Combination, Consideration Transferred   $ 31.5        
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment - Components of Property and Equipment (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 18,276 $ 16,919
Less: Accumulated depreciation (6,162) (4,486)
Property and equipment, net 12,114 12,433
Computer equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 662 648
Useful Life (Years) 3 years  
Furniture and fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 1,199 1,162
Useful Life (Years) 5 years  
Machinery & equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 5,014 4,594
Useful Life (Years) 5 years  
Leasehold improvements [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Useful Life (Years) 15 years  
Leasehold improvements [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Useful Life (Years) 5 years  
Leasehold improvements [Member] | Fortress Biotech Inc [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 10,580 9,358
Construction in progress [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 821 $ 1,157
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Property and Equipment        
Depreciation $ 600 $ 500 $ 1,676 $ 1,414
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements - Contingently Issuable Warrants with option pricing model (Details)
9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Probability of issuance of the warrant 100.00% 5.00%
Caelum Warrant Liabilities [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Risk-free interest rate 0.69% 1.92%
Caelum Warrant Liabilities [Member] | Measurement Input, Expected Dividend Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Expected dividend yield 0.00% 0.00%
Caelum Warrant Liabilities [Member] | Measurement Input, Expected Term [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Expected term in years 10 years 10 years
Caelum Warrant Liabilities [Member] | Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Expected volatility 85.00% 93.00%
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements - Derivative Contingently Issuable Warrant liabilities (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Fair Value Measurements    
Beginning balance $ 27  
Change in fair value 1,189  
Reclass partner company's warrants from liability to equity $ (1,216) $ 0
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements - Exclusive of National Financial Instruments Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Assets    
Total $ 11,723 $ 11,148
Liabilities    
Liabilities   27
Warrants [Member]    
Liabilities    
Liabilities   27
Fair Value, Inputs, Level 1 [Member]    
Assets    
Total 0 0
Liabilities    
Liabilities   0
Fair Value, Inputs, Level 1 [Member] | Warrants [Member]    
Liabilities    
Liabilities   0
Fair Value, Inputs, Level 2 [Member]    
Assets    
Total 0 0
Liabilities    
Liabilities   0
Fair Value, Inputs, Level 2 [Member] | Warrants [Member]    
Liabilities    
Liabilities   0
Fair Value, Inputs, Level 3 [Member]    
Assets    
Total 11,723 11,148
Liabilities    
Liabilities   27
Fair Value, Inputs, Level 3 [Member] | Warrants [Member]    
Liabilities    
Liabilities   27
Caelum Convertible Notes [Member]    
Assets    
Fair value of investment 11,723 11,148
Caelum Convertible Notes [Member] | Fair Value, Inputs, Level 1 [Member]    
Assets    
Fair value of investment 0 0
Caelum Convertible Notes [Member] | Fair Value, Inputs, Level 2 [Member]    
Assets    
Fair value of investment 0 0
Caelum Convertible Notes [Member] | Fair Value, Inputs, Level 3 [Member]    
Assets    
Fair value of investment $ 11,723 $ 11,148
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements - Changes in fair value (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Beginning Balance $ 11,175  
Change in fair value 1,189  
Reclass partner company's warrants from liability to equity (1,216) $ 0
Change in fair value of investments 575  
Ending Balance 11,723  
Caelum [Member]    
Beginning Balance 11,148  
Change in fair value of investments 575  
Ending Balance 11,723  
Warrants [Member]    
Beginning Balance 27  
Change in fair value 1,189  
Reclass partner company's warrants from liability to equity (1,216)  
Ending Balance $ 0  
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Dec. 31, 2019
Measurement Input, Risk Free Interest Rate [Member] | Caelum [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Fair Values Assumptions Risk Free Return   0.12%  
Measurement Input Investments [Member] | Caelum [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Investments, Fair Value Disclosure $ 11.7 $ 11.7 $ 11.1
Fair Values Assumptions Expected Volatility Rate     70.00%
Fair Values Assumptions Risk Free Return     1.60%
Fair Values Assumptions Expected Discount For Lack Of Marketability     28.70%
Fair Values Assumptions Share Price     $ 1.54
Measurement Input, Share Price [Member] | Caelum [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Fair Values Assumptions Share Price   $ 1.62  
Measurement Input, Price Volatility [Member] | Caelum [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Fair Values Assumptions Expected Volatility Rate   70.00%  
Fair Values Assumptions Expected Discount For Lack Of Marketability   28.60%  
Caelum Warrant Liabilities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Proceeds from Cyprium Offering $ 8.0    
Caelum Warrant Liabilities [Member] | Measurement Input, Price Volatility [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Fair Values Assumptions Expected Volatility Rate   85.00% 93.00%
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Licenses Acquired - License as recorded in the Condensed Consolidated Statements of Operations (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired $ 458 $ 700 $ 2,278 $ 1,350
Mustang [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 287 $ 700 1,837 $ 1,350
Aevitas [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 162   162  
Baergic[Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 8   8  
Oncogenuity [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired $ 1   $ 271  
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Licenses Acquired - Mustang expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired $ 458 $ 700 $ 2,278 $ 1,350
Mustang [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 287 700 1,837 1,350
Mustang [Member] | City of Hope (COH) - CD123 (MB-102) [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 0 0 334 250
Mustang [Member] | City of Hope (COH) - IL13R2 (MB-101) [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 0 0 333 0
Mustang [Member] | City of Hope (COH) - HER2 (MB-103) [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 0 0 250 0
Mustang [Member] | City of Hope (COH) - CSI (MB-104) [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 0 0 0 200
Mustang [Member] | City of Hope (COH) - Spacer [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 0 200 333 200
Mustang [Member] | Fred Hutch - CD20 CAR T (MB-106) [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 0 0 300 0
Mustang [Member] | Nationwide Children's Hospital - C134 (MB-108) [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 0 0 0 200
Mustang [Member] | CSL Behring (Calimmune) [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 170 200 170 200
Mustang [Member] | UCLA [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired 0 300 0 300
Mustang [Member] | SIRION LentiBOOST [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total Research and Development - Licenses Acquired $ 117 $ 0 $ 117 $ 0
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Licenses Acquired - Additional Information (Detail)
$ / shares in Units, € in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2020
EUR (€)
May 06, 2020
USD ($)
shares
Sep. 30, 2020
USD ($)
$ / shares
Sep. 30, 2020
EUR (€)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
Sep. 30, 2020
EUR (€)
Sep. 30, 2019
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Total consideration             $ 1,000,000   $ 2,400,000
Stock Issued During Period, Value, Issued for Services       $ 18,000     18,000    
Product revenue, net       9,447,000   $ 9,492,000 30,808,000   $ 23,816,000
Licensing Agreements [Member] | SIRION Technology License [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Payment of Upfront Fees       $ 100,000 € 0.1   $ 100,000 € 0.1  
Licensing Agreements [Member] | SIRION Technology License [Member] | Additional Milestone Payments [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method Payments Due $ 4,100,000 € 3.5              
Licensing Agreements [Member] | SIRION Technology License [Member] | Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method Payments Due $ 5,600,000 € 4.7              
Licensing Agreements [Member] | Columbia License [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Payment of Upfront Fees     $ 300,000            
Stock Issued During Period, Shares, Issued for Services | shares     1,000,000            
Percentage of common shares issued (in percent)     10.00%            
Licensing Agreements [Member] | Columbia License [Member] | Valuation Technique, Discounted Cash Flow [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Percentage of lack of marketability       41.70% 41.70%   41.70% 41.70%  
Percentage of weighted average cost of capital       20.50% 20.50%   20.50% 20.50%  
Net of debt in per share | $ / shares       $ 0.021     $ 0.021    
Amount of net of debt utilized       $ 21,000     $ 21,000    
Licensing Agreements [Member] | Columbia License [Member] | Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method Payments Due             18,000,000.0    
Licensing Agreements [Member] | Columbia License [Member] | Product milestone                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method Payments Due             15,300,000    
Licensing Agreements [Member] | Columbia License [Member] | Sale Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method Payments Due             $ 15,000,000.0    
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Sponsored Research and Clinical Trial Agreements - Summary of Aevitas expense related to its sponsored research agreements (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Total Research and Development - Licenses Acquired $ 458 $ 700 $ 2,278 $ 1,350
Research and clinical trial agreements [Member] | Aevitas        
Total Research and Development - Licenses Acquired 163 272 785 772
Research and clinical trial agreements [Member] | Aevitas | UMass - AAV [Member]        
Total Research and Development - Licenses Acquired 163 0 218 0
Research and clinical trial agreements [Member] | Aevitas | UPenn - AAV [Member]        
Total Research and Development - Licenses Acquired 0 255 567 755
Research and clinical trial agreements [Member] | Aevitas | Duke - AAV [Member]        
Total Research and Development - Licenses Acquired $ 0 $ 17 $ 0 $ 17
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Sponsored Research and Clinical Trial Agreements - Summary of Mustang expense related to its sponsored research agreements (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Total Research and Development - Licenses Acquired $ 458 $ 700 $ 2,278 $ 1,350
Mustang [Member]        
Total Research and Development - Licenses Acquired 287 700 1,837 1,350
Research and clinical trial agreements [Member] | Mustang [Member]        
Total Research and Development - Licenses Acquired 734 1,176 4,900 4,441
Research and clinical trial agreements [Member] | Mustang [Member] | City of Hope National Medical Center [Member]        
Total Research and Development - Licenses Acquired 0 500 500 1,500
Research and clinical trial agreements [Member] | Mustang [Member] | City of Hope - CD123 (MB-102) [Member]        
Total Research and Development - Licenses Acquired 48 269 344 1,028
Research and clinical trial agreements [Member] | Mustang [Member] | City of Hope - IL13Ra2 (MB-101) [Member]        
Total Research and Development - Licenses Acquired 96 244 422 811
Research and clinical trial agreements [Member] | Mustang [Member] | City of Hope - Manufacturing [Member]        
Total Research and Development - Licenses Acquired 0 114 0 343
Research and clinical trial agreements [Member] | Mustang [Member] | City of Hope - CS1 (MB-104) [Member]        
Total Research and Development - Licenses Acquired 65 0 835 0
Research and clinical trial agreements [Member] | Mustang [Member] | Beth Israel Deaconess Medical Center - CRISPR        
Total Research and Development - Licenses Acquired 0 0 0 69
Research and clinical trial agreements [Member] | Mustang [Member] | St. Jude Children's Research Hospital XSCID MB-107 [Member]        
Total Research and Development - Licenses Acquired 107 0 1,665 0
Research and clinical trial agreements [Member] | Mustang [Member] | Fred Hutchinson Cancer Research Center CD20 MB-106 [Member]        
Total Research and Development - Licenses Acquired $ 418 $ 49 $ 1,134 $ 690
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Sponsored Research and Clinical Trial Agreements - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 01, 2020
Jun. 30, 2020
May 31, 2020
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Research and Development Expense (Excluding Acquired in Process Cost)       $ 13,298 $ 14,571 $ 43,868 $ 56,355  
Oncogenuity [Member]                
Cost of the SRA       200   300   $ 0
Funding commitment period     5 years          
Mustang Bio, Inc [Member]                
Payments For Research And Development Expenses       800        
Maximum cost associated with COH   $ 2,400            
Cellvation [Member]                
Cost of the SRA       0 $ 100 0 $ 100  
Maximum [Member] | Oncogenuity [Member]                
Sponsor Research Agreement Funding Commitment     $ 4,800          
Mustang Bio, Inc [Member]                
Cost of the SRA       $ 100   $ 800    
St. Jude - XSCID (MB-107) [Member] | Mustang [Member]                
Payment of Upfront Fees $ 1,100              
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Intangibles, net - Summary Of The JMC Intangible Asset (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Net intangible assets $ 11,039 $ 7,377
Journey Medical Corporation [Member]    
Total Intangible assets - asset purchases 14,661 9,934
Accumulated amortization (3,622) (2,557)
Net intangible assets $ 11,039 $ 7,377
Intangible assets - purchases | Journey Medical Corporation [Member] | Minimum [Member]    
Finite-Lived Intangible Asset, Useful Life 3 years  
Intangible assets - purchases | Journey Medical Corporation [Member] | Maximum [Member]    
Finite-Lived Intangible Asset, Useful Life 7 years  
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Intangibles, net - Cost Of Goods Sold (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2020
USD ($)
Beginning balance at January 1, 2020 $ 7,377
Ending balance at September 30, 2020 11,039
Journey Medical Corporation [Member]  
Beginning balance at January 1, 2020 7,377
Asset not yet placed in service 4,727
Acne product license acquisition 4,727
Amortization expense (1,065)
Ending balance at September 30, 2020 $ 11,039
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Intangibles, net - Amortization Of Intangible Assets (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Net intangible assets $ 11,039 $ 7,377
Journey Medical Corporation [Member]    
Three Months Ended December 31, 2020 354  
Year Ended December 31, 2021 1,286  
Year Ended December 31, 2022 1,019  
Year Ended December 31, 2023 1,019  
Year Ended December 31, 2024 1,019  
Thereafter 1,615  
Sub-total 6,312  
Asset not yet placed in service 4,727  
Net intangible assets 11,039 $ 7,377
Ximino [Member] | Journey Medical Corporation [Member]    
Three Months Ended December 31, 2020 254  
Year Ended December 31, 2021 1,019  
Year Ended December 31, 2022 1,019  
Year Ended December 31, 2023 1,019  
Year Ended December 31, 2024 1,019  
Thereafter 1,615  
Sub-total 5,945  
Net intangible assets 5,945  
Exelderm [Member] | Journey Medical Corporation [Member]    
Three Months Ended December 31, 2020 100  
Year Ended December 31, 2021 267  
Year Ended December 31, 2022 0  
Year Ended December 31, 2023 0  
Year Ended December 31, 2024 0  
Thereafter 0  
Sub-total 367  
Net intangible assets $ 367  
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Intangibles, net - Additional information (Details)
$ in Thousands
9 Months Ended
Jul. 29, 2020
USD ($)
Milestone
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Asset Purchase Agreement      
Intangible asset, net   $ 11,039 $ 7,377
Acquired intangible assets, amortization period   5 years  
Initial discount for imputed interest   $ 200  
LSA      
Asset Purchase Agreement      
Upfront payment $ 1,000    
Intangible asset, net   $ 4,700  
Total consideration 5,000    
Remaining payment due on third anniversary of execution 1,000    
Remaining payments due 3,000    
Remaining payment due on first anniversary of execution 1,000    
Remaining payment due on second anniversary of execution 1,000    
Initial discount for imputed interest $ 300    
Number of Additional Milestones | Milestone 3    
Asset Purchase Agreement, Additional Milestone, Payments Due $ 17,000    
Marketing milestones | Milestone 2    
Expected life term   5 years  
Remaining payment amount $ 1,000    
First Anniversary of Execution [Member] | LSA      
Asset Purchase Agreement      
Term of anniversary 18 months    
Second Anniversary of Execution [Member] | LSA      
Asset Purchase Agreement      
Term of anniversary 24 months    
Third Anniversary of Execution [Member] | LSA      
Asset Purchase Agreement      
Term of anniversary 36 months    
Journey Medical Corporation [Member]      
Asset Purchase Agreement      
Intangible asset, net   $ 11,039 $ 7,377
Minimum [Member] | Journey Medical Corporation [Member] | Intangible assets - purchases      
Asset Purchase Agreement      
Finite-Lived Intangible Asset, Useful Life   3 years  
Maximum [Member] | Journey Medical Corporation [Member] | Intangible assets - purchases      
Asset Purchase Agreement      
Finite-Lived Intangible Asset, Useful Life   7 years  
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and Interest - Long-term debt (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Aug. 27, 2020
Dec. 31, 2019
Debt [Line Items]      
Total notes payable, long-term $ 60,000   $ 89,742
Less: Discount of notes payable 8,607   5,086
Total notes payable $ 51,393   84,656
Interest Rate 2.50%    
IDB Note [Member]      
Debt [Line Items]      
Total notes payable, long-term $ 0   14,929
Interest Rate 2.25%    
Maturity Date August 1, 2021    
2017 Subordinated Note Financing One [Member]      
Debt [Line Items]      
Total notes payable, long-term $ 0   3,254
Less: Discount of notes payable $ 1,200    
Interest Rate 8.00%    
Maturity Date March 2, 2022    
2017 Subordinated Note Financing Two [Member]      
Debt [Line Items]      
Total notes payable, long-term $ 0   13,893
Interest Rate 8.00%    
Maturity Date May 1, 2022    
2017 Subordinated Note Financing Three [Member]      
Debt [Line Items]      
Total notes payable, long-term $ 0   1,820
Interest Rate 8.00%    
Maturity Date June 1, 2022    
2017 Subordinated Note Financing Four [Member]      
Debt [Line Items]      
Total notes payable, long-term $ 0   3,018
Interest Rate 8.00%    
Maturity Date August 1, 2022    
2017 Subordinated Note Financing Five [Member]      
Debt [Line Items]      
Total notes payable, long-term $ 0   6,371
Interest Rate 8.00%    
Maturity Date September 1, 2022    
2018 Venture Notes One [Member]      
Debt [Line Items]      
Total notes payable, long-term $ 0   6,517
Interest Rate 8.00%    
Maturity Date August 1, 2021    
2018 Venture Notes Two [Member]      
Debt [Line Items]      
Total notes payable, long-term $ 0   15,190
Interest Rate 8.00%    
Maturity Date September 1, 2021    
2019 Notes [Member]      
Debt [Line Items]      
Total notes payable, long-term $ 0   9,000
Interest Rate 12.00%    
Maturity Date September 1, 2021    
Mustang Horizon Notes [Member]      
Debt [Line Items]      
Total notes payable, long-term $ 0   $ 15,750
Interest Rate 9.00%    
Maturity Date October 1, 2022    
Oaktree Note [Member]      
Debt [Line Items]      
Total notes payable, long-term $ 60,000 $ 60,000  
Interest Rate 11.00% 11.00%  
Maturity Date August 1, 2025    
LIBOR Rate [Member]      
Debt [Line Items]      
Interest Rate 9.00%    
Subordinated Note Financing 2017 One to Five      
Debt [Line Items]      
Increase (decrease) in interest rate 1.00%    
Interest Rate 9.00%    
Maturity date extension term 1 year    
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Debt [Line Items]          
Interest $ 3,046 $ 2,230 $ 7,823 $ 6,284  
Amortization of fees 3,912 938 5,319 2,459  
Interest and Debt Expense 6,958 3,168 13,142 8,743  
Unamortized debt discount fees 8,607   8,607   $ 5,086
LOC Fees [Member]          
Debt [Line Items]          
Interest     45 45  
Amortization of fees     0 0  
Interest and Debt Expense     45 45  
IDB Note [Member]          
Debt [Line Items]          
Interest 77 86 246 254  
Amortization of fees 0 0 0    
Interest and Debt Expense 77 86 246 254  
2017 Subordinated Note Financing One [Member]          
Debt [Line Items]          
Interest 694 1,072 2,870 3,148  
Amortization of fees 1,374 326 1,890 1,081  
Interest and Debt Expense 2,068 1,398 4,760 4,229  
Unamortized debt discount fees 1,200   1,200    
2019 Notes [Member]          
Debt [Line Items]          
Interest 172 275 710 840  
Amortization of fees 0 104 0 336  
Interest and Debt Expense 172 379 710 1,176  
2018 Venture Notes [Member]          
Debt [Line Items]          
Interest 387 438 1,253 1,299  
Amortization of fees 638 166 1,000 468  
Interest and Debt Expense 1,025 604 2,253 1,767  
Unamortized debt discount fees 300   300    
LOC Fees [Member] | LOC Fees [Member]          
Debt [Line Items]          
Interest 14 14      
Amortization of fees 0 0      
Interest and Debt Expense 14 14      
Mustang Horizon Notes [Member]          
Debt [Line Items]          
Interest 895 345 1,585 698  
Amortization of fees 1,792 234 2,321 466  
Interest and Debt Expense 2,687 579 3,906 1,164  
Unamortized debt discount fees 1,800   1,800    
Interest expense 600   600    
Oaktree Note [Member]          
Debt [Line Items]          
Interest 624 0 624 0  
Amortization of fees 108 0 108 0  
Interest and Debt Expense 732 0 732 0  
Note Payable [Member]          
Debt [Line Items]          
Interest 187 0 492 0  
Amortization of fees 0 108 0 108  
Interest and Debt Expense 187 108 492 108  
Other [Member]          
Debt [Line Items]          
Interest (4) 0 (2) 0  
Amortization of fees 0 0 0 0  
Interest and Debt Expense $ (4) $ 0 $ (2) $ 0  
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.20.2
Debt and Interest- Additional Information (Details) - USD ($)
9 Months Ended
Aug. 27, 2020
Sep. 30, 2020
Sep. 30, 2019
Aug. 29, 2020
Dec. 31, 2019
Total notes payable, long-term   $ 60,000,000     $ 89,742,000
Notes payable, short-term         6,000,000.0
Total notes payable, long-term   $ 60,000,000     $ 89,742,000
Interest Rate   2.50%      
Deferred Fees   $ 8,700,000      
Amortization of interest discount   5,319,000 $ 2,459,000    
Oaktree Warrants [Member]          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,749,450     1,749,450  
Fair value of warrants $ 4,400,000 4,400,000      
Oaktree Note [Member]          
Total notes payable, long-term 60,000,000.0 60,000,000      
Total notes payable, long-term $ 60,000,000.0 $ 60,000,000      
Interest Rate 11.00% 11.00%      
Upfront commitment fee (Percent) 3.00%        
Debt instrument face amount $ 60,000,000.0        
Upfront commitment fee 1,800,000        
Payment of agency fee 35,000        
Deferred Fees   $ 1,800,000      
Payment of expenses to third parties $ 2,500,000 2,500,000      
Amortization of interest discount   $ 4,400,000      
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Liabilities and other Long-Term Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Accrued expenses:    
Professional fees $ 1,672 $ 1,153
Salaries, bonus and related benefits 5,677 6,683
Accrued expense - related party 19 0
Research and development 4,604 4,215
Research and development - manufacturing 0 1,017
Research and development - license maintenance fees 629 361
Research and development - milestones 600 0
Accrued royalties payable 1,908 2,320
Accrued coupon expense 5,476 8,391
Other 547 1,259
Total accrued expenses 21,132 25,399
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 1,996 2,136
Long-term notes payable, net (Journey) 51,393 77,436
Total other long-term liabilities 8,205 7,126
Ximino agreement [Member]    
Other long-term liabilities:    
Long-term notes payable, net (Journey) 3,456 4,990
Oral Acne Treatment Agreement [Member]    
Other long-term liabilities:    
Long-term notes payable, net (Journey) $ 2,753 $ 0
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Liabilities and other Long-Term Liabilities - Additional Information (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]      
Effective interest rate used to calculated imputed interest discount (in percent) 4.00%    
Period of effective interest rate considered for calculation of imputed interest discount (in years) 3 years    
Initial discount for imputed interest $ 200    
Notes payable, short-term     $ 6,000
Long-term notes payable, net (Journey) 51,393   77,436
Amortization of interest discount 5,319 $ 2,459  
Ximino agreement [Member]      
Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]      
Initial discount for imputed interest 1,500   2,000
Notes payable, short-term 2,000    
Long-term notes payable, net (Journey) 3,456   4,990
Amortization of interest discount 500 $ 100  
Oral Acne Treatment Agreement [Member]      
Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]      
Notes payable, short-term 1,000    
Long-term notes payable, net (Journey) $ 2,753   $ 0
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.20.2
Non-Controlling Interests (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Noncontrolling Interest [Line Items]          
NCI equity share $ 120,298   $ 120,298   $ 108,017
Net loss attributable to non-controlling interests (14,417) $ (12,208) (41,264) $ (44,237) (61,700)
Non-controlling interests in consolidated entities 79,034   79,034   46,317
Aevitas [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share (2,297)   (2,297)   (1,249)
Net loss attributable to non-controlling interests     (680)   (694)
Non-controlling interests in consolidated entities $ (2,977)   $ (2,977)   $ (1,943)
Non-controlling ownership 39.00%   39.00%   35.80%
Avenue [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 5,709   $ 5,709   $ 24,269
Net loss attributable to non-controlling interests     (3,206)   (19,011)
Non-controlling interests in consolidated entities $ 2,503   $ 2,503   $ 5,258
Non-controlling ownership 77.40%   77.40%   77.30%
Baergic[Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (1,605)   $ (1,605)   $ 23
Net loss attributable to non-controlling interests     (68)   (1,162)
Non-controlling interests in consolidated entities $ (1,673)   $ (1,673)   $ (1,139)
Non-controlling ownership 40.00%   40.00%   33.00%
Cellvation [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (1,072)   $ (1,072)   $ (732)
Net loss attributable to non-controlling interests     (145)   (158)
Non-controlling interests in consolidated entities $ (1,217)   $ (1,217)   $ (890)
Non-controlling ownership 22.60%   22.60%   20.60%
Checkpoint [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 37,963   $ 37,963   $ 29,389
Net loss attributable to non-controlling interests     (9,000)   (14,687)
Non-controlling interests in consolidated entities $ 28,963   $ 28,963   $ 14,702
Non-controlling ownership 80.00%   80.00%   78.00%
Coronado SO [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (290)   $ (290)   $ (290)
Net loss attributable to non-controlling interests     0   0
Non-controlling interests in consolidated entities $ (290)   $ (290)   $ (290)
Non-controlling ownership 13.00%   13.00%   13.00%
Cyprium [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 784   $ 784   $ (320)
Net loss attributable to non-controlling interests     (843)   (99)
Non-controlling interests in consolidated entities $ (59)   $ (59)   $ (419)
Non-controlling ownership 28.40%   28.40%   10.60%
Helocyte [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (4,890)   $ (4,890)   $ (4,322)
Net loss attributable to non-controlling interests     (236)   (402)
Non-controlling interests in consolidated entities $ (5,126)   $ (5,126)   $ (4,724)
Non-controlling ownership 18.80%   18.80%   19.30%
JMC [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 123   $ 123   $ (211)
Net loss attributable to non-controlling interests     257   325
Non-controlling interests in consolidated entities $ 380   $ 380   $ 114
Non-controlling ownership 6.90%   6.90%   6.90%
Mustang [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 86,572   $ 86,572   $ 62,025
Net loss attributable to non-controlling interests     (27,035)   (25,727)
Non-controlling interests in consolidated entities $ 59,537   $ 59,537   $ 36,298
Non-controlling ownership 77.90%   77.90%   70.30%
Oncogenuity [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (47)   $ (47)    
Net loss attributable to non-controlling interests     (268)    
Non-controlling interests in consolidated entities $ (315)   $ (315)    
Non-controlling ownership 25.30%   25.30%    
Tamid [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (652)   $ (652)   $ (565)
Net loss attributable to non-controlling interests     (40)   (85)
Non-controlling interests in consolidated entities $ (692)   $ (692)   $ (650)
Non-controlling ownership 22.80%   22.80%   22.80%
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Details) - shares
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total of weighted average shares outstanding 18,954,457 17,329,148
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total of weighted average shares outstanding 3,026,693 2,745,364
Options to Purchase Common Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total of weighted average shares outstanding 1,187,600 1,169,293
Unvested Restricted Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total of weighted average shares outstanding 14,305,949 12,622,881
Unvested Restricted Stock Units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total of weighted average shares outstanding 434,215 791,610
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 3,171 $ 3,741 $ 10,319 $ 10,423
Avenue [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 161 298 592 1,585
Checkpoint [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 725 833 2,095 2,444
Mustang [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 606 1,120 2,368 2,174
Other [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 47 84 163 183
Employee Awards [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 1,200 936 3,732 2,791
Executive Awards [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 369 358 1,136 1,065
Non-Employee Awards [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 31 15 136 84
Warrants [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 32 $ 97 $ 97 $ 97
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity - Stock Option Activity (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Stockholders' Equity    
Number of shares, Options vested and expected to vest 1,410,501  
Number of shares, Options Exercised (100,000)  
Number of shares, Options Forfeited (247,011)  
Number of shares, Options vested and expected to vest 1,063,490 1,410,501
Weighted average exercise price, Options vested and expected to vest $ 4.30  
Weighted Average Exercise Price, Options Exercised 1.18  
Weighted Average Exercise Price, Options Forfeited 2.55  
Weighted average exercise price, Options vested and expected to vest $ 5.00 $ 4.30
Total weighted average intrinsic value, Options vested and expected to vest $ 1,044,218 $ 684,752
Total weighted average intrinsic value, Options Exercised 0  
Total weighted average intrinsic value, Options Forfeited $ 0  
Weighted average remaining contractual life (years), Options vested and expected to vest 2 years 10 months 13 days 2 years 3 months 29 days
XML 82 R70.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity - Restricted Stock Activity (Details) - Restricted Stock [Member]
9 Months Ended
Sep. 30, 2020
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares, Unvested balance | shares 13,768,014
Number of shares, Restricted stock granted | shares 1,873,072
Number of shares, Restricted stock vested | shares (1,549,564)
Number of shares Restricted stock units granted | shares 630,126
Number of shares Restricted stock units forfeited | shares (106,250)
Number of shares Restricted stock units vested | shares (368,290)
Number of shares, Unvested balance | shares 14,247,108
Weighted average grant price, Unvested balance | $ / shares $ 2.46
Weighted average grant price, Restricted stock granted | $ / shares 2.57
Weighted average grant price, Restricted stock vested | $ / shares 2.69
Weighted average grant price, Restricted stock units granted | $ / shares 3.82
Weighted average grant price, Restricted stock units forfeited | $ / shares 2.71
Weighted average grant price, Restricted stock units vested | $ / shares 3.13
Weighted average grant price, Unvested balance | $ / shares $ 2.49
XML 83 R71.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity - Warrant activities (Details) - Warrants [Member] - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Subsidiary or Equity Method Investee [Line Items]    
Number of shares, Outstanding 2,741,180  
Number of shares, Granted 1,849,450  
Number of shares, Forfeited (9)  
Number of shares, Outstanding 4,590,621 2,741,180
Number of shares, Exercisable 4,430,621  
Weighted average exercise price, Outstanding $ 3.19  
Weighted average exercise price, Granted 3.14  
Weighted average exercise price, Forfeited 3.00  
Weighted average exercise price, Outstanding 3.17 $ 3.19
Weighted average exercise price, Exercisable $ 3.21  
Total intrinsic value, Outstanding $ 4,111,018 $ 111,000
Total intrinsic value, Granted 1,657,538  
Total intrinsic value, Forfeited 0  
Total intrinsic value, Exercisable $ 3,816,818  
Weighted average remaining contractual life (years), Outstanding 5 years 1 month 6 days 2 years 8 months 23 days
Weighted average remaining contractual life, Exercisable (years) 5 years 18 days  
XML 84 R72.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 29, 2020
item
$ / shares
shares
Aug. 28, 2020
USD ($)
$ / shares
shares
Aug. 27, 2020
USD ($)
shares
Aug. 26, 2020
USD ($)
$ / shares
shares
May 29, 2020
USD ($)
$ / shares
shares
Feb. 14, 2020
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2019
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2019
USD ($)
$ / shares
shares
Jun. 29, 2020
shares
May 31, 2020
USD ($)
Mar. 23, 2020
USD ($)
Dec. 31, 2019
$ / shares
shares
Aug. 16, 2019
USD ($)
Jun. 17, 2019
$ / shares
shares
Jun. 16, 2019
shares
Jul. 13, 2018
USD ($)
Nov. 30, 2017
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Stock-based compensation expense                 $ 3,171,000 $ 3,741,000 $ 10,319,000 $ 10,423,000                  
Proceeds from issuance of Series A preferred stock                     39,075,000 0                  
Proceeds From Issuance Of Preferred Stock, At The Market Offering                     $ 0 539,000                  
Preferred Stock, Liquidation Preference Per Share | $ / shares             $ 25.00   $ 25.00   $ 25.00         $ 25.00          
Interest Rate             2.50%   2.50%   2.50%                    
Common Stock, Shares, Issued | shares             93,748,374   93,748,374   93,748,374         74,027,425   150,000,000 50,000,000    
Common Stock, Par or Stated Value Per Share | $ / shares             $ 0.001   $ 0.001   $ 0.001         $ 0.001   $ 0.001      
Underwriting discounts and commissions and offering expenses                     $ 3,407,000 0                  
Stock Repurchase Program, Authorized Amount                           $ 5,000,000.0 $ 5,000,000.0            
Preferred shares repurchased and held in treasury | shares             5,000   5,000   5,000                    
Consideration for repurchase of preferred shares                     $ 70,000 0                  
Fees incurred for repurchase of preferred shares                     $ 2,000 0                  
Stock Incentive Plan 2013 [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Common Stock, Shares, Issued | shares               13,000,000.0         3,000,000.0                
Common Stock, Remaining Number of Shares | shares                     4,200,000                    
Research and Development Expense [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Stock-based compensation expense                 $ 700,000 1,200,000 $ 2,500,000 2,600,000                  
General and Administrative Expense [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Stock-based compensation expense                 $ 2,500,000 $ 2,500,000 $ 7,800,000 $ 7,800,000                  
Maximum [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Capital Units, Authorized | shares             150,000,000   150,000,000   150,000,000                    
Minimum [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Capital Units, Authorized | shares             50,000,000   50,000,000   50,000,000                    
2020 Shelf                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Common Stock Shares Available For Future Issuance Value             $ 29,500,000   $ 29,500,000   $ 29,500,000                    
Common Stock [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Common Stock issued in connection with the first ESPP offering | shares                     53,268 54,221                  
Issuance of Common Stock for At the Market Offering in shares | shares                 7,064,214 1,213,643 16,378,234 8,604,469                  
Common Stock [Member] | Market Offering [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Average Price Per Share | $ / shares                     $ 2.74                    
Proceeds From Issuance Of Preferred Stock, At The Market Offering                     $ 44,800,000                    
Issuance of Common Stock for At the Market Offering in shares | shares                     16,400,000                    
Payments for Commissions                     $ 1,600,000                    
Underwriting discounts and commissions and offering expenses         $ 1,100,000 $ 1,300,000                              
Preferred Stock [Member] | Market Offering [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Average Price Per Share | $ / shares         $ 18.00 $ 20.00                              
Preferred Stock [Member] | 2018 Preferred ATM                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Gross proceeds         $ 11,500,000 $ 14,400,000                              
Preferred Stock [Member] | Over-Allotment Option [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares   64,600                                      
Preferred Stock [Member] | IPO [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Shares Issued, Price Per Share | $ / shares   $ 25.00                                      
Average Price Per Share | $ / shares       $ 18.00                                  
Issuance Of Preferred Stock For Public Offering | shares   255,400   666,666 555,556 625,000                              
Preferred Stock dividends Per Share Cash Paid | $ / shares   $ 0.19531                 $ 0.19531                    
Annual dividend | $ / shares   2.34375                                      
Preferred Stock, Liquidation Preference Per Share | $ / shares   $ 25.00                                      
Preferred stock exchange term optional   24 months                                      
Initial dividend paid                     $ 49,883,000                    
Preferred Stock, Dividend Rate, Percentage       9.375% 9.375%                                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares       66,666 83,333 93,750                              
Interest Rate   9.375%                                      
Gross proceeds   $ 8,000,000.0   $ 13,200,000                                  
Underwriting discounts and commissions and offering expenses   $ 900,000   $ 1,100,000                                  
Mustang Bio, Inc [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Share Price | $ / shares             $ 3.56   $ 3.56 $ 6.42 $ 3.56 $ 6.42                  
Common Stock Shares Available For Future Issuance Value             $ 32,600,000   $ 32,600,000   $ 32,600,000                    
Marketable Securities                                 $ 75,000,000.0     $ 75,000,000.0  
Mustang Bio, Inc [Member] | Common Stock [Member] | Market Offering [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Average Price Per Share | $ / shares               $ 3.25     $ 3.56 $ 6.42                  
Proceeds from issuance of Common stock               $ 37,200,000     $ 25,600,000 $ 22,500,000                  
Proceeds From Issuance Of Common Stock Net of Issuance Costs               $ 34,900,000     $ 25,100,000 $ 22,000,000.0                  
Stock Issued During Period, Shares, New Issues | shares               11,455,604                          
Issuance of Common Stock for At the Market Offering in shares | shares                     7,200,000 3,500,000                  
Agents Commission, Percentage                     3.00%                    
Underwriting discounts and commissions and offering expenses               $ 2,300,000                          
Mustang Bio, Inc [Member] | Common Stock [Member] | Market Offering [Member] | Founders Agreement                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Issuance of Common Stock for At the Market Offering in shares | shares                     117,405 87,656                  
Checkpoint [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Common Stock, Capital Shares Reserved for Future Issuance | shares             12,300,000   12,300,000   12,300,000                    
Marketable Securities                                         $ 100,000,000
Checkpoint [Member] | Common Stock [Member] | Market Offering [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Average Price Per Share | $ / shares             $ 2.80       $ 2.40                    
Proceeds from issuance of Common stock             $ 20,500,000       $ 8,700,000                    
Proceeds From Issuance Of Common Stock Net of Issuance Costs             $ 18,900,000       $ 8,400,000                    
Stock Issued During Period, Shares, New Issues | shares             7,321,429       3,614,344                    
Agents Commission, Percentage                     3.00%                    
Underwriting discounts and commissions and offering expenses             $ 1,600,000                            
Checkpoint [Member] | Common Stock [Member] | Market Offering [Member] | Founders Agreement                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Weighted average price per share | $ / shares                     $ 2.92                    
Stock Issued During Period, Shares, New Issues | shares                     273,379                    
Oaktree Warrants [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 1,749,450   1,749,450                                    
Purchase price | $ / shares $ 3.20                                        
Percentage of market price 95.00%                                        
Volatility rate 0.868%                                        
Interest Rate 0.74%                                        
Outstanding warrants | shares 4,800,000                                        
Number of Financial instruments | item 2                                        
Fair Value of Warrants     $ 4,400,000               $ 4,400,000                    
Warrant expiration term 10 years                                        
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 3.20                                        
Restricted Stock [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition                     3 years 10 months 24 days                    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options             $ 17,500,000   $ 17,500,000   $ 17,500,000                    
Restricted Stock Units (RSUs) [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition                       5 years                  
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options                   $ 12,700,000   $ 12,700,000                  
Restricted Stock Units (RSUs) [Member] | Mustang Bio, Inc [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Adjustments To Additional Paid In Capital At Market Offering Costs                     $ 500,000 500,000                  
Options to Purchase Common Stock [Member] | Employee Stock [Member]                                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                          
Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period             85.00%   85.00%   85.00%                    
Common Stock issued in connection with the first ESPP offering | shares                     507,783                    
Common Stock, Capital Shares Reserved for Future Issuance | shares             492,217   492,217   492,217                    
Stock-based compensation expense                 $ 38,000 $ 18,000 $ 100,000 $ 100,000                  
XML 85 R73.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies - Lease expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Commitments and Contingencies        
Operating lease cost $ 816 $ 798 $ 2,436 $ 2,397
Shared lease costs (469) (479) (1,409) (1,408)
Variable lease cost   160   575
Variable lease cost 178   411  
Total lease expense $ 525 $ 479 1,438 1,564
Operating cash flows from operating leases     $ (2,127) $ (2,185)
Weighted-average remaining lease term - operating leases (years) 5 years 10 months 24 days 6 years 4 months 24 days 5 years 10 months 24 days 6 years 4 months 24 days
Weighted-average discount rate - operating leases 6.20% 6.20% 6.20% 6.20%
XML 86 R74.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies - Future minimum lease payments (Details)
$ in Thousands
Sep. 30, 2020
USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]  
Three Months Ended December 31, 2020 $ 839
Year ended December 31, 2021 3,114
Year ended December 31, 2022 3,084
Year ended December 31, 2023 3,137
Year ended December 31, 2024 3,190
Other 20,273
Total operating lease liabilities 33,637
Less: present value discount (9,085)
Net operating lease liabilities, short-term and long-term $ 24,552
XML 87 R75.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Commitments and Contingencies    
Operating Lease, Liability $ 24,552  
Operating lease right-of-use asset, net $ 20,265 $ 21,480
XML 88 R76.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions - Founders Agreements (Details)
9 Months Ended
Sep. 30, 2020
Helocyte Inc [Member]  
Related Party Transaction [Line Items]  
Dividends Payable, Date Declared Mar. 20, 2015
Dividends Paid in kind percentage 2.50%
Avenue [Member]  
Related Party Transaction [Line Items]  
Dividends Payable, Date Declared Feb. 17, 2015
Dividends Paid in kind percentage 0.00%
Mustang Bio, Inc [Member]  
Related Party Transaction [Line Items]  
Dividends Payable, Date Declared Mar. 13, 2015
Dividends Paid in kind percentage 2.50%
Checkpoint [Member]  
Related Party Transaction [Line Items]  
Dividends Payable, Date Declared Mar. 17, 2015
Dividends Paid in kind percentage 0.00%
Percentage of Annual fee 2.50%
Cellvation Inc [Member]  
Related Party Transaction [Line Items]  
Dividends Payable, Date Declared Oct. 31, 2016
Dividends Paid in kind percentage 2.50%
Caelum [Member]  
Related Party Transaction [Line Items]  
Dividends Payable, Date Declared Jan. 01, 2017
Dividends Paid in kind percentage 0.00%
Baergic[Member]  
Related Party Transaction [Line Items]  
Dividends Payable, Date Declared Dec. 17, 2019
Dividends Paid in kind percentage 2.50%
Cyprium Bio sciences Inc [Member]  
Related Party Transaction [Line Items]  
Dividends Payable, Date Declared Mar. 13, 2017
Dividends Paid in kind percentage 2.50%
Aevitas Inc [Member]  
Related Party Transaction [Line Items]  
Dividends Payable, Date Declared Jul. 28, 2017
Dividends Paid in kind percentage 2.50%
Oncogenuity [Member]  
Related Party Transaction [Line Items]  
Dividends Payable, Date Declared Apr. 22, 2020
Dividends Paid in kind percentage 2.50%
XML 89 R77.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Details)
9 Months Ended
Sep. 30, 2020
USD ($)
Helocyte Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Mar. 20, 2015
Avenue [Member]  
Related Party Transaction [Line Items]  
Annual Consulting Fee Payable Effective Date Feb. 17, 2015
Mustang Bio, Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Mar. 13, 2015
Checkpoint [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Mar. 17, 2015
Cellvation Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Oct. 31, 2016
Baergic[Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Mar. 09, 2017
Cyprium Bio sciences Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Mar. 13, 2017
Aevitas Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Jul. 28, 2017
Oncogenuity [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ 500
Annual Consulting Fee Payable Effective Date Feb. 10, 2017
Fortress Biotech Inc [Member]  
Related Party Transaction [Line Items]  
Annual Management Services Agreement Fee Income expense $ (4,000)
XML 90 R78.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Jun. 12, 2020
Sep. 13, 2019
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Related Party Transaction [Line Items]              
TGTX     $ 28,000 $ 280,000 $ 1,042,000 $ 1,683,000  
Total notes payable, long-term     $ 60,000,000   $ 60,000,000   $ 89,742,000
Debt Instrument, Interest Rate, Stated Percentage     2.50%   2.50%    
Opus Credit Facility [Member]              
Related Party Transaction [Line Items]              
Common Shares Issued For Opus Debt, In Shares           91,767  
Common Shares Issued For Opus Debt, Issue Price           $ 1.80  
2019 Notes (formerly the Opus Credit Facility Agreement)              
Related Party Transaction [Line Items]              
Maturity extended period   2 years          
Debt pay off     $ 9,000,000.0        
Interet paid         $ 500,000    
Payments of Loan Costs           $ 200,000  
Total notes payable, long-term             9,000,000.0
Debt Instrument, Interest Rate, Stated Percentage     12.00%   12.00%    
DAK Capital Inc [Member] | 2019 Notes (formerly the Opus Credit Facility Agreement)              
Related Party Transaction [Line Items]              
Total notes payable, long-term             3,800,000
Chief Executive Officer [Member]              
Related Party Transaction [Line Items]              
Interest own in percent by principal stockholder or director     10.10%   10.10%    
Executives Vice Chairman [Member]              
Related Party Transaction [Line Items]              
Interest own in percent by principal stockholder or director     10.90%   10.90%    
Fortress's Chairman, President and Chief Executive Officer (Lindsay A. Rosenwald) [Member] | 2019 Notes (formerly the Opus Credit Facility Agreement)              
Related Party Transaction [Line Items]              
Total notes payable, long-term             300,000
Fortress's Executive Vice President, Strategic Development (Michael S. Weiss) [Member] | 2019 Notes (formerly the Opus Credit Facility Agreement)              
Related Party Transaction [Line Items]              
Total notes payable, long-term             2,000,000.0
Credit Facility Provided | Avenue [Member]              
Related Party Transaction [Line Items]              
Maximum borrowing capacity $ 2,000,000            
Maximum aggregate lending up agreement 800,000            
Aggregate lending up agreement $ 1,200,000            
Interest rate per annum (as a percent) 7.00%            
Repayment period following the termination of the SPMA 30 days            
Amounts drawn     $ 0   $ 0    
Dr Rosenwald and Mr Weiss | 2019 Notes (formerly the Opus Credit Facility Agreement)              
Related Party Transaction [Line Items]              
Total notes payable, long-term             $ 2,900,000
Shared Services Agreement [Member] | TG Therapeutics, Inc [Member]              
Related Party Transaction [Line Items]              
TGTX     100,000 100,000 300,000 $ 300,000  
Due from Related Parties, Current     69,000   69,000    
Desk Share Agreements [Member]              
Related Party Transaction [Line Items]              
Payments for Rent     700,000 700,000      
Desk Share Agreements [Member] | TG Therapeutics, Inc [Member]              
Related Party Transaction [Line Items]              
TGTX     400,000   400,000    
Due from Related Parties, Current     0   0    
Desk Share Agreements [Member] | OPPM [Member]              
Related Party Transaction [Line Items]              
TGTX     0 $ 24,000      
Due from Related Parties, Current     $ 400,000   $ 400,000    
XML 91 R79.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
segment
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Segment Reporting Information [Line Items]          
Number of Reportable Segments | segment     2    
Net Revenue $ 9,475 $ 9,772 $ 31,850 $ 25,499  
Income (loss) from operations (23,043) (22,540) (69,967) (80,438)  
Intangible asset, net 11,039   11,039   $ 7,377
Dermatology Products Sales [Member]          
Segment Reporting Information [Line Items]          
Net Revenue 9,447 9,492 30,808 23,816  
Direct cost of goods (3,379) (2,702) (10,313) (6,972)  
Sales and marketing costs (4,649) (4,370) (12,728) (12,064)  
Research and development 0 0      
General and administrative (1,254) (669) (3,556) (1,808)  
Other expense (113) (108) (492) (108)  
Income (loss) from operations 52 1,643 3,719 2,864  
Intangible asset, net 11,039 7,731 11,039 7,731  
Tangible assets 21,108 10,966 21,108 10,966  
Total segment assets 32,147 18,697 32,147 18,697  
Pharmaceutical and Biotechnology Product Development [Member]          
Segment Reporting Information [Line Items]          
Net Revenue 28 280 1,042 1,683  
Direct cost of goods 0 0      
Sales and marketing costs 0 0      
Research and development (13,756) (15,271) (46,146) (57,705)  
General and administrative (9,480) (9,300) (29,074) (27,388)  
Other expense (6,808) (2,322) (12,036)    
Other expense       11,841  
Income (loss) from operations (30,016) (26,613) (86,214) (71,569)  
Intangible asset, net 0 0 0 0  
Tangible assets 263,732 202,891 263,732 202,891  
Total segment assets 263,732 202,891 263,732 202,891  
Consolidated [Member]          
Segment Reporting Information [Line Items]          
Net Revenue 9,475 9,772 31,850 25,499  
Direct cost of goods (3,379) (2,702) (10,313) (6,972)  
Sales and marketing costs (4,649) (4,370) (12,728) (12,064)  
Research and development (13,756) (15,271) (46,146) (57,705)  
General and administrative (10,734) (9,969) (32,630) (29,196)  
Other expense (6,921) (2,430) (12,528)    
Other expense       11,733  
Income (loss) from operations (29,964) (24,970) (82,495) (68,705)  
Intangible asset, net 11,039 7,731 11,039 7,731  
Tangible assets 284,840 213,857 284,840 213,857  
Total segment assets $ 295,879 $ 221,588 $ 295,879 $ 221,588  
XML 92 R80.htm IDEA: XBRL DOCUMENT v3.20.2
Revenues from Contracts and Significant Customers - Company's product revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenues from Contracts and Significant Customers        
Product revenue, net $ 9,447 $ 9,492 $ 30,808 $ 23,816
Revenue - related party 28 280 1,042 1,683
Net revenue $ 9,475 $ 9,772 $ 31,850 $ 25,499
XML 93 R81.htm IDEA: XBRL DOCUMENT v3.20.2
Revenues from Contracts and Significant Customers - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue from Contract with Customer, Including Assessed Tax $ 9,447 $ 9,492 $ 30,808 $ 23,816
Revenue [Member]        
Concentration Risk, Customer none of the Company’s Dermatology Products customers accounted for more than 10% of its total gross product revenue   one of the Company’s Dermatology Products customers accounted for more than 10% of its total gross product revenue  
Accounts Receivable [Member]        
Concentration Risk, Customer     one of the Company’s Dermatology Products customers accounted for more than 10% of its total accounts receivable balance at 14.5% two of the Company’s Dermatology Products customers accounted for more than 10% of its total accounts balance in the amounts of $3.5 million and $2.8 million
Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Concentration risk, percentage     14.50%  
Customer One [Member] | Accounts Receivable [Member]        
Accounts Receivable, Net   3,500   $ 3,500
Customer Two [Member] | Accounts Receivable [Member]        
Accounts Receivable, Net   $ 2,800   $ 2,800
3PL Title Model [Member] | Revenue [Member] | Customer Concentration Risk [Member]        
Concentration risk, percentage   60.00%   76.00%
EXCEL 94 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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ı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end XML 95 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 96 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 97 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 604 567 1 false 184 0 false 8 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity Sheet http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity Condensed Consolidated Statement of Changes in Stockholders' Equity Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Organization and Description of Business Sheet http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 7 false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Discontinued Operations Sheet http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperations Discontinued Operations Notes 9 false false R10.htm 10401 - Disclosure - Collaboration and Stock Purchase Agreements Sheet http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreements Collaboration and Stock Purchase Agreements Notes 10 false false R11.htm 10501 - Disclosure - Property and Equipment Sheet http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 10601 - Disclosure - Fair Value Measurements Sheet http://www.fortressbiotech.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 10701 - Disclosure - Licenses Acquired Sheet http://www.fortressbiotech.com/role/DisclosureLicensesAcquired Licenses Acquired Notes 13 false false R14.htm 10801 - Disclosure - Sponsored Research and Clinical Trial Agreements Sheet http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreements Sponsored Research and Clinical Trial Agreements Notes 14 false false R15.htm 10901 - Disclosure - Intangibles, net Sheet http://www.fortressbiotech.com/role/DisclosureIntangiblesNet Intangibles, net Notes 15 false false R16.htm 11001 - Disclosure - Debt and Interest Sheet http://www.fortressbiotech.com/role/DisclosureDebtAndInterest Debt and Interest Notes 16 false false R17.htm 11101 - Disclosure - Accrued Liabilities and other Long-Term Liabilities Sheet http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilities Accrued Liabilities and other Long-Term Liabilities Notes 17 false false R18.htm 11201 - Disclosure - Non-Controlling Interests Sheet http://www.fortressbiotech.com/role/DisclosureNonControllingInterests Non-Controlling Interests Notes 18 false false R19.htm 11301 - Disclosure - Net Loss per Common Share Sheet http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShare Net Loss per Common Share Notes 19 false false R20.htm 11401 - Disclosure - Stockholders' Equity Sheet http://www.fortressbiotech.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 20 false false R21.htm 11501 - Disclosure - Commitments and Contingencies Sheet http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 21 false false R22.htm 11601 - Disclosure - Related Party Transactions Sheet http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 22 false false R23.htm 11701 - Disclosure - Segment Information Sheet http://www.fortressbiotech.com/role/DisclosureSegmentInformation Segment Information Notes 23 false false R24.htm 11801 - Disclosure - Revenues from Contracts and Significant Customers Sheet http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomers Revenues from Contracts and Significant Customers Notes 24 false false R25.htm 11901 - Disclosure - Income taxes Sheet http://www.fortressbiotech.com/role/DisclosureIncomeTaxes Income taxes Notes 25 false false R26.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPolicies 26 false false R27.htm 30303 - Disclosure - Discontinued Operations (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperations 27 false false R28.htm 30503 - Disclosure - Property and Equipment (Tables) Sheet http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipment 28 false false R29.htm 30603 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.fortressbiotech.com/role/DisclosureFairValueMeasurements 29 false false R30.htm 30703 - Disclosure - Licenses Acquired (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredTables Licenses Acquired (Tables) Tables http://www.fortressbiotech.com/role/DisclosureLicensesAcquired 30 false false R31.htm 30803 - Disclosure - Sponsored Research and Clinical Trial Agreements (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsTables Sponsored Research and Clinical Trial Agreements (Tables) Tables http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreements 31 false false R32.htm 30903 - Disclosure - Intangibles, net (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureIntangiblesNetTables Intangibles, net (Tables) Tables http://www.fortressbiotech.com/role/DisclosureIntangiblesNet 32 false false R33.htm 31003 - Disclosure - Debt and Interest (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables Debt and Interest (Tables) Tables http://www.fortressbiotech.com/role/DisclosureDebtAndInterest 33 false false R34.htm 31103 - Disclosure - Accrued Liabilities and other Long-Term Liabilities (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesTables Accrued Liabilities and other Long-Term Liabilities (Tables) Tables http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilities 34 false false R35.htm 31203 - Disclosure - Non-Controlling Interests (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsTables Non-Controlling Interests (Tables) Tables http://www.fortressbiotech.com/role/DisclosureNonControllingInterests 35 false false R36.htm 31303 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareTables Net Loss per Common Share (Tables) Tables http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShare 36 false false R37.htm 31403 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.fortressbiotech.com/role/DisclosureStockholdersEquity 37 false false R38.htm 31503 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingencies 38 false false R39.htm 31603 - Disclosure - Related Party Transactions (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactions 39 false false R40.htm 31703 - Disclosure - Segment Information (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.fortressbiotech.com/role/DisclosureSegmentInformation 40 false false R41.htm 31803 - Disclosure - Revenues from Contracts and Significant Customers (Tables) Sheet http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersTables Revenues from Contracts and Significant Customers (Tables) Tables http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomers 41 false false R42.htm 40301 - Disclosure - Discontinued Operations- Cash flows from the transaction (Details) Sheet http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperationsCashFlowsFromTransactionDetails Discontinued Operations- Cash flows from the transaction (Details) Details 42 false false R43.htm 40403 - Disclosure - Collaboration and Stock Purchase Agreements (Details) Sheet http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails Collaboration and Stock Purchase Agreements (Details) Details http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreements 43 false false R44.htm 40501 - Disclosure - Property and Equipment - Components of Property and Equipment (Details) Sheet http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails Property and Equipment - Components of Property and Equipment (Details) Details 44 false false R45.htm 40502 - Disclosure - Property and Equipment - Additional Information (Details) Sheet http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails Property and Equipment - Additional Information (Details) Details 45 false false R46.htm 40601 - Disclosure - Fair Value Measurements - Contingently Issuable Warrants with option pricing model (Details) Sheet http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails Fair Value Measurements - Contingently Issuable Warrants with option pricing model (Details) Details 46 false false R47.htm 40602 - Disclosure - Fair Value Measurements - Derivative Contingently Issuable Warrant liabilities (Details) Sheet http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsDerivativeContingentlyIssuableWarrantLiabilitiesDetails Fair Value Measurements - Derivative Contingently Issuable Warrant liabilities (Details) Details 47 false false R48.htm 40603 - Disclosure - Fair Value Measurements - Exclusive of National Financial Instruments Measured at Fair Value on Recurring Basis (Details) Sheet http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Exclusive of National Financial Instruments Measured at Fair Value on Recurring Basis (Details) Details 48 false false R49.htm 40604 - Disclosure - Fair Value Measurements - Changes in fair value (Details) Sheet http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails Fair Value Measurements - Changes in fair value (Details) Details 49 false false R50.htm 40605 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 50 false false R51.htm 40701 - Disclosure - Licenses Acquired - License as recorded in the Condensed Consolidated Statements of Operations (Details) Sheet http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredLicenseAsRecordedInCondensedConsolidatedStatementsOfOperationsDetails Licenses Acquired - License as recorded in the Condensed Consolidated Statements of Operations (Details) Details 51 false false R52.htm 40702 - Disclosure - Licenses Acquired - Mustang expenses (Details) Sheet http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails Licenses Acquired - Mustang expenses (Details) Details 52 false false R53.htm 40703 - Disclosure - Licenses Acquired - Additional Information (Detail) Sheet http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail Licenses Acquired - Additional Information (Detail) Details 53 false false R54.htm 40801 - Disclosure - Sponsored Research and Clinical Trial Agreements - Summary of Aevitas expense related to its sponsored research agreements (Details) Sheet http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails Sponsored Research and Clinical Trial Agreements - Summary of Aevitas expense related to its sponsored research agreements (Details) Details 54 false false R55.htm 40802 - Disclosure - Sponsored Research and Clinical Trial Agreements - Summary of Mustang expense related to its sponsored research agreements (Details) Sheet http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails Sponsored Research and Clinical Trial Agreements - Summary of Mustang expense related to its sponsored research agreements (Details) Details 55 false false R56.htm 40803 - Disclosure - Sponsored Research and Clinical Trial Agreements - Additional Information (Details) Sheet http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails Sponsored Research and Clinical Trial Agreements - Additional Information (Details) Details 56 false false R57.htm 40901 - Disclosure - Intangibles, net - Summary Of The JMC Intangible Asset (Details) Sheet http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails Intangibles, net - Summary Of The JMC Intangible Asset (Details) Details 57 false false R58.htm 40902 - Disclosure - Intangibles, net - Cost Of Goods Sold (Details) Sheet http://www.fortressbiotech.com/role/DisclosureIntangiblesNetCostOfGoodsSoldDetails Intangibles, net - Cost Of Goods Sold (Details) Details 58 false false R59.htm 40903 - Disclosure - Intangibles, net - Amortization Of Intangible Assets (Details) Sheet http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails Intangibles, net - Amortization Of Intangible Assets (Details) Details 59 false false R60.htm 40904 - Disclosure - Intangibles, net - Additional information (Details) Sheet http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails Intangibles, net - Additional information (Details) Details 60 false false R61.htm 41001 - Disclosure - Debt and Interest - Long-term debt (Details) Sheet http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails Debt and Interest - Long-term debt (Details) Details 61 false false R62.htm 41002 - Disclosure - Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Details) Sheet http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Details) Details 62 false false R63.htm 41003 - Disclosure - Debt and Interest- Additional Information (Details) Sheet http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails Debt and Interest- Additional Information (Details) Details 63 false false R64.htm 41101 - Disclosure - Accrued Liabilities and other Long-Term Liabilities (Details) Sheet http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails Accrued Liabilities and other Long-Term Liabilities (Details) Details http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesTables 64 false false R65.htm 41102 - Disclosure - Accrued Liabilities and other Long-Term Liabilities - Additional Information (Details) Sheet http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails Accrued Liabilities and other Long-Term Liabilities - Additional Information (Details) Details 65 false false R66.htm 41201 - Disclosure - Non-Controlling Interests (Details) Sheet http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails Non-Controlling Interests (Details) Details http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsTables 66 false false R67.htm 41301 - Disclosure - Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Details) Sheet http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareComputationsOfDilutedWeightedAverageSharesOutstandingDetails Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Details) Details 67 false false R68.htm 41401 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details) Sheet http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails Stockholders' Equity - Stock-based Compensation Expense (Details) Details 68 false false R69.htm 41402 - Disclosure - Stockholders' Equity - Stock Option Activity (Details) Sheet http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails Stockholders' Equity - Stock Option Activity (Details) Details 69 false false R70.htm 41403 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details) Sheet http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails Stockholders' Equity - Restricted Stock Activity (Details) Details 70 false false R71.htm 41404 - Disclosure - Stockholders' Equity - Warrant activities (Details) Sheet http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails Stockholders' Equity - Warrant activities (Details) Details 71 false false R72.htm 41405 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 72 false false R73.htm 41501 - Disclosure - Commitments and Contingencies - Lease expense (Details) Sheet http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails Commitments and Contingencies - Lease expense (Details) Details 73 false false R74.htm 41502 - Disclosure - Commitments and Contingencies - Future minimum lease payments (Details) Sheet http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails Commitments and Contingencies - Future minimum lease payments (Details) Details 74 false false R75.htm 41503 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 75 false false R76.htm 41601 - Disclosure - Related Party Transactions - Founders Agreements (Details) Sheet http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails Related Party Transactions - Founders Agreements (Details) Details 76 false false R77.htm 41602 - Disclosure - Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Details) Sheet http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Details) Details 77 false false R78.htm 41603 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 78 false false R79.htm 41701 - Disclosure - Segment Information (Details) Sheet http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails Segment Information (Details) Details http://www.fortressbiotech.com/role/DisclosureSegmentInformationTables 79 false false R80.htm 41801 - Disclosure - Revenues from Contracts and Significant Customers - Company's product revenue (Details) Sheet http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails Revenues from Contracts and Significant Customers - Company's product revenue (Details) Details 80 false false R81.htm 41802 - Disclosure - Revenues from Contracts and Significant Customers - Additional Information (Details) Sheet http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails Revenues from Contracts and Significant Customers - Additional Information (Details) Details 81 false false All Reports Book All Reports fbio-20200930x10q.htm fbio-20200930.xsd fbio-20200930_cal.xml fbio-20200930_def.xml fbio-20200930_lab.xml fbio-20200930_pre.xml fbio-20200930xex10d1.htm fbio-20200930xex31d1.htm fbio-20200930xex31d2.htm fbio-20200930xex32d1.htm fbio-20200930xex32d2.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 100 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "fbio-20200930x10q.htm": { "axisCustom": 2, "axisStandard": 34, "contextCount": 604, "dts": { "calculationLink": { "local": [ "fbio-20200930_cal.xml" ] }, "definitionLink": { "local": [ "fbio-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "fbio-20200930x10q.htm" ] }, "labelLink": { "local": [ "fbio-20200930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "fbio-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "fbio-20200930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 811, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 19, "http://www.fortressbiotech.com/20200930": 2, "http://xbrl.sec.gov/dei/2020-01-31": 8, "total": 29 }, "keyCustom": 185, "keyStandard": 382, "memberCustom": 120, "memberStandard": 41, "nsprefix": "fbio", "nsuri": "http://www.fortressbiotech.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Collaboration and Stock Purchase Agreements", "role": "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreements", "shortName": "Collaboration and Stock Purchase Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Property and Equipment", "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Fair Value Measurements", "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:LicensesAcquiredTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Licenses Acquired", "role": "http://www.fortressbiotech.com/role/DisclosureLicensesAcquired", "shortName": "Licenses Acquired", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:LicensesAcquiredTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Sponsored Research and Clinical Trial Agreements", "role": "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreements", "shortName": "Sponsored Research and Clinical Trial Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Intangibles, net", "role": "http://www.fortressbiotech.com/role/DisclosureIntangiblesNet", "shortName": "Intangibles, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Debt and Interest", "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterest", "shortName": "Debt and Interest", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Accrued Liabilities and other Long-Term Liabilities", "role": "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilities", "shortName": "Accrued Liabilities and other Long-Term Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Non-Controlling Interests", "role": "http://www.fortressbiotech.com/role/DisclosureNonControllingInterests", "shortName": "Non-Controlling Interests", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Net Loss per Common Share", "role": "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShare", "shortName": "Net Loss per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Stockholders' Equity", "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Commitments and Contingencies", "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Related Party Transactions", "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11701 - Disclosure - Segment Information", "role": "http://www.fortressbiotech.com/role/DisclosureSegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:RevenuesFromContractsAndSignificantCustomersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11801 - Disclosure - Revenues from Contracts and Significant Customers", "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomers", "shortName": "Revenues from Contracts and Significant Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:RevenuesFromContractsAndSignificantCustomersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11901 - Disclosure - Income taxes", "role": "http://www.fortressbiotech.com/role/DisclosureIncomeTaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:CashFlowStatementOfDisposalGroupIncludingDiscontinuedOperationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Discontinued Operations (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperationsTables", "shortName": "Discontinued Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:CashFlowStatementOfDisposalGroupIncludingDiscontinuedOperationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Property and Equipment (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Licenses Acquired (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredTables", "shortName": "Licenses Acquired (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fbio_AevitasTherapeuticsIncMember_2Yw75YIsy0iJNtU8dd6X-g", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:ScheduleOfExpenseRelatedToSponsoredResearchArrangementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Sponsored Research and Clinical Trial Agreements (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsTables", "shortName": "Sponsored Research and Clinical Trial Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fbio_AevitasTherapeuticsIncMember_2Yw75YIsy0iJNtU8dd6X-g", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:ScheduleOfExpenseRelatedToSponsoredResearchArrangementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Intangibles, net (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetTables", "shortName": "Intangibles, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:ScheduleOfInterestExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Debt and Interest (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables", "shortName": "Debt and Interest (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:ScheduleOfInterestExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Accrued Liabilities and other Long-Term Liabilities (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesTables", "shortName": "Accrued Liabilities and other Long-Term Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Non-Controlling Interests (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsTables", "shortName": "Non-Controlling Interests (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - Net Loss per Common Share (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareTables", "shortName": "Net Loss per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31603 - Disclosure - Related Party Transactions (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "fbio:ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31703 - Disclosure - Segment Information (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureSegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "fbio:RevenuesFromContractsAndSignificantCustomersTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31803 - Disclosure - Revenues from Contracts and Significant Customers (Tables)", "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersTables", "shortName": "Revenues from Contracts and Significant Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "fbio:RevenuesFromContractsAndSignificantCustomersTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:CashFlowStatementOfDisposalGroupIncludingDiscontinuedOperationTableTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2019_To_9_30_2019_00kU3pgG5kWsZwU9vcfgVw", "decimals": "-3", "first": true, "lang": null, "name": "fbio:DisposalGroupIncludingDiscontinuedOperationProceedsFromSaleOfNHLDInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Discontinued Operations- Cash flows from the transaction (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperationsCashFlowsFromTransactionDetails", "shortName": "Discontinued Operations- Cash flows from the transaction (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:CashFlowStatementOfDisposalGroupIncludingDiscontinuedOperationTableTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2019_To_9_30_2019_00kU3pgG5kWsZwU9vcfgVw", "decimals": "-3", "first": true, "lang": null, "name": "fbio:DisposalGroupIncludingDiscontinuedOperationProceedsFromSaleOfNHLDInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "fbio:DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_11_12_2018_5dTx0Pcr_0KraIHvlwoSpw", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_AzGIEuQlf02o697QLwAYxw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - Collaboration and Stock Purchase Agreements (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "shortName": "Collaboration and Stock Purchase Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "fbio:DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_11_12_2018_5dTx0Pcr_0KraIHvlwoSpw", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_AzGIEuQlf02o697QLwAYxw", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)", "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails", "shortName": "Property and Equipment - Components of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Property and Equipment - Additional Information (Details)", "role": "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails", "shortName": "Property and Equipment - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": "2", "first": true, "lang": null, "name": "fbio:FairValuesAssumptionsProbabilityOfIssuanceOfWarrant", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_AzGIEuQlf02o697QLwAYxw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Fair Value Measurements - Contingently Issuable Warrants with option pricing model (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails", "shortName": "Fair Value Measurements - Contingently Issuable Warrants with option pricing model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": "2", "first": true, "lang": null, "name": "fbio:FairValuesAssumptionsProbabilityOfIssuanceOfWarrant", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_AzGIEuQlf02o697QLwAYxw", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2019_9i3QlE0e4kmhr6lLPYTc_A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Fair Value Measurements - Derivative Contingently Issuable Warrant liabilities (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsDerivativeContingentlyIssuableWarrantLiabilitiesDetails", "shortName": "Fair Value Measurements - Derivative Contingently Issuable Warrant liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2019_9i3QlE0e4kmhr6lLPYTc_A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40603 - Disclosure - Fair Value Measurements - Exclusive of National Financial Instruments Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Exclusive of National Financial Instruments Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2019_9i3QlE0e4kmhr6lLPYTc_A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40604 - Disclosure - Fair Value Measurements - Changes in fair value (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails", "shortName": "Fair Value Measurements - Changes in fair value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2019_9i3QlE0e4kmhr6lLPYTc_A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_JCbNes5XJEuVrduFxAAp1A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity", "role": "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity", "shortName": "Condensed Consolidated Statement of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_JCbNes5XJEuVrduFxAAp1A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fbio_CaelumMember_709QE4xyrkiJxfKUVJqNtQ", "decimals": "4", "first": true, "lang": null, "name": "fbio:FairValuesAssumptionsRiskFreeReturn", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_AzGIEuQlf02o697QLwAYxw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40605 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fbio_CaelumMember_709QE4xyrkiJxfKUVJqNtQ", "decimals": "4", "first": true, "lang": null, "name": "fbio:FairValuesAssumptionsRiskFreeReturn", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_AzGIEuQlf02o697QLwAYxw", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Licenses Acquired - License as recorded in the Condensed Consolidated Statements of Operations (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredLicenseAsRecordedInCondensedConsolidatedStatementsOfOperationsDetails", "shortName": "Licenses Acquired - License as recorded in the Condensed Consolidated Statements of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fbio_AevitasMember_T5gwI6fW9k2tj55tNWtZ9Q", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Licenses Acquired - Mustang expenses (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails", "shortName": "Licenses Acquired - Mustang expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfLicensesAcquiredExpensesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fbio_MustangTherapeuticsIncMember_us-gaap_TypeOfArrangementAxis_fbio_CityOfHopecohCd123Member_AHXQePHnmU6rpsVuKLhzAQ", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40703 - Disclosure - Licenses Acquired - Additional Information (Detail)", "role": "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "shortName": "Licenses Acquired - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "fbio:PaymentOfUpfrontFees", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_fbio_SirionTechnologyLicenseMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_QeA08ocaW0eqxwqnD432Gg", "decimals": "-5", "lang": null, "name": "fbio:PaymentOfUpfrontFees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Sponsored Research and Clinical Trial Agreements - Summary of Aevitas expense related to its sponsored research agreements (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "shortName": "Sponsored Research and Clinical Trial Agreements - Summary of Aevitas expense related to its sponsored research agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfExpenseRelatedToSponsoredResearchArrangementsTableTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fbio_AevitasTherapeuticsIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fbio_ResearchAndClinicalTrialAgreementsMember_MHR1_6IMskqKjBar1B7lIA", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Sponsored Research and Clinical Trial Agreements - Summary of Mustang expense related to its sponsored research agreements (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails", "shortName": "Sponsored Research and Clinical Trial Agreements - Summary of Mustang expense related to its sponsored research agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfExpenseRelatedToSponsoredResearchArrangementsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fbio_MustangTherapeuticsIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fbio_ResearchAndClinicalTrialAgreementsMember_zN_EOq7Gk06CNIyRh8mbmA", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Sponsored Research and Clinical Trial Agreements - Additional Information (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "shortName": "Sponsored Research and Clinical Trial Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fbio_Oncogenuity.Member_0PFRNucTRkmORCAcmW5ZsA", "decimals": "-5", "lang": null, "name": "fbio:SponsoredResearchArrangementCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Intangibles, net - Summary Of The JMC Intangible Asset (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails", "shortName": "Intangibles, net - Summary Of The JMC Intangible Asset (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_us-gaap_RelatedPartyTransactionAxis_fbio_JourneyMedicalCorpMember_uf6IVeZPvUGQcI8rwXKluQ", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2019_9i3QlE0e4kmhr6lLPYTc_A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Intangibles, net - Cost Of Goods Sold (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetCostOfGoodsSoldDetails", "shortName": "Intangibles, net - Cost Of Goods Sold (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionAxis_fbio_JourneyMedicalCorporationMember_nEZr5uyew0KxsGUWHdxZyg", "decimals": "-3", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - Intangibles, net - Amortization Of Intangible Assets (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails", "shortName": "Intangibles, net - Amortization Of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_us-gaap_RelatedPartyTransactionAxis_fbio_JourneyMedicalCorporationMember_n7knc9ZCQ0qKgITjBiD8AA", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": "-3", "lang": null, "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40904 - Disclosure - Intangibles, net - Additional information (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "shortName": "Intangibles, net - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfInterestExpensesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Debt and Interest - Long-term debt (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "shortName": "Debt and Interest - Long-term debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfInterestExpensesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestIncomeExpenseNonoperatingNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails", "shortName": "Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestIncomeExpenseNonoperatingNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfInterestExpensesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Debt and Interest- Additional Information (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "shortName": "Debt and Interest- Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Accrued Liabilities and other Long-Term Liabilities (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails", "shortName": "Accrued Liabilities and other Long-Term Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "4", "first": true, "lang": null, "name": "fbio:AssetPurchaseAgreementDeterminationOfImputedInterestDiscountEffectiveInterestRateConsidered", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_AzGIEuQlf02o697QLwAYxw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Accrued Liabilities and other Long-Term Liabilities - Additional Information (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails", "shortName": "Accrued Liabilities and other Long-Term Liabilities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "4", "first": true, "lang": null, "name": "fbio:AssetPurchaseAgreementDeterminationOfImputedInterestDiscountEffectiveInterestRateConsidered", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_AzGIEuQlf02o697QLwAYxw", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "fbio:MinorityInterestEquityShare", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Non-Controlling Interests (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails", "shortName": "Non-Controlling Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "us-gaap:MinorityInterestDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2019_9i3QlE0e4kmhr6lLPYTc_A", "decimals": "-3", "lang": null, "name": "fbio:MinorityInterestEquityShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V96fxDstk0aMfIkLeP0c5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareComputationsOfDilutedWeightedAverageSharesOutstandingDetails", "shortName": "Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V96fxDstk0aMfIkLeP0c5Q", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "shortName": "Stockholders' Equity - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_srt_ConsolidatedEntitiesAxis_fbio_AvenueMember_IZRkYzWI0U2dSVA5SLzZbw", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2019_9i3QlE0e4kmhr6lLPYTc_A", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_V96fxDstk0aMfIkLeP0c5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41402 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails", "shortName": "Stockholders' Equity - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V96fxDstk0aMfIkLeP0c5Q", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Organization and Description of Business", "role": "http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_tX9VZt6k8U2HRHVxCFKP0w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V96fxDstk0aMfIkLeP0c5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41403 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails", "shortName": "Stockholders' Equity - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_tX9VZt6k8U2HRHVxCFKP0w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V96fxDstk0aMfIkLeP0c5Q", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_92POsFq0Y0KvnEUPbElgCQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_V96fxDstk0aMfIkLeP0c5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41404 - Disclosure - Stockholders' Equity - Warrant activities (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails", "shortName": "Stockholders' Equity - Warrant activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tNzRoE9iaECKBsLJfeDAPg", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V96fxDstk0aMfIkLeP0c5Q", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41405 - Disclosure - Stockholders' Equity - Additional Information (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_6_17_2019_OV4_x0i6e0Ws8FiS6S-5hg", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V96fxDstk0aMfIkLeP0c5Q", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Commitments and Contingencies - Lease expense (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails", "shortName": "Commitments and Contingencies - Lease expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41502 - Disclosure - Commitments and Contingencies - Future minimum lease payments (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails", "shortName": "Commitments and Contingencies - Future minimum lease payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "As_Of_9_30_2020_-dSRNllBJkCoDutp5_TkLQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41503 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R76": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_dei_LegalEntityAxis_fbio_HelocyteIncMember_zmiq-gmhDka6rD5tT4k0DQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Related Party Transactions - Founders Agreements (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "shortName": "Related Party Transactions - Founders Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_dei_LegalEntityAxis_fbio_HelocyteIncMember_zmiq-gmhDka6rD5tT4k0DQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_dei_LegalEntityAxis_fbio_HelocyteIncMember_zmiq-gmhDka6rD5tT4k0DQ", "decimals": "0", "first": true, "lang": null, "name": "fbio:AnnualManagementServicesAgreementFeeIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41602 - Disclosure - Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails", "shortName": "Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "fbio:ScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_dei_LegalEntityAxis_fbio_HelocyteIncMember_zmiq-gmhDka6rD5tT4k0DQ", "decimals": "0", "first": true, "lang": null, "name": "fbio:AnnualManagementServicesAgreementFeeIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41603 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_fbio_OpusCreditFacilityMember_AiihQTnqVkWMIbZH_-lQSA", "decimals": "0", "lang": null, "name": "fbio:CommonSharesIssuedForOpusDebtInShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_V96fxDstk0aMfIkLeP0c5Q", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_zFIBSSQqzkW1dPejBrU3fQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41701 - Disclosure - Segment Information (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_zFIBSSQqzkW1dPejBrU3fQ", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41801 - Disclosure - Revenues from Contracts and Significant Customers - Company's product revenue (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "shortName": "Revenues from Contracts and Significant Customers - Company's product revenue (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R81": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_77buJ-JPak2SzI2LOCZiwQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_qEi8bKRMPU645K9A-pBN-w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41802 - Disclosure - Revenues from Contracts and Significant Customers - Additional Information (Details)", "role": "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails", "shortName": "Revenues from Contracts and Significant Customers - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "fbio:RevenuesFromContractsAndSignificantCustomersTextBlock", "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_7_1_2020_To_9_30_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_6PkBEwq-pEuS-9xMpkbIgA", "decimals": null, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCustomer", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Discontinued Operations", "role": "http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperations", "shortName": "Discontinued Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fbio-20200930x10q.htm", "contextRef": "Duration_1_1_2020_To_9_30_2020_Qj1RhfeTEkOmiYtxugIKBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 184, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r490" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r491" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r492" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r492" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r492" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r493" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r492" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r492" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r492" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r492" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r488" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r489" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "fbio_AccruedCouponExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of accrued coupon expense which is classified as current.", "label": "Accrued Coupon Expense Current", "verboseLabel": "Accrued coupon expense" } } }, "localname": "AccruedCouponExpenseCurrent", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AccruedResearchAndDevelopmentExpense": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research and Development Expense", "label": "Accrued Research And Development Expense", "verboseLabel": "Research and development" } } }, "localname": "AccruedResearchAndDevelopmentExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research and Development Expense From License maintenance fees", "label": "Accrued Research And Development Expense License maintenance fees", "terseLabel": "Research and development - license maintenance fees" } } }, "localname": "AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AccruedResearchAndDevelopmentExpenseManufacturing": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research and Development Expense From manufacturing", "label": "Accrued Research And Development Expense Manufacturing", "verboseLabel": "Research and development - manufacturing" } } }, "localname": "AccruedResearchAndDevelopmentExpenseManufacturing", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AccruedResearchAndDevelopmentExpenseMilestones": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research and Development Expense From milestones", "label": "Accrued Research And Development Expense Milestones", "verboseLabel": "Research and development - milestones" } } }, "localname": "AccruedResearchAndDevelopmentExpenseMilestones", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AdditionalMilestonePaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Additional milestone payments.", "label": "Additional Milestone Payments [Member]", "terseLabel": "Additional Milestone Payments [Member]" } } }, "localname": "AdditionalMilestonePaymentsMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fbio_AdditionalUpfrontFunding": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Additional upfront funding to be made under the agreement.", "label": "Additional Upfront Funding", "verboseLabel": "Additional upfront funding" } } }, "localname": "AdditionalUpfrontFunding", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease/increase in additional paid in capital (APIC) and non controlling interest in subsidiaries.", "label": "Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance", "negatedLabel": "Non-controlling interest in subsidiaries" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalAtMarketOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Its represents the amount of marketing offering cost which adjustments to additional paid of shares capital.", "label": "Adjustments To Additional Paid In Capital At Market Offering Costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAtMarketOfferingCosts", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents Adjustments To Additional Paid In Capital Issuance Of Warrants.", "label": "Adjustments To Additional Paid In Capital Issuance Of Warrants", "terseLabel": "Issuance of partner company warrants in conjunction with Horizon Notes" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrants", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsInConjunctionWithDebtInstrument": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from issuance of warrants in conjunction with debt instrument.", "label": "Adjustments To Additional Paid In Capital, Issuance Of Warrants In Conjunction With Debt Instrument", "terseLabel": "Issuance of warrants in conjunction with Oaktree Note" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsInConjunctionWithDebtInstrument", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalPreferredStockOfferingNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from preferred stock offering, net.", "label": "Adjustments To Additional Paid In Capital, Preferred Stock Offering Net", "terseLabel": "Partner company's preferred stock offering, net" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalPreferredStockOfferingNet", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from reclassification of warrants from liability to equity.", "label": "Adjustments To Additional Paid In Capital, Reclassification Of Warrants From Liability To Equity", "terseLabel": "Reclass partner company's warrants from liability to equity" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from stock issuance for license expenses.", "label": "Adjustments To Additional Paid In Capital Stock Issued For License Expenses", "verboseLabel": "Issuance of subsidiaries' common shares for license expenses" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in additional paid in capital resulting from stock issuance for research and development expenses.", "label": "Adjustments To Additional Paid In Capital Stock Issued For research and development expenses", "verboseLabel": "Issuance of partner company's common shares for research and development expenses" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from subsidiary's at market offering costs.", "label": "Adjustments To Additional Paid In Capital Subsidiary At Market Offering", "verboseLabel": "Partner company's at-the-market offering, net" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalSubsidiaryEmployeeStockPurchasePlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in adjustments to additional paid in capital resulting from subsidiary's Employee Stock Purchase Plan.", "label": "Adjustments To Additional Paid In Capital, Subsidiary, Employee Stock Purchase Plan", "terseLabel": "Partner company's ESPP" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSubsidiaryEmployeeStockPurchasePlan", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from subsidiary's public offering.", "label": "Adjustments To Additional Paid In Capital Subsidiary Public Offering", "verboseLabel": "Partner company's offering, net" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_AdjustmentsToAdditionalPaidInCapitalWriteOffOfPartnerCompanyNoteReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of adjustments to additional paid in capital (APIC) resulting from write off of partner company note receivable.", "label": "Adjustments To Additional Paid In Capital, Write Off Of Partner Company Note Receivable", "negatedLabel": "Write off of Partner company note receivable" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWriteOffOfPartnerCompanyNoteReceivable", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_Adjustmentstoadditionalpaidincapitalpartnersaleofstocknet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from partner sale of stock, net.", "label": "AdjustmentsToAdditionalPaidInCapitalPartnerSaleOfStockNet", "terseLabel": "Partner company's sale of stock, net" } } }, "localname": "Adjustmentstoadditionalpaidincapitalpartnersaleofstocknet", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_AevitasIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Aevitas Inc [Member]", "terseLabel": "Aevitas Inc [Member]" } } }, "localname": "AevitasIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_AevitasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Aevitas [Member]", "terseLabel": "Aevitas [Member]" } } }, "localname": "AevitasMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredLicenseAsRecordedInCondensedConsolidatedStatementsOfOperationsDetails", "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "fbio_AevitasTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aevitas Therapeutics Inc", "label": "Aevitas Therapeutics Inc [Member]", "terseLabel": "Aevitas" } } }, "localname": "AevitasTherapeuticsIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsTables" ], "xbrltype": "domainItemType" }, "fbio_AgentsCommissionPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of commission agreed to be paid to the company, percentage calculated over gross proceeds from the sales of stock.", "label": "Agents Commission, Percentage" } } }, "localname": "AgentsCommissionPercentage", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fbio_AggregateLendingUpAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount rrepresents aggregate lending up agreement.", "label": "Aggregate Lending Up Agreement", "terseLabel": "Aggregate lending up agreement" } } }, "localname": "AggregateLendingUpAgreement", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AlexionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alexion Member", "label": "Alexion [Member]", "terseLabel": "Alexion [Member]" } } }, "localname": "AlexionMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_AmortizationOfOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amortization of operating lease right of use asset.", "label": "Amortization Of Operating Lease Right Of Use Asset", "verboseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "AmortizationOfOperatingLeaseRightOfUseAsset", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_AnnualConsultingFeePayableEffectiveDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Date the consulting fee to be paid.", "label": "Annual Consulting Fee Payable Effective Date" } } }, "localname": "AnnualConsultingFeePayableEffectiveDate", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails" ], "xbrltype": "dateItemType" }, "fbio_AnnualManagementServicesAgreementFeeIncomeExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of (income)expense related to annual management services agreement fee.", "label": "Annual Management Services Agreement Fee Income expense" } } }, "localname": "AnnualManagementServicesAgreementFeeIncomeExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AssetPurchaseAgreementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Asset Purchase Agreement [Abstract]", "terseLabel": "Asset Purchase Agreement" } } }, "localname": "AssetPurchaseAgreementAbstract", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "fbio_AssetPurchaseAgreementAdditionalMilestonePaymentsDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of due upon the achievement of certain net sales targets.", "label": "Asset Purchase Agreement, Additional Milestone, Payments Due" } } }, "localname": "AssetPurchaseAgreementAdditionalMilestonePaymentsDue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AssetPurchaseAgreementAmountDue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount repewsents that asset purchase agreement amount due.", "label": "Asset Purchase Agreement Amount Due", "terseLabel": "Remaining payments due" } } }, "localname": "AssetPurchaseAgreementAmountDue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AssetPurchaseAgreementAmountDueOnFirstAnniversaryOfExecution": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount represents the asset purchase agreement amount due on first anniversary of execution.", "label": "Asset Purchase Agreement Amount Due On First Anniversary Of Execution", "terseLabel": "Remaining payment due on first anniversary of execution" } } }, "localname": "AssetPurchaseAgreementAmountDueOnFirstAnniversaryOfExecution", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AssetPurchaseAgreementAmountDueOnSecondAnniversaryOfExecution": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The remaining amount of the total consideration that is to be paid on second anniversary of the execution of the Asset Purchase Agreement, to acquire the intangible asset.", "label": "Asset Purchase Agreement, Amount Due On Second Anniversary Of Execution", "terseLabel": "Remaining payment due on second anniversary of execution" } } }, "localname": "AssetPurchaseAgreementAmountDueOnSecondAnniversaryOfExecution", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AssetPurchaseAgreementAmountDueOnThirdAnniversaryOfExecution": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The remaining amount of the total consideration that is to be paid on third anniversary of the execution of the Asset Purchase Agreement, to acquire the intangible asset.", "label": "Asset Purchase Agreement, Amount Due On Third Anniversary Of Execution", "terseLabel": "Remaining payment due on third anniversary of execution" } } }, "localname": "AssetPurchaseAgreementAmountDueOnThirdAnniversaryOfExecution", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AssetPurchaseAgreementDeterminationOfImputedInterestDiscountEffectiveInterestRateConsidered": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The effective interest rate used to calculate the imputed interest discount based upon a non-investment grade \"CCC\" rate.", "label": "Asset Purchase Agreement, Determination Of Imputed Interest Discount, Effective Interest Rate Considered", "terseLabel": "Effective interest rate used to calculated imputed interest discount (in percent)" } } }, "localname": "AssetPurchaseAgreementDeterminationOfImputedInterestDiscountEffectiveInterestRateConsidered", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fbio_AssetPurchaseAgreementDeterminationOfImputedInterestDiscountPeriodOfEffectiveInterestRateConsidered": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The period over which the effective interest rate used to calculate the imputed interest discount based upon a non-investment grade \"CCC\" rate, that was considered.", "label": "Asset Purchase Agreement, Determination Of Imputed Interest Discount, Period Of Effective Interest Rate Considered", "terseLabel": "Period of effective interest rate considered for calculation of imputed interest discount (in years)" } } }, "localname": "AssetPurchaseAgreementDeterminationOfImputedInterestDiscountPeriodOfEffectiveInterestRateConsidered", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "fbio_AssetPurchaseAgreementInitialDiscountForImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of initial discount on the imputed interest recorded by the company, pursuant to the terms of the Asset Purchase Agreement.", "label": "Asset Purchase Agreement, Initial Discount For Imputed Interest", "terseLabel": "Initial discount for imputed interest" } } }, "localname": "AssetPurchaseAgreementInitialDiscountForImputedInterest", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AssetPurchaseAgreementTotalConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of total consideration to be paid to acquire intangible assets under an Asset Purchase Agreement.", "label": "Asset Purchase Agreement, Total Consideration", "terseLabel": "Total consideration" } } }, "localname": "AssetPurchaseAgreementTotalConsideration", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AssetPurchaseAgreementUpfrontPaymentToBeMade": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of upfront payment to be paid to acquire intangible assets under an Asset Purchase Agreement.", "label": "Asset Purchase Agreement, Upfront Payment To Be Made", "terseLabel": "Upfront payment" } } }, "localname": "AssetPurchaseAgreementUpfrontPaymentToBeMade", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AssetsIncludingAssetsHeldForSale": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of assets including assets held for sale.", "label": "Assets Including Assets Held For Sale", "totalLabel": "Total segment assets" } } }, "localname": "AssetsIncludingAssetsHeldForSale", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_AvenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Avenue [Member]", "terseLabel": "Avenue [Member]" } } }, "localname": "AvenueMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_AveragePricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Average Price Per Share", "terseLabel": "Average Price Per Share" } } }, "localname": "AveragePricePerShare", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "fbio_BIDMCCRISPRMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BIDMC CRISPR Member", "label": "B I D M C C R I S P R [Member]", "terseLabel": "Beth Israel Deaconess Medical Center - CRISPR" } } }, "localname": "BIDMCCRISPRMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_BaergicMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "n/a", "label": "Baergic [Member]", "terseLabel": "Baergic[Member]" } } }, "localname": "BaergicMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredLicenseAsRecordedInCondensedConsolidatedStatementsOfOperationsDetails", "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_CaelumConvertibleNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Caelum Convertible Notes [Member]", "terseLabel": "Caelum Convertible Notes [Member]" } } }, "localname": "CaelumConvertibleNotesMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "fbio_CaelumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Caelum [Member]", "terseLabel": "Caelum [Member]" } } }, "localname": "CaelumMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_CaelumWarrantLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Caelum Warrant Liabilities [Member]", "terseLabel": "Caelum Warrant Liabilities [Member]" } } }, "localname": "CaelumWarrantLiabilitiesMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "fbio_CashFlowStatementOfDisposalGroupIncludingDiscontinuedOperationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Flow Statement of Disposal Group Including Discontinued Operation Table Text Block", "label": "Cash Flow Statement of Disposal Group Including Discontinued Operation [Table Text Block]", "verboseLabel": "Schedule of cash flows statement" } } }, "localname": "CashFlowStatementOfDisposalGroupIncludingDiscontinuedOperationTableTextBlock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "fbio_CellvationIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cellvation Inc [Member]", "terseLabel": "Cellvation Inc [Member]" } } }, "localname": "CellvationIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_CellvationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cellvation [Member]", "terseLabel": "Cellvation [Member]" } } }, "localname": "CellvationMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_ChangeInFairValueOfContingentlyIssuableWarrants": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (income) related to change in fair value of contingently issuable warrants.", "label": "Change In Fair Value Of Contingently Issuable Warrants", "verboseLabel": "Change in fair value of derivative liability" } } }, "localname": "ChangeInFairValueOfContingentlyIssuableWarrants", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_ChangeInFairValueOfShortTermInvestments": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 }, "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the value of change in fair value of short term investments.", "label": "Change In Fair Value Of Short Term Investments", "negatedLabel": "Change in fair value of investment", "terseLabel": "Change in fair value of investments" } } }, "localname": "ChangeInFairValueOfShortTermInvestments", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "fbio_CheckpointMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Checkpoint [Member]", "terseLabel": "Checkpoint [Member]" } } }, "localname": "CheckpointMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_CheckpointTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Checkpoint Therapeutics Inc [Member]", "terseLabel": "Checkpoint [Member]" } } }, "localname": "CheckpointTherapeuticsIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_CityOfHopeCD123Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "City Of Hope C D123 [Member]", "terseLabel": "City of Hope - CD123 (MB-102) [Member]" } } }, "localname": "CityOfHopeCD123Member", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_CityOfHopeCohCsiCarTMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for City of Hope (COH) - CSI CAR T (MB-104).", "label": "City Of Hope Coh Csi Car T [Member]", "terseLabel": "City of Hope (COH) - CSI (MB-104) [Member]" } } }, "localname": "CityOfHopeCohCsiCarTMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "domainItemType" }, "fbio_CityOfHopeCohIl13r2CarTMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for City of Hope (COH) - IL13R2 CAR T (MB-101).", "label": "City Of Hope Coh Il13r2 Car T [Member]", "terseLabel": "City of Hope (COH) - IL13R2 (MB-101) [Member]" } } }, "localname": "CityOfHopeCohIl13r2CarTMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "domainItemType" }, "fbio_CityOfHopeCohSpacerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for City of Hope (COH) - Spacer.", "label": "City Of Hope Coh Spacer [Member]", "terseLabel": "City of Hope (COH) - Spacer [Member]" } } }, "localname": "CityOfHopeCohSpacerMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "domainItemType" }, "fbio_CityOfHopeCs1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "City Of Hope - CS1 [Member]", "label": "City Of Hope Cs1 [Member]", "terseLabel": "City of Hope - CS1 (MB-104) [Member]" } } }, "localname": "CityOfHopeCs1Member", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_CityOfHopeManufacturingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to City Of Hope Manufacturing.", "label": "City Of Hope Manufacturing [Member]", "terseLabel": "City of Hope - Manufacturing [Member]" } } }, "localname": "CityOfHopeManufacturingMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_CityOfHopeNationalMedicalCenterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This stand for City of Hope National Medical Center [Member]", "label": "City Of Hope National Medical Center [Member]", "terseLabel": "City of Hope National Medical Center [Member]" } } }, "localname": "CityOfHopeNationalMedicalCenterMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_CityOfHopecohCd123Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "City of Hope (COH) - CD123", "label": "City Of Hopecoh Cd123 [Member]", "terseLabel": "City of Hope (COH) - CD123 (MB-102) [Member]" } } }, "localname": "CityOfHopecohCd123Member", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "domainItemType" }, "fbio_CohHer2Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "COH - HER2", "label": "Coh Her2 [Member]", "terseLabel": "City of Hope (COH) - HER2 (MB-103) [Member]" } } }, "localname": "CohHer2Member", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "domainItemType" }, "fbio_CohIl13raaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "fbio:CohIl13ra2Member", "label": "Coh Il13raa [Member]", "terseLabel": "City of Hope - IL13Ra2 (MB-101) [Member]" } } }, "localname": "CohIl13raaMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_CollaborationAndStockPurchaseAgreementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Collaboration and Stock Purchase Agreements" } } }, "localname": "CollaborationAndStockPurchaseAgreementsAbstract", "nsuri": "http://www.fortressbiotech.com/20200930", "xbrltype": "stringItemType" }, "fbio_ColumbiaLicenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for Columbia License.", "label": "Columbia License [Member]", "terseLabel": "Columbia License [Member]" } } }, "localname": "ColumbiaLicenseMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fbio_CommonSharesIssuableForOpusInterestExpensesInValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Common shares issuable for Opus interest expense.", "label": "Common Shares Issuable For Opus Interest Expenses In Value", "terseLabel": "Common shares issuable for Opus interest expense" } } }, "localname": "CommonSharesIssuableForOpusInterestExpensesInValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_CommonSharesIssuableForService": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Common shares issuable for service.", "label": "Common Shares Issuable For Service", "terseLabel": "Common shares issuable for service" } } }, "localname": "CommonSharesIssuableForService", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_CommonSharesIssuableForSubordinatedNoteFinancialInterestExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of Common shares issuable for subordinated note financial interest expenses.", "label": "Common Shares Issuable For Subordinated Note Financial Interest Expenses", "verboseLabel": "Common shares issuable for 2017 Subordinated Note Financing interest expense" } } }, "localname": "CommonSharesIssuableForSubordinatedNoteFinancialInterestExpenses", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_CommonSharesIssuableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Shares Issuable [Member]", "label": "Common Shares Issuable [Member]", "terseLabel": "Shares Issuable [Member]" } } }, "localname": "CommonSharesIssuableMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "fbio_CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of non-cash financing and investing activities to common shares issued for 2017 subordinated note financing interest expense.", "label": "Common Shares Issued For 2017 Subordinated Note Financing Interest Expense", "verboseLabel": "Common shares issued from 2017 Subordinated Note Financing interest expense" } } }, "localname": "CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_CommonSharesIssuedFor2019Notes": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Common Shares Issued For 2019 Notes", "label": "Common Shares Issued For 2019 Notes", "terseLabel": "Common shares issued for 2019 Notes" } } }, "localname": "CommonSharesIssuedFor2019Notes", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_CommonSharesIssuedForOpusDebtInShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Number of common shares issued for Opus debt.", "label": "Common Shares Issued For Opus Debt, In Shares", "verboseLabel": "Common shares issued for Opus debt (in shares)" } } }, "localname": "CommonSharesIssuedForOpusDebtInShares", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "fbio_CommonSharesIssuedForOpusDebtInValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the value of common shares issued for Opus debt.", "label": "Common Shares Issued For Opus Debt, In Value", "verboseLabel": "Common shares issued for Opus debt" } } }, "localname": "CommonSharesIssuedForOpusDebtInValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_CommonSharesIssuedForOpusDebtIssuePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the issue price per share of common shares issued for Opus debt.", "label": "Common Shares Issued For Opus Debt, Issue Price" } } }, "localname": "CommonSharesIssuedForOpusDebtIssuePrice", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "fbio_CommonSharesIssuedForOpusInterestExpensesInShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of common shares issued for Opus interest expenses.", "label": "Common Shares Issued For Opus Interest Expenses In Shares", "verboseLabel": "Common shares issued for Opus interest expense (in shares)" } } }, "localname": "CommonSharesIssuedForOpusInterestExpensesInShares", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "fbio_CommonSharesIssuedForOpusInterestExpensesInValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Common shares issued for Opus interest expenses.", "label": "Common Shares Issued For Opus Interest Expenses In Value", "verboseLabel": "Common shares issued for Opus interest expense" } } }, "localname": "CommonSharesIssuedForOpusInterestExpensesInValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_CommonSharesIssuedForSubordinatedNoteFinancialInterestExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of common shares issued for subordinated note financial interest expenses.", "label": "Common Shares Issued For Subordinated Note Financial Interest Expenses", "terseLabel": "Common shares issued for 2017 Subordinated Note Financing interest expense" } } }, "localname": "CommonSharesIssuedForSubordinatedNoteFinancialInterestExpenses", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_CommonSharesIssuedForSubordinatedNoteNhldFinancialInterestExpenses": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Common shares issued for subordinated note NHLD financial interest expense.", "label": "Common Shares Issued For Subordinated Note Nhld Financial Interest Expenses", "terseLabel": "Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)" } } }, "localname": "CommonSharesIssuedForSubordinatedNoteNhldFinancialInterestExpenses", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "fbio_CommonSharesNumberOfSharesIssuedForNotesInterestExpense": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common shares, number of shares issued for Notes interest expense", "label": "Common shares, number of shares issued for Notes interest expense", "terseLabel": "Common shares issued for 2019 Notes interest expense (in shares)" } } }, "localname": "CommonSharesNumberOfSharesIssuedForNotesInterestExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "fbio_CommonSharesValueIssuableForNotesInterestExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Common shares issuable for Notes interest expense.", "label": "Common shares issuable for Notes interest expense", "terseLabel": "Common shares issuable for 2019 Notes interest expense" } } }, "localname": "CommonSharesValueIssuableForNotesInterestExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_CommonSharesValueIssuedForNotesInterestExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Common shares Value issued for Notes interest expense", "label": "Common shares issued for 2019 Notes interest expense" } } }, "localname": "CommonSharesValueIssuedForNotesInterestExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_CommonStockIssuableForNotesInterestExpense": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid in the form of common stock issuable for notes.", "label": "Common shares issuable for 2019 Notes interest expense", "terseLabel": "Common shares issuable for 2019 Notes interest expense" } } }, "localname": "CommonStockIssuableForNotesInterestExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_CommonStockIssuedForInterestExpenses": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the common stock issued for interest expenses.", "label": "Common Stock Issued For Interest Expenses", "verboseLabel": "Common shares issued for 2017 Subordinated Note Financing interest expense" } } }, "localname": "CommonStockIssuedForInterestExpenses", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_CommonStockIssuedForNotesInterestExpense": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid in the form of common stock issued for notes.", "label": "Common shares issued for Notes interest expense", "terseLabel": "Common shares issued for 2019 Notes interest expense" } } }, "localname": "CommonStockIssuedForNotesInterestExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_CommonStockRemainingNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining number of shares available for sale.", "label": "Common Stock, Remaining Number of Shares" } } }, "localname": "CommonStockRemainingNumberOfShares", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "fbio_CommonStockSharesAvailableForFutureIssuanceValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents value of shares available for future issue.", "label": "Common Stock Shares Available For Future Issuance Value" } } }, "localname": "CommonStockSharesAvailableForFutureIssuanceValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_ConsolidatedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "n/a", "label": "Consolidated [Member]", "terseLabel": "Consolidated [Member]" } } }, "localname": "ConsolidatedMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_ContingentEarnOutPaymentsMeasurementSecondModel": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents additional conditions that needs to be satisfied at any time", "label": "Contingent Earn Out Payments Measurement Second Model" } } }, "localname": "ContingentEarnOutPaymentsMeasurementSecondModel", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "fbio_CoronadoSoCoIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Coronado So Co Inc [Member]", "terseLabel": "Coronado SO [Member]" } } }, "localname": "CoronadoSoCoIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "fbio_CreditFacilityProvidedMaximumBorrowingCapacity": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Maximum amount that can be borrowed by the related party under the credit facility provided by the company.", "label": "Credit Facility Provided, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "CreditFacilityProvidedMaximumBorrowingCapacity", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_CreditFacilityProvidedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for credit facility provided by the Company and InvaGen.", "label": "Credit Facility Provided [Member]", "terseLabel": "Credit Facility Provided" } } }, "localname": "CreditFacilityProvidedMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_CreditFacilityProvidedRepaymentPeriodFollowingTerminationOfStockPurchaseAndMergerAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Repayment period following the termination of the Stock Purchase and Merger Agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Credit Facility Provided, Repayment Period Following Termination Of Stock Purchase And Merger Agreement", "terseLabel": "Repayment period following the termination of the SPMA" } } }, "localname": "CreditFacilityProvidedRepaymentPeriodFollowingTerminationOfStockPurchaseAndMergerAgreement", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "fbio_CslBehringCalimmuneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to CSL Behring (Calimmune).", "label": "Csl Behring Calimmune [Member]", "terseLabel": "CSL Behring (Calimmune) [Member]" } } }, "localname": "CslBehringCalimmuneMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "domainItemType" }, "fbio_CustomerOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer One [Member]", "terseLabel": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_CustomerTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer Two [Member]", "terseLabel": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_CypriumBioSciencesIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cyprium Bio Sciences Inc [Member]", "terseLabel": "Cyprium Bio sciences Inc [Member]" } } }, "localname": "CypriumBioSciencesIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_CypriumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cyprium [Member]", "terseLabel": "Cyprium [Member]" } } }, "localname": "CypriumMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "fbio_DakCapitalIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for DAK Capital Inc.", "label": "Dak Capital Inc [Member]", "terseLabel": "DAK Capital Inc [Member]" } } }, "localname": "DakCapitalIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_DebtInstrumentMaturityExtensionPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the extension period to the maturity term of debt.", "label": "Debt Instrument, Maturity Extension Period", "terseLabel": "Maturity extended period" } } }, "localname": "DebtInstrumentMaturityExtensionPeriod", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "fbio_DebtLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt [Line Items]" } } }, "localname": "DebtLineItems", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "stringItemType" }, "fbio_DeferredRentAndLongTermLeaseAbandonmentNonCurrent": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of deferred rent and abandonment charge recognized as of balance sheet date for long term lease.", "label": "Deferred Rent And Long Term Lease Abandonment Non Current", "terseLabel": "Deferred rent and long-term lease abandonment charge" } } }, "localname": "DeferredRentAndLongTermLeaseAbandonmentNonCurrent", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "fbio_DermatologyProductsSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dermatology Products Sales [Member]", "terseLabel": "Dermatology Products Sales [Member]" } } }, "localname": "DermatologyProductsSalesMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_DeskShareAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Desk Share Agreements [Member]", "terseLabel": "Desk Share Agreements [Member]" } } }, "localname": "DeskShareAgreementsMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_DevelopmentMilestoneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Development Milestone [Member]", "terseLabel": "Development Milestone [Member]" } } }, "localname": "DevelopmentMilestoneMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fbio_DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of collaboration and stock purchase agreement text block.", "label": "Disclosure Of Collaboration And Stock Purchase Agreement [Text Block]", "terseLabel": "Collaboration and Stock Purchase Agreements" } } }, "localname": "DisclosureOfCollaborationAndStockPurchaseAgreementTextBlock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreements" ], "xbrltype": "textBlockItemType" }, "fbio_DisposalGroupIncludingDiscontinuedOperationInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disposal Group Including Discontinued Operation Investing Activities Abstract", "label": "Disposal Group Including Discontinued Operation Investing Activities [Abstract]", "verboseLabel": "Investing activities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInvestingActivitiesAbstract", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperationsCashFlowsFromTransactionDetails" ], "xbrltype": "stringItemType" }, "fbio_DisposalGroupIncludingDiscontinuedOperationProceedsFromSaleOfNHLDInvestments": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperationsCashFlowsFromTransactionDetails": { "order": 1.0, "parentTag": "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group Including Discontinued Operation Proceeds from sale of Investments", "label": "Disposal Group Including Discontinued Operation Proceeds from sale of NHLD Investments", "verboseLabel": "Proceeds from sale of National" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationProceedsFromSaleOfNHLDInvestments", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperationsCashFlowsFromTransactionDetails" ], "xbrltype": "monetaryItemType" }, "fbio_DividendsPaidInKindPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage rate used to calculate PIK dividend on common stock.", "label": "Dividends Paid in kind percentage" } } }, "localname": "DividendsPaidInKindPercentage", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails" ], "xbrltype": "percentItemType" }, "fbio_DrRosenwaldAndMrWeissMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dr. Rosenwald and Mr. Weiss.", "label": "Dr Rosenwald And Mr Weiss [Member]", "terseLabel": "Dr Rosenwald and Mr Weiss" } } }, "localname": "DrRosenwaldAndMrWeissMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_DrRosenwaldMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dr Rosenwald [Member]", "terseLabel": "Fortress's Chairman, President and Chief Executive Officer (Lindsay A. Rosenwald) [Member]" } } }, "localname": "DrRosenwaldMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_DueToRelatedPartiesInterestExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of Interest expense due to related parties.", "label": "Due to related parties Interest expenses current", "terseLabel": "Interest payable - related party" } } }, "localname": "DueToRelatedPartiesInterestExpensesCurrent", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "fbio_DukeAavMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for Sponsored Research Arrangement (\"SRA\") with Duke University School of Medicine (\"Duke\").", "label": "Duke Aav [Member]", "terseLabel": "Duke - AAV [Member]" } } }, "localname": "DukeAavMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_EmployeeAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee awards.", "label": "Employee Awards [Member]", "terseLabel": "Employee Awards [Member]" } } }, "localname": "EmployeeAwardsMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the employee stock purchase plan offering fair value reckoning percentage.", "label": "Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage", "terseLabel": "Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period" } } }, "localname": "EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fbio_ExecutiveAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Executive Awards [Member]", "terseLabel": "Executive Awards [Member]" } } }, "localname": "ExecutiveAwardsMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_ExecutivesViceChairmanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Executives Vice Chairman [Member]", "terseLabel": "Executives Vice Chairman [Member]" } } }, "localname": "ExecutivesViceChairmanMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_ExeldermMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exelderm", "label": "Exelderm [Member]", "terseLabel": "Exelderm [Member]" } } }, "localname": "ExeldermMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "fbio_ExpectedLifeTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to expected life term.", "label": "Expected Life Term", "terseLabel": "Expected life term" } } }, "localname": "ExpectedLifeTerm", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "fbio_FairValueMeasurementsWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurements With Unobservable Inputs Reconciliation Recurring Basis Liability Issues", "verboseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementsWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsDerivativeContingentlyIssuableWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "fbio_FairValueOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of fair value of warrants.", "label": "Fair Value of Warrants", "terseLabel": "Fair value of warrants" } } }, "localname": "FairValueOfWarrants", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_FairValuesAssumptionsExpectedDiscountForLackOfMarketability": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Values Assumptions Expected Discount For Lack Of Marketability", "label": "Fair Values Assumptions Expected Discount For Lack Of Marketability" } } }, "localname": "FairValuesAssumptionsExpectedDiscountForLackOfMarketability", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fbio_FairValuesAssumptionsExpectedDividendRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).", "label": "Fair Values Assumptions Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "FairValuesAssumptionsExpectedDividendRate", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "fbio_FairValuesAssumptionsExpectedTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Fair Values Assumptions Expected Term", "terseLabel": "Expected term in years" } } }, "localname": "FairValuesAssumptionsExpectedTerm", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "durationItemType" }, "fbio_FairValuesAssumptionsExpectedVolatilityRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.", "label": "Fair Values Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "FairValuesAssumptionsExpectedVolatilityRate", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "fbio_FairValuesAssumptionsProbabilityOfIssuanceOfWarrant": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Estimated percentage to which the amount of future payments under the under the issuance of warrants.", "label": "Fair Values Assumptions Probability of Issuance of Warrant", "verboseLabel": "Probability of issuance of the warrant" } } }, "localname": "FairValuesAssumptionsProbabilityOfIssuanceOfWarrant", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "fbio_FairValuesAssumptionsRiskFreeInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Risk-free interest rate assumption used in valuing an instrument.", "label": "Fair Values Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "FairValuesAssumptionsRiskFreeInterestRate", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "fbio_FairValuesAssumptionsRiskFreeReturn": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Values Assumptions Risk Free Return", "label": "Fair Values Assumptions Risk Free Return" } } }, "localname": "FairValuesAssumptionsRiskFreeReturn", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fbio_FairValuesAssumptionsSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Values Assumptions Share Price", "label": "Fair Values Assumptions Share Price" } } }, "localname": "FairValuesAssumptionsSharePrice", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finite Lived Intangible Assets Net, Excluding assets that has not been placed in service.", "label": "Finite Lived Intangible Assets Net, Excluding assets that has not been placed in service", "totalLabel": "Sub-total" } } }, "localname": "FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "fbio_FirstAnniversaryOfExecutionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to first anniversary of execution.", "label": "First Anniversary Of Execution [Member]", "terseLabel": "First Anniversary of Execution [Member]" } } }, "localname": "FirstAnniversaryOfExecutionMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_FirstStageMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Stage Member", "label": "First Stage Member [Member]", "terseLabel": "First Stage [Member]" } } }, "localname": "FirstStageMemberMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_FortressBiotechIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fortress Biotech Inc [Member]", "terseLabel": "Fortress Biotech Inc [Member]" } } }, "localname": "FortressBiotechIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_FoundersAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Founders Agreement [Member]", "terseLabel": "Founders Agreement" } } }, "localname": "FoundersAgreementMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_FredHutchCd20CarTMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for Fred Hutch - CD20 CAR T (MB-106).", "label": "Fred Hutch Cd20 Car T [Member]", "terseLabel": "Fred Hutch - CD20 CAR T (MB-106) [Member]" } } }, "localname": "FredHutchCd20CarTMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "domainItemType" }, "fbio_FredHutchinsonCancerResearchCenterCd20Mb106Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represent the information pertaining to Fred Hutchinson Cancer Research Center CD20 MB-106.", "label": "Fred Hutchinson Cancer Research Center Cd20 Mb106 [Member]", "terseLabel": "Fred Hutchinson Cancer Research Center CD20 MB-106 [Member]" } } }, "localname": "FredHutchinsonCancerResearchCenterCd20Mb106Member", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_FundingToAcquireAdditionalEquityInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of funding to be made to acquire additional equity interest under the agreement.", "label": "Funding To Acquire Additional Equity Interest", "verboseLabel": "Funding for additional equity interest" } } }, "localname": "FundingToAcquireAdditionalEquityInterest", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "fbio_GrossProfitPercentageToNetSales": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The ratio of gross profit to net sale", "label": "Gross Profit Percentage To Net Sales" } } }, "localname": "GrossProfitPercentageToNetSales", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "percentItemType" }, "fbio_HelocyteIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Helocyte Inc [Member]", "terseLabel": "Helocyte Inc [Member]" } } }, "localname": "HelocyteIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_HelocyteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Helocyte [Member]", "terseLabel": "Helocyte [Member]" } } }, "localname": "HelocyteMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "fbio_HorizonNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to Horizon Notes.", "label": "Horizon Notes [Member]", "terseLabel": "Horizon Notes [Member]" } } }, "localname": "HorizonNotesMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "fbio_IdbNotePayableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Idb Note Payable [Member]", "terseLabel": "IDB Note [Member]" } } }, "localname": "IdbNotePayableMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "domainItemType" }, "fbio_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase decrease in lease liabilities.", "label": "Increase Decrease In Lease Liabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_InitialContingentPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of initial contingent payments under the agreement.", "label": "Initial Contingent Payments", "terseLabel": "Initial contingent payments" } } }, "localname": "InitialContingentPayments", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "fbio_IntangibleAssetAcquisitionRemainingAmountPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The remaining amount payable for acquisition of intangible asset.", "label": "Intangible Asset Acquisition, Remaining Amount Payable", "terseLabel": "Remaining payment amount" } } }, "localname": "IntangibleAssetAcquisitionRemainingAmountPayable", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_InterestExpenseAndFinanceFees": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense and amount of debt issuance costs.", "label": "Interest Expense And Finance Fees", "negatedLabel": "Interest expense and financing fee" } } }, "localname": "InterestExpenseAndFinanceFees", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "fbio_InvestmentFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investment Fair Value Disclosure", "verboseLabel": "Change in fair value of investments" } } }, "localname": "InvestmentFairValueDisclosure", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails" ], "xbrltype": "monetaryItemType" }, "fbio_IssuanceOfCommonStockForAtMarketOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued during period for cash at the market cost.", "label": "Issuance of Common Stock for At the Market Offering", "verboseLabel": "Issuance of common stock for at-the-market offering, net" } } }, "localname": "IssuanceOfCommonStockForAtMarketOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_IssuanceOfCommonStockForAtMarketOfferingInShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the stock issued during period shares issued for cash at market cost.", "label": "Issuance of Common Stock for At the Market Offering in shares", "terseLabel": "Issuance of common stock for at-the-market offering, net (in shares)" } } }, "localname": "IssuanceOfCommonStockForAtMarketOfferingInShares", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "fbio_IssuanceOfCommonStockForInterestExpense": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of issuance of common stock for PIK interest expense.", "label": "Issuance of common stock for interest expense", "terseLabel": "Common shares issuable for 2017 Subordinated Note Financing interest expense" } } }, "localname": "IssuanceOfCommonStockForInterestExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_IssuanceOfCommonStockForResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of issuance of common stock for research and development expenses.", "label": "Issuance of Common Stock for Research and Development Expenses", "terseLabel": "Issuance of partner company's common shares for research and development expenses" } } }, "localname": "IssuanceOfCommonStockForResearchAndDevelopmentExpenses", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_IssuanceOfPreferredStockForAtMarketOfferingInShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of preferred stock shares issued during the period for cash at market cost.", "label": "Issuance Of Preferred Stock For At Market Offering, In Shares", "verboseLabel": "Issuance of preferred A for at-the-market offering, net (in shares)" } } }, "localname": "IssuanceOfPreferredStockForAtMarketOfferingInShares", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "fbio_IssuanceOfPreferredStockForAtMarketOfferingInValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of preferred stock issued during period for cash at the market cost.", "label": "Issuance Of Preferred Stock For At Market Offering, In Value", "terseLabel": "Issuance of preferred A for at-the-market offering, net" } } }, "localname": "IssuanceOfPreferredStockForAtMarketOfferingInValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_IssuanceOfPreferredStockForPublicOffering": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of preferred stock shares issues during the period for public offering.", "label": "Issuance Of Preferred Stock For Public Offering" } } }, "localname": "IssuanceOfPreferredStockForPublicOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "fbio_IssueOfCommonStockForAcquiringLicenseValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "It represents the amount of common stock issuable for license acquired.", "label": "Issue Of Common Stock For Acquiring License Value", "verboseLabel": "Common shares issuable for license acquired" } } }, "localname": "IssueOfCommonStockForAcquiringLicenseValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_JmcMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Jmc [Member]", "terseLabel": "JMC [Member]" } } }, "localname": "JmcMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "fbio_JourneyMedicalCorpMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Journey Medical Corp [Member]", "terseLabel": "Journey Medical Corporation [Member]" } } }, "localname": "JourneyMedicalCorpMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails" ], "xbrltype": "domainItemType" }, "fbio_JourneyMedicalCorporationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Journey Medical Corporation [Member]", "terseLabel": "Journey Medical Corporation [Member]" } } }, "localname": "JourneyMedicalCorporationMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetCostOfGoodsSoldDetails" ], "xbrltype": "domainItemType" }, "fbio_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "verboseLabel": "Other" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "fbio_LicenseAndSupplyAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This stand for License and Supply Agreement [Member].", "label": "License And Supply Agreement [Member]", "terseLabel": "LSA" } } }, "localname": "LicenseAndSupplyAgreementMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_LicensesAcquiredAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Licenses Acquired" } } }, "localname": "LicensesAcquiredAbstract", "nsuri": "http://www.fortressbiotech.com/20200930", "xbrltype": "stringItemType" }, "fbio_LicensesAcquiredTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for research and development licenses acquired.", "label": "Licenses Acquired [Text Block]", "terseLabel": "Licenses Acquired" } } }, "localname": "LicensesAcquiredTextBlock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquired" ], "xbrltype": "textBlockItemType" }, "fbio_LongTermDebtMaturityDateExtensionTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of extension of maturity date of long-term debt, in CCYY-MM-DD format.", "label": "Long-term Debt, Maturity Date Extension Term", "terseLabel": "Maturity date extension term" } } }, "localname": "LongTermDebtMaturityDateExtensionTerm", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "durationItemType" }, "fbio_MarketOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Market Offering [Member]", "terseLabel": "Market Offering [Member]" } } }, "localname": "MarketOfferingMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_MaximumAggregateLendingUpAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount represents Maximum Aggregate Lending Up Agreement.", "label": "Maximum Aggregate Lending Up Agreement", "terseLabel": "Maximum aggregate lending up agreement" } } }, "localname": "MaximumAggregateLendingUpAgreement", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_MaximumCostAssociatedWithCoh": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount represents maximum cost associated with COH.", "label": "Maximum Cost Associated With COH", "terseLabel": "Maximum cost associated with COH" } } }, "localname": "MaximumCostAssociatedWithCoh", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_MeasurementInputInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Measurement Input Investments [Member]", "terseLabel": "Measurement Input Investments [Member]" } } }, "localname": "MeasurementInputInvestmentsMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_MichealS.WeissMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for Michael S. Weiss, Fortress's Executive Vice President, Strategic Development.", "label": "Micheal S. Weiss [Member]", "terseLabel": "Fortress's Executive Vice President, Strategic Development (Michael S. Weiss) [Member]" } } }, "localname": "MichealS.WeissMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_MinorityInterestEquityShare": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minority interest, equity share", "label": "Minority interest, equity share", "verboseLabel": "NCI equity share" } } }, "localname": "MinorityInterestEquityShare", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "fbio_Mustang2019VentureDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Mustang2019 Venture Debt [Member]", "terseLabel": "Mustang Horizon Notes [Member]" } } }, "localname": "Mustang2019VentureDebtMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "fbio_Mustang2019VentureNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Mustang2019 Venture Notes [Member]", "terseLabel": "Mustang Horizon Notes [Member]" } } }, "localname": "Mustang2019VentureNotesMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "domainItemType" }, "fbio_MustangBioIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Mustang Bio Inc [Member]", "terseLabel": "Mustang Bio, Inc [Member]" } } }, "localname": "MustangBioIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_MustangTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Mustang Therapeutics Inc [Member]", "terseLabel": "Mustang [Member]" } } }, "localname": "MustangTherapeuticsIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredLicenseAsRecordedInCondensedConsolidatedStatementsOfOperationsDetails", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsTables", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_NationwideChildrensHospitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Nationwide Childrens Hospital [Member]", "terseLabel": "Nationwide Children's Hospital - C134 (MB-108) [Member]" } } }, "localname": "NationwideChildrensHospitalMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "domainItemType" }, "fbio_NetOfDebtResultedInPerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share of net of debt utilized resulting in value of per share of an entity during the period.", "label": "Net Of Debt Resulted In Per Share", "terseLabel": "Net of debt in per share" } } }, "localname": "NetOfDebtResultedInPerShare", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "fbio_NetOfDebtUtilizedInValueOfIssued": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net of debt utilized resulting in a value of during the period.", "label": "Net Of Debt Utilized In Value Of Issued", "terseLabel": "Amount of net of debt utilized" } } }, "localname": "NetOfDebtUtilizedInValueOfIssued", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "fbio_NetSalesThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net sales threshold as defined.", "label": "Net Sales Threshold", "terseLabel": "Net sales threshold" } } }, "localname": "NetSalesThreshold", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "fbio_NonCashInterestExpense": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to non cash interest expense.", "label": "Non Cash Interest Expense", "terseLabel": "Non-cash interest" } } }, "localname": "NonCashInterestExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_NonEmployeeAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non-employee awards.", "label": "Non Employee Awards [Member]", "terseLabel": "Non-Employee Awards [Member]" } } }, "localname": "NonEmployeeAwardsMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_Notes2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for 2019 Notes (formerly the Opus Credit Facility Agreement).", "label": "Notes2019 [Member]", "terseLabel": "2019 Notes (formerly the Opus Credit Facility Agreement)" } } }, "localname": "Notes2019Member", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_NscNotesPayableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nsc Notes Payable [Member]", "terseLabel": "Note Payable [Member]" } } }, "localname": "NscNotesPayableMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "domainItemType" }, "fbio_NumberOfAdditionalMilestones": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents that number of additional milestones.", "label": "Number of Additional Milestones" } } }, "localname": "NumberOfAdditionalMilestones", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "fbio_NumberOfFinancialInstruments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of financial instruments.", "label": "Number of Financial instruments" } } }, "localname": "NumberOfFinancialInstruments", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "fbio_NumberOfMarketingMilestones": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of marketing milestones.", "label": "Number of Marketing Milestones", "terseLabel": "Marketing milestones" } } }, "localname": "NumberOfMarketingMilestones", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "fbio_OaktreeNoteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Oaktree Notes.", "label": "Oaktree Note [Member]", "terseLabel": "Oaktree Note [Member]" } } }, "localname": "OaktreeNoteMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "fbio_OaktreeWarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This stand for Oaktree Warrants [Member].", "label": "Oaktree Warrants [Member]", "terseLabel": "Oaktree Warrants [Member]" } } }, "localname": "OaktreeWarrantsMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_Oncogenuity.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "n/a", "label": "Oncogenuity. [Member]", "terseLabel": "Oncogenuity [Member]" } } }, "localname": "Oncogenuity.Member", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_OncogenuityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for Oncogenuity.", "label": "Oncogenuity [Member]", "terseLabel": "Oncogenuity [Member]" } } }, "localname": "OncogenuityMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredLicenseAsRecordedInCondensedConsolidatedStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "fbio_OpusCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Opus Credit Facility [Member]", "terseLabel": "Opus Credit Facility [Member]" } } }, "localname": "OpusCreditFacilityMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_OpusPointPartnersManagementLlcMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Opus Point Partners Management Llc [Member]", "terseLabel": "OPPM [Member]" } } }, "localname": "OpusPointPartnersManagementLlcMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_OralAcneTreatmentAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Oral Acne Treatment Agreement [Member]", "label": "Oral Acne Treatment Agreement [Member]", "terseLabel": "Oral Acne Treatment Agreement [Member]" } } }, "localname": "OralAcneTreatmentAgreementMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "fbio_OtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "fbio_OtherOperatingCostAndExpense": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other Operating Cost and Expense", "label": "Other Operating Cost and Expense", "negatedLabel": "Other expense" } } }, "localname": "OtherOperatingCostAndExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_PartnerCompanyPreviousPaidOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the partner company's amount of previous paid offering cost.", "label": "Partner Company Previous Paid Offering Cost", "verboseLabel": "Partner company's previous paid offering cost" } } }, "localname": "PartnerCompanyPreviousPaidOfferingCost", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_PaymentOfAgencyFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cash flow for payment of agency fee.", "label": "Payment of Agency Fee", "terseLabel": "Payment of agency fee" } } }, "localname": "PaymentOfAgencyFee", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_PaymentOfCostRelatedToAtthemarketOffering": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for payment of cost related to at-the-market offering.", "label": "Payment Of Cost Related To At-The-Market Offering", "negatedLabel": "Payment of cost related to issuance of common stock for at-the-market offering" } } }, "localname": "PaymentOfCostRelatedToAtthemarketOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_PaymentOfCostRelatedToIssuanceOfPreferredStockAtMarketOffering": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for payment of cost related to issuance of preferred stock at-the-market offering.", "label": "Payment Of Cost Related To Issuance Of Preferred Stock, At The Market Offering", "negatedLabel": "Payment of cost related to issuance of Series A preferred stock for at-the-market offering" } } }, "localname": "PaymentOfCostRelatedToIssuanceOfPreferredStockAtMarketOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_PaymentOfCostRelatedToSubsidiariesAtTheMarketOffering": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for payment of cost related to subsidiaries at-the-market offering.", "label": "Payment Of Cost Related To Subsidiaries At The Market Offering", "negatedLabel": "Payment of costs related to partner companies' at-the-market offering" } } }, "localname": "PaymentOfCostRelatedToSubsidiariesAtTheMarketOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_PaymentOfCostsRelatedToPartnerCompanySPreferredStockOffering": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payment of costs related to partner company's preferred stock offering.", "label": "Payment of costs related to partner company's preferred stock offering", "negatedNetLabel": "Payment of costs related to partner company's preferred stock offering" } } }, "localname": "PaymentOfCostsRelatedToPartnerCompanySPreferredStockOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_PaymentOfExpensesToThirdParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of payment of expenses to third parties.", "label": "Payment of Expenses to Third Parties", "terseLabel": "Payment of expenses to third parties" } } }, "localname": "PaymentOfExpensesToThirdParties", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_PaymentOfUpfrontFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Payment of Upfront Fees", "label": "Payment of Upfront Fees" } } }, "localname": "PaymentOfUpfrontFees", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_PaymentsForCostsRelatedToPurchaseOfTreasuryStock": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost related to purchase of treasury stock during the period.", "label": "Payments For Costs Related To Purchase Of Treasury Stock", "negatedLabel": "Payment of costs related to purchase of treasury stock", "verboseLabel": "Fees incurred for repurchase of preferred shares" } } }, "localname": "PaymentsForCostsRelatedToPurchaseOfTreasuryStock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_PaymentsForResearchAndDevelopmentExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash outflow associated research and development expenses paid during the period.", "label": "Payments For Research And Development Expenses" } } }, "localname": "PaymentsForResearchAndDevelopmentExpenses", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_PercentageOfAnnualFee": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents percentage of annual fees paid", "label": "Percentage of Annual fee" } } }, "localname": "PercentageOfAnnualFee", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails" ], "xbrltype": "percentItemType" }, "fbio_PercentageOfLackOfMarketability": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of lack of marketability for utilizing of stock grants.", "label": "Percentage Of Lack Of Marketability", "terseLabel": "Percentage of lack of marketability" } } }, "localname": "PercentageOfLackOfMarketability", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "fbio_PercentageOfMarketPriceOfEntitySCommonStock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of market price of entity's common stock.", "label": "Percentage of Market Price of Entity's Common Stock", "terseLabel": "Percentage of market price" } } }, "localname": "PercentageOfMarketPriceOfEntitySCommonStock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fbio_PercentageOfStockIssuedDuringPeriodSharesIssued": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of stock issued during the period of an entity.", "label": "Percentage Of Stock Issued During Period Shares Issued", "terseLabel": "Percentage of common shares issued (in percent)" } } }, "localname": "PercentageOfStockIssuedDuringPeriodSharesIssued", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "fbio_PercentageOfUpfrontCommitmentFee": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of upfront commitment.", "label": "Percentage of Upfront Commitment Fee", "terseLabel": "Upfront commitment fee (Percent)" } } }, "localname": "PercentageOfUpfrontCommitmentFee", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fbio_PercentageOfWeightedAverageCostOfCapital": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of weighted average cost of capital under utilizing of discounted cash flow in agreement.", "label": "Percentage of Weighted Average Cost Of Capital", "terseLabel": "Percentage of weighted average cost of capital" } } }, "localname": "PercentageOfWeightedAverageCostOfCapital", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "fbio_PharmaceuticalAndBiotechnologyProductDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Pharmaceutical And Biotechnology Product Development [Member]", "terseLabel": "Pharmaceutical and Biotechnology Product Development [Member]" } } }, "localname": "PharmaceuticalAndBiotechnologyProductDevelopmentMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_PotentialAdditionalPaymentsMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The maximum amount of potential payments.", "label": "Potential Additional Payments, Maximum" } } }, "localname": "PotentialAdditionalPaymentsMaximum", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "fbio_PreferredStockExchangeTermOptional": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Optional preferred stock exchange term.", "label": "Preferred Stock Exchange Term, Optional", "terseLabel": "Preferred stock exchange term optional" } } }, "localname": "PreferredStockExchangeTermOptional", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "fbio_PreferredStockSharesDesignated": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents number of preferred stock shares designated.", "label": "Preferred Stock Shares Designated", "verboseLabel": "Preferred Stock Shares Designated" } } }, "localname": "PreferredStockSharesDesignated", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "fbio_ProceedsFromIssuanceOfAtMarketOffering": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of at the market offering capital contribution to the entity.", "label": "Proceeds From Issuance Of At Market Offering", "terseLabel": "Proceeds from issuance of common stock for at-the-market offering" } } }, "localname": "ProceedsFromIssuanceOfAtMarketOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cash inflow from issuance of common stock to an entity associated with a employee stock purchase plan (ESPP).", "label": "Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan", "verboseLabel": "Proceeds from issuance of common stock under ESPP" } } }, "localname": "ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution net of issuance costs to the entity.", "label": "Proceeds From Issuance Of Common Stock Net of Issuance Costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_ProceedsFromIssuanceOfPreferredStockAtMarketOffering": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of preferred stock at the market offering to the entity.", "label": "Proceeds From Issuance Of Preferred Stock, At The Market Offering", "terseLabel": "Proceeds from issuance of Series A preferred stock for at-the-market offering" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAtMarketOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_ProceedsFromIssuanceOfSubsidiariesAtMarketOffering": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of subsidiaries at the market offering capital contribution to the entity.", "label": "Proceeds From Issuance Of Subsidiaries At Market Offering", "verboseLabel": "Proceeds from partner companies' at-the-market offering" } } }, "localname": "ProceedsFromIssuanceOfSubsidiariesAtMarketOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_ProceedsFromPartnerCompanySPreferredStockOffering": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from partner company's preferred stock offering.", "label": "Proceeds from partner company's preferred stock offering", "terseLabel": "Proceeds from partner company's preferred stock offering" } } }, "localname": "ProceedsFromPartnerCompanySPreferredStockOffering", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_ProceedsFromSubsidiaryPerpetualPreferredShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents amount raised from Perpetual Preferred shares offering.", "label": "Proceeds from Subsidiary Perpetual Preferred Shares", "terseLabel": "Proceeds from Cyprium Offering" } } }, "localname": "ProceedsFromSubsidiaryPerpetualPreferredShares", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_ProceedsFromSubsidiarySEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cash inflow from subsidiary's employee stock purchase plan (ESPP).", "label": "Proceeds From Subsidiary's Employee Stock Purchase Plan", "terseLabel": "Proceeds from partner companies' ESPP" } } }, "localname": "ProceedsFromSubsidiarySEmployeeStockPurchasePlan", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_ProductMilestoneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This member stands for product milestone.", "label": "Product Milestone [Member]", "terseLabel": "Product milestone" } } }, "localname": "ProductMilestoneMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fbio_ReclassificationOfWarrantsFromLiabilityToEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the reclassification of warrants from liability to equity.", "label": "Reclassification Of Warrants From Liability To Equity", "negatedLabel": "Reclass partner company's warrants from liability to equity", "terseLabel": "Reclass partner company's warrants from liability to equity" } } }, "localname": "ReclassificationOfWarrantsFromLiabilityToEquity", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsDerivativeContingentlyIssuableWarrantLiabilitiesDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_RelatedPartyOtherInvestmentPercentageInEntityByPrincipalStockholderOrDirector": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related party other investment percentage in entity by principal stockholder or director.", "label": "Related Party Other Investment Percentage In Entity By Principal Stockholder Or Director", "verboseLabel": "Interest own in percent by principal stockholder or director" } } }, "localname": "RelatedPartyOtherInvestmentPercentageInEntityByPrincipalStockholderOrDirector", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "fbio_ResearchAndClinicalTrialAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Research And Clinical Trial Agreements [Member]", "terseLabel": "Research and clinical trial agreements [Member]" } } }, "localname": "ResearchAndClinicalTrialAgreementsMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_RetirementOfPreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the retirement of preferred stock.", "label": "Retirement Of Preferred Stock", "terseLabel": "Retirement of Series A preferred stock" } } }, "localname": "RetirementOfPreferredStock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_RevenueRecognitionMilestoneMethodPaymentsDue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The fact represents payment of revenue recognition milestone method payments due.", "label": "Revenue Recognition Milestone Method Payments Due" } } }, "localname": "RevenueRecognitionMilestoneMethodPaymentsDue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_RevenuesFromContractsAndSignificantCustomersTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenues from contracts and significant customers.", "label": "Revenues From Contracts And Significant Customers [Text Block]", "verboseLabel": "Revenues from Contracts and Significant Customers" } } }, "localname": "RevenuesFromContractsAndSignificantCustomersTextBlock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomers" ], "xbrltype": "textBlockItemType" }, "fbio_SPMMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SPMA [Member]", "label": "S P M [Member]", "terseLabel": "SPMA [Member]" } } }, "localname": "SPMMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_SaleMillstoneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Sale Millstone [Member]", "terseLabel": "Sale Milestone [Member]" } } }, "localname": "SaleMillstoneMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fbio_SaleOfStockPercentageOfSharesTransferredOnTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of shares transferred on a share transaction.", "label": "Sale of Stock Percentage of Shares Transferred on Transaction" } } }, "localname": "SaleOfStockPercentageOfSharesTransferredOnTransaction", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "percentItemType" }, "fbio_SalesAfterJanuaryOneTwentyThousandTwentyNineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business after January 1, 2029.", "label": "Sales After January One Twenty Thousand Twenty Nine [Member]", "terseLabel": "Sales After January 1. 2029 [Member]" } } }, "localname": "SalesAfterJanuaryOneTwentyThousandTwentyNineMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_ScheduleAccruedExpensesAndOtherLongtermLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]" } } }, "localname": "ScheduleAccruedExpensesAndOtherLongtermLiabilitiesLineItems", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "fbio_ScheduleAccruedExpensesAndOtherLongtermLiabilitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Schedule Accrued Expenses And Other Long-Term Liabilities [Table]" } } }, "localname": "ScheduleAccruedExpensesAndOtherLongtermLiabilitiesTable", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "fbio_ScheduleOfDebtTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Schedule of Debt [Table]" } } }, "localname": "ScheduleOfDebtTable", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "stringItemType" }, "fbio_ScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of effective date and annual management services agreement fee income expense.", "label": "Schedule Of Effective Date And Annual Management Services Agreement Fee Income Expense [Table Text Block]", "verboseLabel": "Schedule of effective date and annual consulting fee payable by the subsidiary to the Company" } } }, "localname": "ScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseTableTextBlock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "fbio_ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of effective date and equity fee payable.", "label": "Schedule Of Effective Date And Equity Fee Payable [Table Text Block]", "verboseLabel": "Schedule of effective date and PIK dividend or equity fee payable" } } }, "localname": "ScheduleOfEffectiveDateAndEquityFeePayableTableTextBlock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "fbio_ScheduleOfExpenseRelatedToSponsoredResearchArrangementsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The amount of expense related to its sponsored research arrangements during the year.", "label": "Schedule Of Expense Related To Sponsored Research Arrangements [Table Text Block]", "terseLabel": "Schedule of research and development for sponsored research and clinical trial agreements" } } }, "localname": "ScheduleOfExpenseRelatedToSponsoredResearchArrangementsTableTextBlock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsTables" ], "xbrltype": "textBlockItemType" }, "fbio_ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest expenses for debt arrangements.", "label": "Schedule Of Interest Expenses For Debt Arrangements [Table Text Block]", "verboseLabel": "Schedule of interest expense for all debt arrangements" } } }, "localname": "ScheduleOfInterestExpensesForDebtArrangementsTableTextBlock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables" ], "xbrltype": "textBlockItemType" }, "fbio_ScheduleOfInterestExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the interest expenses disclosures.", "label": "Schedule Of Interest Expenses [Table Text Block]", "verboseLabel": "Schedule of debt" } } }, "localname": "ScheduleOfInterestExpensesTableTextBlock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestTables" ], "xbrltype": "textBlockItemType" }, "fbio_ScheduleOfLicensesAcquiredExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Licenses Acquired Expenses Table Text Block", "label": "Schedule Of Licenses Acquired Expenses [Table Text Block]", "verboseLabel": "Schedule of research and development for licenses acquired" } } }, "localname": "ScheduleOfLicensesAcquiredExpensesTableTextBlock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredTables" ], "xbrltype": "textBlockItemType" }, "fbio_SecondAnniversaryOfExecutionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to second anniversary of execution.", "label": "Second Anniversary Of Execution [Member]", "terseLabel": "Second Anniversary of Execution [Member]" } } }, "localname": "SecondAnniversaryOfExecutionMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_SeriesCumulativeRedeemablePerpetualPreferredStock9.375Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to 2016 market offering Series A Cumulative Redeemable Perpetual Preferred Stock.", "label": "Series Cumulative Redeemable Perpetual Preferred Stock9.375 [Member]", "terseLabel": "2018 Preferred ATM" } } }, "localname": "SeriesCumulativeRedeemablePerpetualPreferredStock9.375Member", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Series A cumulative redeemable perpetual preferred stock.", "label": "Series Cumulative Redeemable Perpetual Preferred Stock [Member]", "terseLabel": "9.375% Series A Cumulative Redeemable Perpetual Preferred Stock" } } }, "localname": "SeriesCumulativeRedeemablePerpetualPreferredStockMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "fbio_SettlementOfRestrictedSharesUnitsIntoCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The fair value of common stock issued for settlement of restricted stock unit.", "label": "Settlement Of Restricted Shares Units Into Common Stock", "verboseLabel": "Settlement of restricted stock units into common stock" } } }, "localname": "SettlementOfRestrictedSharesUnitsIntoCommonStock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of non options vested during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Vested In Period Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant price, Restricted stock units vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of weighted-average intrinsic value of award forfeited under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Intrinsic Value", "terseLabel": "Total weighted average intrinsic value, Options Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageIntrinsicValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award options exercised intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Intrinsic Value", "verboseLabel": "Total weighted average intrinsic value, Options Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedIntrinsicValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average exercise price of shares other than option outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Other than Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, Outstanding", "periodStartLabel": "Weighted average exercise price, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "perShareItemType" }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentOtherThanOptionsExercisableIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Weighted average intrinsic value of shares other than option outstanding exercisable.", "label": "Share based Compensation Arrangement By Share based Payment Other than Options Exercisable Intrinsic Value", "terseLabel": "Total intrinsic value, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentOtherThanOptionsExercisableIntrinsicValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentOtherThanOptionsExercisableNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested other than options outstanding as of the balance sheet date .", "label": "Share Based Compensation Arrangement By Share Based Payment Other than Options Exercisable Number", "terseLabel": "Number of shares, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentOtherThanOptionsExercisableNumber", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "sharesItemType" }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentOtherThanOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average exercise price of shares other than option outstanding exercisable.", "label": "Share Based Compensation Arrangement By Share Based Payment Other than Options Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentOtherThanOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "perShareItemType" }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual life of shares other than option outstanding exercisable.", "label": "Share based Compensation Arrangement By Share based Payment Other than Options Exercisable Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted average remaining contractual life, Exercisable (years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "durationItemType" }, "fbio_ShareBasedCompensationArrangementByShareBasedPaymentOtherThanOptionsGrantedAverageIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Weighted average intrinsic value of shares granted other than option during the period.", "label": "Share based Compensation Arrangement By Share based Payment Other than Options Granted average Intrinsic Value", "verboseLabel": "Total intrinsic value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentOtherThanOptionsGrantedAverageIntrinsicValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "fbio_ShareBasedCompensationArrangementBySharebasedPaymentOtherThanOptionsForfeitedAverageIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Weighted average intrinsic value of shares Forfeited other than option during the period.", "label": "Share Based Compensation Arrangement By ShareBased Payment Other Than Options Forfeited Average Intrinsic Value", "terseLabel": "Total intrinsic value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementBySharebasedPaymentOtherThanOptionsForfeitedAverageIntrinsicValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "fbio_ShareBasedCompensationArrangementsByShareBasedPaymentOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average exercise price of shares granted other than option during the period.", "label": "Share Based Compensation Arrangements By Share Based Payment Other than Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "perShareItemType" }, "fbio_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsForfeited": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net number of non-option equity instruments vested to participants.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Nonoption Equity Instruments Forfeited", "negatedLabel": "Number of shares Restricted stock units forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsForfeited", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "fbio_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of non option equity-based award plans that were not cancelled during the period.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Nonoption Equity Instruments Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant price, Restricted stock units forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "fbio_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsUnitsGranted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net number of non-option equity instruments vested to participants.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Nonoption Equity Instruments Units Granted", "terseLabel": "Number of shares Restricted stock units granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsUnitsGranted", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "fbio_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsUnitsGrantedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of non option equity-based award plans that were not cancelled during the period.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Nonoption Equity Instruments Units Granted Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant price, Restricted stock units granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsUnitsGrantedWeightedAverageGrantDateFairValue", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "fbio_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsVested": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net number of non-option equity instruments vested to participants.", "label": "Share-Based Compensation Arrangement By Share-based Payment Award Non-Option Equity Instruments Vested", "negatedLabel": "Number of shares Restricted stock units vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsVested", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "fbio_SharedServicesAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Shared Services Agreement [Member]", "terseLabel": "Shared Services Agreement [Member]" } } }, "localname": "SharedServicesAgreementMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_ShelfTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The member stands for shelf two thousand twenty.", "label": "Shelf Two Thousand Twenty [Member]", "terseLabel": "2020 Shelf" } } }, "localname": "ShelfTwoThousandTwentyMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_SignificantAccountingPoliciesPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for significant accounting policies.", "label": "Significant Accounting Policies [Policy Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesPolicyTextBlock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "fbio_SirionLentiboostMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to SIRION LentiBOOST.", "label": "Sirion Lentiboost [Member]", "terseLabel": "SIRION LentiBOOST [Member]" } } }, "localname": "SirionLentiboostMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "domainItemType" }, "fbio_SirionTechnologyLicenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to SIRION Technology License.", "label": "Sirion Technology License [Member]", "terseLabel": "SIRION Technology License [Member]" } } }, "localname": "SirionTechnologyLicenseMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "fbio_SlabAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Slab [Axis]" } } }, "localname": "SlabAxis", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "stringItemType" }, "fbio_SlabDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Slab [Domain]", "terseLabel": "Slab [Domain]" } } }, "localname": "SlabDomain", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_SlabOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Slab One [Member]", "terseLabel": "Slab One [Member]" } } }, "localname": "SlabOneMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_SlabThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Slab Three [Member]", "terseLabel": "Slab Three [Member]" } } }, "localname": "SlabThreeMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_SlabTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Slab Two [Member]", "terseLabel": "Slab Two [Member]" } } }, "localname": "SlabTwoMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_SponsorResearchAgreementFundingCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of funding commitment for a sponsor research agreement.", "label": "Sponsor Research Agreement Funding Commitment" } } }, "localname": "SponsorResearchAgreementFundingCommitment", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_SponsorResearchAgreementFundingCommitmentPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period over which the funding is committed to be made under the Sponsor Research Agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sponsor Research Agreement Funding Commitment Period", "terseLabel": "Funding commitment period" } } }, "localname": "SponsorResearchAgreementFundingCommitmentPeriod", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "fbio_SponsoredResearchArrangementCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the cost of the sponsored research arrangement.", "label": "Sponsored Research Arrangement , Cost", "terseLabel": "Cost of the SRA" } } }, "localname": "SponsoredResearchArrangementCost", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_St.JudeChildrenSResearchHospitalXscidMb107Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represent the information pertaining to St. Jude Children's Research Hospital XSCID MB-107.", "label": "St. Jude Children S Research Hospital Xscid Mb107 [Member]", "terseLabel": "St. Jude Children's Research Hospital XSCID MB-107 [Member]" } } }, "localname": "St.JudeChildrenSResearchHospitalXscidMb107Member", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_St.JudeXscidMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "St. Jude - XSCID [Member]", "label": "St. Jude Xscid [Member]", "terseLabel": "St. Jude - XSCID (MB-107) [Member]" } } }, "localname": "St.JudeXscidMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_StageWiseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stage Wise Axis", "label": "Stage Wise [Axis]" } } }, "localname": "StageWiseAxis", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "stringItemType" }, "fbio_StageWiseDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stage Wise.", "label": "Stage Wise [Domain]", "terseLabel": "Stage Wise [Domain]" } } }, "localname": "StageWiseDomain", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_StockIncentivePlanTwoThousandThirteenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tha member stands for stock incentive plan two thousand thirteen.", "label": "Stock Incentive Plan Two Thousand Thirteen [Member]", "terseLabel": "Stock Incentive Plan 2013 [Member]" } } }, "localname": "StockIncentivePlanTwoThousandThirteenMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_StockIssuedDuringPeriodSharePreferredStock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of preferred stock issued for cash during the period.", "label": "Stock Issued During Period, Share, Preferred Stock", "terseLabel": "Issuance of Series A preferred stock for cash, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharePreferredStock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "fbio_StockIssuedDuringPeriodValueCashLessExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued during the period relating to cashless exercise of warrants.", "label": "Stock Issued During Period Value Cash Less Exercise Of Warrants", "verboseLabel": "Partner company's exercise of warrants for cash" } } }, "localname": "StockIssuedDuringPeriodValueCashLessExerciseOfWarrants", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_StockIssuedDuringPeriodValuePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of preferred stock issued for cash during the period.", "label": "Stock Issued During Period, Value, Preferred Stock", "negatedLabel": "Issuance of Series A preferred stock for cash, net" } } }, "localname": "StockIssuedDuringPeriodValuePreferredStock", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_StockIssuedDuringPeriodWeightedAveragePricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weight average price per share or per unit amount of equity securities issued.", "label": "Stock Issued During Period, Weighted Average Price Per Share", "verboseLabel": "Weighted average price per share" } } }, "localname": "StockIssuedDuringPeriodWeightedAveragePricePerShare", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "fbio_SubordinatedNoteFinancing2017OneToFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining from one to five 2017 subordinated note financing.", "label": "Subordinated Note Financing2017 One To Five [Member]", "terseLabel": "Subordinated Note Financing 2017 One to Five" } } }, "localname": "SubordinatedNoteFinancing2017OneToFiveMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "fbio_SubordinatedNoteFinancingFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subordinated Note Financing Five [Member]", "terseLabel": "2017 Subordinated Note Financing Five [Member]" } } }, "localname": "SubordinatedNoteFinancingFiveMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "fbio_SubordinatedNoteFinancingFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subordinated Note Financing Four [Member]", "terseLabel": "2017 Subordinated Note Financing Four [Member]" } } }, "localname": "SubordinatedNoteFinancingFourMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "fbio_SubordinatedNoteFinancingOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subordinated Note Financing One [Member]", "terseLabel": "2017 Subordinated Note Financing One [Member]" } } }, "localname": "SubordinatedNoteFinancingOneMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "fbio_SubordinatedNoteFinancingThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subordinated Note Financing Three [Member]", "terseLabel": "2017 Subordinated Note Financing Three [Member]" } } }, "localname": "SubordinatedNoteFinancingThreeMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "fbio_SubordinatedNoteFinancingTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subordinated Note Financing Two [Member]", "terseLabel": "2017 Subordinated Note Financing Two [Member]" } } }, "localname": "SubordinatedNoteFinancingTwoMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "fbio_TamidMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Tamid [Member]", "terseLabel": "Tamid [Member]" } } }, "localname": "TamidMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "fbio_TangibleAssetsNet": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails": { "order": 2.0, "parentTag": "fbio_AssetsIncludingAssetsHeldForSale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tangible assets.", "label": "Tangible Assets Net", "terseLabel": "Tangible assets" } } }, "localname": "TangibleAssetsNet", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_TermOfAnniversary": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents that term of anniversary.", "label": "Term of Anniversary", "terseLabel": "Term of anniversary" } } }, "localname": "TermOfAnniversary", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "fbio_TgTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Tg Therapeutics Inc [Member]", "terseLabel": "TG Therapeutics, Inc [Member]" } } }, "localname": "TgTherapeuticsIncMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_ThirdAnniversaryOfExecutionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to third anniversary of execution.", "label": "Third Anniversary Of Execution [Member]", "terseLabel": "Third Anniversary of Execution [Member]" } } }, "localname": "ThirdAnniversaryOfExecutionMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_ThreePlTitleModelMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to 3PL Title Model, major customer.", "label": "Three Pl Title Model [Member]", "terseLabel": "3PL Title Model [Member]" } } }, "localname": "ThreePlTitleModelMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "fbio_TreasuryStockRetiredCostMethodAmount1": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.", "label": "Treasury Stock, Retired, Cost Method, Amount 1", "terseLabel": "Retirement of Series A preferred stock" } } }, "localname": "TreasuryStockRetiredCostMethodAmount1", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_TwoThousandEighteenVentureNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Two Thousand Eighteen Venture Notes [Member]", "terseLabel": "2018 Venture Notes [Member]" } } }, "localname": "TwoThousandEighteenVentureNotesMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "domainItemType" }, "fbio_TwoThousandNineteenNoteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "n/a", "label": "Two Thousand Nineteen Note [Member]", "terseLabel": "2019 Notes [Member]" } } }, "localname": "TwoThousandNineteenNoteMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "domainItemType" }, "fbio_UclaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to UCLA.", "label": "Ucla [Member]", "terseLabel": "UCLA [Member]" } } }, "localname": "UclaMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "domainItemType" }, "fbio_UmassAavMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Umass Aav [Member]", "terseLabel": "UMass - AAV [Member]" } } }, "localname": "UmassAavMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_UnpaidAtMarketOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of unpaid partner company's at-the-market offering cost that were incurred during a noncash or partial noncash transaction.", "label": "Unpaid At-The-Market Offering Cost", "terseLabel": "Unpaid at-the-market offering cost" } } }, "localname": "UnpaidAtMarketOfferingCost", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_UnpaidDebtOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of debt Unpaid debt offering cost that were incurred during a noncash or partial noncash transaction.", "label": "Unpaid Debt Offering Cost", "terseLabel": "Unpaid debt offering cost" } } }, "localname": "UnpaidDebtOfferingCost", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_UnpaidPartnerCompanyIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the partner company's amount of unpaid intangible assets.", "label": "Unpaid Partner Company Intangible Assets", "terseLabel": "Partner company's unpaid intangible assets" } } }, "localname": "UnpaidPartnerCompanyIntangibleAssets", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_UnpaidPartnerCompanyOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of unpaid partner company's offering cost that were incurred during a noncash or partial noncash transaction.", "label": "Unpaid Partner Company Offering Cost", "terseLabel": "Unpaid partner company's offering cost" } } }, "localname": "UnpaidPartnerCompanyOfferingCost", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_UnpaidPreferredOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The element indicated Unpaid Preferred A offering cost.", "label": "Unpaid Preferred A Offering Cost", "terseLabel": "Unpaid Series A preferred stock offering cost" } } }, "localname": "UnpaidPreferredOfferingCost", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_UnpaidResearchAndDevelopmentLicenseAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "It represents the amount of unpaid research adn development licenses acquired.", "label": "Unpaid Research And Development License Acquired", "terseLabel": "Unpaid research and development licenses acquired" } } }, "localname": "UnpaidResearchAndDevelopmentLicenseAcquired", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fbio_UnvestedRestrictedStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Unvested Restricted Stock [Member]", "terseLabel": "Unvested Restricted Stock [Member]" } } }, "localname": "UnvestedRestrictedStockMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareComputationsOfDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "fbio_UnvestedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Unvested Restricted Stock Units [Member]", "terseLabel": "Unvested Restricted Stock Units [Member]" } } }, "localname": "UnvestedRestrictedStockUnitsMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareComputationsOfDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "fbio_UpennAavMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Upenn Aav [Member]", "terseLabel": "UPenn - AAV [Member]" } } }, "localname": "UpennAavMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "fbio_UpfrontCommitmentFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of upfront commitment fee.", "label": "Upfront Commitment Fee", "terseLabel": "Upfront commitment fee" } } }, "localname": "UpfrontCommitmentFee", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fbio_VariableLeaseIncomeExpense": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease income (expense), excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease Income (Expense)", "negatedLabel": "Variable lease cost" } } }, "localname": "VariableLeaseIncomeExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "fbio_VentureNoteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Venture Notes", "label": "Venture Note [Member]", "terseLabel": "2018 Venture Notes One [Member]" } } }, "localname": "VentureNoteMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "fbio_VentureNotesThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Venture Notes Three", "label": "Venture Notes Three [Member]", "terseLabel": "2019 Notes [Member]" } } }, "localname": "VentureNotesThreeMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "fbio_VentureNotesTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Venture Notes Two", "label": "Venture Notes Two [Member]", "terseLabel": "2018 Venture Notes Two [Member]" } } }, "localname": "VentureNotesTwoMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "fbio_WriteOffCommonSharesIssuableForNotesInterestExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Write off common shares issuable for Notes interest expense", "label": "Write off common shares issuable for Notes interest expense", "negatedLabel": "Write off common shares issuable for 2019 Notes interest expense" } } }, "localname": "WriteOffCommonSharesIssuableForNotesInterestExpense", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "fbio_XiminoAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to ximino agreement.", "label": "Ximino Agreement [Member]", "terseLabel": "Ximino agreement [Member]" } } }, "localname": "XiminoAgreementMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "fbio_XiminoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ximino member.", "label": "Ximino [Member]", "terseLabel": "Ximino [Member]" } } }, "localname": "XiminoMember", "nsuri": "http://www.fortressbiotech.com/20200930", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r330", "r331", "r339", "r340", "r484" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r330", "r331", "r339", "r340" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r188", "r255", "r257", "r469" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r269", "r272", "r403", "r404", "r405", "r406", "r407", "r408", "r427", "r467", "r470" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r269", "r272", "r403", "r404", "r405", "r406", "r407", "r408", "r427", "r467", "r470" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r188", "r255", "r257", "r469" ], "lang": { "en-US": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r185", "r255", "r256", "r428", "r466", "r468" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r185", "r255", "r256", "r428", "r466", "r468" ], "lang": { "en-US": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r258", "r269", "r272", "r403", "r404", "r405", "r406", "r407", "r408", "r427", "r467", "r470" ], "lang": { "en-US": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r258", "r269", "r272", "r403", "r404", "r405", "r406", "r407", "r408", "r427", "r467", "r470" ], "lang": { "en-US": { "role": { "label": "Range [Member]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails", "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "label": "Scenario Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r239", "r270", "r396" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r190", "r392" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "verboseLabel": "Accrued Liabilities and other Long-Term Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r43", "r111", "r391", "r393" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Accounts payable and accrued expenses - related party" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r28", "r456" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, Net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r28", "r191", "r192" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $147 and $100 at September 30, 2020 and December 31, 2019, respectively)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued expenses:" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r14", "r15", "r48" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r14", "r15", "r48" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties payable" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r14", "r15", "r48" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "verboseLabel": "Salaries, bonus and related benefits" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r40", "r228" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncomeMember": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Cumulative distributions to shareholders (or partners) in excess of retained earnings (or accumulated earnings).", "label": "Accumulated Distributions In Excess Of Net Income [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "AccumulatedDistributionsInExcessOfNetIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "verboseLabel": "Acquired intangible assets, amortization period" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r29", "r299" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r113", "r114", "r115", "r296", "r297", "r298" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Employee Stock Purchase Program, Requisite Service Period Recognition", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Reconciliation of net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r274", "r293", "r300" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r34", "r193", "r199" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for Doubtful Accounts Receivable, Current", "verboseLabel": "Allowance for Doubtful Accounts Receivable, Current" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r80", "r98", "r370" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "definitionGuidance": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of interest discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r70", "r98", "r372" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails": { "order": 1.0, "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of fees" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r98", "r212", "r221" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetCostOfGoodsSoldDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total of weighted average shares outstanding" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareComputationsOfDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareComputationsOfDilutedWeightedAverageSharesOutstandingDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareComputationsOfDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareComputationsOfDilutedWeightedAverageSharesOutstandingDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r107", "r167", "r174", "r181", "r197", "r330", "r339", "r362", "r443", "r457" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r11", "r60", "r107", "r197", "r330", "r339", "r362" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r352" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "verboseLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "verboseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r276", "r295" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r268", "r271" ], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r268", "r271", "r316", "r317" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r320", "r321", "r323" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r319", "r322", "r324" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r102", "r103", "r104" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Unpaid fixed assets" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalUnitsAuthorized": { "auth_ref": [ "r478" ], "lang": { "en-US": { "role": { "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Capital Units, Authorized" } } }, "localname": "CapitalUnitsAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r37", "r100" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r93", "r100", "r105" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r363" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashDivestedFromDeconsolidation": { "auth_ref": [ "r84" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.", "label": "Cash Divested from Deconsolidation", "negatedLabel": "Deconsolidation of Caelum" } } }, "localname": "CashDivestedFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r1", "r93" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperationsCashFlowsFromTransactionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "totalLabel": "Total cash provided by discontinued investing activities", "verboseLabel": "Net cash provided by discontinued investing activities" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperationsCashFlowsFromTransactionDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r106", "r107", "r126", "r127", "r128", "r130", "r132", "r138", "r139", "r140", "r197", "r362" ], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r252", "r273" ], "lang": { "en-US": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class Of Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Purchase price", "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Number of shares, Outstanding", "periodStartLabel": "Number of shares, Outstanding", "terseLabel": "Outstanding warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r238", "r449", "r463" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r235", "r236", "r237", "r240" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r113", "r114" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r246" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscribedButUnissued": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock, Shares Subscribed but Unissued", "terseLabel": "Common Stock, Shares Subscribed but Unissued" } } }, "localname": "CommonStockSharesSubscribedButUnissued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscriptions": { "auth_ref": [ "r26", "r245" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock, Value, Subscriptions", "verboseLabel": "Common stock issuable, 5,451 and 251,337 shares as of September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockSharesSubscriptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $.001 par value, 150,000,000 shares authorized, 93,748,374 and 74,027,425 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r148", "r149", "r188", "r360", "r361" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r148", "r149", "r188", "r360", "r361", "r476" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r148", "r149", "r188", "r360", "r361", "r476" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCustomer": { "auth_ref": [ "r145", "r146", "r149" ], "lang": { "en-US": { "role": { "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures).", "label": "Concentration Risk, Customer" } } }, "localname": "ConcentrationRiskCustomer", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r148", "r149", "r188", "r360", "r361" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r148", "r149", "r188", "r360", "r361" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": { "auth_ref": [ "r336", "r344" ], "lang": { "en-US": { "role": { "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]", "verboseLabel": "Schedule of non-controlling interests in consolidated entities" } } }, "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "auth_ref": [ "r65", "r66" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "negatedLabel": "Direct cost of goods" } } }, "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r75", "r428" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold - product revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "auth_ref": [ "r71" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.", "label": "Cost, Amortization", "verboseLabel": "Amortization of product revenue license fee" } } }, "localname": "CostOfGoodsAndServicesSoldAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r72" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r146", "r188" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r102", "r104" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "verboseLabel": "Issuance of warrants in conjunction with Oaktree debt" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt and Interest" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt and Interest" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterest" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r22", "r23", "r444", "r445", "r455" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r371", "r373" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Debt Instrument, Interest Rate, Increase (Decrease)", "terseLabel": "Increase (decrease) in interest rate" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r50" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest Rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument, Maturity Date, Description", "verboseLabel": "Maturity Date" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r370", "r373" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_NotesPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Less: Discount of notes payable", "verboseLabel": "Unamortized debt discount fees" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r370", "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Noncurrent", "terseLabel": "Debt Instrument, Unamortized Discount, Noncurrent" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeconsolidationGainOrLossAmount": { "auth_ref": [ "r338" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.", "label": "Deconsolidation, Gain (Loss), Amount", "negatedLabel": "Gain on deconsolidation of Caelum" } } }, "localname": "DeconsolidationGainOrLossAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r41", "r372" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Deferred Fees" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r98", "r226" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract Type [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r346", "r347", "r349", "r351" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r61" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "verboseLabel": "Derivative warrant liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of total revenues" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r3", "r232" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued Operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r249", "r454" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "terseLabel": "Partner company's dividends declared and paid" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "Date the dividend to be paid was declared, in CCYY-MM-DD format.", "label": "Dividends Payable, Date Declared" } } }, "localname": "DividendsPayableDateDeclaredDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r249", "r454" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "negatedLabel": "Preferred A dividends declared and paid" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStockCash": { "auth_ref": [ "r249", "r454" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.", "label": "Dividends, Preferred Stock, Cash", "terseLabel": "Initial dividend paid" } } }, "localname": "DividendsPreferredStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromOtherRelatedPartiesCurrent": { "auth_ref": [ "r57", "r111", "r390" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount receivable from related parties classified as other, due within one year or the normal operating cycle, if longer.", "label": "Due from Other Related Parties, Current", "terseLabel": "Other receivables - related party" } } }, "localname": "DueFromOtherRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r111", "r390", "r448", "r464" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Amounts drawn" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r7", "r17", "r27", "r108", "r390" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from Related Parties, Current" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r43", "r111", "r390" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "verboseLabel": "Accrued expense - related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Loss per Common Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r131" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per common share attributable to common stockholders - basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r133", "r134", "r135", "r136" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Loss per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r294" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Options to Purchase Common Stock [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareComputationsOfDilutedWeightedAverageSharesOutstandingDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r113", "r114", "r115", "r117", "r122", "r124", "r137", "r198", "r246", "r249", "r296", "r297", "r298", "r308", "r309", "r364", "r365", "r366", "r367", "r368", "r369", "r471", "r472", "r473" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r98", "r244" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of derivative liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r352", "r353", "r354", "r359" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of weighted average (in aggregate) significant unobservable inputs" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r353", "r400", "r401", "r402" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r358" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r259", "r260", "r265", "r267", "r353", "r400" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r259", "r260", "r265", "r267", "r353", "r401" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r353", "r402" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r357", "r359" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of fair value of derivative warrant liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r357" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r357" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsDerivativeContingentlyIssuableWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r400", "r401", "r402" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r195", "r196", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r220" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails": { "order": 6.0, "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r222" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails": { "order": 1.0, "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "Year Ended December 31, 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails": { "order": 2.0, "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "Three Months Ended December 31, 2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r222" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails": { "order": 3.0, "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Year Ended December 31, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r222" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails": { "order": 4.0, "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Year Ended December 31, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r222" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails": { "order": 5.0, "parentTag": "fbio_FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Year Ended December 31, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r213", "r218", "r220", "r224", "r429", "r430" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r220", "r430" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Total Intangible assets - asset purchases" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r213", "r219" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite Lived Intangible Assets [Member]", "terseLabel": "Intangible assets - purchases" } } }, "localname": "FiniteLivedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r220", "r429" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails": { "order": 1.0, "parentTag": "fbio_AssetsIncludingAssetsHeldForSale", "weight": 1.0 }, "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Ending balance at September 30, 2020", "periodStartLabel": "Beginning balance at January 1, 2020", "terseLabel": "Intangible asset, net", "totalLabel": "Net intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetCostOfGoodsSoldDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r214" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Asset not yet placed in service", "verboseLabel": "Acne product license acquisition" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetCostOfGoodsSoldDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r98" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "verboseLabel": "Gain on deconsolidation of Caelum" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r68" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Intangibles, net" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r110", "r167", "r173", "r177", "r180", "r183" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Loss from continuing operations", "verboseLabel": "Loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share", "verboseLabel": "Net loss per common share - basic and diluted" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share", "verboseLabel": "Net loss per common share attributable to non - controlling interests - basic and diluted" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r305", "r306", "r307", "r310", "r311", "r312", "r313", "r314" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseDueFromOtherRelatedParties": { "auth_ref": [ "r97" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in receivables due from related parties classified as other.", "label": "Increase (Decrease) Due from Other Related Parties", "negatedLabel": "Other receivables - related party" } } }, "localname": "IncreaseDecreaseDueFromOtherRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r97" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r97" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Payable, Related Parties", "terseLabel": "Accounts payable and accrued expenses - related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r97" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent": { "auth_ref": [ "r97" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in related party payables classified as other, due within one year or operating cycle, if longer.", "label": "Increase (Decrease) in Due to Other Related Parties, Current", "verboseLabel": "Interest payable - related party" } } }, "localname": "IncreaseDecreaseInDueToOtherRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r97" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "verboseLabel": "Interest payable" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r97" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r97" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r97" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r97" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r216", "r223" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r216", "r223" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "verboseLabel": "Intangibles, net" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r80", "r242" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "verboseLabel": "Interet paid" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party", "verboseLabel": "Cash paid for interest - related party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r452" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails": { "order": 2.0, "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest and Debt Expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "totalLabel": "Interest" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r91", "r94", "r101" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r15", "r16", "r48" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r59" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r78", "r160" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "verboseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r352" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Fair value of investment" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r384", "r386" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).", "label": "Leaseholds And Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r385" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r385" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "Year ended December 31, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r385" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "verboseLabel": "Year ended December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r385" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "verboseLabel": "Year ended December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r385" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "verboseLabel": "Year ended December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r385" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "verboseLabel": "Three Months Ended December 31, 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r385" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter Of Credit [Member]", "terseLabel": "LOC Fees [Member]" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r47", "r107", "r175", "r197", "r331", "r339", "r340", "r362" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r107", "r197", "r362", "r447", "r461" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r49", "r107", "r197", "r331", "r339", "r340", "r362" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r352" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate L I B O R [Member]", "terseLabel": "LIBOR Rate [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r23", "r241", "r445", "r458" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Total notes payable, long-term", "verboseLabel": "Total notes payable, long-term" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r38" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Long-term investment, at fair value" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r52" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 }, "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Long-term notes payable, net (Journey)", "verboseLabel": "Notes payable, long-term (net of debt discount of $8,607 and $5,086 at September 30, 2020 and December 31, 2019, respectively)" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment [Member]", "terseLabel": "Machinery & equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r450" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input Expected Dividend Rate [Member]", "terseLabel": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input Expected Term [Member]", "terseLabel": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input Price Volatility [Member]", "terseLabel": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input Risk Free Interest Rate [Member]", "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input Share Price [Member]", "terseLabel": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r58", "r107", "r197", "r362", "r446", "r460" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "presentationGuidance": "Non-controlling interests in consolidated entities", "terseLabel": "Non-controlling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest Disclosure [Text Block]", "verboseLabel": "Non-Controlling Interests" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterests" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "verboseLabel": "Non-controlling ownership" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r58", "r74", "r327", "r337" ], "lang": { "en-US": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r93" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash provided by continuing financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r93" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash provided by (used in) continuing investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r96", "r99" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r93", "r96", "r99" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash used in continuing operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r62", "r63", "r67", "r99", "r107", "r116", "r118", "r119", "r120", "r121", "r123", "r124", "r129", "r167", "r173", "r177", "r180", "r183", "r197", "r362", "r451", "r465" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss attributable to common stockholders", "verboseLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r62", "r63", "r123", "r124", "r333", "r342" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Less: net loss attributable to non-controlling interests", "terseLabel": "Net loss attributable to non-controlling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNonControllingInterestsDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": { "auth_ref": [ "r74" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest.", "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest", "negatedLabel": "Net loss attributable to non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Non-Controlling Interests" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r250", "r329", "r335" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "verboseLabel": "Deconsolidation of Caelum non-controlling interest" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r113", "r114", "r115", "r249", "r326" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-Controlling Interests [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "verboseLabel": "Schedule of Restricted stock awards and restricted stock units" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r23", "r445", "r458" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "totalLabel": "Total notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Notes payable, short-term" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r42", "r111", "r391" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, Related Parties, Current", "verboseLabel": "Notes payable, short-term" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r167", "r173", "r177", "r180", "r183" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r378", "r386" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r376" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "verboseLabel": "Net operating lease liabilities, short-term and long-term" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r376" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities - short-term" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r376" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liabilities - long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r377", "r381" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "negatedTerseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r375" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r383", "r386" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r382", "r386" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted-average remaining lease term - operating leases (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r112", "r125", "r153", "r345" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureOrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r14", "r15", "r16", "r48" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": 10.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r76" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost and Expense, Operating", "negatedLabel": "Other expense" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r48" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Total other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Liabilities, Noncurrent [Abstract]", "terseLabel": "Other long-term liabilities:" } } }, "localname": "OtherLiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:" } } }, "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r8", "r10", "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Interest expense" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities and other Long-Term Liabilities" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForCommissions": { "auth_ref": [ "r95" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for commissions during the current period.", "label": "Payments for Commissions" } } }, "localname": "PaymentsForCommissions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r95" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for Rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": { "auth_ref": [ "r87" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.", "label": "Payments for Repurchase of Initial Public Offering", "negatedLabel": "Payment of costs related to partner companies' sale of stock" } } }, "localname": "PaymentsForRepurchaseOfInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r87" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire preferred stock during the period.", "label": "Payments for Repurchase of Preferred Stock and Preference Stock", "negatedLabel": "Purchase of treasury stock", "verboseLabel": "Consideration for repurchase of preferred shares" } } }, "localname": "PaymentsForRepurchaseOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r89" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r87" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Partner company's dividends declared and paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": { "auth_ref": [ "r87" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "negatedLabel": "Payment of Series A preferred stock dividends" } } }, "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfLoanCosts": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for loan origination associated cost which is usually collected through escrow.", "label": "Payments of Loan Costs" } } }, "localname": "PaymentsOfLoanCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r90" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of cost related to issuance of Series A preferred stock", "verboseLabel": "Underwriting discounts and commissions and offering expenses" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "auth_ref": [ "r82" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.", "label": "Payments to Acquire in Process Research and Development", "negatedLabel": "Purchase of research and development licenses" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r83" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Purchase of intangible asset", "verboseLabel": "Total consideration" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r83" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r84" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-term Investments", "negatedLabel": "Purchase of short-term investment (certificates of deposit)" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r276", "r295" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockDividendsPerShareCashPaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Preferred Stock dividends Per Share Cash Paid" } } }, "localname": "PreferredStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends Per Share, Declared", "terseLabel": "Annual dividend" } } }, "localname": "PreferredStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r25", "r106", "r247", "r248" ], "lang": { "en-US": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Preferred Stock, Liquidation Preference Per Share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r25" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 and 1,341,167 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively; liquidation value of $25.00 per share" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r9", "r35", "r36" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r85" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "verboseLabel": "Proceeds from partner companies' sale of stock" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Proceeds from issuance of Common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r86" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Aggregate Offering Price of Debt", "terseLabel": "Proceeds from issuance of Notes" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r85" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Proceeds from issuance of Series A preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from issuance of preferred stock that is classified as callable.", "label": "Proceeds from Issuance of Redeemable Preferred Stock", "verboseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromIssuanceOfRedeemablePreferredStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": { "auth_ref": [ "r81" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments", "terseLabel": "Redemption of short-term investment (certificates of deposit)" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r85" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "verboseLabel": "Proceeds from exercise of partner company's warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r62", "r63", "r92", "r107", "r116", "r123", "r124", "r167", "r173", "r177", "r180", "r183", "r197", "r328", "r332", "r334", "r342", "r343", "r362", "r453" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r40", "r229" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r232", "r481", "r482", "r483" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r39", "r227" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r18", "r19", "r229", "r462" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r18", "r229" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r18", "r227" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful Life (Years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r69", "r201" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for Doubtful Accounts", "terseLabel": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r266", "r389", "r390" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredLicenseAsRecordedInCondensedConsolidatedStatementsOfOperationsDetails", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsTables", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r266", "r389", "r390", "r393" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetCostOfGoodsSoldDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetCostOfGoodsSoldDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Related Party Transaction, Rate", "terseLabel": "Interest rate per annum (as a percent)" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r266", "r389", "r393", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredLicenseAsRecordedInCondensedConsolidatedStatementsOfOperationsDetails", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsTables", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r387", "r388", "r390", "r394", "r395" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r88" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "negatedLabel": "Repayment of IDB Note" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r88" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedLabel": "Repayments of debt", "verboseLabel": "Debt pay off" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Sponsored Research and Clinical Trial Agreements" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r303", "r304" ], "lang": { "en-US": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredLicenseAsRecordedInCondensedConsolidatedStatementsOfOperationsDetails", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock": { "auth_ref": [ "r303", "r304" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.", "label": "Research and Development Arrangement, Contract to Perform for Others [Table Text Block]", "terseLabel": "Schedule of research and development-licenses" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r303", "r304" ], "lang": { "en-US": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r217" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Research and development-licenses acquired, expense" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r302", "r486" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "negatedLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r302" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost": { "auth_ref": [ "r485" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.", "label": "Research and Development Expense, Software (Excluding Acquired in Process Cost)", "terseLabel": "Total Research and Development - Licenses Acquired", "verboseLabel": "Research and development - licenses acquired" } } }, "localname": "ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredLicenseAsRecordedInCondensedConsolidatedStatementsOfOperationsDetails", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r487" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "terseLabel": "Sponsored Research and Clinical Trial Agreements" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r12", "r20", "r100", "r105", "r480" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r30", "r249", "r299", "r459", "r474", "r475" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r158", "r159", "r172", "r178", "r179", "r185", "r186", "r188", "r254", "r255", "r428" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Product revenue, net", "verboseLabel": "Product revenue, net" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue From Contract With Customer Product And Service Benchmark [Member]", "terseLabel": "Revenue [Member]" } } }, "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r73", "r479" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue - related party", "verboseLabel": "TGTX" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r64", "r107", "r158", "r159", "r172", "r178", "r179", "r185", "r186", "r188", "r197", "r362", "r453" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Net revenue", "verboseLabel": "Net Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersCompanySProductRevenueDetails", "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues from Contracts and Significant Customers", "terseLabel": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales [Member]" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of accrued expenses and other long-term liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureAccruedLiabilitiesAndOtherLongTermLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "verboseLabel": "Schedule of JMC recognized expense related to its product licenses" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareComputationsOfDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "verboseLabel": "Schedule of diluted weighted average shares outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r352", "r353" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial instruments, measured at fair value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "verboseLabel": "Schedule of changes in fair value of financial instruments" } } }, "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r213", "r219" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of JMC intangible asset" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "verboseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r40", "r229" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r109", "r391", "r393" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsFoundersAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsScheduleOfEffectiveDateAndAnnualManagementServicesAgreementFeeIncomeExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r303", "r304" ], "lang": { "en-US": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredLicenseAsRecordedInCondensedConsolidatedStatementsOfOperationsDetails", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r167", "r170", "r176", "r211" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r167", "r170", "r176", "r211" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "verboseLabel": "Schedule of continued operations by reportable segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r281", "r286", "r288" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Compensation, Activity [Table Text Block]", "verboseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r276", "r295" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r252", "r273" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "verboseLabel": "Schedule of Warrant activities" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.", "label": "Schedule of Subsidiary or Equity Method Investee [Table]" } } }, "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "verboseLabel": "Schedule of future amortization of intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r154", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r172", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r181", "r183", "r188", "r466" ], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segment [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Information" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r154", "r156", "r157", "r167", "r171", "r177", "r181", "r182", "r183", "r184", "r185", "r187", "r188", "r189" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "negatedLabel": "Sales and marketing costs" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r97" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Number of shares, Restricted stock units forfeited", "verboseLabel": "Number of shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average exercise price, Forfeited", "verboseLabel": "Weighted average grant price, Restricted stock Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "presentationGuidance": "Number of shares, Restricted stock granted", "terseLabel": "Number of shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant price, Restricted stock granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of shares, Unvested balance", "periodStartLabel": "Number of shares, Unvested balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average grant price, Unvested balance", "periodStartLabel": "Weighted average grant price, Unvested balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted average remaining contractual life (years), Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of shares, Restricted stock vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant price, Restricted stock vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityRestrictedStockActivityDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of shares, Options Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "negatedLabel": "Number of shares, Options Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, Options vested and expected to vest", "periodStartLabel": "Weighted average exercise price, Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Total weighted average intrinsic value, Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]", "verboseLabel": "Schedule of Stock option activities" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "periodEndLabel": "Number of shares, Options vested and expected to vest", "periodStartLabel": "Number of shares, Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r273", "r277" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price, Options Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "verboseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Total intrinsic value, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "definitionGuidance": "Weighted average remaining contractual life (years), Options vested and expected to vest", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r253", "r301" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-based Payments [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short Term Debt Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestScheduleOfInterestExpensesForDebtArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r154", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r172", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r181", "r183", "r188", "r211", "r231", "r233", "r234", "r466" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r24", "r25", "r26", "r106", "r107", "r126", "r127", "r128", "r130", "r132", "r138", "r139", "r140", "r197", "r246", "r362" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DocumentDocumentAndEntityInformation", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r56", "r113", "r114", "r115", "r117", "r122", "r124", "r137", "r198", "r246", "r249", "r296", "r297", "r298", "r308", "r309", "r364", "r365", "r366", "r367", "r368", "r369", "r471", "r472", "r473" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetCostOfGoodsSoldDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsTables", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Statement of Changes in Stockholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r113", "r114", "r115", "r137", "r428" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCollaborationAndStockPurchaseAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureDebtAndInterestAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetAmortizationOfIntangibleAssetsDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetCostOfGoodsSoldDetails", "http://www.fortressbiotech.com/role/DisclosureIntangiblesNetSummaryOfJmcIntangibleAssetDetails", "http://www.fortressbiotech.com/role/DisclosureRevenuesFromContractsAndSignificantCustomersAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsTables", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r25", "r26", "r246", "r249" ], "lang": { "en-US": { "role": { "definitionGuidance": "Common Stock issued in connection with the first ESPP offering", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Common shares issuable for service (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r25", "r26", "r246", "r249" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r246", "r249" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Issuance of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r25", "r26", "r246", "r249" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to equity plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r25", "r26", "r246", "r249" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "verboseLabel": "Issuance of common stock under ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Common shares issuable for service" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r25", "r26", "r246", "r249" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Issuance of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r25", "r26", "r249", "r275", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock related to equity plans" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "verboseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r31", "r32", "r107", "r194", "r197", "r362" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity attributed to the Company" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r107", "r113", "r114", "r115", "r117", "r122", "r197", "r198", "r249", "r296", "r297", "r298", "r308", "r309", "r326", "r327", "r341", "r362", "r364", "r365", "r369", "r472", "r473" ], "calculation": { "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r380", "r386" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedLabel": "Shared lease costs" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary or Equity Method Investee [Line Items]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r195", "r196", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsContingentlyIssuableWarrantsWithOptionPricingModelDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockPreferredMember": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Previously issued preferred shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock Preferred [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockPreferredMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockPreferredShares": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Number of previously issued preferred shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Preferred, Shares", "terseLabel": "Preferred shares repurchased and held in treasury" } } }, "localname": "TreasuryStockPreferredShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "auth_ref": [ "r26", "r246", "r250" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.", "label": "Treasury Stock, Retired, Cost Method, Amount", "negatedLabel": "Retirement of Series A preferred stock" } } }, "localname": "TreasuryStockRetiredCostMethodAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r26", "r246", "r249" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedLabel": "Repurchase of Series A preferred stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r246", "r249", "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Repurchase of Series A preferred stock, net" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail", "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredMustangExpensesDetails", "http://www.fortressbiotech.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsAdditionalInformationDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfAevitasExpenseRelatedToItsSponsoredResearchAgreementsDetails", "http://www.fortressbiotech.com/role/DisclosureSponsoredResearchAndClinicalTrialAgreementsSummaryOfMustangExpenseRelatedToItsSponsoredResearchAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r141", "r142", "r143", "r144", "r150", "r151", "r152" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique Discounted Cash Flow [Member]", "terseLabel": "Valuation Technique, Discounted Cash Flow [Member]" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r355" ], "lang": { "en-US": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureLicensesAcquiredAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r379", "r386" ], "calculation": { "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "verboseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureCommitmentsAndContingenciesLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsExclusiveOfNationalFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "http://www.fortressbiotech.com/role/DisclosureFairValueMeasurementsTables", "http://www.fortressbiotech.com/role/DisclosureNetLossPerCommonShareComputationsOfDilutedWeightedAverageSharesOutstandingDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityWarrantActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r356" ], "lang": { "en-US": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant expiration term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average common shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.fortressbiotech.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r237": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4M", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=d3e9120-115832" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r487": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "http://asc.fasb.org/subtopic&trid=2197926" }, "r488": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r489": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r491": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r492": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r493": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" } }, "version": "2.1" } ZIP 101 0001558370-20-013349-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-20-013349-xbrl.zip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

76(VGA M"#+$EEP'XN DNTQ&"?>WK8<<65Z_KM2;J/<7CM0A*"@U;C*)2K9KC\)7^NH. ME7HCR]]79?O(?GV>ZJ'UKMINPM4J6S7@!A4AY?U=)1FCP]VW%8)!1:K/<7(U M5UT&HV0<) 52B1" ;UDA^.Y<7L=20UE+=MK2"^E^)5>"BO5&H=A-#!KY\)GU M<2W9=R.]^^5A;UZ&+\J9T6C+F.')R@#A9'!<34DE96PD0J#5+#U3LPD7-I*M96?5C] Q0%R2XL%Q=KP@4(D9#%;6O-AFV.30 M@+/9AN Z-_><+B1<-.NJ?51):3:U^V6% 6&R'&SCB29"[H<.HT1[DI*]ZZO M]7;;(LF^6P +-4%%V%4>*553/65^

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

L =L'"4<[$C&Q-!NS,RJ!AN@7[MKE-B223Y"8W&SE4"SRH"-KW M9B.3T*&$;WH;O[>JTIT .&P@@*/KE6QYB^4JRO<'S8C\KZB5J8Q.56?=. .6 M-Z0:7ZGA\EI ^@'I5O/$1.4T$4,C\HE&CW2MP@UP3#=$)26,T9:<5Z3X=7ZJ"H\DN M9!)>E+ ^7VOY\[UN > ^P?$%82[H.N6(:O,,#!#;[A40NF4:J*[S.4%3T8%J>"8[HALA'C^#''% M 3"; BF[(_L=DR%2-(ZA]H_-^%6HA?/'/)U;X(YEOD]!RF#5C^ (PE:)"MROE4(M )[H'BCYUI.4- M<&A?&RUU;HT[.^HDZZL_9.T>HP[1MS!/HE$'14)>:C6JLBTVSK!!9^;F.8+$ M^#HZ7TU,NST05UHV':%.?$Z030*\;S#.:O.*KN-+)GR+(QO(.)(8*.V_128% M-C+SO1G9/PO#>@J7!(1+Q0G&)K@(F_'/KPK1.GLO+\,J'&;=&&88RNV4J%-3N)%8V5/< ]?"NBP!;U+/+Y+Z@YCDI1.7QJ&=7:E M.+[J[W-?WUSWGWN$55Y5UVY8Z?.=C&9CA4);"OPS;,0V![5LPR[BIE%8SZJ\ MC:BNIZ8CW:K^_H+XV^K^80ZJ-<7:$Q5T>:-AZ4-_ M&6BE2N8,=E^T0;'7[$Y70L"U&MUL3A&-1FSW(U8)O2,P+HG!^LH8K+-KQ0F4 M/W'Z7Z>"4-00B)E6H(R^-PH%;B&K6N\,Y XW(TC"*XP8(>C4:*&^5.J+=!@I M?TSNH'A= M*C*1*:ASJ4A=[E+2;.8Z2RCZ/C!7J7^>YV+HDBT[%H"UPW8"VZ]&*@>_]>3: MMS;P@.3*D[2MY, "F,XL*KI5P"VS&_99!>WUR"8_[ZU\U Y+E,S+5$F2TD_/E*C6L^;7V66: F.EYO%"LLIDBZGT*"N$T'N_ MGVMS-P-W*1=X,P ?PNZM[E*.^B9'FPHE+Z7;LAE$JJ;;40WQ*,6SJ?P>I]T7 MHM+1#-E@,[^A[D]28!Y C$EIT<6&7LJ2%*C(3@I8,]-9 ?B5J"[X'2\P_;A$ M]/EJ-+< ;.!*)A2;M&+IMN[Y4=4+\%1R^M4Y-F116A< 6C1QJ><23*B=0W(Z MH3(.._.A+&01!%3IJ9P><]J/7_C]?MJ,:]'=]\T!&]8]FRZ6IFB ZE;9XWL- ME#R+]F)E3,R!_HA&*RL,& Z#I\UR^/HYYJI;<9@HSQ/1N%5W7Q)*>]2 M5CQJ7@03D>D=.W!RHP^*[L(*''=/;^]C;^&,WH&MVQ?H'+Q^*_17F:9FIM#C M_4:Q*F2!DE^7@UX)"5KG$.X!DK::W09?1%?M2LXKU)5Y=M4Z)\"\?@_O5\V M.BQ2=@NWT_QJ%E+5)E*K,T)XCADH^<7%LKK2X4B5JT'5YK"Y/([A9?](?.(< M'%-SWV>8X'IZ3L^RS3S?K]0I63?%22YW%LEQ&L5E*]]8VD9?&"R58K^SU!;0 M.6#N]P]47HONOF\.>+?)E:I-JLSK^!0,\WK-';3.L[B:(&-V%+JXT"G:.:FP M6A,+X8TYN!;GX#F5\%]%7_SZ&_[8.0VR"1$DHH$F?STE+(C(U&])(!3]UU'H M/AF*$'!WC@9.[OB?!T<#9S:]B%L=__S?_WG<^OUHI2UG^:A;$Q"1BC_QF+S2 M #)V@60@D@K?_%,R0VGE;;O)LO-#?S[PGM% I*A[EOU7ZO>OT7#LC:4E M+9%'([:ERA 3J/[/S;=VCV*><_?,\?1( GZZP(PE)*K[2:WQM/C.[">.W4=G M\J X(=M>8>0]>:1Y>N;^$;]GY6\I-7$CT/A'MY%]QGK]T2LW'Z.*H-!"Q3/'LE/-+)1^%/$\47*D(T #XUU%Q@A6&3&(V-.=XC)B5U MMJI.HY+[#6V,IIVUWPL1.$[COI@#10=D6B(E[I7,RBJM9R?!TB@4)B0Z#FN+ M8D>#)?<:6C?4%9UVLJY0L(=\;TSXG1+41[ M)2F9$,-%HY:R#J.3>..&H,QI-,*/"AY,R_$3;0R+ X;J(4I1YF7>-.24\'S_+RSUGOL1*DC>'A(_HI#@<88IDCQH,LZ^(PQ &NU#@G50FX%>2FG M=XTY6=>RA4#**I7T(4D9U,6>X:#++$^W+(L<-XF)78H2ANZ5K-N&QCD.EN=Q MVNVALURKL 9Q6HJ]HMA\U.3MC%H0.O-^SNFU6+]BIJ.BNW&"CG*T'M+M8+/F MCK\X%C&^ORP4427+S_VZMRX:A#YH:F)4%-NLH. W@)+VWRJ-'\.!?INJ>]4Z M\ALJX/%"*=4T)?N(YOSM%J?]>(43-4JR5]'V*,;\Y6VXQ+0-I\=,U0" PZZE M8'/+@0T>N,:[@]_THA7A!/8X6C_%3,8">C'0984+2%N)^1+H[!Q^)T9 )\>1 MC11<^,*"T?HM&J"[%%SOQ5^'-?T[*H^C?VT*1G^.'V!__2>J%ZX*X8+# Q&C M8\$&QZV!BS_/"V*W%:Y=P(9-_?W]U'CUWCB'375BCZ/59<[S#52JJ26C"IJH M3+6>+O'3GMA0H1;_?_:^LSEU)5OT^ZMZ_T&U[SVW]JD"KA)IGWFGBB!R!@'F M"R6D!H2$! JD7_^Z6R(9C(U-M#4UL\?&C=2]\EJ] AW=CZN@-Y;@8;;E+7@G MFQ.COS?F>F.HVR9\:V,H&Q8 FNO'-XK9JI+@J_F8GWUFJV?.1@]Z[ MBYD:& LR!-R@9*/7E/L.JHXB*:;$M>5 J%7(/#]NAZEY4&P/J[_^94_<2:_E MCX'?@[BA![ P@M@Y)HHN><=TH(%.J"UY[XU.3$"VH X1C\4$?OWK[+@\08>% MZDMVU-=>].L229_[''4\UA@S#$$;8+\XOMPNJ0A+]%%L#JG9W6<3F- SC6D2 M"D^*\,>&CCXJVQ9J"H8B1?AOP!!E$RD+'.AHP"/$57C:7VL;);BL<\*L4.F1 M+:6R&L356H/+#GX1 -+,!&[7,FQP&^L#!6,@^?1U5=7G2$/C]"O"M,=P#7R$ M24#98$'Z,YW+#D+'@" 0D3XTS(P^I)PUU-:_^U%&XA\G<#N'<'HW9NHB []XO53HF;IJ6^ 6P=*W,QAW MOG=&0N V_OW%?$XZ0)UL*N_AY3YXH>A Y&1]G8<8CV$\O.Q594<]O#P@7CQ! M]IB(\0398^+%$V0/BA=/D#TF8CQ!]IAX00SC(>9ZB#FS+=6[(9B[ 2%R!A"N M*BENE*OT#DS6[TW 9_0,&;XG ]090 =%[Q0TTW_PXIN!\%TMZ,'0(\.;]& [ M:21[(/0XV>/D9P"AQ\D>)S\ ##U.O@@97A>&D?-!>"K;L85_ Y*3I"3 XPH# ML*T*\'RL[\M(&Y@?:3QXW/ <,?QJNBKJ(/_]\O^M=GB8Z] M]ES?"UM+>*; OG7D48MG3^]0B+%.5?=L:(\]/*W]$%#Z8:3T _7R!Z(8'O5X MU/,&]WN M.)/RPO!RBG<=&.E]Y_^=PMMGD;7W(J"+Z>3O0TS *0 &#L0FABP^C<;VJ.AA M8"=#-2YKIBP2,T&U/0JZFB([F!;ZS%3S>PD$P_S[77OOW+'!CV((NHT8B!GN MQ(![J *W%P-J-X ^)@2+2 (1;#4Z0[FM'%%KW&L.4;Z-1W4*/M( M_18) Z> <714W0\6'TEY)DL =V9W!0A?"(NM((A)/&UP9K(<*]74]N#+ H2^ MH0#9D13K"'7,B2ZZ_8M !3DN1^1'38C41#^?+"GC8%(:+,C>D!VA7JM!U,F* M.6PWYHD.3W3\4-%Q]EB'IS<[8H.! 0:"!;)K_[6)W-J$]J.[Q@]\$XA_)-I!??)0;>N]S0^_3W/!*M6Z:12:V MES0-8(RI#5.,HF*CX:]G>7+9L0HIRF2KLR!J.HYZ>1-T@&$.1X0\X[5."+]B M;6I(SQ#9^@+[/I^B.S@<\?OF?5_?'^1^2]67QJ-^LEH%PE*7TH9NFD>4VKQ4 MEI8&-:"X4,7?")6-27C4BZ$FSFCJ,^DCR4/[^.]O0?WWF/I^;W/W#F>^OVBX MC?O\9=EP46?:?$>K"#]=E3@FK"1HS4(3'()H8C%U M.-?,$QE/*C*^DY%P=6_XT@;""ABZ))C#O6;N7S4,-D;LNQXOV4XTZZU&@>+M M_(R-JIK6T54T)RCBD#I%__,]&?VB1/]H_BNQ0=VWNF]U/+24;O0!&L?VO2,O MCQ3$O7MNG><$3^=Y:+@1![\7?X<5SMI4>&T@KFYMTP<@YI M-NPCJ<-[UZ/.H<=X5[L]N3??/0NP'E]*>7[JA^34F9YJ)&&V(V)1J''YY0L= M]9>63(="$P2AITH'@L$?=F7S2"SIR:\?+;\^>=>\E55^J5XKJ6H\IR3TI&U- M@MV&4KB=.^T,M\QJIF786):5K2$P&D-!.Q1>KX36NYYWRLXNYOEA,*[DL_UX MIP-]]92&+*\S/6]/<%WO4OJY>/$C3O_#^O;.*SZ82[V9 >DF4Y.;9&J:]*)3 M/T6IG)TZ_06]\JB9T]%5(EV(S:8Q9;H*2A4VNC"#,303&V=.DR'&QT8_EO[X M=#QRKZN:>_/2VREJ$6K:_A&9M_3H/!R)1.71 ,H, MZ"\' T>R03QQX8F+GR0N;N^V/DV&=&FYR-FA$%/@ETW*7O#]F:0DD.R(8'N# M97WT=TT-N?2-\5-QS.7'H#]O0G1Y9>M+*LF0_%CJLXT:M8BOQG/( VY"="3\ M3D+T_^*IW4\V:?SUD6ZP>Q"7ZJ+BQP2"9[VOB0B'%C03[ Z'=X;)FX$+3H(_*(E_^X#_D??> MB'_^(UL0/N+>8S3$.RK\0@V2,L0&VGP=G1)'3 X^1$K-A AT$'EQ3MYGV)*N M.=&;[3;P+C"7FC&H$&:0U!J( QKPQ7$5_LUEK5Y73@R4E]!P("A3/K8J1;K] M7+8=^T4 J(@F\"66 ;72K1BG,0102JFJ/H?2@, \2YCV&*Z!CS"W-&=LX6TZ M2$#RQ\2X./@;LC3@GQPPR,#T02H451L)HIU/=TER\QXD 4-_O7/!:GS1M+# MA9X;I74TGPAA*TQ,\&?]P^[>4*Z/.^)O+"S\F$RUM8[RJZ!O_1%L2U]_@#68 M\XFK+)TU.]K378,^V1_E9QGKC>W,%/SUT:AI*!I@*&]FX1%JV?G>&6KF@D,^ MR8B'E\?#"S1_0]Z0SP=$C,$>N''>:79\C.;1#SZ3YUL0T 5Z=S*!R'7+\J[4T_]+;;4]$7I]#O@* M! [P?JL"[V<0K'<'"E1WL(6C80:HTX8G6CT.N8YH_3[-GF\PM> ; M$]'%Q.SW(:@CLPHN51^CH[A[ MB=^-:98LR:J-HHYU(-H&OI7F\$TUD%*&/D:7T;:%TP7*?4XP4,:,60&&DXFV M//Z V$(V-^]XE1]0Q$3?M=K19L<**1&>SM0RS44BE:^0\YNGSKU;^;5)7 MT^"L"N4;+KMG0R1;6\\7(WC"]')/5\Y-_3BSL #QWZ.[X#(+O,8PUI^3N MA+$F9UKY5:$PSO.MP: WTY/M[ HW'<;&6I"-^H*AP\#8E=M.>AS_O>R[;R3^ M/,/OJ0R_??GW&<.O6RS'[&&[ME(20G74DP;^_)!W9R] -IAM"-BB+=':E%NQ-H\G4IH])RL MK:CPP&D.'F)('T6?"O)[_/K33*[O+Z,\R^K.4NHSUE3LI1;*-_1VGY2YEVF_ M2[*M;FWN] =G I%3UP+?.8SFF%G]VTQ3^082_1LYE%X\[?%ML\V8HR,238VF M&WDVEI/ A M&Z^86A9:LQ>EQ@F"-!P,VRM Q]V>MG0@?#C$ZAM&S-Z^%_V)TOSI*K$\J^T; M6&U.[/_8G6=$2K*AS+)."EQM4AF#L31I#R!DHG7<5.N\@=)Y1X%[O=S-"5.3/B]3P7LBJ"L*0K_I ZASC M\3B*^>[Q..<5QTH_SYUKY+GOU_-8]R4E R6EI-NHB>TSBLI+S$RZOV0PK4FKT1[H6[L\1+@WJ\-!9FP%=:DIL1#.U#O]4=+K9ZO=BD21_!8 M'QJ]3)$?&Z3@"8&KQ?#N+@/N73UZ=P#6>PSJ#Y[!H=QXHNI+ (6$,9-%<)QA-\R&-VHV=$M0=_^>T$VK MI%LO !YSC2N\9Y=9-RP84BOQPQA+SA:U,]14[NV*MZDRJ M1.GYXP,Z&GDISI)ZI<+9T=Y BKYH+TJVBB=>G@#T/K=<SL3WH MR.M.\/_W_^QUO#_P;EPW9.=8;J=]&GLD ^!W&NH+??CF/X(Z%Y:F>\Q()$!O M!E?^V;@R"!!$,!")_$5L?T3@.( EFDNT [&]N4/.M_8G#[F?O=/5WT6+I4_^ MT%0 7?B.X:_K^0%L@+T2GEY9A,P6*_\1B*&!I,I_-'88T#)K0AQR/#0\(_UYS;MNIKH9P6ZERK5'CZG4BGBTW MN$3&C=UF2XD $2LEB3H?KV>3V5@MR]6O,\#KV*Y.=^O4+6 ZVX1*'X)30A:Z MA'["UT+83D_)FJ")LJ 2T&JSL$NX;>9YH];/NS/R3AWH-Z\)MH2RYO[>]HP\ M*0/W6?@8;PI8AW3[#!EF0G2O*XDBU66%4*\;9:/A+AGIT1(#R'Z8C/YR:%#8 M7/J&JNW0F$TU.#K8";WD4I4@%YE#E1Q^O;+2&\="N4DKPMF2P"3M>40CFU6D MOLG72]5D)U^Q.J4(EY:D%W[)+IF($NO2AP\=1*C.<*J A9*H+F-J)JN:_!*M M/'QH*QJ,BLUJ15)L*AX?C!6!IL"\RZ!XY/[*:;4]G!JUHDX*'%4:Z@+TSFLQ MN))]O7)9G\D+NSQK\*U6Q%\*\Q;7C*)G'FRTWM"GH>"<')&AYG2V(D'_Y26, MGGFXT3$E=:1D2DDIB7HSUZUUEU&%J3I=]5Z=?F;P%)OT&[P=2Z^*2B8O--08 M7'FPT6C,S,RU2;)*TL ?:Y C(/LM],R#C68+9'D2GR:FO#TPV'EC%:>D*.KI M=[A1)LJS.= 8R/PX45B]J'5A%&W%NL'NP#RWXC-:T&ERF7^V& M#M_.A^OM6&4\UKE0OCQ8M@K!6%Y&*P^/-.F"'#.5RS)G6\&7\*J>5EX$5 ]T ML-(?H=LQ=0XQ7L_9*A]5Y6(EAE8>/K3/U;KC*%5JDV75RA3%9G/8KU2[D<.' MCAFFW^#*W1XY[JV8="%+:?H89;T>P,F44Z)M-;42221-E@AY37 M#:8F0F&1XQ/4@(WX6\T.58Q!4_G@[6&]U))J(7^3##72P5 Z3>=:&93 ,/P&M(FM]U8S%S,*#D3L";E\[NS2EF#@#BFW&DQ:%X= LE50[F.W M9@B/ PS3B6(B1;C>3]FHH8V:A]-))V:_$&Z/5A4%B--*#)AI.S:J/OATTKES M+&_DZ&='CEY_GBBT]=U',.% \)ZSW@[GB"$_Y%JNX7LN\!TG(9X>-O]]![L] M&"(H.A!A/4P\ "8\EG@01% !^N0<'0\1GFSZ89CP9-.#(,*338^""$\V/0@F M/-GT((A +.%AXH*8.+-N]MW0QNU.?<.)AZ>9_R9'?NB!T^\JJMM$:JQUJ/ +3OQ5H_P0P]:GUX^/_6 M]N>FE,ZS.3WZ?D#%^%7Z=EJ?.-Z5WO=$VP]5;1]PLSUJ^#'4X%"!K%F&K)FR MZ-'!#S)X4#H]ZD5@"ZI#!JK<]P)N#T?KD8,3O\_0A_]>B+-=,^>.34N_2O5. MHZEG$7170O[%5-L3$P)8 $.43>" :&+(XM.801Y57(TJ9JC[V0^G@R\9/$^, M^]^XP$85X14,H[)MF:BI%RXJQ7W:DD#<[65,;7H94]'KMC&] MN3>P)NRKMN.\\47(\6Z;U^\W3-%=AMKO4K5I.^+4:J.:9%U#74CVNE:YY=MN MEZHH72F;J2GY0N9G&L=7>IPZ2%0_VRHXH0JF6>Z[KW +Q'"]H59RD=%#B<^?#/&>*R&OK>^;+UV@]ZGD@A? M:;Y[,YEP_<$*KWOD[@B15UUR.==AJ"!7X8B B?C3LQ&CMF/\V+\[<<=&PP,,( 'S*X# M\+CY]FD[9A*)&[W%RTN/'!?J7&LJ"XULK0K%3.37OQ1%^:"3]=TES6W,^T<8 MDKG3S.F\UK(78J69;,W(?#)5YP#/:(7X!/)'Y^.]9:_7ROYM-5U;YW$DMO<; M#6",S0T'26#<"(W&T0QGR_P\F,\I07&%%#7JA4;0@3!ST/;]C!N1.WK]F^:M MSE1*=T+[,T2RSN'QGZ([+S\C\C,2P"JM:CH7E04ND8^;A5P?)&.5LZ<[7E\@ M8&(WUU/0CHWH9A.Y3$>JSVN'^LA+CJF,7KR(C+^?'F$0EQ6A:%^!YZ$2V]R@84>UOSU6\@JNXX9H=;Q%BX/_]\A^1_^(HS7NG\_'N=.[-L)Z8\ES7.\HL&X+L,\-;!_7A,%GL M!?M\2Y6+G;KFS]162(IAI_;[WQAYG[K=7P- EP1Q^RIGNG7"F-Z;41]WI:4A.YVO):9F;CL.%Y6(@3"EC M#@51Q.%![*-];UETL]OK)^*VC[CGC^.%'\VNW@SH=M.KR4UZ-4UZX:#O*?W/ M3J:^E0*XWO)_=^,.EP%<2J&\E!YXI?[H<4@;Y4LC.DW4:%!+^QJC[LD#3))V+U[ G M3SQY\IWER8/[E&?'[A\G93K,3XKRTN[,%+D]+\Z8X:+-3)"Y$D'F"DZ:IKP[ MW&=W(C\_KO8: >2GSI">=D$9-+5YE\_'V/D\TJ[IR@RI8IPA'0Q0Y%D9TD]P ML0Z?Z=HG>$CMYUQZ+RAUKKIFH#R1=!N!_/$$RH^( EPLKVJ'?9Q6@T<4,=,% M\40SUKRK+&+:6EYN<02CC^X,DE3RYYO1\' MW64X'J?G.24=KM5F+\JB4/(C"RD"A9 O0H7@_SX6JGAB272G&_*'YK>GBF[< M0)N_%<38?3").AWX?GAH2+%TYL0QQ" MA^5K;E.#?NR66F0S8 M7%_G@9DC^V"H8H8ZB9FG%])B":PKCF M4+F/D0MYUX*" Z%6-]!:]!ZPF,B.]D'(WI4#KE1MK?(AQ9:['QI@G5S!=(CA!/4H^5^43 48+FDR2%:6-83 MF+/KB+$WM.FG=X@SJX >KXWB8RY1[LT:2B.<"N8@<4:#!Z3YUYHRQOA%6]&P M0P\X_R_\#\(I,OV$;>I#VX%[73:(E1$CHX4-=E=!]@+M=H#IJ MT'G^FK@A-B G#2 .,4]!#09U&V& @0PWY#"+N3;&T"92$&=$W<^@QO_@-J8L/CSC%AL;<9KMK4*P/'"!N:!_L62[.7S;7A_3DPVWY;[/9 M7;0!U/P9HD7"L!-$$?H9%B(YR(V"Y2#K#1F'R$8"$&UC6L3L\FHS9C?NU\^(B9K@H6 MYIX=H'P7#1:\1:W5IDXJ!F7G>.UG3J @!U)S ]T:% 1;UEVRBHF%+L>';+9=BC5KD'LD8'P86N7OXBE#%0G MR=\59>^[-$_@=_K/8;0/YX>'=L <]"MLH548]_@65XG/B_-,)Y6!8&:/\ @! M5;N*C:CW52 ;)OTT_&_03T/UU[.DJ!Z(S+K$T(E.AIN6:^?NZO>2ATH.$ M\DKI87=B'81(R1JTQ&5!W3&]C_JV*6NX4NUT*\XMIZ$E,#FJDZL/?OUKS?5# M\I"W#R-PQJ#K$LC(0%:Q_4/TH5!P.'1C6"#3[LC?US;3/.(%HG')UQ 9UXM7( M0CWF,4(H0Q\"407\">A TO=6,']]$ ZN MPR$EX&X04@[$R"9@>8RT]L(0KD<'( U#.D5!); C-?1^'^X1V@D3W%$$K;ZT M;??6#2DVBAK+"=B[QUGC 6_>T7ZNN-CX]>$@NBD[ )S(XQJ0%1T=-FSC5L=M^Z$ ME\+B)5SI=4B;9(5Y-Z<:^2ZRS4^$I:"_"86"^PO6$VZ@RE$7+MY[ !(6V@*R M%5PB0)^_0KP3".+JE0H*-8IKRU8WEECZ0;&M6\?Y620@.2YD?1EA$JKAI+:#8%R; O'&'>O*L9 M"C-$P6 K[R1,CK=+<'TT(756@>PV&)X0)DCY.U$WAI36QYI\EE=C:!3P>W> >O3 MS/P%#$6,8218\/O+/'B1@F4N&:GT6'17?AQ#/J3M)^MK2Q]F77R1-42Q0"A1 MK"&Z>T6\=ZAL,7H1T'WXIQLQYG-IX;.B6&?B?=?790I EE[BZE*!TKO(+*6V M/RH.4,CP,"=XS]>],IX>@SVMG-2U16N8Y6@R,G\9E(1J@?]\M/$+>-+:^2ZH M&!6=H[N3<;*4'KR87.PTGMYB4FCI?YQ'+VFJG^&;N\8(41-D$XVTOH^[<&0 M^UM! G?.:C3 A(-_08 :,MQ6C$C88]L-T]6@3PW&V-*!9O($H*P^HF( Z&,9 M" ?8$U^[AS>^+7Y]\/(V>R"T]I!V+T9%57=CE8+FV&ES0[8L;(3W(&BVKN,< MW=/VEH1LH>+::YCEN_="H=U[H= ;.:)N(/)0!&R0L2L#/BY!LI6R^QVC$"N6 M:NVV EUU,IRI#?Q#UOQL/LO:\B[W]_<'3?,*!O::9HYG6E4[8HR,3B4RP35- M>F$U,I(%!7PH%/+!_YU*@4,YBM>\Q'L:9)TCX_>WY:0 :A*ZLWLOOA-6VJU^ MR52FW#A<#ZW,\B*V6@U\2[P?N?1S1BN;))= 0GE MAKU4(OW&(MBNZL/.JHB9_A3/^Z"PEL4A]I:WR6'R M5A5 B.]E'5XK!?8IA<2'0\-NDC].2H1,BFW!HU@<"_ZPU%YD6#Y4+*>7S*#3 MK-#8)SO6U78G2Q89>@-#-\WM+2X*Z]_&SWHFG)UEO5=<6*8,?;S5R5N)N[_O MHU:\G9)2;"98G'%"+\.1',BAE$V4(.+]O##$W*.:1PB5(P4G96>]Y30T)W7SC2KF?H2?-3-6? M(]-SM3"O,"6AWT&L?,)]3I)G__X'_K-V"T05" 8J"QO^ MLW_[RB!CWBT*(\F_KE+:A4P:8*Q="9K=F>/AN!)TU#D'WC7^]__^G]W='Y:] MN?5I.\<:.CX6C4O5!L#?,X"@^(4^?/,?09T+2],]9B02H#>UIG\V-6X($$0P M$(G\16Q_1. X@.586/AW(.86QOE5T+?^.-]:?X1KVM:?Z2:V>?ZL> MBM%BZ9,_-!5 \TW&\%?W5!0;8*^$IU<.'K-3_0#X(LRE7&-BL43:CD#;'6Q@$6KIH=\"8E.V!*E6N-&E>O$]!2 M;G")C-LD)UM*!(A8*4G4^7@]F\S&:EFN?AU?_=BN_M/;>\M^! )5IIG.-J%! MGMADD"1V,T@VR4S$1@A#B/>N%&\X.,-!G.74@7[SFF!+J!'WWYLMGI:!^RQ\ MC#=?"56GKK+7I;C6(ITAI00WM4KF*J,P %+/>6\U>0]1^ M*&Q3A.X9'7V:F$UP-Y)#]=T,3H1P91?ET(MDDQW0G-UE$^K9@G'U9=H&( M37C*@60[U2KR8EPY=9 @D9B,!CT!8/WB]@\$ZIN$[')JW&ZDO7WVIP0 M*<][\B0\CPM5+V)S&+&Y*[D,D]5)BX].95XH+4HA;D47Z^IE6XI_,5XSJKRT M_1F:67'YHC)/RI5A6"4A(448'\.\F?KR9KP&ZX";!VON)1]P]K!3Z+F6J^YW M2_%Z-;L@NPJ7$,M3L588MG/#*P=M3':T!$QK6B1;L/N7RZVTIG%$M0NI^_2K] D(?/5$L1 M/=,D21!.9QH\$Q\I4-S\2U&!0Z7P_$&>+Y/.3@K:!7A^K%!U1@?=-)DW^5J< MS>7E1.(+]'!NI(>>FN%"KV(7E.6@W9TO*Z8-R,%'(CWW\1=2H&= ZVE)4.PQ MIT'0-$AVHELWC%P(G";TO=S U>J69I3FY[IS?B4&RN+%=M.1-LO_D]G55[#G.03M1S?C"9ZRIB?%-5%(R7& M4"IUE/&%W^YZ\Z8YN1$1M[-"KYF/]?"6_@,Q,DX]L4]X5=U^R*:60P.:SE#_$A;A4D]3& M66%>N^O%H1Z?]N?]5FQ!VF.E8Z;BA50S@[R*4S6)SVM3?IET+FM33H;-1-ND M%D-^VDJ153MFADKR_'8V)=N3%\,7,$APPFS8YL@FS2E^;%,>B0W#/O9] _J:>9-/@ZR[M;SY M>,N4;O"ENU@V_9QB%VO#>H5.6!&^N=-O[H5+] M_WR$XX]IA(Z,2%75-SV\;I:">6O**\.3QM8GW2OR\'=&E?)@4(QS=;]?BDZ6 MG5ZJ_V IF5*V%TD'535%EK5!BVK2_2B+""W$^D)OBY/C/AFJV]]4;% ;)7,# MQ^QNR-^*G4)'SHC:2RBK)-JC=*$=#]NS\MD.V)[8,9T2YO<=L7ZXDVA%+27' MR;EP>. ?INL+^&ZH%#[EB%TS\>YIE,2M7:E>8@E"45)J\R"V*FEM*]X<-Z!B MCP2.8/#I/:GO2PGG.E%FK=#1U"PM<0)E\KW)K*%5EE5401=]N])QM]_P6@VO MS<9-O^%[.1H5VT"'MM8MN5##%G/3?'9K-/@<(>1V'EKWG'6*XPF4#X;K\'<[ M)<._ 639"$Z9("1043"'D,R=W(B;)/X_#=E^/=?$7"N=!(1R19"EH\IGU6HV MA=&(7''T=&:GJ$IPD-9P=S\J&F2.W"YMU8]C1.!^?]AH%#0-69X>/J^,SR00 M5?A_Q_&92L_RP*;J/5Y(9:.ER"K>X,/(F @P[#'G8XM/MR/SEL.).917A&!; M4,C@42$J[O)L8+T(61HW4,8M@&3#M(C?6"MI<-'FL[^)'O07X,\2@(:D,5ZW MVO"K0!M80ZL2.TEH;_D^9:_) M^IU'1/8>(6OO+ ^_0M!"'*+0PWG?@H+CO2_L'^RL,TP.[O^?JK($]M)!'N'"_=U%THFUN:R];FT C M:6.^H!ZUT$.ST4@#4;4EG'[BF+@2<"*"[Y .O4QQ5E#%JZ(.M5-_HD,LO=[TCO3/O;VP;D00ZWHRRX8=\DVI";) M4B,9Y/),*I*3*T4N.$,7Z:S;#^5U3WJB;^CC_4D=LE!.SMHW0 M,FC)$$/XJ:9;A [)%NUL,V%@$Y9%W5AD;$S!Y0A$!]]!AL]!5Q;VM6>')]S( MN GTOHI<4XZ$(T]OT0X:2(/\.K<-)(IB& S*3Q-2CG7?1N]R M.!*UJMVJM84D#>EZ'4E\_S>:[5:^J&S%57[7D] MTTEJRE2HBZV#L[=!Y+9NU 2SPV^SKI&--/KI"F_;9#[? M*@P[%#- ?0%]D6,M'7]?UPM](K3<*J@P,_-FV!KTVUR9;O;SG5IT4)$&'PDJ M_(VTTGY@J;\.*NU=4%RC)?4SC!.\0&+$$(C*1))-$ANXME-\]A MNV/4D1-:6MAD.YWJ !U[)T#EYCJX(U*OE_ 0/2H')"!W"V @J,Z>FT#ZL6Z^ MD(;PGX[?;LK]%SD?'X[J2GD8KT8F&=4_[D##*NQC:,K'TD="[/OY$D?&+=XF MP_3'T,+ETU)[77]'&OOC57):;4*9F^F'\FDY5CTU*W+U2 MJX2"*__B95@F6S)ET=-1<3R).'G);UN5;67KU>K;3(?ZJ;:Q:JM+F-S7 [Y]K6K#Q,'E DG M+MGO>:GNT3/61W(L\ D 0XH:Z:&T2 MB#MKUQE^.$:S?3)\V]TS!%2_(V=KP'4YUCM]8'\CM",O0@=Q MAQK D>V*8%C+AB%HIK,!,[[<_?$!/Q2.36SHOXC!&DZ'Y*L$++]4Q7POF6MD<]&\9 M]HF=%X^$KN7/%$NE&5.9%=I<(C%G>*718YKT "?T?J1EK%#=MV)RIS0)\GD&D9&LU0-5:$O$_PGCR#UP?\!'E"10! M0P"/:.Q^#-D)_IL)) )$2Y"U.6XWNUW@_CVG:W WD%'Q'&\TF5BV;#=[I Z, M&;253*)02&"I$P\0->CF+GTH;<$$D/Y0!L, T;B/&*!",CP#B K[45>7EM!QP: ?CC.JT/A)SLY:4Z(5T<& /P-C[6B(E@Q'HGNXC4TXQ@) M>V5@^(,Z>O^F5L$:0JTP&#I]-\-NM@MQ1Q,';61;%[QKX3A $*"/,O\P$'>+ MD(^ 2G<;CKJ#PG:;T^+?'5@Y!A&R6XY6<6Q77LXB@T^\O46V-K(P826%N8D( M3D#HWA:.KY]U:3,,'M-=C#X'FHA[];D6+^6B![/76)!VY^MNH7\_LDWM3"?T MXVS<];SYMV84[E.*6S"T[T7?;:KWK7W?O*"7BSEVFN3EFM!;Q9HE?Y _O[KV M5>.4G3U"],2L_5=G-2Y42Z;K62UFWHA_:6JOTJE*N5:%W(CRP8B)V)3K@]Q5&6; MSI1VVH8[Y8O6]S JW2N6JJ'(JZ([@YIUVCL@V:'V,3=R@,60&RO$'(]NDD[4[==*5*D'G@&$8/TV'J'!PW[-"!61CQ\!= M>Z8TZ;JF>XX4_'W]4I11M/%F3GEFNZ,[J4C 2>9Q*6?_>=L3C:$KAYR2=3]G M^(_E%-=?1Q2$NQ2#1KQ'+GH%936'>B;9# :5UJROM\MJ?V3U/G\5Y) C8L.M M$W=\P&,YW'^I6*49ET^/AK$QQ\6$.=2SX>")[D+K_),M]Y]PD]_"VZ&CO,M( M;SO+6QK;L.#&67;>N_%H4_':VG,]Z3^7A,T-Q$:<)71CHCN:&,YP@&CR/VQUG7:5YW,7898X= M0&SA.Q&6)OZK\QK(&-LV3X2!;!UTY8MYYFJ]'T^;-\]\=E@JM[T _I\[@/T%R7YWMJZSH M^2KK2.4@%7VEN:*/H;DB70H-M*6B%^5 N6\LRJU^.D("V4K[6\U9J:Y\OO?X MAS57WQC-LXU,S<^W$EPB[F\9S4A_\ G-5=XS8W8S=/=45 Q9/1MZHM92>D?V M;K6>*W)Q8[(^DOU.H!#RQW$2O1MO.3FKFS"FVU3@1 !S?=S'"EY^;TURXT"H MRB::N1=.MGBXP4ZX.@8*GT4FX8G,PR>*@WYO6KE\3#482IA683JN\:UQ@F8T MMINR:)R=?&RTYX/&5+\WTF^0CPPR=6'J[RW[2FCHIY5XFM/HI-,_Z>T(W4[D M9T=-ON4K;N.S6Q?F<6.SN)5[8SD!>YBO :C<9=%R0]UH!V:MSK^B@DM0H]29 MAI1*0285,.](FM8JLT;ADVHC)B%+ <=J&_JVZ0_JP9'5$L($1<%>JY"WLTKE M(=MBU7K'X*:=Y"(V_BAX]B3'95/4E48MM.@DF(&2 MF-=78[9(K0:\(TA.S!LDSC)4=SW$^QBJT,?:4M.%':Y[49,E%0;E FNSW+C4 MFP_H5EEHMNYY8[]49;81*[3"_%10Z_![M)VK.Y;),QFJ/Y-6+F^H^MO93"YC M-0%7'[2BI808&=8 U#NA 'O$<;FSH?HSD7X#0S77*$;]F14_Y_&;O5Y /]Z*Y07N@Y29,2N?&JUFP:&KF M0)]\HAG=U^S9O8E;=>"?U^E6EVNE9"T$K%0UF$ 9J%38QY)'9-(;MBRDO'4# M6ZI\I!,,%WJ[/X,F^X=Z%#8 MLCR*D&AMD:A0Z528EYMQ.SI+4*$:FDG^D=#G1Z]4-HMW+Y(VY=::CM'6TV?@ MZS[PHWF]/T/.1*I]<9FTVPU%YHOE/%DDQZW.7>7,RL@F$C$^9G%^5DD8M7)] M6JZB@6)A7^@883^#F+FP(=2.!,V56B5K?#W?Z/%:>ECR-Z\E9J20GYDNZ],2 M/^:SNA+V=SLO=NQ]Q_6-^3*['LS=A@+<)2?W-@KFQKFY83"K#%4COR3!M,,+ M/7N6JW21$J)/W;RX:3]K6ECGQZ 47?.]'-W7^2I]757U^5KUK'63N:^<8EA MO%7S]#H-$#7CUYR1!*@-WL%^S/WDXB?*"]YII/>0J<';Q*3]EG][K;!OG9E$ M4:X4#W^^*2558-/=B%(M0;M+K*^2:$\FS!8$"6@]VQ@0C:&@0AK57J?$HKS7 M-RM/?;C#AYLU>V0K'\R???V52Z32[D-D#]R;A-J#]SY0;NW3]71=^2<\M9HE M9THZ:E-:O+ELKWJQFR32Y@IJ.C%1:D5EW"V*&IW7(H5H]:*)M/OC!>Z?2WMV MOM_. 7"'@QU5D[9LU&Y4:L6HD'.M7^.6L+=83HJE#)0EIW1>B6!_# MGNPUNN?VV6_(2FR[;>] '#*Y6WO*'T-!-[A2$_N16;+=4$7%[H>CA54[8==" M> !Y^&T+9_]"?=TUXJX9H-\0^Y>_18_&4Y91CJ9)/C0%O20+#>G4&%U[!-A3 M,S*0S67:JN6VJWZH5*YOB/?;7X=E:2D2*18CM)+6:P5UJ?<;8;Z*A,")[AC. M>$=H6]@BIHRME>RV%<63 *UMJ :N@!OX-OWY**\_G]>?S^O/Y_7G>^K^?'?J MN/>13(H=%^1>R11?MBZ^?#MZ:_/$I'2M+>8HCFR9I C(3(HI=.9W<6O9U2@_ MJC74%YZ6R,EHJ(V-:@1EDX<9'Q,^.<3OH>XR/1H[F\8^[/J\05XM%\,?]HPL MD6-S;+X>YD.AT*RD=6DZ4L;-Q:+OYA4JRR0QN-L@E_.N^ILU%SRK9?/1U!VJ-S--W7$5 U J,Z M='"Q>[SQ?IM.M6+^:)U,V!%6K@6;=CF/1O^K@#0QA?SX8[.JX=-ZV%.W![[KYN[BEH&I2H M(I"XIZ4#2!:.K1DAH);F31SNUB@HQG;HTV[?P]V&=?L,(QB3#5K\2Z7 M3G= 86HRHYEV'\2MJ"('C%4W12:&4[7+S&BZ'GP'<<%K_9Y*JGF^AK7+]5K)56-YY2$GK2M2;#;4/8+C,DS"*%A M ,&TH06(#K;M!_IVDF*ADQ=?A 7+D DIF6:GF;3:'4++/N@CCR56O$;Q[H": M+;PE%VV6C%:N^5HV-XC#MAJ^N8*@@48K<#NUW+YS075$U89]T."4\EA^L1;V M()N/?WW6*;1/MNQXT)E5DYP/ -1<;]\'I5:@N.KF5B'%7TQ7Y41-!'8(U\V\ M7<&[&3+U$$7\[P/W([3MQ-=WFYR:ENEZ6@V]L@'R'NT?)7:QEYJ N!T=*7)X MT3"7+XHX0I5(]%%B#[P1';]TX/1U_MM,-N6>K$+S^\]0EB2@P05HI #)_+.; MU";@LEN+JN45XW.JP#2LX1RA\O9+D$HLJR%4R7*(D2=&4/SQ:O:"5D=?\LMZH+-J]29RS!EVZ2[Y>F9QU^;*5:]ID/1*RA;0\5YA8#*X\>#LE M\"7#+Y@6-UZP$XWM1+J#Q1RN/#A1S&"SNC]:+BA"J%9B5VTF5F#0RH-]AEY6 MN420#*5Y/]],C-JI&>GOH;=3U.NEB46BV0S+_KPB).NA:)%?A+)B#)I?!T?J MYU_FF7YV%2%#3(6J32F9SHKS+GNXLEHGXZJ5RUCM/#B\/!O( M5?*EF.0%LIMH\T:L/1_%X,K#PY/#S")FI:@%W^)BR]K$_R))X1@T80Z.5&\U M)S*URDQ)F3*[5JZ6G.83U6[H<*61Y4+U87MA>JPI4'8*K';:E?[M(1A&9I M*1KJ0L4O=-F^"#4[Q0K=/@CV^D%&"C&1@PVWZ7FD*;7+,TY6NE:UTBXEC$7U M&/,QQ6JVD;*S9:Y5[-D]RA^/TX.C+)4JZH!<3I8TOZR0E>JJ[>].$T=9JN9/ M3N)&;2+RY4E[-1G'U."P?Y2EC%1,R-!R-DN.7SB]$A(&30JB]0CU"[75I!6I M3#4.=";,5!5FM7IHCMR4URL58S"M#Y+Y.-^J^%>Y5X0ZKDPJ RY.A@<(]1EN&1UR)NK$<2ET+K0R[*QU54;+'4+:+EU") MA^$/V2G A<9" JN? 9K; BT M2H/<2 Y-X['#L3_'U^%+".@C *@Y)W SEF&#BUU)'$08]NX]P_0Z%""CRR3K MCQ]_\G;H@@H&B!T@87MS#TSWBJD4H7%RW#M2 ?)$5%G NMUIY8U2.;:YC]%-Q0B 0T!'U%Z0<$C603K/IE@,9&1Z0T]8V@94$[SW,U@2/S&EFZ( MP+2 X2.*,4)$B>8X6<0TD1?6%T1L9#BO/?I8.A0@ZC;\%"\Q"4G'[I8!IK9L M.%Z5N 8Z^EA#%OW$M=1\A#R>Z*[SU=_7V: CI,P3W+\J@?EB\O-&XY9ZI\.C?1"N%VGAN;Z$*"/549]!8A M/#NL:NA,Y3YO@A@ZT%&(9::YL;^K3O.<3(,2&V<5T%JBY#;R1-Q]TP 8X)J[ M?=Y[(\D@#ED:UUX, 7"[NUY9,V,8( \4IY,NWKC/%G&-9TB88 =62##GI! ; O<(MF- M#)#!4R6,^'L?IX*=_,7__*\E?0 +0]D"?O@ $67"(>BM3QU@(QY>'A$O3,C# MR^/A)1J@PAY>'@\O=("F/;P\'EX\.?:8>(D&/'9Y0+1XYMBCXH7QT/)X:(D$ M(IYV>4"\T '*XY<'Q L5H*,>7AX/+U".>5[E ^+%,\>NBI?_M0P46+Y8$/EN M0(B< 82K$N27(1!Y#P"G"D&<0M_#?[>5LN[A15U%$/E_OX*_/FMA, &&7M?6 M;RY2)@L"7_H0Z[+]*T/JW;+BC\.N@6_=BLYE&[=_V>9 D2%];X#3HZ6OT1(= M8,/?B99*Z-[6(Z7S2.GAE-&[9SZ[$^KO_\8Y$KIM"IID_OU$:NDKBOD $&=J MZHV H3\K8"@R$&2^DX!!B1\7$AWO7=S@>P_BY MIWI<4E@[.]<\X^DDCQN3^^Q[I\$&!Z;?#P!Z>+F%LYK MWP4."\'PM,(-]0(#W<9 MD@;]52Z"&9E'4?Y)EKJ1% MOX%C_G3^]X68],<8NM11-4J2"L],!NF@TC([Y?F/X;A'P@8=P^8W%PP7#EB\JY@*/1(+6AD:R.^/)WG MIDDS3U$,$@PA*!B.C+.[JF#P+(%'"K!F['YHBHH M.:752374QKP]JM&H17STU[^4CR5O;@I\@ZB,ER[Q+=,E;BX;KASV>5/^30%0W9FS7GI)9>X MN[YCW= 7++M/17+N?=3'"-U?-="#![^M6;2PE>*"G-X>OBL8[=MH9=Y M9F90#3(M9@MFM#A0U<2@&T*A'RI\E?OP;Q'@^79 M/0'QQKV>4B_Z>\%([$4IRSG)#UXJ>DA XB $Q4'H+<^ZB/P>57C?%\P0906F+?*M.3-D]G\BV-E>83,8J8/OKK7Y8ZG*'KY=M\ M(=_FWJSP6#!QXCCWALDCB8&FAH3BV* M] 3#0<\*^'ZI/2)B>LD M =W]^(\D):X<-CHE)>3E"Z4E% M5TLJNCNCW%-0>$['30-0)]LG5$FMH2;K047FTXDR]1*TA6 ,F3DXQ2@88CV+ MXHR8U/_B<>E/-N+]-IMM# $D6575YZAG#H:329CV&"Z"SR"FMJ!9LH6G$A&R MYA W8C6AI]L680U1Y]0QW//R?_Z+B?YC$OI^_QW3!YD2BA2\4I#T"?ZRWH>L MNW<\_/-Z9 $*OTUDD8BPM(_ ;&)"%1=PWZ9']4 ME&6L-[8SL^K71U/Q0J$ 17DSL8Y0R\[W/DXHEYQ5YLV0>TR\>.SRB&BA E'6 M0\SC(8;V9BX^)%Z@'/-&QC\B7J @\X9@/R)B D%/P3PD7KRA\5?$R\=+N]Y" MT+LNYH/-8KI1[N25ZSV?9EIK)!"BOM/J-KK MR].G&E5[B[KY3VJ2 T#J4EWIHFK)AZ] M>P'S#3L8W;2[?$58CJ$:,(^D&;'5;*^2SE-#$K2F9JJ4TENY_*#+H-H&VD?1 MA[VKK]SE[*$,J[MS_9UK/:[.]C^MJ>%-^]6?8'MA%*L+2G85Y=.J4JI,^\%1 M0IQ#M@]AMH\<%C5=N7_9E8WBYV+[AS*2K]C,[0&,W1:V]X'D%^!&A0$@## 6 M9&T[/1 Z3V,"G9>B_CDP@(G?2R 8YE'>^(GV[K.9M1=K[?( )NQ!;KRKR4KV M&#Y+W--*,;-;[N]8GWZI7BNI:CRG)/2D;4V"W892J.XI'K\)Q#^2;2""/ZUV MUBP5_XL8/W!4BI))CB;3]IJNR'T!]=G-"LQ M;X7:-:7-"?E%H] NJ"^@675&_1&A 'L%1OL6-MV/-MV>-8!Y8--)LBG"8U@$ M9![PIC'G13-_2C3S!G/<'] >_&BMY,0V0#>V2F2 MR5AVQAWF% K0-ZZUOK?A^==^'LEW#ES>AL,?S1"]+H>?,%_OQ^'A86D:BM;$ MH%+NI46]EIJ/DK&Y,Y7IUAQ^?XOW+R\N^7X)^&M7YP[EQ(.I3M]]I4[ MN;H:4O#J7KZ4^]$._2#(POU@ 8"Z/21TW,? W'"$<,D>%P>Y6ZD(G!)J22NAGW!:);23)"(E:X(FRH)*0&// F,'XKTKM1,YGEN(M-9',@M_ M\YI@2]#8D/[>IA>>E('[+'R,-X6U71@,I^KEG#*5R2D?RD?H2F+>H*M( ?YR M:&^SLFMTF$4BWDYS2\5/)]+3',CYYUVZ2[Y>N4HFXHNIG(_QH5$L%EP&.R^% M:0RN/'CF+)58-=I3O:?0O!I)L(G^E((KF<-G^BTVE30B28.7J_%5AGY1"YEZ M%:X\>"89*BK@I2V]<$NQWXFV2Z-669QWV<-GTC7*;P^2C2B7+N>-^F00$QLE(B6^KK68##7K#?LB MZEMVL%*+&\&.6@F6E?2PD!>I<#;=T6+=R.'*PFC"=ENQ>(<<^_-@7*C7I4ZO M"DV3PWURH68J/6N9G%!/=_) DL)9#F*3/%S:"&<7S5E1YDAZ&NJ%$[EHL%*+ M=2GJ<.F+/U&G1BMH^=A\+,[J(YZOT'CI&OA00[LFB=/RQC5?4LM$L*CX*P,R MT6F5!KF1')K&UV;)F]\Z:NJG#": M P\<*_M28:_#&W&!GC5."()Q-V^$90;X')JH*]YR?U0K'7O/)?3IO[SU^^XG-D W#0!V+\SVTBK]:V:D]<)97&YGY+1#?@+S@P]J.E9:&DJQ:62 M(R[/9XLYAC>+K=3<*>6+,*<&D'S*V+@G72,(O"OHJ.]G*MPHB?7>8NN2V>*> MB+J!B$K:H 3WTY@#=08<.^2(@)KW4@-IE CG^'QAGFUT4UV@%ZM.M0?CHZA3 M$PV^C['V(=E%>T;:CS'2;I*KZ(G!VXA!Q-V-N7Y$^H5K2KZ6R5=;O%#KV+-, M,]'QSV-.+C+C(R-G2K]O(.08ST#S##1/,MU2,J% T;$)MQ(@IX61V>=HAA>I M239*9TPTY=RQS)C#+C _UC)C/KK>GY"=:$I7[>T_UO(0<]F\VRV![39CH@\NCNO#E8K12.7/7'9#BW]8!:+ MH:U"6XWQA<[U51];LB% _2$F!C A1(B9H-K;;B:>#>?9<$]OPQT<_N(=6.\I MRGAMS:Q XA8B7!H;H]^.R+5:)EQ/5!),F9.E!3,*QT:=L(Y+G*!@B_K(TRU9 MOX\M5P+6*4O.1YA#W;#\N"TGI 1"U;4!_LVS\6YJX^T+%08*%4FW407;(TC0 M6^2]W1T W]E ?$.>'I&;L<@R[K?&.8$3TD*\49?B\V5[@(HXD0_,^H+!4TU@ M#AJ#[!9N?I?6(%4A7F)E8M\OXQ"&%@ *>DWD=80T D M]#&$\9(8"N;!6KT'-XE_- E+Q^_5^_"OP'">+AO\Q"0-,;6!:J+#"M,4A(0I0O$'R"1"-(8!?'PHS0/0 T @-ODH5Y#'> M/>HMX,/;?GWL]3'P']T#PJ>;MH%A#K\+)1_T7DSW??B1 :)B&Z8M:/A$6Z@Z M*!)564/2F+ ,U,? A%+X%;PGACZ3)7 (=/@T_!K\'73(-;0@5TNXI,X,W(%/9=1W'7*M:B-(POT9UOJ% MB)>@YC!U#4);UD:V@=@"2DFX#D\PVB)FMFI.N*8PUY8V7PZJ&KB&)" &^?XB"5WQM7!82^LX^NNV@OK M0,#M]98(TVOR07)8L_[X\2=O"T$J%"!<"!$81,0NC.YE)32.\']B*,B(>WU0 M9 -31J?#O)H8RJ!/< L@VJB$FR@[&L^'-)$,=9(-67?I*DHL]#8:".+%1)H= M^AI(9T-Q, 18@\YTA^>Q36 ZI=_PR5A2Z"H4'D##L@4_69]K2 )/H"!:0+/9 M O"S:W=U-0VKVY MU/HMNSEE;"&;^"\8(AN N/ HXMR9KE*.%ENUCMA2A!=A M$&NU4IG!Z.Q^L/BV;)>Q\ 5V5IM!0P:9#6YS2"@ILQH'6<9:QI<5 ^H'>2*H M=0NRVA"2+C#*1M(U5@[Z2)8$P^AFTDI MQ%]O:0[9-&U72>JV92+H(_3"96.(&[P=0L!Z9S/:F6!('X% C:VP@R=NJ:T) M8;M#FG4+M;,>0#F6A':CJD\0-!")F ]#(0AWW#FPQ=*377MI4,CA_55UZ&12]NO>V78 M;TO)^E P\#QRZ%] GX2(K:UVQVAOI+$' 540Q+0(S;>L)MY-H!_92X#X_3]3 M6[?^::0;;>>GOP\<&EQF#)#?A]P2Z.\94#T-G%,BUP*! ']!U*$5B\PY5[BC MZQG!@#(=2_$=9@3CB:HO ;3A+L#:4,M SE9-'>]A^]WUU_#;G;N#-_04VC," M0(#@43TA?@X*G6[LX U6?7@=Q*VJPM/)XQYV&?X_>^_6G#C2K O?[XC]'XC> MZ_UB)L+J)0DD1,]:$R% G,\@3C<*(15"Z 0Z(.#7?U428##8;=SF9&LN>FQ< M2%59F4\]F565N2^LL15^WQ%UY%2@=X=+E1N(!_;4<2RX;*'%/E 1V!@^8B>1 MV$A$V>N\&7*L)1@8RAW\:&/HYH+"TI$#M_Q7YOFP?(93'5[;:LAJ:N_+&R,KM%L< > M1.NH,Z)U+12W\$ .>EA[8X*NT Y%Z3T0S/? M4^ML#.*%'L1>X#1>>)I>UN:[_30-Y X]DL:8QM<3QKQ:D"N]-M&\TC2M9I94 M3S)ZC8=V.VAD:EU.E-FWI^D)0>$,FBD$'7WU;*JF:MZYI9[V^FZO EJ'QVM. M>YC3>O1 85MQVVI0_I548#TLCYH-OXIS9=G5/888 &+E(Q4X/E=V'4L]747S M]M-$]98F/JHW/8Z4;+?..=.>M;R6I1;:@*\R^;;"KQS6K@%SJ L-]NUI>FFI M=?.$28:6* 9;UC'9 V$,[6!9=A$;0;QDCROM>1^?KPHOG8_;S[TG)JM)D<[[ MW$JJ>D[)X>A"]"-7'OW3J"<>/3Z[?RH'( D>+M=%NZC/+=+;. U0H!!OU1J-ZP\TBJ&8F")5T MRUB/*/N[AC'SG%C#@FY$$.8*HMA5T125#;6N5#+0'8%/)/%_T)"#'XE__G[: MD>H_H;83$87)U8O3I=?6RC?L" DOL*5GT6UL:.6H+#VM]0R-GE&$V!A."YW2 MQY>YO8($K7V[V4=-Q9\D%RU38[5,UNAQ;J(P%.B AAZ?(+P'&OHAN3;Y0IZO M-/DNKN92:6TV$2B,_SC1?X] MSB\]:6B7UBK7XO^EK&[S M)3#I:;19KF0%KR,G9[^9HD-B^;0Y2+$Q.+3:??9)I,^R,+1J!XOV=LU^7K(K M^J?,9;Y=[A(RWIOSHE:4L4:O6AX,E#?F,B@%"^<3)1!V@/F'81>A6NJ6LYDB M[U5G,SS;Y\>V G'95/7CR42S=E5@_+!+=_EIJ]8JJ0:3]&=XNVWJHMDBL);; M_"B___VD[9/[J<:R]M3NZ5POT_/&R:+13>K-X&#;*7+_TO@V?%*U4?C4#ORQ M,(J]B?<&:RX*Q+[7 7S+[7MV#GW1N?1YP]NBLEBDINDJ$_:C;?,.93CGR QO?IK%_>JCW! M("K8PICA7I\LQV?DV,QU/KZPGCV#^@+,J7(;#+4RUDGX2ZL[;365M]?6YY- MCUPW+![5#8OJAD5UPZ*Z87=4-^R5DDUOG[D[XX0>^;EG\MX91+QIQ,1FQ=1U0(0=7 M^_^)QNR?UFGQA9QJ;R2)<"3HB/-[SIVF!"*^YPAM?]F2G"P8N473<6WOD.$$ MW44M-[PFZ56;_F+!YS2Q3:< *Y.E@NH?DU'9LU^0T> 0U>%KJALI<4AT#NQE M _;?DO=HC+Q.\?D>7Z$XDEZ.&A(1IQP'$E'7MV(K:(+.2[J"7(>70H)K8*RS M?PYE;R)$7;=\9Q<9WVH$?(HA:B VL^QP\H.;'.C\CN-NSFIOCG=!GV6V"5N& M!25 ( OTA< 7>O40N!2>QW+"\UCA*?3@+L'>QZ^='_=&T#+U%>;:(M(XQQLY MJJR*MOK*=8Z]"PHHQ.D&5R9L@/ZV4=C-#2CTI5DPHN#3/7 7T;CAI] P@_T( MRW-C,V!"2PFO=\3,0)[PF\'2^AQI?4NK8R.4$^U9L.[%#Q.>J^\:;BN%KD+T MM'E+7C=!IYYO40?>.7D.C3]X:W$S;E2#/%@7Y>>#A*9< M +A4R^(R- ?B^!+:?] E 3AEL#\_8[?"7FX\#J,%NXQWL3BQ1> /M&I9,@3 M%IL#B_ WUU9''B(-4$]$QP'HK!>T""6XY!3<2P+R[OH&4F=DP<%-C0EX_GX0 M*D2?7,;G)$@A3GP,09E^G)"9X;K$JY,IV6L#,>5:;X7I?G-!'(H&@1MZ_4E/ ML$R:P_)XT;*TNNHGL?E@VLK1T!-,_3P.\.P"X>.M@4(X@E"'"!T"- @,*,RS ML?6_4-G(YVC0WDKV#+"[Y7$"=!FM55FV',N(,T0N-B#9W MSWT7M4U7C@,W[UX0RT-QT2CA/9SNN!5?YY+#7OZ"TSFIZ8ETKP0)8+ZU8"E_ M5F\,"!;ZO3^95Z?S[W]VJ+]90\Z]@A"KJ*;LP%6!_0EQ J[JOJA#,E3]F;W& M!)X[)[^) SGIU?Y?]O3!WHUM\Z22E6G5$]HRQ6.%MK/4J&8M7?SXP9O?SJXQ M;;CU1+LGF/;TS^=E9;DX4!9+P2 MYWJK=:DC4D6GNT!A]C<@&,XJLL<%)'66A_:@W2!!Q?;F\.8:!/P=&JB^=PXZ M:^]9:-"Z:C_LM)XT3=:4J_;^=-;S5 E@9K:BT4FLA$UP8S&??SS6^MOI%%9% MDEQC^DRKIWC:&@NK4D;WT70>W]+836=(DMU7W!!9E=&B&H-V:"H@] ,.3PL% M-X]M@/R5\#KRI]XU/HO509]RR[?F'IPQN#R\=D3BT,_V$(_8^B2S\+:R$SJV M0=A U%QT[ *))'!$X'ICC<<7H7'OW-9]MQY3LHR-BOFJ-B_,@3^O82WG#U2P MM?,IZ^-7U5 CEY@Y:[4U;25F)\VUFL\(#/L;8C<2]>#J/'3R%@A8T*V_O4M" MSV[;?K#"V4X*@?]],ZT[Y[#WTRD+.AS5BSO_%SW1]O;)C_?J6(JKU:I.QY:Y M.ELQ6K;+^>GLQYGFUOODEC,4L7U5S?K#.<=R;2/)K_H&,1_,I$*5#RC)<"J,BFU#*"?#;N@8'H8Z R)S+4E]G'8J? /)T][]"TJTUK"_S0CWY)L;#Q4U3I:,(BG)'WB M].0F?BFZO]/H+&*C(-#GC:SY2E+J48"5>=+FG&R=K;7TOG(OLGY/R.X=LD8? M-&P(*2>EO2021GI:8LJ:4:Y5$\I8L(@FNLS[DSFQ/J-@72"[FZVO_Z.^7C_Y MQ[]L<*SH*'Z[._< 1W2AW;QW[?"4/(C4!+E=_'F_R%,V%F ?FBZNX)X:S MV^/9C/NXQ?.I^I S!5D74#X%V$DSP"RLN5<,STH& X4QD-EFH3JY*F%EJS.:U=0$ODX,U:^:]%9E'KOGK:])^ MU//9>3FA9K_9BHDYP$4##:FI#53S9^SD/6ZT JIN>/K0#M6X(LK('!\^-G.L$^JR8P"50E/ITJ<*I>YJE#.^HM.0()?C[H^[>O" M7G:&:.H^-G7GSIE=9EAZ6+8KVAQ7QBNSN-2]O((6X#>,.YPT\=/W(7=DYWF: M(-NYRSD3M'36;P^M%F?T>Z)LU\MY7E8^NN7Y2E?0GN?I/4YOT"XD]%P[CH/R MO#\Z9B@[FUQ/GN;P?Z4&.1YC-SZH+L(6MM&.OOGYL$%[OXR]9;U:%K@TP7'6X-<^[CP]5=DK)S0F M0T6('[?4$_,5MS#:5:Z75FIF-ZD-QK8B)(Y;*C5YI=#Z*,W/W;B6XHS#/E2_(LZ)E:O038$2\)%EU))Z MV9)363YOY_4Y3I(36JRU?*RU1BV/I919=*?QK&AQ/4GM5TIR!U2RJ$SGT=LY M?M[HKHR'R4EEKCUBKT.&I)35#+8_>KE4: MTTZ-'@JN;1VSO68NA4 MNL,I#O(-3L#7OF*K/BI.<_3Z:7?L]4FYWL9!.[4H6WZ\*W2#.C9'[Z\4N_A( MY\TZM(]R)>^N;&YE!DV/.I WO9E+]JL:GN'%4L7#%DY]%51Y..I ?MY9EP?" MC,!5NY?NC:84OB@%38\Z,.@NN+4PIN/\7%X7L"8]S.AE'S4]ZD!KJ26K:J4E MX^5,$6M,V_*(EWSDK1UUH&++J!?<-+ \JME%C4]ZJO2$=-,;C!?M2!A9,DA;YJ-J&P MN$HEJPY;?CYH>M0!W\T[,F7Y4%G[Y+KL=>?X? #[FCCN0%*ET^FFUB&U>4.R M^?A\5,P80=.C#IA=FBI8?&JE&2NL5Y6Q9;>_5%#3HPZPF50\[DQGU>V2 MG*%7R2%\ZBE +?+,=+K@%SS=E3KY=!7'5VT?-3V:+7/@)9(3+IOBYWYG#!() MTRE1P5./^DH,&L.*WYW(7-M9E@L>-DQJX5.W?3W_QA%YUHVC^"5_&=P*]Q/ -* M!0K-025>MM<3@M/SL#OA1B3878;8OQ3VBHABC6(Y%ISR!"B/,^QTH$FQ,0"[ M.S:N]2+OT%$]FJ,,O"?>=E+ZS^58]D4>B'6_P(US5.'FUQ4KCWQ2[8C-#&Z" M%6'9+;3')\X<\&O[PW[?D'N_<>V1*R*%#NTV-!-$$D3/M;8?A'&$X).#:,-> MY:Y-F^-HCFMO.[:-)80C_W#-QD3B)T.\56MNS^7:>R4J+#"&&K\5Y/9W##WZ M5QBM03&WWP9*-O,3O'C;5!Q!O]5SP34B)*]7O=O[WOMU9R_H]<>U4A.):%[N M;UX(^B?]9LW*:&)N9C!T-"_W-R\$]9-,1A-S?Q,3_XDST;S*9H.=O1BY@S!7I3?WD*U M[EI@OR6>D=+],4>,E.Y<\O;'$F/.U[FW]HX;Q7*X%9[=Q,HVV6J>-[LO2YHB M#3J7S7P?V'H_\;@FR_@ ^V).':SYMJSAQB)Y$%YP>\6YNY7_UHKS:&N[&*[E M_PG_9XW#_X\]75]]X=7]#K3D > E6K\?0INB]3M:OZ/U^YNNW[**0LARM%9' M:W6T5M^_-D5K=;161VOU-UVK]Y( 1NOUXZ[7GZP5&5UTG,/P2W!G_E!%/K;V M;D[:;@_LSI:QX/9B;'L[^,)2^K!,=O43-K7#MN>O/\EL+KX*_]'@0QTX_O>3 M!K]9;V^L&I]H0+O[()M-2M$%>P)SO-DQ/-&GX$E73;"[3HX.XZ";YNC]+P0, M/X9O)2!D>;.'6-KO6AO#1?SK:*,4%CM0U\%5C4=9Y^]=1;X48(59+G^[OA_G M]) D ,;C4WAT-QYW >B6M'+!J7E_[X!NOGR?QWH_1FL_2QA79ADC1TYR]()2V+*W0+\41RHLT) M)F=S5Q21A2R0=-A6SHJK*OHR:\H#^.4?NXO 2M5;97K+ @<:57'>CN/C4@YE M-R!__!O>6R3#/-74<5W7BQK!C0,"6Y"_H&Y?W,-_&1H*[@CNCSK^)%J-<@X PBC$2 M>U(=Y^FD.+3[%:DL95DAB0A(#HQL3[17,2+Y?@[RA:C&%V 4-R,4!^I-X4.H MX,F*P]5%7&EDQJ"96YU=A/5C7"()&DXZI8M-?,YF^6IM0G33&1\J> )E_SZN MY/ ($97?4X;3H,CH2=5#&X1*%#R)@B=_0%LV M6I16K6=7L3R>425OXM>Y_%*>Y%I\OB=4K\)>\'FAQ@T[U30GJEJK#NIKW2FJ?K4^3Q@H<6@40(D"*(\80,E,@*3-+!45*HN"*%$095O 8J<6G0F M@P4>E(GSC,'9A9>E%8SLX"1CM+"R)K6F_:LPD]RTVR\(RZ6-@YPY*J!1G^1IQE@S0]<7F@%84:HE"+1\G-SM% M>D;X5!7*8JF* &]7/!?GB71[E?:O06C%XE8"') M*++R:)SB=I1B7[LKS40I*ZS6.:U<4IVT5<6*AN-?)XRB6=E1G]9]G9]C6E*B M,'G!+9I(OZ,XRKOB*(DHCO(UXBAI$< _2E$0)0JB_ %MV6C1-GS2'"U=N4\S M>&;:X5*U_,"9U"Y_T2>L2"YWYTN")/-\F4PD[$YFE6\6FS_^W=4QVVP(I8YH MRZ=A(_7ZO>*O$XVY)Y.Z0XIUN[#-H2DJ7-F="7S6U.;>$%LV/-%=$5-$G?9[%O:+"*)EFA;6Q*^T-]?(""WK5N*&M M%AF_TVC.I&PJ*+9^!M7X>HSB6Q&'APR_L&"ANJ@,3Q1^B<(O'[_E'&K1,Q9C MJMSTJ>3:USPNP0 *2XI)]2JI5F1,$&US-C.U-IVB?;?-+1I#7R 2PM+DH&A)%0W:PNZ<7/S? V^?< M F?K;!F?"V*WC[?H;-9AK[,;-$SWJ*YH]BDM,\P5VM2,$&G=A[0;NK%ZC"01 M$R'QETPD=I6]H(>C,#>PD8C2O&U;F4R.3,VRB34WCSN57K:?5U;:E4B-9E6! ME&(DBJ=[K?QH7"QI<1(R?>IKQUR^89SEOUV$N!?HUM1S7'6\VI?$"Y@)_[)+ M&4S.WEWO)NCSCE"&F8M M$/8^V2X])T3ZX]^:M1#&+B\PCWGMD+_[@;_O-C(<-R/!$V MAP^!^BM-#L:G0LDO+ G:RRI\ 7P=Q)> X*%OV$ "R*[W['\'&' R0I'M@$8* M5T<'"@KV/S#ZX)MP'(:SG;R].C!L#"+:&-AHE$XPIV( 1 $".4\(@-!@X$\V M4(T1'$DP. ?!AX7D"COCN+8Z"E1E_XU07R$A"\0$E76A2K _SY+;3/G13&]T M!?V(_G2,6T^()@9_FT$3L.38V+:,-R#PY;0@D6X% J$Q4'#8=$]O CD&XM\? MSIX2_T1ZOYO14R]YBJF& > 2X (XJ]"'0UT.FTJZ!2%7V79O8S0=6S2=#4\/ M.+.<#(@1@4/A/^/UH??K@_Q>U\?BJ;C C% M&_& L#S%GE-0(*1P7ICS%J_V.#3GK]]A%\!%,'OP6]#3?IL5_;:"68^ MX.8^^[3U,1N(,0>.W=L@>+2T)\U&Q2X;^+R:3I4'GCMBN^QIWW97??V4\(-: M[+%-G=?87@VYV&&IF[7E7Q6I+\[<7]5.A_0:7GTZY# '+:[,A M1]P53O,A1=HMIP%90K8V]&Y '2Q1N[_:$#%" MF?[][70NB"&Y+ZF6T<;__!WM(RHT&HVD4*X%/[[/_"?K5 E'3K%*+ V>2&B.)+) M)JR&HO&7CYZ1B6WX;!<[BU/A2(->!__^W_^SW_OC_H^9 &;83+,3S+QGV?3VW0+"2)&_628_\2>?T3B.)*E(2ZQ M/8EM]!C3P=C]%7YK^U$PI]O/(+]&D_/+!I!"0Y1#SSYXZDY-2>(G,F8(7+N- MDL3/Q(7FZ45,,_X\*_\CQB8VHB7_KU//_'BCXO:YKPQ_10^":@Q)AWY0B7#S MT9[^(,G"_G3"D!.D"(@R05O=A2O%,&3Y.0+9[TM0KNRM.##L5J[>ZK2X=CN6 M+M8[7*;PM''_:YF?,;:6C;7Y=+N8+;*M(M?^Q&[^IE=OEE]#T+QQM"&+A>*4 M$33)Z*>@HERP7N;@NFE**F2ZD,BZH7N]J]AVI0@[ O#8.P;T%V^*G@Q71OGO MYZ)R;V+@H0F?LDTQ8+("A2?),8.G!)JA1T)"IE)"BB"!0. R(8]'<4F4I!^A M#HJ[>EGYM8(ODA6&SSB4:^0X:]W+^D)P._JPY6HNT<-).F_@*LFM%*.B$I4! M*Y "_K)E+]6CA(2JK'DPR@\K"W_>*26:L"7YLF5?]E3,KS8MSNB,U75&SSD% M$3WSZ.UE6TE6QM.,P&B0;PG"E8;R=F,9S96N>5H3$\3.+H-J.J^EY0Q.-E3:H)^)5;N'# MEM3+ELN.22^\H5WFU'A-=X;#<2^^4@3J^)F<6Q[&<8!4K%1R5%#EJ62[ELZ3DCWQM7NF4['DC'<^[*'WW M44N5@CU(]FM=C:ZD6)S1*IS81-D%CUH";35OM5M=2LM08XV=I9>#G.>C9#Q' M3=W4G,[8]:6MJ05&L[P!PPT+"KIK?]2TFW)Y;%&)DQRY8COM^8+JX9TFNC%V MU#35JS/C=H5;<)A-- =-MRG7\L$%AZ.FK10VRHFS48;W%H(T'VI2O8AM#XOP/N4WH"M MZG.XL;T--^X\E_#<\H=/D32G1&LR!AU.JQOJP%UZ2K&<;AZXZVUI F1/A\[Z MSKM"I)8UY=!Y?^[>MG>[SD&_OFA"8@NXY0PM#\'RVX%=2^N6I/W8SH$XGZ2) MWM1P.7HMDM6:2Q 4K_R( 0@Z4Q]Z>B(.0 M.?0E=]'WT$]$(4=1-7>VMKD,VGX+[B)MGDJ'QW%^QI 8QM#' MM'P4)-FXHIX!104E^=H>81#VA5[T-L:]"9)!?70\W44/0H&R[R/O795C$[3?$]_J&./R&OR.^(86L=>M_ M!>Z"Z+G6]H/060@^.7 I]LXW;-HW8UF$(1_[;(Q;!4ZC$3SK^UGF* M/1*U]WP+/G,,=6PKM>WO&(I*_ K]+Q_*Z;>NSUZ<:-=4'$$FZKG@&C[/ZZ>T M]K[W?D79PI 7P T4O1.T72PHQZP* SC#X,$I!^\+(._I.Z+.HQY^O?6QL0830MC,-4VVSX0PZ MY]V(\Y:#?>S?Q!JV(8O9,A9LTL2VFZ 7EM*'9?+:+OFA3.[7P/YH\/M7= ^O MZW[*X#<(?6/5^$0#VH6G0S&A('6D)QQP-1P(*7ZUSMN9 M:9;',ZKD3?PZEU_*DUR+S_>$ZF47']<;+TBL-%.UU3HIC*T26^IW?8$ZRO(> M.:/?UQF]0I[->US$[L0C/0F]MC[S*R*N, M%N2K)YNYZN*<87JS>D7LK[B\9=/ZRBAUY:8/8> CB_.C.NT9H.N+8+8COR7R MV__$^'>*]&SPJ2J4Q5(5 =ZN>"[.$^GV*OWN*FT?6MM]JZ4T\Q)3X44K4Q]7 MW5Q_M6P*2;2VUR770H5J-SM^,*Q)$OZ+F_4:G^.Z+8#UK MQ?;5EEA'^92^E4?^>BGTR!EY7*)^;7?\8L73/[2:4PM#E.0YE\?%PGAJUGJD MG"!8.) /%4V/["!RRN_9UA^2&7P$,6YUU#O.25AV*1I:OI_@ZDUIUS%&,U2X.BMEJ98J'1[B6;O2!/Z4?* MD4>J_-#K\WU:Y4,NP^^V[1NMO8/VM&(;LP:&B\T, 53=,6;]P.Z_DY/^FRK= MD8/RN.3]RFOYI]?U_M!J3BLM7J'KXYI6SRWH@5IS%]J\B5*)'URVPB,?_0Y\ M]!OFZ7@H8=T\$\[CLI S4.E6,0"^31:$-370Z,18D[ D8"DS*'[P!8, VX19 MD>OTJ/[&'4CA6\[\W2^8G^U4WWJL9QE![*\[6>^V )M6+1=(DV?O6^T7-+*9 M:&HX*/1J8GF=8^/*]2+?4(S_^P,[L?R)5M\=UD!WS6/Q5E9/ S&-@Z"@#US^ M$D_XB07P[R_IB;^9!^Z@;-G;2>$BS^4K.._77H(C7;F2EQN'"YEL>:C0SCVL MVM=(0W9S 7Q&:I-M9=HO6-#I 4LT[WWRS@K-Q+W7!H=+O.39-J1/^NI4Z6Y4 MM$P&N@KG9+4M9K9)G]9N5-F]0G"N%1,-RU2>-G]_.BA8AIY3-!=B'IBQQD2$ MA$\*[C="#K@IZVI*/V-_;0K%;5KN:L7]Y5I*4/ Y?.BF5="!A@B5!>S*RH4- M]O_RHHLQ7T2#B8F[*N?[%>IZX1]WG/+YL3//=CP1-HI"A28D(ZF&$ML5M(,\"THRYD YP?X' M9=F#;Z*BZ\YV%C*ZZ&QDQ\9F-A@#&XW2<2U)"\0=U,T&J%KV3%P%Q>&>8#]4 M8P1'LBG.MZV9#3OCN+8Z"N9\_XW&6? MMD7Z8C.HRY8<&]N6\4;YO)?3LBV'MZU"ORDROZ82WQ]\=+J'\VN_@@^=I4 M(98321I/$DEA1%"RD"!3*8%)BJ20)' J2=* IDA49?.@&"O=MI.T6?;KFMK3-=E.:1B6';6& M3$EL%]A3M85;&!M?J-U,'_>*2W^B+P6KZS9/U18N\ LWDS'+F@:Z>+HAKI:9 MY6R3+.JPI3]4T[E1@^MK\W0AZWIKHCG+*&%"F,.6LP&NC4O)^1A?\7ZGEY@+ MS%IF84OF94LI9<6-=);P^545#*?E/B!GB6X M:;&$6A[U$\PF6+VZ[HB:",RX)J] JB0KI^HJ\XPYLBC2Y34QAR\3G=XPZ=3\ M4W65.\)*<-A^,\O5:5'(9$JZ:.CLJ;K*O"RG1">=7.'U?BYC5E+#Q-Q13M95 MKJL+31YWTRD.KG!L+Y&?#DSA=%UEG]=]*4\00PZ4V7(YA\TJK-6<).V]RE#7">ZXFJD9S7M62L.F) MS&N*-SO2G3 MX\041N&\T-B!$[H?SY2$+$UP;9QF,G1K7%IA!0X^]83ZDD/EPYN ME*?3ZDIRFG,[:'HD@6ZN1V%9H$QYD1RU*LVZCAG3)FIZ;"CS++Z(,]Y4:[,& MR-2=H9;/!T_="NM"990]!U-$48G63!9EEVTH8PX0K#)!9]XUVF_K5EZF@?!0^.Z@UFR2W!%R%2ZSI M_L*"3U[XR'OEK8GDS]A&,I#6A!'2;9:)2T_(KK3URZG9ZTAZM?GC\225[8*3 M&YB$I6%E#<_.YM!D#/]XDDZWN^@DG5/FVH+4%)(FQ+C>NZWLA"(1UKEBNMUN MSM=:CY ;8)JV^?BX>5:H_;6I>@Z<%VNY@] YY@ )A<]1?4#G^3S+=E:ANHR M71^'DXG(VF8"G9?A\9IHV\)02BBEN%R;\9E9.5&;LHMBD6_^^-?UK:/(./0J MML^,;40 78TL0%VS=$M9Q1JV)7N2&VO#]SB!7W#H P8?;38/S,.O9,$"Z-8, M/32LORU*$O0G@KK9,TM7)>3B;5VB%X7!MYV)09H<-'"@2!#3=2>6 PX+BS^3 M6_)DG6_GN=#W2^\%J8@<,&SY::,VZ&N0FGLZ?'E IW?*OVV _*S1ZH3HH@K> M]U3!F_J93$1U/$]HR][WWJ\HGU=@E?Q)1O-RA_-"_(Q'!8GO<5Z(GP093$#A>(OXU/?5 )'\?4K'8!_FP7>0B3;MV3@$$:V"I]: /H"H&&A M-XBF@YTL$'T=@?V.GGUZ8/,]Q:X?2X:_8U(/;8=_7FZ=(']>5CR?7$W]<*OC MM6/S7TE'K@3-;_/:3U&#WU\].O[W%G$R[XD+[NU2!Z# M>=U82G>];D;A5#=OP0BVG4]VO4[>GUBW.CG7ZH+NRL=8^6/ M?__Z+Q7=1;$\Z+_+SM\1 8L6C9.+QM[)Q.^P>$0*3'2QR4^! MGNL&:=?2GJ.:P'&VZ2F>LTSO[=ML(RD!D=GDFIZG#!SC^!'# XQC&''8F&+9 M@PH+6/P=R::W"3-:H;D_I\>([[)'ZURS,*V/RUV^[M5G\;7%TNI:$6@A_N/? MU%,BD7RC>L)% ..>//T(,"+ N!/ .#QYS9KRP<;>!D/V:.X&2/S_J ZG-D;^EZ7F>6%V7E$@BQX--ME@,^K67P M>%I2W:[JZ"@_9"J@&DGJ$PLUW=X'RZHVD%PXCXZ+#NUSIG0=SDS+05NOC/+)42+ V17FXI:1[:(:R8 8M6@U&!G_6 M ?H!MF,-E%%R'7Q^ O5L:I8N-.L5 3?809F9S%+U@<-"T4 '*_X43Z;>JLYS MO^')"":^.$P\$*NYFF^T!O!9HC.Y"G#(4K>1[>;''0W46Z,*5S#C*)UV$CE4 MNPHK[_"J(N1X !_I@:_;/C3!N+Q#=!%L* A^;[GTLVE.S3I$O>L[=%YN0G&D MWD$JOM!&UW,29MA* T&N8N1QG?2THEVM+QFD?ATZOU"D^I$P];I.6QOH.IP* MB)G5+02\+!6^%X*J@Z%3X[("#^:3/(%E9:NS9 4&.6.))SKQ3F_WZ\["EKE6K8JU">[A&;6L9Q*N790'"%O.]-P[J>ZZR:V$!0T""C\'5D M_'=L_(_$8>[E5.!YT" X>%TKXEF@&06I)*X'10&;HE*MT%,BXD])BH[VQ*.= MK=985V.2^'S#[U'K/_0KM6>6 ">U,I5)0- MU50=UP[J6D3;5M\FV'Q/PHA(U_WN;VW IT).("*UW%VF2R7W:)5C_-@5:2& MPES+CS4?U;>'KA?Q1%*):)(HHR! HH.;'PP> =(WWAF[)V%$/N9]^9CG@PVVMBMTJU2)XV(52]E$ME^< ME .P06XF_I2,OTE_WK^3]IH.W8C@G!C]. 1(A MRY_LZ=W:VJZYYW?KL7X59+F\OW8F:LRX=B*O:3*M85*E:GN3S* )6(0:*80: M*9+X)EN"F[F*J:9D&2#VEVXYSM^Q:#OPJE'Y0YB)0YB1+6^D@[O U&OD8KNY M *)#F1_!W"W %@/PJ$#H. &U;<;.-G&[*/-SK-;04KQ15*6F0)#(\:/(Z&I* MA#T/(:T'0*I'HH1WXFR>A# H7/B<$UC6ZA2+9::MJ[CHY.ER@9U5VFJ 9=#9 MC.-/./'.$Z01H%UL1_'F%GKKE)0W%\!7@:@K>*WGP4^Q-\!SN7ARC-=;^0*3 M)LCU8J4@^(%>*YEZ2M&?M,5X+][IVP58-JZKZ#C@,^O!W7K,W_ :SPW&?(0]&$7%Y1D2L2HCR^RD=!?EUBL4U"'N&&"I+K,N^F1X'_8#"><(2[@/4Z:\>?:W./\Y:$X7A M(IR)<.;.<.:#NP -+;<8F0H?YS-N)>UW!UYFNOY0=IFSH2=5:M1J1*L?+]SZ ]&\?LO>N+_9A'/ M6POE4;'Q.OX?>M6OSCMP,4=UYDPI:9/XRN*RTKPTKZ26OD!0R-\CB2?BQ"G_ M*& <@4D$)O< )E=S\OX,9)SAFVU:W%LJCHLSEW+EW(\B EUJ[0RJ/#TIY^2EJ)5ULHD0!)W/ M8A)/3.(XX\R7W.KK6*ZHQYP7)[2BC;[H8'_XBNA2T1TCZ16=OQ!-B^:F*F'X M:P'H:Q:/TYB_T/#TU&E0$&3IH+ Q^40DDE'\/8*>"'H> M$7KNP%7\ "2Y8&9T.26_YNM+S9MXG4G/]UD$26=ZCA$F1=>"ON6UH'O&I L[ MEA_ F_ET-?;6F%[B@<97V_WFO,C; 04*[@%13\R)0LPO_,S_=D4X^1>8VZGG MN.IXM:].+^ @_,LNPD'"%N]%B'!,-<^ O9!._"ZKBW__!_ZS?96D ]%&%C+Y MY_"M<=2OC7W@^'\NHN42U"-@;P5!)K:6OU/R.!V.*NAU\.___3_[O3]&@(VI M[@UK$MZ)(@.K50 VLH&H8>(8OOF7J/OBRMD,DV$"'SF$@5\["B%$_&>8_ ML>&HP M+:XU^T42/VD$E/#7S:B(Q,_$A>;I!1S'GV?E?\38Q$:8\?\Z]_B#)!IOD"*6M<2R#\,Q$@92-18BA57R.0(YNV+VJ MR:&8+V2+;*G+M3^SF;WKU MYHW!&N223MA-UT+BE%&>(#FVC_"QG&J*IJ2*>FRW-CQ?+KS\& )M1)CXGBN0 M?_&F"%<-V.V_G^\_OHF!AR9\RC;%8)41$F(B$1_CE!"G1X20P E*8' J)3#B MF);QA)08,_2/4 ?%77VE7'?=<\9+AB?7Y0R.6Z-V"6W3"M3+EMVJ(U7C\8JD MU99-(=NIW2.+&'L]EZTN&HN"+$!?)ERV*"3TVI5DWF MP;A%)JTB,#LE%K8\>B8_Z%6M#C_(XH8A2ZF64A\/6KZ0$/"7+?LLPS=XR^GP M[82M5NJ&F*_64,NCM^,CN2>-!L:$K]?SM%3IYMM&0H$MC][>GS8:_"P;5WDZ M3@(^3=>TCLL*U/';M<)L*@\]8\'5Y0S+Y-8@IW1]V/+H[32=6=>7R2;!T9B5 M$08U'U37"FQY]'9_Y<\ZG*,W<+I.K9GY+$Z -'HF<]3/.E9ERA.OJP&@EN4) M._3Z!BO0Q_W,,TYU4&LG 3^GJ':='O0!VQ28XY;33'.TR'G$B&NG!#U-4\,%7_(A M?SQJZ0VGU:2BS-M\?F*O5R5EO*YW693V^:CI4!@XE$![<[Y=E;W9(C6MN_4F M2CIV//-BJD.GD\F"EO<[59-UVS0Q]M%-[Z.FK0JI-%/)>A\GE^F$G\EY?*(6 M7 H_DCZ1$W"+ZN5T/D^5J$Q2(@G29E'3(_$OL7RJYG?T)4^S&;MKIIF$.0HR M71S)ORK.O5:YT!KC92P!:6Z"=X@X[&O\N*_CRA2K9PI,AL_+DMQ?YN;ZEG8ZV5?XSM6L)=R/*WKKK%.IE=Q+9.B.J0*)V(U"]SO MHZ9ZEY5K@E?*;U[BN/HL0757PUZ&I4^"ZMS,<'ZY MD52T'C8LRL*,S!'08$^ *CZMZQ8[-D2>Y,E%+V<-DDQ/.06J9HXL)YJ^W.'R MH)+.Z.U$70A:'D/ZE%353DK$>) @\UY''6>T_DE0!3A(D3TZYW%>/3V=#=H, M:^$G0=6K<6S>UXR!ELD)%K:J+:QB &O'=EW$%FQ&&+6U-B[D.PNY8:OKYBE0 M70KD7*?<9DVCL\V*U<7SJWC?/P6JI)(OX@MFX>/ D/M%OC:*9V7_)*B.U\5) M6X@7^+PYZ-%XV1KW>NPI4+4SS,0NP5'A2T(*[7 M7+E!V%3!G4)D4T[!;[N324YSN*_P]=JD6-**%3GN;DK:OQA1GVU/2ZMB#L_@ MQ85 348-)7X2J(F%'Y]X$ !X;]:1"[5\15^HF[JP+XE$H[0 3*^'9Z3D>%*= M->=3_32D)[MK;F@O!%53Z:D_P].TR["G(;VU9EENDFN;G&BFLJKM)2BYH)R$ M]'RAW>^DNFI*\T:-LE4:C:LNU3P)Z>4J)YC]I3CD@4Q)> &XO7)=.8G3*ZMD M-#U:;V@9*@FHS%2@#>8T3C>6@X5ETOB*%^>+>EG61\L*VSR)TW,_U7*-5BZI M999D-L/DM69"WMZ'>(%/7=;--I3J7,N#T;3:7]@,2_HG(7W5'VL5J4WZW-RK MI1C'F:7G>>4DI-M6S6"9DE3!,;%M^JEI9@ <_R2DIQ,I*3Y=HJ52S!B=>K\[ M[F7]DY ^BP_3^7FYG.)(@U=ZQ3ZW+I64$Y >)QAB-!X3 I,DDP+DQ0F!(44@ M)"!M'C%C*1DGY99_P$8V<**6Z>3DPH MK#8D\#I["M);^5&GRS3K'+_JR:UASQ 6^(H]!>GQGI/TXQX&H!DFDMB@1&,= MHGD*TJOCF;'NE&B/SZLVDU+ZF8788D]!^JJ4K1,U(I[!\Z5NOY"9#IB*WSP% MZ2Z;%H3, "]H\[7;FMNSA)KIG>3)GIAJB_%.8X1GF@SC"!1%Z863/%DOC[5I M?8KE\;JXJJ;]K#O/&REMQLLHZ?9JC=<['IJ;OCVGC3/P7I25&N M8G:G+&J>6W.'8[67JG=.0KJ32ND9OFY*&H0LND!P]LAO-4]!NFG@!@]6C3'? MZWI3WDP1K@P7OA.0/EDL^OFXL^AP]79/9$Q9J]A]_Q2D,S1CZ4;/PWB#6HW7 M%2I=DY?*24A?YI2.Q["LHQEMJCJ;+)GY-*V7=0XM2(5V7D9BA?X)R%=)5:K'&D#6:.[_7%M3)ERUFV>9.FN MV^XK+9#B-,A/0+8U%]9YX31+5Z8=;5@AJ0Z7,5UUI74%RX(:=0K]ZRL#JY8- M.L%[E)^F=;R7F@[8D^B_5))_9P/-"T MM37JG";TLN%)#;\J:[B'=W-+LY/M&CWV)/K/%9O+&F7)TWH,&S=68C6KK-A] M]%>7O]#V@FIZ0;*Q\(LC(5EF$@R^PM8XH!2KFRS(+-M6!-24^/'JM\IVPBYUO:#,%P;?'(0U-W;"=JT.0Z:N_:V8]N0;1BU>O\5I#-A5'CJ5[+KAPU/GE MILA>PS/V0YYW#BY\"#F:B"M-Q.]NST<3<:V)^-W-_6@F(FSZ7A,18=.]3$2$ M379Q&NAT:\B/U\Q07@-HO@]P2'B Y]=6OX!OQ(-.4O28HB M(+R9#"+:=,9!C"^X-'XM(/@&:\!>7IIH+?B>*G"0#B12@H@01(3@40D!\PZ% M0#__4EW8/^EX]#_^_>N_8JH96YT#_P/D[X@;?=F'8)JJ+UH1O/?_1]$>4 M(*($%Z4$-\Q/?4P9WH*$SL0&(%:%?Y@X,<)(1S?\;]'H_VL->+&ZO$G:TB0Y#92@^^N!GOI12-E^'-E2- /K0W[ MN<$.!?29Z?JOSC;?3),&W)@-C<#TP&L&\*B):E^RJ5MGIKTZQ;Y&]NN;)Y*] M6!;9K&<'%[>%I$ (B#0*'6N;5!;^\GDY]NM*+[T*K:F>5$LW,="M M!9D;48I[YJVR1A%*1"AQ7T&VAT6)$ZGH)^-NLY=-F!,MDW Y80@HQA63R+:9P=[N/QSJ>56T@N7#B'!2@>97'^>1\4$2U ;V0I4 MM]P4Q\B"&312-1@9_%D'Z ?8CC4L..?KX/,3R+68Q@?^5)K+7)M+NQEZ#@;- M!$I1BJI'/R7Q8^3Z.[+\R/(CXG%]]V0-X+-$9W(57&AUZ]8BS75XCA;CXC0S ME!-#M1GFN4260I#_?(6"S]\%&&Y3LOFVKLM]#ZA*#'VM06J82.$27KMW\@'#XP-&G:@-=1Y4%3;FZM6IN.4.EKTY@7R_>;Y'Z>MG6/+E08;)R@HT3 M*$\W])423_'D<:3WI*\4@4,$#G<+#I';]5ZWZRSH:#O"G/2M<8DS$OE1;N0* MH\YJ4[7E'';R6Q&:HC MDGH'ZWB S:46<(!H2Y/ MY+W#YA&T:0[!;,HS/P%_*+7>,W6'B$Z[=&GU_%I M7.+5>D*NR7P&[]6 "6]0#ST24#=54'=<.$NM'L9DO%)OY#G'=^P:] MZV[Z;,P:;78?&/7K$*A7>3P5CX,1OXJO6CU5ZME+*ZB1"IT6=I?.!H]^M%WK$A%/P?)QAZW1S-2^3 7#0Z&9 '(_VC+\V=-S3Z"//Z\:> MU_GX,?03Q?0HP>6UMC(H-K-T,R/* 7X$-XM2;U./!]C]J;L38,= *( H4'0. MCMTP<\A=""&D3+>6PL/"W75]KL#.T8ED"'X;N*O/ !J+J9PZ+S/1B5)<&[9X M.D>N)LR\QHP+$/<(Y' 1.!,%F2/LB+#CF[MC9V**A+D4B4TIE_>R2G9.YW/J M0O 1IJ \#4]Q,KKK&*'*)VQMW5H*#XLJEW? SD0,8YPOX(:64G"/$#N9O&&, M%DP3(49PVRD1/_?LW+)J3)BHIH?VV*^V/63GE\$)P*1"$0>]-;(_8+(Y7RK=P-$,V_4 M!RIIC'AUSN6M>+JSG@X"DH'."!'Q)X9*GN=-/@LS(V2)D"5"EF_LN'T <<8Z&(X[L]48!XW:(B3GD?B'GPF[>!^!$'QML-E%,"#C(^3@H\.HXB[$(3I#71Q)/ M%'.C-3NU#/84JKXLS!_S:_K#_5AJ^:A)>&#'$)1;, MM;GM"*:#L?M+]%QK^T&@;N$G&\T.V^RI^J8-^F1C-3C^'S0: MB-\=RHMF(L*F[S41$3;=RT1$V'0G,Q%ATYU,1(1-]S(1OSMQ',W$>3/Q ,=Z M7QDU<\:H'^!,SEZ$3@*F"^QW"^$HA<<7NFG]<:E\T50"#Z$;7]UB)$M''_[O M#_+'1Q6'_'E9"3'O$-!;28 .M_L>*@G0O6/&I8'S'5,?5C;[S)K/5[X'=L&) MC1C1P]MQQ(@B1G1?NO'5+>8;,"+1E",:%*'E@V?RBHC3UR=.$>A_&NCOG:?_ M)N ?*<5OE2)V<3)\:9,I!C;3!S@PM*H3[$\:?P!Q(G\4R"N[D/Y)B1&IPF>C2[KKT(RG#XZ!$@GYH_=B_ 'LHH$?.'_3V MV@K/\U*/)P&9*XS;J=9TT12"+#[$$YX@(YR(<"(J8G%IG#B1D(?,.CQG5X0\ MGZ^6,);RYE9Z=!$,J"S+J9ZF5#P<)+U9ML'VBD4684 *D@7BB:&.BS+?\3;D ML9)G51M(+IPYQXU9XYAB67)4PN)^,>DS(_^W+T=[N?+P#^:M9*#YU<=Y9'R0 M![6!O5 EP"TW.<*R8 :-5 U&!G_6 ?H!MF,-"\[Y.OC\!'259J) VU0M@=.# M-H55L1$](GTAN2E($2?B;]63CTP_,OUK48]=!;E(^;Z!\MV^BO0=KSN7)[L7 M66N2Y%AGIOW:BC?J[>J 4%N985J!:TWJ/6O-(^\K!*P@!O4E!C_6H+A,)6#3 M47&"KQ0+>!W_OD[@\+Z!\;J$O UT'67G->7JUJJYY0R8SJG\O!6GMJ! II#@ MR@DL5^FF2E255P0F(-KD4Y(\WE X2;0C=(C0X6[1X0S.'NEQI,<1_;]3^G_6 MRJ9,%Q0A&H,1-SJO831]>'*EGK/RO8 X>\6<(!H2Y. P,O[!^.B4,3# M@=177E,CY8N4[SLMA/=R."1<'N#[]][U^GJ9H*B2W 89H&%+%0X%PS"QS4() MT#_^3=!/1.*X!GBTY?(]K#VBO3<^XG&>)4OEOBLPS189,FI M]UCR(P>T\\ $MJ@'C%B4#=54'=<.LE)'OG[DZT<4YT$CVANS1EMY!T;]1E@[ M60/U*:;-<",W*/GD(I\8I'R!P(.#\D\4]4XR$T%$!!$11#RP%W0^=*Q'XWE5 M(7LMKEQIK<=#,,9H+X .5 W]80G$Q%V1-@1;24\M$]U/B[DY2*?6=02"E=N M+ U\4)>]F:@@7$#'Z+R?M"92% L=0 ][WE-7A52G&_;G;69]A$2A*>JJ+-/ M53W,WM)F=F*J*5D&B/VE6XX3Q7TN'/< !Z>&XI*LM(IE MS6DS2]O?GZKS'U1YDJ><*N!&8G?NDRJ,U\1;;)SMBTN( 10+B6@Q)A_>W_YV MSTA"[)B -J;JG-Q&"&FFM^F^NJ?GHD\M"D2!52E3K)42G@I;WHORJZ!8S M[R(CZ&3NCEX>C/'JPJ0L%-L&BNO6XTUG)\CP]S^?ZMGFN?HSW]=)17TYLX]: MC\.-XZI3%>9'+M5GTAYK=ITJ]C6QYT16A:M?W=^BTSL[D7O'MT;>LN[.;8BL MBK0?CYC)%SA*G&KK$*?9Q\Z,\+X]7.!3794?WW5S#@;9.=6N[@;]]M5)HYD7 M/Q4TN2#^"7&M[+4:VE/OZ_&O$^=[31<_2VWM^K&+:V5MC;4R 2!DCJ^&7GV;]42RAJR^) M&7'-L[RX"4B$"8B "-Q6;&PK-BSTN'TZ?6[IW8?"0\.^/!I^_>$T?OUY?5IV M;1MBWO>OY;[3^2S4W&.GMNEBU87#03$2%*UF*D67WD(6&)2*4W# MEC7!FJK5X,@1KVK;EUK:^%K&$$,Q9ATO=/>,&/;QG&CM4\/$=\[K]*!^JIC7 MST_V0];2_AS_?CDW\E=@--DIRU)&+%9X$H9;%FY98FA98A"X;6!QND\E\;3V MW;:>^G=?&E\N+S1#^CY$B_/*.(Z;'&YRTEFB'U^3L^,P;P-S(I^^-.JGC]_! M?[)NK-:U+E9'S3J:$XSZ:J5,M;(R-?:/+0/G8Z/I=#2^V#,Y!9'7Y(%%#KT_ M@F\MPZMZK&R_+[]D*:]U7VRS&NG803G.4GFC5UR5R.??X5AMTWNK^S21S6%+ M:<.V^CSG^08\LZ,90X\DWNK7(+Q-6QR=1$=\WHP(WPY;H&'N;B_[M3R)(S(B1&K*HQX8P(BQ&KZKLX M)[AMVB]&<-L4%T9PVQ033G#;%!-&<-L4%T:L*A/FG'@=)Q)0BKM@UM57S#H! M!3-]&93P9%R MNZ50=0T"+>NS,IG+2U2?E;C;#&XXH]CNM4,JPEI\!*J:S@)^/>A:L/XE%ES^.;CP5M5%^R>X5@0*N Y1]Q? MX$N#A\N[6_;V9%7@$K&N1.R)0' W@;L)H;D)$7;>F'4CEMF :U4GPA5<[UG" MB=XF;>&>#&RZ'XK!C(5\AOTAY?&LLV28BM?1(-B0?+(Y>6LW:T+$TO$W:P;= M\,_%8-_%(+ 7FPO#WPM#L9QH:0CNI9TD4));$2U?-XDMF* $ND,6*0#?U9_0 MYM9A] E)[Y[\J1/TQ%K@!#WXL,5^0^7L0/Q<$/6'QL/Q%\,>/&F?FMV-.UG? M,6V>=PCPW?G/H7/ULR(_]!^^&)4'^;1L6=U'VEE(*F2J8IFW^> &@1N$71N$ M#=L$.;(RJ%BJ:IS\-OJ?'NP?WW_5?NS$4/P9%LC#[>=A/3]2OX\>6_J=>5W\ M\D@; HF9Y%IW_>/#8J^6SM>[%_T;O^<4V^[,(& M2&+G5)>Z7T[STJ_2U0_QT^EMO83. G;Q*66*M82?;W&LFD2Q@7.6+1@=H6L8 M;7[(17QM4HH.,OVP^_.^$Q.M-$#];CIGJ'S@!]T3\UE5R,F+VV[LF Q 254Z M,_A;(_@'W%?O&\#S/_3Z'-/EO'S[U#]^;AP]J!>%Z^;WX:=J51\^5C#.*6=J ME=ENAN^YYG/-C]61?CW*Q M,[B1SXZ[L-34UEAJDIQ5H#Z! .(BP.4GH);>I;XT/^4@34C /AP7'6^[&*X[ M?D\T#=O\ZNTK3ZM/7@9$M^8U^M5Z7^1^QS;EI_O>X]U-_T_GT]?G+X]5>EJT ME,F7B^OYV=PZ<.L06^O 3X'FJ]SNO?]7K6SG%]KY:?GV[.ZI_$!. M[Y_JO6*K,H25K;;.RI8 \/N.6$0VE1YUX-O!(CB.1"3.2*5Y3>7"QX5OGQ;" MN)2&L.4!WA]XU^+ULE@\/7>TEI+/2Z?=7]\^BQ>7]ZTA4*#\YF.IDJGD2SSC MLJ?:SMW>B L\7J?)ZN]L]O2N^>7EZ?=WM=J]ZRK#_-T7F%UM'4U.,J!]1G1B MRAKUB.5V7]55RS9I!VP>Z_-8G[LX"46T7;7&3-Z$4B\V@:4_9J5S?B87GAK- MTEWI3OPSO)*'CV*>XMJ9:K[*86UN(KB)2'T4]'K3<36R/]^5'I3V$[E7BI=/ M52O?_EE'TX$GZ58RA2JW'=QV\%1"LF.J#>R"[9SK]>')]P>Y\#P@9[>C^_)% M%^T"/1(W(]9F=]XE*Z%P8_>(*1!& 0[MO,8^1;AA?O= ;]232ZP9"S=*HNJ+ M!9)@U%PS=C,@.!>].R\_6FY=&<6AWG^0L_*UHCUGKSIW$"*)-$1:-T#B)H&; MA'B9A,3L#(PV0,(A,)/A&XE)VP$F \@+3YOG"_6DPE7Q\Z_R"2G]TH60^,>Z*>7!JLQ^Y"I+^R#,?7L_$&^ MM"N]JQ/Y^M<9]2IJU#)4"LOZ#B0Y]^2R2%!UQ>@3X4 S+(OC0CO&A28M20$L M2=MP6AJ)QDZ&T9LE\AFGP7B&')AY9O2"FH9+, QS+.?EU4GY85#\^>VA\:/] M0[N3?N8?3KJ/HD0[.V6J<^I5N77AUF5_K$N\L9YXI+OFFYJ%WEJK6:@=/ST^ M=A_ZOY\N+AXO3FHM,D2; W%<1R1#[]UBM/ZL7UYV.Q\NM3U: 6!3?35S\);D;!,J611)VO$DL M8*^T3S(.-4/A3YL+<&HFR04XO;S=$P&.OO)JXVDG&1^_T,%-[JKHUC/O*"/H M9.YF91Y,\L+)V*X_.\:XZ];C36ZK7LWW6R53S/Z02D_-^L9Q MX:D*\R.7ZC-ICS6[3A7[FMAS^S'\ZCKY@?CCZ:;_\_YW<="HJZ/NHUA$?+N2 MJ136*QG@QB&AQB%.LX^=%>$=B;C IWJ_07R7S3D0ZK??BEU[^G[7S#>>+[Y^ MZ]P:S1_US2'45R^5MU___"GWR=G)"?F4OSV[>NDV3N^^X%)96[U4)@!";4X& M CQ YY6!>U]7''O'GY8%-M>P7D=5I]('/T2VUB0 MJ977.Z*,FX!$F(#(0.BHJ9!(6[%AFGS'U,^N_@ZK#0;&VXZ M6,>&O#1^70U^EIO-A]]V_T?K]JP_J.(F[!+=A)V7,M4:WV' C0C?BI"RD&EM M W'W63(?*^W3BWP_>U0IY]ND&B>^<8S2MHU_9=OY2?LR?G7>/ MY*93K7]Y!J-)#X\6JYER;9G-Y):%6Q9N6?8X<-O XKQD'\K.8^NH=_)-*W;N MC<[@4OY#+<&@_B:G!V'>1N8D_/?O:_]XF_K^\/HYXGQ=7!R M>:0<#=&<8-0GB9G2G.9\4U'?/[8,G/](;T-"J;HCL_MVK?N!&^'+=2U!,H:9 MXD$%=/>78]EJ9[1DG.P;'T^27L'HMOK\\5_XQWN4HA'91 O7^S#YU *^U[5O M^?R[G5@I!4P!,;V)2L6QC7+M5*$2]]S__$QS]K 5W36U@6CVV=T:B5K=+ MLBV3R$]9N0-O/I2UH3RRW&E6JSFIZ)GQ0]]<(R&$4JY:?2>,_T1RS-"R+[]D M Q1S;7Q6(QW[D/W*NT3-LW?-L%34N4.3:+0[(#Y[XJF4+;8Q.)3$7!D%&#ZZ MLQ*+N>*.^!18/.@",N;*O[+0,]'L_V_SIC%/A39])?N(#P+;"M9=^Q#<_>1> M"L@/4I9F^G&5-3I" Y\.[F_%XXN;IHG MC?,,RV-?7#=R0OWZ6+A_.+J_.+ZHWUVQ5*E5*W5.E)!J;QA,BA[ MKH7\]?**2"^%7O[S=?W\QC2,XY.G+[@_<_K.VLUCI_UX>GWWE#W+?F[\?/K5 M55_ "7FL3M]9,!I'9\UA*9N_/SEN%O]<'I]=7M8?I=EG5O.=7Y7J^4OC02;U M'S^N;LKGWYTO<&=I^LX+L:EJBOSMZ2E[]_Q\UGKZTWHJ#^'.F;?KC^;#\:WQ MCQUVGI_E1^DM3:[=?*;4TR'KJ/ASMMW_XY2+%;QS M9O*5VK=*W[I_/#DYZ_[6OC]>GM^J!MXY,_GRX.5KO_$M__WA[%/%&A4[QS\& M-WCGS.3;E;ON42G_PX#X\[PJU4H_?I)/>.?LY+^6OCFCXK/RYZG\[;PT>/G^ MJ:_^[#Z69J=T>Z_>56M:JYYWY$KYA_I[V/J9K3^69^\TB_;][_[%YT*^+#W> MY']DG3.]_@7NG)G\1;>O&#>??V"M%ZR4-S6C_:#@G3.3_W+^J6SDC3_7#PW; M>FK^^G'='%;PSIG)GPZL_)54=O[DG7O[YNQ']_+T:P_O]"?/7.1KIP\ZKBS; MFRSE WN3X<.77^)=KT.:)T\W??6'_>)T+SX??9GPZ^_(,]$=8IV:1A_-/OKA M]+1NL!EJ!X(WW6Z 'V7 NZTFO/9(,Y0GU\5O/?[NW(^^_S!_FB?EL\9@^&P5 MLJ18?R,0" 8&\ K;=,C6%M(9LS3A&%0DS]ZI:&WMPRR]LMC>B=6Z,#T M!7_^]$B2 4$GP0[<9]G+''0$:!3@HC,8)P^!!^-F!H$@7#CL6K)W:Y)NO0K M7+E9NLF=5M!AW9$,>563DR.YZ;@CH![%K-C<]7X^B'=6J_)P0YIYY[)^\>?W MYUV)S:J(P$7C!),-65 M($]_8*JX8 -)/QF.J9,1+?JN? !1@>7+/8(=;ABX MB8-#H0D/E=O&"RS[E>*'C'#IO ")]+;WN4% MN0V\3Z?O$#T3,P^^TQ%[KL* M+JG!+N2$>Z=EV2!]X"%H(P'^P='8/>*],SAB$P6D#>-1=7K+0^X^)S3ACP9, M1=;'HZ<+,(Y;-NU1\ E, WI$>1H8JF[[/X!X0)-;KO0)0]7N"C$9F]9ZE='%VHH] P$_-?!\ Y[9 >GU2.)]SB(L M>1++2=Q?RR&?.'^6%SY(A8X M7^+'%^Z/Q9,O8J[*UY=8\H7;L3CRA>-C\>0+^&.<+3MCRRO[:ZQ$D2,C0O45 M1-AI?!!28_7U]%M6VM.DB;AQ_HVTQ^DW M5L)4R&>\UB$M+F*AB%@I31)VC0G>*R9@)R$)6$KEBZ]GL3,VKU<6)NNS_\XW M(]*F9D3,YZ14K518![*U4QJ69W-2+16E0KJD0JPEQ3&)LU2(Z1**K9F*54!C MJH6BE#*IV*:I2)Q0)-!Y7,9-O\HY&;;_=9YR2+YQN/OKXS#G5?F\W6\ACP$1 M=N[^QI#Q^RCLJXIPTCCG_33DRY.N:9QS.(8\7G/>>2P2RSGOGVS'P/..PFXG M=,K;ZD\::Z@[;>\5?>15F)[OMOMW^7NI*W/W M4E=3]M.M_"3=_[F0+F\:/]7AYD?5N !(<.O^-]7N>9O5)YIUP?_:3?EE M3INNS^2+KGR=GW-B'6Y9*E< MOS5^_*@/"1J$,C4(-2E4@\ ]A%C%0MQ#V))!>%VWE4@-@FD.+XJU^\JOIYM" M[^GKRZ;:FX^%?*::7];&OA]4_OVM6G39LD]Y\E J9 MJKC>J7%;=!(2:A&2E)-G$)$K0>P49/'#9$-KJF?J.)#X^;BNMF^&V'K[-J;CV(F M7UP/U]U'L(8K_')\)NJIQDGAP\-O5BI\N7/T^%1MG6@/ZN.5];58_GQ1U[^ MPB-*(V;*U<*.EOB$*GPJZGC8*ZZ)7\/#DW.A9NLC/[TNXNQ=Y/./QV(0)K0S MS_8_5 J=T:>1>G?25\CO3Y7A7;O0ZSZ6W:J>2HE7]7 [$6793^3SCY.=" <4 MFF7,QK@+BAV%&14.3S MCY.A" >%FFGB0X%+0TJ98JU&B\-6A^."AZ M/C[ +V%GBNWFP,3\?!(O.S!QP9F.VQ[I4K).#_YTXD"\^7TX_6/P,L(Z)SG. M!Q]6#^OUW-?]T\?7(.JJ_^0B$(-ZIB-,'#AX3-&9@.KHCP1VJ)2@>TP594<"X M8.$:GDC8-TSD $B1F'^'3U3A9IL>I@E&R+*FSUR0"_? $GPB;::%VO9^"8Y+'^Y^SBQ/FB=?*24:Y5OEP.ZS]>7H>C M6*;]>"7_,DS?V%.QQ9./'VG?XUN-CIP.W)7%T(5_R0N;HP&9>)?WT)E[W6>I MOVY?%.E:5TZ.\$XO;4'.CFTUGY8=12 MFK^;9Y=J1>^&)Q!#Z<_5W=5P4,NK>4.]&WYU&C^4[IN/E=D- N\R8%RL 5'P MG )M%)ZEG%IEZW;4RVF=65#KCBA$?<8 P.6FE&_E2R_2^=W)?>NJ_$LJ?AV\ M.-U-ULG6[_KUQ4NV\^.I\6C^_/FM;2]^2*67[*?/S:?? MM6_2R;!'[FP5[+@(7L6LXD;FY,S75G1:UM?6Z25B>P)QKE:/BD7S(=O7QOU;NW/4M1M0I71K=7:^2)7KTY>OY6*S[\_L(D405'NEVW ME]SWB+?!,D: ?0/$_TR'; W8I1^#;8==^#BKD8Y]6)&\!4J%:%BW#[/TRF+7 M4JSE!$82P99?B!65BWNA4U?;T"T8B,'6CYNO%\=9L2: :+1)7U4R[K)B&KK\ MK)J.)=35=D:X(YI*.M3:G #E#;@3%F#%,4'2A+IB"P?_]]LQ[ ^-.CBI>(%] M?"\,94NP8'BPY*@ZO%23AP)8J"O95'J"5&%N=DYHXDN]WV9PF=&[@@%#0; ! M*&]EX.>X21FH S1$7 )%':;"=J+"+3@EDW0]<5Q3$KJ$P38X;Z1/LU32IP$>98U!QY+W^H]MC,U M!O<]'54']P'?[QTT1\,]1V,^A$M5I ZCHM43\$0[*[(P,#AS'!).PG):EMI6 M95.%]\K@,\&%7Q"P(C$>[H4.:<,L-'J[92-AU("R!U5?("\#@MJ'K$5,COI: M+NU [$R0-U:D/R*R&612&T@/W G(-[Z-_@S\MR[USZAP@Z33'\B616Q&54V5 MZ9*@XF".5]]$IPA1FM'5@8;,5<0W=1S;,=EP%+0AOQU8SO%VVS;5ED-35D@2 MD'EX!_NN1>PA("XP$& MP:!MC;29ZA+X'=/!-60"22X'Q&@\'=4*B@%\-3$%U](Q S0VSOAZ) QE;QN> MLX"^5,; ^,'E%JB:P(P*M:<:6 :=$ JF>\UQD#5<>O8;A7L@Y!++X!OK5Q MG#24T=0G1)MI1(,FDH[,PA$#09GM06A:TS*>SLV2AYD[9F!A@& V8.[S?3EV MX&3@6$U% WYB:KKW83)K6D#;LHMS-1>>%2$5O:2T;]D*U>G#,O_S/Q.'@LZD MWMT*BL"TW,-()9I1[Y(L.W-4[L";#V5M*(\LKXJKFI.*7G7&H5^%@8002KEJ M]9TP_A/),4/+OOR2#5!LP@%CO_(NT:H+[]J*@T]=MMC&X% 2<]C9H@\?O2-6 MB[GBCO@TM=X4 DEL6>B9Z'C_;_.F,>_F#0&@A0M(FO%KW4D!^D+*X M_E%;!>J!&#:Z/W[8(&\S5S[C82\[]02S6#=W37 M[H6CBYOF2>/FFCY1YN$=&(AUG2L<_+*P8,N.[!^DO;[\>DK2VW@I K/TTTPJ:YK MR6S_TMC0C?DB]PL[JH8K,O6"?$X&G#63@*,$B[IJ]R9]1_2DO*5^_+B>C&NR M4$4,SA2Z8%*!28(QU(EI]=2!'RSDA/O5#_/C ^;_^X^E"^3XF;C\XEWNNMWV M%MEI/''1%'&A&%!/ HGANF/P>/!#!K(YZ0.[] !%1:(Q[S\C*,2T97BK8ICH M[MCH-MC,(9D:E#77=;3\.7A^)[ROA:EMF*W1Z>!:SH8UY8#!U^@4PGLH@UB0 MZ;W;G3CS!UR_EH07C= @?29:Z&R0PI?R]$;$[] _0M>XC0XA]<_@M7W*45D' MQ=-O70Q],> MNU>;3$2F*\ZC*)-2BY#28[O8%A^+8D%^E)6R_%BKR/EB39*K+4P/.!9BC[!6U759&UFJ971.757;#A[7](AQ/H*46WP&8\OKN;'L*6."C-.X/F'H*NZ1!CDTCA@PI%!]!/INC*K> M^*CJED.)'9+RE*%QV4O#>$)P+8QP:)'7'QBR.KG@4,52;?BY M_^,!S!ZAF. MUD:DB,&Q'0/1*YQ!>Y*'\DN3NPU[-0-.^AB$\TB0_" 750/Q@>@.--%J(\@Y,]/Z9 MXXX5!&:;P7@XVH?$* 0 ,=*AJ:*QJ!5^.3W%T46=I2O$6J% 7^C?+9[,N?ODQ45&QS\K"@=X$RJK ME/\0O(%>$C^\]Y)5,)X,':/AV($$3R8X!9-T87)TY$!M!O$RIF=8CJ=#6-E3\^XP_2NRO!D11W MLZ:_H:]M3U]U,T_3E_OR:/H2N(:Z>RGC7;,(>?)N0]P:J*+)$)(!#1TP@Q E M:MHRED\&AR G;4-Q*-B,\_?C'%5G=0%4K)YE>(<;)3J6%P:A2 LH^@9+; X) M0L#P+- 1P6B!B6 _QQ\-Z,T88%L.1-R+QP>!DXK;O);9#2S)7O&8#(Y&T62U MSZ!V$[26B:DKHI;<@<'+9@OE@?U_$<5<11H'^;>F^HS3"8CY)?S'G>X=0WCQC M[3(91K4>?V,R)@LMU1B ]/=EA3AT7R"B/PP (VW,N+M)..6WHYK4#+?!9&F8 M0^JR5+/1[Q,3)5C]@]>FGH:WP#M Z7HZJZ8;>-5T^)6W+4*!#W1I1(6E6!RH M;=L0W)0\\-4V464T?'D&+R/_^UA+!9%I%O&X-JL4\"ZALF+= ER?3#O#3;\, M4!KA&>0:S#^\D2Z7]A@W&Z(F.%1H7&GSQ]1'?4.XS0KLA8,HB+XT@ MZSCLH MCC]XBD\*8+R(;KN/QH4$AJ73[)UG%UP*4UML$[F?H3P!Q:.J&EJ]B P[C)':^9K:J&IZT->P([:E&% ;-DTT1WP M%BOOAY2Z#!&F(&3'6YVUMN_UPWA)W[!LK-\#1;,H5VF]!*'E,N , :<1D&0S MGJ< ]!>^]R$T*'L[PCGXDL(UM6-PZQ75$8@@*'J0$4[19SMW; 6<*0O(TT". MF!A2L!=[]]W;.>$3++Y"HZ=J;9/H_M#]6\\-:X +748X!D\N>PHK%#S)?>"% M-X&,.Q8(&^<\;/R,!LQ$U76X=_%=,[-I&)K3;ZFR\."1<<1J:,:?D22W1->M MD?8,-).9*-;1H_I)=*+(PD!30JY!&5NY4]\WIFCM"S#30G 6O >*!R/ 35'K MH$B[$H4N&U@/MJB"3H">PG3I@@6VCWK(LJ\KJ!_3:D/E&NV5"=[8U'KI*G$' MR\3 ;W4@HC!,(*X&/JPVHK1[1!4(FP#KGG%B\A0-\U0.69DS&C M9GB+3E/SZ'D(+=. 0(MJ&,[8=E57&!^*GSN5O:I;Z806T22S"=B4Y]Q M=AM )!O>QU0X=DS/HKTNCT458\$Z/!(^P46=C,:+@)M.1*D^<+UR]YY U.E] M<=48A^S,,W,)Z+L675@.3 :2.[JO@#05SLV[A)X2>M(AS[$3[*-^4T&>$.A/#)C@! M\H":8UAKF!UV19O=X4FW<'!=OS^N?SD4ZLWO%^]SW@/ 9(-]IEX]=8C;IM.E ME8MNT;+_N.OCNO\L=*N#4\ :1RQ:P')GMN+"%>]OF)6%S@36X%FVBV@^XS*' MOK%C6@Y&(O ##X8KY4L'K?<'TGO/HSEURVM/#0/6O6,Z0AW+:*P^@8F[U>=L MF*?'C?$XX05^[$SC9N%&%VX@], +HN19%Y<4L@[20@,:U7;W*%*R8$6$!C8! M75Q6.G]);"S0\-[9N+LU M0\"%^N[9-PJJN.6> ?:[X&3;?1P5A '\RHM_9(R-&+LQIC,)1N2T,@6"<0/W M%JBL8(4B6A[^X3_3?11(SP#=31B,+[PL+NT38K, LT?:#L;-5&VHY!S7Q\7+ MH$=P^;<#JH35-1U6(T'+E2G^S%YK60[0AY',*XFYN\P).VGTL6F;H&1EH(MY MGH'F&>C(,]!A56_Y*PQ;71:$3L'(R37I[IV^64>$TM''6*9K]5BYO;__!TW@ ME;?'I]Y&?(,()ZS^_T"VJ-T/0/_WMJ$\";<.!+FRQ7SP*V)V8;CU+CCEU.V8 M="&$^]LK?ZUY3XVNH5"7!4QWVUFVDXRACYB8L_QA@[$']H"=T]RI> 12Z482 MTA]X>[GD9U@=O,I"/QMCL4H_+]YEN1""*51FM^S8EX4#AK& +Q.X1QQ7C#,?,3#1& U-U^@$OU-_7=^(@B@=\HB$N(G&@J^#(C7Q% M/1DK*+JKU*-GKM2-.>B-?PGBZ_<$H)X.^K=,&)\#^VMT;S1C=0AXH(''4N_T MF&!*8?S=++E!+S2+[LUT]]J ;EN"QZ ,'8,'TE/_D5HA?-85T9]@NJ"L!*Q5 M;NHS-1F"B?#8]RS$K4^D31UWBX*E YBS;./V9N]V178LEAC'H!Y#A[[CIMK] M/7AL\.!*ZQ8B@@@GUYNWE3HK6D"'$EVJJ>N)#(ILVRGC;G3/LBI;;I LHSY.GP"!O&!O*':1SB=.0N8TL9<@0;1 MHV,^J\^R-D=UO:H RXT!W>@:9 OWZ_DJ<'#2?,\6Y+%UH)B'9S:PM06]'3[# M2FH;IIOZHDE3X>"\@7Y3#PC"ZFXHK$%?@ML@3'^SM2NF6)2 >M>&)_;@U_(? MB+]!S> >X;]"/B?!^P?_I]D?\CF0P:/W-.= MK%1RHHMQOI^8C9@K^#>5-]RG>[%]I!H56Q7Q5(*!!Q;;)MOU M>&UH&L4)$/)BY6:NT;]V80+?-KL>+5I>MXJJHYJ@>)/@ 6C.16=FJ<2'J1;K M?_B,/B'XO'UYA+M)P6'OJFX5DJL"-!>GLB0\KBM BF?#47JX[C#O&12.[41M MHW=.Y<9HT4S^] ]IVT5:H-1B>[-M%\ZF.;_ "L[J#>B0+. A&G>ZX+'E.3)K MG6AW\^H()*?R#_Q'RE? CKT(8!\,X1+=FF<5X4N&U7H;MWR'Y9Z!HPVV=PEB M!0SZ#!^M R?O^WWCXOC]M,]:*A0*-;%4#MMGG5B#KARL[^K.\UI]MX6TU_%; M0*P9"=V<(BB&-J8=^FOX5"#@:+[GY-/3!9L5CY[J##U=IYF2=9S]H2[JDXY; MV," MYP6[4]GC+P5C&Y#U\E0&V5A'EW=L&A0W9%IL1[-QM(I /LSKQV\#Y?2 M)8L.C*Z30PJ;C_U-;SEP5[8>P1S?P%"I+VMA+;I"L.,)]5XU&-DD9GQ^WVCZ M<0)UX^@.0@-]B.QX0"K"MFX-U7X8@S7$?IR6?)7D+PJ4?'%?(,U4!!8+W*2\ M;56H4$C6%8[(W)!828Z)-YC9P?N/?_N MJCXV).U@].F-TKH_13M#Z&?WT\7F$#+O=$2A(,-P3FMDIKTS#IZV>%X9%]"-!5 MEE/#G &X2=(XD+JDPV, MB$[[IXGYP%+2,S+P59?0ZD/Z"K$T_IK]8IQL< L;)N;$7J4Q'.Y5]:2T,4^+ MC$-H^GZIA+L$,/<[#Q (CIR5RE$B=+'?,:YT;/H,!1N-<1*('@>TS,][)Y;] M@.!AV9(7^K.?NHSTHTEL[.417N$&8C?!< M@\!X0<$%VOH"S<+U\5+.L-!\KJ9G5ZHZEH(LBB8H"A#PY#R_'R2%J;XO_P?, MT+_/"2R^&ONOWMXO3WU1;J2 SKN;)4#EW/*]/BWOV4SG9"]7QY3/&P5JS0*A MIBM1JM8PV M1"2X.X\@OM_XG"WD112 [5B"R-)%[>"3+!<_[";P?I(66AC*X!UOT4E*X"[&_ M@3U4>*2YD%DLLP>\DN?07)+^7>^Y^YFS7 CK'N-[:SVO03J@C)2,9\S M(/$JVUE-\]XTQ4'WU-!G@6G/TD7=DWUW(7>]@9ZL=<9N;'V\1R>X_=;=M>WI M !-]-SU"MSWB'6L6N*_:2#$<#G,-5\F:^"(KUS6>7:/KMG]U=R>J0,+K1C-? MD$2IF"]Z#A9WH#?8^0(6OWYRRRX-8PS0>S8"@:E1!_ M*4!/L7XIR/V19JAML"+6^SA,^)7E!\OI$ROFSEO^9*)-%3'-A,A#PU7A C5- M;@-BG^^S;&2!MA<@,7/6QQ[JMN5'[OZBD/'V\E$-G0K."7T[]B<$6Z?-#(,B M^#3B=Z&/_U>HY*<&XZ]XGIX'QS8PC:XI]_UFZ=88]_'V';)FRVP2LMF?:*?N MTX V>\'\50 \NC<:?M@WT&"9:6.;1:?OP$(99K1^ZU69@/IUL[ASP+/(\C]B MBP5M ]Q'R?:*LS7R CT?W0M\[T=]]$%!4&!R]0!M#R[NZ^]97?[$T@]TQ;=A M8X_I4I.#2A4[4-!=?O"R0L6OHJ!;.!V3."Q;DSO)7MP9-N3:LH5 M#=PR;WL9YK +A[$@[H4Y'>%O2MK^V4=!6$@X:QZ)4R#+ _L! MU^^$IINY90J^MPO75'F#5 VQ)'=V"^&"_,R[%CAO?3GGEU?#^. M%YDIOZ<+*JQ,X]9F$ZTO,- C)B/D+&DHQYBS@*6.KOEW6YV,?^@SB"YR-(\^ MWAT+'XO"T'V]P>Q M MW9)BMT,R73'4$'3TV;F?K\2A6W&I_IG@E/TSTXRDO/S2$UVZ"/P0.^HT^Q M*[]\RX."?'[YC>D8WH-9,D4>>*!J2V5I.9I;&9]K(]+"=INRA+9/]]MD>X>, M,(@(YX%CTUG]Q/%U/2<$1$75GV7L/()?>/A2CVCJ"W-1:0-EA7B_IEL2W#8> M>IM2 *,.VGC 9IM4^W?P(+8O"3LJT98P. 66DT)0$6O@0*TI5L?*>W+"!05H MW :[2W&&.[1V7981_L.R'V7O1%Q=X]20<,EH=RCK>?N&'B6*&]'[+\K6^131&U)"!Q_O!7!#9S6POE=(0[6B].#=PM,0>$MH.Z];=@L6V@?JF0]X"I&\;N MW &%'&2A6,JV80DQ!EX5X\#;2>H,W T:@0Y+$X/V&^3)6,^ K?=WQD&M\P MG,%DKP/2,AU(Q\6S[#%%P5YT6 B(^\-;LX$9T"J>B=+^U29]IKJML#:+@D7%C8S QH$;-!'W:EZ-U8MY5+#F@GB?JO:?+MJOMO!_&;K.I#FG4?W^!^_\G (M&FR5J5>@&&"\9A0T_T M=BXO&U1VCG+"G:J1$2T0M0@K")&[K"EM%P$XNH]PO&9:=+8+SJ-6V&PMRDWA M%)V33[).!56<$HIKW%*&XE+ROQ@?:^-M5YV0.K$<:,$T-HW!=RZP&&^+Q7&O M)FITL$LP:WGGS7ELA:1\RH#7<3N/NLCQ&D-XLO"V MG/<-@6:@'9@,=&_D)QOK/ANRVVW4/ZUA7'+@WH(GODTC4VX RRR/6_$!;CE] M$X60Z)YT]*30K^HP*]J2-9F&H(9C(Y;4GFQH >M(!<\",TRVP;Y-W^R=#('- MCMV[JL)7UJ>2WN#M4V+?U=BUX#AGI@^Q'IA:AQT.,"9E*:)NC@T*0&(3#G:2 M.T58(/Y7O ;)#Q:5XQ/W?*O(.C[>N\(@2'YWE/6/_PN5N&.KM.#\D)B!<>/Q MNE%>5.=$GVYT)AL%(,:@\=M:KC350U+$C>#S>DC2,VL#/2CI9Q92O:859<9M M_F8%>C^X,NIYY%Y+S18B4"X*3L>,.8%@R^VI& "<903,Z #$7'[5^[$;AE\\ M%' 8_10K;H_VC)&;L6B>3?0\G&QYV#QK?A^;W_J"(,3MVTW#;EE16,CL-\BS MF7=8J8P9 ZYU#PN]:1?UD5^"S,[@\'CI=P:E)AY/,T;$DN8?+""G,MF5VVOD MW"%XO8_'2=I8'CT^ L*T7K"*$N$4A. ^?W\%^&"[OHSNT_B^,$6K"V\*T M_1#SN<(2,Z08%ELINH8!;@WM(C!''N<8%5_/9SKM3G;ZP)AKC$Z7"JKJ\)R[@%I4'=[?(_C+1'Z^=]+08BQ5#TZRL3C2?^1YL&+3]P!-J M9Q&9U&'-0Z1'""T M7BJ=HJ[>![<0#ZGE[[-\)FY:'W\Y62)!38:.VLJ:,+"B;<8+_^ 7=QW2G0Z, MBK4@GRJT\ X9HH]#@H#]-Q1UO"E^?-(![OBB "KMY2_;;*UV_17\WGV ST8L M"=#4T%<&:<'*L.Z)P4O\#Q\)I\'K+/)>F%I(BKGR@I[H@3IO-.+MZ?[PZP_6 M=1&HV$Z-*#_M8.?'Z\KT,D)7L"F-H&O Y"D;KH9 Y'QMZ(IL]1;KIG^"<_#0 MLH6D[6S(*\RH!.?E>>#2[IO1K[,MP:8.5PNF.?2.XBKED:/0TLB@JFX/=]F> S5/!PKI39I"X^Y12 M.5>KO0M.WWV?1XH SAAX/B8>.B!"'DF\S]DA1(.'#)3&LPY7XL$N/D]?[-TJ MM\"%!8]JQT#P_*I1>N-@[7:K 3#_WW_L]AID[\'ZF84'* @+([F\:>:*5=CJ%((%21O-ED,%G&:OCNHYR>*^TH4R MY56A[GXL[LM]ZGV@P:H ;Q]H$"\Y>,V4DQW%K%'ZMX?F_V]IH!@:7OSOF]*; M#>DA%7*%W1*DNH8+T9IXR63?JR:M9[IB]4PGDQ4X;/-1(9_QNF:VN(PLE)'" MIC*"YQ%Z.S.]#:KBX$6@&Y$$;]-GC$7H'1,/H\/^:QLV[OS9DJS$:3WY*UG9 M;(&)6"S^LJG>P5NV(\=P+.R7\SY!"\WL[)>I )/\V7]GU, W%]+&YD+,%<3( M!>-O[ 76=&YO+=FM%Q9?,-K"B-RDNQ8[$X&\ AT1S?HL&8,<.0LPX M+T7O$\1&YV/(^ZW 4V#"XQ.U[+3UB M%%0&CI+8V:3"2)G^]5Z77?W=2P/W%W]M)%= M$G"-G2R:\?=RWR:R/,-V7+_2@:#>NH=WL"[I M*K$.4Q9JQPA?B<"'#"%&B]S#C!N3D^AN)AA W;V(1^VEQHW%,7)94P.7QHW' MR0'>T@^W3AZIR6X+M-;CHI)2C+9.>X(G$V78"X1V:U!*]$[T)@%\L5SF,&UR MW>.$><&;2*B8J>2W*Z.)-3&1>[A3_"LF'O;;+[16E#A<&R_W<'ST45\XJ&X_8)02WD.H<;+1;S!(U;_M9S)U] ?5G(EN$53 M=9+U&NQCPWO;&+"BB\E9P64,\X"_SB!MX7J\T*EHVPE%"-=&/>NMP[DP: [G MA@+G1BTZ4<"]4<]YZY4,>3$#D2(0XMS@B'2#BKN#BY'!W+7U? M5K64#D&(.YK\844OM29V$!86]Q,33EX&>)I\4KI'KM-=+:+SF*+6[?6%XNVV MN)TXGW\Q51:Z-(6,5*LFI<=N7-4C;NY]*.J1- ]_ ^4H9DH5,<%KQVO;D":W MT?#VA $\_WQB>@Z_DN?OTM)=. 3=WQKD6;5E*R, MJP@'V-M=,'1M]#XC-(BF/JG 8JZX(SY-Y2H+@95$%GHFZ?SWS?\V;QKSPH]-7\D^ MXH/ ,IE]69MHG.Y>"L@/4A8!$&HIC8[0@+M!I"S?C,H? _*S2.HGF3:/&]LA M:&!VB]K"S[$O4VP0QVPX(V!>9(T:@'H;A$*U;)..V4-\6%/-K:OMZX8F3PZ- MN$,#NZA;<%D 0Z*-,1^*/6#9O=-%0M(JC,]+?QW";3 ^#P.>T _.;] M-B>0F$20!T"*%[4/ MQ %JOA5+N:( [-: ,O3';\%>%+PK.&UK0!1\CC;*"=>&KLA6+P/B8BA/V99L M40KW\05T6?)>-C'M=<;6F3?OI3,>RI;P5LJ5)D M;& @N+BY"QN:9869\\F%-! \!%J/3"Z MNF]U5LFV1S6!/A+N4IY6; 26$@" MSS?@F1V0!(\DWF<:31TRKV,(1%BYX+L.&'VQ=ZO<@K#2LQM[9CN(@S(B1&Y'.UI57MG!$A,:*:6PJC<#Z$Q <&,T9 M$18CQ)RX=%<)YP3WFC@C.",B8$0IQ_D0!SZLR@)R1H3$B'(NSQD1!T9PC=@N M(UY;R[L*Z@MOUM57S#H!-5BKCKU>3(2_+6!4# TO_O=-ZB\C=XP2;\FC6=]8 MZB]&9MMXGR([\K58P99C]=T8S?!,B;6I":KEBM/[-W](*JT.W9#%6 M5;5$/M<0Y4*4U/8[V2)C?/I;.W78Q:0:[:3)#NV:^HX$_W MY'<>8,1Z]JMJU5,^^U4%XBF?_E[;_/V>?2CE$7&=?!2M?^(S^W *(N(Z^R3Q M/NX5$E,G1IP:IFT2RTH"NA6'\YHBB#K>;F'8H80+VSY>)B-5:]OC7#*#AOC' M!ML0SY"<^BT+:#%36WJD+;>?L9CDU@Y,"[L\>2O'+F]50.-QT$(L?>=M\VVK M!VG&[%R$Q*0$;MWFFPV_^29'-U*$Y^_^I)Z8^=W"!+_9;8'V9QS5WRM4/X2C M_N+FU\=: ?;;_L!H:JVRD#1F(4%\?*PTYI6F MZR-F2I4"3P/P-$ *T@!K"GPQ M'X; [[=]CY7OGU+8?SUQSZ<3N)T;+J05M>><3B3H_NFJ\:_E3+Z$_JR2*\$- MFJH3_ZA6;*3M'20\-2<\E_G-1T1(G4%"<1D.X:<]CBAEJA(OZT]P5+ 7SG\I MDR]4$XUP3FXQ9 M>!'G*.+&[A%S>SB^Q''\Y)TPM$.)*J(6@YUF":*>W+:1 MOO*R19I;\5A,2<#9FL8,!#YSZ6&)>(2;L.R$ >'D94!T MBRPZ;R+!V,[L40Q_?Q3)=E,94=N#]07I[:[E(VG!R6)B+81:2IE"M;!K.D8= MP\1,SV(8[42K9\D+D3;0M&*F4%AX@A)?T5)#CM<>++6C[$ZZE2F_\+2Z!.<' MEI^#O.L))RX:Y&+S>K&A0>4_MMS22&Q@-3H:GP],_H 'FCRPR*'WARN8AWE\ MR=+$&94@S#,MY%&AO%N^>-H3N.*EPP+B_&,TR@M= MT9PVO$@Q+%LP.H+AV);AF J!T)1"]#;?= MDX%-^BUB"H5\1L S1P59;PMXM"0^\*V4JPDP)4TU=/H%7"AY%S*"2:P!41 ? MT$:Y!2*=6ED2Y[#)E1PI*LF9/R9?3E (.D!R8PCC$ 9NPVG%;S@MU,FS:LM6 M1CB2"3Q$$0ZH2!BZ-GJ?$1I$TYYEF[*^,1J8JM//".=$,Y2133+"C:X87:([ M8%V"OZ-RTX3IM?$JRA5>720NVZ$*^X@/6GBBYAR-FK";M VWJ5H@^* (KU.= M5QC1P,!1;MV$?5]^@7MUF^B^*&@0:*[T&&6G^J/]U8O_<\$;LW" MADI.*BY;+]OJ\YSG&_#,#@B6MZYXG^E*?]@RB?R4'0(1/@P,2T41.C2)1J'% MJ6<&;*!_J]P"E\>QR=1$PSF7E=XX6+\+)GZ2G.B/ 84>&,B $CJKD: M9T0<&"'EBDNW6'!&A&>:EN+XG!'AF2;.B#@P@GM-,6'$JFUXG!$A,:*4JW*O M*0Z,X*8I)HPHYPI<(^+ B%6Y&E-YL&]X6<5$LSB=(I."EJ8!=S(JQRJ/>""%P=UG D M]X((.R^PJ:ZFP?2^*NX()5Z!8^,(15B MX;D+]_80\L6KEC9PLEDV0)3F4(^ ML[P$-F52M:D0%3<5(K&8*Q<3+42-GJQW%^[\BMMB$:)\;+;(1"P)JPBQM&CJ MS<>#MX*J"W;/<"Q9;UOO$[0>_:T>,#LY^^^,9OA&0]K8:.1SQ>A%Y6^(A?5P M6S(9JXH-(I]KR((1[8[0OQ<,<>&>*VXQ-A:,U?U+>?YEA"'>/-Y&YTP M$@(J;-;_(0JT89G,WA'W(/9=[\1*8E.A+Q7 M%:FF>_:K*D/3/?O]MOD1'$40H]F'DR>-Z^SW6_+#R8S&=?91]!S8=/9Q3Y5. M-;Z^-8VVH]B"R6*6C* 3.PFX0DP:GH:ME-O ?,*)';;<];*6*18KVVPZG<0( M(OZ!PI;D,X1A;U\^:U*"LG=QD,\(W/EMR&?H]8K3\KFN3!X42TE**.^PO7?H MA85S6)9/ HP?3L/FB'U>%Y\7T*")X@>!;F,RWDO+ MVG&*5)*6!2H)UI'=2T'D%4QK2,%!+?\^9?F!OSCJ,H)RI6OB(_S)1 *B O>C MUJO=P"&I#$IJF6*EQ#,$Z8TR4AY,U#*5BL2MF.ND M)]T73T:*(EYX2C+7$+ZU(*%;"X0833^9?C_?6\#W%G"CS_<6)&AO09R,_GZ+ M?@2;"^+%?+Z[(*RMT3<#8LHV'I=&7@9$MXB5E.85<4"](@A,MIQSB _<.FF! MV&V!,^!"X6)$S>RY5E_2,2+.UA[3&(#[^E4LKR 0G: M33"SE]HBLJGT!%EO"VV(%C1CT"]U\AZL<3[!7%]_OAJ'H24?6U0P"I MR/OU)!9+QY"A4.+]>.(2,YP1G9BR1D,&N=U7==6RL4;^F;?JX:UZTMFJ1RQE M"M4"Q^!YKYZ$]NI9%\,O%)95E'%;SAO[)%_*,_EB,=%"OC]-?J;X6^%Y@PCW MR38-&[Q^8\Z&V%1%U#%"C1(5)_ #");5ZDN9DLB3"OP0 GX(P4?0A8(XMW$H M7S7XV0)I/5M@HQTO^3+/6J3TE($I>1!Y>B/"T.;2L"RA8QI]+[PQ]+EA3?PU MBV\(2%1UTOH9[$(F7]QF%6LR X4D%QDEK99H?=F$X+:83W:%-2_^3V?E3RG/ M2_]C4L6@_F\=W]RK7V"J_YC-'O>NS^!3GB"MP#$:/;);-7)C7Y"MP/$ M:/:\=_\>BS[OW9_DMJ%3L[6-080QS(W=(Z:@ZHK1)\*!6XZTG;WE2=30^ <> MZ<'M8]B0.)FQ1/Q#AO0 ^E-"RR:VM>GMA='DH'VZC"8']-/&ST2[U\E('TSM M![[0;6(2RW8]<1XZIRA5P!L$S2_,+)=X=B!]V0'>(&A^@Z!"&#M7]MNVQRJP M2!;0OXTRH>+R#J$)EO$]:1!4+O(&0;$+"%Q(GG8*ZJBZK"NX;[A#>*.@)'K\ M27/LUS;^Y4RM5.6E]0EVSY/FA:\MFH6,6-ZF:.Z%U8R5+YU:E[F0J=02ONDC MM5"\*.63"::GH;I^^M#:GJQWB:#J0D=63>%9UAR"A]BVX3'/M&VFH*DR,XHI MBSUCA*_$RI-.#7:^]F)17;X-BR/F'#&/JZ^^"6).3T^1>#$Q1\U3C9J'9-5C M%1FD!C6?#AGR%/,O(P8!,7J5195D*S%WY_ MDMU[[L5SDYL GSQIKG?DEC16OG8Z7>JD>\Z)1.'/9/"F#5UH$\70:1-0VN41 MO>J&3#2GG[( -D8@#>]BGX#^LS&#-9/IT/,V]GO4QCYF&K/?:PSO><\U)@$: MP_O>\[1#C&*D#_ZA7K23CENNGTP4@9_BNV6\-@9SVU)QOR3RXOX4!R!IBS/6 M%FTI4RPDO *;G]>[_?1%U'/;RG[<3+&V3:L=*U\_[2Y]M<33'E&V]F]-/'-( M: NFEJ&UX.Z,[H< %TN&TX+8U$L^PLE1// M>NU62N:%&1&09<6*M9A.BUVS6J9&6Q+LEGY1!R/QT[(9UYYKV=R()QU:5LS4 M*OF=:QE?RU9&4%S+Y@9?J= R4++:[I>R*)0L>J&9%]O%2VBF'W=UTVXW>3$TY PB<2,#G]L"+?:+*;26[C[):$!55IW4P2B;RF?Y)[85Z3 M>6!:+'>?1&U>]T)>$WK*60*\\4TGF>2,SB6QK$-!)[:@&98ER+9MJBW'EC%$ MM U!-W28@&Z;AJ9A@U75[;^:MG ]/N7&B2K]XEM:EE0:B,5,4:SP'2U\1PO? MT;*>PD@9*<_/@^ ;6OB&EC7/"@)]J:537_AVEMG:MY1E/Y*UFV5EZ=O<^$DQ M^GT#]=A0GGIP+S$7EL?%7R=W43F0]F*WMUMB=VK+V<12IE2L+*P!2%@H%)E6 MQ*$**Q*MB,/$=Z 54J92EK:E%?NY5B2NF&Q;6I':578?A=_ M25OC>?QKO/ZAP4-\0*BV^OSQ7_C'^YVB$=E$2O?K*1BH!D;FV*Q&!@U_?<__Q,<_6R\[*I"8%H]QB.)RD>79%LFD9^R<@?> M?"AK0WED>>Y'E<:A3,T.?75"0@A@A*OOA/&?2(X96O;EEVR 8JXT9C72L0_9 MK[Q+[+![]YIAJ=AA[M D&CWE!9\]\53*%ML8'$IB#IO4]>&C.RNQF"ONB$\! MY:8*'M!N6>B9I//?-__;O&G,1^HGF3:/&UL7_%^.9:N=T32-1%M/E<0X/4:;4EH"H5W0LH1H\ZSY/2?<(0?AI0/9 MM$<3KUN?6JJN:$Z;$5[R"4])CB_QGS9P3*6'0P4I5#15QU5,Z,/K316[IL!% MD*L6T=2^W!)T V<_T. FERCX",4Q31!>X;<#XR5F3J"B&X'H-0S+QB%W#:-M M(8"*0_0$L#5"4E2",BB50A%"_($W#H]F&O;=+J" ^3!+P73E0WWN>0%[(7E/L051MI?JO+! C::3X0*DFFT'<460!/L MC@'3SX7%(N#*';' 9H$RH8"W09@U8X -_KUF/!-60IRT$K6=,B@G-'NH5YIF M#"FUJ3D& S&TF&#[AQ28B^9@P10HIT"\3H&Z<*-%;U)MB^JO#N]3C#YP2276 M88ADW\3)<@G@NBC,:Z?V:V"10^^/X$!P47<7=%R.%+:,33H0 ?_6=1]F'33; M]-[JN0=L#FOB\.5<;6D,%5A \\WX)D=8+U'$N\S#?0.F;:2IP1L2 $=QKB@DC5NW!XHP(B1&K]HEQ M1G#3M%^,*.?*W#3%@1&K<$:]CQ&MK;E=A?>'-NOJ*62>@1&1A>GLE$?ZV MKDHQ-+SXWS>E-YL&]X6<5-LIB:IK4&A9B463)B2N6$+B9#(AP4IN"OG,5FMO MXBXU>]%58;N*LAMG>A]H$(O2TXAIL,J%W <:A%-Y%XY1Y)Y33-0^!9Y3A/L/ M_]:SXF[41A)3W%1BQ&(NV0+3H&4]22GE7F.VTYN4-UL8(N;H*GFGQ;6J#>-7 M9LWFFX\';VEEG>%8LMZVDG2NRM^*,^/^[+\S NZKOK2QZN>I"YE@W<>ROZWM M\5Q>4!#Y7$,6C(3+A5A+BL.0(+DHYRJQ]Q7>S9U&,>GRM*D-.]^Q7U?ZF>_8[]X]C/?M5 M5:[IGOVJTM)TSWZ_;7[4*==H9Q]ULI5+?G2SCSK!&C7O$]TJ/VYQSCWV:LRV MZ+9HW$!,=(ON%D\"6K'#H\*3&5'$,G!8ORO2))(0?^1\M_*70+\^ENY[9/*7 M3"\E_F[XUA@4@1/-12RN!841FHE$.[3)0/3]OGEE^GROAPX/4E,$R<_-L"8+ M9-_VB1GY< YDX@A\J@0]5D[Y>F*Y=]/>"\F.> 8OJ \]U+>^3H^;H2?E"I+FO3P$4\%9@YO.2@ M5'[/D?*8A OC ^=X*)_ & ?_'RQ5-X>]Y+ISR?9;=\+[[RR+-W/K6C,?>W4 MNM12(4F=S^(@E[%PD,7"7 R9;W+0U(.J*?=T99"*P5K-?D<"-'U-.+J!W3E\'_7!%,@+_LT+_W>8ZH!2>2/$C4D]ZV11)XI"2=3$K7H1)))B7K2V\BTE$2>:0DITQ)O M<3DH2CP3$V6H1+,OPK(SOCA$D;BRK(177_&F0)MF.1(K?[&JA^(=6S9-0B13 M_GA3H$2(6!PJAWA3H'UH"L3;Z/-=#/NRBT$L\5[Z?!?#ONQB*/%&XWP70[IW M,11J$L?6]V(70T7DV#EOH1\+O4JR^Y]P+Y^CY1PM3Y'\[87]BY6+'$M/F*/E M'"WG:'DBT'+>0I]CY?N!E1?S18Z5,&3Q1,O0VO!ED[;E7]QO4CCQ&O.W4@T2S) F MZ8G2)[H#C$ MW0<\7+>P"51I$\4DLD4$%;5@P<&#'<.D)/SM .6 <$1OPRWW9&"3?@L^%_(9 M@.P63 M:#(R''XS?I<_]H%IP'-L08%?JFVXTDHAZK= VJI9CN+A@.%5[%!(6:G.2"F9>@ZT?P9NER'&:"@!$>-4Y'R M'VAY _U;_$#'F<^)ZXV3S@Z?A(RT>R8A0A\$N6Z"G46*@/BZMJZM/G_\%_[QU%/1@&'HJ_2F#'L! ME\3"2% \%-])XS_1'+,T+(O MOV0#%'-7WZQ&.O8A^Y5WB7J;WC7#4M%T'%)!59\)/GOBJ?[B*HDY]#[ FOA5 M-L5<<4=\FC*TA0"$(0L@JIW_OOG?YDUC7IRQZ2O91WP0^%QF7]8^!/U4]U) M?I"R:/BI1H+&-N!N$"G+=Q#ECVM(_233YG$C'/?WC( C!(89S9?N4$4#?*^\R0LL;'BG/S.;8<7,=[YXQ9"Z=TH-% M@9K3[N)Y^,M :R1XAR30^]!8S;J"87D2.XT] @-!Y745%\5.8>(Z:2@"D:!K M)F8-L6UZ;_7, )O#FF6$U5QQ*:0>4)3 \PUX9@>8[Y'$^TR1E$-F58= A)4& MS5U@Z(N]6^461/Z.379LR>:B(NQ&^')=2&2\&NVX%( S(C1&%)9N:N&,"(D1 MM9S(35,<&"'EI*7; #@CPC--2V%BSHCP3!-?K./ ".XUQ801J[9&7 &?$Z1KQVR_ JK"^\65=?,>L$;+!9F,9: M280ME6)M&>**FBJA$&$5O+071%@%[>P%$5;!*GM!A%60QEX0(>[+15I;FL9N MA5P51>\##6)1IAZY'"R/'?>!!CLO3J^NMHG3/0EXZ!,3]8TN]%$,#2_^]TWI MS:;.;R$GU2+=>;*&Y"_? 4^KM:Y8M=;)9+464YE"/N/ISOQ-32F3JDV%J+BI M$(F%7%%,M! U:+7>UN0C+8M%Q!Q=)?#X]Z%JP_B565/ZYN/!6UJ";CB6K+>M M)+7._UMQ#A[P.WG8;VN![DL;ZWX^5XIVP_G?$@NK>;>D^3N'DKA@A"H88BTI M+D."!*.<$V/O++SE/-\2;A!O/K]+BKOW6N=NLU9G\8 (5KAUWKX@UNNL/K&C MAK=#W_GLPTB;QG7VX>1+XSK[_WS8_ZF1HM+./ M.@T:SNRYF$>>YXS:Q(7??FO3V2<@\WF_H%]1$G"%';;#3V;X$,LH8?T6JY/8 M3OQ![MW*7V*L7'+*&,.5OV1Z*?'WN;=XYDGH'O.&(K8_\A2.J7#T/'GH^2O.22^F#"W_BW/2(\"_;]WFM8W)YK4<^8FC MT[_%(YWCY> G'_F.1/["-FW;E+]8N2(<^>;(-T>^]QSYCLB*&+[>I>8^*U&@?$TP>(AR+LL?+/UX,*2QP33R$FOGMICQP87U?"#TJU M9=T1.!J>/#0<7G)0J*3MP.8$8>!3L<'X,%&. R70V]\'I[Y47N;5[X7SGF0? M?1]<\7*IF* N3G$0T5@YUJGUGZNE#;J+[8\0QL(;%@MSO>&D.[V)1,JO',N6 M]2['4SA4GG:ONA!*16TRW6V.E:?-02]4P\@,[;=MCY5+OW]8>5'D6'GZL')1 MY%AY7**#&[M'S'\M9_(U](>57 ENT52=9+WC$?&X0ML8T+%-S0HNP^,DD&%G MP!&C5X4.$;9MW3DN'_72H_P8A0M12 ML,NL0-1SVTHDL;3J)GT!0]+ZQZ\3-Y3S/*L0:9]%IY6U#5O6X-'S.RX*Y 7_ MYG7Y.TXV1*VHD20CHI[TEATM*5.L%'BZ(I1T1=2B$TDZ(^I);UU?2H4\3WB$ MDO"(6G0B28A$/>FM;"ZH\(3)#A(F\1:- XGG4Z*,BV@.15A^5!;'TA)72I7P MBBG>CV?3;$5BY2]6-4R\'\^FN81DRA_OQQ,_>8I#N0_OQ[,/_7AX@WJ^S6!O MMAEDJN5E>R,Y^5:#!&XUV*@)E;C-;61/H?'.3R>(OG;"_L7*Q'Q/X''> MKIZ#X_L!CA?9(=]WWPSRO%+9ZSL!=V-%;>]CXXU5*IQ#O3 M),A'+B83@D]##YHI)_G356-[G2O%Q9TK.8S#(?HT>>ZE3*56X2 ]!^GW!*0O M9?(%?JPLA^GW!::O;#4IQ44[=C&(6.) ?4QBD"6G:^W%ZI'D(& ??'TQ(]5X MS_H$>^[[X*"+F5)A Q!TKRUIK-SMI'G5ZPKF@50L\+[Q%SXN M_G!XYTEQU(;WD^?]Y .ER$M/[N&8/N\FS[O)!ZHNJF%L4]GOM87WDD^+MH@U MGE'8048A.5)2$7G&(<*6.?^V)IXY9.%3R]#:\&63'LFUK/V\<.(=R]5* [XV M0X-]/:MWJ5B\W1*W$Q6IE291>(TQ25,*T]C!]:4)1Z0!CC"$,31BX/885O\>P4"?/JBU;&>%()O!< M13B@@F/HVNA]1F@037NF9YC#WZ.!J3K]C'!.-$,9V20CW.B*T26Z S8H^#LJ M74V8<1NOHO3AU9R UDG*?Z#).KJY6\': PD7J22&7H73,(D,IV-T'4A*B2:/ E0N7.V MJ/J*N;ROOO"RRCM!M01@"8P)IB?(MFVJ+8>I*!#R$Q@/G8R0SF+E@S7Q2F90 M>D1N*X:CVQG&A4+)_<(D [Q_C?D ;Y^MG%#,KW<[3E^VA"%(%?YWW,YC[BC] MV9M$DVUX',QJ8!H=8EE Z!8A\"72#95?R8@.":[$[ZTF&1$( <,=C3HV9+%-6C88 MGY'1Z63\BTI/UKN4T1U9-85G68.7@Z##VJ$^,_G75)EZ..JD$."OA[)IRKH- M$F-9#EQNC3P#194EGZOZU#")@BM2VY/1M:BR30'Z^W1+6WW^^"_\X_U.T8AL MH@/=FUHA"O@2UWW&,J)=Q 8*0='P9B45 ]5.;(IX+(H_:OKO?_XG./K9!(D; MX 2FY=9"273][Y+_S]Z;-KEM9(FBWR=B_@-"+4_(\5 TMR)94KX2"2(S3YY]O9H" M!7VY\A:P\FLON/^")2W>.4%;TSC27YDX ]"%CDE M22H@UG?P-*!4HC'>.P3KBY=6=1LUH$49)L26-098#AL':S!'-2Q(DI M%@S5G,1"OZ^D@N>$ZIVD!/0-QO9H(5%^V74NC1XG,SK.2=BC@5F@I ;^[$V% M64X#,V(_0;5HX81^>+A99/+8AK#ZPTPL8U5D+9*M(%',F)B*;,QPGD@FMBTF MTEBMJI@4G^' \.^XTQOL<]889&R\/X)W+L X42!1_R8_XFOF^?< A ?9K6%M MZT>]:1(%62J>F<]6(RT]"%\^2L++_SYK*,%>Q,DNHF\IH@D7<6-OH0&WL#?Z M;V_A=$S)7D03+L(RI2;<@E66&G(1#]7MVHLXT46,.F/+FIIP$98U->0B1IW! MWL1V>Q$GHXC]^4#V(AYW$8^M\'C(Q7>Z4T\><>IFY^5.]H76#LA),X=9%@=; MEE+P9E& 0/G+B^L73S7@^U3A4V.2XM<"ZU>,#?S"L8&?BK$!AMJ@Z^X 7WO1 M9S>&M+'9SAZ&\+69NYI"AD^ED-ZH4V^UQ]<2R#M*R:A(=<>.O_>4E7>G7.#::?8W?'.4:G[F.Z.!K?(;&=G48Y?LX MZDI]\;GSAYD]1Z87'17>?>"8B@J4>_;-Y? MM].MWM,_%)X^[]-?-N8_%(@][]/7T0WAJ:=O>F2QU)W[MSB:9[/4B=EV<;%* MI@WN@R:TNJ_!%#F&:Z=>&^(IS48'77?2W3>O[_PMA^8;")>)FOV!.^F-6A0E M:P)VUJ#''P,[3Z. 'QE!1^[-,<=]701^GD;;/ORB^S=M" 6<9II-S?JR]/%3 M/Y]>[XUNS8'MA3;6_GU>KW_=30+WAK6>Q<]9]XF//M:O.SS%E(T6*OC'#0W4 MC3>64KZ:4D;8?]RZ54\04*@;=4Y,+&S&U'WH8\SB' U[^Q)4+8T<+_30;'1Y M-9A4#OQL<0#B*\;1U) 7AH&Z791O) MTQ8TM#&7VVG0V5MH ]@"AC8B?8..?MF\WA8P7.[I+QOS:RA@:)*HMQ4,QSW; MOC+L#VN!,\3"6SU%JRUM+IK@1FBG.=(\!>QP1TB13_%CQJB2DP"DA5K)15@< MS\UU MF<:Z6.9L[?PSBF:<)+V\.=SML/3QKCOHG2)_O(5Z2HMC&!;5MU%]Y-Z,3U%3 M=-E\O0:3Y%25$"W#]X$[&/8LOI]%O.)PU!A.SBP\T:+ZAJT2\$1X\6Q)H[3G M8% $T7HE0MLVJ8TFPMFK1\.!.QG9WDEMU>O/'C^O,')&)7P22MZW=4:]K M Q(U5@Q_CE(P"Z**TF!KI=N1#;81_9Y*@IX[Z8UML,(.;;AD6NEUK]V;P=B* M"SN*X>@ACKH/_4 NS=#M];O/W%[_DC&_\98,(8&=KU"G^?*/*$F<11RME D3 MA96FRT407IMSGEJ5\'%PINSHQKT9'3-3MH6V0)OSD\X3*R===TB#@:QCM:VY M1)>0,M0#-!WOJ^BU6-K '"!4BGL#6V5@9QBTF.A:7%;0H-/;&087>>WM["C: M5J1OT-$OF]>WLSEINXH2FGKZR\9\.\.@S2U-FV:\?$B7(G;\;6WA,_+XV_8J%;%CMW^2AA,MU-!;[.:WF%Z% MZ3=[VX1:MMY2Y_X%-!(Z.&-MW-^;1&EQO#UN_ =2AP9CFU#?.*-!.N&I>]#" M#[UPAJ7""V&;![71*FB52G2PB.@-W-ZP;U/MVZK!GR=63MSQ<& S[5NL;)^M M3CUT!SVYOLE2C6ZVZ][LW#[Z=XW6E$2]^F%EN_^UG[W4_& MT2\;RYMF5?2ZE6:%=<(WR*SPPSN1I':^;J--@],?LGVJU/7XB%-.6V@9M-D M.'OD?%C/MYRVX5I[VY3SVGGH1:!H2U3NMFO6K?3D_]4#;3L*G;F812%U&Z7& MDJAUO_-$D*VL)6R;XQ_7_5GWB5OK'FVAPF^;XUM:,1/X)^YU?U^;0RM9;!_] M,^ZC?V D@JC$AB)LTWWL+]I][KD+#3.C&F4MO=%3PZA3CV[1LZ>V^")(\)Q- MG;/2T@X7.GT0.L=LE-Y":^6.>]H 92TRB8PY>_BM0)HB3Y\W?3L[;3 MMXY>NS=XRYP8 .7.HVP:B'K$TEX\43+K>;%D2YK5 ),'Q-EN(.TN*^V[PYOK M;Y\;>+6:*\VCKRVMS]+7F=+7:.*.N\]/7U:$/6A861*KM,G.@LIZ W=\T[54 M5G^$IUGH5/9D[2/!?O?YT>?T[6KWG?B;XH%;$"VJPPM] ;X:6\_2T,$R;;*R MSK5FY?PQU7+5F@8II$31B$<($SC* BP ZPO&\2>L_5>N]>Y/4EB-L=_EZMKV'/[HZ$M MA['E,)94'B*5H=L?C&V>ORV'L>4P>[+;W)OQWK[2EDHNIAK&3LQH?C+Z;K/,S4 #:9!;V=J0)NLHMKH MH5VY-)8>]M%#?^@.1Y-CT<-EBHC6I9<=BR3.-X%LY(Y' TL5QZ[X:19R/"8= M;'1S-&1H?M;7=V1--,8&/SHB_"M+4G^Q,5$!_W^OKW$!S:M8W(DP@S7\$"3 U'US'T3R; MY0]'"^?EN-/56_>2))KY].-[/UTZ?X^R.!0;ZJXU?I,X )@O K^5+TJ<>>S# MJYSIAK8O_H#+263K.A^^5@L&<*Z$QCE&0!=>$#B)%\ GMW%TGRY=>'R1P"'@ M-1YVP>,-X^ZZG9'>'1Q@%@6!![R#^^.I8TQ%>B]@%^^68O9E'?EA2DM]_NOG M_]-QZD*5=U&2XA%NHVB>H -G;B ,'/3EH#,P<09DP?/AC#//A'K>1 AYP147 MJ_$II!_-LC@6 %=<[(H6<]8 HV@..(.^A;47,\;APVOX(I;?=XX(_Z_WVLW] MN^__#/]1OYL%PHN1-R_ER[5$PD4D9^YVOWD6N3,3&,Y6I^H/C;Z0?,3AV-@U M_?<__\/<_;;+30I/XUA+YNI]DBBWXFH*=__EREO RJ^]X-[;)/*8DTFG/U2" M^;46P @(Y[HS >S,_T1P;,%RY?UQ94!,RJ^K0"S2U_PK]1$)7/59E/A(S*^) M:P$SP7<7WDK7DD;KU_U>!_MEKN"?\E2]86?X3/=4(NR!H0]XSC(6B[^\^-/G M#^^J5*JG+LG_Q!>!:A"OO."-*9?E1P;^(&1A/Y_)Q8>]0N%I0*E$8[QW"-87 M+ZWJ-D[ /&&9CR*!7J)[S$)AGVJRC.X3YHUZ8D*\ZPP)' %1'QG_SU&G$:PGK$1D-? M)*]/);/*;+3( U&8'6H32)A(OL3*/0GK=2)>JS_,O2$E2RI&')PQ[A:YAJ$& M2YZQS9736*VJ> (?ZV#__6"OVFU0C?%^5&(6@ T*).K?9"F^9A9[#T!XD+M) M2-/"ZE%O"LI"EHI3L+5NIWM='2XW?G^EW!D-[+\V[%^!C]EJ:=RW QNR]-/!>K#K6S'MYJ'C,WDL]]_)0O9N] M%\O'[+V8]-*SYDL#[^6AJ+2]EZ^ZE\=G&^_W5M8&A,DC@-""G)F=0;K'PN1K M4VQF48 ?_N7%]8NG.B#ZG>%I!P_6"[&+0*LS:DS1+IB?Q^NPE MPN39,QPGCP9)N0+4ZF-G3OR-T<=J+/%\/)GLKSC$#)I?.(/FIV( /7H.ON M[UM[WBCW5 P;/A7#>M>=P>B<,.P=Y5>U*L^^%NQYFO2J&4\>"1?*CO13.,YL MFYF_^/[52TY8CK+$"^=)FZ;Q')EHF.5N_W>+C#3#Z3^9X<"NSDJD8=+GL2J! M'\C_:-K13XPV]?.?HZ)-[WC58);;[ #-N#.NMY'0XT'WTF+$;HSX&@=+J[#@ MFS9HK\_B0WEJ.](&.E<>T#]U$:OU&^?'O 3D#%MG/0"PNKLS[D]4ORA@ M/)0=?E' >':5O$W >" /^J)@\5#R\44!PPJ3&F=2[ M)< X=4.?(P*C?6'P3]C6]&I*S0&PC%Z$";6(:8/CY<'#[>Y3?8DV42--GP>[ MB6W?Y]%NM7Y[YI@(>H'X>8(SUXF?9\1 S\(.:*2Z;Q'T*$=YI#9=U3FIU M^R(C(UI"];"RIO7%A#,J@]CM"E \BF\=-!=GU.O9B,6%12R>FQ":9@X<.$7M M'$>H-9H0ZC=&GI42&FAW'$0)O9/,W:R?$DXQ/:]QQLQ@?-XA@Z^:A%9W$. W MV4?W7;&/;MN= [4,LJ_9V#B:NZ"!AD5QG#T_:;0W/LD-GX5%T3;#X9A(W30C MH0E(?8FLNGXCX(B^Z\8I_!:KSRPZT0"*K5_)MP&,%]^_I>E&YVVA-\A7U62+ MXM)C&/V!C6%<6@SC)-30-!OE(&JX[EY?A/NV0=309!OF?*(9^S%@]R#P\7!? M%Y7S(8A+B&=L'?K5-=ZNC6@TU$K)!]J>A2/!1C+.*Y)Q6&;(J&_C%C9NT6J; MX/KFG/RY-DK1ZBC%$Q7YFW&;NB%>=%#B56]N'M>9O# M#?(/-5F)O_3@0<_M78]L^,"&#VSX0-%#[Q3T8 5$2\R+\PD@/-']T[T(:KB$ MZ,$6 @QMZ*"Q1LJ'="GB/R=9<27Z[;@#C[T)_%! MR3FYC^N*@=2-%B>,D=1]U&.T^Z;;QN<-,&W-2[?34 !@\ M!SV-!K:(I)884-W(5'>(H.EVUWX,VIF[UAO>V"*48X:16H4CKT:V1J6YQAH% MFIQ]@P_/P%=B*U?.JW*E"8U=SL(<.I_,M?8GJ#4!J2^153<3QG-?@S8&0(9C6T(Y&PJ:;8._6I87?%O8QR-B''8R2(VJM$\0Z,!]WD6 M]L3YF WMMPZLM]?&,&P,XSRQVL8P; SCW&(8=HZ(C6#8"(9,>^]=VTDB-H9A M8Q@RAC%V)P,;Q+!!#!O$T'4GU> M8UI8XY[-E6D4S.'+SS2 9'=?6^N;NAP+;VH)4[1[KAML^>Y'LY7-C M3QL-IMT VVD^#=S):/+]7OGP!QZK9J M]X+@F^+YR>S]+O6F@7B&Z_I7EJ3^8F-"HR1C^!N-6VB_'BAE6K59 K#&-*8G MP++ 6R?BM?I#$MKK+JZ[-VQ*N\80XTXL'(R>%_,*0) ?J5!H!4Q??/]KE JG M5]E?KDG;?!_.@FP.*Z5+X2S@8J)[V)JSEHWR9KI1GO-6W/FIE[C.#YZ ]\Z< M5_UNO^M$8;#YUG7>B2"XHY&N\/=F'?O9RG7^)H)HMDF%ZWP(9]&M"#/ &_-W MCA?.G<]PXCE^VKOA3SOUD2LQ%P2>9"V? 2I^.(N%E^ ?SLXYMHLH)A"&?BB< M%:RX3!P1SN&Q3V*=BM44@#GHN@Z=W4\<@!"L"@=PYIEPTLA!G, W>8$C_DUP MNHV],$WPNR]BXXC5.H@V HZ*, NC\,KX)'54#W;Z5B8@=T[%-ZJ@-AA'D@".+P&WX$V4]O M_ :./IU'*S^,UH$'1Z;%$F\AX,\DS>: Q&_H'6IG\"VLCI2(R^4EE;2;86>@ M-^,CA-/8GV;,UO*[@UT!\+*%-TNS&%\TBQ*XLE@$7@KOAZ_A W\J OC!%!$I MBV/X'$!R&*X 1> I[D4,3TO"+>38C M>,$/9H$?(E>5VT2F $X8O@J M/T 4WP(W^U\B6>!D7@*@#0+\7W@VR8*4D 'Q9@W_CO"N"H?7 (2SP7^]VU@( MA$32<&P-3?@U@%>-"Y#T<58"MT#.#7,:/>P2B6XW-Y M-^9E\[5Y21+-?,+ >Q^0+A M_NN/;R7?G_MWW_\9_J/XUBR "T U=%D2<@/D-E()Q=2DYU# 9W!T$2M>UQ\J M_5/SNN'$V#7]]S__P]S]MIHMK0CC6#*_JD\JS*VXF@(*?+GR%K#R:R^X]S:) M%?EYGGJDOQ/?!'HG_'*"]Z8-H?\R, ?A"Q*1*(HH/]W\#0R#*TL M>]\?@/7%2ZNZC=-8!W\50.?(^%"VS.&2_00X+.Y!B?+$X& @1'N*U[G >YU> M]QO76<31ZG#>=# ?ZW>9!^S)0@XXLVWNX^AIT-REJ2,B#AC!"ZR#L/L-]IA%DD^C=6JBC'PL8Z4*VN0CO'^"-ZY M 'Q0(%'_)O?::^:S]P"$!UF:KN7O461]E[JN9>'"CGMO=1S+P\E!=A[J8V/V6MIWK4\5'YK[\6J8_9> M#B] MO=2S[V,.OVQO9?FW8OE8\V\EU%G9.FE@??R4!:.O9>ONI?Q^NPEPN39,[HGCP9)N?;9KTJAE/'@D72I'T4SC.;)N9O_C^U4M.;8ZRQ OG29M&#QR9:)CE;O]WBXPT MP^D_F>' KLY*I&':YY'8S;,WA6@WVM3/?XZ*-KV;MN@X[46;<:?>]@6/A]Q+ MBQ"[$>)K_"NMPH)OVJ"\/HL+I7T-X$9/5#]5(0MW@WM;J &QK>C/9"I/@^9/ M-'!\3Y'9GW.WM9/@ND7UY@[F.16JU\_6&X0'ES%RYQ11YH?/:%'[I*A]\J!Q MDUA<[=V^GHH';8H9LUWS:4>WH3:X*4[73OXL#(WSMR?.R&RX0.O@_(V UC'0 MNJ;2G 5--E]SM_AXCGKX1:O;[8LOR $SJA.4M;!/.@ZF3F!4QH+/.!QPX'C+ MX4WW!-=?O_+?+%HX;U)HFJ5P$"D,W.N3D((5"XTR0)Z5%DY>M'8D6KCI6DJP M(8C^]7D''O8/SVRL"<.AA-]DZ]IWQ=:UUN?0OFC#,>>/-\T*<:JZ'.<=A4]R MPV=A?+3-QC@F4C?-GF@"4E\BJZ[?6CBC<(53"U.Z.)QMH%[?#/95M_9OXR"P M!@_N)=<3:R,3Y12:>2!#7 M0TL.EQ:7V$*5GBW6:+!!\R%=BOC/259!(OCS$WV41HI"5@ R&UXVP#M?AFL*^Z=7T;"'EC!Z[8,(@-@Q@^ M+CMRQ49!;!1$T<-@?(I*+BL@6F+A7'H0Y,;68=D(R-@&0)IKS=AA*S;RT78S MI._>3/8E8UVBM7$^1L6%V Y]=]0_XL2@2V3%3;8$+D3A'XQL2[MSBWWTAF<1 MO#BW7EU2@?_[+^^.UY6XM[LKL;76;7#CLH(;([<_.44&[UG8&S:Z%)!GM9@FBXA61#' VVD/:,HKQ$.CPC$^5"+)&A MV^O9^(:-;[3:>ABZHYZ-;]CX1E,T_OWWN7-5M#S"L06$5[V>G4?2 M8 W^=+,7K<5NAY?8X26/$(@]M[LW;<4&2>SP$CN\Y'!ZFO3W)=!8\61'E]C1 M)8\13S?[I@Q;(.U#FI='PH4VVG2[X;)[^I<[N)X<"60-,^-J M(Y_ZT:8)U-, ,#P[]?3<_JAKA<^QHV!UXTWMY--&B^T)Y.-V;XXE>RSUM-,Z M>P+:](['<>NVW?8RDV^*QR3C[KO4FP;B&6[J7UF2^HN-"8T22O,W&JTP>'<@ M4M.>M>'-V E&=^"M$_%:_2'1]G47U]UKP]*N,=BW\V('H^>]3 4$XQ,5DZP MZ8OO?XU2X?0JVT\W:)?OPUF0S6&A692D3K1PHBQ-HBR>"=BM%\ 7BPC^@?]U MTJ5P0C\4S@I67B:.".?PU">Q3L5J*F)GT'6=?K??=;QP#G_T;O!]+\>=:P=. M%/A12%_ !T/U@>O$(EF+&9KUP::S ^_/%I6(G@[&I7Y=N'3P-C4R(:8LX&*B M>]B:LY8]V6>Z)[OS5MSYJ9>XS@^>@/?.G%>$.%$8;+YUG7?X*6(??MIQD#GUNV\HY8#^ M[KUQ[OUT";AWZ\5SV&T$0(MF7ZZF7@((C=L484+K.X)]38ZOCO;W7][MPM,3 M\&>2)G@?4I;\_ BR=.E).$@L/#J10$Z"\%<$/#I-L*M3[,$P)W I@6P MK6B]$K@W9&)^ZN-!\VT&@&*!!B;L;T;KX5OPM;QA6A2>3J*93[L@[/3#.P%H M&3NT-]A*PGA7 Y:Q3S:BF=, O6@EG%?R3-\"$!0X7_:'G4'.VF'K_>[X&]=9 MQ-%*_0[1J=?KC#4^'2Y8@*+A]A1!THOZAFQYC(1R#>0U,._6 Z* 5\&1 -RH M/S,3@+7>>2+(5KSJQ%@UAD=C7 1^>? Q# 0!5N%,H8 M>6L?B?*C8&TMJ>O2_RF 70$NQP*V%PL'U9%4,DZ-S #]118@L3''I".L$7-C M1.#;##A<%&_@%P$\SJ(BFJ9(CL:WWAKX\IT72&Z8" W)#E]I2#TUA[9 M4_"ZC@/@7'H@?W'3L"M\F=PZ<"2$(Q[*X%[YK@2]'5$;;T*B"?(#/D#^_JD( M?+@&^(F7T@+P;8S\8^;!@4D@X1_X%@ V?)&@M$^RQ<*?^?@ M%@!%ITQ(@$-."ESN3M%3Q_D :RT\/R!H1D[L^<#T9A*1/8;+_5*$\&.!A[^/ MLF#.X/ 8"D@*SXX!WT>N24HDW#3R)[QO8QK\#VP;L9 QB+XCL&[P37769P MO\=/M10GG4?<*O"LO U 3'RA,R8:P!*H<$Z"J<9MN%DR0<#\8,T)48 DI1?' M7G@K5@1!$ND@*M;X&%P5$ZTK,0(N#3#NBT"VN*TNL^(&YT)\85T#-I/X#'KX M+3Y>*[-R_^_[/\!_%/&9PC3$Z4I8E0V" )"_= M*)B3^QS>HQD<4,2*X?2'RH.B&<[PQM@U_?<__\/<_7:07[K C&/)Q.(^F7FW MXFH*HNC+E;> E5][P;VW251(8]+IZYC&:^U&0T XUYW)Y!LG_Q/!L07+E??' ME0$Q::U=!6*1ON9?J8]X]H#\+.+;?JHVQ?J^#UBHH[SI=&C2& M9[JGDA@8Y+?R9\]9QF+QEQ=_^OSA795?]*LD)+T(;/1XY04%F2D_,O '(8LJ M*^D>J+C!TTB!VC?E?7\ UAHV:A"U[T,M797R!WQ7D%'B.FR\1JR&\OBS MW )3+-Y#V9<@2W+-YYQY!-L.HY34:^"J^)GFN#FG]8&3!6 &7<$WJX+YD\(Q M,6>?F! ]IM450\&^C^)@#I %!@C2WYOC!=$V/OQ_[W^\ C7MSH\S8,-_B^[A MW7%QCWXB>6 F50H^##TC%@N1;]$03-,-BA\?] ?ZT=)<6:^*>\:OT(;#'\&! M ^+; %!67Z<>BS7:G^*L49;FISJZ5L@XC[+1GVWKB0]Y<=^A"/\YB.X3K=O^ MBM?S"^NV/SWDNCN5.GEJA[.Q-V2;DF4BP<^84119M!$@,(;#%%EK&JM5%0/F M8QV6CS6^?B"(9; HX_T1O',!UZM HOY- 9/7+,\ +^&894AD_XPQ$GNHA>9SBP%]& BWBH,MU>Q,E8TV!O MG;B]B-.Q)GL13;@(8$U61ASQ(AY91?"@UGJZ4T\><>IGU0]/>^2O338#BP@_ M_,N+ZQ=/A4>_,ZPW\VRRSW5X0++5'HN8"_3 +%:5>EM968\FEIH!]1!B[74W MO/C^U4L.<499XH7SY(@M4YZ=KK9/OP\I^,*W_[N5?Z@IJ/]4"NIU.]WZ$>-K M* A]1L7DB-1H-1R]$ /88/L,@G-:NI1='8=]1/J9<*E6Y!@=(%>5GG M7NJ]WD4*Q^N9<7(5Y/DKU1]R]SRW7E5O<75#NO^5.A,\_ZT_.[NO"95/?:AF MH?()"/EK4;D%EB[G6Y)P>94EE%SX[7>8^^2CC3+=5":"MUF47(3$.'/!T&;^ M?Q%L_E*X>3OL#)W5QCU1/NC\U+R0X,PLB09I*C4(D)=G;424KW=GM^71P.W= MC/9Y#UML8#0+PT]]^N?&\'JET>$8?N/>=&^V,;SI=D=)(+VG\K.'!=)%R)WF MBY?SF49Q,*%=N]?T%-, -G%LB@%)>GV] M/36OZ7;5&VZ,8'9YV%UHC1_&8'?%_HS:D<#WUNAZNFP< -+/HPP+PVHA]4J7 MR!'$7PWG.C(UCT;NJ+MOTO)%2+DC"+,S0?$FD.ZQ4?S&'0YV6'[';1GVU6AY MFD)?+.2.0I)SQ=PY:O6SAKOV9\'F*HT]3'/8:H/A8+,8_%?L4Z7[XG5=1V,;FQMC7YMG=5F-WLG==N+.-E%]&RU61,N8M096];4A(NPK*DQ%V%9 M4R,N8M2YWMM8WEZ$94V7=A$]VSZD"1=AM::&7$2/)AW9BVC 15C6U(B+L*RI M(1=A65-C+L*RID9?G2/:2>J %1CVTZ51.E-;;;T+AS4V]RX!$HBN9[$6R2 M;+W-O$95S N[T^L1"2@XU2B[\GC "+,W>H!JV=IBVM=A6@,XT-=@&L]5.=K@ MV+<7LRSKRP_1XN'"AO>Y:CPN_9$GJA;?GC C/<.V33J_= M:CRU9'J>%H>U&+J-;7%8@PE\BKYP^Y,T&I(&_$RG?\C'WXQ.0A:5+2I_=9*/ M1>5VH7(+R^(L5_YJ5&Y.!PR+RA:56X7*#;KUR\;YAZ+3S<#Y%L1\3]%LN5'J MTT4H_&[LY=UO^L.>M>G&(M@,?R\,+QFN_%@ M#!^XPW[7(O@9.L4M"R<$[_7<46_O/ (;]K$8WF8,[X_=R7!H,=QB>,MLYH,Q M?-=TLJ:',Y> M2]6B9B-TEO/AFD_I+H\WV.L?M_=$"W5NBZ8-Y*!]]V8X.2X'M:C99-1LCX6W M8VCHV01,3SV/L9W*S7'#274/6CMQK0G+H;H/?>QA/>3YL>$I2S#/%:2M^] G MMS\LQ1PO&% W\E@1\_44TQ^[UZ/M^:4V>F8)QA),%<$,A^YHT+4$8PGFN6+2 M=1_Z1$/EFQZ^?E/_B.QV*IE'L+[.87YPE?1K__S@8<_M#XXX(MNB>*M1?-N' MT"P4/]@%/WPH$]SB]6%*VGG@]3FR[MZU>W-]7-;=0@/%HO@YH_C G0PF%L4M MBN^PIMN/XJ.1.^IN.M$ MO%9_F!O!J1ER/L;*^P.>#5,PN-5-705BD9I7=T4@ID^*TZC26*UJC,5Z<33G M@QV[9>*BDTE[$XRZB!3F0 M.TX]><2I6YU(4SPR_=0;O'UOX&B9.#^%.-WFDUBG8C45\J%!U^4_^MW>S8/#;@\@GYHA]Q"JX=^O_13V M/]M&MQ??OWJ)F'PMIKV]$V$FCC=H_G+Q MH-[RIJ_%@W=+,?NRCOPP/1XN/&^JG<6%Y\*%7[(D]<);BPA?B0B33J_=BCU- MK7Q016]'#Z.'SOHI][R*%%G>?.,FXZ!;.5#R; MH1GUC8NVJ'QNJ-RLUJ46E=O5]]^B%?RU4,RS^-5;_M?AG\<_B7[/PK[765#L"B7H8RHC>_V$M8N^ *9@M=DHW MR%-0@P+]S'.9VS*P<.S>]'HG&LML$?R,$+PU\^1Z;G\TL!A^FD[P%L-/C^&] MD3L:#D^$X2WLLV@QO.T8WA^ZW9M3:2D6P\\&PVLWF0_&\-&->].MF&G?].!D MR6I^']Z)Y "K^2(TJ^:;"$<<+]VLV.1!1'?C#B?C%M5E6B1MN0/_8&EP[7:[ M=LI%\Y67\T'-YYGB>A'*MT739J-I[]H==/=-@K18>EY86KO5]R0LO7''%=KH MN813?_9#+YS9<.HIHTUU#R@]<:Y]U92[]D]E';K#;L\&KRS!V+G?!Q',H.\. M!@-+,';NMR68@PAF[(Z[-S:R9NG%TLMA@_VNW5YO9 G&$LQSQ:OK/O2Q39C> MC7M]O2UBFA[:AG?^*E+'#V>Q\!*![5RI M<+Y_R'^'?FWWF!"-.$/HQ%DL;^ M+!7\O8W;/-WV.H>YME7^B/;/M<7IY&,;-;N0.^M<6Q2V*[S"FVX_BHQMW M.-B1)_!=ZL')&H.6M!OM(N%[F$5!X*T3\5K](2_H=1<7V>L-($#BB(N=-SX8 M/2]R:I=,/_](C>(PKOE?69+ZBPWZ#Z)4.+W*[EQ-VN;[Y/.M0-0"W G-)<,7IQ&M)JYA\)&G444TQ,A M3C=:133=2!2G&SF#KMS7LU);Q<64DFGP.A6GV-WQG-Z#!X[IK*\S.$V, V3* MWRA/I62#9L>#MT:*SI1IN89#HO.-_&RRXYT352$$'(C<@T&@,6<;0Z M^&9=1NPXQYB'?]7O=IS/C%O2/0A[R82!$V;D, S]R)POVH MZAIHCP^^['=&QCM+/DH"F8;!;.F%MP"K(@P3>!M3>N![Q,Z)P!+G7@0!_B\M MTQMT)I7KA+"7($J23EWX\2Q$D!H/%U9ZA_SXBJL9@G-1 :5RW/!*A^DP"(? D MW(DBQ)>]L?'RG%*9U."D8J4EUPR5C06H&RF?:RYH="4 IHCV^,MU!O)*$C>( M2T'B"PEI+NY$$*UIW 3(31$F$DC]G &8A)R/UT,ZZU5NE2&!,)C["3 ' $)& M5U)Q'T4&5,U(.L:(2V-FYRR 8Z!.O2QI$0-$Q.<8VKES@DE_:*2/,AE<=\N# M.?_S/PH31[<"<)*BC6/) 6I]TA%OQ14/-/46L/)K+[CW-HF:[S+I]+5%]%I; M" @(Y[HSF7SCY'\B.+9@N?+^N#(@)E6]JT LTM?\*_41603JLP>FJAJ:7+_7 M055W!?]48^&&G>$SW5.).0T,@\5SEK%8_.7%GSY_>%>R$;YJ2?XGO@@4_'CE M!869>/(C W\0LK"?SV1P(*;#TQB6T]:(]_T!6%^\M*K;. Y M\35D66<;(B7/9!53Y$R9=4.N*PI;@!3PH,W\AC95I0:)&RO M.S=JW8[S8Q;CVP]_'6X3=C@38LYZF9\D&>R17OX)+@@V^!:>$ L1XUF3-)I] M8=C!B<>Y["F\B*2*!T;U4ES!?7X1."0)W@![X_,B8=!R[\CPVY"0\T%KE :A MO)[QJ*!)H.VXM8PR(:4-N7$2CVG5V.KU,)>!IIA\.33TY[7GDT*B3_V;/C40 M-EQA.$\>"6%$DYT[3JC,;?S& ,V] "OTY:C7Z>X#[);1K%ZT"^+\VOZ->5_5 MP)23W.0+$^=O4>S_+\ &_0V*9 8YQ71,K\S)>=B'Q>+J!R\@;/VT%'"8MW&, M.MN*6?1I%&O8R#\%N0_"**6[V2!'0$R$&[B:R@TFM,$4]I<@[8,*U7'@=TOO M#G_HW&8>?)4*5.MB)YK"8L1]X9]PI<@@/!KZ"U3/+A#01Y$#9#1^C 67,\T2 M0,DD4<88+G)",#S%E>1F^KO7G<]_'TXF\]]ONKWKWR>S M06\XOQYTA]W9"Q:W_(OW0&>#_QJG)$4!G^&?@?S7CZ#1@@V9Q?)'SX2; M!05LW%"O0T7V_^:+)R=+./\.^ = 2[$$ M?WY%@L!) +P>2K /60Q;6Q,R($Q6Q?/._5C,TF!C^CI! ?3O")$2%_XQ30F_ M,$T-M@ZJX1AA&8/^K2_J?SJ>/,,:00 M ^A _4_@U'#&8.."6%7L&U0]^ 94!%06? "^F $;]F*2!!GP:=!Y@*;!YLY MGPAG&WP>+G.6,KLG%I\#N0!+NJ$0[$K3VZ;?$Z-;@23)/**-? FC>Q=O'S^ M':X#%!R12]LPEJ@F$]3-DK6896R:X.84MJZS&' &%_M;="_N1.PB],6P6@ M13$MC@$>HC8X"-P(2P-DQ=4 V(7;]\!OD2W[H#53+BW%>8K[]E<<,!6 M=Z9>@MX_'')=<-65SN(Q5X?#3 4@),)&?<"'8G^B>4'PVBG%%K*U],^;^^"# ML@=1'Q9XJK@#5';2S9KOI[0-?E)>"0$0926<.\J"N;E_)%7X/Q%E";(Q0A;] M;V**TM67>"OD&;>Q$":+F8K !P; "^)*.GO93%PFUI@ O9+S,TRU1)^+A8=" M'+#-D("U\@KS:H#7!AM) 600/PK)4(04KQ+ DBSI"J:"G=[$;69>EI+)_BZG M^(4'R@@K,HP=T_L&0=7_!KZ)?29J5$5"!]VT*]S4K0!S$' $Q(H7\@T! M60/C7DW''> M!DGD\AL,QE#>I5%LZIA^6'P?OXV?4W%H%G8K#Y%\@[E]8?8,7W-)M+15O M(\#CK[:%"C[T16PT5$YJ(/Z@D!J9!I_7!X52.< V@$7*D_(C:%#L2.'@_80( MJ?SI#?LQU N(5/V5$B7I,HZRVV6EW^L>&1L\#:H>ZJDEG 7F___TK@K\?[DV&B I\XJV2G,(+ N()6F+$]Q9=;S%>]'_OCN>3 MWX?#&^_WZ?6X^WM_TNL"1*^]Q7 H[?&V18EZ-DIDHT2U1XERU]<0EXBC( &> M\AMZ<.?HV?D="',PZ#;>YS4\FL]+@8%X:PZ(VC)'_,*:C$)^"C^?P;<_H8S0 M0?/<(^?L/(5?6WK(_V#0CW64#,0I"@)41L-YGI^GW53J1"C#V%6!\LY%DR/( MR'> WX ]'N+3 :BF8I:Q>V$!M@&I.'/C^UQZRN])7(,^-,_(;D/5MP#*7'S# M2]$![DJ;K$KRR^?G FT36EE[R]4AYOG5S,RK6>NKH062#%1 U"'(;286I$J M@O#3'U)9> NR_6,6P"WU!MY5[_J5^);>T[N>\[\ZCE:)TB6\)#^6^[4P8_L+ MMD\9F'-2'158:.-L51]V7#)K-(11/P'%E=R'J)#ZX0*I-N4$2;#G9% 4=!CY M:C:V,]:V8<4"A-C0)]4>T]9 ZLU=7CM)\$\PA3'[YG_Q;ZZ&Q>>E'2556O2M M2K4O(0<6&)UY4NBGG][IB%9,]R&UQE7B2JT,CD%0,<^">42S6;:2Q@:5YT:K M5192,H_V;CX3RL-5>6L PSKVI2T&%EYT3T?%3"0X8T)N[%C<>C&MJ8&?W^@Q M5<=MGK:;?QA6+3G$0-E7;(Y]/S_K$W]4CI[:4N&BLG:/NYV9N\WO)W=+13/R MP@*T\Y#P*D*[0*!"J5.1B6$"$:U1U9W'S^_??_C\MY\^OO_UYP\??WG[^?V'7W^?C ;] MWC,K(#L5]XJKQ6TZ[]]W9.(W;M(6J=S2%BB#@&" XH>GY:Q2>+F3P=:;NH#>Z7O1N^F#@3D:_#V=#\?MT/KK^ M?>@-!N/9C>C.!]Y6O+KW%H.M/Y,'*?G]YF8P?FY2.09JO3T:;N'I'7G\TR2, M[57'\XQLJ96\ ^$.8O\3Y@VY,@V(=V[F M'7R)ES%R-ZY%&OD@%1C+UAC#0! MF1]S9/%5&MT*>A870KSJ=]]\TM_3![TWWV+R;139\B9K_^ ,E+-%AH) QH70H5]V=( "&Q[J#2AUSCMM#JD@YK%4]"(\E07TB5SE*T!F[CZ#ZEC$=2 M=C#Q7\8]3&T%8'BCC1ITJ:,O QEF^5 DV\'^&( @C>R ?K@ MC]'JH(ND'\8*P3>L).$UK&12Q]95F%[Z34YP< SOWE-&#X?[4"$GA)[+R\F? MQ6P+1.&IH,2']1HNB70XJ0+N0C*V*LE:\PM($8I;&93/4K!#*/!8C&!3]B/^ M7.5RB#_0)A) .8S;H0:C7AU!HQ=WBZYL5;6G\@N7(%,(QP!JM([*1#1?XKSB M;7]+40IY.YUM7\:VSW1!_^_-T85!;W* -/BL[U-R4,;G;$V$AH4KF.TYC2,/ MFS"EXC9"\?#:T0<[K"CUB%68QB>Z"!/WWSH]YV0_CV5:-J,6Z>K"N?SY8]QNK55)%00'PJQ <5$71]%Z'E'_ZPY>% M8:CR2!$).D)U48A%UP:AZ^!9,E7GX4K.%^ JW%6W$JV=]!VPG%QOE% MS!&*%B\;A9?#<\5+U+%_4.48@(^H,6Y<_ L3T&-.T/\0WWJA_[]D25G$;!1B M7I\K8GX48*51?5_H?%[Z\=SY#>.X5F(W# %'YXJ & X, H%E.!1H6(LX9:_0 M;SHO_D<_66=4<8ANC7]0PX,H3C"-.A;1PJ)JHU!U?*ZH*@N45R*>D9]4)XD MVF(NBO,.T)8*DO\0MWXB2WN09WX4MZK2YRWGY\CHRP]^M%YZ M\.:9R/)*A \4 WD?SC/L*&_1MF%H>W,.:/M7KD91E<65"%:=5TQ]!75&<[W1 M88P'>-,(<^BTMY^" A0""#8R[).'G63D)Q9W/FQ.>+-E7D%$_2-0WTFRZ=52 M>!Q%X<9.0-P8A^3X[)HKDY%*!?5=83>XC3C7D;-+=V=65-#*@=UG6U8DT+=% K9(H/8B@6=&_"I&:L+T MZ1T2#XF!';O;S(&'VB\)*=7JQ?>_8.ZG"J]+ V&F#022'9C>X,4L/&Y5.\"\ MLQ\*!*.N,LEFF /-N3WR.A%G :RO:0J%YQ'F'%!7A\*96-(GE3" ME#-AU)J8N(JB)6:E,HHWG()\1R5HQX;]XSJ%&, 5RM]?<>18K#Q?]T)]"-A4 M$BZSIE$V4V4T.B 664R:\LQ;XX53(@4FPG#NO_$:UTE%'A0S $=42RT1OE,P MI$:2F,H3%2[0XSI@[OE:W%_%1>C,^(0K0!-LQ0 ?4_&D*_MH8>X'7JA*%U:% MVML BIHD%_)SXL\.9J)Z&1S*(E26 M^4SJJ*K"699=!UFL,X-T$RD""A>D[DZ_ZUHXYI07GI&\QY2C*F) M@0*=6:DR%ZL("W6YC)JKAC$%\4IFT:."7F::=$L[^'Q>*L-Y60#C.Q![B#%3 ML(X6?GI%*5KP<\Q")/S/=!M8'U@$HGU*EL-,=BN2Z82)$%^XUF,+C74K0=^\ M?NJ'UW$^,:;@$LP5R^>91X*9QDIX,A4/LS+CK0>W<8]2-BM 6O1*ZZ( U>* M'42^\@TD&=; ^'AMB;<0G%$K\#-OAEB>K)'$EMZ=E &W,54*Z9N#58B)Y^LQ MBU8="F0!?2CX\F5AF4[Z*_S2N&O5XHU[[Z24RB@+X)!7O%/=^)Q%K'H$T5&P M]Y+1!B,1*5H"W%6 I?(6/<"?_^%GL'YN*,FSG?4E>,4/6AH2QIV=AS!MH48"?8#ZGL M%HFXLX6$LB&&!D[%H25_ S$N L8IS4=DGK(4X]@TAM;P_%5B-,BB9/G$C[4> MP#6GBK5L:TKLZJCBO:Q#5=SRAH\!Q*^5/;TIR0$(5>YE8R-7MNK2K6*TVD!?$E"O49" MH=%LMYJ >;JSI9AG!/M,U_2^R\7:)]9ZL747%F/BXCXW MO: !V9-0A_!6J& M*)"*KK T1,^=;*ZV 7ZD$YE!SB6@H'F@"ZL<;O)L(0L3)6 :N>2$^=NGEMR8 M\_BK*?.H/4Z.:3%^J+ZU7,#PC6FZ+)@';+'\2Q85@LXD_8*QC@AHI0^V1;IW MDJK^3E@NB_49VS5I^\*,@NO5GBRO/^;/^DF5IX:W 8BRU P."\JXP7@@_O!E>D0(&PO234FP)*IF;%X0,0AM M4^LLZ\**:JD0B\M_)*LV5"<#7]5)%U$ER^(V7-0,*0E8GMJ/!@G[ZX)%!S\A0L.$ HA+(L:8?G#8 '>S<&5LBR_9S,OR!Y1VSZ4';_/'4)&^X2(&H>9;48!+'. A*SLE^PJ5ZH15Z6[)PK0%J)W MY 3-6BM7K:L6!KSK)36FR#U9V H@%GD9'R!.*2Q<UMAJ4OC-9C6CN&+4_*FOSPN- VKA)UP$Y(UV";).DT>MZRI8J MA\=MQ_HK /NH\+\J^BK%TQ\5Y7]T3)\6+4;F_^M/-Z/QS9L'IO29JN/S1/ / MBE'ED_L4.XEB4RE0XG^/)0W\QJ.:95T,*SOMH&&!\@P)N,"(2V9G'@*N/RW% MXFH;<)4]TP4Y9;AS52M;T,\7LHVFU"00O]FS5\%,4:GV%E(V:7> 9*CELU>>^GYGAH37<@*3) M2(/2XJC%T:>SXVV+CYH0KF.1VWDY>\88FL+H),WFTK5EC4"+D<=5$(QP^@Y7 M;\7#_ R':XHGZ1A_+4 MP"=BO#D%9!B3D#YJ.:JI]*B1R",??@/+-H@^#JO=L>11.WEX#\44#+\(DI$1 M/PHV1HM<#TDB).\UQJ=UO[^"+NZ'1AJ7J6RH9G;:Y:+C/*BZT)XJ<^2R,$^B M,]_7V4T*3:@R^F>I^V\I@NJ6XB\<+Z((H;>*, RF;1-@$2XGC>4A/KI6?"5Z M5>$SU8?.I2B"C R:F6T*ZCK@YLU7<&WD+..8,94OJ5;:E .*PEV-T*+V?C[/ M\LL]OZ7L%MD F3(&$B?V.#6-\IT(SSP:0,EN.<[O S67RQPE7. 4@I2RAG-5B@O(C7->4&(Q'QYV&"('2\GH@$V_9S1,2]0 _,_M;-N>4 MA*42^_/]F[%9F6GAF['3JO1.3J*AIPL/PDH-*.9O#%5 MOAAZ.38#H8 (%Z6!\J)U]2CW3"A\Q%=X,?8G,/K/)3HE\MW'#WE#>D9M\C[X MND$T+P "OI!?7)F#&HK;*/5E.K*9!3S7/^ DZ#]O#[ XI_% MO\?A'V^/G+=Y?,WG$=UD_C.W6]),EMML7^JFQ3"+83N":'/AI4N7DA[8JXLN M2PP44PL-%0J0P3(9HUXMDB[Y&= M5R+$:G!*C@")32X%C%7H <\R[%ORG]HT!(N$C_9E*>/F%467UH&'L>1O<[R[ M7T;N(71SS6/OWIEG/"291\NIX+-,SJ4\( #HQBTF M)J@@KNLL8 .WY@R_TIJZ.G(-KR>#S$^23'!C"!7_Y0+')B0D/"KRI\/*CPJ; M4A^@1P8Y=]0/E_('5N8H1)X7*IM/8)\"@GB T_4P7NCE ?&JC5=ESU(CD"P MTP/6QO COTL6JX4\A;MR]]7NGTXKNY4.;;F/+?>IO=SGN?-'\C%EV,(O"XTP MB9(4,@=)"@QB,90IO[\#WT']LV1W&^JNLB/QB*;" L'$V3IU%3M%DR!:;[V. M4YJV._CM9UI&3E15JI*YF84::\SS4KD+7:F!%<=D9/N/STMRV\ VLCATY>8> MRB?BI#6>^UKA3,<%;JF'N&Q404.]Y+NP-Q$WM,LGYNZX(0)[BX6>IF0FN#*-IN5W<6HI:3J/L*5_++YAJL:&Y54&Q.Y,D(D MK0L5ELYU('YE4Q.W/A53L+84DG4@MA.19*^- U*RJ+)?^H5QLWJ\KY0 M'>?=+HW*R 3S\N:#I#.MIJ!;1QG=JQYC3&S/7^6U3C&%<_T9JF:BE ^Y,QRW MW8Z%>X=XU+J56/,]I^!JDC5;WW OCK(GNN/\S V W6UX2@AQY!H[JW+JX)S; MKJK$018A&77]<=Y__('^=RL\0PESE"XM&=(J JLGBJ737#VUSS'D$A$0:P5%M--[BYF.]IB%'Q?.N(26TQ/EU*D^\["-A/OP(_9M%H9S7 M0I64*V4UL>]!OW^).I/%9HO-C\)FM"HI0!]G@4A4W]N\V9IBE!:S+&8]#K,R M[&,L0$M5!5+2/:ZZ9JM&BISI2:IHI9,=7H$2O&"TRU:D5-CV!A7V!F&GC3JU M #D#;_:%Y*=JN8D3.>1P#NZ5GHD*=&Q$(&>WN?^.<@QDZ>)NX_8V\UEE)B,= MK==H-LMB[AI:&H7@K;#;_';DB[5G?"(6BT"P@IX(F>: A8GX0UZ3ZQRYRWHF M?Y-D4VQDN>_%8".S_S$65^(/3[$*U<-Z)4,\61RB4N0I&T%[=\!\YSEX>3M4 MFG[C+Z-H+DOX\E$IRIU$%;#E:T?7(@ &.Y+&/I4.[?%%\ 05? M0*6-OKOC^'I*AW3)Y%"I:JY.GDG8C:L[\&^_D"K">9R%X=[9 M';E+\MC=\P7=FN?%?"^#I8 C@")T?.E/A'L77LI$HAWM;%-4C'O!)QCU]\P3 MFY)3J#BLB7M8Y.OG?N""BYEZZ .5SKY@8$177=/'Q;%)L=E/D>Z,W%_FF!NW MC%F@9D9QFH6(PI5^J-T(&POX@IUI AU(Y$RKV[6*M;%3/TK%;!EB"W+NR%WJ MI.SKL;KE[OP@5'V^'1KH@6,.U)OHE\Q':3P1T(SLZ$P R<53)+]2-VMT=-Z> M(:?Z=N^.CE!0P)N!2%SY,TR*4*GFP QNT>,8\NMD5V(WKQHRG^7&\0\!9J9& MXW1X@KNJ& HC'GM%XHF'A^0GH6)^LI9EJ@$/HJ&)"(=-OXBF240.??0Z1Z$& MW)W0_EU\@TLIH^;*Y1;8I8 F_ XBXG&)YP61;OZ,PM\6G#N7^,0ZBF$1034006B]WC0*\4+>Q%02:8$^0>/!X8$MA-@CMFS(#3JUUL M'RF1@ZCD8+,LR64R;5MU,"QLAB=)%082W**L J/$^NVM6;7+K%+#,4$R &[- M;+VE1:$GU@RM."HMT<@4OYQM&0J>T9FK&1;5+*H]DEL5S>_C6RE6:"%D9UHD& J>E+RN>;,K1$!Q,=5@A43=PMA''NDP3JARL%0"U3Y*-V1,(BX#O.)T#Q@$>3XSSY#9 #:/>Y9SX_ MB6R;'I4\F>:Q75D:##<>T[[!IKA=&JW/T8/IQ3$&-8S&P0%-,*>$\P3)P$^6 M,A?NJ<&A"A+="9),K ZEB:H\Q ; J.A&K;Q 7(EXG15%F;U^'%E/-L4U=[#C&,N5@HT M1H9-HI*=Y-L[SMMB/9T?5I6YN_0UAN\0Z8T$%B]E55"K+CO(3N7=Y+G=#$UJ M'<,Q0Y4+D_/A_$XHOJ)NQ2U,0=CBIZX1WS/87S%[297,%48RE*.#50=AC $, M T02@5^:(2XSAY#"=E7+SG4NDUY8MDK'(GX^.NZR='\[*B8QT D\)P[E. $1 MWOEQI&"6K)%82GB"99U+H7HU!)R;JBK;YFZN X$:,1=Q*:FE&O<:*_ _[L@7 M\_0D::/Z%AB^*M8RRA4H60=OE%CK@O)$BH7 FI[-A*6\^Q9G LL1JCPM@;C& M%/.$S:RBNO-[WM+4[,KIX7D16QD86I*P#E65N^69$)YCNUZ50%4Q7#:'?"&K M3F7)T5 +M3$]TFU!?/J^D## ^8;X:;XK-;IVZ^H)X>7KDL(B*A$2A0^-5"H6 M01?VHS +ASW3MKADN0R5(C&6%#H-B6 C+1G6/L#0*_Q0"365*48EG*;(44*O MI$ >=_+[GI$O2YQ78V@FN)_9,D+DP>XH4JD0TEB4S6,-JY'26.1#9FT&GA[; M??;&;Y*<"RM>F;^#NR(K@XF6!:;/K]H:OD8C7A122!3<50M:[O,""T2I,+>7 M5)*,B0;ZE(J.*-^DO ,B DYSDJU.H\7BBLXL&Y[R>?%%R**I W85+=5.J M@ZG.S/)X+ OEK@E-"NO8IS'16E$$4/[7GWJC[ILD6@G^2S M@?'X\ MRU8)J;T@BC[NG"I# T$_R:)Q&AP:R4PV^@4#;RJ +?H1%=<:>,,_][&=7.1+ M]5KKB#L7G8-.N8SN06V)7:WH*>U;W0* >5>2GA.%4B/G_$64=PKV"'1B"Y(> MX?JY.RU.UKZ3321 U=3U]!O=4"EO@:'42\Q,1Q06>;N%8G?P>R]&BX:3%4EW M%EAF(KO[R&'>TXTK7[][(!'NUJ@R741!$-T3 Z-"*+YEE2S/6W(XHL5% OJD M3"US\HB2$X"PBEHPY$)3HD^>"*[Z,JAUMIEPJ46#JS/HT1N'%,*&@T+>!0.- MO%C%Q@<@DVZC^%;W/P+"$ @6:5(.IO4_$E.S*(XEM+'.!7:BO_*PEE>UAA3 M(FY@^MM=E< LA;ZT">)5@1<_#\FEBSF6NL ,FR1CM93C=4O@. #@[0U#J7U.JE M%Z%_R=I.[3V&WJ;.)[%.!;:"875FT'6=?K??E:-A(@21M\*IE>JB*7\]]4)N M%!,*%5KD+T%CH1F7H.TESLOK7F?HP#D".*RR/S5.L(,NF@;80)D5&'P-]D+ M*A$)7'HK._IF =H'^(RQ!;D[0-,5V@KLS5M[&VG>WK*#B*[>F\WB3'#5#MZV MJQQ6=#7 $\$$221*KP,QOZ5X5H!Z?8RM>;BJ3O8JVX'D.WN-SX^EA6: "TU(;#\6Z+UW$0$K0%8A!&6V7HW%8AB'UBAHPER8\5-HU5"*R/%DO^I'Q;;?"3P9[) S9]9 M;/ M\MS("$R46X_FY*)G?^VQ!2 [HA9856XR=9Q/Z..LYB=&8+;85H\6DK$.P_SB M1JF*#?(H7?*]2Q]UOKYTFP#3GWU1-)2%%)&^%WS+6[2# #1K ."?VQ\K;H45OD36<^[=Z#DO1]U.5S$?)Q$A6N1H M[N S2CJHH5M%V?!S1II!/DH7T>\?_WB7UR)3:592,>.*AXPCSQ'PT2MD'\H+ MYBK?AUQ&C7KA@B6U]M;.M(#2L@-(#G1$-O-@0SIDDV.9QCT90#RJT )*D-X8 ME,$)LBW>H$G@+@;)>%@H]LB7PAVW'D@/C1 M V#FXO@5/,JPI-P&5-IIRTEQ$)O: M.^/,E(;)J=IS%5E!(YE @.\S@DC!A@=.8\F]TJ?D[._M*;A5 B[3891=("O$ MQ[1C@OL>L3>PO$GN!/ UZA4[FY'V9==6^6L3PTBFF!DLQ%;A[)[RK2 *W6,: M(KIAX>2&[BDCB316&#>_:SM3.++6+4Z;@?#X>)*R$CQI)[!JH?U* 2E#4OM- M* EN)GW JH99MYQ I2P+E01?(TK(?@XT.)!02,I=?FT>M[N7*4*Z":=IG,@8 MA.X82V&8XN]PE")\S7>3<)89#IA/)6K4K5__4^;#A15I6ALMLG7C!NXY,15Z MX#@[^0.\.*5E9Z%$$&A"EX5^FXNT/1@#*4L04[4_]0 M8?F7O6ZO,]92'$_WLC?H=B;Z(]7B8@-[!T2ESIT_BAF9-,Z@A_I![X9^"'], M7-6Z0$IDYL6XL0>V]7)L:A-JT1!T+W3*IDNUM#:G'&5)=1S3RG)R ^L>29#L M9="!,PKW">QKBPI>6@&*X7CD/%H)A847P(T]U#67[,P&6L3&DD255+2L,IPJ'MVPUGC4I49D>+ M)_NQ(*E7<4K\&Y^DKK&J[;-L>R.MX/LH_D)7P2:(JRQO6$5>C:G7*XF#405B ME!G"_07 MF:WIC5896 "A>T27\SE44C83NVP,O3%_CCTZ/&"4&37NQA\%'K _ 4L6M4D MB#-73<'%Z6UF?NO2IXSXJN*,8CTY\MO88ZM7QJG-Q'+*XP%F DLF6_4?+EI; MG/0NBQ/PC10>$6;*HB&>;+&;I<_'T:<49CK;J]A+&%MNPO,[TW50^(D8,\-T MMH]?SBNC9F'L)PTV6AFQF&HQ]=&S,6-ENYHIQWFGQLS*9;"6>RUV/M4SHJYIWF*!8>5@&\B.FIC4"F@4AW7<<^:.E MA954%6RVK^/.AZ+/7')S%58*A.QVD'"[@Y*'78?49[^FPT M@/.P^9)Y;6&Y'-$&NBQKVZN:6:Q]:ONYPGR"X@3D \<][$==KB&005Z7TNGS-'M,]V%7D]7K+!H_NJHH_WJ2T>@-KFHHI ;H$"CH$87Y1%N=(HY.#HU0*G=KD#_) M_D2LIE4F)NTJ,5(IL%&>+L<0$KQO$;R9,ZU$EN7)RN6P)55)Z8P^SKG7>FRJR,4I;W#RK M'C_6DXO*N81B ;(_Y>H $2> K 5TB;"+!O4?P,X#"&6=GT?IW4:JZULJ-L/< M3NF8KSP9GXJ+!"@/#E@4Y;Q@$%X6^5/A)/QNPU5;*D^QJ5V&P-[ ,JX20"0U MQG?4M4+5Y%$IC4Q-R"N(J'I(-<9AA9]_\PF[J,K>#&^=WV(!MX$,X!/F-1:2 M\DS>D!LBA=3P/-T/LW9V6R:4T_.068*=0?+.!SR(;1-)*%!.413(!$_D,3EY MK(1(QZ0!"L5J0LO0"3"T69&BZH\!=A'SE&L MA*/ L+[B5:&YQ:XKIMJ\RN:4% [6,6)Y<7CKNJ@U*ICF9EVDOD!BT;+4L IK M-%OGRLN(@\Y4@568):7+U->!A[^BJA0/'2CY5Q2Z5N)696MPM1^*54J'IMQB ME_LNR=]0HH>1AUQ(K:;R.?%%%M@SW_;R\GGY$^">^68IQ3[1WHMYE+/4M8<% MN/+$Q$1%H.;K"97974KEY@.@A88JTA54:F@K, T4^UB2OP@!X4,ZJOW MZVLP.U'*ACD*!$Q'>8%E9?O#5';5!.0W^VSE:]\.L>'%>#3,MYE/GK]?= M+LM[DOGQT7U8N2VN[LUD4U!9>4P;W=Z#[MB3[WD;3J6*7/8.&5AGE&SKFE6 MS1)DC.SR3-4%L4[AWQXO:_898JTOY*QR777G%GK4+'CT7]X:J=BNTI#J'T@$ M5XF)IU"KK \NPJCP?6CHQP$>TTLB"5NL?#8*G57GR'8(C)+T+PJ,>B3%QT+! M:$6!/),V/J"Z64@JES@@J2R__>G&^3N\*!2LP6*HKBP/)"'!+_*">EG"#K]6 M):HNPZM09:^K#3MZD6UUWE7MT^7':YP_G"IG*>V@6/)*99#T8U6+:@HM&A4K MQ9W4Z8%T=$"<8&8 E.6_V1[#E$9LH9C*CGJ!+FKFEYG#=G-+@O:KZ;_8(X// MO,YBK&,ND$15%9VZBT(-GM'( 0QAZLIO!EFI+[-,0]G-MSNM;&\VL?E<-I^K M]GRNYGE;V$X OH@2OC :7/E@=OJZ5-:GJ;B;?A/)-)7OR_BITIZY?E[WTE+E MJ!4%KZ=L9/!AWZ%?R?XI'_\+C+\W/ZK^*1H8BMVS.6$6E6V;J>;(";4@=1[) M2QI$7C:\W45>%\.M_0!N+X$O1:F[O?RP.-<%]HHR6U4P>S/9;,4M3E(QSXX. M6Y+XVE&1QSW=O!C.Y0HYZ:DRFM?@(]%$<;LVVO#UM,HU"]PNCOH?OQHK''WH$HO(WH9 2K3 ;. M=+*_[(T]UYWIC&OFTFA'F2O:1E4]>\S*0-6:V'AHMN7<9A-H#2IJGB&5&T'< M%"Q?7C;:VHIT,-BKW*MH3/"O)$, BF9M5Y!+(A\4(*W'ZAB PAFS1_YCR;V1 MKNE_5A[7R$$![##:DK/CBO3K0A<9])=A+V4>D\"P(;-;9:)@ _;(4.MD>Q07 M/RT,F9KKO!=E0^;9=$G>$ WO*'A(RIRXJH;5N,3Y-Y(K*I%7N?M!VE0A+8W(7&:)DN"1VLJTX& M*+/3?UH1]<%/<=#_JC0*";O(!)L"M8+ M@@(=?8'..A6J5)O9XT-MG903O1 //I!&I.?0& &G#\-]F_(W;IV*7-1Y+T9W M.^*G[DWD7N#H'M%SZ2,] J:7$;'/H7DD ^L*WN0S> N M-^' =U&72ATRI![PTF=% 0AJ]9ABWWGT] ?4K#RM'.JG-)-<'=X>\"+#PA2- M#;#;V;Q F>P.R7ND.;,E5O(Z MSH^L>>YJDB3[OI8[)2&GIYY!J+LH.."<'Q-?2NF<'R/**1>[B4T%+BD%24G0DF.7PQZF'-S#G4W>, !MQ1K9P"[7MV(667F/6MNP!28UZGR'@XLH(MHG5K7EQYO1Y]R (S>6:IJMGP52OD5AA1I,%&!2IN3+E(5"GJM22V 06XCE MA=@^6U(57&OKZF4S\BJJ26C.HORW23HNMF>7*FS>WJJ$^ ;?01.!&*6:4[UK M:B1-1XI1%Y&FF='^O# ES/#Q8!RY!O;UU:-W[&R@(P?/;FSPS ;/SB1XUI#9 M0&BIZ"% '[3%\5&:19]P*M^JV>V[?\YD&05O>4J6!ZHGU"11Y^'AF R.W& M\'<:S?O_#RKED>M\AIUY\^@/$MX__2%0:UFY2A8&T3WU/L(NUJJ[+6J?^<=4 M&"#N.'+#;9]/JP^2PRY!Z?VOR)R3DIN3H/I@FK?R,F"O/3"B.,%##CKCO0;.2N)\A]5 MPA87R2R-2_3-D>L/W2,'LXK]:HUBC,(T0EL^7I7"P-6=/E@?='/ON$R^S:T#.>4W MOT\])I2+1E+VW'#-GI$C940MT.N#(;U$9=<6"93[1\=BRJ6N*CS&+^8(8.D!]@39VN=/"G3Z'2@ MG"]02D/7P2MQ_@R_V6/MD[E+]6N5#8 UZBA*"TA*:1'FY7Y M@2IUVSOCO!FO,V]##/Y*JIKL4">0AJ)I8 M15[>9_!03QM?A7"-#&*5!EL9(>!]$G%Y1-F[U^*;2QW4*YJ-\QI0@L]0YAJ3.?$=8F*[@,WL(+1YF]>0TI2") M9'-T8_M$S Z^3R&^*L&1P^,!4GA$*4\SE2 P&,VJ;J5\TW0AI'"T(OP\@X5; MD_-X+(Q]DE*8U_>K VF4=T*?)1QH_@,)P[[0"*/4-U'78&ZEVBX] M?US>+SG*EQQ5,%7F:DHY/QU$@)SU1M4+'>6 W,D%H(P=/JI%IN)W-6HX65EE& M)A[E&9?2D?^S\0N,7T\-1X8ZG=#=FD%OIT0EM9=$%X[H4HV+LN6%Z,]$XAYXCMY##FX"[8C M9\)@O',G)5$13TAW[DH6'!;?JTKHS0I@&1[-ZT9,485F0ZI$G>$C4/B15_G M!>QD"IR.:NR#54B5+9 '*M0S-#4LS0XE^USH M7OR;1O(8Q?W%K>LG"G:];(*C7RVKD^:R'9JLN5U' 692),7,-X+ %C*Y/.GD MR,RID0+E8P&2RE68YV:"WJ'IT@P$RDL7MRQM=X_X*HH"4EG]-)]M1[]4V1#8 M;,-$%IULVX0)@.@D"N=YVH92%G.]Q2C\TT=00T"10A.-QNKF,$#PTF$)QK$9&:B( M49OUJ457L4I+9G+6NC3$9)^O_91Z2 M][T!7HRU#Y(/@(Q VI?C/>5GY.P0LD^':>5@T&B&LI)UC;*P($+;"23BPL_ ML2UU;5?'G5T=O=RRE;8^-_% 0UM2$>9+VZZW%K$>AU@8=G?S*!UK=NR,"#:Y MT]@BED6L1W*L-:>AH^S7037,;5J@1X9S*"Q66:QZ'%:AF_A*FI,Z%^9[J:>%B32A"IYE MF2=&V]T56%9[H)<9E9CH822_:^Z9*Z=U[88O^6Z+$)=[V_(<)P7G.Z;J2K<\ M!G9FT9JG6%!9J IU*'\F^D/1=XC:/W>_)%-T(VW;ZCZA*BI$F9[<@KQ03MIQ MWNK*'"S^!1: _<-E8DC!)UX&-X\_MA^=PM9RJ87;;\WK*%+R[;C M 'S3%%/C7#C#7Q*(6S\)\N"H,1?&J"_&)0U?<;))4K$J]>5337&,HKF]T27T MO.<1"HY$<*HWK/!+!')6AWK?44*B\D MS6B$(S>X6L*5*=NE8"2E[79=::^4M&O ]LN%: MQ:JR^1IR1?70N[>N^O3>P^8-WDP*'7R]C.B@:#:2H4M75> (TKNY3;.X&]!YX4Z*\-K=Y21:U,9M'PXO06!";\J7*'9T)7L^Y),,?$">M3MH;0 M;@\-,BV<+X--N9 _8>]=RAH2@L9Q #W*MM$R*50/R.*<2L;'1+EUD,&!>H>, M;DM0%2/[4D5R4;-$,R"BMC^* ) VU<@M4,8!#61:@I1(9F*2D;MBV# &3SI@ M +LE#TL>U>2AYS1)84-)="1DL'_G*ENI$BZ2+YHZ8D[YQZ D1VERU3ED9*D2(X73P#Q"451[.E MD\5^B_V/]I*!@2!SP U^"MI5QNCF3=&&QE'IY4CX0LRIA>?/H*:#3AIX_BHA M75;5IZH'W@*;O_IO?_:%:FP_$76!U83%EP8W-QQTU(;]7J4/B'#Y?]E[VR:Y MC2-;^*\@]M[=(",P8U*R+*G*RM>3)\D9\N;&>[/,8KMIN0D"$3%77/A@ ]F'#9B?++ M2W#E'Z3=G*%M72]%SOXF-A"4IGL[LE^ROA>/BIID_*/#9>,\P+J21I' *0AT MOWEP[O_GH-2,(N*DL'WT %[Q8JD=S^&V*Q?@"&S@1HNUG+GES-W5W!Q<,#9/,K5@S1H(,G:];:6UM:-T"O(?X;JG6ZIN M$.A/#;_Z=,&O+OC5>\>O+F9@,0.W11WLW+"&7W<5TK?P5(+"#I2DJV-*24B] M9RB>U'5[S82/"-.##Q8N$;PCJI1&AD)K,Y"Y.F:\=/ -BV)^*D"@>6XS:NTK1_.LGG[^EQ#Q:W"TIR<[2&U7:B[^,2S'8>QYN[/- M7%RTY6S^@K,)Z@9-TH8HA,0^QC,Q]_7Y'Y]\Q7FOUX)DD,37(H6+%-Y-"DG] M"JJ(2XA1RE1QOO*NOP]$9;*F5L)U3FA%DXGI3TSG%'HB%U%<1/%#\D1&&)DO M@"IJ8"'!,"F@*GJ,P^XG933)8P9:(6J^5'@:(=64=FX1SD4X/U X RQB7QRV MU](FA\*2 ?6M*A^C^25P,IV,P5FCXO;GX&D=1Q6FO] PC M*BDA7>1Z[0+M7H3^PX1>P%EGSY$+ CG48)YEB=VZAPY12E' =6%C6%I CZ= 9((%S5;WUZ>'." M=[T=]F3SLN?MX(W2J<00Y(/DSO*_8J#'HJ?%;RG7F;4> QX2Y\/=*VR+/H+&80NZ8']X#>_Z,D'(&A7 MH_.VE8M1?@4R&XPA15'(_6SP;P7:HQ&2=:[F^3;^X_\:&L>T'WXM_W1O@+;7 M?NUQHK(?NF&WS_SK,9\,(>X98$0HU(-P& *[#3B0(&^] ^78/(E<"0JP06*2 MB'PV54?5-:$]9)H.^KQJBN%RD.E"M-V$$R; LG^";WYVZP&G]Q4X$OW"@WP1 M9U,VBM!):R'*NBXJQLXS)6 2>AAT'N-LB8_6Q9'M*2YQ-?@;\N /SD;E&?9! M\=-B.,_6C&LJ_0)WQPA\O#]DX@LO4MYG+;ICD*HO2BMC+BA;=]4-' 7,\XROH(X(E_QU]^$K^?9=^TUC^ZJ,&K&VTABRKJJ MW#6I GX8EKS^X/;^Q:^+3K'B?4^IQ%N?35.#!1 ZZ2/ZU7Y)=L&N]:;5/.;H M-O3/]UWN*:;_NU:Z(-Y@DBZO+>'$Z0[^:_8EWGF7H='7O]@1T,B?)HMDCF#E M+X0@,= XEQ4 %%IPP+04%FX\NV47AX/;[0\!\/O685 56XHO$";YI\4A ME$LFP.$4F?*5.Y"2P/.>Q%K3XSMP-ENJ-& X=;$B3=YV09Y*UK^ MSAV.DD^Z=]6&SJ85;>F930.6OHHD4.:G^$FEVKVQD%;3F_: M@?!?I&Y-,$H>I=#./(<=^%YPFQ1I?YX;3J-=>PT2;_0A>9&P;*7W_*J#._4R M*T>O.WV?']']!I$-SA4Q?#>MMT#4J%4<5&9B X%NE>88(X)?* =5G*M>IZ8' M+%S+PNQ1@0"OT5/5>_XLMC;KS+TEGRE=?F:83:")J7S2Y LP# MQ60TYGJD _@M6Z[_P3!4S#J5H:=?YJ$S2PWH;*O$.'I8D09II F+KP-;\-6% MF0N9XFM_)826F*P$'<6J8H0G0QONGY[\.QV#+Y[\N]=2]4%GMYHB'_150+T$ M_"\G&9.\HM>__E1)$V;5FXIE\J(!QX878(\W)H/ZZ=+=J^ ]??IG4B]J_>A8 MNI_W-;'")KX*4SJJ4UIVW)3LF.=VS$"(G3K/_M&B93"7R/4GYOC>5=Y?X"W^ M:>BJON0Q=R-?Y-&W,GKUN?XB%\\HC[U=>?9]L1**JM>,=>KM#V"WO:="&+YC M_,/C7">Z=^\(;K>_]4V)ZY9&_;@Z#5.FS8,4;_&$SLJ;L]==Z\,7\@0"JVVB MB4A>M\40(K)9J=9^1*]]_4]S?2C$WP7F08IJJ-MVOVUK[B/S^H$70(>(DC7P MQX)U=\3@FQ9%]N79@_VF<=TEATK/N8=>T?E0 M\*CMF);S&!'^>NA6&-IZ9AE_5\YO607WBE<^'>2>+GM"#GD([_1C<13N3HQ? M]:M=6'F);W7R17;X@GGNY)6L9XRR[42%T$7D7!I]6ZWCEO1J+GG",9/TDE3X M<(?\B'V0*#)N1J7)\!IO%?F5@ZAR,2]0<.*EYN8CR5!93AMIDVB X,ZLN5*Y M8IC2ITH]^=D"W5N@>_<.W;NOC#/;VJ@!V^:DDNDP5J,F-;L]8P+=>%_@H -'B=>S6^LC GI0Z8&^;/!?RP[2@]_ M*A,5DG#>*]A2DDZ]8,K*G=%8$/J [&>OFM:OB4NTWP%&M1YZ>_+AYTF##[+ M34!R6SINU;5%:N\??7?^YCQC0H;L/ZO3#/'_]K=OZNJG8IM]'2Z,*;!R$&:#8MDJ )X7Y-8"&>8V%ZH+UJG MIG'QCMY/Q&D<_@6B(ZUK)PG-I"]MZH"/GBUQ!=^>9Y_]Z8]^;V_>5WJFU_;" M"4]6D4MK%R4E-/VF\5M28 SU3X3V7B(I08>#$FI15+G0.3"\1\@T)B46ME!? M.TKV:/)-["54]N!?R.MPGF24M1YZ(XZ4GQ69Q)ZU?P^Z&D"H:0ID'X'_A!>V7@XX'[H^F$\ 6S M32)A#IKTO-V<.8ZZ:E#:=?6.#H96G."6A/7GN4$ZSG3*0<3\"VS1[TNP:?%H MW55"83).B[88:;<6,4#53E'Y/_Z9O"B M7[QC#"UG5 !^A'AWC7 IAGQ!Z7[V9KMT-5Q3+B10U,&ZG69\'A@UJ6-,]G*C M>#XCG(#5&X\9BJ 2(NW#8 X,L^)949F0LRE_GO#Y7:)@VV;_//=&EH6&P1C^ M.R,K#(T&JK?F)QFPJ"/H7/;MUQ=Y7+##=3M9?";LP:_P^H@,4A^0_+^_9H^> M/I9)+;>L-L]]W%6'Y.*4U!R1XR.E_-S[]F7!X="CS^067F0W!WKX['*H2NPP M7Q+>]20'Q/>19F*2[BD-/[C\T#-975:-M*9(:,3$9CHLA6;9X!P'[KA[U3)! M18NE5+,8LX#;Z6B5M0\I]@0U,4$2SR[8R]2".'Z-L5^.'.TP&(TVHZ9,+>(W M4FU:"Q#JK!/6?,:,Z) R2?V.W6[[)F84M,W]K28%AO'KVGK A&;$1WV]V R> M\!+4DL!RJ!9*H+PB?2EVQ+R+UO)!I=Q]$[:07TNK(V$X4C>B\6,KGUNS@CPDTW% MLW7?8]:BC"1*7RI,410O"@-FNS0%D_Z"7F0\M7@A1UN@Q">AQ Q/WV&0E9#/ MGIXY+ 2V5OM)FFYIW%@$[VZ"-^&W/8#X%3&*D":O7 U&9T(L%=XI&TUI7+J% M%J'[94('%X\'LOK0;-"*=R02#_C A$E\D;M%[NYN9>$0PVDL?G8AFI1P0I. M5#LZ+CUABXA]D(A-(O@"R= 'T7IU8]]%3$3%:(HK(&E%K<4PW#"4>2[:&0VC MB%K[YOK2.:I&TQ:0SY[DV;C#AQ(4B!+]<:5N+I3 S]^>G[UT/U?K]HRS4=FC M?[Y]^?SB,:5<:0R'0Y:2?X)T0N@8." 2Y_G?@L;C!1C/Y0B\PF&:8G-P8$L? MN(]U#R85 $U0S,;LCWT@;[?K1KD05*6SH8F#U%US576M3+]<=VVO68_#EKC] M/DHV*TK&^&!!T$NW;CF;\E>4NNJJ<<^HAL?;^M=M5?J]P<']RV=//G]F1VU_ M:LBGSQ?DTX)\^OTAGU+!GS$![WGJ1W\9'8)_^]N;JG_79Z\9%B%5!#('7TD[ M0?:6\K+N\IC3?TGEGUS^5R8K9_7'QS9]4UE*S)(5AU5;E_X7/\H\$H7<%CW3 M#19+](L4-:/Q;UST M6-WP0D0A!'5-@42:[;X%X%U]YT5P5?W>-3#&Y_3I<_>'- MY.)'N.KSPM4#4Q!=U-X7\G]ZG1;11G>JQT M6Q^'860\;\]1\K\PL ^EU"><$)7/>?+99B3?]*_QP(E<1CWXV >;86G\)*^6T,Q2%2V9.R$7U(:NF>N,:N]<3FZ',+A2NIKK#O]O6^X&$@N)*<"X%)Z]' MI.V3_Y5[S_:RN)32++<3BTV@ DI C4CU#G0(>WYK%3#*C5_#4Y^CAY&SZ0V83@J,:D=7K+(X 3W-T/@%?AC1YK"_JG M':T^7;R,]8<_)KOD*R^]XO?7^,$&P2 M0=7,RZ1SOWS,91654N3K)X]9!]+A:]Q(NX*NQ"I7'0PX=)T#PFYT0KQ;3>BO MC*A/SFASLJNB'ASC$?"&4*99WZMO?#3 MAX*U(OLZK+Q#0$!O(%%XOW2$Y775\W%3U@P(V+#WC\+J^P]AV*5>$? /2-D5 MCA,W2?<8NJ2\!--92^Q)[*55+FS(S(M2SOX2,Q!+(#"2L9QQ/)M.I4L;_Q,M M4;;K(=(A<'I O\@F[4B'WW_S]*+C_,#Y#>'I'5;E/1%*D[S&[N2+X;7LE(.W#L&T(UF M79I^3%WA'C DZC=U!/O\S8ZS/\%OMWAG4N,T3I/ 7>3W<]9CY'S>YGCJ*,H; M#V[VQ%N7GL#O9=M!XDF4@@6NZ)OY5+^+//S5-R,3'UOZVK/X"^_ M0!2*C%',(^6@#$NY78'HYNESOH=#+J^ILU.]L!N "ZV#?R,13 4<"? +@3! M+2&D=@)S;39OG Q623O-U_[- M?.S2,;R/EH5<\CQCHJ1!45+T3< MO$2V:\;%0V2U0J0JR;H54#O49T+?OG'1 MXB"+Y-SKI.'0ASEZ&$KQUMPL(/R*TCJ 9##B*)*9\$A=T(+A=HSNMIWEX>OA M% HQ4S61^FHSLR>G6F@MF.?COP:M]LS*%4928Q'6/5Q M\(DC/JG;6BP :?5R5A64"_]K]J@2("60[JD9]T_VXK]I!7=%V=;9([YQ.'ZU M*\JI^_#XF;^F7M0?!E=K5ZZ]EL%]%PP//HL1SZ@/N:Z]Q*&%0O?#/JDL M^M??7/"!I.YX==VW#ED UZ6@EX9H-@45JX,X3A+%@Z/C!%O MO<-YJ8!G8[-."F2:S]'<3WVB0A,8/K*/ZZ#@HPK.T%_/_GC^IQOK#>]95?AM MO*E73?;*.RN4,.+^.2I%A;Q-TP[2XUF@+8F<21_JNNH*X?-SU71ON&O,9=\S M)=0C0UOR_,WW__&OH3T\>YS*&"/'24I'QYI>#FTI%RR%H:_%R^$/00X)+NDO MG:WAL92.!\^#:,Y@Z$U,2_V3?HE"-."/!.D+/1,]4P+B3O0&N=6,FVTZB(CQ@<.6U,<]OT'_\G\^_)"HC1V1M=)'1>=7HB/V=H^2>52*,+6BQD#=NH^1Z"4Q(WQG MNW9F-$4L7O]F1^[A*H,741FP(E#=2U(S$#NK'"M1$*H6!$)'UNFE9N,O9##T M-ZR-9_)!2 0AT0I/"O.FAB!.ZD#SWC]_]=\OOCY[^J4_,%Y.00?9W"35O.5= M^Q,[IR'3G0BDE!' !<*]:MZT]YB]$%\<90-FS8-1O_*'&C(NIDN:!D:VJR\YTBN3Z^N!YT<:G3(2G@JMX[GWT>G771&3R]QLI*:P_9F$1Q/^D)8 M3WY3'(%[$_SD3L_]KU9=Y:_\'64M*""DN_B-.9O>ZBE!<'Z?E?D_+I7YI3+_ M.ZG,W\#".5/A I@<%D)]JX.R6#Z+!_#!6R']@0Z0(;>VZK+H:!D/M.Z_8$K:V[7 M5(BT25)680QGXD/+)WJZF^:E+]) M]-K4,-""Q5HZ;I-X=H_*SHKJ'?!2BAT3'\+#J;J2:Z_^H59H>97;GGJKN5>A M10IOTS]$8,+'D0^1AM*M#E8DL%G"S_!>*V;1#1<^T#D4_J.O"N??<$T5UKJ^ MBN[D\^.^JX;=.;$XW"0I\IC'CR8R-,6.7,GW%!RN]MRR#E)1FN0G(\1 UIR? M*"@VTI(""):195("'#J"U/*!,VRL-RAE)@8P"N!U.LH[89BT(PF"S@HM)@K!(BE@HQH*^0X$?B1A\C$ MWUN5YPM^SI"5-*B($C"0%A9=Y1B>R^C)"?5?SHW?HL+GE>@6\%T$[JCG>&3 M4A_@&D?]$'Z%_C%>>=F8HT9[H.&@I*J\9=6DZ_X6SL!KF6?!Z5I.Q7_X#IB$ MO2X8)]"\-PA"\GBHJ]%F71LN9=)/,D\KAK(G=Y?BZ?_[^9_.GQ#4H(9/)2F> M;1(["^+$+]VP%RWP*V%,$O0!X^&85284\P.X8/S:O"!Y++&O8F6Q\[']L!>O M0/3S(P/0D>;!K"-8/..LY!TF=R%'&-_8>@\+%5QY Y,KG7EQ5.Q$:RELCMQ\J>]";4DU7>AV2J+]-M0R6)O3(4WL<2EUG9-\LU0ZA^KG$(ULU[+!4($C'FC4_60Z3YY98UFJ&9S(PE[_@J-CMQ?*-B MFOAW92*I&GM);B1.[#-MOHLT+])\-VD& K5#HQ/BQI@3Y:POU81JGCU)H[^H MI4#ROR$PDSAT,W)9%UE<9/%NLKCUW]#L#B5EF6HPBI20X'*TRH2,_4(3Q)Z]:1T*NWX@MV*P>2X5,>0_:X\8^S7;.4. M-6R;D[,1*6ZQBR533=15S:8KPG"J"2A(JJE*T@(;7!>HIH]:MQ/LD>D0IP9R MXIN7%GFNY_P\' +"/4^ ]H1H,\HF O!G)M/994W!GA94/"8J_;;M]"28^42!C@ MIP3URN4,+;4?<-=]3<0<&&VFZA< J!*T'F.+L^.^;V$F"*^B':,%V*>\XJMZ M:+8PM]%@(2\IX=Y5W/:97D:XW011%YX)K0[AD3#9R(Q]A#K;F9;^YA(X3%RV MI3E*.O:G\E8/Y#GEP Q&H[O;_: G;=J&\&- DQ7TQ QYQ-LQ?QHSSO7N7X,+ MU0-^]-A7J%=G(0#.0 D[:LJF,/DO47G41;4#Z(:$.$!M^2XT%4:[6PA_U^V4 M-'*VK^2A:N*WPK\(8\[T21@KFQQPPG W9&MJALTQM+$G9))2*^,"_*/0JRGB M$KJ7JRYL9X#8*69<6T3#W]4T,+V>N>MOJO N#ME;MS\8-.[G3[2E_ONJ*7O_ M%A?G_C:]:ZX+&@7[\OSK9Q"A]Z M"*X) _OTR?G3?]>UH**8](&VPX&*9U!(TN^LK" W/?)+KT0+5]/LU!]=I?R! M\5'^FZ#Z\;F%2:):9U_'HO*IY_SRCL_YU3&[JKQR5"BMEP[:84S>A6;#&T"? M"V#QJY;FTOEO?ZW"F6=?=^?\DF$+&%^M'^,UA8;11QA>X\CTM4T]<"4R@7K( M0P.&[U!V./4L[(IH<)'JLWA5CG("+8W^+ ML+.OCE+4)B1V7'#^%:E9!B515#!")#&C%V@EMYK73^X53HO$8FEWPD/ Q/8) M$E9@NXJ#Y4B*-OM]]S=?+?=,PD3G!0=!4Q%*H)N$09R0.AP89-^TIK5L*=0M8G?7 MHK(!O\:T&CL_Y!MU:98-/D8(*F.4LTC>(GEWD[Q(#^6-I"81D*D((ZZGF?3 M,&]XIHHX!I"\A$8ZN"4CH#QVT4VFMH)%7A=Y_8!I69''R@PT95(U$ :_C^@N MDK=(WMTESV_&6A)V:(-WESR^B]IC$0K:E #1LE>'(3 .CW+6%[SR.,T_QB NX:Q'0NPIH+ 0E,*\PKW<& MI)A@$IG+0I-!4IY/.N:O.-'XT&=G;G@& .,*> *D]Z0%!.%.0!DF6;-06K?L M\TG5TZ3Y*">F RAN0C#,#6PQEV$B>VG@8#Y[H#[,Y7(3NB)0B*%KVK[)5URY M.!C*3$30_!V:[[ PF)<1>NKN(6G^_]Q@RS\O",,%8?@[01@^D,&6;UQ=%2A] M-MD/8*![S8"C!S_ ,E*U=93VV7>N;(EI"A^!:,I2,,*L-P.QD!($BSF<0,<) MA",R0_J/$?I1>A+Z,#]&1N2UD;,%3[!UQ56E]W:[!"O)A("$H& #6PX81*VL MUO$>"I(*(%"M02N%.V^5!8S&GHEQR5)S$Z:8".21\.#AJ?NV=N^Q8/_E+]*X M8P#R)/3TI7E>+DJ8IX5/1+>[[;GNG]V2GSK=R$C*:):CXQ9Z)>7!#AQY=L80 MMWOTBS7-6SAD29+3+G&@3F2^.,9'82/,N X=.&+)Z<@OE8D+,0$%)S124]JA M')KR%-8 *2\'KWVP;0WGTWE&I%+S HB[K)S>ODR\:8!96=FP*_WWEZ_U M#?AG_;#Z24Y7U2!L9$#D,0XN:80)D?.VWH(W 1A7#/Y!I34\U&I_&KJJ+RNY M$A_;3=7M%%VFCS0BD\,6Z$V5+$&FB9G;E([I[5RD!9Q?&*%D$S+C2K,PO 1M M9]])=E%"7Q 2UMX3]P\5%-2!Q$2/^RI.=60>!UE%&5(3?P6PY."55BT.-0A, M^O%@+05-D 3L.T+Q$24BX1#A/(_'\1K9C*N9ZT:I?@OT5?K(@]\%ALT0S@7% M_&I#" C_;JL!7GOXKM?315VK.QZIW'B.6.E-\Y''>'2!TT4C$:"/ JQ:P-XR M[4L/'B484+O*_4%?O\-\SSS3R4(Y(34Z+V@YQZ%1$BK& M"5AXP&1FUFG1T8E31TWMAZ_WYR^TLX::8I)QI ]FF@DBUR A9 M7R>;S(.\_/_4_O32%:]Y;@.9HUW+?*T4KC=8-1+][;&FZ(Y$[QBQ.:)%A'.7 MU/X1ZI :. M7!OE-96C.BO0VVCK>A-7&\]HANV.V5YCCF"D# '^[4239?V. ')Q4':\.2:' M"B!=,8ATC/8!\-<5U^;Q0D/&T*LYBQ9[;!C)A6BAYKE)!4SW@HB]$CY5G<9' M=C7,[YFT""EK?OHP CX^N0.CSI1XR,9/99#?.K)HJJQ//P@K7HNZ@A(.4ZKY M7%!)S/P*Y[9M<%,SP8D(5:5%(MU2Q>7[$U?1C+95+;I^-#H(ZB05AC"N6C5[ M.B$HT8_BZ/QF#-2R%3&.8.K=K>T>(ADMO"V*8[3CC-%I%#,Y*C"%#>LM;U3Y M%34/QA2QTE!E8QAO:-7QC>.BA++WI+R]FH],3D41W( !Z1AM=I"MG%T2?WR) M_IA>L/9^,T: S=]FSC$G&0_VR9;!XEH@++E%39\V@(:GU*L;01ZTG($\8\IS M@E#OZ-$[> ZD1NK?2,P^*)Z>QK!V(U5-)(1BG%:5M==19+>X!?<O,?Q6[_[&O+[\9=*!)R\&A1-./ M-V1_@BUTB& Q0.N1^YEFE :O2SRLQ[!LPIHO\Z>L\F^\,R,D[-[Q$A@]_<=> M!M[!PSW9AX 7+[DZN!YV YL&GOC'CC0=VI\Q^,VOQO_]XQ=?G/])2)TJ_%472Z@ MBT6\[B9>!C;IH]:NV 3_-\#(T5(1.]!CGCJ)9&&Z8HQJU*$T\"Z0BT4\[RR> M$G%(]0FU*VK3H6+,60@)QDYFZ>!NJ!QSA^(D8/RE?#OW.%$+"1;R)TJW\_'N MH9-9Q2Z9#NPZJ@A(GUHC*>V8/U$7/1VR.YJ;*HB*D+IT9V&T_'2*0[_E;!;_ M $4M$T/AAOQKOQDZ+00-X!K6QF[Q:90:0['W>6A[E3[,L6*D#3=>ZO*TI@ # M'3;U!.6KA9#/%MD5S&GG6E3?KZ'Z,*HW)*- Q$.Y3+;(.SX1)*<408@10MZW+QN5/X\?W'/J<#G5\&P%'>@D 7)Z6KV<]L("#0O6;,5Y#$P-FJ>M*&22%^ F8:RZX@-QUIX$]-E:_ MWCHS&<-6,^\;LCF'2@GA/\WQ+3I"[G67_EC^KP%->@OL;$](^@TC%CMB@8OI MDK!5_6$H _(PLC&-%8N>[CF U(_N)CCQ6%;S0!QUR_OE-[]<;L2-)MB>_M[. ME?B:]HZ&Q0L7$%5P63#_EEFVWE#)W7W95'T^?_,*Z9?D+C%?G1Y,H$B1+FP) M-, XL%BE)+[0,,I*GE*!=W(NA<2)J+9 &G@ E'F&\H]<:@V7H?/=VLK9B7FBZC+;'%9B,[OS?ZKJ]]C:*>.[(U>24*G%! M^R6B2H]KB!N-AVR#WFP6C^4%HJG5)UB'J== P.F5:)HMM>EM7-:#(O.W'.@-$AS610'^Q\6*#V= MRI1W\]NN+T.1! M!]<+0B-4VT2ZO3_PN](]Y;+MBTSX8IG(#8PV"Y[1$+YV9-G?__^ M-?[KZ;/'P-O'+@4+?M7.#3$3?>#FC#AZU=;@WZ0A\+ J1G'U_##&"O"C]/%9 MGK_NP\-L6,E(M$[+0B\'%?B%QE.,%7!E^BZ4D MWF'TP6!2NX_",$Q=R9YQ*T3(N5$28K WC$,I-*KC[0QEB49N0?L.FWF>O3%! MA.F!<615UBXH/-.3H#@RXJ)KO2^9=/6$>T+@X=G-^Y7"D!X,GU8:Q>:-G8X3 M3K]VMUL9,"J1]C)/;>U(C8IQ/&'02\)34P(".DCWQ'00F0X? OA[I99$969! MZ8KSI4TUD60/1H^QXK8!CNZ40=0DBOA-F7V: @]I1A-90]!/(@.?SS2+H)N" M.,%GG_8H,V;1 MI8UT_D=$;7[:/V.0>W^8Z!B=(C%->Y'K>DDZ$U-\S^0HDH?LA7]5]-Y /9?? M_,"!C?]VCF4AWE5N1J3'\X9\TQ4[F+>XBCX2\R]"S.#1N]FPWZUI$ )&880(QC\9[Y!FIRNSG=$#SY_$0>QW#A M3D%:10V\/Q*%O_A9R+KKQJ%;S/0><'C!ST2$>N?96_\ :S 2(S)D>V>TU"]] M&B'8[=.+]M*IH];=_#PX\IMV/8SUQD&#XR+SRS5T. @^7.&F&[92G.LJ9&[- M38]_V]/SVF'RP'7;O0,.6OL#)>[3Y%Y+MEN5A?:][+Q&V%&@.=<\QBWA/72# M]6+1BD GC%(HH='-JY+0;TR0]1.BG30O?^"6Z2K3H5\1 )UM#%P\G7 1O&6_ M.NT T=:I+NLMM7IBE!^U6_(B)>3<'T<-?$!:^7=*LO*7I1R^E,/OO1S^H&M( M"6U(6F>,\9JX7RC <%_RJ/3$+ ^DZXD"3[I;@(F4=CSO$FA,AY*/AA:_[="3 MR-N/W+@0]I,:K\BM9*O3QME#UAH1@SE&6+^42>1W+D[R$.G 15H0C!2!AA,",@Z@Z0-WA7 9$$9.*E3D13 MD_IXA_G+YC:@];= R!B#9DF4SU65R>N ;/.LE/B@Y WL]J:6U!*XMN=_K]KA M)BU?C+/0,*%IEVL>0 $Y<@HD+Q-2R3@=?9A]-!IEF4#@)] +S<,$,T M4GMFMJ-5GM=K MVL#)>K2@%YG00UF1)H2N811HJ\.5I%QRZN4"7_N(H'T\I(>5 =I961=TPV6B M$"0W)WB;>RM-\*J8$%YW;O3>1A6Q:=H3E087FT>OEFO#!&*I'%4COW.Y4EAQ M 63Z?(J@B944VF;2C1D7D$:4L/&&_*S)@,43)&F.0& M50_P*N!1J:"[>G/&*'7&O@077OT MC^-?I3A*E: =O2BGH-H5UW3Y_5JO0BY#4L@2F&A2;I>/UEG7+!)L@-^57E)7 M&MF, _FCZ4'A58@WN3?5\8TJ3QX9=D)A>BWW#K3H'SK?1!2GW M7"K]"(T#9']>;T_'/#@3N> J^/:1 B>TLUGE,,+;A>ZV&;] JJQ2?](N.&" Q>:!.P*;0V"2 M0_!,C:%9)VZ@S1P':CD>D"SW#^00S)F"\\+X$1AU88WA*,%_B&IXH4L93 <[ M1#+T$31>D2+I[3"KV5'P4*J?1%V=6!JKQ, B)_E#&NR8N.I*_'+E-9.Z$O'^ MY&69N< C(0Q:&OY8<4!BM.)1O;S/I--$%P80CDQYGCSXO2F1ER95>[*LD>Z) M0!*@OY>FQJ5!X?3()A,@AMH+!^)Q^*BMS[ABMW0S+E)VUS888&F"'1R!&PP) M4G"_ [1)!I P'=?\3RJ%7B@VP>K"A>9B$=@["VRD@//^;[M.!#>)5W>4VMW7 M/SUQJ?DTF.>8*OJWX_A++@ M]R"KHL $_2WMYF%/IYA+@RNM.OIWA1&?J@Z<,CP(WE);'$QZW?!H]LJ3CA3# MVB^:B0]\50A^*:' ZI8 MJ!7]]4W=SD"8DJS+M /QU'UTEB'8RI'0O]?JT2L4P#@-SWEW *V9+E3R\6TS M?G<1A/F]/U$@XA18X/30VNG02Z>Q7LU4*@/1-%6PXUR%=%*]-$T+(397G0,/ M^8T0+FUKE'*1&>$0$E^5"B$J7WA Y&ZN%9L>))A22$347^I[C&K>*Z<-@2>> M6AB:'/,ST<$[S='$F2_.:I$+N60W%C?^Y(# R;&*Z?&8\ 7;M,@W5TY8FD-/ M51#T1,KCI;@;4&'GI(U/9#YOT06F8A-T"1?F4$19:*26 W#' S#R$*CCC\'Q MC$U":3A]H3P VZ"%HXZ*H1$.76C;GE8UB":RWGDD=8TE].\G.8[3PWOG'K1]H3M MB==FZ+1Q-OOG^=MSTQ=D((PR6T):,>)7"/_5EG).^$ EEF_J[H):IT+%3T*$ M _X;]V_@K+T]A.[VLNH=S94YD'K9Q?/+N$7C=6((TXZ&NF+R"[<7^5/J_Q># MD0INRKQNN[J\IOMM'0T MU,4UL4GU(Z0;_]6IZ60PRK#?NAJ^' ZGOV.'\9 2QH2F4AO/%_Z<\T$(0YAY MH QL=)Y$^D(#'(UKJ-D_A(3TW?!V"9G$V-I3 H'=<%C\,R9")Y02_S%T()4@ M2O$W+7F*],[K-VIV)+C)5?L.(^JJ;CWL:&H8_6M#:6!!1PR-]$732N4I<8BZ M_8$1K#DFCG]1TKB_XM*-YCFIXH[1?)$@O EZ3J^&0!WX9,!]&&!2$3JA.RB@ MYY]OL]?B8_AG_J$K: I9]RY[15FBV&[_^H=7VN&.EUBY-1'[2%L>-T7O-6-) M M555P7_=^>(XT"*=GGVG]7I%-J__0UF!:XA39ZM_B98[!S]K&>7'>./&9YM M_+1F+0.U7 D\J^Z= F_EG E-G$1CHP\%/2N)%!XA'MADDHLK&L0XO.P(>F-7 M4:M!S[P-@0)! >D)"E;*C8%*C6>/7\?!B);9BX-,X5HKS/!%Z9YU,K>(LTQ^ M4]7.1K#311.^K=W8@<8D\'-':=$30RAAD@1T"N=F(6@9ZTHY(F15A"S#FGQZ M>/1:3X]"/%;Y=)M$I\T1M9W,$\I(Q63V$)\H TL2G YW+U.C@2 0&5R,!XLQ M/8^PL5V7=N[6F#8M$I/+I:MF0UA>AO.:$VI?=-2<*FE=*@Z5ARTC$_T*7AZV M@A!3QTG41JGCX%3#,:WT-&ZH@/,FC8_PI]*NHQ*ZHG1F7!$0&P8$18Z2H)O" MR AC-R;K(!/G0*IT @7%735F9YE)Z."FW">:)S#G";/HOM(L3J4 6^,<-M$ DV1\<)7I+ULVCQJ)^,)KG:1FM=0:@U MBEN4&\K'[J="\3;HK'5=5#N=ZHUULDKH#V.H8K@)XS;1^71%&H:;S\V\R02P M*#<3=M"$LU.2!W0]*%6P<@2%"_4%U78B!WFO8T6E,%2'ZEXZ:+1#(LAY;S6. MDPO4K^]\*'&V)3LQ6?I$V5R8@:^,!"_>.8H>W#[9ME1?3.\]-.*6E^'6=B!8 M.EQGS*]#%VC:YFQ(4.4SG5CYY#TM:1OW7:G+4/04PG-\/KJFV^WK]N@G@Q_[K"]VC),/"-OX0%431D72_/.OO0(G;@#V MG<3[R5-^/GL_;#<9O#5#M*0:)!*]$5]@_,(13MFX=,4/^Y6#B="9@V (2B'B59V($G-K\]T4>M M#](QFDQKIN]PB/E^*1J@P[4=29S$H=%_F&.6++.-;ZJ$=^749J;G4F?-$!J] MN&:9"'5O^)E&/$UQ!*Q&T6(BN)HJH^MHJ9HV-H^HO>"6$\04)(+^+]=;)@/E MDO9 O4%>"BJ_.; G;(F9F2L6N-OT1(4:D(L]-B]^V=)$F:+J\QU6Q2;_49#2 MH")&*]0;J)UUGQBRZXLG"[)K07;]_I!=[\41;&(91#HCP,CMQF3>-J+B%$/:C1A, M=JS4,T4?D.&6J7.>6,#;O?T@\XZ=5_&;>F :NFS<;;U).#'I(/[ MGKH^_PZB/;*N =TRLP%QA/SFIAC%;H.T%>_RDZDJ<9T?]8]Y/"]G4^@VCUS_ MV.] =MPUG5K3T&G-V-W\'#%U,UI, M6,G4?I.K&#M291=,6F$.-)?Z@:-07YZ(VUC1$C;?G'93$UB@9N9<"C/\HLUJ MSB$W1XN&3G3*W753@##)18&. L"RKC!M(61"RJCQKR8#+<$B1+J2/'>_\B5 M+O:QC[N,8RU0IHJH(LQ90ER#/#KZF3B,^F>?'V6=ZMI0K @)Z M:EBZD! 3)T^?;;U=)G(:581YY )D/LN?,P1-3/8G+-G*ZJ(3T'N>K$>^8';T MNKUGU2,D_ZBB^$?<42 74]JC6*AI[2Y,"LE)SG:C^2"DL'DO1Z]+ZB]9$A45 M>EHO8MTE"S.4A1R]?[Y-4)Y^<0?I*+$!V5M8[D ?$E:.?XL<&%F,4"?4DJ4I M1X5,B*3UI%B$%(!T&1=, *^7XSLG/H%J7' ^Q;!XJFU)T+V5WA4_!1:5,3OV M-P,E&HO&9/+(3/L'7Q]Z8W+,>!JVT,(O+& !?=+ML"-,:UL>>8U07_4+1Y/E/JBP]6O5M1XA0)ZL!U81BL]\5Z+DQ[]6,8SM]4@G MC6@X0: O-=.(EO!?,= YB M*F;<'MTTMQ [!RH:YM$RCU>@BP$,..JB6A1*:8UL7B#)<%L7 MY#Q[#J9**% !CWSD0'8M: M186EGKY:) 8OQ7$_0E5+N2TB44.6N1E\F$DC+M85%79H6 U8:JC@WHX^9:F5 MFQCMR+QY/%IN%XHB@J07S4,5XZBLR7+1-H/2'VO#H5)57#9>O8"8Q+"Y=3SN M5F?DV,M)Q6G\RHH"+;.Z];^$L2Z(JG]?AQACZE#X3T9&MFI*[Z]TQR3SR$]0 M]0A@D&M':\QUX)V@6 1>UL9OF?N9AEU4,O^9MRP.$-I4'9PP4I=KIZT;NE;, M,3Z1]$TPYA=K&0Y S#G7@8U=$K(G?(J$SD+\"ZZ&87*$*;)K =N(?J4XHN"\ M8EL2K7QOKN,;]M!4@SJ0W==$=UY;D(&<+9=&R(-=E;+R5NMW(2'3[]SQ[ MNR.ANO#ZT]_..Y=7V)2+]2$T""3?H\^O:9*-7SRE*_0"Q&9\]$T]KJ"T'N@Q M0!-CH)UKT<#^(FG*/HJF-M?HT3<_,?38(B\"#,(!.#NT9VR^!224]4?O)N\8 MFF2_*5:^[>@GY-J,?E T@6KHNCB.^R0PZR+ LG@AS"@C/E<"9_HAC"6YV'O/ ML\9I M+OJ^77,9*022LY<5UX"J2H5,4IG?05[.7I#L#=JTU@@40N^[?X.7E%!+CL;G M(_7'3B:HW2ASBO8P+0?E2$V(1AR+/E)\C.T7,IZ]H4I*8N+L.Z\MPV28\878 MU>TCG^U#5CJYCLVS"9SW@U,$@DZ.+R;8BOMC.9,4ZJEUP@J0*Q36 %4V=9'Y MSW!08#DX!UPQXR40EH-.2B!>5Q].^GTBK'@TV?EI($V$RR@4*IT"-W.+$V#. M5Z-VVU&&+X))NQ<5@G B,8C)IDU'^3=FH= M;Q(83^7T&@XWF<1 P3PG'2U21FFV](R+2SJ7BPU@FJ3?.*IER-0$E+S.MXX'>)$-(5.M9+15C68OK2\ZZF)*'-! M:ES:(.U!!+R%SH0V?32K8@+S=TE9]L2FGV?_4 8.6.J"YV>B)#..>BE(/-T/K.8) M^/GK^0D2X(F..2M7ESWG@66H,_W6N)+1\NGX[CB"8N5BO:$X)#DILN-UL8^! M99K6NPVX-GMHSK.O',\CF L(B)F$4JX<+JV5^//L+;LD% 2 M[JK@5I53]]S$;9W55YC=<>W_ZSQ[C:98Q;)O;%(T$!C',4_)&GOW[KBG-&XM=RY1!R@H4!7AM2($IZCF!3+>#@C4@2.F=CW:?$G@321G^0)^6\S0-7)TR _ MLVEG*AM(#P[(\\?ZX O>E9/52RI-0R_3=0F''!O-;#W2-H&8_[;Y!TROST>ND:?@^A>O?7D:]1X2+QMQ)I5RF8VRL&\:0 7O.$PJ% MDTZBB-4=BEP)SB\ ?]TZ!Q)DWR9TUU^T[O&'8-7N$$O*REL!F"1UXY2?JA[ MA.%V)V+O(^EZK13R2>/\4I==56TM]:)Y]X8=F8=T'A96J$_P./#D,\2J),^J M;YG=9MWY4Z%D1/WI$/J9_.PAL#*=#I4 82AM0$1QAP&W7*4QUE3Y5!3J2LHCHAT$.J/S:(+I?*B37'^,.4�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end

Z%(^.85D\! DV5>:R<("D'+LH(>0:F\C]7EQVP:)(MVV8 M4,V%&!MHB2M/JHQYLW47D.9"5K- :CG+S5$<;")QUQM;TB02"D_\VI?#!*^5'9\6F1)7%$ M-[J&JJ\**I"<=QU8(;W]E 0JDUV-0S*$]"^![V1S1V0B(6B]U4D!>]]LJ#;J M-V3G=$VV4=J-JQ,KZ-;$22W%CL7(![61<0"EW=\H8R?H=\J.&#^@"7X^4A_8 M;#E&&L&I]SJ:_C QP)B;7071R/34WDW+!D6NV\(8:%BN9:GC;],5I>UM0S2E M?K/]*:5'-)SQO#F!D]^?\$T_\A=*L]=8J_J^;'*07# MV.1T72+:[GBIWFU\*LB*J;Q@Q]5,-%L=5\(O4",>B?+I#::J!7Z:+38R[:+E M1]XO*4LNBTS!I]FZA]?S0&'52\^T!0HK8T7G1J)+A7YSP!15^JQ1WLP"XR,N:H@.8J+W[AUV,')55%9(C:W, MJ#4U5\<;/BC/&*S+]&^(,KE-XUU,JMB6F1ZB+K&# FUM8@,Q3-C5CDAC"@V/ M9.!^H[.+5\#NEN/TF-XG'TDC\5."5T6!R^(S5MX>4!!!O$BJ@]J^17I* >-G M&ACR[;B*#@6,T'-6>6^4G! 12HA'4H?UZ90W3YG Z[0*4/!__HP36HZ([KA4 MJ.T\$'=0'15I+Z):&(!NHSJA,EU)S;:5E:"XEE+_84?DL&LD!9'D^T+J,,4J M]VSX:G^EG*SB%>6=QW.S,DBTGCOT.U&AJ*C.D89[\_#7CFZ#_\GR];$HLST9 MFC0OSZF(_+]MI(=:/VDD4WA]R4C7O!S;KFA GIC['.SQ9MO!JGU,SD#K__M; M@==FH"7T:@T6%/+A'Z&G=\H8!VI-!.QMM[X*6"&/25*J9&]2;,A1DHD@4I1T M4-L,I5,*ORE\FN;UWY,0@F;_3(EW AM\_)K9;5 @ K1!":ID@PT%C V>-*__ MIH1P"38X"=XQD0SR*[Y+V+.;MUF$$[TE:DDAHAIFV&UL0TT'%.$P@3&5'HZ% M++ #SDLR%[*KT!GZX>X&\<==F< +M&>3?5A9C>_@2"\%&36Z2T0%(%VR'_J3 MGE] W$KJJW] OQAU,%C,Y0 M$\-[0A>)DQO4+'#6LPI#5AWJ'HN3T$PLMC-48@8L6HR3T;BT&%/(A M8RA9*QL M%BO\"+[Q%U";]_L*0J#)2 NY,PM)5/ZG'PT$C4TTQ4"!M_#]4&P% M/(K&O$67Z:"651K W>74"1' ,DJ)0/N&(#<'V+WUE)!''+8]X)P]9;P_)NR^ MS#V.,-[3Y0+9S1QP>0R2.\*/\QQ'>L,=)PK@L&ZDVLUAWD Y,(=]H\ JKEA2 M:6B%PD8@RAN)=%O+1:)#+1,55*CG \!9E&[%H58>:@2B1B+H6#.#_C]^^\-? M__G_H.;;]^P(R-O;%/'*82QSXH"ZOVU5HGN!6TL.<(/;@D4_OBS#F3PJ,N$S MX-0=307/]-0+>.Q;!J]]W[LE7<:3WJ=X')ZS9B/GK+:MG2// KVM?%I/%5RQ M^YNB'G,<%,?\E;]/48\5QCG*S (S2;FH($WB/6$513$='N S4^:"./$ '#2Z*= X<3 S^#Q[L:.0# MB(8'429TG:**#=@QABA#*=\[:.#US(UOO7!T28N=Q$]'JE1QG7[Z(\0T/OH9 ME]=IF.W5Z[\1F)*I02^\[2DG1%PLJO\B?Z52 M*QCYNF*'!35/B\*ZRC!%WJ\5FLSR/,*O9*-\S/'GK#2$'A1$ !$'+=0FT"!1 MP,07-#"D#UW1(4HXS[-RVB#"$(B0$0-7O-]_]^%?4:=?Y[I\*2 JV,T?)_?I MDL(ZD0JVRI5$.G"'DL&8W0HQ>C#G&@9W(9[F )[XVX\5\AE\;!-\*0D"\^2D M(((H4J>#VE:F.Z4 *D>GAC'L^F@EC%N Y[-B5T5$C)".-2G>$4[U M#_DM+E17IU4$$"E5*HAMHI3X*U#ZDPQ!/A6D-(@2(4KE.56I'\#AF=DV(U/F M6:M)( U-SJU6_0YL;.8W69NOZ3LKKB<\H)3O:;&.<(VK."]*U@0?V_6K'!TE M@*.803?^HB:#<1L3%NF3,V+$/SPG].M$(\%"KFP&0X<_2ZE?9%^%?SO&!3O* M-=PBTU+#G*!8P(N')QI2[^_0!DXYW6 M%;D$*,+;..6C;O 2Q E-H/:]@36#I#_/$" AD@RQ$>%7(&O2142:G^ LREP7 M?#$V98XQ,*L"C(2, CC2\(UER4\(@,Q?7XZ\\RN<$]C*>R_'#VQ(F:4!%TV? M!.=(KS 62C\A /(*?8'TSJ]P7F$K.+X5!9Z1-AM5?#)/??6B*>=W0ELRA;R,'3-S200DQ M8FD@]QZKM&*1S*>Z5].PH)H'/!ZNT<48"[?P+,J>]#%P(\-2;,JXQ3-8%6C< MVX\N'@O&!(DFF5%) 5001@;9*0#3_NR_X,MIV_+T2BF@J[F,1#EFG4P%K[8$ MXK\'Z3'(7\DN]?$K\8+7QUUV+((TXO_Z'!L#+P.D0*RV!RO;+LA[BP!:LP_$ M*5\ZS^,]84=D91^D84P?46T&RC XL'$2TQ'T$!0%S>_-\0M.CQC1?F?OW=+: ME\]9%A7LH?0"YR]Q2(PYQVF$:86*.&7IPBE-%DY02/JB8#Q/]5ED0-5 E1[H MPP4B9ORC[WW%5/W)/7G548E&AC@[JJ75_Z;R0/<8UU8)_H.8 MIG[(.B& >#A;!;%])5O\%68,44"0;[IS&I#,MS[X %UH"IACBK$%.#GNUUGZ M@O.2OF5ON2!CIH%-*Q*YH!EC00(/_.T3'VKXVT]=XCQ^ M895"K].BS-GX1Q^P, 2PS"PP.RX7-<0MF(G>^Y[,#D:RJ)8%M3S@ :P6%:MJ M$83EXZOE.4 S"[0QZ=50&Y-,#VA,.C F8ZIYEO FX$2:S)!W\3' ^7,\;I,2Y? M#;4:9"*(6@TZJ&VMAE,*H%H-:AB*E[#C NWY/:6B#-*H0-LL1P*[[]H,CL % M.M#2#!/"]5B"F#2PV:[RG$!D@4;#ZEQ#"U1TV 2\4VU81>B_S+ >A>R)=(&4 M;9% S<*YM*9;(/SMD?QO0=8AK,@C] )= %NLTHA@%:"*2(TG;+VE )4F':9L MIS!I/Q'^RY(.P2?'V@0I:,5M6&_"H >#,RAL=]KI-Q!K,J]LMC]G!QQFNW7T MX?L?#.%'+2U$Z-$"O T[:@B!WH$PHI'C=73:)V,[94#OUIN?OT'OT?J2L'E^ M &( [ V'31@0XP -E4[5[>C=[ MJ60 =4N#"@K?5%!#.Z@6DNM>2&E%US*@W1471I M1-@0YT.$D2BR"-?NJ8SFR]3?9)[7EW8_X_Q[@T-W"4#>6%) %)Y5$GZ%>DE) M@B!_W\W/Y(/^_.G^>]_O)#E@([Y#B6 ?0W+ J?(1VJ65A_PP_Q2X+N(>\]\) M-?3DIP2OGODZI N8]A1X1LUYZX?KSH3W3Z 3GHMVTFQ'F!8VU3FKH?H:]7>8 MW84?#D%HJH9F((9V8!5TM?^*E MP7QG.*._EXB ]UD$AR6$YSV*\U54%=>?/ MX:97.8Y^/I8AV0Y__YUYFM620M0L-,-NBQ:JZ8"J%IK N#HG%8*8%!:,^/Z[ MSISZ+[[GU'XZ"> I/?Q<.AB^LN_G<-#/S)R^QA%>[^(DRG%:_)P5^@<.79D MG-99E<9]K1PPCNP(:Z$WL >C;_A0PXAJ3D@GGE"A/PL:$1?_\,,_5<[]K_,L MDHOD(][EU/,.YVVOXP M__IE?;/R[$Q6X)0 TEGL $FGS7(E.<[)%[HAGRQ^RC+- Z5&2HBKQ4;0[?5A M)1G0%6$#EN%O^SQHD * PS )^BO$HMY7U"Q:!6#N*"P/-$+8JV:GX.]N;[78,D+=* 34KW,&*5 MF*49LAZCP9C1C<:8F33$Q"$J#[PBTO2ZZQSYPEUY?\Y]$X3NR0AI6"RB6MFWDE$E&F0CU4_!:C\E8X??5_541/<1 MYDG83([[ISBPNK&&$"2!TP!92.144$$E=&JA..>M5"* _+&/!J=08=- 9\ ] MIC)8%+$#TB"YC1-%1KC])7[!27:@\IL&]?YNH@9P=#OXQL/U MI'[+G]EP*(K9- R"20":]LP:C+#ENSR+CJ&+'>LH 6S8#+JQ7S49S+1DPN*Z M:CQP&>W4XWG&Z:5#1;P,_QN$O.GFB6MD$Q2)Q=>49$!5KC5P.V6L3VC\3@]: M ,K"P:@AA:Z%W _S!%/ -$'P7X/DR(8Y%M&(_W;$AA-8'3%,^-L,78Q]JRF] M![Y-,"1+:8C1ZD"FBB#[=*HV$?;=0ZJJIHIO=X9S& M!J^R?%/N2"=^?*75[ P+H(EDP[CQI!TC>O@D@KT[_X2H%>%G+IO-5F+T1Q!_ MT99F+C-4-<&KF+)&+JK:T\#+O!'=1/$;UX03R3X[=Y([9B)W:@6?DSN=HM:[ MTTKO3D+)]M:;KAIO6D(A=R]=-,&(,WV=1T'S-:&.PR!YS.,@L63>]>0%"*GU M5:R)L[DR^@V^]4-E]M-: &(2X'/W)E60>EE8*U@R!8-9,_M^V=-D^N#%IV=I. M*""L30FRM;;.SYZM3=&V_ TI$;BU.2&]HTAGL[;+XQ=L-+83 H@\"Q7$-K5" M_!7F1%H!P?4@^N&0I45&2\RT\[>PKG[WIX?[U9^^05_CB%JN]?<&ZC;TDTU3._/2\2V&#B%LS4P9LJI>YN6\3S XV+H$P5). M$ETNYOD"1^BUZ7IYM: JNQX8JN3(-#"ES95 Q>KF'0*P N<*%-)WIK3_UM!6 MM;R]ESMW0=J\%A" 5LUQ1=OU'_8J0##SLP"->]\&Z7$;A.61%K9R&?V5#*"S M@$$%Q6R@H(9>[VDA#:^\TYE..O+!RBJ[:ZD'OXPIL:H%F1 OP]&<4&>=CI[SG8&/UY>W MZ_7]]@Z!I=HENR MAUNC>_+_#^B._!?RQ6Q7X+@DJ^8B#PBB2QP0"\-%<1J!>%]]@BEOU)3?_ONQ MK:?\4$>DZ^+(_UF$<73[].&[OQJNV_26 7$79Z"B[46=G@* BJ$,0JE?ZMIJ M3);?(MH>$@MK-Z<:385M])\/ZVOBEW1V^*OOZBG3]$BC:2V(C"VRHDP88M) M[T?-I+/RXXK?=M:72^*TR-)U0/P\KU'P@9&^Z4"U^1?] ".1K)WU5E=]! M<94 _$)*/YB#QZGV00_6(.(MML9<3;#LJ0_^Q@?4\RHC.\154?HH"Y.VB$=9 M/"G=?MU9:L'Q09>/K;;%4H<*;CFD 'NZX!%(0)Y.'$UNN!U+PDPER &*"E>=>C![OU"0V]L\CS :^+J MZ@$_O7:JXD)?]#'HVZ/.=6\IB[-;U_K6/44LR7Y[U':^.JN:UE/JK//;1=:R M-BFN6OOUX%N>@TKK0V>F13FA<0MA=CO8Z^1#E1+T"+@>[]&!H-L%!2XFW/G\ M9[R/TTR_Y^G^#K#;40%L]CGBCS ['!F!]"DY295,[CDVX0X/< LS'N3@R:/( M2V'B(/\ZG33(G\@6*RA9?O]#B-,@CS/%/L1 Y]=IK("I\VB)O WZ%@3R[K4B MF7KI[V8 5>._I,4!A_$VQI%R86^A!3 $&_#&&'2$?@W"C$)O% (#T*IZ#/P+ M)_QCCF'BO"A7*;^*%.2OF^VG/W!XI'.:X=C%S@1QS.*J2GNL8N, .D9Q@S4\ MDW%+&T!!VP)-^,%U&[[/2 9JR_B0P$ASK1I6T .0R33*7#0:<[B!B5-%?=W? MA0OB\,-9F?8PQ,H"=#CBB&OX$%"P%I8R!@S6ES,NYQX''79SW'@8< MF !& 6=5FD' R@$S!CC"&CX$E+2!I8P 0[5E?(OT_^DTFMO[J\> 5FGT<#P< MDM>FBH_>]ZTL )[OJ$;C]Q9Z&*]W F6[JUZ_[D3_S<6T=:,: _+LX,,4JS59 MF30!<.Z!VCRLIER\'Y^R/(K3H,31YZS$5^1_TY ,[H]?#5%[%RZ(Q;NS,NWB MWI'M8M;)ZAU&U69R#;,B&.(? MBCGD-1Q<(Z&9RG.<0*HGW,0 MYF4ZATTKNW.85!OA'+^2+P-=< M%&A_SU+*_.&O_5SDZ51EE[3"WY/ M0?IEL]WB'$?W9*J[N?ZX49<*ZMB4-"^AU$P R5Y M]$8X\*R7=BFB[^2RU"^R,6#;AT+)IJA1M>2J3CC8?"Y"MC:X"UZ#I\0PJF@( 88/(^1FG%!2^5U^&B!(GY_0 M5HNTBAK2G'L!IZ9JPSSF]8O@RSI@I6NNTU!OGDHRB)Z/M-"V?XA%+$"?K A3OH;NE36M+F\:60&L9#-5$Z173W[_:!%_*'..J*%%2P2Q?#%!LF905:VT*!53V9!\5M)@!5C&SX!ZS2\COLP*G M7X/$4,Q-002Q0]!!;?<'IQ1^MZV:YN7U*1D^:T+0%;4CWJLL)W98%'\NT'H7 MQ/D^2"_0'?E+'-&L8SHTK'T-N&[FYAL>8)7M/JVU7F6NNFW M<;C#0?+P[6\X+@S3AIH.XFC0 +@]$E00PB2N>UXJ@=;]?O@6,1D72#"L MUG1^)8;36M<%>BCSH,3/<2@^/^YYMNFA?$7:: EZ_ND.>_BG0.]./^PL_LVK MFCC6<15RH&8 [ ML.(>LR_+@V05IO@QQT%)&W%P13L/Q&[-49%VXV9A -K#.:&2]Q2$#5$^U##Z MLG?]7N[L5+'L\7SJXR\$N?H:Y-$C:<40N#ZA@0DS*H&*@<4.@?=0HJ)UR188 M#:)$X)'GAUV0XX]!@:-UMC_@M&!#DO"2>_'QM:6Y"UZ9Q5/\K:)I=$?4LQ;Y MG:\N,9\2B3RIZY(4_>A@#EM) +P!E0CW&F.IYC]28U(80[F2"W_J2B\AOR-T"0 M/W435UN ATPV99:ZCOE:4HB,2C/L-J=230UA+,9 MA)R&(Y"CFAZDQK<*N+;(MXEX&0:B+O.MIP0W$G.VEMI,P"I]SZS B$7'>H?# M+X=Z'AG2RE M 1U#)-[" Q04=5&D$]TT,?@/4]K1Z$)E+2UX0/\$O#$BKZ&%L1XC<-%JE(3> MK<6 PFHEP*'D6:#[L_![7)1Y')+UPT.9A5]^2>.RN'_XQ5@DP<(#8_%.BHB6 M;V3P[@$.:!1Y134/8DR(<:%[](!^ :Y\,*$Z[PC?R#RY:5SECLC">5ZI9/00 M-2F,8YA@B_Z@HO/N!GH0DKDTI)6UP!K\#, ]+IJ/3T4+-EN$P+ M9CT]T&+9ID!GH:PC]K](-B.1#^0)%;U<5MD-=+9+BYF>@F^VCWF0%D%(@^GF MW!4'1B [I1;[7E,2[6 MQ_TQ">CQ]#V.,-[3A!N+6/&2N.X6R_????@7M.=&G=5&S1&@%6I!H!8%:F"@D]6Q]\?D)N^H M2O.>>C.YL$_03=X3K!ANJ^?J\19N\;IYP?DJ23)V=V!ST+Y6YT /LU2U*B"N M4+7$WA>F%B3R30]"CQH&Q#F ]_I#='COK(/'TXTJ?<8>SU)2 IULZ$%WSC5D M,O^G&CH,^M36)82R)H?MSZ*O[S9&.Q9^A[%>":!HL\V/WBWUI&5YL8?NT ;8 M+*T8[_0(QVR==CC9/G[-'G?9L0C2Z/$K&<-?#5LC(SW$UL=!@79K8R &VKI8 M$2F*:F!%38V""D+E5_IX+1=%_D%E^=YB]%>(L;"'(VHFQ+E -PC]]:#>A1@? MZ($W)JZS6Z614)GCTQ_T%IBZ-'$O3K##;U>E3H[ ;6P0!^%NF%3GQXR3W304 MJZY4S/!'XF,5"WHJYL^K?L(IIE?YTV@5[>,T+FCYF_@%N_B5(R^,9_523/0M M)T;OWM4#E62&%2]SKR[W0CQL"N6"_LIYS$"I+AP;CN:[)$ 9)PJ8G4P3X7?_ M&292XW*"1GM+'?B(W:D4Q#**.-C++P 73G"ZK;^4 @43@1VS[Z4AG6ORV5,Z M"-*FQ+7^+LY+C-4A\_[L$+OB_NJUFV1W7J ]>QX]O__NPP]SQ,ZNLF,:$84Z[5#4M:DB5#,MPY[]*#*FA#TNOK &FU8,U4,,Q! E[6W0V]+V M.DK/)>[-,.12]X2^JJ36"G "IZAVT;(CRH88-/%@CZU1#,S\^965;BIVI MU3';69=G 7:F M33SF#?I/*HD<]3V1><'O$5L4""E, ,R]_B*JP6XYL1TI%>HT=Y+.Z)[TCA()< H\ 5[%02J3BJA85,M%5#"J M):-*-#OEJH2+G@)\A#QGK\"OU%9A2/;X97&/0QR_:-^*MI,#%5.WP._45=?0 M^B^Q;@0B5UNOR%%+#^P4,RE0_?\-:9'\F_R+_,]34.#_^_\!4$L#!!0 ( M /F :5&@Y<7'7XP ))+"@ 5 9F)I;RTR,#(P,#DS,%]P&UL[+U; M<^,XMB[X/A'S'S1U'O8^$2>K?$E+=D?WG/"URCVVY;&=77O/2P9-0A([*5+- MB]/N7S\ +Q(IXDH" @@YSNE=518 8JWOP\)M8:V__N_W93!Z W'B1^'??CG\ M]>"7$0C=R//#^=]^R9(O3N+Z_B__^__^/_^/O_Y?7[[\U\73W+T4NT6CGAZ![$L1\$HXO8]^9@-#K[=?SKY.1D_.OQR?CP=/3E M2]G2A9/ FE$XRIL\^O5P_/C;V6]'!T<'H[._'(S_KQ? M%[R'O9SYS)*!'_YXA5\;04G#Y&^_+-)T]9???OOY\^>O[Z]Q\&L4SV'%@^/? MJH*_%"7_\I[XC=(_CZNRA[_]U_W=L[L 2^>+'R:I$[J;6J@97+W#L[.SW_)? M8='$_TN2U[^+7"?-=<_LUXA8 OW7EZK8%_2G+X='7XX/?WU/O%^@#D:CO\91 M )[ ;)1WX"_IQPK\[9?$7ZX"U/'\;XL8S/[VR^S5C[X@/1Z<'1^@^O_CJH2[ M^N=YZ%V'J9]^W(:S*%[FO?]EA-K_]G3;$ /^G,8@26"3*7 7O[K1\C=4[C>^ M)G_KV_/G%!()M7\9A1X((>'@OR11X'N(8!=.@'![7@"0)H(""+6\2SD>G1B6 M6X#4=YU G5!;GU$LX?K79#J;KD"<\T,N9*1/[$JRZ>QRX81SD-R&SVGD_EA$ M@0>-\O6_,C@JU$C*^.0.,;UTDL5-$/U4!VGM"[WENO(3-XB2+ ;3>.Z$_K]S MKD 3=@42-_97Z+^FLXLL\4/8:5'+*-BX1&F>L^72B3^FLV=_'L*)U76@87;= M*(.6.9P_0K6Z/N@N#V_S$B5"_Q:AYC/@=;8;[.8D]O@R"@+G-8HKU/.!^9C% M[@).[.?S&!2$[BP"=_L297J,(ZBL] --\M"VK- 7.@N ;TQB;V\^2ZR?,FY"]41 Z]S5]L-R;0M*V288:M/( $.I!O$[Q+6 M10'=F;SXA"N#A) M85.PPKQ287=)B.W)[#-([Z(D>03Q9;1<1N'S B[[N_<8WYI,*]-WY4QO2NH\ MOUSZ:6Z+D)7*5Q5S$/9:8%';E-CW)Q"@Y37< J8?+[$3)H[;;UU%;E F-\ < MJ:;'F06U*:GZ?0-PB9G2?3L.ZU)U;N*GEVGMJEPA]&S MVZ3F].PV>@K3X4O*=AX]1<$WIFX7TM?HX%O3M2/I*4VG;ZG?G?24BM&JZIU* MW][3VE2Z:^EKE(@-[F8'T[/['"WO8#?34PA6LTIW-GWY0VQ0TRZG-Q;BGU*^ MYE[?2*%>U1AR!5+'#V0OQIE?V_T=1E]!13^C>!\"K19<"Q:WC;C?^XK;ZYN* M93_W/!^AX 0UFZ%"8/J'5._7UE-1&GS<)DF&3,6?3@Q'4YK\Z:>+:7X[^QC# M;7LXOX\\$/35@>QNJ-;0%8C]-PC*&Z!TLK:25:*?SIU0K9WK=S?($MBOZ>S! M*6A\XX<.7-D@/B=IG/M")645[SQ=MS(-GX";Q3$4YL))?#5Z4] ]Y2.R5_WV>0!)%L0?@GE[ 1:NO+A3U1J&^[C/D<#J_ M?E_E?Y:M %+S"B6B4$^:6-1OZ#E[7-\#G(,W/W624N7EUO$ENH5%6JU)6S_O MOJ.:M=PDML%:[M=1/5I6,D])^[ZR,_5D L& ML:^0W3ZF2UHE.$OL@?J[U;["LII5?;N*#I^SM-CV3F=7?I#!5>J?P)\OX#_/ MW^".> [R@LDT2]&"%CTI[2VT_)XHO42@).EL,"]'_K+;)GWX]'YD'2WW.>CNY%> MQ:%IU\_MP!_G)LI"-,#D'/*?7^ZCV=D5O4Y/^%%K-.^/'\ M&$=>YJ9EU?[02>N!)KTH8K2L#I1:6<$/0C[EO]U!)92J0)^5&2VFKG3PG@)H MP[WU7_T4?>P *OQ@]&54-53_5[@K'!6MCNK-YB) (8+(;7PA0&%[HKB)*Q(F M@=+DP7D2X/XZC]Y^\X"?QR5"_Y*#_N7@L S-\S_@G[Y?1G"'>OZ:Y(JNV@N< M5Q#\[1?,[[^I[U&EDVT'4$SG2$6_CX\G7P].3HXFI\=?STXFXZ/C6M?KC#B/ MFV(XL5M]!_YKBR3-N$=EB=]6>3B:+^["#]:8SR!_L1HLOQ9UD Y!,1_^^7P MEU&6P'Y%JX+\OXQ6L1_%D#M_^^6H"T050C,G>#:S4A/RQ2DG$O8>+%]!3 )^NYQQ MN'/BA@&<2S3M>+?7=.@OW^$."&Z>+[-E%N0NJ4_ @SLA9,,>0;P"*=PN/58] M),/3@3%!NO0E68ZT&@<9RS*XG :WT)QNS_*LXL9PHL*<( MPM6"'WG7H8>.K"GX-LOFI?'Y*R1RSVT5MA)U+QA+Y$^VC MMCB1O?$#\)!A]D6X(C:!QB5;"=;8$+">P-Q'1ZUA^N L<1865\P^T#CD*X&; M#-.^5E)8IC%G]<1AX9?&HM^[@@+FY)C5/M^]1"@!?G_=:# M6LCO_U!7&-:84-X^9$4$+3$],\1.GWL>NFTM_X%$/R3BB2EK'Y:\0E9'% =F M 7D)_W4:OT0_MR^'*"6M!9$A8@4A[:Y/ X3YU#"-'^/HS2\R"E%QW"K>E'0R M&1^=V0$FCYP5HK2370V(/D9)Z@3_G[^B+H=PA:U%DRUEA:7^0R-D1LYCX!#0 MJ_]L$UY,N2J$<$=#NT4(I4\+'A=12#X@V"YB$U)49A@N#W#H]> M7Y!+'@:M[2(VH<4E6X66_O./Y:O48"!JO&[33BQ!:M &NC9347$ MZW9C%22W&"CY@*-9[AG$!HQ6U"4EC. M"E%33F/R]]M.]9;&*26A'*#BBMN'J("@GB M.9Q %>*XTZD!(%[IZ<9/7"?X;^#$-_ OM.<36R7K2CDY@.)\/1@LZB(B5K@/ M],"KW#AN)"4[ ).*VH2\D(P5]+C#KP% WV1YX?7,-^AK96T"7TS("GW<09D< M]/_ZVW:$"$EQ(S9/C7$!_"^

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